CENTER FOR DRUG EVALUATION AND RESEARCH

BLA APPLICATION NUMBER: 125156

MEDICAL REVIEW

Medical Officer's Review #3 - Labeling and Postmarketing Commitment

Application Type Submission Number BLA 125156

Primary Reviewer

Rhea Lloyd, M.D.

Date of Labeling Submission Date of Postmarketing Commitment Submission Date of Labeling Review

Name

Applicant

June 28, 2006 June 29, 2006

June 29, 2000

Lucentis (ranibizumab injection)

Genentech, Inc. 1 DNA Way South San Francisco, CA 94080 650-225-1558

Submitted

The applicant has submitted labeling based on previous review, internal discussions and correspondence between the applicant and the Office of Antimicrobial Products with revisions to Section 12.2. In the second sentence of paragraph 2, the word "months" was capitalized. In the last sentence of paragraph 2, the phrase, \Box \Box was replaced by "Foveal retinal thickness data."

Also submitted, as agreed during the 29 June 2006 teleconference between the Agency and the applicant, are the following additional Postmarketing Commitments:

- 1. Submit the final Clinical Study Report from Study FVF3689g by 30 June 2008.
- Provide safety and efficacy data from a 2-year adequate and well-controlled clinical trial of a mutually acceptable design exploring multiple dosing frequencies of Lucentis. The timelines are outlined below:

Protocol Submission: Study Start: Final Clinical Study Report: 14 November 2008 21 September 2009 1 April 2013

<u>Reviewer's Comment:</u> Acceptable.

<u>7</u> Page(s) Withheld

§ 552(b)(4) Trade Secret / Confidential
§ 552(b)(4) Draft Labeling
§ 552(b)(5) Deliberative Process

Withheld Track Number: Medical-

Recommendations

cc:

It is recommended that BLA 125156 be approved with the labeling contained in this review.

The application supports the safety and effectiveness of Lucentis (ranibizumab injection) for the treatment of $\Box - \Box$ neovascular $\Box - \Box$ age related macular degeneration.

Rhea A. Lloyd/M.D. Medical Officer, Ophthalmology

William Boyd, MD 176/2000 Wiley Chambers, MD WAC 1/3-4ac Janice Soreth, MD Mark Goldberger, MD, MPH

Deputy Division Director Review

BLA

125156

Application Type Submission Number

Established Name Trademark

Therapeutic Class

Lucentis Vascular endothelial growth factor

(VEGF) inhibitor

Ranibizumab injection

Applicant

Genentech, Inc. 1 DNA Way South San Francisco, CA 94080 650-225-1558

Proposed Dosing Regimen

Lucentis is to be administered as an intravitreal injection 0.5 mg (0.05 mL) every one to three months.

Indication

Treatment of c_{-2} neovascular c_{-3} age related macular degeneration

Intended Population

Adults with neovascular (wet) age-related macular degeneration

Formulation

Ingredients	Amount and an angle of the second sec	Function	Reference to Standard or Specification
Ranibizumab		Active ingredient	
α, α-trehalose dehydrate	Γ	_ ۲	
- histidine HCl			Ph. Eur.
L - 7			1 n. 15ur.
L -]			USP and Ph. Eur.
Polysorbate 20	1	<	NF and Ph. Eur.
Water for Injection			USP and Ph. Eur.
		<u>_</u>	Cor and the Eur

^a Target fill volume of *m* per vial.

Page 1 of 41

Table of Contents

DEPUTY DIVISION DIRECTOR REVIEW	1
EXECUTIVE SUMMARY	4
RECOMMENDATION ON REGULATORY ACTION	
RECOMMENDATION ON POSTMARKETING ACTIONS Risk Management Activity	4
Risk Management Activity Required Phase 4 Commitments	4 4
Other Phase 4 Requests	
SUMMARY	
Efficacy	
Safety	
Dosing Regimen and Administration Drug-Drug Interactions	
Special Populations	
INTRODUCTION AND BACKGROUND	
PRODUCT INFORMATION	
PRODUCT INFORMATION CURRENTLY AVAILABLE TREATMENT FOR INDICATIONS	
AVAILABILITY OF PROPOSED ACTIVE INGREDIENT IN THE UNITED STATES	
SIGNIFICANT FINDINGS FROM OTHER REVIEW DISCIPLINES	
CMC (and Product Microbiology, if Applicable)	
ANIMAL PHARMACOLOGY/TOXICOLOGY	7
DATA SOURCES, REVIEW STRATEGY, AND DATA INTEGRITY	
Sources of Clinical Data	
TABLES OF CLINICAL STUDIES	
Review Strategy Data Quality and Integrity	
COMPLIANCE WITH GOOD CLINICAL PRACTICES	10
FINANCIAL DISCLOSURES	
CLINICAL PHARMACOLOGY	
PHARMACOKINETICS – SEE PRIMARY REVIEWS.	. 10
PHARMACODYNAMICS – SEE PRIMARY REVIEWS.	. 10
EXPOSURE-RESPONSE RELATIONSHIPS	. 10
INTEGRATED REVIEW OF EFFICACY	. 11
Efficacy Conclusions	. 18
INTEGRATED REVIEW OF SAFETY	. 19
	. 19
Human Carcinogenicity	. 24
Withdrawal Phenomena and/or Abuse Potential	
Human Reproduction and Pregnancy Data	
Assessment of Effect on Growth Overdose Experience	25
Postmarketing Experience	
ADDITIONAL CLINICAL ISSUES	. 25

DOSING REGIMEN AND ADMINISTRATION	
DRUG DRUG INTERACTIONS	25
SPECIAL POPULATIONS	
PEDIATRICS	
PEDIATRICS Advisory Committee Meeting	26
LITERATURE REVIEW	26
POSTMARKETING RISK MANAGEMENT PLAN	
OTHER RELEVANT MATERIALS	
OVERALL ASSESSMENT	
Conclusions	
RECOMMENDATION ON REGULATORY ACTION	
RECOMMENDATION ON POSTMARKETING ACTIONS	
Risk Management Activity	
Required Phase 4 Commitments	
Other Phase 4 Requests	Error! Bookmark not defined.

EXECUTIVE SUMMARY

Recommendation on Regulatory Action

Lucentis (ranibizumab injection) with the labeling changes listed in this review is recommended for approval for the treatment of \Box \neg \neg neovascular \Box \neg \neg age related macular degeneration.

The applicant, Genentech Inc. has conducted three adequate and well-controlled studies, FVF2598g, FVF3192g, and FVF2587g which demonstrated statistically and clinically significant differences in the proportion of subjects who lose fewer than 15 letters in best corrected vision at 12 months compared with sham treatment.

Recommendation on Postmarketing Actions Risk Management Activity

No post marketing risk management activity beyond the usual collection of adverse events is recommended.

Required Phase 4 Commitments

T

Other Phase 4 Requests

There are no other Phase 4 requests.

Summary Established Name (Proposed) Trade Name Therapeutic Class Route of Administration

ranibizumab injection Lucentis 0.5 mg vascular endothelial growth factor (VEGF) inhibitor intravitreal injection

Age Related Macular Degeneration (AMD) is clinically manifest in two distinct forms: the nonexudative (dry) or the exudative (wet) form of the disease. The etiology of the disease is such that new abnormal blood vessels proliferate from the choriocapillaris through defects in the Bruch's membrane under the retinal pigment epithelium (RPE), forming neovascular membranes. These new vessels leak serous fluid and may give rise to serous and hemorrhagic detachment of the RPE and neurosensory retina and may stimulate fibrous disciform scarring with subsequent loss of central vision.

Neovascular AMD is characterized by CNV in the macular region. Vascular endothelial growth factor-A (VEGF-A) has been observed in surgically excised human fibrovascular lesions. It is

reasonable to suggest that active forms of VEGF-A are targets for therapeutic intervention in neovascular AMD.

Efficacy

The three phase 3 studies submitted, Study FVF2598g, Study FVF2587g, and Study FVF3192g were designed to demonstrate the safety and efficacy of Lucentis (ranibizumab injection) in the treatment of neovascular AMD. All three studies were prospective, multicenter, randomized, double-masked, parallel group. Study FVF2598g and FVF3192g had sham controls, and Study FVF2587g had an approved photodynamic therapy as a control. All three studies demonstrated clinically and statistically significant differences between ranibizumab and the control arm. The effectiveness of dosing every three months appeared to be only one third as effective as monthly injections. Based on the population studied, there does not appear to be any difference in Lucentis' effect based on age, race, ethnicity or iris color.

Safety

The population studied was predominantly elderly and white which is representative of the population usually affected by age-related macular degeneration. The demographics of the patient population do not reflect problems with recruitment.

The most common adverse events identified are conjunctival hemorrhage, eye pain, increased intraocular pressure, retinal disorder and vitreous floaters. These adverse events are often associated with intravitreal injections.

Dosing Regimen and Administration

The sponsor has performed adequate dose ranging and dose frequency studies of Lucentis (ranibizumab injection). Lucentis has been proven safe and effective when administered as an intravitreal injection 0.5 mg/0.05 mL once monthly. This dosing regimen achieved and sustained a statistically significant difference in the proportion of patients who lost 15 letters of vision compared to baseline relative to the control group. When Lucentis is dosed every three months, it appears that 2/3 of the effectiveness is lost.

Drug-Drug Interactions

In Study FVF2587g, Lucentis (ranibizumab) was dosed with verteporfin PDT. Significant inflammation was observed when Lucentis was administered 7 days following PDT, but not when dosed at intervals longer than 7 days. No drug-drug interaction analyses were performed.

Special Populations

Subgroup analyses did not reveal any differences in the safety or efficacy with respect to age, sex, baseline visual acuity, CNV lesion type, lesion size, or prior laser photocoagulation. The population studied for this indication was predominantly elderly and white, reflective of the population most affected by this disease. The number of patients outside of this demographic group was too small to draw any definitive conclusion regarding the safety and efficacy. No pediatric trials were conducted for this drug as age-related macular degeneration is a disease seen only in adults.

INTRODUCTION AND BACKGROUND

Product Information

Established Name	ranibizumab injection
(Proposed) Trade Name	Lucentis 0.5 mg
Therapeutic Class	vascular endothelial growth factor (VEGF) inhibitor
Route of Administration	intravitreal injection
Chemical Class	VEGF Inhibitor
Indication	Treatment of neovascular (wet) age-related macular degeneration

Currently Available Treatment for Indications

There are currently two approved drug products for the treatment of age related macular degeneration – Visudyne (verteporfin for injection) and Macugen (pegaptanib sodium injection). Visudyne was approved under NDA 21-119 on April 12, 2000, for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration. Macugen was approved under NDA 21-756 on December 17, 2004, for the treatment of neovascular (wet) age-related macular degeneration.

Availability of Proposed Active Ingredient in the United States

Ranibizumab is a new molecular entity and has not been marketed in the United States.

SIGNIFICANT FINDINGS FROM OTHER REVIEW DISCIPLINES

CMC (and Product Microbiology, if Applicable) Formulation

Ingredients	Stretigth Amount per Amount - 10 mg/mL / 41 ^m	Finction	Reference to Standard or Specification
Ranibizumab		Active ingredient	
α, α-trehalose dehydrate	Γ	1	
- histidine HCl			Ph. Eur.
<u> </u>		-	USP and Ph. Eur.
Polysorbate 20			NF and Ph. Eur.
Water for Injection			USP and Ph. Eur.
^a Target fill volume o	► . per vial.		

Genentech intends to use a life-cycle approach for setting ranibizumab specifications. This lifecycle approach will use interim acceptance criteria based upon the limited data available at the time of submission. Since campaign-to-campaign variation can be larger than the variation within a campaign, Genentech proposes a post-approval commitment for re-evaluating the

interim acceptance criteria after three commercial post-approval campaigns (consisting of a minimum of - additional lots). The re-evaluation is expected to take place within two years after approval but will ultimately depend on the currently unknown manufacturing schedule for ranibizumab Drug Substance.

Teet Code 1	'est Name		Acceptance Criteria		Release	Shelf-life
<u> </u>						
L						Į
						, ,
		\backslash				
					· • ·	
						-
						_
_						
1						
					· .	
Animal Pha	armacology/To	xicology				
There were n the clinical o	o significant find	ings in the pha	armacology/toxicolo	ogy reviews wł	nich woul	d affect
and onlinear o						

Lucentis Drug Product Release and Shelf-Life Specifications.

DATA SOURCES, REVIEW STRATEGY, AND DATA INTEGRITY Sources of Clinical Data

This review is based on the primary reviews from the Clinical, Pharmtox, Product Quality, Biopharm and Statistical staff and results of the applicant supported trials for AMD conducted under BBIND — Three phase 3 safety and efficacy trials were submitted to support the indication currently being sought by the applicant. In addition, the results of four phase 1/2 dose ranging and safety trials were also submitted. This NDA was submitted in electronic format as a hybrid CTD (i.e., CTD structure with PDF tables of contents), according to ICH and FDA guidelines for electronic submissions.

Tables of Clinical Studies

Study	Design (Sites)	Population	Control	No. of Enrolled Subjects	Treatment Frequency and Duration	Ranibizumab Dose(s)
FVF2587g	Randomized, double-masked, double-sham active treatment- controlled (US, Europe, Australia)	Subjects with predominantly classic subfoveal neovascular AMD	Verteporfin PDT (+sham injection)	423	Intravitreal injection q month, max. 24 injxns over 2 yrs, or verteporfin PDT q3mos as needed	0.3 mg (n=140); 0.5 mg (n=140), sham injection (n=143)
FVF2598g	Randomized, double-masked, sham-controlled (US)	Subjects with minimally classic or occult subfoveal neovascular AMD	Sham injection	716	Intravitreal injection q mo., max. 24 injxns over 2 years	0.3 mg (n=238), 0.5 mg (n=240), sham injection (n-238)
FVF3192g	Randomized, double-masked, sham-controlled (US)	Subjects with recurrent subfoveal CNV with or without classic CNV secondary to AMD	Sham injection	184	Intravitreal injection q month for 3 doses (Day 0, Month 1, Month 2) followed by doses q 3 months (Mos. 5, 8, 11, 14, 17, 20 and 23)	0.3 mg 0.5 mg sham injection (Target: 61-62 subjects per group)
FVF2508g	Extension (US)	Subjects with neovascular AMD who completed a Genentech Phase 1/2 ranibizumab study	None	70	Intravitreal injections every 28 days (± 5 days) through October 2006 or until 30 days after product launch	0.5 mg (n=66)
FVF2425g	Randomized, open-label, multiple-dose escalating regimens	Subjects with neovascular AMD	None	.:9	Intravitreal injections at 2- or 4-week intervals, max. of 5, 7 or 9 total injections	0.3 mg to 1.0 mg escalating regimen with 7 total injxns (n=9); 0.3mg to 2.0 mg

Page 9 of 41

Draft Deputy Division Director Memorandum Wiley A. Chambers BLA 125156 Lucentis (ranibizumab injection)

Study	Design (Sites)	Papulation	Control	Nd. of Enrolled Subjects	A Frequency and Erequency and Durition	Ranibizumab Dose(s)
	(US)		· · · · · · · · · · · · · · · · · · ·	-	over 16 weeks	escalating regimen with 9 total injxns (n=10); 0.3 mg to 2.0 mg escalating regimen with 5 total injxns (n=10)
FVF2128g	Randomized, open-label, dose-escalation (US)	subjects with classic neovascular AMD	Usual care ^d	64	Intravitreal injections q 4 weeks, maximum of 8 total injections over 28 weeks, or usual care with crossover to ranibizumab treatment after 14 weeks	0.3 mg (n=25), 0.3 mg initial dose escalated to 0.5 mg for subsequent doses 9n=28), usual care (n=11)
FVF1770g	Open-label, single-dose escalation (US)	Subjects with neovascular AMD	None	27	Single intravitreal injection	0.05 mg (n=6), 0.15 mg (n=6), 0.30 mg (n=6), 0.50 mg (n=7), 1.0 mg (n=2)
FVF2428g	Randomized, single-masked, sham-controlled, combination treatment (US)	Subjects with predominantly classic neovascular AMD	Verteporfin PDT (+sham injection)	162	Intravitreal injection q month, max. 24 injxns over 2 years, in combination with verteporfin PDT q3mos, as needed	0.5 mg (n=106), sham injection (n=56)
CRFB002A 1201	Open-label (Japan)	Subjects with subfoveal CNV secondary to AMD	None	Target 84	Intravitreal injections every month	0.3 mg 0.5 mg (Target: 42 subjects per group)
CRFB002B 2201	Öpen-label (Europe)	Subjects with occult or predominantly classic subfoveal CNV secondary to AMD	Verteporfin PDT	32	Intravitreal injections every month in combination with verteporfin PDT	0.5 mg (n=30)

Review Strategy

This review relies primarily on the results of the three Phase 3 trials submitted by the applicant.

The submitted clinical study reports, clinical protocols and literature reports related to trials FVF2598g and FVF2587g were reviewed. The application is in electronic format as a hybrid CTD (i.e., CTD structure with PDF tables of contents), according to ICH and FDA guidelines for electronic submissions.

Data Quality and Integrity

There is no evidence that Phase 3 studies reviewed in this BLA were not conducted in accordance with acceptable clinical ethical standards.

There were no significant problems identified Division of Scientific Investigations (DSI) audits that are likely to affect the data quality. The case report forms for the three studies were provided by Genentech, and these were reviewed for completeness and quality.

Compliance with Good Clinical Practices

The studies were conducted in accordance with the International Conference of Harmonization E6 Guidelines for Good Clinical Practice (GCPs), the Declaration of Helsinki and in compliance with relevant local and national regulations for informed consent and protection of subject rights in the country of conduct.

Before initiation of the study, the original protocol, all protocol amendments, the informed consent documents and all supportive information were reviewed and approved by the appropriate ethics committees (EC) or institutional review boards (IRB) for each of the centers involved in the study. The studies began only after receiving written approval from each EC/IRB.

Financial Disclosures

The applicant has adequately disclosed financial arrangements with clinical investigators as recommended in the FDA guidance for industry on *Financial Disclosure by Clinical Investigators*.

There is no evidence suggesting problems with the integrity of the submitted data.

CLINICAL PHARMACOLOGY

Pharmacokinetics – See primary reviews.


Pharmacodynamics – See primary reviews.

Exposure-Response Relationships

The retina is the site of disease in neovascular AMD. Therefore, systemic ranibizumab concentrations after intravitreal administration are not expected to correlate with efficacy.

INTEGRATED REVIEW OF EFFICACY


The study designs of the three Phase 3 studies are included in the Primary Medical Officer's Review. Additional analyses and cross comparisons between studies are presented below. It is recognized that there are potential risks in comparing across studies. With respect to treatment by an intravitreal route of administration, these studies utilized essentially the same population.



Best Available Copy

APOTEX V. REGENERON IPR2022-01524 REGENERON EXHIBIT 2024 PAGE 015


Page 11 of 41



The 0.5 dose was consistently more effective than the 0.3 dose and each were more effective than the control group. The slope of the best fit line between month 3 and month 12 demonstrated a two thirds reduced effect of ranibizumab when the product was administered every three months compared to monthly treatments. The month 3-12 slopes for sham were -.87, -.85, -.84. The month 3-12 slopes for the 0.5 dose monthly were +.23 and +.26. The month 3-12 slope for the q3month injections was -.56. For the q3month injection, this becomes a 5 letter loss over the 9 month period

Draft Deputy Division Director Memorandum Wiley A. Chambers

BLA 125156 Lucentis (ranibizumab injection)



Noted above, there is no correlation between OCT and visual acuity. Treatment with ranibizumab results in a thinner macula even when the visual acuity decreases. The month 12 values illustrate this point. At month 12 for the ranibizumab 0.5 group, the mean macular thickness has its lowest value; however the visual acuity is at its worst.

の語言語 ほどう

This graph illustrates that a substantially larger proportion of patients treated with ranibizumab injection develop thinner maculae and have improved visual acuity. While there is not a direct correlation between visual acuity and macular thickness over the course of this study, there is a general tendency for patients treated with ranibizumab to do both. For any individual patient, there is no significant correlation between macular thickness and visual acuity.

This graph presents a comparison between a change in OCT and the visual acuity at the next visit. Although not shown, data looks very similar for predictions of visual acuity at visits after the next visit. The graph illustrates that macular thickness is not predictive of visual acuity at later visits.

This graph illustrates the variation in visual acuity for any given macular thickness. While it is expected that thicker maculae will ultimately lead to poor vision, within the time frames of this study, there is no direct correlation between visual acuity and macular thickness. As a general rule, it appears that macular thickness below 200 often leads to better vision.

Best Available Copy

An attempt was made to see if OCT criteria or vision loss criteria might have aided in the decision to treat patients with Lucentis. Although no formal criteria have been defined for normality of OCT, an increase in 100 microns might be considered the smallest change reliably available to use as a basis for treatment. In addition, although a 15 letter loss is the smallest clinically significant change, a single line change (5 letters) is commonly reported for safety parameters and was therefore investigated as a small visual acuity change. The results are listed below:

Percentage of Patients Meeting particular OCT or Vision Loss Criteria

	OCT Increas	ed by at least 1	100 or Vision	Loss by 5 or m	ore letters
	Month 2	Month 3	Month 5	Month 8	Month 12
Sham	64%	53%	75%	75%	78%
0.3	19%	38%	51%	54%	59%
0.5	5%	30%	43%	54%	54%
	OCT Increas	ed by at least	100		
	Month 2	Month 3	Month 5	Month 8	Month 12
Sham	22%	11%	22%	17%	14%
0.3	0%	5%	16%	16%	11%
0.5	0%	0%	16%	16%	8%
	Vision Loss	by 5 or more l	etters		
	Vision Loss Month 2	by 5 or more l Month 3	etters Month 5	Month 8	Month 12
Sham		*		Month 8 69%	Month 12 75%
Sham 0.3	Month 2	Month 3	Month 5		
	Month 2 50%	Month 3 47%	Month 5 69%	69%	75%
0.3	Month 2 50% 19% 5%	Month 3 47% 35% 30%	Month 5 69% 41% 38%	69% 46% 54%	75% 59% 51%
0.3	Month 2 50% 19% 5%	Month 3 47% 35% 30%	Month 5 69% 41%	69% 46% 54%	75% 59% 51%
0.3	Month 2 50% 19% 5% OCT Increas	Month 3 47% 35% 30% ed by at least	Month 5 69% 41% 38%	69% 46% 54% ss of 5 or more	75% 59% 51%
0.3 0.5	Month 2 50% 19% 5% OCT Increas Month 2	Month 3 47% 35% 30% ed by at least Month 3	Month 5 69% 41% 38% 100 with no los Month 5	69% 46% 54% ss of 5 or more Month 8 6%	75% 59% 51% e letters Month 12

As noted from the table, even a change as small as 100 microns or loss of 5 letters is not likely to have led to additional treatments and if used as the sole criteria would have resulted in fewer treatments than once every three months.

Efficacy Conclusions

The submitted pivotal studies in BLA 125156 Lucentis (ranibizumab injection) demonstrate the efficacy for the use of ranibizumab 0.5-mg in the treatment of neovascular age-related macular degeneration.

The submitted phase 3 studies both demonstrate a clinically significant treatment effect of ranibizumab and 0.5-mg compared to sham and Verteporfin PDT, respectively, for the primary efficacy endpoint, the proportion of subjects with a loss of fewer than 15 letters in the best corrected visual acuity score at Month 12 compared with baseline.

Macular thickness is not predictive of current or future visual acuity, although macular thickness above 200 μ m and particularly greater than 400 μ m is associated with poorer vision. Ranibizumab is capable of doing more than just thinning the macula and vision may be lost in spite of a thin macula.

Appears This Way On Original

INTEGRATED REVIEW OF SAFETY -Reported Adverse Events

TOUDTON OF BORING OF BRITISHING	-	Were broken	1.	COLOR DOI NO.	CONSISTENCES OF STREET		SAN STRAIMS	GV/52	1.5360675	54561926	\$V(340267	5 01 5 1 1 17	1 # 1/2 25 87/9 1 8 10 8 mg 1 9 8 9 (40 %	EVE25980	EVE25984	EVE25980	EVF259
	122	3.4	100					ET THE	21.21023	F/F3192g		5 1 5 1 1	STATE OF STATE	5003 md	ab 0.3 mg	ab 0.3 ma	1 ab 0.3
Preterred Term	运用管	Mex	Ma	Charles and Charles	Sham wer	12.626	S		ST PADE:	CON-State		6.5.65	10000	潜NH238 常	SN#238	N=238	N-23
Contractional the meeting of	294	77%	43%	66%	29%	168	70%	181	76%	26	43%	87	62%	169	71%	184	77%
Conjunctival hemorrhage	173	47%	23%	67%	39%	86	36%	109	46%	14	23%	50	36%	88	37%	111	47%
Macular degeneration	134	37%	18%	33%	11%	71	30%	89	37%	11	16%	. 34	24%	77	32%	86	36%
ye pain /itreous floaters	102	32%	10%	10%	3%	53	22%	71	30%	6	10%	25	18%	59	25%	76	32%
Retinal hemorrhage	96	26%	17%	56%	37%	40	17%	58	24%	12	20%	26	19%	46	19%	61	26%
nevcular pressure	92	24%	16%	7%	3%	39	16%	57	24%	13	21%	22	16%	38	16%	57	24%
Atreous detachment	78	22%	10%	18%	13%	40	17%	53	22%	6	10%	19	14%	39	16%	52	22%
	66	19%	10%	20%	6%	36	15%	46	19%	6	10%	14	10%	34	14%	38	16%
ye initation	61	19%	7%	14%	6%	39	16%	45	19%	6	10%	10	7%	41	17%	43	18%
	55	16%	5%	13%	5%	18	8%	38	16%	3	5%	14	10%	21	9%	32	13%
lasopharyngitis	53	17%	6%	16%	8%	20	8%	39	16%	5	8%	9	6%	20	8%	41	17%
ypertension	49	17%	3%	16%	0%	27	11%	39	16%	2	3%	8	6%	32	13%	41	17%
acrimation increased	45	13%	5%	3%	1%	22	9%	30	13%	3	5%	12	9%	13	5%	17	7%
itritis	44	13%	0%	12%	3%	17	7%	32	13%	0	0%		9%	18	8%	23	10%
ye pruritus	43	14%	5%	9%	2%	23	10%	33	14%		5%	12	5%	20	8%	27	11%
fisual disturbance	41	14%	3%	9%	4%	26	11%	32	13%	2	3%	7	5%	16	7%	26	11%
kepharitis	38	13%	4%	19%	10%	10	4%	15	6%	<u>-</u>	8%	18	13%	18	8%	22	9%
ubretinal fibrosis		13%	4%	9%	0%	· 10	4%	27	11%	1	5%	- A	6%	15	6%	26	11%
rthralgia	38	15%	3%	10%	3%	14	6%	24	10%		3%	1 11	8%	24	10%	36	15%
leadache	37			9%	0%	26	11%	30	13%	é	0%	7	5%	20	8%	27	11%
etinal disorder	37	13%	0%		1%	17	7%	24	10%	3	5%	9	6%	16	7%	24	10%
cular hyperemia	36	10%	5%	10%							0%	10	7%	15	6%	29	10%
ronchitis '	35	· 10%	0%	8%	0%	13	5%	25	10%		3%	10	7%	15	5%	23	8%
taculopathy	35	10%	3%	11%	3%	16	7%	23	10%				4%		5%	20	11%
isual.acuity reduced	33	17%	4%	24%	10%	16	7%	24	10%		7%	-5	4%	15	10%	26	11%
the second se	33	11%	4%	15%	3%	17	7%	22	9%	6	10%	5					
Try Eye	33	10%	3%	8%	5%	23	10%	24	10%	2	3%	7	5%	10	4%	16	7%
tetinal degeneration	31	11%	2%	7%	1%	17	7%	24	10%	1	2%	6	4%	19	8%	25	11%
Cough	31	10%	3%	7%	. 2%	16	7%	25	10% -	2	3%	4	3%	20	8%	23	10%
Doutar discomfort	31	8%	4%	5%	0%	10	4%	17	7%	5	8%	9	6%	15	6%	18	8%
ritis	30	8%	2%	8%	1%	15	6%	19	8%	1	2%	10	7%	15	6%	19	8%
	29	14%	3%	8%	2%	19	8%	22	9%	2	3%	5	4%	22	9%	34	14%
fision blurred	29	8%	4%	8%	3%	10	4%	18	8%	4	7%	7	5%	6	3%	17	7%
viemia	28		2%	6%	4%	13	5%	21	9%	1	2%	6	4%	14	6%	21	9%
lausea	28	9% 8%	2%	6%	4%	14	6%	20	8%		2%	7	5%	13	5%	18	8%
Sinusitis Spportesprency dect	20	15%	2%	10%	4%	11	5%	18	8%	1	2%	8	6%	15	6%	36	15%
		10%	1%	9%	0%	13	5%	22	9%		5%	2	1%	14	6%	24	10%
lack pain	27					11	5%	20	8%	- 3	2%		4%	14	6%	16	7%
lood pressure increased	27	8%	2%	8%	0%		5%	17	7%	0	0%	0	6%	6	3%	7	3%
Conjunctival hyperemia	26	9%	0%	7%	0%	13			7%	<u>v</u>		8	6%	12	5%	21	9%
Irinary tract infection	25	9%	0%	8%	0%	10	4%	17			0%	•	3%	10	4%	23	10%
ntiuenza	24	10%	2%	5%	1%	10	4%	19	8%	1	2%				3%		6%
ostenut capaule	23	8%	2%	5%	0%	6	3%	19	8%	1	2%	3	2%	8		15	7%
Cataract	22	7%	2%	7%	2%	9	4%	13	5%		2%	8	8%		3%	17	
Vithritis	21	8%	0%	8%	2%	10	4%	19	8%	0		2	1%	7	3%	17	7%
Retinal exudates	20	9%	2%	11%	3%	14	6%	16	7%	1	2%	3	2%	18	8%	21	9%
Dizziness	20	8%	2%	10%	2%	5	2%	11	5%	2	3%	7	5%	11.	5%	18	8%
Cataract, nuclear	20	6%	3%	6%	2%	8 .	3%	9	4%	3	5%	8	6%	8	3%	10	4%
	19	7%	0%	8%	0%	0	0%	13	5%	2	3%	4	3%	0	0%	15	6%
Constipation	19	6%	2%	7%	2%	9	4%	14	6%	2	3%	3	2%	5	2%	12	5%
Depression	18	6%	2%	6%	1%	- Ťi	5%	14	6%	1	2%	3	2%	6	3%	10	4%
nsomnia	10	8%	1%	5%	2%		3%	13	5%	2	3%	2	1%	4	2%	10	4%
typercholoesterolemia				6%	3%	+	3%	11	5%	ō	0%	6.	4%	9	4%	16	8%
Pneumonia	17	8%	0%		0%	8	3%	12	5%		0%	5	4%	2	1%	4	2%
njection site hemorrhage	17	5%	0%	2%			2%	10	4%	2	3%		3%	10	4%	18	8%
Diarrhea	16	8%	2%	8%	0%			12	5%	-	0%		3%	11	5%	16	7%
Photopsia	16	7%	0%	6%	0%	1	3%						1%	8	3%	15	6%
Pain in extremity	16 .	6%	1%	6%	0%	8	3%	13	5%	1	2%			6	3%	10	4%
Anxiety	16	5%	2%	6%	0%	8	3%	12	5%	1	2%	3	2%	4	2%	10	4%
Atrial fibrillation	16	5%	2%	4%	2%	4	2%	11	5%	2		3					1%
	16	4%	3%	2%	0%	7	3%	10	4%	2	3%	4	3%	3	1%	3	
Gastroenteritis, viral	15	5%	0%	2%	0%	0	0%	11	5%	0	0%	4	3%	0	0%		2%
ปล่อยบประบุที่เอฏชอการแน่ง	14	6%	0%	6%	2%	6	3%	9	4%	0	0%	5	4%	6	3%	15	
Diabetes mellitus	14	5%	2%	2%	0%	5	2%	9	4%	.1	2%	4	3%	4	2%	7	3%
Dyspries mainus	14	5%	0%	3%	1%	2	1%	8	3%	0	0%	6	4%	7	3%	12	5%
	14	5%	1%	2%	1%	9	4%	11	5%	1	2%	2	1%	1.1	0%	3	1%
Cetaract, cortical	1 13	9%	0%	5%	0%	7	3%	7	3%	0	0%	6	4%	16	7%	21	9%
Eye discharge	13	7%	0%	11%	4%	10	4%	12	5%	1	2%	C	0%	3	1%	6	3%
Macular edema	13	5%	0%	2%	0%	5	2%	10	4%	3	5%	0	0%	8	3%	13	5%
Herpes zoster			0%	8%	2%	4	2%	9	4%	1 1	2%	3	2%	3	1%	10	4%
Contusion	13	4%	2%		1%	5	2%		4%	1	2%	3	2%	3	1%	7	3%
Fali	13	4%	2%	4%			2%	9	4%	0	0%	4	3%	4	2%	8	3%
Blood glucose increased	13	4%	0%	5%	0%				3%		2%		4%	+	2%	8	3%
Vitreous hemorrhage	13	4%	1%	3%	1%	3	1%	7		1	0%	12	9%	24	10%	+	0%
Cataract NOS	12	13%	0%	11%	0%	31	13%		0%			3			1%	10	4%
Cardiac failure congestive	12	5%	1%	4%	2%	2	1%	6	3%	3	5%	3	2%	2		11	470
Rash	12	5%	0%	4%	2%	5	2%	9	4%	0	0%	3	2%		4%		
Punctale keratitis	12	5%	1%	4%	1%	4	2%	9	4%	1	2%	2	1%	6	3%	11	5%
	12	4%	0%	3%	0%	7	3%	10	4%		0%	2	1%	7	3%	8	3%
yelid edema	12	4%	0%	4%	1%	4	2%	9	4%	0	0%	3	2%	1	0%	2	1%
Blood cholesterol increased		4%	0%	3%	0%	6	3%	1-7-	3%	0	0%	5	4%	. 4	2%	6	3%
	12			- 370	1%	6	2%	8	3%	0	0%	4	3%	4	2%	8	3%
Corneal abrasion	12	3%	0%	2%			2%		4%		0%	2	1%	6	3%	11	5%
Pruritus	11	5%	0%	4%	0%	5	2%	9			2%		2%	6	3%	9	49
Prunitus		4%	2%	2%	0%	4	2%		3%	i			1%		1%	5	2%
Pruritus Seasonal allergy	11		0%	4%	2%	5	3%	9	4%	0	0%	····		2	1%	5	2%
Pruritus Seasonal allergy Diverticulitis	11	4%				1	3%	9	4%	0	0%	. 7	1%	1 3	1%	1 3	
Pruritus Seasonal allergy Diverticulitis Syncope		4%	0%	2%	1%	1					V/0	-					
Corneal abrasion Pruritus Seasonal allergy Diverticultes Syncope Conjunctivitis, allergic Conjunctivitis, allergic	11			2%	0%		3%	10	4%		0%	0	0%	9	4%	17	7%
Pruritus Seasonal allergy Diverticulitis Syncope Conjunctivitis, allergic Edema peripheral	11 11 10	4%	0%	2%			3%		4%	0	0%	0	0%	9	2%	10	4%
Pruritus Seasonal allergy Diverticulitis Syncope Conjunctivitis, allergic	11	4%	0%	2%	0%		3%	10	4%		0%	0 1 3 0	0%	9 4 8			

Immunogenicity

Serum samples for the evaluation of immunoreactivity to ranibizumab were obtained from subjects at screening and prior to study drug administration at Months 6 and 12. The assay demonstrated immunoreactivity in a small percentage of subjects in all three treatment groups prior to initial administration of study drug, possibly due to preexisting anti-Fab antibodies.

The assay indicated positive results in a small percentage of subjects in all three treatment groups prior to initial administration of study drug, possibly due to preexisting anti-Fab antibodies. All three treatment groups had increases in positive results during the treatment period.

	S	1.1.7 HV102592	Bg America	Stu	dy FYF2587	S	
*71.14		Rinbi	zuminb	Verteporfin 2	Ranibizumab		
Visit	N=236	0.81mg N=238	0.5 mg §#239	PDT N=143	0.3 mg N=137	0.5 mg N=140	
Screening	5/215	6/215	7/218	8/131	12/125	7/123	
U U	(2.3%)	(2.8%)	(3.2%)	(6.1%)	(9.6%)	(5.7%)	
Month 6	19/201	15/211	17/207	6/114	11/120	10/116	
	(9.5%)	(7.1%)	(8.2%)	(5.3%)	(9.2%)	(8.6%)	
Month 12	20/206	22/222	26/219	7/125	9/123	16/129	
	(9.7%)	(9.9%)	(11.9%)	(5.6%)	(7.3%)	(12.4%)	

Immunoreactivity to Ranibizumab in the First Treatment Year- Safety Evaluable Subjects

Note: Table entries are numbers of subjects with positive immunoreactivity over numbers of subjects with evaluable samples. LTR=0.7 log titer.

Exploratory subgroup analyses based on immunoreactivity to ranibizumab were performed to determine whether the appearance of immunoreactivity was related to key safety and efficacy outcomes. The analysis population was divided into three subgroups: subjects who had a negative or missing test result at screening and negative post-baseline results, subjects who had a negative or missing test result at screening but at least one positive post-baseline result, and subjects who had a positive test result at screening. Visual acuity outcomes and the occurrence of intraocular inflammation and autoimmune adverse events were examined by treatment group for each immunoreactivity subgroup. No clinically relevant differences between immunoreactivity subgroups were identified in study FVF2598g.

In Study FVF5287g, with regard to intraocular inflammation adverse events, proportionately more ranibizumab-treated subjects who were immunoreactive at some timepoint experienced intraocular inflammation events than subjects who were never immunoreactive. Twenty- eight percent (5 of 18) of ranibizumab-treated subjects who were immunoreactive during treatment only and thirty-two percent of subjects (6 of 19) who were immunoreactive at baseline experienced inflammation adverse events in the study eye, compared with 10% of ranibizumab-treated subjects who were immunoreactive. Of the 12 verteporfin PDT-treated subjects who were immunoreactive at some timepoint, none experienced an intraocular inflammation adverse event.

Safety Evaluable Subjects

Study	Treatment Group	Subject		infrautoreactivity MSSIV Dog Tyter		Study Visit of Intraocular Inflammation Diagnosis
FVF2428g	Verteporfin				No CRF	
	PDT + sham	91103	34 / Month 1	1.200	found	
	Verteporfin PDT +	91308	- 7 / Screening	0.884	No CRF found	4 A.
	Ranibizumab 0.5 mg		366 / Month 12	0.767		
FVF2587g	Verteporfin	319001	3867 Month 12	0.797	No	
FYF250/g	PDT	334008	-12 / Screening	1.130	No	
			190 / Month 6	0.902	No .	
	1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 -		1907 Woldin 0	0.702	No CRF	
		401002	-8 / Screening	1.820	found	
			186 / Month 6	1.780		
			361 / Month 12	1.800		
	Ranibizumab					Screening and
	0.3mg	321003	-7 / Screening	0.945	Yes – Vitritis	Month 1
		334003	176 / Month 6	2.300	Yes – Iritis	Month 4 ²
· ·		337012	-26 / Screening	0.938	Yes – Iritis	Month 5 ³
		351004	344./ Month 12	2.190	No	
		352006	-10 / Screening	2.070	No	
			180 / Month 6	1.890	No	
			362 / Month 12	1.860	No	
		403003	-1 / Screening	0.910	No	
	Ranibizumab	306020	174 / Month 6	1.530		Months 1 and
	0.5mg		362 / Month 12	1.850	Yes – Vitritis	2
	_	337009	364 / Month 12	1.270	No	
		342007	174 / Month 6	2.450	Yes – Iritis, Vitritis	Month 11 ⁴
			360 / Month 12	3.060		
· ·		346001	182 / Month 6	1.260	No	
			361 / Month 12	1.770		
		389001	-28 / Screening	1.240		
			182 / Month 6	0.993	Yes – Uveitis	Month 7
			365 / Month 12	0.952		
FVF2598g	Sham	102008	183 / Month 6	1.230	No	
			358 / Month 12	2.090		

			Sho Die Ville		Auto Sala	Study Visit of
	Treatment	Subsaar	na o Prantzana finnostra otivity		t intraocular: -	Intraocular Inflammation
Study	Group	D		NS WE DON THERE	Diagnosis	Diagnosis
Journal	Group	17 August State Aug	463 / Early term.	2.060	drifte (here, here, here, all and a dispersion in the second second second second second second second second s	
		116002	723 / Month 24	2.560	No	
		139004	-28 / Screening	2.100	Yes – Iritis	Day 7
			176 / Month 6	2.060		
			358 / Month 12	2.170		
			729 / Month 24	2.340		
		150005	181 / Month 6	0.864	No	
			393 / Month 12	0.863		
		182003	355 / Month 12	0.903	No	
	Ranibizumab				No CRF	
	0.3mg	101021	361 / Month 12	1.850	found	
			719 / Month 24	1.810		
		110004	728 / Month 24	1.490	No	
		112002	716 / Month 24	0.866	No	
		125007	183 / Month 6	0.918	No	
		141009	721 / Month 24	1.270	No	
		143001	-13 / Screening	3.550	Iritis	Month 2
		110001	177 / Month 6	3.740	N	
		146001	714 / Month 24	1.080	No	Month 15 ⁶
,		149006	364 / Month 12 717 / Month 24	3.150 2.120	Iritis	Month 15
		159013	360 / Month 12	2.000	No	
		139013	724 / Month 24	1.890	110	
		165002	-21 / Screening	0.910	No	
		105002	175 / Month 6	0.993		· · · ·
·			368 / Month 24	0.793		· · · · · ·
		170010	365 / Month 12	2.770	No CRF found	
		110010	715 / Month 24	2.800		
		177006	358 / Month 12	1.870	Iritis	Day 7
			717 / Month 24	1.850		
	Ranibizumab	102001	722 / Month 24	0.922	No	
	0.5 mg	104002	719 / Month 24	1.140	No	
		106002	722 / Month 24	1.130	No	
		122002	359 / Month 12	1.630	No	
			723 / Month 24	1.770		
		124003	722 / Month 24	0.782	No	
		126001	174 / Month 6	1.700	No	
			357 / Month 12	2.040	-	
			727 / Month 24	1.480		
		141008	181 / Month 6	1.570	No	
			362 / Month 12	1.940		
		A REAL PROPERTY AND A REAL	726 / Month 24	2.340		

Study	Treatment Group	Subjest.	time - the total	tallininoreactivity Avsay Log filter	Influenmation.	
		141013	715 / Month 24	2.610	Vitritis	Day 0
		143010	722 / Month 24	2.440	No	
		152004	522 / Early Term.	0.752	No	
		153006	183 / Month 6	1.900	No	
			365 / Month 12	1.530		
			718 / Month 24	2.070		
		159017	716 / Month 24	0.780	No	
					No CRF	
		167002	717 / Mont 24	1.230	found	
		188005	717 / Month 24	1.250	No	
FVF3192g	Sham	534001	-7 / Screening	2.520	Vitritis	Month 1
	Ranibizumab	507018	357 / Month 12	0.875	No	
	0.5 mg	522002	367 / Month 12	1.530	No	

1 In Study FVF2428g, intravitreal injections (sham or ranibizumab 0.5 mg) were given every month and verteporfin PDT every 3 months.

2 Iritis diagnosed 1 day after Month 4 injection.

3 Iritis diagnosed day of injection. Injection was not held.

4 No resolution of uveitis noted in CRFs submitted.

5 Uveitis diagnosed 3 days post Month 7 injection. Serious AE led to treatment discontinuation in Month 9.

6 Treatment discontinued.

The Immunoreactivity Assay still requires refinement (see Product Quality Review). Based on this assay, Titers above 3 were associated with Intraocular Inflammation in 100% of cases.

Thromboembolic Events

Serious Adverse Events Potentially Related to Systemic VEGF Inhibition during the First Treatment Year: Studies FVF2598g and FVF2587g

	Sindy EVF25982						
Type of Adverse Event	N=236	0) along $\hat{X} = \{\hat{y}\}$		nin Poli Nei P	0.85 mg N=1317	0.5 mg N=140	
TOTAL ^a	2 (0.8%)	8 (3.4%)	9 (3.8%)	3 (2.1%)	4 (2.9%)	8 (5.7%)	
Hypertension events	0	1 (0.4%)	0	0	0	0	
Arterial thromboembolic events	2 (0.8%)	5 (2.1%)	8 (3.3%)	2 (1.4%)	2 (1.4%)	4 (2.9%)	
Non-ocular hemorrhages	0	1 (0.4%)	0	0	2 (1.5%)	3 (2.1%)	
Other potentially associated events	· 0	1 (0.4%)	1 (0.4%)	1 (0.7%)	1 (0.7%)	1 (0.7%)	

Note: Multiple occurrences of the same type of event for a subject were counted once in the overall incidence.

Page 24 of 41

Draft Deputy Division Director Memorandum Wiley A. Chambers BLA 125156 Lucentis (ranibizumab injection)

I concur with the Medical Officer's assessment that there is a trend in the occurrence of serious adverse events potentially related to systemic VEGF inhibition noted at Month 12, but not at 24 months, particularly in the ranibizumab 0.5-mg dose group. This includes trends in serious arterial thromboembolic events and, to a lesser extent, in serious non-ocular hemorrhages (but not in serious hypertension or proteinuria).

The sponsor applied the Antiplatelet Trialists' Collaboration (APTC) classification (Antiplatelet Trialists' Collaborations 1994) to the adverse events which mitigates some of these issues by focusing on a more restricted but well-defined spectrum of serious adverse events: vascular deaths (including deaths of unknown cause), nonfatal myocardial infarction, nonfatal ischemic stroke, and nonfatal hemorrhagic stroke.

APTC Arterial Thromboembolic Events during the First Treatment Year: Studies FVF2598g and FVF2587g

Type of Adverse Event	Study FVF 2598g Sham Sham			Study FVF25872 Vertepo RambJaniab ctin 0.34ng 1055 ng PDT N=143			Pooled Ranibiz umab 0.5 mg N=379
TOTAL ^a	2 (0.8%)	3 (1.3%)	5 (2.1%)	3 (2.1%)	3 (2.2%)	6 (4.3%)	11 (2.9%)
Vascular deaths	0	1 (0.4%)	1 (0.4%)	1 (0.7%)	1 (0.7%)	2 (1.4%)	3 (0.8%)
Nonfatal myocardial infarction	1 (0.4%)	1 (0.4%)	1 (0.4%)	1 (0.7%)	1 (0.7%)	3 (2.1%)	4 (1.1%)
Nonfatal ischemic stroke	1 (0.4%)	1 (0.4%)	3 (1.3%)	1 (0.7%)	1 (0.7%)	1 (0.7%)	4 (1.1%)
Nonfatal hemorrhagic stroke	0	0	0	0	0	0	0

Note: Arterial thromboembolic events, defined according to the Antiplatelet Trialists' Collaboration classification (1994), are presented.

When applying the APTC classification to the serious adverse events, there is an overall trend in the ranibizumab 0.5-mg dose group compared to subjects in other treatment groups, but this is only a trend, the numbers are small and it does not hold up for the 24 month data.

Human Carcinogenicity

No studies have been conducted.

Special Safety Studies

Safety analysis was based on an evaluation of other safety parameters, as well, which included visual acuity (best corrected), intraocular pressure, ocular signs by slit lamp examination and indirect ophthalmoscopy the results of which are included throughout the safety review.

Withdrawal Phenomena and/or Abuse Potential

Not applicable. This is not a therapeutic class with known abuse potential or apparent withdrawal potential.

Human Reproduction and Pregnancy Data

There are no adequate and well-controlled studies in pregnant women. There was no inadvertent exposure to the product in pregnant women during the development program.

Assessment of Effect on Growth

The intended population for this product is adults with age-related macular degeneration, a disease that does not exist in the pediatric age group. This application contains no pediatric data.

Overdose Experience

This product has minimal overdose potential and no studies were performed. Planned initial single doses of ranibizumab injection 1.0 mg were associated with clinically significant intraocular inflammation in 2 of 2 patients injected. With an escalating regimen of doses beginning with initial doses of ranibizumab injection 0.3 mg, doses as high as 2.0 mg were tolerated in 15 of 20 patients.

Postmarketing Experience

This product has not yet been marketed.

ADDITIONAL CLINICAL ISSUES

Dosing Regimen and Administration

The sponsor has performed adequate dose ranging studies during the drug development program. Lucentis (ranibizumab) 0.5 mg dose has been demonstrated to be safe and effective in two Phase 3 clinical trials. The dosing interval in the two pivotal Phase 3 trials was once monthly resulting in the improvement and maintenance of visual acuity and function, and for the reduction of vascular leakage and retinal edema, in patients with neovascular (wet) age-related macular degeneration.

Drug-Drug Interactions

No important drug-drug interactions have been identified.

Special Populations

The sponsor has adequately evaluated gender effects on both the safety and efficacy outcomes. Subgroup analyses did not reveal any differences in the primary efficacy endpoint between males

and females. The safety profiles seen in males and females, including the types and rates of adverse events, are similar.

Trials for this indication were conducted in a population that was overwhelmingly elderly and Caucasian. This is reflective of the population in which age-related macular degeneration occurs and does not reflect a problem with study enrollment.

Pediatrics

The applicant requested a waiver of the pediatric study requirements for the original Biologics License Application. The waiver was requested because the disease under study age-related macular degeneration does not occur in the pediatric age group.

Advisory Committee Meeting

Not applicable. No Advisory Committee Meeting will be held regarding this application.

Literature Review

The medical reviewer conducted a PubMed electronic literature search to supplement the submitted review of the relevant literature. There was no significant new information found in the published literature.

Postmarketing Risk Management Plan

No postmarketing risk management plan has been submitted.

Other Relevant Materials

Comments received from DDMAC and the Office of Drug Safety have been incorporated in the labeling review as appropriate.

<u>|</u>⁴ Page(s) Withheld

§ 552(b)(4) Trade Secret / Confidential
§ 552(b)(4) Draft Labeling
§ 552(b)(5) Deliberative Process

Withheld Track Number: Medical-

Page 41 of 41

Draft Deputy Division Director Memorandum Wiley A. Chambers BLA 125156 Lucentis (ranibizumab injection)

OVERALL ASSESSMENT

Conclusions

The submitted studies in BLA 125156 are sufficient to establish efficacy for the use of ranibizumab 0.5 mg injection in the treatment of the neovascular age-related macular degeneration. The phase 3 studies demonstrate replicative results in the ability of ranibizumab to stabilize and prevent vision loss in patients with neovascular macular degeneration when give intravitreally every month when compared to sham and verteporfin PDT treatment. A clinically significant effective is still present if Lucentis is administered once every three months after the first four doses.

Recommendation on Regulatory Action

BLA 125156 is recommended for approval from a clinical perspective for C

> patients with neovascular (wet) age-related macular degeneration.

Recommendation on Postmarketing Actions

Risk Management Activity

Not applicable. No postmarketing risk management activity is recommended at this time.

Required Phase 4 Commitments

Wiley A. Chambers, MD

Wiley A. Chambers, MD Deputy Division Director Division of Anti-Infective and Ophthalmology Products

cc: Rhea Lloyd A William Boyd Janice Soreth Mark Goldberger

Clinical Team Leader Labeling Review (Medical Officer's Review #2)

Application Type Submission Number

Primary Reviewer Clinical Team Leader

Letter Date Stamp Date

Date of Labeling Submission Date of Labeling Review

Established Name Trademark

Therapeutic Class

Applicant

BLA 125156

Rhea Lloyd, M.D. William M. Boyd, M.D.

December 29, 2005 December 30, 2005

June 13, 2006 June 13, 2006

Ranibizumab injection Lucentis

Vascular endothelial growth factor (VEGF) inhibitor

Genentech, Inc. 1 DNA Way South San Francisco, CA 94080 650-225-1558

Submitted

Submitted is revised labeling based on previous review, discussion between the applicant and the Deputy Division Director on June 12, 2006, and input from the Study Endpoints and Label Development (SEALD) Team.

In this submission, the applicant has accepted all requested changes to the package insert.

$_{\bigcirc}$ Page(s) Withheld

§ 552(b)(4) Trade Secret / Confidential
 § 552(b)(4) Draft Labeling
 § 552(b)(5) Deliberative Process

Withheld Track Number: Medical-

Recommendations

It is recommended that BLA 125156 be approved with the labeling revisions listed in this review.

The application supports the safety and effectiveness of Lucentis (ranibizumab injection) for the treatment of $\sub - \Im$ neovascular $\boxdot - \sqsupset$ age related macular degeneration

William M. Boyd, M.D. Clinical Team Leader

MAC 6/28/06

CLINICAL REVIEW

Application Type BLA Submission Number 125156 Submission Code Original

156 ginal

Letter Date Stamp Date PDUFA Goal Date December 29, 2005 December 30, 2005 June 30, 2006

Reviewer Name Review Completion Date Rhea A. Lloyd, MD June 21, 2006

Established Name (Proposed) Trade Name Therapeutic Class

Ranibizumab injection Lucentis Vascular endothelial growth factor (VEGF) inhibitor

Applicant

Genentech, Inc. 1 DNA Way South San Francisco, CA 94080 650-225-1558

Priority Designation 1P

Proposed Dosing Regimen

Lucentis is to be administered as an intravitreal injection 0.5 mg (0.05 mL) once a month or once every three months after the initial — monthly injections.

Proposed Indication

Ľ

Intended Population

Adults with neovascular (wet) age-related macular degeneration

Formulation

Amount -	<u>xinn</u> Xinnnin yer Tinni Arri	Function	Reference to Standard or Specification
··· · · · ·	-	Active ingredient	
		-	Ph. Eur.
		_	
			USP and Ph. Eur.
	``	١	NF and Ph. Eur.
			USP and Ph. Eur.
	Amount I	Shepath Amount Manager Amount - Angung Manager C	Active ingredient

^a Target fill volume of — . per vial.

Best Available Copy

2

APOTEX V. REGENERON IPR2022-01524 REGENERON EXHIBIT 2024 PAGE 037

. .

TABLE OF CONTENTS

C	CLINICAL REVIEW	
1	EXECUTIVE SUMMARY	
	1.1 RECOMMENDATION ON REGULATORY ACTION 1.2 RECOMMENDATION ON POSTMARKETING ACTIONS 1.2.1 Risk Management Activity 1.2.2 Required Phase 4 Commitments 1.2.3 Other Phase 4 Requests 1.3 SUMMARY OF CLINICAL FINDINGS 1.3.1 Brief Overview of Clinical Program 1.3.2 Efficacy 1.3.3 Safety 1.3.4 Dosing Regimen and Administration 1.3.5 Drug Interactions 1.3.6 Special Populations	
2	2 INTRODUCTION AND BACKGROUND	10
	 2.1 PRODUCT INFORMATION	
3		
4	 3.1 CMC (AND PRODUCT MICROBIOLOGY, IF APPLICABLE)	
	 4.1 SOURCES OF CLINICAL DATA 4.2 TABLES OF CLINICAL STUDIES 4.3 REVIEW STRATEGY 4.4 DATA QUALITY AND INTEGRITY. 4.5 COMPLIANCE WITH GOOD CLINICAL PRACTICES 4.6 FINANCIAL DISCLOSURES 	13 14 18 18 18 18
5		10
	5.1 PHARMACOKINETICS 5.2 PHARMACODYNAMICS 5.3 EXPOSURE-RESPONSE RELATIONSHIPS INTEGRATED REVIEW OF FREICACY	
Ĵ	6.1 INDICATION	
	6.1.1 Methods 6.1.2 General Discussion of Endpoints 6.1.3 Study Design 6.1.4 Efficacy Findings 6.1.5 Clinical Microbiology 6.1.6 Efficacy Conclusions	21 21 21 21 75 97
7	INTEGRATED REVIEW OF SAFETY	

ţ

Original BLA Rhea A. Lloyd, MD 125156

	5150			
		nibizumab injection)	<u> </u>	_
		METHODS AND FINDINGS	9	8
	7.1.1	Deaths	10	0
	7.1.2	Other Serious Adverse Events	10	1
	7.1.3	Dropouts and Other Significant Adverse Events	10	5
	7.1.4	Other Search Strategies	11	2
	7.1.5	Common Adverse Events		
	7.1.6	Less Common Adverse Events		
	7.1.7	Laboratory Findings	11	8
	7.1.8	Vital Signs		9
	7.1.9	Electrocardiograms (ECGs)	119	9
	7.1.10	Y	120	0
	7.1.11		12	5
	7.1.12	Special Safety Studies	12	5
	7.1.12		12	5
	7.1.13		12	5
			12	5
	7.1.15			
	7.1.16		. 12	5
	7.1.17	ADEQUACY OF PATIENT EXPOSURE AND SAFETY ASSESSMENTS	12	5
		ADEQUACY OF PATIENT EXPOSURE AND SAFETY ASSESSMENTS	12. [Jood to	2
	7.2.1	Description of Primary Clinical Data Sources (Populations Exposed and Extent of Exposure)		ر د
		ate Safety	12	5
	7.2.2	Description of Secondary Clinical Data Sources Used to Evaluate Safety	12	ð
	7.2.3	Adequacy of Overall Clinical Experience	12	8
	7.2.4	Adequacy of Special Animal and/or In Vitro Testing		
	7.2.5	Adequacy of Routine Clinical Testing	12	8
	7.2.6	Adequacy of Metabolic, Clearance, and Interaction Workup	12	8
	7.2.7	Adequacy of Evaluation for Potential Adverse Events for Any New Drug and Particularly for	Drugs	
	in the	Class Represented by the New Drug; Recommendations for Further Study	12	9
	7.2.8	Assessment of Quality and Completeness of Data	13	0
	7.2.9	Additional Submissions, Including Safety Update	13	0
	7.3	SUMMARY OF SELECTED DRUG-RELATED ADVERSE EVENTS, IMPORTANT LIMITATIONS OF DATA,	AND	
	CONCLU	SIONS	14	0
	7.4	GENERAL METHODOLOGY	14	0
	7.4.1	Pooling Data Across Studies to Estimate and Compare Incidence	14	0
	7.4.2	Explorations for Predictive Factors	14	3
	7.4.3	Causality Determination	14	3
8	ADD	ITIONAL CLINICAL ISSUES	14	3
		DOSING REGIMEN AND ADMINISTRATION	14	z
	8.1	DOSING REGIMEN AND ADMINISTRATION	14	2
		DRUG-DRUG INTERACTIONS	14	2
	8.3	SPECIAL POPULATIONS		
	8.4	PEDIATRICS		
	8.5	ADVISORY COMMITTEE MEETING		
	8.6	LITERATURE REVIEW	14	4
	8:7	POSTMARKETING RISK MANAGEMENT PLAN		
	8.8	OTHER RELEVANT MATERIALS	14	4
9	OUT	RALL ASSESSMENT	14	4
9				
	9.1	CONCLUSIONS	14	4
	9.2	RECOMMENDATION ON REGULATORY ACTION		
	9.3	RECOMMENDATION ON POSTMARKETING ACTIONS	14	4
	9.3.1	Risk Management Activity	14	4
	9.3.2	Required Phase 4 Commitments	14	4
	9.3.3	Other Phase 4 Requests	14	5
		LABELING REVIEW	14	5
	2.7			

5

APOTEX V. REGENERON IPR2022-01524 REGENERON EXHIBIT 2024 PAGE 040

÷.

1 EXECUTIVE SUMMARY

1.1 Recommendation on Regulatory Action

From a clinical perspective, Lucentis (ranibizumab injection) with the labeling changes listed in this review is recommended for approval for the treatment of patients with neovascular (wet) age-related macular degeneration

The applicant, Genentech, conducted two adequate and well-controlled Phase 3 studies, FVF2598g and FVF2587g which demonstrate statistical and clinical significance on the primary efficacy endpoint (i.e., the proportion of subjects who lose fewer than 15 letters in best corrected vision at 12 months compared with baseline).

1.2 Recommendation on Postmarketing Actions

1.2.1 Risk Management Activity No post marketing risk management activity is necessary.

1.2.2 Required Phase 4 Commitments

1. Develop and validate assays to detect and characterize immune responses to ranibizumab:

A. Develop and validate a confirmatory assay capable of detecting both IgG and IgM isotype responses.

B. Develop and validate an assay to detect neutralizing anti-ranibizumab antibodies.

The assay methodology and validation reports will be provided by September 28, 2007.

2. To characterize further the immune response to ranibizumab, serum samples collected in studies FVF2587g, FVF2598g, FVF3192g will be assayed using the validated methods described above in Postmarketing Commitment — The data obtained will be analyzed to discover and evaluate any association between immunoreactivity and dosing frequency as well as any potential impact of immunoreactivity on efficacy or safety outcomes.

Date of submission of protocol and statistical analysis plan: February 28, 2007

Date of submission of final study report: September -, 2008

The need for an additional clinical study will be determined based on the results from the analysis described above.

1.2.3 Other Phase 4 Requests There are no other Phase 4 requests.

1.3 Summary of Clinical Findings

1.3.1 Brief Overview of Clini	cal Program
Established Name	ranibizumab in
(Proposed) Trade Name	Lucentis 0.5 m
Therapeutic Class	vascular endot
Route of Administration	intravitreal inje

ranibizumab injection Lucentis 0.5 mg vascular endothelial growth factor (VEGF) inhibitor intravitreal injection

Age-related macular degeneration (AMD) is a common cause of severe and irreversible vision loss in older adults. AMD is clinically manifest in two distinct forms: the non-exudative (dry) or the exudative (wet) form of the disease. Though the exudative (wet) form represents approximately 10% of AMD cases, it is responsible for 80-90 % of the vision loss due the vascular leakage associated with the characteristic choroidal neovascularization. An estimated 150,000 new cases of neovascular AMD are diagnosed each year in the United States. As the median age of the population increases, it is likely that ophthalmologists will encounter increasing numbers of patients with AMD.

The etiology of the disease is such that new abnormal blood vessels proliferate from the choriocapillaris through defects in the Bruch's membrane under the retinal pigment epithelium (RPE), forming neovascular membranes. These new vessels leak serous fluid and may give rise to serous and hemorrhagic detachment of the RPE and neurosensory retina and may stimulate fibrous disciform scarring, with subsequent loss of central vision.

Neovascular AMD is characterized by CNV in the macular region. Vascular endothelial growth factor-A (VEGF-A) has been observed in surgically excised human fibrovascular lesions. VEGF-A is alternatively spliced and post-translationally cleaved to generate multiple active forms, of which at least two have been observed in excised human CNV lesions. An increase in VEGF-A expression has been noted in experimental models of CNV in rodents. In addition, transgenic mice with increased VEGF-A expression in photoreceptors or retina pigment epithelium developed neovascularization reminiscent of CNV seen in humans with neovascular AMD. These results suggest that active forms of VEGF-A are reasonable targets for therapeutic intervention in neovascular AMD.

Ranibizumab is a recombinant humanized antibody Fab fragment that neutralizes VEGF as a therapeutic intervention in neovascular AMD.

1.3.2 Efficacy

Study FVF2598g and Study FVF2587g, were designed to demonstrate the safety and efficacy of Lucentis (ranibizumab injection) in the treatment of neovascular AMD. Both study designs were prospective, multicenter, randomized, double-masked, parallel group. Study FVF2598g had an inactive control and Study FVF2587g had an approved therapy as a control.

Study FVF2598g met its primary endpoint and all of the secondary endpoints for the first treatment year. The primary endpoint was met with nearly 95% of ranibizumab-treated subjects maintaining or improving vision at 12 months, compared with 62% of sham-treated subjects (p < 0.0001 for each of the ranibizumab groups vs. the sham-injection group). Visual acuity results assessed at a starting test distance of 2 meters were 1-2 letters better than those assessed at a starting test distance of 4 meters. The robustness of the primary endpoint and key secondary

endpoint results was demonstrated by the consistent results from sensitivity analyses. The treatment benefit of ranibizumab on visual acuity was also consistent across the subgroups evaluated.

Study FVF2587g met its primary efficacy objective for the first treatment year. The primary efficacy objective was met with approximately 94% of subjects treated with 0.3 mg ranibizumab and 96% of subjects treated with 0.5 mg ranibizumab maintaining or improving vision at Month 12, compared with approximately 64% of verteporfin PDT-treated subjects ($p \le 0.0001$ for superiority for each of the ranibizumab groups vs. the verteporfin PDT group). The 1-year results demonstrated a beneficial effect of ranibizumab on visual acuity. Visual acuity results based on assessment at a starting test distance of 4 meters were 1-2 letters better than those based on assessment at a starting test distance of 2 meters. The robustness of the results of the primary efficacy endpoint was demonstrated by the consistent results from sensitivity analyses. The treatment benefit of ranibizumab on visual acuity was also consistent across the subgroups evaluated.

1.3.3 Safety

The population studied was predominantly elderly and white which is representative of the population usually affected by age-related macular degeneration. The demographics of the patient population do not reflect problems with recruitment.

Based on the population studied, there does not appear to be any difference in Lucentis' effect based on age, race, ethnicity or iris color.

The most common adverse events identified are conjunctival hemorrhage, eye pain, increased intraocular pressure, retinal disorder and vitreous floaters. These adverse events are often associated with intravitreal injections.

1.3.4 Dosing Regimen and Administration

The sponsor has performed some dose ranging and dose frequency studies of Lucentis (ranibizumab injection). Lucentis (ranibizumab injection) has been proven safe and effective when administered as an intravitreal injection 0.5 mg/0.05 mL once monthly. This dosing regimen achieved and sustained a statistically significant difference in the proportion of patients who lost 15 letters of vision compared to baseline relative to the control group.

The sponsor also-performed a Phase 3 trial, Study FVF3192g in which Lucentis (ranibizumab injection) was administered as an intravitreal injection 0.5 mg/0.05 mL once monthly for 3 months and then every three months. The 12-month results show that Lucentis achieved statistical significance in the primary efficacy endpoint. Study FVF3192g is reviewed in more detail in another review.

1.3.5 Drug-Drug Interactions

In Study FVF2587g, Lucentis (ranibizumab injection) was dosed with (separated by 1 week) verteporfin PDT. No drug-drug interaction analyses were performed.

1.3.6 Special Populations

There were no statistically significant differences in demographic data, diagnoses, or baseline lesion characteristics between treatment groups within each study.

.8

Subgroup analyses did not reveal any differences in the primary efficacy endpoint with respect to age, sex, baseline visual acuity, CNV lesion type, lesion size, or prior laser photocoagulation. The safety profile was also similar in each of these groups.

The population studied for this indication was predominantly elderly and white, reflective of the population most affected by this disease. The number of patients outside of this demographic group was too small to draw any definitive conclusion regarding the safety and efficacy. There do not appear to have been any race or ethnicity effects.

No pediatric trials were conducted for this drug. Age-related macular degeneration is a disease seen only in adults.

The demographics of the patients enrolled in the trial during the development program for this product are representative of the targeted population. There is no additional data need from other populations.

Appears This Way On Original

2 INTRODUCTION AND BACKGROUND

2.1 Product Information

Established Name
(Proposed) Trade Name
Therapeutic Classranibizumab injection
Lucentis 0.5 mgRoute of Administration
Chemical ClassLucentis 0.5 mgRoute of Administration
Chemical ClassIntravitreal injection
New molecular entity

Proposed Indication

→ adults with neovascular (wet) age-related macular degeneration

Formulation


Ingredients	Strength Amount Tofng/mLw1ab	Function	Reference to Standard or Specification
Ranibizumab		Active ingredient	
α , α -trehalose dehydrate	15	٦.	
histidine HCl		l	Ph. Eur.
C~ 2			USP and Ph. Eur.
Polysorbate 20	Ι.		NF and Ph. Eur.
Water for Injection			USP and Ph. Eur.

Target fill volume of vial.

The release and shelf-life specifications for the Certificate of Analysis (C of A) testing of Lucentis Product are presented above. Shelf-life criteria for tests that are part of the stability program are only listed where they differ from the release criteria. Otherwise, the shelf-life criteria are identical to the release criteria. All release and shelf-life testing for the Lucentis Product is performed at Novartis Pharma Stein AG.

Genentech intends to use a life-cycle approach for setting ranibizumab specifications. This lifecycle approach will use interim acceptance criteria based upon the limited data available at the time of submission. Since campaign-to-campaign variation can be larger than the variation within a campaign, Genentech proposes a post-approval commitment for re-evaluating the interim acceptance criteria after three commercial post-approval campaigns (consisting of a minimum of —additional lots). The re-evaluation is expected to take place within two years after approval, but will ultimately depend on the currently unknown manufacturing schedule for ranibizumab Drug Substance.

T



Lucentis Drug Product Release and Shelf-Life Specifications.

Lucentis (ranibizumab injection) is a new molecular entity and is not currently marketed in the United States nor has it been marketed or withdrawn from the market in any other country.

2.2 Currently Available Treatment for Indications

There are currently two approved drug products for the treatment of age related macular degeneration – Visudyne (verteporfin for injection) and Macugen (pegaptanib sodium injection).

Visudyne was approved under NDA 21-119 on April 12, 2000, for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration.

Macugen was approved under NDA 21-756 on December 17, 2004, for the treatment of neovascular (wet) age-related macular degeneration.

2.3 Availability of Proposed Active Ingredient in the United States

Ranibizumab is a new molecular entity and has not been marketed in the United States.

2.4 Important Issues With Pharmacologically Related Products

There have been no additional safety concerns raised with pharmacologically related products other than those discussed within this review.

2.5 Presubmission Regulatory Activity

Ranibizumab was evaluated in six clinical studies in neovascular AMD: two Phase I studies (FVF2425g and FVF1770g), two Phase I/II studies (FVF2428g and FVF2128g), and two Phase 3 studies (FVF2598g and FVF2587g).

On October 6, 1999, Genentech submitted the Investigational New Drug application (IND) for ranibizumab. Study FVF1770g was the first clinical trial performed to evaluate the safety, tolerability, pharmacokinetics, and activity of a single-dose intravitreal injection of ranibizumab. Study FVF2128g was a dose escalation study evaluating the safety, tolerability, pharmacokinetics, and activity of multidose intravitreal injections of ranibizumab. Study FVF2425g evaluated the safety, tolerability and pharmacokinetics of escalating multiple-dose intravitreal injections of ranibizumab. Study FVF2428g evaluated the safety, tolerability and efficacy of multiple-dose intravitreal injections of ranibizumab in combination with verteporfin photodynamic therapy (PDT).

A Type C Meeting was held on February 2, 2002, in which Genentech received FDA guidance on the requirements for a clinical development program to support the licensure of ranibizumab. In addition, the Agency informed Genentech that reproductive/developmental toxicology studies for bevacizumab (the full-length antibody counterpart of ranibizumab) could be cross-referenced in the Ranibizumab Biologics License Application (BLA) in lieu of conducting separate reproductive/developmental toxicology studies with ranibizumab.

On October 31, 2002 an End-of-Phase 2 Meeting was held in which Genentech presented its plans for the Phase 3 clinical program in AMD. The sponsor incorporated many, but not all of FDA recommendations into the Phase 3 protocols, including the testing of two ranibizumab dose groups (0.3 mg and 0.5 mg) in addition to a control. The most notable differences included the use of 2 meter testing instead of 4 meter testing and the use of sham injections. The Agency agreed that the BLA could be filed and reviewed based on the 1-year safety and efficacy data from each Phase 3 study; though these studies would remain masked and controlled for 2 years.

Study FVF2598g was initiated March 19, 2003. Study FVF2587g was initiated May 20, 2003. On September 21, 2005, Genentech discussed with the FDA the clinical portions of the BLA at a pre-BLA teleconference. The majority of ranibizumab studies have been sponsored by

Genentech in the United States, with the exception of Study FVF2587g, which was co-sponsored by Novartis and included sites outside of the United States, and Studies CRFB002B2201 and CRFB002A1201, which are Novartis¹sponsored trials. See table in section 4.2 for a complete list of studies.

2.6 Other Relevant Background Information

There is no other relevant background information.

3 SIGNIFICANT FINDINGS FROM OTHER REVIEW DISCIPLINES

3.1 CMC (and Product Microbiology, if Applicable)

The application is approvable from a CMC perspective (see Product Review).

3.2 Animal Pharmacology/Toxicology

There were no significant findings in the pharmacology/toxicology reviews which would affect the clinical outcome.

4 DATA SOURCES, REVIEW STRATEGY, AND DATA INTEGRITY

4.1 Sources of Clinical Data

This review is based on the results of the applicant supported trials for AMD conducted under BBIND — Phase 3 safety and efficacy trials were submitted to support the indication currently being sought by the applicant. In addition, the results of four phase 1/2 dose ranging and safety trials were also submitted.

This NDA was submitted in electronic format as a hybrid CTD (i.e., CTD structure with PDF tables of contents), according to ICH and FDA guidelines for electronic submissions.

Lucentis (ranibizumab injection) Rhea A. Lloyd, MD Original BLA 125156

Tables of Clinical Studies

4.2

PIVOTAL PHASE 3 TRIALS predominantly Subjects with Subjects with neovascular minimally subfoveal subfoveal classic or classic AMD occult sham-controlled active treatment double-masked, double-sham,^a double-masked Randomized, (US, Europe, Randomized controlled Australia) (SN) m m Π Π

FVF2598g

J

Ongoing^b

0.5 mg (n=140),

injection q month,

Verteporfin

FVF2587g

11

Ú

Intravitreal

max. 24 injxns over 2 yrs, or

423

injection) (+sham PDT

sham injection

(n=143)

q3mos as needed verteporfin PDT

0.3 mg (n=140).

Agnibizumab.

Frequency and

Enrolled No. of

Population

Design (Sites)

Study

Munica

Treatment

Best Available Copy

Ongoing

0.5 mg (n=240),

injection q mo., max. 24 injxns


716

Sham injection

Intravitreal

0.3 mg (n=238)

sham injection



						E		
Study	Phase	Design (Sites)	Population	Control	No. of Enrolled Subjects	L reatment Frequency and Duration	Ranibizumab Dose(s)	Status
						17.20 and 23)	-	
FVF2S08g	Extension	Extension (US)	Subjects with neovascular AMD who completed a Genentech Phase 1/2 ranibizumab study	None	70	Intravitreal injections every 28 days (± 5 days) through October 2006 or until 30 days after product launch	0.5 mg (n=66)	Ongoing
FVF34268	Extension	Extension, open- label (US)	Subjects with subfoveal CNV secondary to AMD who completed a Genentech ranibizumab study	Ranibizumab naïve	Target 600	Intravitreal injections q 30 days for up to 24 months or until 30 days after product launch	0.5 mg (Target: 600 subjects)	Ongoing

The active ranibizumab groups also received sham PDT with saline infusions, and the verteporfin PDT group received sham intravitreal injections. Excludes 5 subjects in Study FVF2128g and 3 subjects in Study FVF2425g who were enrolled but discontinued from the study before Day 0. Standard of care as determined by the treating physician and/or investigator.

0.10 Q φ

Novartis sponsored study.

ė.

APOTEX V. REGENERON IPR2022-01524 REGENERON EXHIBIT 2024 PAGE 050

Rhea A. Lloyd, MD BLA Ö

Lucentis (ranibizumab injection) 125156

 Al BLA Rhea A. Lloyd, MD 125156 Lucentis (ranibizumab injection)) tab injection)			-				
Study	Phase	Design (Sites)	Population	Control	No. of Enrolled Subjects	Treatment Frequency and Duration	Ranibizumab Dose(s)	Status
	۲۰۰۰ ۱۳ ۱۳ ۱۳ میلومی ۱۳ میلومی		PHASE 1/2 D	PHASE 1 / 2 DOSE RANGING TRIALS	TRIALS		× -	
FVF2425g		Randomized, open-label, multiple-dose escalating regimens (US)	Subjects with neovascular AMD	None	296	Intravitreal injections at 2- or 4-week intervals, max. of 5, 7 or 9 total injections over 16 weeks	0.3 mg to 1.0 mg escalating regimen with 7 total injxns (n=9); 0.3 mg to 2.0 mg escalating regimen with 9 total injxns (n=10); 0.3 mg to 2.0 mg escalating regimen with 5 total injxns (n=10)	Completed
FVF2128g	1/2	Randomized, open-label, dose-escalation (US)	subjects with classic neovascular AMD	Usual care ^d	64°	Intravitreal injections q 4 weeks, maximum of 8 total injections over 28 weeks, or usual care with crossover to ranibizumab treatment after 14 weeks.	0.3 mg (n=25), 0.3 mg initial dose escalated to 0.5 mg for subsequent doses $9n=28$), usual care (n=11)	Completed
FVF1770g	-	Open-label, single-dose escalation (US)	Subjects with neovascular AMD	None	27	Single intravitreal injection	$\begin{array}{c} 0.05 \ \text{mg} \ (n=6), \\ 0.15 \ \text{mg} \ (n=6), \\ 0.30 \ \text{mg} \ (n=6), \\ 0.50 \ \text{mg} \ (n=7), \\ 1.0 \ \text{mg} \ (n=2) \end{array}$	Completed

16

APOTEX V. REGENERON IPR2022-01524 REGENERON EXHIBIT 2024 PAGE 051

Lucentis (ranibizumab injection)	nab injection							
Study	Phase	Design (Sites)	Population	Control	No. of Enrolled Subjects	Treatment Frequency and Duration	Ranibizumab Dose(s)	Status
FVF2428g		Randomized, single-masked, sham-controlled, combination treatment (US)	Subjects with predominantly classic neovascular AMD	Verteporfin PDT (+sham injection)	162	Intravitreal injection qmonth, max. 24 injxns over 2 years, in combination with verteporfin PDT q3mos, as needed	0.5 mg (n=106), sham injection (n=56)	Ongoing ^b
			NOVARTIS	NOVARTIS SPONSORED TRIALS	RIALS			
CRFB002A1201*	1/2	Open-label (Japan)	Subjects with subfoveal CNV secondary to AMD	None	Target 84	Intravitreal injections every month	0.3 mg 0.5 mg (Target: 42 subjects per group)	Ongoing
CRFB003B2201*	7	Open-label (Europe)	Subjects with occult or predominantly classic subfoveal CNV secondary to AMD	V erteporfin PDT	32	Intravitreal injections every month in combination with verteporfin PDT	0.5 mg (n≖30)	Ongoing
					: 		-	

17

O. BLA Rhea A. Lloyd, MD 125156

.

-6.-

4.3 Review Strategy

This review evaluates the results of two Phase 3 trials submitted by the applicant. Each individual study was evaluated in depth to determine if the data supported the primary efficacy endpoint. The integrated safety and efficacy database was finally evaluated to determine the overall risk/benefit profile for this drug product.

The submitted clinical study reports, clinical protocols and literature reports related to trials FVF2598g and FVF2587g were reviewed. The application is in electronic format as a hybrid CTD (i.e., CTD structure with PDF tables of contents), according to ICH and FDA guidelines for electronic submissions.

4.4 Data Quality and Integrity

There is no evidence that Phase 3 studies reviewed in this BLA were not conducted in accordance with acceptable clinical ethical standards.

There were no new Division of Scientific Investigations (DSI) audits completed by the time of this review. The case report forms for the three studies were provided by Genentech, and these were reviewed for completeness and quality.

Several investigators who participated in Study FVF2598g and FVF2587g were inspected by DSI within the past 24 months. (Was inspected in August 2004 and given a final classification of VAI.) (Was inspected in March 2005 and given a final classification of NAI.)

4.5 Compliance with Good Clinical Practices

The studies were conducted in accordance with the International Conference of Harmonization E6 Guidelines for Good Clinical Practice (GCPs), the Declaration of Helsinki and in compliance with relevant local and national regulations for informed consent and protection of subject rights in the country of conduct.

Before initiation of the study, the original protocol, all protocol amendments, the informed consent documents and all supportive information were reviewed and approved by the appropriate ethics committees (EC) or institutional review boards (IRB) for each of the centers involved in the study. The studies began only after receiving written approval from each EC/IRB.

4.6 Financial Disclosures

The applicant has adequately disclosed financial arrangements with clinical investigators as recommended in the FDA guidance for industry on *Financial Disclosure by Clinical Investigators*.

There is no evidence suggesting problems with the integrity of the submitted data.

5 CLINICAL PHARMACOLOGY

Pharmacokinetic and pharmacodynamic data for ranibizumab are available from six clinical studies, in which ranibizumab was administered either as a single agent or in combination with verteporfin PDT to subjects with neovascular AMD.

5.1 Pharmacokinetics

Ranibizumab is administered intravitreally for the treatment of neovascular AMD and subsequently absorbed into the systemic circulation. Attempts were made to measure systemic pharmacokinetics from serum samples. Elimination of ranibizumab from systemic circulation is believed to be absorption rate limited based on nonclinical pharmacokinetic data. In the noncompartmental pharmacokinetic analysis of serum concentration data from 10 subjects in the Phase I study FVF1770g, ranibizumab serum concentration versus time profiles were observed to decline monoexponentially and ranibizumab area under the concentration-time curve (AUC) increased in a dose-proportional manner, which suggested linear pharmacokinetics over the dose range studied. Results from these 10 subjects also indicated that ranibizumab serum concentrations following a single intravitreal ranibizumab dose of 0.3–1.0 mg/eye were lower than the concentration range of ranibizumab expected to reduce VEGF-induced endothelial cell proliferation by 50% (IC50); 0.23–0.56 nM, which is equivalent to 11–27 ng/mL, based on a molecular mass of 48 kDa for ranibizumab.

A population pharmacokinetic analysis (Study 05-1181) was conducted to summarize data obtained from five ranibizumab clinical studies: four studies in which ranibizumab was used as a single agent (Studies FVF1770g, FVF2128g, FVF2425g, and FVF2598g) and one study in which ranibizumab was administered to subjects concomitantly with verteporfin PDT (Study FVF2428g). This analysis included a total of 675 measurable ranibizumab samples from 228 subjects who received doses of ranibizumab, ranging from 0.05 to 2.0 mg/eye, either as a single dose or in a multiple-dose regimen at a frequency ranging from every 2 weeks to every month. In all studies, ranibizumab was administered intravitreally as a bolus to one study eye. Based on the final model, several covariates were correlated with population pharmacokinetic parameter estimates. Serum creatinine clearance (CrCL) was found to be the most significant covariate for apparent systemic clearance (CL/F) of ranibizumab. However, when compared with the large intersubject variability of CL/F, the effect of CrCL on CL/F was determined to have no clinical significance. Verteporfin PDT was found to decrease the elimination rate of ranibizumab from the eye. Although this finding is consistent with expected anatomical changes of a lesion following verteporfin PDT, it has no effect on ranibizumab systemic exposure. For a typical

subject, the CL/F was 23.8 L/day, the apparent volume of the central compartment was 2.97 L, and the elimination rate of ranibizumab was 0.0800 day -1. In summary, there is no covariate that affects the systemic exposure of ranibizumab with clinical significance.

5.2 Pharmacodynamics

In vitro, maximal inhibition of rhVEGF-induced proliferation of human umblical vein endothelial cells was observed at ranibizumab concentrations of approximately 1.29 nM (which is equivalent to 62 ng/mL assuming a molecular weight for ranibizumab of 48 kDa). The population pharmacokinetic model for predicted minimum vitreal ranibizumab concentration with a monthly dosing regimen of 0.3-mg ranibizumab is 12 μ g/mL (range, 2.3–41 μ g/mL) and above the concentrations necessary to inhibit VEGF activity.

In vivo, neovascular AMD may be associated with foveal retinal thickening as assessed by optical coherence tomography (OCT) and leakage from CNV as assessed by fluoresceinangiography.

Foveal retinal thickness was assessed using OCT in a subset of subjects in Study FVF2598g (46 of 716 subjects with a baseline evaluation) and Study FVF2587g (53 of 423 subjects with a baseline evaluation). In subjects treated with ranibizumab (pooled data from the 0.3-mg and 0.5-mg groups), on average, foveal retinal thickness decreased by Day 7 and continued to decrease through Month 12. On Day 7, the average change in Study FVF2598g was – 84 μ m for ranibizumab compared with – 23 μ m for the sham-injection control (p = 0.099). In Study FVF2587g, the average change was – 105 μ m for ranibizumab compared with – 26 μ m for verteporfin PDT (p = 0.008). At Month 12, the average change in Study FVF2598g was – 123 μ m for ranibizumab compared with – 15 μ m for sham-injection control (p = 0.009). In Study FVF2587g, the average change was – 190 μ m for ranibizumab compared with – 87 μ m for verteporfin PDT (p = 0.0004).

In subjects treated with monthly injections of ranibizumab in Studies FVF2598g and FVF2587g, the area of leakage from CNV as assessed by fluorescein angiography decreased, on average, by Month 3. In Study FVF2598g, the average change was approximately -1.0 disc areas (DA) for subjects in both the 0.3-mg and 0.5-mg ranibizumab groups versus +0.8 DA for those in the sham-injection control group (p < 0.0001). In Study FVF2587g, it was approximately -1.3 DA for subjects in both the 0.3-mg and 0.5-mg ranibizumab groups compared with +0.2 DA for subjects in the verteporfin PDT group (p < 0.0001). However, it is known that the area of leakage from CNV does not correlate with visual function.

5.3 Exposure-Response Relationships

The retina is the site of disease in neovascular AMD. Therefore, systemic ranibizumab concentrations after intravitreal administration are not expected to correlate with efficacy.

Ranibizumab systemic pharmacokinetics were characterized throughout the clinical program, including a population pharmacokinetic analysis.

6 INTEGRATED REVIEW OF EFFICACY

6.1 Indication

The proposed indication is

related macular degeneration.

In patients with neovascular (wet) age-

6.1.1 Methods

The submitted Phase 3 studies (FVF2598g and FVF2587g) were reviewed independently to determine if the results of each trial demonstrated efficacy for the primary efficacy endpoint. The primary efficacy endpoint for each trial was a responder analysis of the proportion of patients who lost fewer than 15 letters of visual acuity from baseline (doubling of the visual angle) at 54 weeks. This analysis was done for two populations which represent different ranges of data to evaluate the robustness of the results; an all randomized patient population with last-observation-carried-forward (LOCF) and the per protocol population with observed cases only.

6.1.2 General Discussion of Endpoints

Visual acuity is a well-established and validated measure of visual function that has been used for decades in ophthalmology research. The methods used in this study follow methods used in clinical trials of both diabetic macular edema and AMD.

Reviewer's Comment:

In choroidal neovascularization secondary to age-related macular degeneration, a recommended endpoint is a statistically significant difference between groups in the percentage of patients with a halving of the visual angle (15 letters or more on an Early Treatment Diabetic Retinopathy visual acuity chart measured at 4 meters).

6.1.3 Study Design

6.1.3.1 Study FVF2598g

Title:

A Phase 3, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) in Subjects with Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration.

Objectives: Primary:

- To evaluate the efficacy of intravitreal injections of ranibizumab (0.3 mg and 0.5mg) administered monthly in preventing vision loss, as measured by the proportion of subjects who lost fewer than 15 letters in visual acuity at 12 months compared with baseline
- To evaluate the safety and tolerability of intravitreal injections of ranibizumab administered monthly

Secondary:


- To evaluate the efficacy of monthly intravitreal injections of ranibizumab in preventing vision loss as measured by the following:
 - The mean change from baseline in visual acuity over time up to 12 months
 - The proportion of subjects who gained at least 15 letters in visual acuity at 12 months compared with baseline
 - The proportion of subjects with a visual acuity Snellen equivalent of 20/200 or worse at 12 months
- To investigate the efficacy of monthly intravitreal injections of ranibizumab on vision-related functioning and well being assessed during a period of 12 months, as measured by the National Eye Institute (NEI) Visual Function Questionnaire-25 (VFQ-25)
- To evaluate the efficacy of monthly intravitreal injections of ranibizumab on the size of CNV and amount of leakage from CNV at 12 months, as assessed by fluorescein angiography

Study Design: This is a prospective, multicenter (96 sites), randomized, doublemasked, sham injection-controlled trial of intravitreally administered ranibizumab.

Test Drug Schedule:

Eligible subjects were randomized in a 1:1:1 ratio to receive 0.5 mg ranibizumab, 0.3 mg ranibizumab or sham injection. Subjects received a ranibizumab or sham injection monthly $(30 \pm 7 \text{ days})$ for up to a maximum of 13 injections during the first treatment year (Day 0 to Month 12). The second treatment year of the study is ongoing. Subjects have continued to receive monthly ranibizumab or sham injections during the second treatment year with the last injection administered at Month 23. Subjects will have a final safety visit at Month 24.

Page(s) Withheld



Withheld Track Number: Medical-

APOTEX V. REGENERON IPR2022-01524 REGENERON EXHIBIT 2024 PAGE 058

Study Design

This was a Phase 3, multicenter, randomized, double-masked, sham injection–controlled study of intravitreally administered ranibizumab. Approximately 720 subjects with primary or recurrent subfoveal CNV secondary to AMD who have minimally classic or occult lesions were enrolled.

Consented subjects participated in a screening period lasting up to 28 days to determine eligibility. Fluorescein angiograms were sent to a central reading center to determine CNV classification for study eligibility. Eligible subjects were randomized in a 1:1:1 ratio to receive 0.5 mg of ranibizumab, 0.3 mg of ranibizumab, or a sham injection. Randomization was stratified by the visual acuity score at Day $0 (\leq 54$ letters [approximately worse than 20/80] vs. \geq 55 letters [approximately 20/80 or better] based on the ETDRS chart and assessment at a starting distance of 2 meters), by type of CNV (minimally classic CNV vs. occult CNV without classic component), and by study center. A dynamic randomization scheme was used to obtain approximately a 1:1:1 ratio among the treatment groups. Subjects received a ranibizumab or sham injection monthly for 23 months of treatment (24 injections). Only one eye was chosen as the "study eye." Only the study eye received intravitreal injections of ranibizumab or a sham injection.

After careful review of data, including 12-month data from this ongoing study, Genentech believed that it was in the best interest of subjects randomized to the sham-injection group to

cross over to receive ranibizumab. Specifically, subjects randomized to the sham-injection group who had not completed their Month 23 visit (last possible injection visit) would cross over to receive monthly injections of 0.5 mg ranibizumab for the remainder of the treatment period upon approval of the current protocol amendment (dated 9 September 2005) and Informed Consent Form by the site Institutional Review Board (IRB). Subjects who had discontinued the study and/or treatment were excluded from the crossover.

A minimum of two investigators per study site was required to fulfill the masking requirements of this study. At least one investigator was designated the evaluating physician, who was masked to the treatment assignment and conducted all ocular assessments. At least one other investigator was designated the injecting physician, who was unmasked to the treatment assignment and performed the ranibizumab/sham preparation, but was masked to study drug dose (0.3 mg vs. 0.5 mg of ranibizumab). Once the designated roles were determined, the roles could not be switched at any time during the conduct of the study. The injecting physicians (and designated unmasked assistants, if needed) were not permitted to be involved in the conduct of the study in any other manner and could not communicate with any other personnel or subjects regarding the treatment assignment.

Subjects had scheduled monthly visits throughout the study for the evaluation of safety and efficacy. Subjects had either the first injection of intravitreal ranibizumab or a sham injection by the injecting physician on Day 0 and underwent safety and eye assessments by the evaluating physician (e.g., indirect ophthalmoscopy and slit lamp examination) 7 days after the first injection. At subsequent visits (every month), the subject had a safety evaluation by the evaluating physician prior to study drug injection. The monthly visits were scheduled every 30 days relative to Day 0. Subjects were contacted by the site personnel 2 days after each injection to elicit reports of any decrease in vision, eye pain, unusual redness, or any other new ocular symptoms in the study eye. Subjects were also asked whether they had taken the prescribed self-administered post-injection antimicrobials. Subjects will have a final safety visit at Month 24.

Study Treatment

Ranibizumab was administered in a multiple-dose regimen of either 0.3 mg or 0.5 mg of ranibizumab every month (Day 0-Month 23) for a total of 24 injections. Sham injections were given monthly or until the subjects crossed over, and then 0.5 mg ranibizumab was to be administered monthly during the crossover period for the remainder of the treatment period. The cross over was to be implemented upon approval of the current protocol amendment and Informed Consent Form by the site's IRB. If verteporfin PDT had been given in the study eye within the last 28 days, then the ranibizumab/sham injection was held.

Study Population Inclusion Criteria

Subjects had to meet the following inclusion criteria to be eligible for study entry:

- 1. Age ≥ 50 years
- 2. Active primary or recurrent subfoveal CNV lesions secondary to AMD in the study eye, as defined in the following table.

	Table 6.1.3.1-2 - Definitions of Terms Pertaining to AMD Inclusion Criteria
Term	Definition
Active	Any of the following:
	1) Exhibiting $a \ge 10\%$ increase in lesion size, as determined by comparing a fluorescein
1	angiogram performed within 1 month preceding Day 0, inclusive, with a fluorescein
	angiogram performed within 6 months preceding Day 0, inclusive; or
	2) Resulting in a visual-acuity loss of ≥ 1 Snellen line (or equivalent) and occurring at
	any time within the prior 6 months; or
	3) Subretinal hemorrhage associated with CNV within 1 month preceding Day 0
Primary	Newly diagnosed and previously untreated
Recurrent	Previously diagnosed and regressed but currently presenting with a new, active component
Subfoveal	Including the center of the fovea within the boundaries of the CNV
CNV lesion	A contiguous area of abnormal tissue in the macula that encompasses angiographically documented CNV with possible additional components of subretinal hemorrhage, blocked fluorescence not from hemorrhage, serous detachment of the retinal pigment epithelium, and fibrosis
AMD	Clinical and/or angiographic signs consistent with AMD (e.g., drusen, retinal pigment epithelial changes, choroidal neovascularization) with no other likely etiologic explanations for the degenerative changes

- 3. Lesions with occult CNV or with some classic CNV component were permissible. However, if classic CNV (well-demarcated hyperfluorescence boundaries in the early phase of the fluorescein angiogram) was present, the area of classic CNV had to be < 50% of the total lesion size.
- 4. Total area of CNV (including both classic and occult components) encompassed within the lesion \geq 50% of the total lesion area.
- 5. Total lesion area ≤ 12 disc areas (DA) in size
- 6. Best corrected visual acuity, using ETDRS charts, of 20/40 to 20/320 (Snellen equivalent) in the study eye
 - Only one eye was assessed in the study. If both eyes were eligible, the one with the better visual acuity was selected for treatment and study unless, based on medical reasons, the investigator deemed the other eye the more appropriate
 - candidate for treatment and study.

Exclusion Criteria

Subjects who met any of the following exclusion criteria were ineligible for study entry:

a. Prior/Concomitant Treatment

- 1. Prior treatment with verteporfin, external-beam radiation therapy, or transpupillary thermotherapy (TTT) in the study eye
- 2. Treatment with verteporfin in the non-study (fellow) eye less than 7 days preceding Day 0
- 3. Previous participation in a clinical trial (for either eye) involving anti-angiogenic drugs (Pegaptanib, Ranibizumab, anecortave acetate, protein kinase C inhibitors, etc.)

- 4. Previous intravitreal drug delivery (e.g., intravitreal corticosteroid injection or device implantation) in the study eye
- 5. Previous subfoveal focal laser photocoagulation in the study eye
- 6. Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1 month preceding Day 0
- 7. History of vitrectomy surgery in the study eye
- 8. History of submacular surgery or other surgical intervention for AMD in the study eye
- 9. Previous participation in any studies of investigational drugs within 1 month preceding Day 0 (excluding vitamins and minerals)

b. Lesion Characteristics

- 1. Subretinal hemorrhage in the study eye that involved the center of the fovea, if the size of the hemorrhage was either \geq 50% of the total lesion area or \geq 1 DA in size.
- 2. Subfoveal fibrosis or atrophy in the study eye
- 3. CNV in either eye due to other causes, such as ocular histoplasmosis, trauma or pathologic myopia
- 4. Retinal pigment epithelial tear that involved the macula in the study eye

c. Concurrent Ocular Conditions

- 1. Any concurrent intraocular condition in the study eye (e.g., cataract or diabetic retinopathy) that, in the opinion of the investigator, either
 - i. Required medical or surgical intervention during the 24-month study period to prevent or treat visual loss that may have resulted from that condition, or
 - ii. If allowed to progress untreated, could likely have contributed to loss of at least 2 Snellen equivalent lines of best corrected visual acuity over the 24-month study period
- 2. Active intraocular inflammation (grade trace or above) in the study eye
- 3. Current vitreous hemorrhage in the study eye
- 4. History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the study eye
- 5. History of idiopathic or autoimmune-associated uveitis in either eye
- 6. Infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
- 7. Aphakia or absence of the posterior capsule in the study eye
 - Previous violation of the posterior capsule in the study eye was also excluded unless it occurred as a result of yttrium aluminum garnet (YAG) laser posterior capsulotomy in association with prior posterior chamber intraocular lens implantation.
- 8. Spherical equivalent of the refractive error in the study eye that demonstrated more than -8 diopters of myopia
- 9. Intraocular surgery (including cataract surgery) in the study eye within 2 months preceding Day 0
- 10. Uncontrolled glaucoma in the study eye (defined as intraocular pressure $[IOP] \ge 30$ mmHg despite treatment with anti-glaucoma medication)
- 11. History of glaucoma filtering surgery in the study eye
- 12. History of corneal transplant in the study eye
- d. Concurrent Systemic Conditions

- 1. Pre-menopausal women not using adequate contraception
 - i. The following were considered effective means of contraception: surgical sterilization; use of oral contraceptives; barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel; an intrauterine device; or contraceptive hormone implant or patch
- 2. History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicated the use of an investigational drug or that might have affected interpretation of the results of the study or rendered the subject at high risk for treatment complications
- 3. Current treatment for active systemic infection
- e. Other
 - 1. History of allergy to fluorescein, not amenable to treatment
 - 2. Inability to obtain fundus photographs or fluorescein angiograms of sufficient
 - quality to be analyzed and graded by the central reading center
 - 3. Inability to comply with study or follow-up procedures

Outcome Measures

Primary Efficacy Outcome Measures

The proportion of subjects who lost fewer than 15 letters (approximately 3 lines) in the best corrected visual acuity score at 12 months compared with baseline, based on the ETDRS visual acuity chart and assessment at a starting distance of 2 meters.

Secondary Efficacy Outcome Measures - For the First Treatment Year

- Proportion of subjects who lost fewer than 15 letters in the best corrected visual acuity score at 12 months compared with baseline, based on assessment at a starting test distance of 4 meters
- Mean change from baseline in the best corrected visual acuity score over time up to 12 months
- Proportion of subjects who gained at least 15 letters in the best corrected visual acuity score at 12 months compared with baseline
- Proportion of subjects with a visual acuity Snellen equivalent of 20/200 or worse at 12 months (legal blindness is defined as both eyes with 20/200 or worse)
- Mean change from baseline in the VFQ-25 near activities subscale score over time up to 12 months
- Mean change from baseline in the VFQ-25 distance activities subscale score over time up to 12 months
- Mean change from baseline in the VFQ-25 vision-specific dependency subscale score over time up to 12 months
- Mean change from baseline in the total area of CNV at 12 months (based on assessment by the central reading center)
- Mean change from baseline in the total area of leakage from CNV at 12 months (based on assessment by the central reading center)

The secondary efficacy outcome measures for the second treatment year of the study are the following:

- Proportion of subjects who lose fewer than 15 letters in the best corrected visual acuity score at 24 months compared with baseline
- Mean change from baseline in the best corrected visual acuity score at 24 months
- Proportion of subjects who gain at least 15 letters in the best corrected visual acuity score at 24 months compared with baseline
- Proportion of subjects with a visual-acuity Snellen equivalent of 20/200 or worse at 24 months
- Proportion of subjects who lose fewer than 15 letters in the best corrected visual acuity score at 24 months compared with baseline, based on assessment at a starting test distance of 4 meters
- Mean change from baseline in the VFQ-25 near activities subscale at 24 months
- Mean change from baseline in the VFQ-25 distance activities subscale at 24 months
- Mean change from baseline in the VFQ-25 vision-specific dependency subscale at 24 months
- Mean change from baseline in the total area of CNV at 24 months (based on assessment by the central reading center)
- Mean change from baseline in the total area of leakage from CNV at 24 months (based on assessment by the central reading center)

Safety Outcome Measures

The safety outcome measures are the following:

- The incidence and severity of ocular adverse events
- The incidence and severity of non-ocular adverse events
- Changes and abnormalities in clinical laboratory parameters
- The incidence of serum antibodies to ranibizumab
- Changes in vital signs

Reviewer's Comment:

As noted in Section 2.5 regarding previous correspondence and meetings, the Agency does not agree with the sponsor's primary efficacy endpoint.

Visual acuity testing is recommended to be performed with at target distance of a minimum of 4 meters, not 2 meters, from the patient. This distance measure (4 meters) is recommended to minimize the potentially confounding influences of accommodation and patient positioning on the measurement.

For the purposes of this review the Agency will consider the primary efficacy endpoint as the proportion of subjects with a loss of fewer than 15 letters in the visual acuity score in the study eye at 12 months compared with baseline, based on assessments at a starting test distance of 4 meters, not 2 meters.

The VFQ-25 scale and its subscales have not been validated against actual activities of daily living.

SAFETY PLAN

Following each injection (ranibizumab or sham), subjects were to remain at the clinic for at least 60 minutes (\pm 10 minutes). Finger counting was tested on each subject after each injection; hand motion and light perception was tested when necessary. Intraocular pressure was measured before and 60 minutes (\pm 10 minutes) after each injection. If there were no safety concerns in the 60 minutes (\pm 10 minutes) following an injection, the subject was to leave the clinic. If any concern or immediate toxicity was noted, the subject was to remain at the clinic and be treated according to the designated evaluating physician's clinical judgment.

Subjects were to return for a follow-up visit at Day 7 after the first injection. In addition, subjects were to be contacted by study site personnel 2 days ($\pm 1 \text{ day}$) after each injection to elicit reports of any decrease in vision, eye pain, unusual redness, or any other new ocular symptoms in the study eye. Subjects were also asked whether they have taken the prescribed self-administered post-injection antimicrobials. If determined necessary by the evaluating physician, the subject was asked to return to the clinic as soon as possible for a safety assessment visit and was evaluated by the designated evaluating physician. Subjects were instructed to contact their designated evaluating physician at any time should they have health-related concerns.

Detailed ocular examinations, including indirect ophthalmoscopy, measurement of intraocular pressure, visual acuity testing, and slit lamp examination, was performed throughout the study by the designated evaluating physician. Routine hematology, chemistry, and urinalysis profiles were obtained for all subjects. In addition, blood samples for serum ranibizumab concentrations and antibodies to ranibizumab were obtained for all subjects.

Study drug administration was temporarily held for subjects who experience certain ocular events or infection events. Study drug administration was also held at a visit if the evaluating physician suspected that the lesion in the study eye had converted to predominantly classic CNV and verteporfin PDT treatment was being considered. In the event any subject developed an adverse event in the study eye that was considered by the designated evaluating physician to be severe in intensity, serious consideration was to be given to discontinuing the subject from study treatment. The investigator or Sponsor could request that a subject be withdrawn from treatment or from the study for safety reasons at any time.

Subjects who were discontinued from study treatment were to continue to undergo the scheduled monthly assessments. Subjects withdrawn from the study prior to completion were asked to return for an early termination evaluation 30 days (\pm 7 days) following their last injection/study visit for monitoring of all adverse events (serious and nonserious; ocular and non-ocular).

Preliminary findings from FVF2428g (see Section 1.7.4) suggest that administering the ranibizumab injections 7 days (± 2 days) after treatment with verteporfin PDT in the same eye might result in a decrease in visual acuity of ≥ 30 letters due to temporary intraocular inflammation (uveitis). Therefore, if verteporfin PDT treatment was required in the study eye, it was to be administered at least 28 days prior to ranibizumab/sham injections and no sooner than 21 days after ranibizumab/sham injections.

A formal Data Monitoring Committee DMC) was established to monitor subject safety. The DMC conducted semiannual reviews of unmasked safety data including serious adverse events, adverse events (ocular and non-ocular), deaths, clinically significant decreases in visual acuity, and results of ocular assessments.

Concomitant Therapy and Clinical Practice

Subjects who received prior treatment with verteporfin in the study eye were excluded from the study. Verteporfin therapy in the non-study eye less than 7 days prior to Day 0 was not permitted.

Subjects who are confirmed (by fluorescein angiography and written documentation) by the central reading center to have changed lesion classification from minimally classic/occult CNV to predominantly classic CNV could receive alternative therapies (e.g., verteporfin) in the study eye.

Pegaptanib sodium injection was not permitted in either eye due to the potential safety concern of concurrent treatment with two anti-VEGF agents.

Concurrent use of systemic anti-VEGF agents including treatment with intravitreal or intravenous Avastin was not permitted in either eye. Subfoveal laser photocoagulation in the study eye was not allowed prior to Day 0 or during study participation. Juxtafoveal or extrafoveal laser photocoagulation for AMD was not allowed in the study eye within 1 month preceding Day 0 and during study participation. Elective vitrectomy surgery was not allowed in the study eye during study participation. Transpupillary thermotherapy (TTT), external beam radiation therapy, submacular surgery, or other surgical intervention for AMD was not allowed in the study eye during study participation. Onset of glaucoma during study participation should be treated as clinically indicated. Catafact surgery in the study eye could be performed if clinically indicated and should occur ≥ 28 days after the last ranibizumab or sham injection; the next ranibizumab or sham injection will be held for ≥ 28 days following cataract surgery. At least one monthly injection was to be missed when cataract surgery in the study eye is performed.

Dose Holding and Treatment Discontinuation

Dose interruption and treatment discontinuation due to adverse events were determined using the criteria in the following Table. If any of the listed events occurred, the reason for dose holding was recorded on the Study Drug Administration Case Report Form (CRF) and, if applicable, on the Adverse Event CRF.

Event	Study DrugaDare Hinding-Criteria
Intraocular inflammation	Dose was held if intraocular inflammation was $\geq 2+$ in the study eye.
Visual acuity loss	Dose was held if there was a treatment-related decrease in best corrected visual acuity of \geq 30 letters in the study eye compared with the last assessment of visual acuity prior to the most recent treatment.

Table 6.1.3.1-3 Dose Holding and	Treatment Discontinuation Criteria
	A Company Discontinuation Criticita

Intraocular pressure	Dose was held if IOP in the study eye was ≥ 30 mmHg. Treatment was permitted
	when IOP had been lowered to < 30 minHg, either spontaneously or by treatment, as
	determined by the evaluating physician.
Vitreous hemorrhage	Dose was held if there was $a \ge 2+$ vitreous hemorrhage and ≥ 30 -letter decrease in
	visual acuity in the study eye compared with the last assessment of visual acuity prior
	to the onset of the vitreous hemorrhage. Treatment was permitted when the vitreous
	hemorrhage improved to <2+ or visual acuity score improved to a <30-letter decrease.
Sensory rhegmatogenous	Dose was held if a retinal break was present in the study eye. Treatment may have
retinal break or	been resumed ≥ 28 days after the retinal break had been successfully treated.
detachment (including	Subjects with a rhegmatogenous retinal detachment or Stage 3 or 4 macular hole were
macular hole)	discontinued from treatment for the duration of the study.
Subfoveal hemorrhage	Dose was if there was a subretinal hemorrhage involving the center of the fovea in the
Ŭ	study eye, if the size of the hemorrhage was either \geq 50% of the total lesion area or \geq
	2 DAs in size.
Local or systemic	Dose was held if any of the following were present: infectious conjunctivitis,
infection .	infectious keratitis, infectious scleritis, or endophthalmitis in either eye, or if the
	subject was receiving treatment for a severe systemic infection.
Intraocular surgery	Dose was held if intraocular surgery had been performed in the study eye within the
	previous 28 days.

Analysis Populations

Randomized Subjects

These subjects were enrolled and randomized in the study. This population was used for summaries of demographics and study conduct and for most summaries of efficacy. Treatment group assignment for this population was as randomized (i.e., ITT).

Per Protocol Subjects

A subset of randomized subjects who were considered more compliant with the protocol. Treatment group assignment for this population was as randomized. This population was used for supportive analyses of visual acuity efficacy outcome measures at Month 12.

Safety Evaluable Subjects

Randomized subjects who received at least one treatment with study drug. Treatment group assignment for this population was defined as follows:

- Sham: subjects randomized to the sham-injection group who received a sham injection on Day 0
- 0.3 mg Ranibizumab: subjects randomized to receive 0.3 mg ranibizumab or subjects who were randomized to sham but received a 0.3 mg injection of ranibizumab on Day 0 in error
- 0.5 mg Ranibizumab: subjects randomized to receive 0.5 mg ranibizumab or subjects who were randomized to sham but received a 0.5 mg injection of ranibizumab on Day 0 in error.

Efficacy Analyses

Comparisons of efficacy were performed between each ranibizumab dose group and the sham injection (control) group. All pairwise comparisons for treatment difference were performed using a statistical model that included only two treatment groups (active vs. control) at a time. For the primary efficacy endpoint, an adjustment was made for multiple treatment comparisons of each ranibizumab dose group with the control group. For secondary efficacy endpoints, adjustments for multiplicity of endpoints were made to manage the Type Terror.

Primary Efficacy Endpoint. The proportion of subjects with fewer than 15 letters lost in best corrected visual acuity at 12 months compared with baseline, based on assessment at a starting test distance of 2 meters, was compared between each ranibizumab group and the sham control group using the Cochran χ 2 test stratified by CNV classification at baseline and baseline visual acuity score. The test was performed at an overall significance level of 0.0497 after adjusting for interim analyses. The Hochberg-Bonferroni multiple comparison procedure was used to adjust for the two pairwise treatment comparisons. If the p-values for both comparisons were 0.0497, both ranibizumab groups were considered statistically significantly different from the sham control group was p > 0.0497, the other ranibizumab group was considered statistically significantly different from the control group only if the p-value for its comparison with the control group was 0.0497/2 (0.02485). Results of tests for treatment difference using the Cochran χ 2 test stratified by the baseline visual acuity score and CNV classification entered into the IVRS at randomization were also provided as supportive analyses.

Reviewer's Comments:

For the purposes of this review the Agency will consider the primary efficacy endpoint as the proportion of subjects with a loss of fewer than 15 letters in the visual acuity score in the study eye at 12 months compared with baseline, based on assessments at a starting test distance of 4 meters, not 2 meters.

Determination of Sample Size

The sample size of 720 subjects with minimally classic or occult CNV will provide 95% power in the intent-to-treat (ITT) analysis to detect a statistically significant difference between one or both ranibizumab groups and the control group in the percentage of subjects with fewer than 15 letters lost at Month 12, assuming a rate of 65% in each ranibizumab group and 50% in the control group.

Interim Analyses

An independent DMC was established to monitor safety and study conduct and met approximately every 6 months to review unmasked safety summaries prepared by an external statistical coordinating center. Because the analyses involve visual acuity, which is the basis of the primary efficacy endpoint, each interim analysis conducted prior to the analysis of the primary efficacy endpoint will be allocated a Type I error of α =0.0001.

-39

Table 6.1.3.1-4

Study Flowchart: Screening, Treatment Phase Day 0 through Month 12, and Early Termination

Study Period	Srnon	Real west.	and the last free	An Print School	Salar Salar	「「「「「「「「」」」」	Tre	atment	Treatment Phase	State of the second	Barbara and			いたの時間の		ALL REAL
	÷.,			Contraction of the second s	Contraction of the second	A COLUMN TO STREET		Sale of the second			Contraction of the second					
		Day	1.1.2.5.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.	「「「「「「」」」	an a second second		ののないので	an a set	IOIA	MOILE	10 A	12 (division)	いたのでの	Contraction of the		
	-28 to		Ash Terra	Constanting of	1.1		A PARK A	1		and a		0		11		
	-1			Part and			学行社で								State of the	
Assessment Window (Days)	and the second second	A Date of the second	12	CTF 1	plant a	THE P	1528	14			A State of the second				1	and the second sec
Informed Consent	×							_								
Inclusion/Exclusion Criteria	×															
Demographic data	×															
Medical and surgical history	×															
VFQ-25 °		x		×	×	×	-		×			×			×	×
SF-36 Health Survey °		x							×						×	×
HUI (at selected sites only) ^c	X	×				×				×			x			×
VAS ^c	x			×	x	x				x			x			x
Review of Body Systems	x														×	x
Seruth pregnancy test ^d	×									,						
Best corrected visual acuity (2 mercr starting distance) ^{e, f}	×	x ^g	×	×	x	×	×	×	×	×	×	×	×	×	× ⁸	x ⁸
Slit Lamp Examination	×	X.	×	×	x	×	×	×	×	×	×	×	×	×	×	×
Dilated binocular indirect and	-															
high-magnification	*	×	×	×	×	x	×	×	×	×	x	×	×	×	×	×
Uputtautuoscopy		x													>	
Fundus Photocranhv ^e	~					*				ŀ	ľ				• >	>
Fluorescein Angiography	x					× ×		1	- ×						- ×	
Contrast Sensitivity ^{e, †}	x		×	×	x	×			×						×	×
OCT (at selected sites) ^e		x	×	×											×	×
Laboratory Samples ^{e, h} .	X														×	×
Serum samples for antibodies to																
ranibizumab and ranibizumab	×								×						×	x
concentrations ^e									-							-
Intraocular pressure ^{1, J}	×	×	×	×	×	×	×	×	×	x	×	x	x	x	×	x
Ranibizumab administration or sham injection (study eye only)		×		×	×	×	×	×	×	×	×	×	×	×	×	-
Finger count, hand motion, light		×		×	×	×	×	×	×	×	×	×	×	×	×	

-28 to			reatmen	Treatment Phase				and the second		
-28 to				Month	th			LINE AND LINE		1. Term
	2 3	4	N.	ę	C	8	6	0 E	11 12	12
Assessment Window (Days)	LT _ LT	41	6 #	. 1	L#	Ę	Ц т	1	±7.	+7 30±7
perception		,	,	;	:	-				
at Medications ^m x	< ×	<	<	< >	< >	<,	<	×	× ,	× ,
ires x x	+	< ×	< >	< x	<	< >	< >	< >	<	<,
x x	-	×	: ×	×	< ×	. ×	< ×	< ×	< ×	
Follow-up contact ° x x	x x	×	×	х	×	×	×	×	×	×
 VFQ-25 , SF-36 Health Survey, HUI questionnaire (selected sites only), and VAS should have been administered to the subject prior to the subject's completing any other study procedures. For women of childbearing potential. Performed pre-injection. Performed prior to dilating eyes. Also assessed at a starting distance of 4 meters after assessment at a starting distance of 2 meters. Laboratory evaluations included hermatology, blood chemistry, and urnalysis Obtained pre-injection for both eyes and 60 minutes (±10 minutes) post injection for study eye only The measurement method used for a subject wand only eye only. May prescription drugs or OTC preparations other than protocol-specified procedural medications (e.g., dilating drops, fluorescein dyes, etc.) and pream dypertered post-injection for study visit. Adverse events are subject on the study visit. Adverse events were collected from Dav o through the last study visit. Adverse events have events were collected from Dav o through the last study visit. Adverse events are subject on the study visit. Adverse events were collected from Dav o through the last study visit. Adverse events assessed hyperochinal previous of the mast study visit. Adverse events assessed hyperochinal prevaluations (e.g., proparacine, antimicrobials) used by a subject within 7 days preceding Day 0. 	ites only), an and urinaly and urinaly utes) post inj isistent throu istion for stu cition for stu ol-specified als) used by dv visit. Ad	nd VAS g distant sus fection ff jection ff idy eye c idy eye c rocedu	should 1 ce of 2 r or study he study only. rral med	neters. eye onlicetons cations 7 days	y y (e.g., di precedii	lating c g Day	to the su trops, flu	ubject p	rior to the indyes,	he subject etc.) and I
were followed, even after the subject's study participation was over, until the event resolved or the event was assessed as irreverable, chronic, or stable. ⁰ Subjects were contacted 2 days (1 day) following treatment to elicit reports of any decreases in vision, eve pain, unusual redness, or any other new ocular symptoms in the study even. Subjects were also acked whether they had taken the activated to accurate the study even.	over, until t elicit reports	the event s of any (t resolve decrease	d or the	event w ion, eye	as asse pain, u	ssed as i nusual r	irrevers edness,	jble , chr or any c	onic, or st other new

APOTEX V. REGENERON IPR2022-01524 REGENERON EXHIBIT 2024 PAGE 070

		i in a Sumber	of Subjects	
	a miccion -	Karibizunalt D 3 mil N (%)		Total N (%)
Randomized -	238	238	240	716
Completed Month 12 ^a	212 (89.1%)	226 (95.0%)	226 (94.2%)	664 (92.7%)
Discontinued Treatment Prematurely	31 (13.0%)	10 (4.2%)	11 (4.6%)	52 (7.3%)
Discontinued Study prematurely	21 (8.8%)	6 (2.5%)	6 (2.5%)	33 (4.6%)
Safety Evaluable Population received study medication, as treated	236 (99.2%)	238 (100%)	239 (99.6%)	713 (99.6%)
Intent-to-treat Population ≥ 1 on therapy study visit	236 (99.2%)	238 (100%)	239 (99.6%)	713 (99.6%)
Per Protocol Population (for the analysis of 4 m BCVA at Month 12) No on-therapy study visits or protocol violation	176 (73.9%)	200 (84.0%)	196 (81.7%)	572 (79.9%)
Excluded from PP Population	62 (26.1%)	38 (11.8%)	44 (18.3%)	144 (20.1%)
Pharmacokinetic-Evaluable Population	218 (91.6%)	226 (95.0%)	225 (93.8%)	669 (93.4%)

Table	6.1.3.1-5	Subject	Disposition
-------	-----------	---------	-------------

a Defined as having a visual acuity score in the study eye at Month 12. Data from subjects who missed the Month 12 visit but stayed in the study for the second year were not counted.

Reviewer's Comments:

Overall, the study had good retention of subjects through Month 12. The sham injection group had significantly more discontinuations than either ranibizumab treatment group.

Two subjects in the sham group and one subject in the ranibizumab 0.5mg group did not receive any study treatment.

Table 6.1.3.1-6 Major	Protocol Deviations during the Fir	st Treatment Year
	Randomized Subjects	

	Sham	A STATE AND A DESCRIPTION OF A DESCRIPTI	zumab
Deviation	(N=238)	0.03 mg (12.04 (38)	0.5 mg (N=240)
Any deviation	55 (23.1%)	57 (23.9%)	62 (25.8%)
Re-randomized	0	0	1 (0.4%)
Dosing error: Overdose	0	1 (0.4%)	1 (0.4%)
Dosing Error: Procedure (injection) accident	0	1 (0.4%)	1 (0.4%)
Dosing Error: Sham injection performed	0	2 (0.8%)	1 (0.4%)
Treatment assignment unmasked ^a	1 (0.4%)	0	4 (1.7%)
Ineligible per protocol off-label PDT use	9 (3.8%)	0	0
Received PDT <21 days after a study drug injection			
Study eye	1 (0.4%)	0	0
Fellow eye	4 (1.7%)	9 (3.8%)	2 (0.8%)
Pre-treatment procedure not followed	5 (2.1%)		4 (1.7%)
Dose-holding criteria not followed	1 (0.4%)	4 (1.7%)	1 (0.4%)
Visual acuity (4 m) not assessed at baseline: study eye	9 (3.8%)	9 (3.8%)	10 (4.2%)
Visual acuity (2 m) assessment incomplete: letters smaller than			
20/20 not adequately tested			
Study eye	0	2 (0.8%)	3 (1.3%)
Fellow eye	24 (10.1%)	10 (4.2%)	13 (5.4%)
ETDRS chart with notation for 2-m testing was used	1 (0.4%)	3 (1.3%)	2(0.8%)
ETDRS charts switch usage (left eye chart vs. right eye chart)	0	0	1 (0.4%)
Slit lamp was performed after injection			
On Day 0	1 (0.4%)	2 (0.8%)	1 (0.4%)
At any visit other than Day 0	1 (0.4%)	2 (0.8%)	1 (0.4%)
Required a reader/translator's help for VFQ-25 and other questionnaires	1 (0.4%)	0	1 (0.4%)
Vital signs assessed pre-dose	7 (2.9%)	6 (2.5%)	9 (3.8%)
Inconsistent method for IOP measurement	11 (4.6%)	20 (8.4%)	22 (9.2%)

Only study coordinators were unmasked for one case in the sham-injection group and two cases in the 0.5 mg group.

Reviewer's Comments:

There were slightly more protocol deviations in the ranibizumab 0.5 mg group.

The protocol deviations which occurred most frequently were an inconsistent method for IOP measurement, incomplete assessment of 2 m visual acuity in the fellow eye, and failure to assess 4m visual acuity at baseline.

Study Site I	D. Storese D		Study Day
		Second Grand The Second Second	
S07438	101015	Subject's Decision	332
S08127	102010	AE - Worsening AMD	127
S08536	102014	AE - Pneumonia, COPD Exacerbation x 2	2 65
S08255	103006	AE - Worsening AMD	148
S08215	104010	Subject's Decision - no improvement in VA	284
S08165	106006	Physician's Decision - Intra Vit Kenalog given	236
S07439	112005	Randomized in error	93
S08082	119005	Lost to follow-up	36
S08239	121004	Subject's Decision / AE – Mild iritis	158
S08235	- 124001	Subject's Decision - Never received treatment	1
S08130	125008	AE - 30 letter loss of vision - Worsened AMD	50
S08246	131011	Subject's Decision	239
S08111	133001	Subject's Condition Mandated Other Treatment	154
S08248	140001	AE – Lung lesion, elevated liver enzymes	259
S08586	141017	Randomized in error	1
S08088	142002	Subject's Decision	127
S08212	144002	AE - Worsening AMD	127
S08212 S08212	144005	Lost to follow-up	331
S08212 S08187	149003	Subject's Decision	36
S08187	149007	AE - Worsening AMD	359
S08187	149009	Subject's Decision	127
S00399	162003	Subject's Decision	8
S08133	164002	Subject's Decision	120
S08133	166001	AE - Worsening AMD	295
S08231 S00266	167008	Publicate Condition Mandeted Other Treatment	309
	175002	AE – Lung cancer treatment	176
S08146	176005	Subject's Decision	317
S08194	186002	Subject's Condition Mandated Other Treatment	162
S02507	and the second se	AE – Acute Gout	359
S07387	187002		133
S08252	193004	AE - Worsening AMD	333
S08882	205002	AE - Death due to Asthma / COPD	333
·····		0.3 mg Group	
S07438	101020	AE - Death - Myocardial infarction	12
S08127	102006	AE – Lymphoma	372
S08536	102015	Subject's Decision	258
S08144	110002	Subject's Decision	324
S08092	111005	AE – Severe aortic stenosis	96
S08190	120005	AE - Worsening AMD	66
S08246	131003	AE – Vulvar adenocarcinoma	210
S08189	160001	AE – Iritis	121
S00399	162002	AE – Loss of vision	100
S08084	196004	Lost to follow-up	218
		0.5 mg Group	
S08092	111003	AE – Cardiac arrhythmia	100
S08082	119004	Subject's Decision	1
S07442	127002	Subject's Decision – Did not receive treatment	28

Table 6.1.3.1-7 Discontinued Subjects and Reason Study FVF2598g

Best Available Copy

APOTEX V. REGENERON IPR2022-01524 REGENERON EXHIBIT 2024 PAGE 073

	Jizumao mjecnony	Maria	
Study Site I	D Subject it	is the second state of the second states and the s	SuniteDay
S08081	130013	AE - Fractured pelvis	39
S08246	131001	AE - Stroke	244
S08246	131007	AE - Death due to small bowel infarct	178
S08238	138002	AE - Recurrent iritis	153
S08231	166002	Worsening AMD	241
S07479	173002	Non-compliance	
S08232	181004	AE – Death – Asthma	155
S08084	196003	AE – Cough and wheezing	92

Reviewer's Comment:

The majority of subjects who discontinued treatment were in the sham-injection group. The most frequent reasons for discontinuation were worsening AMD, worsening vision, or subject's decision with no improvement in vision.

In the ranibizumab groups, adverse events related to systemic disease were the most frequent causes of treatment discontinuation. There was no pattern of non-ocular adverse event which led to discontinuation.

		Rambizumab	
	Sham	0,3 mg	0.5 mg
Demographic	(n = 258)	(n = 238)	(n = 240)
Age (yr)			
Mean (SD)	77.0 (6.6)	77.4 (7.6)	76.8 (7.6)
Range	56-94	52-95	52-93
Age group (yr)			
50 to < 65	11 (4.6%)	13 (5.5%)	16 (6.7%)
65 to < 75	67 (28.2%)	64 (26.9%)	64 (26.7%)
75 to < 85	132 (55.5%)	130 (54.6%)	124 (51.7%)
≥ 85	28 (11.8%)	31 (13.0%)	36 (15.0%)
Sex			
Male	79 (33.2%)	85 (35.7%)	88 (36.7%)
Female	159 (66.8%)	153 (64.3%)	152 (63.3%)
Race/ethnicity			
White	231 (97.1%)	229 (96.2%)	232 (96.7%)
Asian or Pacific Islander	2 (0.8%)	3 (1.3%)	2 (0.8%)
Hispanic	5 (2.1%)	5 (2.1%)	6 (2.5%)
Other	0	1 (0.4%)	0

Table 6.1.3.1-8 Demographic Statistics by Treatment Group Intent-to-Treat, Randomized Subjects

Reviewer's Comment:

The demographics of the treatment groups were balanced. The majority of the patients randomized and treated in this study were elderly and white.

Best Available Copy

Table 6.1.3.1-9 Baseline Ocular Characteristics in the Study Eye
Intent-to-Treat, Randomized Subjects

		Ranibi	zumab
Characteristics	1.100 Sham (1.100 m≠238)	0.3 mg (n = 238)	0.5 mg (n = 240)
Years since first diagnosis of neovascular AMD			
N	235	238	238
Mean (SD)	0.8 (1.3)	0.6 (1.6)	0.7 (1.3)
Range	0.0 - 10.9	0.0 - 18.9	0.0 - 13.3
Visual acuity at a starting test distance of 4 meters	-		
N	229	229	230
Number of letters (0–100)			
Mean (SD)	53.5 (14.7)	53.2 (13.6)	53.2 (14.9)
Range	0-88	. 0-82	0-80
≤ 54	111 (48.5%)	• ••••••••••••••••••••••••••••••••••••	110 (47.8%)
<u>≥ 55</u>	118 (51.5%)	115 (50.2%)	120 (52.2%)
Approximate Snellen equivalent			
Median	20/80	20/80	20/80
20/200 or worse	26 (11.4%)	28 (12.2%)	36 (15.7%)
Better than 20/200 but worse than 20/40	171 (74.7%)	172 (75.1%)	159 (69.1%)
20/40 or better	32 (14.0%)	29 (12.7%)	35 (15.2%)
Intraocular pressure (mmHg)			
N	238	23.8	240
Mean (SD)	14.8 (3.2)	14.8 (3.1)	14.8 (3.2)
Range	7-24	5-25	8-25
0-21	234 (98.3%)	233 (97.9%)	236 (98.3%)
22–29	4 (1.7%)	5 (2.1%)	4 (1.7%)

Reviewer's Comment:

There was no significant difference in baseline vision or intraocular pressure characteristics between the treatment groups.

Best Available Copy

Lucentis	(ranibizumal	o injec	tion)
----------	--------------	---------	-------

Table 6.1.3.1-10 Fluorescein Angiography and Fundus PhotographyCharacteristics of the Study Eye at BaselineIntent-to-Treat, Randomized Subjects

		12 CONTRACTOR OF A DECK OF	ibizumab
Characteristics	(a.= 238)	089mb1	0.5 mg (n = 240)
CNV classification			
Predominantly classic	0	1 (0.4%) ^a	$1(0.4\%)^{b}$
Minimally classic	87 (36.6%)	86 (36.1%)	91 (37.9%)
Occult without classic	151 (63.4%)	151 (63.4%)	· · · · · · · · · · · · · · · · · · ·
Total area of lesion (DA)			
Mean (SD)	4.41 (2.48)	4.26 (2.54)	4.47 (2.62)
Range	0.20-11.75	0.10-11.80	0.25-12.00
$\leq 4 \text{ DA}$	124 (52.1%)	134 (56.3%)	
>4 DA	114 (47.9%)	104 (43.7%)	(/
Total area of CNV (DA)		,	
Mean (SD)	4.28 (2.41)	4.13 (2.47)	4.27 (2.51)
Range	0.20-11.75	0.02-11.80	0.12-12.00
Area of classic CNV (DA)			0.12 12.00
Mean (SD)	0.17 (0.36)	0.16 (0.35)	0.17 (0.38)
Range	0.00-2.50	0.00-2.50	0.00-2.25
fotal area of leakage from CNV	plus intense progressive		c
Mean (SD)	3.54 (2.47)	3.59 (2.50)	3.47 (2.63)
Range	0.00-12.85	0.00-11.95	0.00-13.50
Area of serous sensory retinal de	tachment or subretinal fl		
Mean (SD)	4.45 (3.44)	4.52 (3.54)	4.50 (3.48)
Range	0.00-16.00	0.00-17.00	0.00-16.00
Decult CNV present	238 (100%)	235 (98.7%)	

a The subject was enrolled as a result of the site misinterpreting the lesion eligibility confirmation from the reading center.

b Re-categorization as predominantly classic CNV by the reading center post-randomization.

c n=220 for the sham-injection group, and n=218 for each ranibizumab group 1

Reviewer's Comment:

There was no significant difference in the baseline characteristics of the CNV lesions across the treatment groups.

Approximately two- thirds of the subjects had occult lesions without any classic component in each treatment group.

Table 6.1.3.1-11 Concurrent Ocular Procedures and Select Concomitant Medications during the First Treatment Year: Randomized Subjects

		Ranib 0.3 mg	izumab 0.5 mg
Procedure or Medication		(n =238)	(n = 240)
Concurrent ocular procedures, study eye ^{a, b}			
PDT ·	25 (10.5%)	1 (0.4%)	0
Any procedure other than PDT	10 (4.2%)	14 (5.9%)	12 (5.0%)
AMD-related	8 (3.4%)	0	3 (1.3%)
Cataract	1 (0.4%)	4 (1.7%)	2 (0.8%)
Glaucoma	0	0	1 (0.4%)
Vitreoretinal disease	0	2 (0.8%)	2 (0.8%)
Other disease	1 (0.4%)	7 (2.9%)	5 (2.1%)
Concomitant ocular medications, study eye ^c			
Any medication use	183 (76.9%)	194 (81.5%)	199 (82.9%)
IOP lowering agents	23 (9.7%)	34 (14.3%)	33 (13.8%)
β-adrenoceptor blocking agents	13 (5.5%)	18 (7.6%)	17 (7.1%)
Dermatologic agents	12 (5.0%)	16 (6.7%)	19 (7.9%)
Fluoroquinolones	11 (4.6%)	12 (5.0%)	15 (6.3%)
Mild analgesics	6 (2.5%)	13 (5.5%)	15 (6.3%)
Ophthalmic preparations	36 (15.1%)	38 (16.0%)	40 (16.7%)
Pharmaceutical aids	10 (4.2%)	18 (7.6%)	17 (7.1%)
Steroids	14 (5.9%)	11 (4.6%)	16 (6.7%)
Vitamins and minerals	123 (51.7%)	145 (60.9%)	141 (58.8%)
Concomitant Non-Ocular Medications d	Anne and a second of the second s		r ng kabépa
Any medication use	236 (99.2%)	238 (100%)	238 (99.2%)
Antacids	30 (12.6%)	20 (8.4%)	20 (8.3%)
Antianemic agents	35 (14.7%)	23 (9.7%)	31 (12.9%)
Antianxiety agents	18 (7.6%)	37 (15.5%)	35 (14.6%)
Antidepressants	36 (15.1%)	43 (18.1%)	53 (22.1%)
Antihypertensive agents	38 (16.0%)	53 (22.3%)	62 (25.8%)
Antirheumatic and anti-inflammatory agents	84 (35.3%)	69 (29.0%)	80 (33.3%)
β-adrenoceptor blocking agents	71 (29.8%)	81 (34.0%)	76 (31.7%)
Bronchodilators and anti-asthmatics	20 (8.4%)	30 (12.6%)	30 (12.5%)
Calcium regulators and replenishers	80 (33.6%)	87 (36.6%)	81 (33.8%)
Diuretics	73 (30.7%)	82 (34.5%)	76 (31.7%)
Expectorants	18 (7.6%)	16 (6.7%)	8 (3.3%)
Histamine H2-receptor antagonists	29 (12.2%)	17 (7.1%)	28 (11.7%)
Hypolipidemics	104 (43.7%)	114 (47.9%)	109 (45.4%)
Mild analgesics	147 (61.8%)	143 (60.1%)	153 (63.8%)
Penicillins	13 (5.5%)	27 (11.3%)	21 (8.8%)
Steroids	60 (25.2%)	65 (27.3%)	50 (20.8%)
Supplements	45 (18.9%)	47 (19.7%)	35 (14.6%)
Vitamins and minerals	144 (60.5%)	138 (58,0%)	127 (52.9%)

a Based on data recorded on the Verteporfin PDT CRF pages.

b Based on the procedures reported on the Concurrent Ocular Procedure CRF pages, which were designed to capture all procedures other than PDT.

c Tabulation was based on medication use reported on the Concomitant Medications CRF pages for medications used by $\geq 5\%$ of subjects in any group.

d Tabulation was based on medications reported on the Concomitant Medications CRF pages. Only the medications satisfying any of the following criteria were presented: used by $\geq 25\%$ of subjects in any group at

APOTEX V. REGENERON IPR2022-01524 REGENERON EXHIBIT 2024 PAGE 077

screening, used by \ge 30% of subjects in any group during Year 1, or with a >4% difference between sham and either ranibizumab group.

Reviewer's Comment:

In the ranibizumab 0.5 mg group, the procedures other than PDT performed were usually related to cataract surgery.

Table 6.1.3.1-12 Prior Therapies for AMD in the Study Eye Randomized Subjects

	Shari (1=23)	0 3 me ¹ (n=238)	20mab 0.5 mg (n=240)
Any prior therapy for AMD	134 (56.3%)	140 (58.8%)	137 (57.1%)
Laser photocoagulation	22 (9.2%)	13 (5.5%)	14 (5.8%)
Medication	4 (1.7%)	3 (1.3%)	3 (1.3%)
Supplements	119 (50.0%)	132 (55.5%)	125 (52.1%)
Other	8 (3.4%)	3 (1.3%)	2 (0.8%)

Reviewer's Comment:

The treatment groups were well balanced with regard to prior treatment for age-related macular degeneration. Almost twice as many patients had prior laser photocoagulation in the sham group than in the ranibizumab groups.

Table 6.1.3.1-13 Concurrent PDT and Intravitreal Steroid Treatment in the Study Eye – Randomized Subjects

	Shain (n=238)	0.3 mg (n≢238)	2µmab 0.5 mg (n=240)
Concurrent PDT	25 (10.5%)	1 (0.4%)	0
Intravitreal steroid injection	6 (2.5%)	0	0

Reviewer's Comment:

The vast majority of on-study PDT treatments and all intravitreal steroid injections were received by those in the sham injection group.

6.1.3.2 Study FVF2587g

Title:

A Phase 3, Multicenter, Randomized, Double-Masked, Active Treatment-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) Compared with Verteporfin (Visudyne) Photodynamic Therapy in Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration.

Objectives: Primary:

- To evaluate the efficacy of intravitreal injections of ranibizumab administered monthly compared with verteporfin photodynamic therapy (PDT) in preventing vision loss, as measured by the proportion of subjects who lost fewer than 15 letters in visual acuity at 12 months compared with baseline.
 - The non-inferiority of ranibizumab to verteporfin PDT was evaluated; if non-inferiority was demonstrated, then the treatment differences between ranibizumab and verteporfin PDT were also to be evaluated for superiority.
- To evaluate the safety and tolerability of intravitreal injections of ranibizumab administered monthly.

Secondary:

• To evaluate the efficacy of monthly intravitreal injections of ranibizumab in preventing vision loss as measured by the following:

- Mean change from baseline in visual acuity over time up to 12 months
- Proportion of subjects who gained at least 15 letters in visual acuity at 12 months compared with baseline
- Proportion of subjects with a visual acuity Snellen equivalent of 20/200 or worse at 12 months
- To investigate the efficacy of monthly intravitreal injections of ranibizumab on vision-related functioning and well-being assessed during a period of 12 months, as measured by the National Bye Institute (NEI) Visual Function Questionnaire-25 (VFQ-25)
- To evaluate the efficacy of monthly intravitreal injections of ranibizumab on the size of classic choroidal neovascularization (CNV) and amount of leakage
 from CNV at 12 months, as assessed by fluorescein angiography
- Study Design: Phase 3, multicenter (100 sites), randomized, double-masked, active treatmentcontrolled study of intravitreally administered ranibizumab compared with verteporfin PDT. Approximately 426 subjects with primary or recurrent subfoveal CNV secondary to AMD who had predominantly classic lesions were to be enrolled.

Test Drug Schedule:


Eligible subjects were randomized in a 1:1:1 ratio to receive one of the following:

<u>، ۱</u>

- 0.3 mg ranibizumab and sham PDT with saline infusion,
- 0.5 mg ranibizumal and sham PDT with saline infusion, or
- Sham injection of ranibizumab and active verteporfin PDT.

Verteporfin/sham PDT was administered prior to the ranibizumab/sham injection to ensure the best practice with respect to aseptic technique and to attempt to minimize the risk of infection. Subjects received a ranibizumab or sham injection monthly $(30 \pm 7 \text{ days})$ for 23 months of treatment (24 injections) and active (verteporfin) or sham (saline) PDT on Day 0 and every 3 months if needed (as determined by the assessment of fluorescein angiograms by the evaluating physician) for 21 months of treatment.





<u> </u>Page(s) Withheld

<u> </u>	§ 552(b)(4) Trade Secret / Confidential
	§ 552(b)(4) Draft Labeling
	§ 552(b)(5) Deliberative Process

Withheld Track Number: Medical-<u>S</u>fle

APOTEX V. REGENERON IPR2022-01524 REGENERON EXHIBIT 2024 PAGE 081



This was a Phase 3, multicenter, randomized, double-masked, active treatment controlled study of intravitreally administered ranibizumab compared with verteporfin PDT. Approximately 426 subjects with primary or recurrent subfoveal CNV secondary to AMD who had predominantly classic lesions were to be enrolled. The study was to be conducted at approximately 100 study sites. The study design was essentially the same as Study 98.

Fluorescein angiograms were sent to a central reading center to determine CNV classification for study eligibility. Eligible subjects were randomized in a 1:1:1 ratio to receive one of the following treatments:

- 0.3 mg ranibizumab and sham PDT with saline infusion,
- 0.5 mg ranibizumab and sham PDT with saline infusion, or
- Sham injection of ranibizumab and active verteporfin PDT.

Randomization was stratified by the visual acuity score at Day 0 (\leq 44 letters [approximately worse than 20/125] vs. \geq 45 letters [approximately 20/125 or better] based on the ETDRS chart and assessment at a starting distance of 2 meters) and by study center. Verteporfin/sham PDT was administered prior to the ranibizumab/sham injection. Subjects received a ranibizumab or sham injection monthly (30 ± 7 days) for 23 months of treatment (24 injections) and active (verteporfin) or sham (saline) PDT on Day 0 and every 3 months if needed (as determined by the assessment of fluorescein angiograms by the evaluating physician) for 21 months of treatment. To preserve masking, administration of sham PDT with saline infusion mimicked that of active verteporfin PDT, and administration of active verteporfin PDT was in accordance with the Visudyne prescribing information.

There was a minimum of two investigators per study site to fulfill the masking requirements of this study. At least one investigator was designated as the evaluating physician, who was masked to the treatment assignment and conducted all ocular assessments. At least one other investigator was designated as the injecting physician, who was unmasked to the treatment assignment and performed the ranibizumab or sham injection procedures and the active or sham PDT infusion procedures, but who was masked to the ranibizumab dose (0.3 mg or 0.5 mg).

Study Population

Inclusion/Exclusion Criteria

Essentially the same as Study 98 except that patients had predominately classic choroidal neovascularization.

Outcome Measures

Essentially the same as Study 98 except that patients had predominately classic choroidal neovascularization.

Reviewer's Comment:

As noted in Section 2.5 regarding previous correspondence and meetings, the Agency does not agree with the sponsor's primary efficacy endpoint.

Visual acuity testing is recommended to be performed with at target distance of a minimum of 4 meters from the patient. This distance measure (4 meters) is recommended to minimize the potentially confounding influences of accommodation and patient positioning on the measurement.

For the purposes of this review the Agency will consider the primary efficacy endpoint as the proportion of subjects with a loss of fewer than 15 letters in the visual acuity score in the study eye at 12 months compared with baseline, based on assessments at a starting test distance of 4 meters, not 2 meters.

Study Treatments

Dosing and Administration of Ranibizumab and Sham

Ranibizumab was administered intravitreally in a multiple-dose regimen of either 0.3 mg or 0.5 mg of ranibizumab every month (Day 0-Month 23) for a total of 24 injections. Sham intravitreal injections were administered according to the same dosing schedule as ranibizumab injections: every month (Day 0 – Month 23) for a total of 24 injections. Dosing was not to occur earlier than 14 days after the previous treatment. Missed doses were not to be replaced.

Verteporfin/sham PDT was to be administered prior to the ranibizumab/sham injection to ensure the best practice with respect to aseptic technique and to attempt to minimize the risk of injection. The injecting physician(s) (and any assistants, if applicable) performing the ranibizumab/sham injections could not be involved in any other aspect of the study in any way, and could not divulge the treatment assignment to anyone. The evaluating physician(s) was responsible for all other aspects of the study except for the intravitreal injection procedure, intravenous administration of verteporfin or saline, and 689-nm (\pm 3 nm) diode laser irradiation of the macula. Visits for injection days had to be scheduled when both physicians were present. The subjects, all site personnel (except for the injecting physician(s) and designated site personnel needed to assist with the injection procedure), and all Sponsor personnel (with the exception of drug accountability monitors, corporate compliance staff, and finance) were masked to treatment assignment.

Dosing and Administration of Verteportin PDT

Verteporfin PDT was to be administered every 3 months (if needed) as determined by the evaluating physician's assessment of fluorescein angiography. The injecting physician determined the spot diameter of the area to be treated. Active verteporfin PDT or sham PDT with saline infusion was only to be administered on Day 0 and, if needed, at Months 3, 6, 9, 12, 15, 18 and 21.

Dosing and Administration of Sham PDT with Saline Infusion

The sham PDT with saline infusion minicked active verteporfin PDT and was administered in accordance with Visudyne prescribing information. On Day 0, all subjects received either active or sham PDT followed by an injection of ranibizumab or a sham injection, respectively. The injecting physician and assistant and/or pharmacist were aware of the treatment assignment. If a subject received an injection of ranibizuamab, he or she received sham PDT (saline infusion followed by 689-nm [\pm 3 nm] diode laser light dose and intensity was to be the same as those used for verteporfin PDT (i.e., light dose of 50J/cm2 at an intensity of 600 mW/cm2 administered over 83 seconds). If a subject received a sham injection, he or she received active PDT (verteporfin infusion followed by 689-nm [\pm 3 nm] diode laser irradiation to the macula). Following Day 0, the evaluating physician determined the need for PDT every 3 months (i.e., 3, 6, 9, 12, 115, 18 and 21) based on his or her assessment of ophthalmoscopic findings and fluorescein angiography results.

REAL CONTRACTOR AND A DATE	
Event	Avion to restar to the second second second
Intraocular inflammation	Hold active/sham PDT and ranibizumab/sham intravitreal injection if intraocular
	inflammation is $\geq 2+$ in the study eye.
Visual acuity loss	Hold active/sham PDT and ranibizumab/sham intravitreal injection if there is a
	treatment-related decrease in BCVA of \geq 30 letters in the study eye compared with
	the last assessment of visual acuity prior to the most recent treatment.
Intraocular pressure	Hold active/sham PDT and ranibizumab/sham intravitreal injection if IOP in the
	study eye was \geq 30 mmHg. Treatment will be permitted when IOP has been lowered
	to < 30 mmHg, either spontaneously or by treatment, as determined by the evaluating
	physician.
Vitreous hemorrhage	Hold active/sham PDT and ranibizumab/sham intravitreal injection if there is $a \ge 2+$
- 4	vitreous hemorrhage and \geq 30-letter decrease in visual acuity in the study eye
	compared with the last assessment of visual acuity prior to the onset of the vitreous
	hemorrhage. Treatment will be permitted when the vitreous hemorrhage improves to
	<2+ or visual acuity score improved to a <30-letter decrease.
Sensory rhegmatogenous	Hold active/sham PDT and ranibizumab/sham intravitreal injection if a retinal break
retinal break or	was present in the study eye. Treatment may be resumed ≥ 28 days after the retinal
detachment (including	break has been successfully treated. Subjects with a rhegmatogenous retinal
macular hole)	detachment or Stage 3 or 4 macular hole were discontinued from treatment for the
	duration of the study.
Subfoveal hemorrhage	Hold active/sham PDT and ranibizumab/sham intravitreal injection if there is a
	subretinal hemorrhage involving the center of the fovea in the study eye, if the size of
	the hemorrhage was either \geq 50% of the total lesion area or \geq 2 DAs in size.
Local or systemic	Hold active/sham PDT and ranibizumab/sham intravitreal injection if any of the
infection	following were present: infectious conjunctivitis, infectious keratitis, infectious
	scleritis, or endophthalmitis in either eye, or if the subject was receiving treatment for
	a severe systemic infection.
Intraocular surgery	Hold active/sham PDT and ranibizumab/sham intravitreal injection if intraocular
	surgery had been performed in the study eye within the previous 28 days.

Table 6.1.3.2-3 Study Treatment Holding Criteria

In this study, no subject was to receive both active verteporfin PDT and active ranibizumab injection in the study eye. If unmasked personnel discovered that a subject randomized to receive active ranibizumab injection received active verteporfin PDT in the study eye in error, then the active ranibizumab injection for the current month was to be held and the next ranibizumab injection for the subject was to be administered no earlier than 28 days after the day on which the active verteporfin PDT was received.

Additionally, the evaluating physician could discontinue a subject from treatment for other safety reasons. If a subject missed more than two ranibizumab/sham injections in a treatment year, serious consideration was to be given by the evaluating physician and the Sponsor to withdrawing the subject from the study.

Efficacy Analyses

The primary, secondary, and most of the exploratory efficacy endpoints were analyzed for randomized subjects based on the treatment assigned at randomization. Missing data were imputed using the last-observation-carried forward (LOCF) approach.

Comparisons of efficacy were performed between each ranibizumab dose group and the verteporfin PDT (control) group. All pairwise comparisons for assessing treatment difference were performed using a statistical method that includes only two treatment groups (ranibizumab vs. control) at a time. For the primary efficacy endpoint, an adjustment was made for multiple treatment comparisons of each ranibizumab dose group with the control group. For secondary efficacy endpoints, adjustments for multiplicity of endpoints were also made to manage the Type I error rate.

Primary Efficacy Endpoint. The primary efficacy endpoint was the proportion of subjects who lost fewer than 15 letters in BCVA score at Month 12 compared with baseline, based on assessment at a starting test distance of 2 meters. The primary efficacy endpoint was analyzed for randomized subjects based on the treatment assigned at randomization, with missing data imputed using the LOCF method. Supportive sensitivity analyses were performed as well.

For each ranibizumab dose group, non-inferiority to the control group was tested using a onesided testing procedure (or equivalently, using a one-sided CI) and a non-inferiority limit. Subject to the procedures for controlling overall Type I error, a test for a treatment difference compared with the control group could also be performed for each dose group.

To adjust for multiple comparisons of two ranibizumab dose groups with the control group, a Hochberg-Bonferroni multiple comparison procedure was used (Hochberg 1988).

The non-inferiority limit was based on the results of the Phase 3 trials of verteporfin PDT versus placebofrom the TAP Study. The value of 0.07 is approximately one-half of the minimum estimated difference (lower limit of a two-sided 95% CI) in the proportion of subjects with predominantly classic CNV who lost fewer than 15 letters at Month 12. For subjects with predominantly classic CNV, these proportions were 0.673 for verteporfin PDT-treated subjects and 0.393 for placebo-treated subjects, for an estimated treatment effect of 0.28 (95% CI, 0.153 to 0.407, using the normal approximation to the binomial distribution). It is also the case that 0.07 is equal to 25% of the treatment effect of verteporfin PDT versus placebo.

Laboratory Tests. Descriptive summaries of laboratory values, including changes from baseline and treatment-emergent abnormalities, were generated. The number and percentage of subjects with serum antibodies to ranibizumab at baseline and during the treatment period were tabulated.

Vital Signs and Physical Findings. Descriptive summaries of vital sign measurements and changes from baseline were generated.

Ocular Assessments. Results of the following ocular assessments were summarized by timepoint and by eye (study vs. fellow) using descriptive summaries: visual acuity, intraocular pressure, slitlamp examination, indirect ophthalmoscopy, fluorescein angiography, and fundus photography. The changes from baseline in intraocular pressure were tabulated. The presence of intraocular inflammation and vitreous hemorrhage, as determined from the slit lamp examination, were tabulated by grade (according to grading scales for flare/cells and vitreous

hemorrhage density). The presence of retinal break or detachment as determined from indirect ophthalmoscopy was tabulated.

Determination of Sample Size

The sample size was determined based on the analysis of the primary efficacy endpoint for treatment differences between each ranibizumab dose group and the control group. The planned sample size of 426 subjects was based on calculations using the following assumptions: 1:1:1 randomization ratio (0.3 mg of ranibizumab vs. 0.5 mg of ranibizumab vs. verteporfin PDT), the Pearson χ^2 test for comparison of two proportions (for each ranibizumab group vs. verteporfin PDT), and the Hochberg-Bonferroni multiple comparison procedure at an overall Type I error rate of 0.0497 (after adjustment for three planned interim safety analyses prior to the analysis of the primary efficacy endpoint). The power of the Hochberg-Bonferroni multiple comparison procedure was evaluated using Monte Carlo simulations.

The sample size of 426 subjects with predominantly classic CNV provided 96% power in the primary ITT analysis based on randomized subjects to detect a statistically significant difference between one or both ranibizumab groups and the verteporfin PDT group-in the percentage of subjects who lost fewer than 15 letters in visual acuity score at Month 12, assuming a rate of 84% in each ranibizumab group and 67% in the verteporfin PDT group.

Appears This Way On Original

Table 6.1.3.2-4

Study Flowchart: Screening, Treatment Phase Day 0 through Month 12, and Early Termination

	Screen	and the second second second	C. C. GORDENCE	and the series	and the second second	Apple Science St.	Lte	reatment Pha	Phase	State State	and the second second	「「「「「「「」」」」」」」」」」」」」」」」」」」」」」」」」」」」」」」	一般のないのない	「日本」を見たることの	加速日元の大学の	
		Dav				1.0.0	and the second secon	日の教授	Moh	the second	a state of the state		「日本の日本			With a set.
	-28.to	0	4	1	2		4	÷	6	đ.	8	6	-QU	ų	10	
Assessment Window (Days)	The second second	No. of Street, or	đ	1 LF	4Ŧ	-47	「「「」	14		たんか	1		ALL .	14	14 H	
Informed Consent	x							A MARK C. BOARD	-		and the second se					
Inclusion/Exclusion Criteria	×				<u> </u>											
Demographic data	×															
Height and Weight	×															
Medical and surgical history ^b	×				-	$\left \right $										
VFQ-25 °		×		×	×	×			×			×			×	×
SF-36 Health Survey ^c		×				-	-		×	-					×	×
HUI (at selected sites only) ^c	×	-				×				×			×			×
VAS ^c	×			×	×	×				×			×			×
Review of Body Systems	×								-						×	×
Serum pregnancy test ^d	×															
Contrast Sensitivity test ^{c, f}	x		×	×	×	×	-		×						×	×
Best corrected visual acuity (2 meter starting distance) ^{e, f}	×	x ⁸	×	×	×	×	×	×	-	×	×	×	×	×	x ^g	x ⁸
1								-					1.140			
														20000		

a For subjects who withdrew from the study early. Performed 30 days (±7 days) following the last injection or study visit.

c VFQ-25 (where local languages were available), SF-36 Health Survey (where local languages are available), HUI questionnaire (selected sited only), and VAS b Significant medical/surgical history, including chronic and ongoing conditions (e.g., trauma, cancer history, and ophthalmic history).

were to be administered to the subject prior to the subject's completing any other study procedures.

d For women of childbearing potential.

e Performed pre-treatment

f Performed prior to dilating eyes

g Also assessed at a starting test distance of 4 meters after assessing at a starting test distance of 2 meters

al BLA

Rnea A. Lloyd, MD 125156

ion)

Day
0 7
<u>_</u>
x x
×
X
××
x x
X
×
x
×

h Fluorescein angiography and color fundus photography were to be performed within 7 days prior to the scheduled study visit to allow adequate time for the evaluating physician to determine if PDT was necessary.

i Laboratory evaluations included hematology, blood chemistry, and urinalysis.

j The measurement method used for a subject was to remain consistent throughout the study.

k Obtained pre-treatment for both eyes and 60 minutes (± 10 minutes) post-injection for study eye only.

Active (verteporfin) or sham (saline) PDT, if needed or required by the protocol (Day 0), were to be administered prior to ranibizumab/sham injection (all timepoints).

m Active (verteportin) or sham (saline) PDT was administered based on need, as determined by assessment of fluorescein angiograms by the evaluating physician (Months 3, 6, 9 and 12 only).

n Injecting physician was to be performed within 15 minutes post-injection for study eye only.

o Performed post-treatment

	ДЮ
BLA	Lloyd,
7	Ś
ں	Rhea

Lloyd,	
Ř	56
hea	2515
Ч	1

Lucentis (ranibizumab injection)

(vicinity commence of the second se	-															
Study Period	Screen						Tre	atmen	t Phase				. :		: 3	Early
		Day							Month	th					- T	Term?
	-28 to -1	0	~	-	2	6	4	in .	9	2	~	6	10	Z,	12	
Assessment Window (Days)	-	1	1	17 1	14	±7	±7	77	11	Ľ#	14	t±	1 ∓	±7	1 4	30±7
Concomitant Medications ^p	×	x	×	×	×	×	×	×	×	×	×	×	×	×	×	×
Concurrent ocular procedures		x	×	×	×	×	×	×	×	×	×	×	×	×	×	×
Adverse Events ^{e. ö. q}		x	×	×	×	×	×	×	×	×	×	×	×	×	×	×
Follow-up contact ^r		×		×	×	×	×	×	×	×	×	×	×	×	×	

p Recorded any prescription drugs or over-the-counter preparations other than protocol-specified procedural medications (e.g., dilating drops, fluorescein dyes, etc.) and pre- and post-injection medications used by a subject within 7 days preceding Day0.

were to be followed, even after the subject's study anticipation was over, until the event resolved or the event was assessed as irreversible, chronic or stable. r Subjects were contacted 2 days (± 1 day) following treatment to elicit reports of any decreased in vision, eye pain, unusual redness, or any other new ocular q Adverse events were to be collected from Day 0 through the last study visit. Adverse events assessed by the evaluating physician as related to ranibizumab symptoms in the study eye. Subjects were also asked whether they had taken the prescribed post-injection antimicrobials.

Lucentis (ranibizumab injection) Ruwa A. Lloyd, MD al BLA 125156

Study Flowchart: Screening, Treatment Phase Day 0 through Month 12, and Early Termination Table 6.1.3.2-4

Study Period						Treatment Phase	t Phase	-					Early
	and shares and a					Month	th T						lerm.
a de la companya de La companya de la comp	13	14	15	16	17	18	-19	20	21	22	23	24	
Westman Window (Dws)		- 475-51	475	4 F3		14	11 ST	47.1	-47	4.4.4		2.F	- 1406
VFQ-25 ^b	×	*	x			×			×			×	x
SF-36 Health Survey ^b						×						×	x
HUI (at selected sites only) ^b	1		×				×			×		-	Х
VAS ^b	×	×	×				×			x			
Review of Body Systems			-									×	فيز
Best corrected visual acuity (2 meter starting distance) ^{c. d}	×	×	×	×	×	×	×	×	×	x	×	Xe	x
Slit Lamp Examination ^c	×	×	×	×	×	×	×	×	×	х	×	×	×
Dilated binocular indirect and high- magnification ophthalmoscopy ^c	×	×	х	×	×	×	×	×	×	×	×	×	x
Lens status assessment												×	
Fundus Photography			xŕ			x f			×			×	x
Fluorescein Angiography			xf			xſ			x			×	×

a For subjects who withdrew from the study early. Performed 30 days (±7 days) following the last injection or study visit. b VFQ-25 (where local languages were available), SF-36 Health Survey (where local languages are available), HUI questionnaire (selected sited only), and VAS were to be administered to the subject prior to the subject's completing any other study procedures.

c Performed pre-treatment

d Performed prior to dilating eyes.

e Also assess at a starting distance of 4 meters after assessing at a starting test distance of 2 meters.

f Fluorescein angiography and color fundus photography may have been performed within 7 days prior to the scheduled study visit to allow adequate time for the evaluating physician to determine if PDT is necessary.

	<u>n</u>
BLA	A. Llovd.
ð	Rhea

ШM	
Lloyd,	
thea A.	25156

	(injection)
	ranibizumab
0010	centis (

Lucentis (ranibizumab injection)													
Study Period					Ľ	Treatment Phase	nt Phase						Early
						Moi	uth						Term
	13	14	S.	16	17	18	19	20	21	22	23	24	
Assessment Window (Days)	#1	41	14	4	۲ ±	4	1 ∓	±1	L T	74	47	1 4	30±7
Contrast Sensitivity ^d								-		1		×	X
Laboratory Samples ⁸										-		: ,	; ,
Serum antihodies to ranihizumeh and												<	<
serum pharmacokinetic sample ^c												×	×
Intraocular pressure ^{h. t}	×	×	×	×	×	×	×	×	×	×	×	×	x
Active (verteporfin) or sham (saline)			, k			×			-			:	
photodynamic therapy (study eye only)			×			×			x				
Ranibizumab administration or sham													
injection (study eye only)	×	×	x	×	×	×	×	×	×	×	×		
Finger count, hand motion, light											-		
perception	×<,	×	×	×	×	×	×	×	×	×	×		
	A REAL PROPERTY AND ADDRESS OF TAXABLE PROPERTY.							-			-		

g Laboratory evaluations included hematology, blood chemistry, and urinalysis.

h Obtained pre-treatment for both eyes and 60 minutes (± 10 minutes) post-injection for study eye only.

i The measurement method used for a subject was to remain consistent throughout the study. J Active (verteporfin) or sham (saline) PDT, if needed, was administered prior to ranibizumab/sham injection (all timepoints).

k Active (verteporfin) or sham (saline) PDT was administered based on need, as determined by assessment of fluorescein angiograms by the evaluating physician.

.al BLA Rnea A. Lloyd, MD 125156

	e.	10 1	3					
	Å			7				
	-	lerm.		벌	×	×	×	×
	12							
			in the second			-		
				調約。 第2、57				
		14. 6	S.	1	×	×	۰×	×
	2.4	1			L			
			gar.					
			ER	EF.	×	×	×	×
		19			·			
	97. .e.		a	Ŧ	×	×	×	×
			6 5 5 K		-	•		
			2. 68 2. 1	141				
		100	5	Ŧ	×	×	×	\sim
	4					_		
			2.24 26 - 27					
		5	ă	्म	×	×	×	×
	•		1.17					
	as							
		ے ا	19	Ŧ	×	×	×	×
	i.			45				
	timer	Σ,	6	1				
	eat		H	H I	×	×	×	×
	E.	語を		9 1970				
			1	1				
			100	#	×	,×	×	×
					_	-		_
				.				
				Ę.	×	×	×	×
	R		- 142	100			-	
		ЦČ (S	L.	×	x	×	
			्र न्त र्थ	ΔŦ	\sim			×
		18 S	5 - 2 K Salar (2	18 18 - 1		-	-	-
			4	F	×	x	×	×
		20		47				1
			11月2日日 1月1日日	100 C				
				1				
			F	洲	×	×	×	×
	のないという	1	1.					
(III)								
cti		新聞語	6.2	(9		1	s	
-je			[]]	Jays	****	IS V	dub	
р. П		22		E		ion	Š	
ma				No.	ļ	cat	prc	2
ΠZ				Pa		edi	ar	а ú
idi	Ð			X.		Ž	cul	nts
ran	Ô.			10	s a	II	t o	vei
is (9			ssment	E,	nit	ren	H
Sut				2	S	10	Sur	ers
Lucentis (ranibizumab injection)	Ĕ.			ŝ	Vital Signs ^m	Concomitant Medications	Concurrent ocular procedures	Adverse Events c.m.n
	9				>	Ő	Q	Z

×

×

×

×

×

×

×

×

×

×

×

×

Follow-up contact o

1 Injecting physician was to be performed within 15 minutes post-injection for study eye only. m Performed post-treatment

n Adverse events were collected from Day 0 through the last study visit. Adverse events assessed by the evaluating physician as related to ranibizumab should o Subjects were contacted 2 days (± 1 day) following treatment to elicit reports of any decreases in vision, eye pain, unusual redness, or any other new ocular be followed, even after the subject's study participation is over, until the event resolves or the event is assessed as irreversible, chronic, or stable. symptoms in the study eye. Subjects were also asked whether they had taken the prescribed post-injection antimicrobials.

Table	6.1.3.2-5 Sub	ject Disposition
	Randomized	Subjects

	i seine ann an taraige ann an taraig	ounderor Shipes Kind	GA MODELD - S. S.
	1.1 	043(1)g - 1997 (664140) - 1	0-5 mg (n=140)
Completed Month 12 *	127	128	1 31
	(88.8%)	(91.4%)	(93.6%)
Discontinued Treatment	15	14	9
Prematurely	(10.5%)	(10.0%)	(6.4%)
Discontinued Study prematurely	10	10	5
	(7.0%)	(7.1%)	(3.6%)
Safety Evaluable Population	143	137	140
received study medication, as treated	(100%)	(97.9%)	(100%)
Intent-to-treat Population	143	140	140
\geq 1 on the rapy study visit	(100%)	(100%)	- (100%)
Per Protocol Population (for the analysis of 4 m BCVA at Month 12) No on-therapy study visits or protocol violation	114 (79.7%)	101 (72.1%)	103 (73.6%)
Excluded from PP Population	62	, 38	44
	(26.1%)	(11.8%)	(18.3%)
Pharmacokinetic-Evaluable	136	135	137
Population	(95.1%)	(96.4%)	(97.9%)

Note: Three subjects (301010, 345001, and 403004) in the 0.3 mg group did not receive any ranibizumab during the study.

Reviewer's Comment:

Overall, the study had good subject retention with 386 subjects completing Month 12 (91.3%).

The verteporfin PDT group (10.5%) and the ranibizumab 0.3 mg group (10.0%) had an almost equal number of subjects who discontinued treatment prior to Month 12. The ranibizumab 0.5mg group had the fewest subjects discontinue treatment at 6.4%.

Appears This Way On Original

Table 6.1.3.2-6- Major Protocol Deviations during the First Treatment Year	
Randomized Subjects	

.

	- riquellits	Ranibi	zumab
Deviation	Fina Ciectii	0.3 mg (N=140)	0.5 mg (N=140)
Any deviation	21 (14.7%)	36 (25: <u>7</u> %)	26 (18.6%)
Treatment error: incorrect treatment	2 (1.4%)	7 (5.0%)	2 (1.4%)
Treatment error: received verteporfin PDT + ranibizumab at the same visit	· 0	2 (1.4%)	2 (1.4%)
Treatment error: incorrect administration	1 (0.7%)	3 (2.1%)	1 (0.7%)
Treatment error: received study drug kit from Study FVF2598G	. 0	3 (2.1%)	0
Treatment: off-schedule verteporfin/sham PDT	0	1 (0.7%)	1 (0.7%)
Treatment assignment unmasked	2 (1.4%)	1 (0.7%)	4 (2.9%)
Pre- and post-treatment procedure not followed	4 (2.8%)	9 (6.4%)	6 (4.3%)
Treatment holding criteria not followed	2 (1.4%)	, 1 (0.7%)	2 (1.4%)
Open-label verteporfin PDT in fellow eye <21 days after last ranibizumab/sham injection	5 (3.5%)	7 (5.0%)	3 (2.1%)
Open-label verteporfin PDT in fellow eye <5 days after last ranibizumab/sham injection	1 (0.7%)	2 (1.4%)	1 (0.7%)
Received excluded concomitant treatment in study eye	1 (0.7%)	0	0
Cataract surgery in the study eye within <28 days of a ranibizumab/sham injection	0	4 (2.9%)	1 (0.7%)
Visual acuity (4m) not assessed at Day 0 (study eye)	2 (1.4%)	7 (5.0%)	1 (0.7%)
Visual acuity (2 m) not assessed at Day 0 (study eye)	0	1 (0.7%)	1 (0.7%)
Visual acuity (2m) assessment incomplete; unknown if vision was better than 20/20 (study eye)	.0	1 (0.7%)	0
Inconsistent method for measuring IOP	2 (1.4%)	2 (1.4%)	4 (2.9%)
Vital signs assessed predose	5 (3.5%)	3 (2.1%)	5 (3.6%)

Reviewer's Comments:

The most protocol deviations occurred in the ranibizumab 0.3 mg group (25.7%) followed by ranibizumab 0.5 mg (18.6%). Treatment errors, as a group, represented the majority of the protocol deviations in the ranibizumab 0.3 mg group.

The protocol deviations which occurred most frequently were the following: pre- and posttreatment procedures were not followed, open-label verteporfin PDT was administered in the fellow eye <21 days after the last ranibizumab/sham injection and vital signs were assessed predose, not post-dose.

Study Site I	D Subject ID	Relation Decombination	Study Day
	and the second sec	ker morin PDT Group	
S08190	301006	Subject's Decision	25
S08201	306018	AE - COPD Exacerbation, Recurrent pneumonia	106
S08586	315004	AE – Lung cancer	191
S08187	316003	AE – Perforated gastric ulcer	211
S08214	321009	AE Glioblastoma	177
S08146	326002	Subject's Decision - Decreasing vision	272
S08541	337006	Lost to follow-up	29
S08366	360002	AE - AMD requiring Macugen injxn, fellow eye	344
S08151	361001	Subject's Decision	130
S08314 -	364004	AE - Physician's Decision	302
S08221	368002	AE Myocardial infarction	239
S02891	373001	AE - Bilateral blepharoconjunctivitis	3
S09325	381008	AE – Retinal detachment	211
S09311	384007	AE - Death, Cardiac arrest	121
S09339	403002	Lost to follow-up (after Month 8)	368
		0.3 mg Group	· · · · · · · · · · · · · · · · · · ·
S08190	301010	AE – Progression of AMD	1
S08220	302007	Non- compliance	271
S07441	303001	AE – Retinal detachment	58
S08214	321003	AE – Death, respiratory arrest	235
S08130	335004	AE – Blurred vision (unchanged VA)	361
S08541	337003	AE - Death, cardiac arrest	282
S07438	343005	AE – Lung cancer	278
S08222	344004	AE – Stroke	136
S08252	345001	Subject's Decision - never received treatment	7
S02201	352003	Subject's Decision - multiple medical problems	183
S08133	358003	AE - Recurrent CNVM, fellow eye	337
S08258	374003	AE – Death, viral infection	289
S09308	389003	Subject's Decision -	182
S09339	403004	Physician's Decision - never received treatment	1
ter (US ng Group	
S08220	302011	Lost to follow-up	180
S08165 ···-	1 31/004	AE - Death, Congestive Heart Failure	219
S00444	319008	Subject's Decision	31
S08222	344005	AE Progression of CNVM	175
S08234	349006	AE - Afferent pupillary defect	357
S08224	350004	Subject's Decision	212
S08083	369001	AE – Multiple infections	225
S09311	384003	AE - Death, cardiac failure	98
S09308	389001	AE Severe uveitis	271

Study FVF2587g

Reviewer's Comments:

Treatment discontinuations occurred at about the same frequency in the verteporfin PDT (15/143) and ranibizumab 0.3 mg group(14/140). In both groups, the reasons for discontinuation were most frequently adverse events due to systemic disease.

		Rani	bizumab
	Verteportin	di ang	0.5 mg
Demographic	(由新闻43) (加加号1 40)	(n = 140)
Age (yr)			
Mean (SD)	77.7 (7.8)	77.4 (7.5)	76.0 (8.6)
Range	53-95	54-97	54-93
Age group (yr)			
50 to < 65	8 (5.6%)	9 (6.4%)	14 (10.0%)
$65 \text{ to} < 75^{-17}$	35 (24.5%)	28 (20.0%)	41 (29.3%)
75 to < 85	74 (51.7%)	84 (60.0%)	64 (45.7%)
≥ 85 ·	26 (18.2%)	19 (13.6%)	21 (15.0%)
Sex		- 7	
Male	64 (44.8%)	73 (52.1%)	75 (53.6%)
Female	79 (55.2%)	67 (47.9%)	65 (46.4%)
Race/ethnicity			
White	140 (97.9%)	137 (97.9%)	136 (97.1%)
Black	1 (0.7%)	0	1 (0.7%)
Hispanic	1 (0.7%)	3 (2.1%)	2 (1.4%)
Other	1 (0.7%)	0	0
Any prior therapy for AMD	64 (44.8%)	63 (45.0%)	58 (41.4%)
Laser photocoagulation	19 (13.3%)	23 (16.4%)	20 (14.3%)
Medication / Supplements	52 (36.4%)	49 (35.0%)	46 (32.9%)

Table 6.1.3.1-8 Demographic Statistics by Treatment Group Intent-to-Treat, Randomized Subjects

Reviewer's Comment:

The demographics of the subjects in the study were well balanced. The predominance of white elderly adults is representative of the population affected by this disease rather than a problem with enrollment.

Approximately 40% of subjects reported prior therapy for AMD in the study eye and approximately 15% reported prior laser photocoagulation in the study eye. No subjects had prior verteporfin PDT therapy because the study excluded it.

		Ranib	izumab
Characteristics	PDT (n=143)	0,3 mg 140)	0.5 mg (n = 140)
Years since first diagnosis of neovascular AMD	····	2	
N	142	140	140
Mean (SD)	0.4 (0.9)	0.3 (0.6)	0.3 (0.6)
Range	0.0 - 5.4	0.0 - 5.4	0.0 - 7.3
Visual acuity at a starting test distance of 4 meters			
N	141	133	139
Number of letters (0–100)			
Mean (SD)	45.1 (15.2)	47.4 (13.7)	46.4 (14.8)
Range	3-73	1-74	0-75
≤ 44	62 (44.0%)	52 (39.1%)	57 (41.0%)
≥ 45	79 (56.0%)	81 (60.9%)	82 (59.0%)
Approximate Snellen equivalent			
Median	20/125	20/100	20/125
20/200 or worse	39 (27.7%)	37 (27.8%)	35 (25.2%)
Better than 20/200 but worse than 20/40	100 (70.9%)	92 (69.2%)	98 (70.5%)
20/40 or better	2 (1.4%)	4 (3.0%)	6 (4.3%)
Intraocular pressure (mmHg)			
N	143	140	140
Mean (SD)	15.2 (3.2)	15.2 (3.7)	15.4 (3.4)
Range	3-24	9–26	9–26
0-21	136 (95.1%)	133 (95.0%)	133 (95.0%)
2229	7 (4.9%)	7 (5.0%)	7 (5.0%)

Table 6.1.3.2-9 Baseline Ocular Characteristics in the Study Eye Intent-to-Treat, Randomized Subjects

Reviewer's Comment:

The baseline ocular characteristics of the study eye were well balanced. The mean visual acuity ranged from 45.1 to 47.4 letters (Snellen equivalent 20/100 - 20/125) at a starting test distance of 4 meters.

Table 6.1.3.2-10 Fluorescein Angiography and Fundus PhotographyCharacteristics of the Study Eye at BaselineIntent-to-Treat, Randomized Subjects

		Ranib	izumab
	The Yean man	0.3 mg	0.5 mg
Characteristics		(n =140)	(n = 140)
CNV classification			<u> </u>
Predominantly classic	141 (98.6%)	134 (95.7%)	135 (96.4%)
Minimally classic	2 (1.4%)	5 (3.6%)	5 (3.6%)
Occult without classic	0	1 (0.7%)	0
Total area of lesion (DA)	-		
Mean (SD)	1.88 (1.40)	1.89 (1.44)	1.79 (1.54)
Range	0.07-5.75	0,12-7.20	0.05-10.00
< 2 DA	93 (65.0%)	98 (70 .0%)	93 (66.4%)
>2 to 4 DA	34 (23.8%)	32 (22.9%)	34 (24.3%)
> 4 DA	16 (11.2%)	10 (7.1%)	.13 (9.3%)
Total area of CNV (DA)			
Mean (SD)	1.48 (1.25)	1.48 (1.33)	1.31 (1.24)
Range	0.07-5.55	0.11-6.80	0.05-7.50
Area of classic CNV (DA)			,
Mean (SD)	1.36 (1.13)	1.28 (1.05)	1.21 (1.12)
Range	0.07-5.55	0.00-6.40	0.05-5.30
Total area of leakage from CNV plu		E staining (DA)	
Mean (SD)	3.06 (1.81)	3.00 (1.92)	2.92 (2.08)
Range	0.20-8.20	0.20-11.00	0.25-9.00
Area of subretinal fluid (DA) ^a			
Mean (SD)	4.34 (2.15)	4.17 (2.43)	4.26 (2.53)
Range	0.00-9.00	0.00-14.00	0.00-12.00
Presence of occult CNV			
Absent	114 (79.7%)	107 (76.4%)	111 (79.3%)
Questionable	13 (9.1%)	12 (8.6%)	11 (7.9%)
Present	16 (11.2%)	21 (15.0%)	18 (12.9%)

a Subretinal fluid is also known as serous sensory retinal detachment. n=135 for the verteporfin PDT group, n=124 for the 0.3 mg group, and n=123 for the 0.5 mg group.

Reviewer's Comment:

There was no significant difference in the baseline characteristics of the CNY lesions across the treatment groups.

The vast majority of subjects had predominantly classic CNV lesions in each treatment group.

6.1.4 Efficacy Findings

6.1.4.1 Study FVF2598g Efficacy Results

The efficacy analysis was based on all randomized subjects with treatment groups as assigned, the intent-to-treat population with the LOCF method used to impute missing data. Some subjects did receive a treatment for which they were not randomized. These subjects were included in an "as treated" population in the safety analyses.

Reviewer's Comment:

As noted in Section 2.5 regarding previous correspondence and meetings, the Agency does not agree with the sponsor's primary efficiency endpoint.

Visual acuity testing is recommended to be performed with at target distance of a minimum of 4 meters from the patient. This distance measure (4 meters) is recommended to minimize the potentially confounding influences of accommodation and patient positioning on the measurement.

For the purposes of this review, the Agency will consider the primary efficacy endpoint as the proportion of subjects with a loss of fewer than 15 letters in the visual acuity score in the study eye at 12 months compared with baseline, based on assessments at a starting test distance of 4 meters not 2 meters.

Appears This Way On Original

STUDY FVF2598g - PRIMARY EFFICACY RESULTS

Table 6.1.4.1-1

Proportion of Subjects Losing <15 Letters in Visual Acuity for the Study Eye at 12 Months Compared with Baseline at a Starting Distance of 4 Meters:

			2000
	Sinn	Ranib Ranib	
Rand	lomized subjects of		
N	229	229	230
Responders ^c	138 (60.3%)	213 (93.0%)	209 (90.9%)
95% CI of the % ^a	(53.9%, 66.6%)	(89.7%, 96.3%)	(87.1%, 94.6%)
Difference in % (vs. sham) b		32.3%	29.9%
95% CI of the difference ^b		(25.3%, 39.4%)	(22.7%, 37.1%)
	er Protocol Subject		
N	176	200	196
Responders ^c	106 (60.2%)	187 (93.5%)	181 (92.3%)
95% CI of the % ^a	(53.0%, 67.5%)	(90.1%, 96.9%)	(88.6%, 96.1%)
Difference in % (vs. sham) ^b		33.3%	32.1%
95% CI of the difference ^b	A	(25.3%, 41.3%)	(24.0%, 40.3%)

a By normal approximation; b Weighted estimates adjusting for the strata by using CMH weights; c From Cochran Chi Square tests adjusted for the strata (p<.0001).

Reviewer's Comment:

Based on the Hochberg-Bonferroni multiple comparison procedure defined within the protocol, the ranibizumab 0.3 mg and 0.5 mg doses demonstrate efficacy in this trial. The primary efficacy endpoint result for both ranibizumab groups is strongly statistically significant at p<0.0001 for each.

There is an approximate 30% treatment effect with both ranibizumab doses. At the 12 month primary efficacy endpoint, 93% of subjects in the ranibizumab 0.3-mg group and 90.9% of subjects in the ranibizumab 0.5-mg group lost fewer than 15 letters of vision from baseline compared with 60.3% of subjects in the sham injection group.

The number of subjects considered in each group was decreased in the Per Protocol analysis because some subjects did not have baseline visual acuity tested at 4 meters.

Table 6.1.4.1-2

Sensitivity Analysis of Visual Acuity for the Study Eye at 12 Months (Worst Outcome Imputation) at a Starting Distance of 4 Meters

	Sha (Yi-2 U)	0.9 mz (0.9 mz (0229)	izumab 0.5 mg (N=230)
Rango	mized Subjects Lt	DCF	
N	229	229	230
Responders	118 (51.5%)	201 (87.8%)	194 (84.3%)
95% CI of the % ^a	(45.1%, 58.0%)	(83.5%, 92.0%)	(79.7%, 89.2%)
Difference in % (vs. sham) ^b		36.2%	32.8%
95% CI of the difference ^b		(28.5%, 44.0%)	(24.8%, 40.8%)
p-value (vs. sham) ^c		<0.0001	< 0.0001

a By normal approximation; b Weighted estimates adjusting for the strata by using CMH weights; c From Cochran Chi Square tests adjusted for the strata.

Reviewer's Comment:

The statistically significant demonstration of efficacy is preserved with a greater than 30% treatment effect in the worst outcome imputation – sensitivity analysis.

Appendia into very **On Original**




Table 6.1.4.1-3 Study Eye Visual Acuity Comparisons between Baseline and Month 12 Starting Test Distance of 4 meters: Randomized Subjects

Efficacy Variable	20 (10 (1) (i	$\sum_{i=1}^{n} \frac{\sin i \pi i}{(1-2i)}$	Rini 3 - 0 J mg 3 - (C= 729)	0.5 mg (N=230)
Gain of \geq 15 letters from baseline	Yes	14 (6.1%)	42 (18.3%)	72 (31.3%)
Loss of <30 letters from baseline	Yes	193 (84.3%)	226 (98.7%)	226 (98.3%)
Mean change in visual acuity from baseline in ETDRS letters (SD)		-11.0 (17.9)	5.4 (13.4)	6.3 (14.1)
Number of Lines VA Change from Baseline		-2.2 (3.6)	1.1 (2.7)	1.4 (3.0)

Reviewer's Comment:

The differences were all statistically significant at the p < .0001 level. There appears to be a dose effect in the gain of ≥ 15 letters of vision from baseline, though this comparison was not a planned statistical comparison.

There is a statistically significant difference between sham and ranibizumab treatment groups in the prevention of vision loss defined as a loss of <30 letters. There is a statistically significant difference in the change in visual acuity from baseline, p<0.001, though this change is not considered clinically meaningful.

Table 6.1.4.1-4Study Eye Visual Acuity at Month 12Starting Test Distance of 4 metersRandomized Subjects

ing shirts a start		Ranib	izumab
Efficacy Variable	onse (n. 287)	0.3/mg (N=238)	0.5 mg (N=240)
Mean Visual Acuity in ETDRS letters (SD)	42.5 (19.1)	58.8 (17.1)	59.9 (17.9)
Snellen Equivalent VA $\leq 20/200$	102 (43.0%)	29 (12.2%)	28 (11.7%)

Reviewer's Comment:

There is a clinically meaningful and statistically significant (p<.0001) difference in mean visual acuity at Month 12 in ETDRS letters between the sham and ranibizumab treatment groups of 16 letters in the 0.3-mg group and 17 letters in the 0.5-mg group.

Table 6.1.4.1-5

Mean Change from Baseline in the Total Area of Lesion, Area of Classic CNV, and Area of Subretinal Fluid and the Proportion of Subjects with a Significant Growth of CNV in the Study Eye at 12 Months Randomized Subjects

Change from Baseline and Months	Silian I Ali	and Ranibizumab	
) - 1 migazi 2 (3) - 2 (8)	+ 0.5 mg (N≡240)
Change in the total area of lesion (DA)	un de la companya de		
N ·	238	238	240
Mean (SD)	2.33 (2.89)	0.11 (2.07)	0.14 (1.97)
Difference in LS means (vs. sham) ^a		-2.21	-2.18
Change in the area of classic CNV (DA)			
N ^b	87	. 86	91
Mean (SD)	0.79 (2.06)	-0.22 (0.44)	-0.23 (0.61)
Difference in LS means (vs. sham) ^c	-	-1.02	-1.02
Change in the area of SSR detachment/subretinal fluid			
N	220	218	218
Mean (SD)	1.08 (4.57)	-2.08 (4.31)	-2.62 (3.69)
Difference in LS means (vs. sham) ^a		-3.12	-3.66
Significant growth of CNV (≥ 0.3 DD increase)			
N	238	238.	240
Mean (SD)	118 (49.6%)	31 (13.0%)	39 (16.3%)
Difference in LS means (vs. sham) ^a		-36.5%	-33.5%

NOTE: The LOCF method was used to impute missing data. Strata were defined using two factors: baseline CNV classification (minimally classic vs. occult without classic) and baseline visual acuity score (2 meters, ≤ 54 vs. ≥ 55 letters).

a Based on pairwise analysis of covariance models adjusted for the two stratification factors and baseline value of the endpoint (p<.0001). b Included subjects with minimally classic CNV at baseline only. c Based on pairwise analysis of covariance models adjusted for the baseline value of the endpoint and the baseline visual acuity category.

Reviewer's Comment:

Ranibizumab groups showed statistically significant differences when compared with the sham group (p < 0.0001) in the mean change from baseline to 12 months in the total lesion area, the area of classic CNV, and the area of subretinal fluid. These differences are not necessarily clinically significant.

Table 6.1.4.1-6 Mean Change from **Baseline in Retinal** Thickness and Total Retinal Volume in the Study Eye at 12 Months: Randomized Subjects in the OCT Subset

	A & A & A & A & A & A & A & A & A	
Change from Baseline and Colorins.	Shant (Ni-16)	Ruubizumab poolee (N≡37)
Foveal retinal thickness ^c (µm)		
N	15	31
Mean (SD)	-15.1 (131.6))	-122.5 (138.7)
Difference in LS means (vs. sham) ^a		-89.9
p-value (vs. sham) ^a		0.0088
Central retinal thickness ^d (µm)		
N	10	25
Mean (SD)	-1.8 (67.1)	-139.3 (113.9)
Difference in LS means (vs. sham) ^a		-103.2
p-value (vs. sham) ^a		0.0017
Total retinal volume (mm ³)		
N	10	23
Mean (SD)	-0.07 (0.82)	-1.42 (0.99)
Difference in LS means (vs. sham) ^a		-1.40
p-value (vs. sham) ^a		< 0.0001

a Based on the analysis of covariance models adjusted for baseline value of the endpoint.


b Only the measurements based on the nominal scan diameter of 6.0 mm are included.

c Defined as the average thickness in microns of the center of the fovea based on the intersection of 6 radial line scans.


d Defined as the average retinal thickness in microns of the central retinal subfield (encompassing the foveal region), which in turn is one of 9 subfields modeled after the ETDRS macular grid (central, four inner and four outer subfields).

Reviewer's Comment:

Within the subset of patients who were assessed with optical coherence tomography (OCT), the pooled ranibizumab group experienced statistically significant decreases in foveal retinal thickness, central retinal thickness and total retinal volume.







APOTEX V. REGENERON IPR2022-01524 REGENERON EXHIBIT 2024 PAGE 108

al BLA Rnea A. Lloyd, MD 125156 Lucentis (ranibizumab injection) SUBGROUP ANALYSES – PRIMARY EFFICACY VARIABLE

Table 6.1.4-6 Subgroup Analysis for the Proportion Losing <15 Letters in Visual Acuity in the Study Eye at 12 Months Compared with Baseline at a Starting Test Distance of 4 Meters: Randomized Subjects

-						
a incomina 1441 articula Trans 1830 incomination (1920)	Sitem -	Ranibizunab	dilling to the second second	Sham	Ranbis	unab.
n in Suntayo		0.3 mg 37 4	0.5 0.5		and the state of the second	12 DIC
NATE OF THE PROPERTY AND A CONTRACT OF THE PROPERTY AND A CONTRACT OF THE ACCOUNT OF		Age < 75 Years			Age ≥ 75 Years	
Z	73		51	156	154	155
n (%)	47 (64.4%)	70 (93.3%)	70 (93.3%)	91 (58.3%)	143 (92.9%)	139 (89.7%)
95% CI of the %	(53.4%, 75.4%)	(87.7%, 99.0%)	(87.7%, 99.0%)	(50.6%, 66.1%)	(88.8%, 96.9%)	(84.9%, 94.5%)
Difference in % (vs. Sham)		28.9%	28.9%		34.5%	31.3%
p-value (vs. sham)		<0.0001	<0.0001		<0.0001	<0.0001
		Female	-		Małe	
Z	152	148	148	79	81	82
n (%)	90 (59.2%)	139 (93.9%)	135 (91.2%)	48 (62.3%)	74 (91.4%)	74 (90.2%)
95% CI of the %	(51.4%, 67.0%)	(90.1%, 97.8%)	(86.7%, 95.8%)	(51.5%, 73.2%)	(85.2%, 97.5%)	(83.8%, 96.7%)
Difference in % (vs. Sham)		34.7 %	32.0%		29.0%	27.9%
p-value (vs. sham)		<0.0001	<0.0001		<0.0001	<0.0001
		< 54 Letters	-		≥ 55 Letters	
N	103.	110	114	126	119	116
n (%)	74 (71.8%)	104 (94.5%)	108 (94.7%)	64 (50.8%)	74 (91.4%)	74 (90.2%)
95% CI of the %	(63.2%, 80.5%)	(90.3%, 98.8%)	(90.6%, 98.8%)	(42.1%, 59.5%)	(86.6%, 96.6%)	(81.0%, 93.2%)
Difference in % (vs. Sham)		22.7 %	22.9%		40.8%	36.3%
p-value (vs. sham)		<0,0001	<0.0001	-	<0.0001	<0.0001

Lucentis (ranibizumab injection)	-			•		
Loss of < 15 Letters from Besoling of Month 12		Ranib	Ranibizumab		Ranib	Ranibizumab
in the Study Eye	олаш	0.3 mg	0.5 mg	Snam	0.3 mg	
	Minimal	mally Classic CNV at	at Baseline	Occult with	Occult with No Classic CNV at Baseline	at Baseline
Z	80	85	88	149	143	141
n (%)	51 (63.8%)	79 (92.9%)	81 (92.0%)	87 (58.4%)	133 (93.0%)	127 (90.1%)
95% CI of the %	(53.2%, 74.3%)	(87.5%, 98.4%)	(86.4%, 97.7%)	(50.5%, 66.3%)	(88.8%, 97.2%)	(85.1%, 95.0%)
Difference in % (vs. Sham)		29.2 %	28.3 %		34.6 %	31.7 %
p-value (vs. sham)		<0.0001	<0.0001		<0.0001	<0.0001
	Base	aseline Lesion Size ≤ 4 DA	4 DA	Base	Baseline Lesion Size > 4 DA	4 DA
Z	119	130	119	110	66	111
n (%)	72 (60.5%)	121 (93.1%)	81 (92.0%)	66 (60.0%)	192 (92.9%)	98 (88.3%)
95% CI of the %	(51.7%, 69.3%)	(88.7%, 97.4%)	(88.8%, 97.8%)	(50.8%, 69.2%)	(87.9%, 98.0%)	(82.3%, 94.3%)
Difference in % (vs. Sham)		32.6 %	32.8 %		32.9 %	28.3 %
p-value (vs. sham)		<0.0001	<0.0001		<0.0001	<0.0001
	With Pri	Prior Laser Photocoagulation	igulation	With No P	With No Prior Laser Photocoagulation	oagulation
Z	20	12	14	209	217	216
n (%)	10 (50.0%)	12 (100.0%)	13 (92.9%)	128 (61.2%)	201 (92.6%)	196 (90.7%)
95% CI of the %	(28.1%, 71.9%)	(100%, 100%)	.(79.4%, 100%)	(54.6%, 67.8%)	(89.1%, 96.1%)	(86.9%, 94.6%)
Difference in % (vs. Sham)		50.0 %	42.9 %		31.4 %	29.5 %
p-value (vs. sham)		0.0040	0.0068		<0.0001	<0.0001
Reviewer's Comment: The approximately 30% treatment effect was maintained and was statistically, significant to the 0 0001 11	ment effect was mai	ntained and was sto	unoficanis vilnoiti			
entroune which had small muchan of antions. In additional to the	mon syses musicing	In workfords with L	וואוורמווא אוצוואורמוו	LIO LITE D_U.UUUI	evei in ait except fo	or a jew

There was a small number of patients in the prior laser photocoagulation subgroup (N=35). The treatment effect was higher in this subgroup with the Ranibizumab 0.3 mg dose, 50.0% (p=0.0040) than with the Ranibizumab 0.5 mg dose, 42.9% (p=0.0068). approximately 22%.

subgroups which had small numbers of subjects. In patients with baseline visual acuity of ≤ 54 Letters, the treatment effect was

APOTEX V. REGENERON IPR2022-01524 REGENERON EXHIBIT 2024 PAGE 110

C. J BLA Rhea A. Lloyd, MD 125156

Original BLA Rhea A. Lloyd, MD 125156 Lucentis (ranibizumab injection)

6.1.4.2 Study FVF2587g - Primary Efficacy Results

The efficacy analysis was based on all randomized subjects with treatment groups as assigned, the intent-to-treat population with the LOCF method used to impute missing data. Some subjects did receive a treatment for which they were not randomized.

Reviewer's Comment:

As noted in Section 2.5 regarding previous correspondence and meetings, the Agency does not agree with the sponsor's primary efficacy endpoint. Visual acuity testing is recommended to be performed with at target distance of a minimum of 4 meters from the patient. This distance measure (4 meters) is recommended to minimize the potentially confounding influences of accommodation and patient positioning on the measurement.

For the purposes of this review the Agency will consider the primary efficacy endpoint as the proportion of subjects with a loss of fewer than 15 letters in the visual acuity score in the study eye at 12 months compared with baseline, based on assessments at a starting test distance of 4 meters not 2 meters.

STUDY FVF2587g - PRIMARY EFFICACY RESULTS

Table 6.1.4.2-1

Proportion of Subjects Losing <15 Letters in Visual Acuity for the Study Eye at 12 Months Compared with Baseline at a Starting Distance of 4 Meters: Randomized Subjects

	V jepořní půdi 107745	Rauli 0:5 mg n 140	The second s
Land	omized Subjects 1.01		
N	141	133	. 139
Responders	93 (66%)	126 (94.7%)	136 (97.8%)
95% Cl of the % ^a	(58.1%, 73.8%)	(90.9%, 98.5%)	(95.4%, 100%)
Difference in % (vs. verteporfin PDT) ^b		29.0%	
95% CI of the difference ^b		(20.4%, 37.6%)	(24.0%, 40.2%)
Non-inferiority test			
One-sided (1- a) 100% Cl of the difference (vs. verteporfin PDT) ^{b, c}	-	(20.4%,)	(23.9%,)
p value (vs. verteporfin PDT) ^{d, e}		<0.0001	<0.0001

Note: Strata were defined using baseline visual acuity score (4 meters, ≤44 vs. ≥45 letters).

a By normal approximation; b Weighted estimates adjusting for the strata by using CMH weights and normal approximation of the weighted estimates; c $\alpha = 0.0246$; d From normal approximation tests adjusted for the strata.; e From Cochran Chi Square tests adjusted for the strata

Table 6.1.4.2-2

Proportion of Subjects Losing <15 Letters in Visual Acuity for the Study Eye at 12 Months Compared with Baseline at a Starting Distance of 4 Meters: Per-Protocol Subjects

	V-riporu a Phr n⊇ s n Status Status	。 新聞語語的在了1.02~2.02~	2000ab 0:5 mg n=140
N	114	101	103
Responders	70 (61.4%)	95 (94.1%)	100 (97.1%)
95% CI of the % ^a	(52.5%, 70.3%)	(89.4%, 98.7%)	(93.8%, 100%)
Difference in % (vs. verteporfin PDT) ^b		32.7%	35.7%
95% CI of the difference ^b		(22.6%%, 42.7%)	(26.2%, 45.2%)
Non-inferiority test			
One-sided $(1 - \alpha)$ 100% CI of the difference (vs. verteporfin PDT) ^{b. c}		(23,2%,)	(26.4%,)
p-value (vs. verteporfin PDT) ^{d.e}		<0.0001	<0.0001

Note: Observed cases only. Strata were defined using baseline visual acuity score (4 meters, \leq 44 vs. \geq 45 letters). a All tests and CIs are two-sided (except non-inferiority tests) and based on pairwise models. b Based on normal approximation for binomial proportions. c α =0.0246 d From normal approximation tests adjusted for the strata.; e From Cochran Chi Square tests adjusted for the strata

Reviewer's Comment:

The number of subjects considered in each group was slightly decreased because baseline visual acuity at a starting test distance of 4 meters was not obtained in all subjects.

Based on the pre-specified criteria for assessing significance, the ranibizumab 0.3 mg and 0.5 mg doses demonstrate efficacy in this trial. The primary efficacy endpoint result for both ranibizumab groups is highly statistically significant at p < 0.0001 for each dose for the Intent-to-Treat and Per Protocol populations.

There is an approximate 30% treatment effect with both doses. At the 12 month primary efficacy endpoint, 94.1% of subjects in the Ranibizumab 0.3-mg group and 97.1% of subjects in the Ranibizumab 0.5-mg group lost fewer than 15 letters of vision from baseline compared with 61.4% of subjects in the verteporfin PDT group. The favorable treatment effect of each of the ranibizumab doses over the verteporfin PDT group was statistically significant, p<0.0001.

For each ranibizumab dose, the lower limit of the one-sided CI (at α =0.0246) for the difference in the percentage from the verteporfin PDT group far exceeded the pre-specified non-inferiority limit of -7%, and the non-inferiority test was statistically significant, p<0,0001.

Table 6.1.4.2-3Sensitivity Analysis of Visual AcuityIn the Study Eye at Month 12(Worst Outcome Imputation) at a Starting Distance of 4 Meters

Primary Efficacy variable Loss of <15 Letters from Baseline	19 (Per 19)		and the second
Rind			
N	141	133	139
Responders	79 (56.0%)	113 (85.0%)	122 (87.8%)
95% CI of the % ^a	(47.8%, 64.2%)	(78.9%, 91.0%)	(82.3%, 90.5%)
Difference in % (vs. Verteporfin PDT) ^b		28.9%	31.7%
95% CI of the difference ^b		(18.7%, 39.1%)	(21.9%, 41.6%)
Non-inferiority test		•	
One-sided (1- α) 100% CI of the difference (vs. verteporfin PDT) ^{b, c}		(19.1%,)	(22.2%,)
p-value (vs. Verteporfin PDT) ^{d,e}		< 0.0001	<0.0001

Note: Observed cases only. Strata were defined using baseline visual acuity score (4 meters, \leq 44 vs. \geq 45 letters). a All tests and CIs are two-sided (except non-inferiority tests) and based on pairwise models. **b** Based on normal approximation for binomial proportions. **c** α =0.0246 **d** From normal approximation tests adjusted for the strata.; e From Cochran Chi Square tests adjusted for the strata

Reviewer's Comment:


The statistically significant demonstration of efficacy is preserved in the worst outcome imputation – sensitivity analysis. The treatment effect of approximately 30% is preserved in both the intent-to-treat and per protocol populations.

Appears This Way On Original

O. BLA Rhea A. Lloyd, MD 125156 Lucentis (ranibizumab injection)

SECONDARY EFFICACY ENDPOINT RESULTS

Chart 6.1.4.2-1



Reviewer's Comment:

The difference in mean change from baseline in visual acuity between each of the ranibizumab groups versus the verteporfin PDT group was highly statistically significant (p<0.001) at each monthly assessment.

Table 6.1.4.2-4Study Eye Visual Acuity Comparisons between Baseline and Month 12Starting Test Distance of 4 metersRandomized Subjects

	22			
Efficacy Variable			Ranib Quing (N≡140)	20.5 mg (N=140)
Gain of \geq 15 letters from baseline		N=141	N=133	N=139
	Yes	15 (10.6%)	37 (27.8%)	51 (36.7%)
Loss of <30 letters from baseline		N=141	N=133	N=139
	Yes	125 (88.7%)	131 (98.5%)	139 (100%)
Mean change in visual acuity		N=141	<u>N=1</u> 33	N=139
from baseline in ETDRS letters (SD)		-8.5 (17.8)	7.2 (15.3)	11.0 (15.8)
Number of Lines VA Change	and the property of the second se	N=141	N=133	N=139
from Baseline Mean (SD)		-1.7 (3.6)	1.5 (3.1)	2.3 (3.3)

p<.0005 for all comparisions to sham

Reviewer's Comment:

A clinically meaningful and statistically significant gain in 15 letters of vision was noted in the 0.3 mg ranibizumab group and the 0.5 mg group, 27.8% and 36.7%, respectively when compared to the verteporfin PDT treatment group, 10.6%. There appears to be a dose effect in this increase in vision though this comparison was not a planned statistical comparison.

There is a statistically significant difference between verteporfin PDT and ranibizumab treatment groups in the prevention of vision loss of <30 letters.

There is a statistically significant difference in the change in visual acuity from baseline though this change is not considered clinically meaningful.

Table 6.1.4-5Study Eye Visual Acuity at Month 12Starting Test Distance of 4 metersRandomized Subjects

			Rame	uzumab
Efficacy Variable			(N=238)	0.5 mg. (N=240)
Mean Visual Acuity at Month 12		N=143	• N=139	N=140
in ETDRS letters (SD)		36.3 (16.6)	54.6 (19.1)	57.6 (18.6)
	p-value		< 0.0001	< 0.0001
Snellen Equivalent VA of 20/200		N=143	N=139	N=140
or Worse		81 (56.6%)	32 (23.0%)	23 (16.4%)
	p-value		- <0:0 001	< 0.0001

Reviewer's Comment:

There is a clinically meaningful and statistically significant difference in the mean visual acuity at Month 12 between the verteporfin PDT and ranibizumab 0.5- mg treatment group. The difference between the verteporfin PDT and ranibizumab 0.3-mg is statistically significant and approaches a clinically relevant result.

There is a statistically significant difference in the number of patients with Snellen equivalent visual acuity of 20/200 or worse between the sham and ranibizumab treatment groups.

Appears This Way On Original

Table 6.1.4.2-6

Mean Change from Baseline in the Total Area of Lesion, Area of Classic CNV, and Area of Subretinal Fluid and the Proportion of Subjects with a Significant Growth of CNV in the Study Eye at 12 Months Randomized Subjects


	Contracting (Ranio	zumab
Change from Baseline at Month		0. mag (t)[=140)).÷	0.5 mg (N=140)
Change in the total area of lesion (DA)			
N	143	140	140
Mean (SD)	2.56 (3.09)	0.36 (1.06)	0.28 (1.29)
Difference in LS means (vs. verteporfin PDT) ^b		-2.20	-2.30
Change in total area of CNV ^d (DA)			
N ^b	143		140
Mean (SD)	1.63 (2.27)	0.20 (0.97)	0.22 (1.25)
Difference in LS means (vs. verteporfin PDT) ^b		-1.42	-1.45
Change in the area of subretinal fluid ^c			
N	135	124	123
Mean (SD)	-0.58 (4.02)	-2.68 (2.74)	3.39 (2.90)
Difference in LS means (vs. verteporfin PDT) ^b		-2.23	-2.89
Significant growth of CNV (≥ 0.3 DD increase)			
N	143	140	140
Mean (SD)	84 (58.7%)	30 (21.4%)	38 (27.1%)
Difference in % (vs. verteporfin PDT) ^{e.1}		-37.3%	-31.7%


NOTE: The LOCF method was used to impute missing data. Strata were defined using baseline visual acuity score (2 meters, ≤ 44 vs. ≥ 45 letters).

a Based on t-distribution. b Based on pairwise analysis of covariance models adjusted for the stratification variable and baseline value of the corresponding endpoint. c Subretinal fluid is also known as serous sensory retinal detachment. d 95-95% of subjects had predominantly classic lesions. 85-92% of each CNV was classic in type.
e Weighted estimates adjusting for the strata by using the CMH weights and normal approximation of the weighted estimates. f From Cochran chi square tests adjusted for the strata

Reviewer's Comment:

Ranibizumab groups showed highly statistically significant differences with the verteporfin PDT group (p < 0.0001) in the mean change from baseline at 12 months in the total lesion area, total area of CNV, area of subretinal fluid and in the growth of CNV.





Best Available Copy

Note: The LOCF method was used to impute missing data.


Reviewer's Comment:


There is a statistically significant difference in foveal retinal thickness (µm) between the verteporfin PDT group and pooled ranibizumab group at Month 1 (p<0.0045) and at Month 12 p<0.0004)

Best Available Copy

al BLA Rnea A. Lloyd, MD 125156 Lucentis (ranibizumab injection)

Chart 6.1.4.2-3





Note: The LOCF method was used to impute missing data.

→ Verteporfin PDT (N=17) → Canibizumab pooled (N=44)

Reviewer's Comment:

There is a statistically significant difference in central retinal thickness (μ m), between the verteporfin PDT group and pooled ranibizumab group at Month 1 (p<0.0009) and at Month 12 p<0.0527)

O , BLA Rhea A. Lloyd, MD 125156 Lucentis (ranibizumab injection) SUBGROUP ANALYSES – PRIMARY EFFICACY VARIABLE

/ Table 6.1.4.2-7 Subgroup Analysis for the Proportion Losing <15 Letters in Visual Acuity in the Study Eye at 12 Months

Compared with Baseline at a Starting Test Distance of 4 Meters: Randomized Subjects

-

5

	たち、そうちろうというできたいないにないできたいのうかい	「「「「「」」」」」」」」」」」」」」」」」」」」」」」」」」」」」」」			
HUL .	0.3 mg	0.5 mg	ie Fora	3 0.3 mg	USIN
	Age < 75 Years			Age > 75 Years	
43	37	55	66	97	85
26 (61.9%)	35 (91.2%)	53 (98.1%)	67 (67.7%)	91 (93.8%)	83 (97.6%)
(47.2%, 76.6%)	(91.9%, 100%)	(94.6%, 100%)	(58.5%, 76.9%)	(89.0%, 98.6%)	(94.4%, 100%)
	35.3%	36.2%		26.1%	30.0%
	Female			Male	
78	64	64	63	69	75
51 (65.4%)	61 (95.3%)	63 (98.4%)	42 (66.7%)	65 (64.2%)	73 (97.3%)
(54.8%, 75.9%)	(90.1%, 100%)	(95.4%, 100%)	(55.0%, 78.3%)	(88.7%, 99.7%)	(93.7%, 100%)
	29.9 %	33.1%		27.5%	30.7%
	≤ 44 Letters			≥ 45 Letters	
65	58	60	76	75	78
49 (75.4%)	55 (94.8%)	58 (96.7%)	44 (57.9%)	71 (94.7%)	77 (98.7%)
(64.9%, 85.9%)	(89.1%, 100%)	(92.1%, 100%)	(46.8%, 69.0%)	(89.6%, 99.8%)	(96.2%, 100%)
	19.4 %	21.3%	-	36.8%	40.8%
Occult	CNV Present at B	aseline	Occult	CNV Absent at B	aseline
16	17	18	125	116	121
7 (43.8%)	15 (88.2%)	18 (100%)	86 (68:8%)	111 (95.7%)	118 (97.5%)
	43 26 (61.9%) 47.2%, 76.6%) 51 (65.4%) 54.8%, 75.9%) 54.8%, 75.9%) 54.9%, 85.9%) 54.9%, 85.9%) 7 (43.8%) 7 (43.8%)	43 37 37 $26 (61.9\%)$ $35 (91.2\%)$ $35 (91.2\%)$ 47.2% , 76.6% $(91.9\%, 100\%)$ 35.3% Female Female 78 64 78 64 $61 (95.3\%)$ $90.1\%, 100\%$ $51 (65.4\%)$ $61 (95.3\%)$ $61 (95.3\%)$ 54.8% , 75.9% $61 (95.3\%)$ $90.1\%, 100\%$ 54.8% , 75.9% $90.1\%, 100\%$ $90.1\%, 100\%$ 54.9% , 85.9% 844 Letters 58 $49 (75.4\%)$ $55 (94.8\%)$ $90.1\%, 100\%$ 54.9% , 85.9% $89.1\%, 100\%$ 19.4% 74.9% , 85.9% $89.1\%, 100\%$ 19.4% $74.3.8\%$ $15 (88.2\%)$ 17 $7 (43.8\%)$ $15 (88.2\%)$ 17	$\begin{array}{c c} 37 \\ 37 \\ 35 (91.2\%) \\ \hline (91.9\%, 100\%) \\ \hline 35.3\% \\ \hline Female \\ 64 \\ 64 \\ 64 \\ 64 \\ 64 \\ 64 \\ 64 \\ 6$	37 55 99 37 (91.2%) 53 (98.1%) 67 (67 . $91.9%$, $100%$) $94.6%$, $100%$) $67 (67$. $91.9%$, $100%$) $94.6%$, $100%$) $58.5%$, 7 $53.3%$ $36.2%$ 42 (66 . $53.3%$ 64 64 63 64 64 63 42 (66 . 61 ($95.3%$) 63 ($98.4%$) 42 (66 . 61 ($95.3%$) 63 ($98.4%$) 42 (66 . $90.1%$, $100%$ $(95.4%)$ 42 (66 . $90.1%$, $100%$ $(95.4%)$ 42 (66 . $29.9%$ $33.1%$ 42 (66 . $29.9%$ $33.1%$ 44 (57.6 $89.1%$, $100%$ $92.1%$, $100%$ 44 (57.6 $89.1%$, $100%$ $92.1%$, $100%$ 44 (57.6 $89.1%$, $100%$ $92.1%$, $100%$ 44 (57.6 $89.1%$, $100%$ $92.1%$, $100%$ 44 (57.6 $19.4%$ $21.3%$ 146 (57.6 $19.4%$ 128 125 15 15 12 128 <td< td=""><td>37$55$$99$$37$$53$$98.1%$)$67$$67.7%$)$35$$91.2%$)$53$$94.6%$, $100%$)$67$$67.7%$)$835.3%$$35.3%$$36.2%$$58.5%$, $76.9%$)$(1)$$35.3%$$36.2%$$36.2%$$58.5%$, $76.9%$)$(1)$$53.3%$$36.2%$$36.2%$$42$$66.7%$)$(1)$$64$$64$$64$$64$$63$$84%$)$(1)$$61$$95.3%$)$63$$98.4%$)$42$$66.7%$)$(1)$$90.1%$$100%$)$(95.4%, 100%)$$(55.0%, 78.3%)$$(1)$$29.9%$$33.1%$$42$$66.7%$)$76$$29.9%$$33.1%$$76$$76$$76$$58$$60$$76$$76$$76$$58$$60$$76$$76$$76$$58$$60$$76$$76$$76$$58$$96.7%$$100%$)$(146.8%, 69.0%)$$(1)$$19.4%$$21.3%$$12.3%$$125$$125$$15$$15$$18(100%)$$86$$68.8%$$00$$15$$15$$18(100%)$$86$$8%$$00$$15$$18(100%)$$86$$68.8%$$00$</td></td<>	37 55 99 37 53 $98.1%$) 67 $67.7%$) 35 $91.2%$) 53 $94.6%$, $100%$) 67 $67.7%$) $835.3%$ $35.3%$ $36.2%$ $58.5%$, $76.9%$) (1) $35.3%$ $36.2%$ $36.2%$ $58.5%$, $76.9%$) (1) $53.3%$ $36.2%$ $36.2%$ 42 $66.7%$) (1) 64 64 64 64 63 $84%$) (1) 61 $95.3%$) 63 $98.4%$) 42 $66.7%$) (1) $90.1%$ $100%$) $(95.4%, 100%)$ $(55.0%, 78.3%)$ (1) $29.9%$ $33.1%$ 42 $66.7%$) 76 $29.9%$ $33.1%$ 76 76 76 58 60 76 76 76 58 60 76 76 76 58 60 76 76 76 58 $96.7%$ $100%$) $(146.8%, 69.0%)$ (1) $19.4%$ $21.3%$ $12.3%$ 125 125 15 15 $18(100%)$ 86 $68.8%$ 00 15 15 $18(100%)$ 86 $8%$ 00 15 $18(100%)$ 86 $68.8%$ 00

Rhea A. Lloyd, MD al BLA 125156

Lucentis (ranibizumab injection)

	の一般になったいであるというないないないである。	の時代のないというないのであったい			「「「「「「「」」」」というないので、「」」	
TOSS OF STOLENES	Vertenorfin	Kanibizumab	zumab	Verteporfin	Kaniolzunano	AUMAD
from Baseline at Month 12 du the Study Fee	PDT	0.3 mg	0.5 mg	PĎT	0.3 mg	0.5 mg
95% CI of the %	(19:4%, 68.1%)	(72.9%, 100%)	(100%, 100%)	(60.7%, 76.9%)	(92.9%, 99.4%)	(94.8%, 100%)
Difference in % (vs. PDT)		44.5 %	56.3 %		26.9 %	28.7 %
p-value (vs. PDT)		0.0067	0.0002		<0.0001	<0.0001
	Basel	aseline Lesion Size ≤ 4 DA	4 DA	Basel	Baseline Lesion Size > 4 DA	4 DA
Z	125	124	126	16	6	13
n (%)	82 (65.6%)	117 (94.4%)	124 (98.4%)	11 (68.8%)	9 (100%)	12 (92.3%)
95% CI of the %	(57.3%, 73.9%)	(90.3%, 98.4%)	(96.2%, 100%)	(46.0%, 91.5%)	(100%, 100%)	(77.8%, 100%)
Difference in % (vs. PDT)		28.8 %	32.8 %		31.3 %	23.6 %
p-value (vs. PDT)		<0.0001	<0.0001		0.0608	0.1194
	With Pri	Prior Laser Photocoagulation	agulation	With No P	With No Prior Laser Photocoagulation	oagulation
Z	19	19	20	122	114	119
n (%)	11 (57.9%)	19 (100.0%)	20 (100%)	82 (67.2%)	107 (93.9%)	116 (97.5%)
95% CI of the %	(35.7%, 80.1%)	(100%, 100%)	(100%, 100%)	(58.9%, 75.5%)	(89.5%, 98.3%)	(94.7%, 100%)
Difference in % (vs. PDT)		42.1 %	42.1 %		26.6 %	30.3 %
p-value (vs. PDT)		0.0015	0.0011		<0.0001	<0.0001
Note: The LOCF was used to impute missing data.	e missing data. The 95	5% CIs were based on 1	The 95% CIs were based on normal approximation. p-values were from the Pearson Chi Square test	p-values were from the	Pearson Chi Square te	est.

Reviewer's Comment:

The approximately 30% treatment effect was maintained and was statistically signifigant to the p<0.0001 level in all except for a few subgroups likely due to the small number of subjects in those subgroups.

verteporfin PDT, p=0.0242, perhaps due to the small number of subjects or worse disease. In this subgroup, the ranibizumab pooled group was significant with a p-value of 0.0199. Similar results were seen in the subgroups with occult CNV present at baseline and In patients with a baseline lesion size of > 4 disc areas, only the ranibizumab 0.3-mg dose achieved statistical significance versus 1 Million with prior laser photocoagulation.

6.1.5 Clinical Microbiology This is not an antimicrobial. Not applicable.

6.1.6 Efficacy Conclusions

The submitted Phase 3 studies in BLA 125156 Lucentis (ranibizumab injection) demonstrate the efficacy for the use of ranibizumab 0.5-mg in the treatment of neovascular age-related macular degeneration.

These studies both demonstrated an approximately 30% treatment effect of ranibizumab 0.3-mg and 0.5-mg compared to sham and verteporfin PDT, respectively, for the primary efficacy endpoint, the proportion of subjects with a loss of fewer than 15 letters in the best corrected visual acuity score at Month 12 compared with baseline.

Appears This Way On Original

7 INTEGRATED REVIEW OF SAFETY

7.1 Methods and Findings

The Phase 3 studies presented in this Biologics License Application, FVF2587g and FVF2598g, included 754 safety evaluable patients. In Study FVF2598g, subjects were followed monthly from Day 0 through Month 12 and received an average 12 of a total 13 possible intravitreal ranibizumab injections. The number of treatments received was slightly lower for the sham-injection group compared with the ranibizumab groups. There was no imputation of missing values due to patient discontinuation or missed visits performed in the safety data set. In Study FVF2587g, subjects were followed monthly as well. The mean number of injections in the ranibizumab and sham intravitreal injection groups was approximately 12 for each group.

Safety was assessed through the summary of ocular and non-ocular adverse events, serious adverse events, ocular assessments, deaths, laboratory test results, vital signs, and antibodies to ranibizumab. Safety analyses included all subjects who received at least one ranibizumab or sham injection. Unless specified otherwise, safety analyses were performed for the safety-evaluable subjects. Subjects were analyzed according to the actual treatment received. Safety summaries for this Clinical Study Report include data from the first treatment year.

In Study FVF2598g, the safety evaluable population was defined as randomized subjects who received at least one treatment with study drug. Treatment group assignment as follows:

- Sham: subjects randomized to the sham-injection group who received a sham injection on Day 0
- 0.3 mg Ranibizumab: subjects randomized to receive 0.3 mg ranibizumab or subjects who were randomized to sham but received a 0.3 mg injection of ranibizumab on Day 0 in error
- 0.5 mg Ranibizumab: subjects randomized to receive 0.5 mg ranibizumab or subjects who were randomized to sham but received a 0.5 mg injection of ranibizumab on Day 0 in error

In Study FVF2587g, the safety-evaluable population was defined as randomized subjects who received at least one of the following treatments: ranibizumab injection, sham intravitreal injection, active verteporfin PDT, or sham PDT with saline. Treatment groups for this population were defined according to the actual treatment received during the first treatment year.

- If a subject received only one type of active treatment (verteporfin PDT, 0.3 mg ranibizumab or 0.5 mg ranibizumab), regardless of any sham PDT or sham intravitreal injections received, the subject's treatment group was the active treatment received.
- If a subject received a combination of different active treatments, regardless of any sham PDT or sham intravitreal injections received, and one of the active treatments received

was the treatment the subject was randomized to, the subject's treatment group was as randomized.

- If a subject received a combination of different active treatments, regardless of any sham PDT or sham intravitreal injection received, and none of the active treatments received was the treatment the subject was randomized to, the subject's treatment group was the first active treatment received.
- If a subject did not receive any active treatment but received any combination of sham PDT or sham intravitreal injection, the subject's treatment group was as randomized.

In Study FVF2598g, the most common ocular adverse events in the study eye reported more frequently in each of the ranibizumab groups than in the corresponding control groups in both studies were conjunctival hemorrhage, eye pain, increased IOP, retinal disorder, and vitreous floaters. Many of these adverse advents appear to be related to the conjunctival anesthetic or intravitreal injection procedures.

Key serious ocular adverse events of endophthalmitis, intraocular inflammation, retinal detachment, retinal tear, increased IOP, and traumatic cataract were all uncommon in ranibizumab-treated subjects (reported in < 1% of subjects for each event). Per injection rates for the serious adverse events of endophthalmitis, intraocular inflammation, retinal detachment, and traumatic cataract were all very low ($\leq 0.12\%$ per injection in each dose group).

A trend in intraocular inflammation adverse events was observed, with rates of approximately 10%–15% in the ranibizumab groups compared with rates of approximately 3% or 10% in the verteporfin PDT or sham-control groups, respectively. However, the reported intraocular inflammation adverse events were generally mild in severity. The incidence of intraocular inflammation adverse events was consistent with the results based on slitlamp examination.

As expected with a drug injected intravitreally, there was a small trend in increased IOP adverse events toward higher rates in the ranibizumab groups than in the control groups, with no difference in frequency or severity observed between the two doses. Most of these events were mild to moderate in severity.

Appears This Way On Original

7.1.1 Deaths

Three deaths occurred during the first treatment year of Study FVF2598g. One subject in the 0.3 mg ranibizumab group died from a heart attack. The other two subjects were both in the ranibizumab 0.5 mg group; 1 subject died as a result of a small bowel infarct and the other died from chronic asthma / chronic obstructive pulmonary disease (COPD).

Seven deaths occurred during the first treatment year of Study FVF2587g.

	dat to S	nog nyi 192593		Stu		
Primary Cause of Death	Shame N=236			Verteportin PD/C N=143		zumab 0.5 mg N=140
Total	0	1 (0.4%)	2 (0.8%)	2 (1.4%)	3 (2.2%)	2 (1.4%)
Cardiac Arrest	0	0	0	- 1(0.7%)	1 (0.7%)	0
Cardiac Failure	0	0	0	0	. 0	1 (0.7%)
COPD	0	0	1 (0.4%)	1 (0.7%)	0	0
Myocardial infarction	0	1 (0.4%)	0			
Respiratory Arrest	0	0	0	0	1 (0.7%)	0
Small bowel infarct	0	0	1 (0.4%)			
Viral Syndrome	0	0	0	0	1 (0.7%)	0
Worsened of chronic CHF	0	0	0	0	0	1 (0.7%)

Table 7.1.1-1 Deaths Occurring during Phase 3 Studies

Reviewer's Comment:

There were considerably more deaths in the FVF2587g trial though there were no imbalances in the causes or association to treatment noted.

The deaths were not considered to be related to therapy.

Appears This Way On Original

APOTEX V. REGENERON IPR2022-01524 REGENERON EXHIBIT 2024 PAGE 125

7.1.2 Other Serious Adverse Events Table 7.1.2-1 Study FVF2598g Serious Ocular Adverse Events in the Study Eye during the First Treatment Year Safety Evaluable Subjects

Study Site II	D Subject D	And address and a second s	Day of Onset	Action Taken
		Sham Group		
S08215	104005	30 letter loss of vision	99	None
S08087	105001	Serous hemorrhagic macular detachment	305	None
S07441	107003	Subretinal hemorrhage	63	Dose held
S08216	108006	30 letter loss of vision - Worsened CNV	246	None
S08201	118004	Cerebrovascular accident	319	None
S08130 -		30 letter loss of vision – Worsened AMD	32	None
S08220	143005	30 letter loss of vision – Worsened AMD	239	Dose held
S08212	144002	30 letter loss of vision – Worsened AMD	94	Dose held, PDT
S08366	148001	30 letter loss of vision – Worsened AMD		
S08133	164002	Progression of AMD	155	Dose held
308135	104002	Progression of AMD	57	Dose held,
S02796	185005	30 letter loss of vision - Worsened AMD	107	D/C study
S02201	188006		127	None
502201	188000	30 letter loss of vision – Worsened AMD	62	None
		0.3 mg Graup		
S07348	101001	30 letter loss of vision - Worsened AMD	126	None
S08127	102005	30 letter loss of vision	122	Dose held
S08217	123002	Iridocyclitis	33	None
S06531	126002	Retinal tear	58	Dose held,
			_	Procedure
S08246	131003	30 letter loss of vision - Subretinal fibrosis	127	None
S08246	131013	Increased intraocular pressure	239	None
S08208	141014	30 letter loss of vision -Vit. hemorrhage	84	Dose held
S08220	143011	Endophthalmitis	270	Meds / Surgery
	143018	30 letter loss of vision - Worsened AMD	60	None
S08189	160001	Iridocyclitis	94	Study drug d/ced
S00399	162002	Retinal hemorrhage, Depression	15	D/C Study
S08131	179002	30 letter loss of vision - Worsened AMD	148	None
S08125	183001	30 letter loss of vision - Worsened AMD	183	None
S08165	. 184001	RPE Tear / Detachment	30	None
S08252	193001	Corneal abrasion	343	None
		0.5 mg Group	1	
S07441	107008	RPE Tear / Detachment	33	Dose held
S08110	117002	Hyphema	29	Meds / AC Tap
S08246	131012	Increased intraocular pressure	183	Meds / AC Tap Meds / AC Tap
S06530	138002	Iridocyclitis – Recurrent		Study drug d/ced
S08208	138002	Accidental penetration of lens with needle during	37, 119	Cataract extraction
308208		injection		
	141016	Fat embolism, retinal artery	204	Hospitalization
S08220	143017	Uveitis	62	Study drug d/ced
S08150	15306	30 letter loss of vision - Unexplained	308	Dose held
S08083	163004	Endophthalmitis	66	Meds / Surgery
S00266	167007	Incorrect route of administration	240	Dose held

Original BLA Rhea A. Lloyd, MD 125156 Lucentis (ranibizumab injection)

Study Site II	D. Sudering		Day of Onset	Action Taken
S08211	170009	Round refinal hole	8	Laser
S08252	193003	30 letter loss of vision - Worsened AMD	254	None
S03675	200004	30 letter loss of vision Vitreous hemorrhage	210	None

Table 7.1.2-2 Study FVF2587g Serious Ocular Adverse Events in the Study Eye during the First Treatment Year Safety Evaluable Subjects

· Study Site ID //	SUBJECT	30466 - 1741	Day of Onset	Action Taken
	「「「「「「「「「「」」「「「」」「「」」「「」」「「」」「「」」「「」」「	A Phepor in Philleboup		
S08214 ····	321011	30 letter loss of vision - Subretinal hemorrhage	43	None
S08130	335003	30 letter loss of vision - Worsened AMD	184	None
S08222	344002	30 letter loss of vision - Unexplained	29	None
S08263	363002	30 letter loss of vision - Worsened AMD	31	None
S08255	365001	30 letter loss of vision - Worsened AMD	186, 235	None
S09325	381008	Retinal detachment	114, 189	Surgery, Study drug d/ced
	1	0.3 mg Gtoup		· .
S07441	303001	Retinal detachment	58	Surgery, Study drug d/ced
S08215	305002	30 letter loss of vision - Wørsened AMD	126,169	None
S00444	319007	Vitreous hemorrhage	276	None _
S08214	321006	30 letter loss of vision - Unexplained	295	None
S08325	354006	Medication Error	302	None
S08314	364002	Incorrect injection procedure - no lidocaine admin.	358	None
		0.5 mg Graup		
S08235	304005	Medication Error	367	None
S08146	326001	Occludable narrow angle	104	Iridotomy
S08596	334009	Corneal abrasion	29	Medication
S08211	339004	30 letter loss of vision - Submacular hemorrhage	95	Dose held, Surgery
S08248	340003	30 letter loss of vision - Worsened AMD	92	None
S08207	341003	Endophthalmitis	122	Dose held, Procedure
S08234	349006	Corneal abrasion	296	None
	349006	Afferent pupillary defect	357	Study drug and Study d/ced
S09308	389001	Recurrent uveitis	231,270	Study drug and Study d/ced

¹ Subject's vision fluctuated throughout study and was suspected of peaking at certain visits.

Reviewer's Comment:

The most frequent cause of a serious adverse event was the loss of 30 letters of vision which was usually due to progression of macular degeneration. The greatest number of these occurrences was in the sham- or Verteporfin PDT- treated groups, followed by the ranibizumab 0.3mg- and 0.5 mg-treated groups, respectively.

Table 7.1.2-3 Study FVF2598g Serious Ocular Adverse Events in the Fellow Eye during the First Treatment Year Safety Evaluable Subjects

Study Site I	D ડાઇલ્વાઇ	199 CAME TO MARKED AND A CAMERAN	Day o Onset	
		Sham Litaup	and the second sec	
S07847	115009	30 letter loss of vision - New CNVM	306	Surgery - TPPV
		Elevated intraocular pressure - Postop	327	Medications
S08201	118004	Visual field defect – CVA	319	Hospitalization
S08239	121007	30 letter loss of vision - New CNVM	31	None
S08130	125008	30 letter loss of vision - New CNVM	50	PDT,D/C Study
S08249	136009	30 letter loss of vision - New CNVM	92	PDT
×.		0.3 mg Group		
S08218 -	114005	30 letter loss of vision - Worsened AMD	218	PDT
S07847	115002	30 letter loss of vision - Unexplained	160	None, resolved
S08248	140005	Retinal detachment	299	Surgery
		Recurrent retinal detachment	341	Surgery
S08194	176003	30 letter loss of vision - Worsened AMD	164	PDT
		0.5 mg Стонр		
S08216	108004	30 letter loss of vision - New CNVM	66	PDT
S07439	112004	30 letter loss of vision - Unexplained	127	None, resolved

Table 7.1.2-4 Study FVF2587gSerious Ocular Adverse Events in the Fellow Eye during the First Treatment YearSafety Evaluable Subjects

Study Site I	D Subject D	Adverse Ryene a former a	Day o Onset	
	- <u>9</u> .791 -	Certeporfue 202 Group	御道でいった。 A. A. A.	
S08314	364004	Medication Error - Nonstudy eye injected	264	None
		0.3 mg Group	(* 1).	
S08214	321006	30 letter loss of vision - Unexplained	337	None
S08214	321013	30 letter loss of vision - Subretinal hemorrhage	295	Laser tx
S08150	329008	30 letter loss of vision - Worsened AMD	85	PDT
S08133	358003	30 letter loss of vision - Recurrent CNVM	68	PDT, steroid injxn
S09326	390001	Sudden loss of vision - Blindness	337	PDT
		0.5 mg Graup	5 - 1 - 1 N	
S08220	302013	30 letter loss of vision - Worsened AMD	246	PDT
S08214	321007	30 letter loss of vision - Worsened AMD	330	Laser, steroid injxn
S08205	342003	30 letter loss of vision ¹	234	None

¹ Patient with short term memory loss, difficult to assess vision.

Reviewer's Comment:

The most frequent cause of a serious adverse event in the fellow eye was the loss of 30 letters of vision due to progression of macular degeneration in both studies regardless of treatment group.

Original BLA Rhea A. Lloyd, MD 125156 Lucentis (ranibizumab injection) Table 7.1.2-5

Non-Ocular Serious Adverse Events during the First Treatment Year (Occurring in ≥ 2 Subjects in Any Group) Safety Evaluable Subjects - Study FVF2598g and Study FVF2587g

Weiling the free manual and	at the second second	A STATE ROOM	Zhimate	S. Verteportine	Como a como como como como como como como	interfecture and
		an Smarth	10.5 mg	PDT	0.3 mg	1012 Include
TOTAL ⁴	39 (16.5%)	43 (18.1%)	44 (18.4%)	28 (19.6%)	20 (14.6%)	28 (20.0%)
Pneumonia	4 (1.7%)	7 (2.9%)	4 (1.7%)	2 (1.4%)	4 (2.9%)	4 (2.9%)
Diverticulitis	1 (0.4%)	2 (0.8%)	3 (1.3%)	0	0	0
Syncope	4 (1.7%)	0	1 (0.8%)	0	0	0
Coronary artery disease	4 (1.7%)	0	1 (0.4%)	0	3 (2.2%)	0
Cardiac failure, congestive	3 (1.3%)	1 (0.4%)	1 (0.4%)	3 (2.1%)	0	2 (1.4%)
Chest pain	2 (0.8%)	3 (1.3%)	0	0	0	0
Cerebrovascular accident	1 (0.4%) ^b	1 (0.4%)	3 (1.3%) °	0	0	0
Cellulitis	3 (1.3%)	1 (0.4%)	0	0	0	0
Hip fracture	0	3 (1.3%)	1 (0.4%)	0	0	0
Asthma	1 (0.4%)	1 (0.4%)	2 (0.8%)	0	0	0
Attist (fibrilistion	2 (0.8%)	1 (0.4%)	0	1 (0.7%)	1 (0.7%)	2 (110%)
Lung neoplasm, malignant	2 (0.8%)	1 (0.4%)	0	0	0	9
COPD Exacerbation	1 (0.4%)	0	2 (0.8%)	2 (1.4%)	0	3 (2.1%)
COPD	0	0	0	0 -	0	3 (2.1%)
Abdominal pain, upper	2 (0.8%)	0	. 0	0	0	0
Non-cardiac chest pain	0	0	2 (0.8%)	0	0	0
Osteoarthritis	2 (0.8%)	0	0	0.	0	0
Renal cell carcinoma, stage unspecified	2 (0.8%)	0	0	0	0	0
Transient ischemic attack	0	0	2 (0.8%)	0	0	0
Subdural hematoma	0	0	0	0	2 (1.5%)	0

gm group of either study are highlighted.

parietooccipital CVA (reported as an ocular serious adverse event) had received a single injection of 0.5 mg ranibizumab in error approximately 8 months prior a Represents the number of subjects with at least one non-ocular serious adverse event. b The sham-treated subject (118004) who experienced a subacute to the event. c Included one case reported as a cerebral ischemia.

(m	Reviewer's Comment: The adverse events which were seen more frequently in the ranibizumab 0.5 mg group versus either control are highlighted. In the FVF2598g study, serious non-ocular events were evenly distributed across the ranibizumab treated groups; but, slightly less frequent in the sham treated group:	In the FVF2587g study, serious non-ocular events occurred with approximately equal frequency in the verteporfin PDT and ranibizumab 0.5 mg treated groups. The frequency was somewhat less in the ranibizumab 0.3mg- treated group.	 7.1.3 Dropouts and Other Significant Adverse Events The case report forms of all subjects who discontinued study participation were evaluated. Refer to Table 6.1.3.1-7 and Table 6.1.3.2-7 for details. 	•		Appears This Way On Original	105
O BLA Rhea A. Lloyd, MD 125156 Lucentis (ranibizumab injection)	Reviewer's Comment: The adverse events which were see In the FVF2598g study, serious noi frequent in the sham treated group	In the FVF2587g study, serious non-ocult ranibizumab 0.5 mg treated groups. The	7.1.3 Dropout The case report forms of a 7 for details.	· · · · · · · · · · · · · · · · · · ·		•	

al BLA Rhea A. Lloyd, MD 125156 Lucentis (ranibizumab injection) 7.1.3.1 Overall profile of dropouts

Table 7.1.3.1-1 Subject Disposition and Reasons for Discontinuation: Randomized Subjects

		Study FVF2598g			Study FVE2587g	
	N	Number of Subjects	(S	A .	Number of Subjects	Contraction of the second
	Sham	Ranibizumal	zumab	Verteporfin	Ranibizumab	zumab
	N=236	0.3.mg	0.5 mg	PDT	0.3 mg	. 0.5 mg
Randomized	238	238	240	143	140	140
Received ranibizumab or sham injection	236 (99:2%)	238 (100%)	239 (100%)	143(100%)	137 (97.9%)	140 (100%)
Received verteporfin or sham PDT		-	1	143 (100%)	137 (97.9%)	140(100%)
Completed Month 12 ^a	212 (89.1%)	226 (95.0%)	226 (94.2%)	127 (88.8%)	128 (91.4%)	131 (93.6%)
Discontinued treatment ^b prior to Month 12	31 (13.0%)	10 (4.2%)	11 (4.6%)	14 (9.8%)	13 (9.3%)	9 (6.4%)
Death	0	1 (0.4%)	1 (0.4%)	1 (0.7%)	3 (2.1%)	2 (1.4%)
Adverse Event	6 (2.5%)	3 (1.3%)	5(2.1%)	6 (4.2%)	3 (2.1%)	4 (2.9%)
Lost to follow-up	2 (0.8%)	0	0	1 (0.7%)	0	1 (0.7%)
Subject's Decision	15 (6.3%)	6 (2.5%)	4 (1.7%)	4 (2.8%)	4 (2.9%)	2 (1.4%)
Physician's Decision	2 (0.8%)	0	1 (0.4%)	1 (0.7%)	2 (1.4%)	0
Subject non-compliance	0	0	0	0	1 (0.7%)	0
Subject's condition mandated other theraportic intervention	6 (2.5%)	0	0	1 (0.7%)	0	0
international and a second	and the second se	and the second se	and the second of the second se			

a Defined as having a visual acuity score in the study eye at Month 12. Data from subjects who missed the Month 12 visit but stayed in the study for the second year were not counted.b Two subjects were discontinued from the study at Month 12 after assessments.

Reviewer's Comment:

In both studies, the sham injection and verteporfin PDT groups had higher rates of study dropout and treatment discontinuation than the ranibizumab groups.

Approximately 50% of the treatment discontinuations were due to subject decision.

C ، BLA Rhea A. Lloyd, MD 125156 Lucentis (ranibizumab injection) 7.1.3.2 Adverse events associated with dropouts

Treatment discontinuation and study dropout was most frequently associated with the subject's decision with no change in vision from baseline, subject's loss of vision and progression of age-related macular degeneration.

Table 7.1.3.2-1 Ocular Adverse Events in the Study Eye Leading to Discontinuation of Study or Treatment

1000 - 「たいしたいはならい」の記録は認識の時間にないはないに、 アド・ビー・シー・シー・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・		のために見たいであり、うちになるのものは、からったいで	「ロートランジア」という語言であるというなどで	「大学の大学家は「「「「「「「「「「「」」」」」」」」」」」」」」」」」」」」」」」」」」	Nation 100 100 100 100 100 100 100 100 100 10	A DAMAGE AND AND A DAMAGE AND AND A DAMAGE
Madine & Drafornal Trans.		Ranibizumab	ZumaD	Verteportin	Rahibizun	izumab
	N=236	03.me	0.5 mg	PDD	0.3 mg	
		100 C 208	OFTEN A	Station of	STATE DOLLARS	THE OFFICE AND
TOTAL'	8 (3.4%)	3 (1.3%)	4 (1.7%)	1 (0.7%)	2 (1.5%)	4 (2.9%)
Cataract subcapsular	0	0	1 (0.4%)	0	0	0
Choroidal neovascularization	4 (1.7%)	0	0	0	0	0
Conjunctivitis allergic	0	0	1 (0.4%)	0	0	0
Conjunctivitis bacterial	0	0	0	0	0	1 (0.7%)
Corneal deposits	0	0	1 (0.4%)	0	0	0
Eye pain	0	0	1 (0.4%)	0	1 (0.7%)	0
Iritis	0	2 (0.8%)	0	0	0	0
Iridocyclitis	0	0	1 (0.4%)	0	0	1 (0.7%)
Macular degeneration	3 (1.3%)	0	0	0	0	0
Ocular hyperemia	0	0	0	0	1 (0.7%)	0
Pupillary reflex impaired	0	0	0	0	0	1 (0.7%)
Retinal detachment ^b	0	0	0	1 (0.7%)	1 (0.7%)	0
Retinal hemorrhage	2 (0.8%)	1 (0.4%)	0	0	0	0
Uveitis	0	0	1 (0.4%)	0	0	1 (0.7%)
Vision blurred	0	O	0	0 -	1 (0.7%)	0
Vitreous detachment	2 (0.8%)	0	0	0	0	0

during the First Treatment Year: Safety Evaluable Subjects

one ocular adverse event in the study eye that led to discontinuation of study or treatment. b Both events verts verter rhegmatogenous retinal detachment.

Reviewer's Comment:

In Study FVF2598g, the adverse events which led to discontinuation of subjects in the sham-injection group were primarily related to progression of age-related macular degeneration. The adverse event which led to discontinuation in ranibizumab treated subjects most frequently in both studies was intraocular inflammation (iritis, iridocyclitis, and uveitis).

Ocular adverse events that led to discontinuation in the ranibizumab groups were generally those associated with intravitreal injections.

al BLA Rhea A. Lloyd, MD 125156 Lucentis (ranibizumab injection) Table 7.1.3.2-2 Non-Ocular Adverse Events in the Study Eye Leading to Discontinuation of Study or Treatment during the First Treatment Year: Safety Evaluable Subjects

		Study FVF2598g			Study EVE2587g	
		Ranib	Ranibizumab	Verteporfin	Ramb	Rambizumab
MeWKA Preterred Lerns	Sham 	0.3 mg N=238	0.5.mg N=239	PDT N=143		0.5mg
TOTAL ³	5 (2.1%	2 (0.8%)	5 (2.1%)	6 (4.2%)	5 (3.6%)	2 (1.4%)
Acute myocardial infarction	0 - 0	1 (0.4%)	0	0	0	0
Asthenia	0	0	0	1 (0.7%)	1 (0.7%)	0
Asthma	0	0	1 (0.4%)	0	0	0
Blood pressure increased	1 (0.4%)	0	0	-Ò	0	0
Cardiac arrest	0	0	0	1 (0.7%)	1 (0.7%)	0
Cardiac failure	0	0	0	0	0	1 (0.7%)
Cardiac failure chronic	0	0	0	0	0	1 (0.7%)
Cardiogenic shock	0	1 (0.4%)	0	0	0	0
Cerebral infarction	0	0	0	0	1 (0.7%)	0
Cerebral ischemia	0	0	1 (0.4%)	0	0	0
Chronic obstructive pulmonary disease exacerbated	1 (0.4%)	0	0	0	0	0
Chronic obstructive pulmonary disease	1 (0.4%)	0	0	0	0	0
Cough	0	0	1 (0.4%)	0	0	0
Gastric ulcer perforation	0	0	0	1 (0.7%)	0	0
Glioblastoma	0	0	0	1 (0.7%)	0	0
Increased upper airway secretion	0	0	1 (0.4%)	0	0	0
Intestinal infarction	. 0	0	1 (0.4%)	0	0	0
Lung neoplasm malignant	2 (0.8%)	0	0	0	1 (0.7%)	0
Myocardial infarction	0	0	0	1 (0.7%)	0	0
Non-Hodgkin's lymphoma	0	1 (0.4%)	0	0	0	0
Non-small cell lung cancer Stage IIIb	1 (0.7%)	0	0	0	0	0
Pelvic fracture	0 .	0	0	0	0	1 (0.4%)
Pneumonia	1 (0.7%)	0	0	1 (0.4%)	0	0
Respiratory arrest	0	1 (0.7%)	0	0	0	0
Viral infection	0	1 (0.7%)	0	0	0	0
Wheezing	0	0	0	0	0	1 (0.4%)

Lucentis (ranibizumab injection) Rhea A. Lloyd, MD BLA 125156

a Represents the number of subjects with at least one non-ocular adverse event in the study eye that led to discontinuation of study or treatment.

Reviewer's Comment:

No pattern of non-ocular adverse events leading to study or treatment discontinuation was noted in either study. The non-ocular adverse events reported were conditions commonly seen in an elderly population.

7.1.3.3 Other significant adverse events

Table 7.1.3.3-1 Serious Adverse Events Potentially Related to Systemic VEGF Inhibition during the First 'Treatment Year: Studies FVF2598g and FVF2587g

		Studies EX 1025986			STILL VERNESSAND	
		Rath	Timeh.	Vertennefin	All and the second second	Thursday
1 Yppe al Adverse Lycal	Sham	- OBTRE		Idit	A DAMES	0.5mp
						and the second second
TOTAL '	2 (0.8%)	8 (3.4%)	9 (3.8%)	3 (2,1%)	4 (2.9%)	8 (5.7%)
Hypertension events	0	1 (0.4%)	0	0	0	0
Arterial thromboembolic events	2 (0.8%)	5 (2.1%)	8 (3.3%)	2 (1.4%)	2 (1.4%)	4 (2.9%)
Non-ocular hemorrhages	0	1 (0.4%)	0	0	2 (1.5%)	3 (2.1%)
Other potentially associated events	0	1 (0.4%)	1 (0.4%)	1 (0.7%)	1 (0.7%)	1 (0.7%)
Note: Multiple accurrences of the same time of event for a subject were counted and in the averall incidence	e of event for a sub	ient were normted	once in the overal	l incidence		

Note: Multiple occurrences of the same type of event for a subject were counted once in the overall incidence.

Reviewer's Comment:

In the two phase 3 studies, a small trend in the occurrence of serious adverse events potentially related to systemic VEGF inhibition was noted at Month 12, particularly in the ranibizumab 0.5-mg dose group. This reflects trends in serious arterial thromboembolic events and, to a lesser extent, in serious non-ocular hemorrhages (but not in serious hypertension or proteinuria). No imbalance in overall adverse events potentially related to systemic VEGF inhibition was observed among treatment groups.

events: vascular deaths (including deaths of unknown cause), nonfatal myocardial infarction, nonfatal ischemic stroke, and nonfatal Differing definitions, assessment methods, and reporting of arterial thromboembolic events makes there analysis challenging. The adverse events which mitigates some of these issues by focusing on a more restricted but well-defined spectrum of serious adverse sponsor applied the Antiplatelet Trialists' Collaboration (APTC) classification (Antiplatelet Trialists' Collaborations 1994) to the nemorrhagic stroke.

Lucentis (ranibizumab injection) Rhea A. Lloyd, MD 125156 al BLA

Table 7.1.3.3-2 APTC Arterial Thromboembolic Events during the First Treatment Year: Studies FVF2598g and FVF2587g

		Study FVF2398	Although States	Vertenorfin	Bioczary Anno	and the second	Rentrizmen
Lype of Adverse Event	Sham N=236	0.3 mg N=238	0.5 mg N=239	PDT Nelas	0.3.mg N=137	0.5 hg N=140	0.5 mg
TOTAL ²	2 (0.8%)	3 (1.3%)	5 (2.1%)	3 (2.1%)	3 (2.2%)	6 (4.3%)	11 (2.9%)
Vascular deaths	0	1 (0.4%)	1 (0.4%)	1 (0.7%)	1 (0.7%)	2 (1.4%)	3 (0.8%)
Nonfatal myocardial infarction	1 (0.4%)	1 (0.4%)	1 (0.4%)	1 (0.7%)	1 (0.7%)	3 (2.1%)	4 (1.1%)
Nonfatal ischemic stroke	1 (0.4%)	1 (0.4%)	3 (1.3%)	1 (0.7%)	1 (0.7%)	1 (0:7%)	4 (1.1%)
Nonfatal hemotrhagic stroke	0	0	0	0	0	0	0

ourbochroolic events, delined according to the Antiplaterer Linguists. Collaboration classification (1994), are presented.

Reviewer's Comment:

compared to subjects in other treatment groups. The overall frequency of such events in the ranibizumab 0.3-mg group was 6 events in 375 subjects (1.6%), 5 events in 379 subjects (1.3%) for the control groups. The overall frequency of such events in the 0.5-mg Applying the APTC classification to the serious adverse events, an overall trend is noted in the ranibizumab 0.5-mg dose group ranibizumab groups was 11 events in 379 subjects (2.9%).

Appears This Way On Original

G i BLA Rhea A. Lloyd, MD 125156 Lucentis (ranibizumab injection) Table 7.1.3.3-3 Intraocular Inflammation in the Study Eye during the First Treatment Year Studies FVF2598g and FVF2587g: Safety Evaluable Subjects

A Preferred Texms Study FXF2598 Study FXF2587g A Preferred Texms N=236 1 N=236 0.3 mg 0.5 mg DDT N=238 N=238 N=239 N=143 N=137 N=137 N=130	26 (10.9%) 34 (14.2%) 4 (2.8%)	16 (6.8%) 15 (6.3%) 15 (6.3%) 2 (1.4%) 7 (5.1%) 10 (7.1%)	22 (9.2%) 2 (1.4%)	2 (0.8%) 0 0	0 1 (0.4%) 0 0
r MedDRA Pred	TOTAL ^a	Iritis	Vitritis	Iridocyclitis	Uveitis

Reviewer's Comment:

There was a dose dependent relationship between ranibizumab and intraocular inflammation in both studies.

those subjects discontinued treatment as a result. One case of serious uveitis (0.5-mg group) was treated with intravitreal antibiotics. In Study FVF2598g, four ranibizumab subjects had serious intraocular inflammation, two subjects in each treatment group. Two of

In Study FVF2587g, one subject in the ranibizumab 0.5 mg groups experienced a case of uveitis deemed serious. The first episode in this subject was treated with antibiotics. The second occurrence led to treatment discontinuation.

Appears This Way On Original

7.1.4 Other Search Strategies

No other search strategies were used to analyze adverse events.

7.1.5 Common Adverse Events

7.1.5.1 Eliciting adverse events data in the development program

The protocol adequately defined an adverse event. Each investigator evaluated study participants for adverse events, volunteered and elicited, at each intraocular-pressure check on each study visit. An Adverse Event Form was completed to document a description of the event, onset, severity, treatment required, outcome and relatedness to the use of the study medication. Checklists were not used.

7.1.5.2 Appropriateness of adverse event categorization and preferred terms

The study utilized the MedDRA preferred terms for adverse event recording. The terms were sufficiently descriptive to assess adverse events expected to be experienced by the study population.

7.1.5.3 Incidence of common adverse events

Table 7.1.5.3-1

Adverse Events Occurring in ≥ 1 % of Patients during the First Treatment Year: Pooled Safety Evaluable Subjects – Study FVF2598g and Study FVF2587g

MedDRA System Organ Class		Merteponfin .	a Ranibizumab Pooled	
Preferred Termina - Preferred Termina	Spuin 5) 一次の点	PLACE PDT 15	0-3 mg N=375	0.5 mg
		N=143	III N≅375	N=379
Blood and Lymphatic System Disorders				
Anemia	8 (3.4%)	4 (2.8%)	11 (2.9%)	17 (4.5%)
Thrombocytopenia	0	0	3 (0.8%)	0
Cardiac Disorders				
Atrial fibrillation	5 (2.1%)	3 (2.1%)	6 (1.6%)	7 (1.8%)
Cardiac failure congestive	4 (1.7%)	4 (2.8%)	3 (0.8%)	5 (1.3%)
Coronary artery disease	5 (2.1%)	0	3 (0.8%)	4 (1.1%)
Ear and Labyrinth Disorders	· .			
Vertigo	2 (0.8%)	5 (3.5%)	7 (1.9%)	3 (0.8%)
Endocrine Disorders		and a second		
Hypothyroidism	2 (0.8%)	2 (1.4%)	3 (0.8%)	0
Eye Disorders				
Abnormal sensation in eye	4 (1.7%)	0	6 (1.6%)	1 (0.3%)
Altered visual depth perception	3 (1.3%)	0	0	0
Anterior chamber flare	6 (2.5%)	0	7 (1.9%)	7 (1.8%)
Arcus lipoides	0	0	6 (1.6%)	7 (1.8%)
Blepharitis	14 (5.9%)	6 (4.2%)	22 (5.9%)	33 (8.7%)
Cataract	26 (11.0%)	10 (7.0%)	37 (9.9%)	43 (11.3%)
Choroidal neovascularization	27 (11.4%)	14 (9.8%)	4 (1,1%)	8 (2.1%)
Conjunctival hemorrhage	139 (58.9%)	65 (45.5%)	261 (69.6%)	255 (67.3%)
Conjunctival hyperemia	14 (5.9%)	5 (3.5%)	19 (5.1%)	22 (5.8%)
Conjunctival edema	3 (1.3%)	2 (1.4%)	4 (1.1%)	2 (0.5%)
Conjunctivitis	7 (3.0%)	0	7 (1.9%)	7 (1.8%)
Conjunctivitis, allergic	3 (1.3%)	1 (0.7%)	3 (0.8%)	9 (2.4%)
Corneal abrasion	7 (3.0%)	0	6 (1.6%)	11 (2.9%)

Original BLA Rhea A. Lloyd, MD 125156

120100			
Lucentis (ranibizumab	injection)

Lucentis (ranibizumab injection)		-	•	
A MERIDI & ASSISTANT CLARK				hab Pooled
Preferred i ering a second			n ting Nava	0.5 mg
	a analas aba		the second s	N≕379
Corneal dystrophy	2 (0.8%)	0	17 (4.5%)	13 (3.4%)
Cutis laxa	1 (0.4%)	0	4 (1.1%)	3 (0.8%)
Detachment of retinal pigment epithelium	30 (12.7%)	5 (3.5%)	26 (6.9%)	22 (5.8%)
Drug hypersensitivity	4 (1.7%)	6 (4.2%)	1 (0.3%)	3 (0.8%)
Dry Eye	12 (5.1%)	12 (8.4%)	15 (4.0%)	30 (7.9%)
Eye discharge	14 (5.9%)	4 (2.8%)	20 (5.3%)	13 (3.4%)
Eye hemorrhage	7 (3.0%)	0	2 (0.5%)	3 (0.8%)
Eye irritation	43 (18.2%)	8 (5.6%)	40 (10.7%)	40 (10.6%)
Eye pain	57 (24.2%)	24 (16.8%)	110 (29.3%)	105 (27.7%)
Eye pruritus	20 (8.5%)	7 (4.9%)	28 (7.5%)	29 (7.7%)
Eye swelling	4 (1.7%)	2 (1.4%)	3 (0.8%)	4 (1.1%)
Eyelid margin crusting	1 (0.4%)	0	6 (1.6%)	1 (0.3%)
Eyelid edema	4 (1.7%)	2 (1.4%)	10 (2.7%)	9 (2.4%)
Eyelid pain	1 (0.4%)	0	3 (0.8%)	6 (1.6%)
Eyelid ptosis	3 (1.3%)	0	. 4 (1.1%)	2 (0.5%)
Eyelids pruritis	4 (1.7%)	1 (0.7%)	Z (0.5%)	2 (0.5%)
Foreign body sensation in eyes	27 (11.4%)	15 (10.5%)	49 (13.1%)	49 (12.9%)
Glaucoma	0	2 (1.4%)	2 (0.5%)	2 (0.5%)
Injection site hemorrhage	3 (1.3%)	3 (2.1%)	8 (2.1%)	13 (3.4%)
Intraocular pressure increased	7 (3.0%)	10 (7.0%)	59 (15.7%)	61 (16.1%)
Iridocyclitis	0	0	0	4 (1.1%)
Iritis	16 (6.8%)	2 (1.4%)	22 (5.9%)	25 (6.6%)
Lacrimation increased	30 (12.7%)	6 (4.2%)	41 (10.9%)	35 (9.2%)
Macular degeneration	125 (53.0%)	89 (62.2%)	138 (36.8%)	136 (35.9%)
Macular edema	20 (8.5%)	6 (4.2%)	4 (1.1%)	10 (2.6%)
Macular scar	2 (0.8%)	1 (0.7%)	6 (1.6%)	5 (1.3%)
Maculopathy	19 (8.1%)	5 (3.5%)	15 (4.0%)	26 (6.9%)
Migraine with aura	0	2 (1.4%)	0 .	0
Ocular discomfort	7 (3.0%)	1 (0.7%)	20 (5.3%)	19 (5.0%)
Ocular hyperemia	16 (6.8%)	1 (0.7%)	23 (6.1%)	26 (6.9%)
Optic disc hemorrhage	3 (1.3%)	0	0	0
Optic nerve C/D ratio increased	0	2 (1.4%)	0	1 (0.3%)
Photophobia	6 (2.5%)	2 (1.4%)	6 (1.6%)	9 (2.4%)
Photopsia	13 (5.5%)	8 (5.6%)	14 (3.7%)	11 (2.9%)
Posterior capsule opacification	7 (3.0%)	2 (1.4%)	11 (2.9%)	9 (2.4%)
Punctate keratitis	6 (2.5%)	2 (1.4%)	9 (2.4%)	6 (1.6%)
Retinal degeneration	11 (4.7%)	2 (1.4%)	21 (5.6%)	23 (6.1%)
Retinal detachment	12 (5.1%)	2 (1.4%)	15 (4.0%)	8 (2.1%)
Retinal disorder	15 (6.4%)	2 (1.4%)	28 (7.5%)	33 (8.7%)
Retinal exudates	18 (7.6%)	5 (3.5%)	20 (5.3%)	17 (4.5%)
Retinal hemorrhage	101 (42.8%)	76 (53.1%)	66 (17.6%)	66 (17.4%)
Retinal edema	4 (1.7%)	0	5 (1.3%)	1 (0.3%)
Retinal pigmentation	1 (0.4%)	0	5 (1.3%)	3 (0.8%)
Retinal scar	3 (1.3%)	3 (2.1%)	5 (1.3%)	3 (0.8%)
Retinal vascular disorder	7 (3.0%)	1 (0.7%)	0	6 (1.6%)
Scleral hyperemia	3 (1.3%)	0	1 (0.3%)	1 (0.3%)
Scheral hyperenna Sebaceous gland disorder	0	0	1 (0.3%)	4 (1.1%)
Subretinal fibrosis	24 (10.2%)	27 (18.9%)	33 (8.8%)	28 (7.4%)
Vision blurred	15 (6.4%)	9 (6.3%)	27 (7.2%)	24 (9.0%)
v ision blurred	15 (0.4%)	9 (0.5%)	27 (1.270)	24 (7.070)

APOTEX V. REGENERON IPR2022-01524 REGENERON EXHIBIT 2024 PAGE 138

Lucentis	(ranibizumab	injection)

MedBRA system			a standard	ugh Popled
Preferred Containing to				
				N=379
Visual acuity reduced	23 (9.7%)	21 (14.7%)	25 (6.7%)	21 (5.5%)
Visual disturbance	14 (5.9%)	6 (4.2%)	30 (8.0%)	30 (7.9%)
Visual distuicance Vitreous degeneration	3 (1.3%)	0	2 (0.5%)	0
Vitreous detachment	30 (12.7%)	26 (18.2%)	60 (16.0%)	59 (15.6%)
Vitreous disorder	0	0	4 (1.1%)	1 (0.3%)
Vitreous floaters	14 (5.9%)	6 (4.2%)	75 (20.0%)	78 (20.6%)
Vitreous hemorrhage	3 (1.3%)	3 (2.1%)	8 (2.1%)	8 (2.1%)
Vitritis	7 (3.0%)	2 (1.4%)	21 (5.6%)	34 (9.0%)
Gastrointestinal Disorders	1 (5.070)			
	1 (0.4%)	0	1 (0.3%)	4 (1.1%)
Abdominal discomfort	4 (1.7%)	3 (2.1%)	0	1 (0.3%)
Abdominal pain upper	3 (1.3%)	1 (0.7%)	3 (0.8%)	4 (1.1%)
Colonic polyp	0	3 (2.1%)	4 (1.1%)	4 (1.1%)
Constipation	12 (5.1%)	6 (4.2%)	16 (4.3%)	9 (2.4%)
Diarrhea Diverticulum intestinal	0	2 (1.4%)	0	0
	7 (3.0%)	3 (2.1%)	5 (1.3%)	3 (0.8%)
Dyspepsia Gastroesophageal reflux disease	6 (2.5%)	8 (5.6%)	10 (2.7%)	11 (2.9%)
Hemorrhoids	4 (1.7%)	1 (0.7%)	1 (0.3%)	4 (1.1%)
Hiatus hernia	0	2 (1.4%)	0	3 (0.8%)
Nausea	10 (4.2%)	7 (4.9%)	20 (5.3%)	19 (5.0%)
Stomach discomfort	0	3 (2.1%)	0	0
Toothache	4 (1.7%)	2 (1.4%)	3 (0.8%)	3 (0.8%)
Vomiting	2 (0.8%)	6 (4.2%)	6 (1.6%)	3 (0.8%)
General Disorders and Administration Sit	the second s	0 (4.270)		
TARK AND	4 (1.7%)	3 (2.1%)	3 (0.8%)	5 (1.3%)
Asthenia	7 (3.0%)	· 0	7 (1.9%)	4 (1.1%)
Chest pain	4 (1.7%)	2 (1.4%)	6 (1.6%)	4 (1.1%)
Fatigue	9 (3.8%)	0	9 (2.4%)	7 (1.8%)
Edema peripheral Pain	2 (0.8%)	0	4 (1.1%)	3 (0.8%)
Pyrexia	2 (0.8%)	2 (1.4%)	9 (2.4%)	5 (1.3%)
	2 (0.870)	2 (1.470)) (2.470)	5(1.570)
Immune System Disorders	2 (1 20/)	1 (0.79()	4 (1.1%)	5 (1.3%)
Drug hypersensitivity	3 (1.3%)	1(0.7%)	6 (1.6%)	6 (1.6%)
Hypersensitivity	1 (0.4%)	3 (2.1%)	7 (1.9%)	7 (1.8%)
Seasonal allergy	2 (0.8%)	6 (4.2%)	7 (1.970)	7 (1.0%)
Infections and Infestations		0.46.004	00 (5 20()	22.76.10()
Bronchitis	12 (5.1%)	9 (6.3%)	20 (5.3%)	23 (6.1%)
Bronchitis, chronic	0	2 (1.4%)	0	0
Cellulitis	3 (1.3%)	0	5 (1.3%)	3 (0.8%)
Cystitis	1 (0.4%)	2 (1.4%)	6 (1.6%)	8 (2.1%)
Diverticulitis	2 (0.8%)	0	7 (1.9%)	7 (1.8%)
Ear infection	2 (0.8%)	3 (2.1%)	4 (1,1%)	4 (1.1%)
Fungal infection	1 (0.4%)	0	1 (0.3%)	4 (1.1%)
Gastroenteritis, viral	5 (2.1%)	0	6 (1.6%)	11 (2.9%)
Herpes zoster	3 (1.3%)	0	10 (2.7%)	5 (1.3%)
Influenza	6 (2.5%)	1 (0.7%)	13 (3.5%)	14 (3.7%)
Kidney infection	4 (1.7%)	0	3 (0.8%)	2 (0.5%)
Localised infection	5 (2.1%)	0	3 (0.8%)	4 (1.1%)
Nasopharyngitis	23 (9.7%)	15 (10.5%)	42 (11.2%)	22 (5.8%)
Pneumonia	10 (4.2%)	5 (3.5%)	15 (4.0%)	13 (3.4%)

-

Lucentis (ranibizumab injection)	all Anderson and a second second	an chi		-
A. ANTIDRASSIANO TO A			Con Dran	nuib Pooled
Preferred Term			N= √5 -1	0.5 mg
Sinusitis	9 (3.8%)	9 (6.3%)	20 (5.3%)	21 (5.5%)
Skin infection	3 (1.3%)	0	0	1 (0.3%)
Tooth abscess	3 (1.3%)	0	2 (0.5%)	2 (0.5%)
Tooth infection	0	. 0	4 (1.1%)	3 (0.8%)
Upper respiratory tract infection	15 (6.4%)	6 (4.2%)	23 (0.1%)	19 (5.0%)
Urinary tract infection	12 (5.1%)	9 (6.3%)	21 (5.6%)	18 (4.7%)
Injury, Poisoning and Procedural Compl				
Contusion	6 (2.5%)	5 (3.5%)	8 (2.1%)	7 (1.8%)
Excoriation	2 (0.8%)	1 (0.7%)	5 (1.3%)	5 (1.3%)
Fall	5 (2.1%)	1 (0.7%)	7 (1.9%)	8 (2.1%)
Hip fracture	0	0	4 (1.1%)	1 (0.3%)
Muscle strain	6 (2.5%)	0	4 (1.1%)	1 (0.3%)
Post procedural pain	3 (1.3%)	1 (0.7%)	1 (0.3%)	2 (0.5%)
Skin laceration	3 (1.3%)	2 (1.4%)	9 (2.4%)	4 (1.1%)
Tooth injury	0	2 (1.4%)	2 (0.5%)	0
Wrist fracture	3 (1.3%)	0 -	3 (0.8%)	2 (0.5%)
Investigations				
Blood cholesterol increased	4 (1.7%)	2 (1.4%)	2 (0.5%)	7 (1.8%)
Blood glucose increased	4 (1.7%)	3 (2.1%)	9 (2.4%)	8 (2.1%)
Blood pressure increased	14 (5.9%)	3 (2.1%)	18 (4.8%)	17 (4.5%)
Heart rate irregular	0	2 (1.4%)	1 (0.3%)	0
Prostate specific antigen increased	2 (0.8%)	2 (1.4%)	4 (1.1%)	4 (1.1%)
Weight decreased	3 (1.3%)	2 (1.4%)	2 (0.5%)	0
Metabolism and Nutrition Disorders				
Dehydration	0	2 (1.4%)	3 (0.8%)	1 (0.3%)
Diabetes mellitus	0	1 (0.7%)	4 (1.1%)	9 (2.4%)
Gout	3 (1.3%)	1 (0.7%)	4 (1.1%)	8 (2.1%)
Hypercholoesterolemia	5 (2.1%)	4 (2.8%)	7 (1.9%)	9 (2.4%)
Hyperlipidemia	1 (0.4%)	2 (1.4%)	4 (1.1%)	5 (1.3%)
Hypokalemia	4 (1.7%)	3 (2.1%)	7 (1.9%)	2 (0.5%)
Musculoskeletal and Connective Tissue D	isorders			
Arthralgia	14 (5.9%)	9 (6.3%)	19 (5.1%)	18 (4.7%)
Arthritis	14 (5.9%)	5 (3.5%)	9 (2.4%)	12 (3.2%)
Back pain	13 (5.5%)	13 (9.1%)	22 (5.9%)	15 (4.0%)
Bone pain	0	3 (2.1%)	0	0
Bursitis	6 (2.5%)	0	1 (0.3%)	1 (0.3%)
Exostosis	0	2 (1.4%)	0	1 (0.3%)
Joint swelling	4 (1.7%)	0	3 (0.8%)	1 (0.3%)
Muscle spasms	3 (1.3%)	3 (2.1%)	6 (1.6%)	5 (1.3%)
Myalgia	0	2 (1.4%)	0	0
Neck pain	1 (0.4%)	0	4 (1.1%)	5 (1.3%)
Osteoarthritis	5 (2.1%)	0	4 (1:1%)	1 (0.3%)
Osteoporosis	0	5 (3.5%)	1 (0.3%)	4 (1.1%)
Pain in extremity	7 (3.0%)	4 (2.8%)	13 (3.5%)	10 (2.6%)
Rotator cuff syndrome	3 (1.3%)	0	0	3 (0.8%)
Shoulder pain	7 (3.0%)	1 (0.7%)	6 (1.6%)	4 (1.1%)
Neoplasms Benign, Malignant and Unspe	cified (incl. Cysts a	nd Polyps)		
Basal cell carcinoma	8 (3.4%)	2 (1.4%)	10 (2.7%)	6 (1.6%)
Seborrheic keratosis	0	2 (1.4%)	1 (0.3%)	1 (0.3%)

Original BLA Rhea A. Lloyd, MD 125156

Lucentis (ranibizumab injection)

And DRASS AGE STREET		an a	1	hab Pooled :
Proto da Constantia de la const				
			N-376	0.5 mg N=379
Skin cancer	1 (0.4%)	0	4 (1.1%)	3 (0.8%)
Skin papilloma	0	2 (1.4%)	1 (0.3%)	1 (0.3%)
Nervous System Disorders		2 (1.470)	1 (0.570)	1 (0.576)
Dizziness	16 (6.8%)	4 (2.8%)	14 (3.7%)	12 (3.2%)
Headache	15 (6.4%)	7 (4.9%)	35 (9.3%)	25 (6.6%)
Syncope	4 (1.7%)	3 (2.1%)	2 (0.5%)	6 (1.6%)
Transient ischemic attack	0	2 (1.4%)	0	2 (0.5%)
Psychiatric Disorders		1 2 (1.170)		2 (0.570)
Anxiety	1 (0.4%)	8 (5.6%)	11 (2.9%)	11 (2.9%)
Depression	8 (3.4%)	7 (4.9%)	9 (2.4%)	12 (3.2%)
Insomnia	7 (3.0%)	2 (1.4%)	8 (2.1%)	14 (3.7%)
Renal and Urinary Disorders	, (5.070)	1 2(1.470)	0(2.170)	1 (5.770)
Nephrolithiasis	0	3 (2.1%)	3 (0.5%)	0
Renal cyst	0	3 (2.1%)	1 (0.3%)	0
Reproductive System and Breast Disorde		3 (2.170)	1 (0.570)	
	1 (0.4%)	2 (1.4%)	3 (0.8%)	8 (2.1%)
Benign prostatic hyperplasia Prostatitis	0	2 (1.4%)	3 (0.8%)	1 (0.3%)
A REAL PROPERTY AND A REAL		2 (1.470)	0	1 (0.3%)
Respiratory, Thoracic and Mediastinal D		2 (2 19/)	8 (2 10/)	7 (1.90/)
Asthma Channia abatating airmann diagaan	2 (0.8%)	3 (2.1%)	8 (2.1%)	7 (1.8%)
Chronic obstructive airways disease, exacerbated	1 (0.4%)	2 (1.4%)	0	11 (2.9%)
Chronic obstructive pulmonary disease	0	1 (0.7%)	3 (0.8%)	4 (1.1%)
Cough	10 (4.2%)	8 (5.6%)	32 (8.5%)	20 (5.3%)
Dyspnea	3 (1.3%)	4 (2.8%)	10 (2.7%)	8 (2.1%)
Emphysema	0	3 (2.1%)	1 (0.3%)	2 (0.5%)
Epistaxis	0	2 (1.4%)	2 (0.5%)	1 (0.3%)
Hypoxia	3 (1.3%)	0	2 (0.5%)	0
Pharyngolarygeal pain	1 (0.4%)	4 (2.8%)	3 (0.8%)	3 (0.8%)
Rhinitis allergic	0	2 (1.4%)	0	0
Rhinorrhea	3 (1.3%)	1 (0.7%)	7 (1.9%)	4 (1.1%)
Sinus congestion	3 (1.3%)	0	5 (1.3%)	2 (0.5%)
Skin and Subcutaneous Disorders	an in the first part in the second	ىرىنى بىر يەرىكە يەرىكە يەرىپەر بىرىغان بىرىغان بىرىغان بىرىغان بىرىغان بىرىغان بىرىغان بىرىغان بىرىغان بىرىغان يېرىمى بىرىغان ب		
Actinic keratosis	6 (2.5%)	1 (0.7%)	4 (1.1%)	1 (0.3%)
Decubitus ulcer	0	2 (1.4%)	0	0
Pruritus	2 (0.8%)	1 (0.7%)	4 (1.1%)	8 (2.1%)
Rash	9 (3.8%)	. 4 (2.8%)	9 (2.4%)	8 (2.1%)
Surgical and Medical Procedures	and a strategy of a strategy of the strategy o			
Nasal sinus drainage	0	0	0	5 (1.3%)
Vascular Disorders		Anone	· · · · · · · · · · · · · · · · · · ·	al accor ste ref am
Hypertension	23 (9.7%)	12 (8.4%)	23 (6.1%)	29 (7.7%)
Hypotension	4 (1.7%)	3 (2.1%)	3 (0.8%)	0
Orthostatic hypotension	0	2 (1.4%)	0 .	0
Note: Multiple occurrences of the same ave			he overall incider	

Note: Multiple occurrences of the same event in a subject were counted once in the overall incidence.

Reviewer's Comment:

The adverse events which were seen more frequently in the ranibizumab 0.5 mg group versus either control are highlighted.

Adverse events which occurred most frequently (i.e. $\geq 10\%$) in the study eye of the ranibizumab treatment groups were conjunctival hemorrhage, eye pain, increased IOP, retinal disorder, and vitreous floaters. Many of these adverse events are commonly associated with conjunctival anesthetic and intravitreal injection procedures.

Elevated intraocular pressure was seen in a higher percentage of subjects in the ranibizumab groups than the sham-injection group. The ranibizumab subjects were also found to use ocular hypotensive and antihypertensive agents more frequently. This trend with the use of antihypertensive agents was noted at screening as well.

Intraocular inflammation including the Med DRA preferred terms iritis, iridocyclitis, vitritis, uveitis and anterior chamber inflammation was experienced at an increased rate in ranibizumab treated subjects in both studies. In study FVF2598g, 60 of 477 subjects (12.5%) and in study FVF2587g 35 of 277 subjects (12.6%) in the ranibizumab groups experienced intraocular inflammation in the study eye. Findings from the objective slit lamp examination were consistent with occurrence of intraocular inflammation adverse events and are diseussed

Table 7.1.5.3-2 Ocular Adverse Events in the Fellow Eye during the First Treatment Year Occurring in ≥ 5 % of Patients: Safety Evaluable Population

MedDRA System		CHETHODORATION STATE	Ranibizumab Pooled	
Preferred Term	1 - 236	2011 N=143	0.3 mg N=375	0.5 mg N=379
Total ²	168 (71.2%)	104 (72.7%)	258 (68.8%)	265 (69.9%)
Macular degeneration	60 (25.4%)	32 (22.4%)	91 (24.3%)	83 (21.9%)
Retinal hemorrhage	47 (19.9%)	26 (18.2%)	68 (18.1%)	71 (18.7%)
Vitreous detachment	31 (13.1%)	17 (11.9%)	43 (11.5%)	39 (10.3%)
Blepharitis	16 (6.8%)	6 (4.2%)	25 (6.6%)	29 (7.7%)
Cataract	10 (4.2%)	5 (3.5%)	16 (4.3%)	19 (5.0%)
Choroidal neovascularization	11 (4.7%)	6 (4.2%)	28 (7.5%)	29 (7.7%)
Dry Eye	13 (5.5%)	12 (8.4%)	12 (3.2%)	19 (5.0%)
Retinal disorder	11 (4.7%)	2 (1.4%)	17 (4.5%)	21 (5.5%)
Visual acuity reduced	18 (7.6%)	9 (6.3%)	13 (3.5%)	15 (4.0%)

Reviewer's Comment:

Ocular adverse events seen in the fellow eye during the first treatment year are those expected in this patient population.

7.1.5.4 Common adverse event tables

Refer to Section 7.1.5.3 Incidence of Common Adverse Events

7.1.5.5 Identifying common and drug-related adverse events

Reviewer's Comment:

Intraocular inflammation which includes Med DRA preferred terms iritis, iridocyclitis, vitritis, uveitis and anterior chamber inflammation was noted to occur in a dose dependent manner in the ranibizumab treated subjects in both studies. In study FVF2598g, 60 of 477 subjects (12.5%) and in study FVF2587g 35 of 277 subjects (12.6%) in the ranibizumab groups experienced intraocular inflammation in the study eye. Findings from the objective slit lamp examination were consistent with occurrence of intraocular inflammation adverse events.

10,18

Refer to Table 7.1.3.3-3 Intraocular Inflammation in the Study Eye during the First Treatment Year Studies FVF2598g and FVF2587g: Safety Evaluable Subjects for details.

7.1.5.6 Additional analyses and explorations

Not applicable. There were no additional analyses or explorations performed regarding adverse events.

7.1.6 Less Common Adverse Events

The overall safety population was not sufficiently large to identify rare events of significant concern.

7.1.7 Laboratory Findings

During clinical trials FVF2587g and FVF2598g, laboratory assessments were to be performed on all of the subjects at the Screening Visit and Month 12 or Early Termination Visit.

Reviewer's Comment:

None of the laboratory abnormalities noted were serious adverse events, led to treatment or study discontinuation.

7.1.7.1 Overview of laboratory testing in the development program

Laboratory testing during the development program was performed to determine systemic ranibizumab concentrations, immunoreactivity to ranibizumab and if any significant changes in blood chemistry, hematology or coagulation measures could be found.

7.1.7.2 Selection of studies and analyses for drug-control comparisons of laboratory values Such analyses were not performed. Laboratory investigations were limited by the low to non-detectable ranibizumab concentrations after intravitreal injection.

7.1.7.3 Standard analyses and explorations of laboratory data The analyses of laboratory data consisted of description of the findings.

7.1.7.4 Additional analyses and explorations

No additional analyses and explorations were performed.

7.1.7.5 Special assessments

Laboratory abnormality adverse events were reported in less than 2% of subjects. None of the laboratory abnormalities were serious adverse events, led to treatment or study discontinuation or were considered by the investigators as study drug related.

7.1.8 Vital Signs

Vital signs were measured at the Screening Visit and at each monthly visit post treatment. Overall, on average, both ranibizumab-treated and sham-treated subjects showed little change from baseline in vital signs throughout the first treatment year. There were no meaningful between group differences in the mean change from baseline in the temperature, pulse rate and respiration rate.

Regarding blood pressure, at Month 12, the mean changes from baseline were -1.6, -0.6, and -4.4 mmHg in systolic pressure and -2.0, -1.7, and -0.5 mm Hg in diastolic pressure for the sham, 0.3-mg, and 0.5-mg groups, respectively.

Some subjects had adverse events of increased blood pressure, worsening of preexisting hypertension, or newly diagnosed hypertension during the first treatment year. There was no imbalance among treatment groups in the proportion of subjects with such adverse events (15.7% in the sham group, 13.4% in the 0.3-mg group, and 12.6% in the 0.5-mg group.)

7.1.8.1 Overview of vital signs testing in the development program Refer to Section 7.1.1.

7.1.8.2 Selection of studies and analyses for overall drug-control comparisons These analyses were not performed.

7.1.8.3 Standard analyses and explorations of vital signs data These analyses were not performed.

7.1.8.4 Additional analyses and explorations Additional analyses and explorations of vital signs data were not performed.

7.1.9 Electrocardiograms (ECGs)

Electrocardiograms were not obtained during the development program for this product.

7.1.10 Immunogenicity

Serum samples for the evaluation of immunoreactivity to ranibizumab were obtained from subjects at screening and prior to study drug administration at Months 6 and 12. The assay demonstrated immunoreactivity in a small percentage of subjects in all three treatment groups prior to initial administration of study drug, possibly due to preexisting anti-Eab antibodies.

There was no imbalance between ranibizumab-treated and sham-treated subjects regarding immunoreactivity to ranibizumab. The assay indicated positivity in a small percentage of subjects in all three treatment groups prior to initial administration of study drug, possibly due to preexisting anti-Fab antibodies. All three treatment groups had similar increases in positivity during the treatment period.

	In Star	nide av F2/59	8g	i i i i i i i i i i i i i i i i i i i	dy FVF2587	No. Jacon and
Visit		kindo	KOUPD-	Verteporfin	Ranibi	zumab
VIBIT.	N=236		0.5118 2.11	PDT N=143	0.3 mg N=137	0.5 mg N=140
Screening	5/215	6/215	7/218	8/131	12/125	7/123
	(2.3%)	(2.8%)	(3.2%)	(6.1%)	(9.6%)	(5.7%)
Month 6	19/201	15/211	17/207	6/114	11/120	10/116
	(9.5%)	(7.1%)	(8.2%)	(5.3%)	(9.2%)	(8.6%)
Month 12	20/206	22/222	26/219	7/125	9/123	16/129
	(9.7%)	(9.9%)	(11.9%)	(5.6%)	(7.3%)	(12.4%)

Table 7.1.10-1 Immunoreactivity to Ranibizumab in the First Treatment Year

Note: Table entries are numbers of subjects with positive immunoreactivity over numbers of subjects with evaluable samples. LTR=0.7 log titer.

Exploratory subgroup analyses based on immunoreactivity to ranibizumab were performed to determine whether the appearance of immunoreactivity was related to key safety and efficacy outcomes. The analysis population was divided into three subgroups: subjects who had a negative or missing test result at screening and negative post-baseline results, subjects who had a negative or missing test result at screening but at least one positive post-baseline result, and subjects who had a positive test result at screening. Visual acuity outcomes and the occurrence of intraocular inflammation and autoimmune adverse events were examined by treatment group for each immunoreactivity subgroup. No clinically relevant differences between immunoreactivity subgroups were identified in study FVF2598g.

In Study FVF2587g, with regard to intraocular inflammation adverse events, proportionately more ranibizumab-treated subjects who were immunoreactive at some time point experienced intraocular inflammation events than subjects who were never immunoreactive. Twenty- eight percent (5 of 18) of ranibizumab-treated subjects who were immunoreactive during treatment only and thirty-two percent of subjects (6 of 19) who were immunoreactive at baseline experienced inflammation adverse events in the study eye, compared with 10% of ranibizumab-treated subjects (23 of 230) who were never immunoreactive. Of the 12 verteporfin PDT-treated subjects who were immunoreactive at some time point, none experienced an intraocular inflammation adverse event.

La BLA
 Rhea A. Lloyd, MD
 125156
 Lucentis (ranibizumab injection)

Table 7.1.10-2 Intraocular Inflammation in Subjects with ImmunoreactivityBased on the Initial and Confirmatory Assays (ECLAs 4.FBV.8 and 4.FBV.10)Studies FVF2428g, FVF2587g, FVF3192g (First Treatment Year) and FVF2598g (2-Year Treatment Period)Safety Evaluable Subjects

of		1 Sector 1, 1990, March 19 And Andrea March 1990, M		the second s			and the second
Internation Intrinuoreactivity Intrinuoreactivity Verteporfin PDT + 91103 34 / Month 1 1.200 kham 91308 -7 / Screening 0.884 Verteporfin PDT 91308 -7 / Screening 0.384 Verteporfin PDT 91308 -7 / Screening 0.975 Verteporfin PDT 334003 -12 / Screening 0.767 Verteporfin PDT 334003 -12 / Screening 0.992 Antibizumab 0.3 mg 334003 -7 / Screening 1.130 Ranibizumab 0.3 mg 334003 -7 / Screening 0.992 Antibizumab 0.3 mg 331003 -7 / Screening 0.995 Si / Month 12 186 / Month 12 1800 995 Antibizumab 0.3 mg 337012 -26 / Screening 0.945 337012 -36 / Month 12 1800 996 Antibizumab 0.5 mg 337003 -1 / Screening 0.945 Antibizumab 0.5 mg 337003 -1 / Screening 0.910 Antibizumab 0.5 mg 360200 -1 / Screening				Study Day / Visit of Positive		Any Intraocular	Study Visit of Intraocular
Verteportin PDT + 91103 34 / Month 1 1.200 Sham Verteportin PDT + 91308 -7 / Screening 0.884 Verteportin PDT + 91308 -7 / Screening 0.884 Readbirenseb 0.5 mg 366 / Month 12 1.200 Verteportin PDT 319001 386 / Month 12 0.767 Verteportin PDT 319001 386 / Month 12 0.797 Verteportin PDT 319003 -12 / Screening 1.130 Nonth 6 1.2 / Screening 1.130 0.945 Ranibizumab 0.3mg 321003 -7 / Screening 0.945 Ranibizumab 0.3mg 334003 176 / Month 12 1.800 Sizo06 -10 / Screening 0.945 2.300 337012 -26 / Screening 0.945 2.900 Sizo06 -10 / Screening 0.945 1.800 Ranthizumab 0.5mg 337012 -26 / Screening 0.945 Sizo06 -10 / Screening 0.910 0.910 Sizo06 10 / Month 6 1.800 0.910				Immunoreactivity	Tumunoreactivity	Inflammation	Inflammation
sham 91103 34 / Month 1 1.200 Verteporfin PDT + 91308 -7/ Screening 0.884 Verteporfin PDT 314001 366 / Month 12 0.767 Verteporfin PDT 314001 386 / Month 6 0.797 Verteporfin PDT 314002 -8 / Screening 1.130 Netteporfin PDT 334008 -12 / Screening 1.130 Netteporfin PDT 334003 -7 / Screening 1.130 Anthiz 190 / Month 6 0.902 0.902 Rantbizumab 0.3mg 321003 -7 / Screening 1.780 Statibizumab 0.5mg 337012 -26 / Screening 0.945 Statibizumab 0.5mg 351004 344 / Month 12 1.800 Anthiz 176 / Month 12 1.800 0.910 Rantbizumab 0.5mg 3521003 -1 / Screening 0.910 Statibizumab 0.5mg 3521003 -1 / Screening 0.910 Statibizumab 0.5mg 360 / Month 12 1.500 0.910 Statibizumab 0.5mg 360 / Month 12 1.530 0.910 Statibizumab 0.5mg 360 / Month 12 1.530 0.910	FVF2428 ^{g¹}		Service Service		いたいです。「「「「「「「」」」」」」」」」」」」」」」」」」」」」」」」」」」」」」	Iritis	Month 4
Verteporfin PDT + 91308 -7/Screening 0.884 Rsathfistensish 0.5 mg 3566 / Month 12 0.767 0.767 Verteporfin PDT 319001 386 / Month 12 0.797 0.767 Verteporfin PDT 319001 386 / Month 6 1.130 0.797 Verteporfin PDT 319001 386 / Month 6 0.902 0.767 Ranibizumab 0.3 mg 314002 -8 / Screening 1.820 0.902 Ranibizumab 0.3 mg 321002 -8 / Screening 0.945 1.800 Ranibizumab 0.3 mg 321003 -7 / Screening 0.945 2.300 337012 -2.6 / Screening 0.945 2.300 2.300 337012 -2.6 / Screening 0.945 2.300 351004 344 / Month 12 1.800 9.936 Ranibizumab 0.5 mg 3602 176 / Month 6 1.800 337003 -1 / Screening 0.910 2.300 337003 362 / Month 12 1.860 1.860 337003 362 / Month 12 1.860	0		91103	34 / Month 1	1.200		
Rantbizumus 0.5 mg 366 / Month 12 0.767 Verteporfin PDT 319001 386 / Month 12 0.797 34008 -12 / Screening 11.130 11.130 Arteporfin PDT 34008 -12 / Screening 11.130 Arteporfin PDT 34008 -12 / Screening 11.130 Arteborfin PDT 34002 -8 / Screening 11.800 Arteborfin PDT 34002 -8 / Screening 1.780 Arteborfin PDT 34003 -7 / Screening 0.945 Arteborfin 12 176 / Month 12 1800 945 Art / Month 12 -26 / Screening 0.945 2.300 351004 344 / Month 12 2.190 0.938 357005 -10 / Screening 0.910 0.938 Arnibizumab 0.5mg 362 / Month 12 1.860 0.910 Arnibizumab 0.5mg 36020 174 / Month 6 1.530 337009 364 / Month 12 1.860 1.270 337009 366 / Month 12 1.7450 1.7450			91308	- 7 / Screening	0.884	No	
Verteporfin PDT 319001 386 / Month 12 0.797 34008 -12 / Screening 1.130 34008 -12 / Screening 1.130 34001 386 / Month 6 0.902 401002 -8 / Screening 1.820 861 / Month 6 1.780 1.800 334003 -7 / Screening 0.945 334003 176 / Month 6 2.300 337012 -26 / Screening 0.938' 351004 344 / Month 12 2.190 352006 -10 / Screening 0.910 90038 -1 / Screening 0.910 90103 -1 / Screening 0.910 90103 -1 / Screening 0.910 90200 174 / Month 12 1.860 90200 174 / Month 12 1.850 942007 362 / Month 12 1.850 9038 -1 / Screening 0.910 906020 174 / Month 12 1.530 91704 362 / Month 12 1.270 920070 364 / Month 12 </th <th></th> <th>Ranibizamab 0.5 mg</th> <th></th> <th>366 / Month 12</th> <th>0.767</th> <th></th> <th></th>		Ranibizamab 0.5 mg		366 / Month 12	0.767		
334008 $-12/$ Screening 1.130 334008 $190/$ Month 6 0.902 401002 $-8/$ Screening 1.820 401002 $-8/$ Screening 1.820 $361/$ Month 6 1.780 1.800 321003 $-7/$ Screening 0.945 337012 $-7/$ Screening 0.945 337012 $-26/$ Screening 0.945 337012 $-26/$ Screening $0.938'$ 351004 $344/$ Month 12 $2.0704'$ 352006 $-10/$ Screening $0.938'$ 352006 $-10/$ Screening $0.910'$ 352006 $-10/$ Screening $0.910'$ 36020 $174/$ Month 6 $1.800'$ 306020 $174/$ Month 12 $1.800'$ 342007 $364/$ Month 12 $1.530'$ 342007 $174/$ Month 6 $1.270'$ 342007 $174/$ Month 12 $1.270'$ 342007 $360/$ Month 12 $3.060'$	FVF2587g	Verteporfin PDT	319001	386 / Month 12	0.797	No	
190 / Month 6 0.902 401002 $-8 / Screening$ 1.820 401002 $-8 / Screening$ 1.820 $361 / Month 6$ 1.780 $361 / Month 12$ 1.780 $351 / Month 12$ 1.780 37012 $-7 / Screening$ 0.945 337012 $-7 / Screening$ 0.945 337012 $-26 / Screening$ $0.938'$ 337012 $-26 / Screening$ $0.938'$ 351004 $344 / Month 12$ 2.190 352006 $-10 / Screening$ $0.938'$ 352006 $-10 / Screening$ 0.910 352006 $-10 / Screening$ 0.910 352006 $-10 / Screening$ 0.910 337003 $-1 / Screening$ 0.910 36020 $174 / Month 6$ 1.530 306020 $174 / Month 6$ 1.530 342007 $364 / Month 12$ 1.270 342007 $174 / Month 6$ 2.450 342007 $174 / Month 12$ 3.060			334008	-12 / Screening	1.130	No	
401002-8 / Screening1.820186 / Month 61.780361 / Month 121.800351 / Month 121.800321003 -7 / Screening 0.945 321004 $34/$ Month 6 2.300 337012 $-26/$ Screening $0.938'$ 351004 $34/$ Month 12 2.190 352006 $-10/$ Screening $0.938'$ 352006 $-10/$ Screening $0.938'$ 352006 $-10/$ Screening 0.910 36020 $174/$ Month 6 1.530 37009 $364/$ Month 12 1.270 342007 $174/$ Month 6 2.450 $360/$ Month 12 $3.60/$ Month 12 3.660				190 / Month 6	0.902	No	
186 / Month 6 1.780 $361 / Month 12$ 1.780 $361 / Month 12$ 1.800 31003 $-7 / Screening$ 0.945 334003 $176 / Month 6$ 2.300 337012 $-26 / Screening$ $0.938'$ 337002 $344 / Month 12$ 2.190 352006 $-10 / Screening$ $0.938'$ 352006 $-10 / Screening$ $0.938'$ 352006 $-10 / Screening$ 0.910 352006 $-10 / Screening$ 0.910 $362 / Month 12$ 1.860 $362 / Month 12$ 1.800 306020 $174 / Month 6$ 1.530 306020 $174 / Month 6$ 1.530 337009 $364 / Month 12$ 1.860 342007 $174 / Month 6$ 2.450 342007 $174 / Month 12$ 3.060			401002	-8 / Screening	1.820	No	
361 / Month 12 1.800 321003 $-7 / Screening$ 0.945 321003 $176 / Month 6$ 2.300 337012 $-26 / Screening$ $0.938'$ 337012 $-26 / Screening$ $0.938'$ 351004 $344 / Month 12$ 2.190 352006 $-10 / Screening$ $0.938'$ 352006 $-10 / Screening$ 0.910 352006 $-10 / Screening$ 0.910 $362 / Month 6$ 1.860 403003 $-1 / Screening$ 0.910 306020 $174 / Month 6$ 1.530 337009 $364 / Month 12$ 1.850 342007 $174 / Month 6$ 1.270 342007 $174 / Month 12$ 1.270 $360 / Month 12$ 3.060				186 / Month 6	1.780		
321003 -7 / Screening 0.945 334003 176 / Month 6 2.300 334003 176 / Month 12 2.300 3351004 344 / Month 12 2.190 352006 -10 / Screening 0.938 ' 352006 -10 / Screening 2.070 / 352006 -10 / Screening 2.070 / 352006 -10 / Screening 0.910 352003 -1 / Screening 0.910 362 / Month 12 1.860 1.860 306020 174 / Month 6 1.530 337009 362 / Month 12 1.850 342007 174 / Month 6 2.450 342007 174 / Month 12 1.270 342007 174 / Month 12 1.270 360 / Month 12 3.060 3.060				361 / Month 12	1.800		
334003 $176 / Month 6$ 2.300 337012 $-26 / Screening$ $0.938'$ 351004 $344 / Month 12$ 2.190 352006 $-10 / Screening$ 2.0704 352006 $-10 / Screening$ 2.0704 352006 $-10 / Screening$ 0.910 36020 $-10 / Screening$ 0.910 403003 $-1 / Screening$ 0.910 306020 $174 / Month 6$ 1.530 337009 $364 / Month 12$ 1.530 342007 $174 / Month 6$ 2.450 342007 $360 / Month 12$ 3.060		Ranibizumab 0.3mg	321003	-7 / Screening	0.945	Yes - Vitritis	Screen.,Month 1
337012 -26 / Screening 0.938 351004 344 / Month 12 2.190 352006 -10 / Screening 2.0704 352006 180 / Month 6 1.890 362 / Month 12 1.890 362 / Month 12 1.800 362 / Month 12 1.800 306020 174 / Month 6 1.530 306020 364 / Month 12 1.850 337009 364 / Month 12 1.270 342007 174 / Month 12 1.270 342007 364 / Month 12 3.060			334003	176 / Month 6	2.300	Yes - Iritis	Month 4 ²
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$			337012	-26 / Screening	0.938	Yes – Iritis	Month 5 ³
352006 -10 / Screening 2.070 f 352006 180 / Month 6 1.890 f 180 / Month 12 1.800 f 362 / Month 12 1.860 403003 -1 / Screening 0.910 306020 174 / Month 6 1.530 307009 364 / Month 12 1.850 337009 364 / Month 12 1.270 342007 174 / Month 12 1.270 360 / Month 12 3.060		-	351004	344 / Month 12	2.190	No	1
180 / Month 6 1.890 ∮ 362 / Month 12 1.860 362 / Month 12 1.860 403003 -1 / Screening 0.910 306020 174 / Month 6 1.530 337009 364 / Month 12 1.850 342007 174 / Month 12 1.270 360 / Month 12 3.060			352006	-10 / Screening	2.070	No	
362 / Month 12 1.860 403003 -1 / Screening 0.910 306020 174 / Month 6 1.530 305020 364 / Month 12 1.850 337009 364 / Month 12 1.270 342007 174 / Month 12 1.270 360 / Month 12 3.060 3.450		-	-	180 / Month 6	1.890	No	1
403003 -1 / Screening 0.910 306020 174 / Month 6 1.530 30509 362 / Month 12 1.850 337009 364 / Month 12 1.270 342007 174 / Month 6 2.450 360 / Month 12 3.060				362 / Month 12	1.860	No	{ *
306020 174 / Month 6 1.530 362 / Month 12 1.850 337009 364 / Month 12 1.850 342007 174 / Month 6 2.450 360 / Month 12 3.060 3.060			403003	-1 / Screening	0.910	No	-
362 / Month 12 1.850 364 / Month 12 1.270 174 / Month 6 2.450 360 / Month 12 3.060		Ranibizumab 0.5mg	306020	174 / Month 6	1.530	Yes - Vitritis	Months 1 and 2
364 / Month 12 1.270 174 / Month 6 2.450 360 / Month 12 3.060				362 / Month 12	1.850	-	
174 / Month 6 2.450 360 / Month 12 3.060			337009	364 / Month 12	1.270	No	
			342007	174 / Month 6	2.450	Yes - Iritis, Vitritis	Month 11 ⁴
			-	360 / Month 12	3.060		
346001 182 / Month 6 1.260			346001	182 / Month 6	1.260	No	1

C. I BLA Rhea A. Lloyd, MI

) nab injection)	•
Rhea A. Lloyd, MD 125156 Lucentis (ranibizumab	

	1				<u>.</u>				T	<u> </u>	 -=				T	1			1			T	T	T		T	T	_	<u>, </u>	1	
Study Visit of Intraocular Inflammation Diagnosis			Month 7						Day 7						6 B t			3				Month 2			Month 15 ⁶						
Any Intraocular Inflammation Diagnosis			Yes – Uveitis ⁵		No			No	Yes - Iritis				No		No	No		No	No	No	No	Iritis		No	Initis		No		No		
Immunoreactivity Assay Log Titer	1.770	1.240	0.993	0.952	1.230	2.090	2.060	2.560	2.100	2.060	2.170	2.340	0.864	0.863	0.903	1.850	1.810	1.490	0.866	0.918	1.270	3.550	3.740	1.080	3.150	2.120	2.000	1.890	0.910	0.993	0.793
Study Day / Visit of Positive Immunoreactivity Assay	361 / Month 12	-28 / Screening	182 / Month 6	365 / Month 12	183 / Month 6	358 / Month 12	463 / Early term.	723 / Month 24	-28 / Screening	176 / Month 6	358 / Month 12	729 / Month 24	181 / Month 6	393 / Month 12	355 / Month 12	361 / Month 12	719 / Month 24	728 / Month 24	716 / Month 24	183 / Month 6	721 / Month 24	-13 / Screening	177 / Month 6	714 / Month 24	364 / Month 12	717 / Month 24	360 / Month 12	724 / Month 24	-21 / Screening	175 / Month 6	368 / Month 24
Subject ID		389001			10200	•		116002	139004				150005		182003	101021		110004	112002	125007	141009	143001		146001	149006		159013		165002		
Treatment Group		,			Sham								-		-	Ranibizumab 0.3mg						-									
Study					FVF2598g																										

| 10/002 717 / Month 24 1.230 100 100 188005 717 / Month 24 1.250 No 1 Sham 534001 -7 / Screening 2.520 Vitritis

 | IOU002 IIII MOUL 24 III200 NO 188005 717 / Month 24 1.250 No $\sqrt{10}$ Sham 534001 -7 / Screening 2.520 Vitritis

 | Sham 534001 -717 / Month 24 1.250 NO

 |

 |

 |

 |
 |

 |

 |
 |
 |

 |
 | |
 |
 | | |
 |

--
--
--
--
--
--

--
--
--
--
--

--
--

--
--
--
--
--
--
--
--
--

--

--
---|--
--
--	--
Sham 534001 -7 / Screening 2.520 Vitritis	

 | Sham 534001 -7 / Screening 2.520 Vitritis

 | Sham 534001 -7 / Screening 2.520 Vitritis

 | Treatment Group Innumoreactivity Innumoreactivity </td <td>Treatment Group Subject ID Nasy Lurraceular Instruction Subject ID Subject ID Jasay Lurraceular Instruction 170010 365 / Month 12 2770 No Instruction 175006 358 / Month 12 2770 No Instruction 715 / Month 24 1.870 Irtits Instruction 717 / Month 24 1.130 No Instruction 722 / Month 24 1.700 No Instruction 722 / Month 24 1.700 No Instruction 737 / Month 24 1.700 No Instruction 362 / Month 12 1.600 No Instruction 11/4 0.782 No Instruction 12200 1.700 No Instruction 1.140 No No</td> <td>Treatment Group Bubject ID Subject ID Nasty Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group 170010 355 Mouth 12 2770 No Interment Group 175006 358 Mouth 12 1870 Intrins Interment Group 177 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 106002 721 Month 24 1770 No No Interment D 5 mg 120001 174 Month 24 1770 No No Interment D 5 mg 120001 722 Month 24 1770 No No Interment D 6 1770 No No No No Interment D 6 1740 No No No</td> <td>Treatment Group Bositre
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity JTeatment Group Subject ID 3ssy Asay Asay Lugrandia 170010 365/Month 12 2770 No No 170010 358/Month 12 2870 Infrimmation 177006 358/Month 12 1870 Infri 177006 358/Month 24 1.140 No 106002 719/Month 24 1.140 No 122002 339/Month 24 1.1700 No 124003 722/Month 24 1.700 No 122002 339/Month 12 1.690 No 124003 721/Month 24 1.700 No 124003 722/Month 24 1.700 No 124003 722/Month 24 1.700 No 124003 721/Month 24 1.700 No 12400 733/Month 24 1.700 No 12400 131/Month 24 1.700 No 1</td> <td>Treatment Group Bubject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td> <td>Treatment Group Bositre
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity JTeatment Group Subject ID 3ssy Asay Asay Lugrandia 170010 365/Month 12 2770 No No 170010 358/Month 12 2870 Infrimmation 177006 358/Month 12 1870 Infri 177006 358/Month 24 1.140 No
 106002 719/Month 24 1.140 No 122002 339/Month 24 1.1700 No 124003 722/Month 24 1.700 No 122002 339/Month 12 1.690 No 124003 721/Month 24 1.700 No 124003 722/Month 24 1.700 No 124003 722/Month 24 1.700 No 124003 721/Month 24 1.700 No 12400 733/Month 24 1.700 No 12400 131/Month 24 1.700 No 1</td> <td>Treatment Group Bositre
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity JTeatment Group Subject ID 3ssy Asay Asay Lugrandia 170010 365/Month 12 2770 No No 170010 358/Month 12 2870 Infrimmation 177006 358/Month 12 1870 Infri 177006 358/Month 24 1.140 No 106002 719/Month 24 1.140 No 122002 339/Month 24 1.1700 No 124003 722/Month 24 1.700 No 122002 339/Month 12 1.690 No 124003 721/Month 24 1.700 No 124003 722/Month 24 1.700 No 124003 722/Month 24 1.700 No 124003 721/Month 24 1.700 No 12400 733/Month 24 1.700 No 12400 131/Month 24 1.700 No 1</td> <td>Treatment Group Bubject ID Subject ID Nasty Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group 170010 355 Mouth 12 2770 No Interment Group 175006 358 Mouth 12 1870 Intrins Interment Group 177 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 106002 721 Month 24 1770 No No Interment D 5 mg 120001 174 Month 24 1770 No No Interment D 5 mg 120001 722 Month 24 1770 No No Interment D 6 1770 No No No No Interment D 6 1740 No No No</td> <td>Treatment Group Bubject ID Subject ID Nasty Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group 170010 355 Mouth 12 2770 No Interment Group 175006 358 Mouth 12 1870 Intrins Interment Group 177 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 106002 721 Month 24 1770 No No Interment D 5 mg 120001 174 Month 24 1770 No No Interment D 5 mg 120001 722 Month 24 1770 No No Interment D 6 1770 No No No No Interment D 6 1740 No No No</td> <td>Treatment Group Bubject ID Subject ID Nasty Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group 170010 355 Mouth 12 2770 No Interment Group 175006 358 Mouth 12 1870 Intrins Interment Group 177 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 106002 721 Month 24 1770 No No Interment D 5 mg 120001 174 Month 24 1770 No No Interment D 5 mg 120001 722 Month 24 1770 No No Interment D 6 1770 No No No No Interment D 6 1740 No No No</td> <td>Treatment Group Innumoreactivity Innumoreactivity<!--</td--><td>Treatment Group Intranceditive Intranceditie Treatment Group Subject ID Assey Assey Intranceditie 170010 365 / Month 12 2770 No No 170010 365 / Month 12 2770 No No 170010 365 / Month 12 1870 Irrinia Irris 177006 358 / Month 12 1870 Irris No 177006 358 / Month 24 1390 No No 104002 712 / Month 24 1140 No No 124003 722 / Month 24 1330 No No 122002 359 / Month 24 1770 No No 124003 722 / Month 24 1770 No <t< td=""><td>Treatment/Group Intranscription Treatment/Group Innumoreactivity Intranscription 170010 365/Month 12 23700 Nio 170010 365/Month 12 2300 Nio 170010 355/Month 12 1870 Irritis 170010 355/Month 24 1870 Irritis 177006 338/Month 24 1360 Nio 177005 355/Month 24 1370 Nio 104002 712/Month 24 1140 Nio 122002 359/Month 12 1500 Nio 122002 359/Month 12 1500 Nio 122002 359/Month 24 1300 Nio 122002 359/Month 12 1500 Nio 124003 722/Month 24 1300 Nio 124003 722/Month 24 1300 Nio 124003 722/Month 24 1300 Nio 124003 722/Month 24 1700 Nio 124003 722/Month 24 1600</td><td>Treatment Group Politive
Innunoreactivity Intrancentiar
Innunoreactivity Intrancentiar
Infammination Arsay Leg Titer Subject ID Assay Leg Titer Digenosis 170010 365/Month 12 2800 No 177006 338/Month 12 1870 Irritis 177006 338/Month 24 1870 Irritis 104002 717/Month 24 1140 No 104002 722/Month 24 1130 No 122002 359/Month 12 16300 No 124003 722/Month 24 1130 No 122002 359/Month 12 16300 No 124003 722/Month 24 1130 No 124003 722/Month 24 1770 No 124003 722/Month 24 1770 No 124003 722/Month 24 1700 <</td><td>Treatment Group Positive
Innumerativity Lurrancettisty Lurrancettisty Treatment Group Subject ID Assay Log Titer Diagnosis 170010 365 / Month 12 2770 No Diagnosis 170010 365 / Month 12 2800 No Diagnosis 170010 365 / Month 24 1870 Lirtis Diagnosis 177006 338 / Month 24 1870 Lirtis Diagnosis 104002 712 / Month 24 1140 No No 104002 722 / Month 24 1130 No No 122002 359 / Month 24 1170 No No 124003 722 / Month 24 1770 No No 124003 722 / Month 24 1770 No No 12400 722 /</td><td>Treatment Group Routing and the seture of the particular function of the particular function of the particular function of the particular desired by the partin desired by the particular desired by the particular</td></t<></td></td>
 | Treatment Group Subject ID Nasy Lurraceular Instruction Subject ID Subject ID Jasay Lurraceular Instruction 170010 365 / Month 12 2770 No Instruction 175006 358 / Month 12 2770 No Instruction 715 / Month 24 1.870 Irtits Instruction 717 / Month 24 1.130 No Instruction 722 / Month 24 1.700 No Instruction 722 / Month 24 1.700 No Instruction 737 / Month 24 1.700 No Instruction 362 / Month 12 1.600 No Instruction 11/4 0.782 No Instruction 12200 1.700 No Instruction 1.140 No No

 | Treatment Group Bubject ID Subject ID Nasty Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group 170010 355 Mouth 12 2770 No Interment Group 175006 358 Mouth 12 1870 Intrins Interment Group 177 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 106002 721 Month 24 1770 No No Interment D 5 mg 120001 174 Month 24 1770 No No Interment D 5 mg 120001 722 Month 24 1770 No No Interment D 6 1770 No No No No Interment D 6 1740 No No No

 | Treatment Group Bositre
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity JTeatment Group Subject ID 3ssy Asay Asay Lugrandia 170010 365/Month 12 2770 No No 170010 358/Month 12 2870 Infrimmation 177006 358/Month 12 1870 Infri 177006 358/Month 24 1.140 No 106002 719/Month 24 1.140 No 122002 339/Month 24 1.1700 No 124003 722/Month 24 1.700 No 122002 339/Month 12 1.690 No 124003 721/Month 24 1.700 No 124003 722/Month 24 1.700 No 124003 722/Month 24 1.700 No 124003 721/Month 24 1.700 No 12400 733/Month 24 1.700 No 12400 131/Month 24 1.700 No 1

 | Treatment Group Bubject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit
 | Treatment Group Bositre
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity JTeatment Group Subject ID 3ssy Asay Asay Lugrandia 170010 365/Month 12 2770 No No 170010 358/Month 12 2870 Infrimmation 177006 358/Month 12 1870 Infri 177006 358/Month 24 1.140 No 106002 719/Month 24 1.140 No 122002 339/Month 24 1.1700 No 124003 722/Month 24 1.700 No 122002 339/Month 12 1.690 No 124003 721/Month 24 1.700 No 124003 722/Month 24 1.700 No 124003 722/Month 24 1.700 No 124003 721/Month 24 1.700 No 12400 733/Month 24 1.700 No 12400 131/Month 24 1.700 No 1

 | Treatment Group Bositre
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity JTeatment Group Subject ID 3ssy Asay Asay Lugrandia 170010 365/Month 12 2770 No No 170010 358/Month 12 2870 Infrimmation 177006 358/Month 12 1870 Infri 177006 358/Month 24 1.140 No 106002 719/Month 24 1.140 No 122002 339/Month 24 1.1700 No 124003 722/Month 24 1.700 No 122002 339/Month 12 1.690 No 124003 721/Month 24 1.700 No 124003 722/Month 24 1.700 No 124003 722/Month 24 1.700 No 124003 721/Month 24 1.700 No 12400 733/Month 24 1.700 No 12400 131/Month 24 1.700 No 1
 | Treatment Group Bubject ID Subject ID Nasty Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group 170010 355 Mouth 12 2770 No Interment Group 175006 358 Mouth 12 1870 Intrins Interment Group 177 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 106002 721 Month 24 1770 No No Interment D 5 mg 120001 174 Month 24 1770 No No Interment D 5 mg 120001 722 Month 24 1770 No No Interment D 6 1770 No No No No Interment D 6 1740 No No No

 | Treatment Group Bubject ID Subject ID Nasty Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group 170010 355 Mouth 12 2770 No Interment Group 175006 358 Mouth 12 1870 Intrins Interment Group 177 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 106002 721 Month 24 1770 No No Interment D 5 mg 120001 174 Month 24 1770 No No Interment D 5 mg 120001 722 Month 24 1770 No No Interment D 6 1770 No No No No Interment D 6 1740 No No No
 | Treatment Group Bubject ID Subject ID Nasty Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group 170010 355 Mouth 12 2770 No Interment Group 175006 358 Mouth 12 1870 Intrins Interment Group 177 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 106002 721 Month 24 1770 No No Interment D 5 mg 120001 174 Month 24 1770 No No Interment D 5 mg 120001 722 Month 24 1770 No No Interment D 6 1770 No No No No Interment D 6 1740 No No No
 | Treatment Group Innumoreactivity Innumoreactivity </td <td>Treatment Group Intranceditive Intranceditie Treatment Group Subject ID Assey Assey Intranceditie 170010 365 / Month 12 2770 No No 170010 365 / Month 12 2770 No No 170010 365 / Month 12 1870 Irrinia Irris 177006 358 / Month 12 1870 Irris No 177006 358 / Month 24 1390 No No 104002 712 / Month 24 1140 No No 124003 722 / Month 24 1330 No No 122002 359 / Month 24 1770 No No 124003 722 / Month 24 1770 No <t< td=""><td>Treatment/Group Intranscription Treatment/Group Innumoreactivity Intranscription 170010 365/Month 12 23700 Nio 170010 365/Month 12 2300 Nio 170010 355/Month 12 1870 Irritis 170010 355/Month 24 1870 Irritis 177006 338/Month 24 1360 Nio 177005 355/Month 24 1370 Nio 104002 712/Month 24 1140 Nio 122002 359/Month 12 1500 Nio 122002 359/Month 12 1500 Nio 122002 359/Month 24 1300 Nio 122002 359/Month 12 1500 Nio 124003 722/Month 24 1300 Nio 124003 722/Month 24 1300 Nio 124003 722/Month 24 1300 Nio 124003 722/Month 24 1700 Nio 124003 722/Month 24 1600</td><td>Treatment Group Politive
Innunoreactivity Intrancentiar
Innunoreactivity Intrancentiar
Infammination Arsay Leg Titer Subject ID Assay Leg Titer Digenosis 170010 365/Month 12 2800 No 177006 338/Month 12 1870 Irritis 177006 338/Month 24 1870 Irritis 104002 717/Month 24 1140 No 104002 722/Month 24 1130 No 122002 359/Month 12 16300 No 124003 722/Month 24 1130 No 122002 359/Month 12 16300 No 124003 722/Month 24 1130 No 124003 722/Month 24 1770 No 124003 722/Month 24 1770 No 124003 722/Month 24 1700 <</td><td>Treatment Group Positive
Innumerativity Lurrancettisty Lurrancettisty Treatment Group Subject ID Assay Log Titer Diagnosis 170010 365 / Month 12 2770 No Diagnosis 170010 365 / Month 12 2800 No Diagnosis 170010 365 / Month 24 1870 Lirtis Diagnosis 177006 338 / Month 24 1870 Lirtis Diagnosis 104002 712 / Month 24 1140 No No 104002 722 / Month 24 1130 No No 122002 359 / Month 24 1170 No No 124003 722 / Month 24 1770 No No 124003 722 / Month 24 1770 No No 12400 722 /</td><td>Treatment Group Routing and the seture of the particular function of the particular function of the particular function of the particular desired by the partin desired by the particular desired by the particular</td></t<></td> | Treatment Group Intranceditive Intranceditie Treatment Group Subject ID Assey Assey Intranceditie 170010 365 / Month 12 2770 No No 170010 365 / Month 12 2770 No No 170010 365 / Month 12 1870 Irrinia Irris 177006 358 / Month 12 1870 Irris No 177006 358 / Month 24 1390 No No 104002 712 / Month 24 1140 No No 124003 722 / Month 24 1330 No No 122002 359 / Month 24 1770 No No 124003 722 / Month 24 1770 No <t< td=""><td>Treatment/Group Intranscription Treatment/Group Innumoreactivity Intranscription 170010 365/Month 12 23700 Nio 170010 365/Month 12 2300 Nio 170010 355/Month 12 1870 Irritis 170010 355/Month 24 1870 Irritis 177006 338/Month 24 1360 Nio 177005 355/Month 24 1370 Nio 104002 712/Month 24 1140 Nio 122002 359/Month 12 1500 Nio 122002 359/Month 12 1500 Nio 122002 359/Month 24 1300 Nio 122002 359/Month 12 1500 Nio 124003 722/Month 24 1300 Nio 124003 722/Month 24 1300 Nio 124003 722/Month 24 1300 Nio 124003
722/Month 24 1700 Nio 124003 722/Month 24 1600</td><td>Treatment Group Politive
Innunoreactivity Intrancentiar
Innunoreactivity Intrancentiar
Infammination Arsay Leg Titer Subject ID Assay Leg Titer Digenosis 170010 365/Month 12 2800 No 177006 338/Month 12 1870 Irritis 177006 338/Month 24 1870 Irritis 104002 717/Month 24 1140 No 104002 722/Month 24 1130 No 122002 359/Month 12 16300 No 124003 722/Month 24 1130 No 122002 359/Month 12 16300 No 124003 722/Month 24 1130 No 124003 722/Month 24 1770 No 124003 722/Month 24 1770 No 124003 722/Month 24 1700 <</td><td>Treatment Group Positive
Innumerativity Lurrancettisty Lurrancettisty Treatment Group Subject ID Assay Log Titer Diagnosis 170010 365 / Month 12 2770 No Diagnosis 170010 365 / Month 12 2800 No Diagnosis 170010 365 / Month 24 1870 Lirtis Diagnosis 177006 338 / Month 24 1870 Lirtis Diagnosis 104002 712 / Month 24 1140 No No 104002 722 / Month 24 1130 No No 122002 359 / Month 24 1170 No No 124003 722 / Month 24 1770 No No 124003 722 / Month 24 1770 No No 12400 722 /</td><td>Treatment Group Routing and the seture of the particular function of the particular function of the particular function of the particular desired by the partin desired by the particular desired by the particular</td></t<> | Treatment/Group Intranscription Treatment/Group Innumoreactivity Intranscription 170010 365/Month 12 23700 Nio 170010 365/Month 12 2300 Nio 170010 355/Month 12 1870 Irritis 170010 355/Month 24 1870 Irritis 177006 338/Month 24 1360 Nio 177005 355/Month 24 1370 Nio 104002 712/Month 24 1140 Nio 122002 359/Month 12 1500 Nio 122002 359/Month 12 1500 Nio 122002 359/Month 24 1300 Nio 122002 359/Month 12 1500 Nio 124003 722/Month 24 1300 Nio 124003 722/Month 24 1300 Nio 124003 722/Month 24 1300 Nio 124003 722/Month 24 1700 Nio 124003 722/Month 24 1600 | Treatment Group Politive
Innunoreactivity Intrancentiar
Innunoreactivity Intrancentiar
Infammination Arsay Leg Titer Subject ID Assay Leg Titer Digenosis 170010 365/Month 12 2800 No 177006 338/Month 12 1870 Irritis 177006 338/Month 24 1870 Irritis 104002 717/Month 24 1140 No 104002 722/Month 24 1130 No 122002 359/Month 12 16300 No 124003 722/Month 24 1130 No 122002 359/Month 12 16300 No 124003 722/Month 24 1130 No 124003 722/Month 24 1770 No 124003 722/Month 24 1770 No 124003 722/Month 24 1700 <
 | Treatment Group Positive
Innumerativity Lurrancettisty Lurrancettisty Treatment Group Subject ID Assay Log Titer Diagnosis 170010 365 / Month 12 2770 No Diagnosis 170010 365 / Month 12 2800 No Diagnosis 170010 365 / Month 24 1870 Lirtis Diagnosis 177006 338 / Month 24 1870 Lirtis Diagnosis 104002 712 / Month 24 1140 No No 104002 722 / Month 24 1130 No No 122002 359 / Month 24 1170 No No 124003 722 / Month 24 1770 No No 124003 722 / Month 24 1770 No No 12400 722 / | Treatment Group Routing and the seture of the particular function of the particular function of the particular function of the particular desired by the partin desired by the particular desired by the particular |
|

 |

 |

 | Treatment Group Subject ID Torrative frammoreactivity Intransition Assy Asso Asso <td< td=""><td>Treatment Group Subject ID Assry Lurrarectifix Intransition JTeettment Group Subject ID 365 / Month 12 2770 No No 170010 365 / Month 12 2770 No No No 177006 358 / Month 12 1870 Irtitis Diagnoits 177006 358 / Month 12 1870 Irtitis No 177006 358 / Month 12 1870 Irtitis 177006 358 / Month 12 1870 Irtitis 104002 719 / Month 24 1140 No 122002 339 / Month 12 1630 No 122002 722 / Month 24 1770 No 122003 727 / Month 24 1770 No 122003 727 / Month 24 1770 No 122004 537 / Month 24 1700 No 122004 362 / Month 12 1770 No 141008 181 / Month 24 1.570 No 123006 193 0.022</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID 34sy Assy Assy Assy Diagnois T0010 355 / Month 12 2770 No No No T77066 358 / Month 12 1870 Irtits No T77/Month 24 1.870 Irtits No 106002 719 / Month 24 1.140 No 102001 722 / Month 24 1.130 No 120001 124003 722 / Month 24 1.700 No 12001 174 / Month 6 1.700 No No 12001 722 / Month 24 1.700 No No 12001 174 / Month 6 1.700 No No 122003 722 / Month 12 1.6400 No No 122004 131 / Month 6 1.700 No No 141008 181 / Month 24 1.770 No No</td><td>Treatment Group Bositre
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity JTeatment Group Subject ID Assy Assy Assy Intrancicular 170010 365/Mouth 12 2770 No No 177006 358/Mouth 12 1870 Intrinsion 177006 358/Mouth 12 1870 Intris 177006 358/Mouth 24 1.140 No 106002 719/Mouth 24 1.130 No 122002 722/Mouth 24 1.130 No 122002 722/Mouth 24 1.700 No 122002 722/Mouth 24 1.700 No 12300 11/4 No No 124003 722/Mouth 24 1.700 No 122004 131/Mouth 6 1.700 No 123006 181/Mouth 64 1.570 No 12400 717/Mouth 24 1.700 No 12400 717/Mouth 64 1.900 No 121003</td><td>Treatment Group Subject ID Monthize activity Immunoreactivity Immunoreactivity</td><td>Treatment Group Bositre
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity JTeatment Group Subject ID Assy Assy Assy Intrancicular 170010 365/Mouth
12 2770 No No 177006 358/Mouth 12 1870 Intrinsion 177006 358/Mouth 12 1870 Intris 177006 358/Mouth 24 1.140 No 106002 719/Mouth 24 1.130 No 122002 722/Mouth 24 1.130 No 122002 722/Mouth 24 1.700 No 122002 722/Mouth 24 1.700 No 12300 11/4 No No 124003 722/Mouth 24 1.700 No 122004 131/Mouth 6 1.700 No 123006 181/Mouth 64 1.570 No 12400 717/Mouth 24 1.700 No 12400 717/Mouth 64 1.900 No 121003</td><td>Treatment Group Bositre
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity JTeatment Group Subject ID Assy Assy Assy Intrancicular 170010 365/Mouth 12 2770 No No 177006 358/Mouth 12 1870 Intrinsion 177006 358/Mouth 12 1870 Intris 177006 358/Mouth 24 1.140 No 106002 719/Mouth 24 1.130 No 122002 722/Mouth 24 1.130 No 122002 722/Mouth 24 1.700 No 122002 722/Mouth 24 1.700 No 12300 11/4 No No 124003 722/Mouth 24 1.700 No 122004 131/Mouth 6 1.700 No 123006 181/Mouth 64 1.570 No 12400 717/Mouth 24 1.700 No 12400 717/Mouth 64 1.900 No 121003</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID 34sy Assy Assy Assy Diagnois T0010 355 / Month 12 2770 No No No T77066 358 / Month 12 1870 Irtits No T77/Month 24 1.870 Irtits No 106002 719 / Month 24 1.140 No 102001 722 / Month 24 1.130 No 120001 124003 722 / Month 24 1.700 No 12001 174 / Month 6 1.700 No No 12001 722 / Month 24 1.700 No No 12001 174 / Month 6 1.700 No No 122003 722 / Month 12 1.6400 No No 122004 131 / Month 6 1.700 No No 141008 181 / Month 24 1.770 No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID 34sy Assy Assy Assy Diagnois T0010 355 / Month 12 2770 No No No T77066 358 / Month 12 1870 Irtits No T77/Month 24 1.870 Irtits No 106002 719 / Month 24 1.140 No 102001 722 / Month 24 1.130 No 120001 124003 722 / Month 24 1.700 No 12001 174 / Month 6 1.700 No No 12001 722 / Month 24 1.700 No No 12001 174 / Month 6 1.700 No No 122003 722 / Month 12 1.6400 No No 122004 131 / Month 6 1.700 No No 141008 181 / Month 24 1.770 No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID 34sy Assy Assy Assy Diagnois T0010 355 / Month 12 2770 No No No T77066 358 / Month 12 1870 Irtits No T77/Month 24 1.870 Irtits No 106002 719 / Month 24 1.140 No 102001 722 / Month 24 1.130 No 120001 124003 722 / Month 24 1.700 No 12001 174 / Month 6 1.700 No No 12001 722 / Month 24 1.700 No No 12001 174 / Month 6 1.700 No No 122003 722 / Month 12 1.6400 No No 122004 131 / Month 6 1.700 No No 141008 181 / Month 24 1.770 No No</td><td>Treatment Group Subject ID Torrative frammoreactivity Intransition Assy Asso <td< td=""><td>Treatment Group Subject ID Terminion factority Intranscrints Intranscrints Assy Jase Month 12 25770 No No No 170010 365 / Month 12 25770 No No No 177006 358 / Month 12 1870 Irtitis Diagnois 177006 358 / Month 12 1870 Irtitis 177006 358 / Month 12 1870 Irtitis 177006 358 / Month 12 1870 Irtitis 177006 358 / Month 24 1130 No 122002 722 / Month 24 1130 No 122002 722 / Month 24 1770 No 122002 727 / Month 24 1770 No 122003 727 / Month 24 1770 No 122004 522 / Month 12 1670 No 141008 181 / Month 6 1940 No 141008 181 / Month 24 2640 No 153006 11750 No No <td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Arise 170010 365 Month 12 2.770 No No 170010 365 Month 12 2.800 Infiguois Assive Log Titer No 170010 355 Month 12 1.870 Infiguois No No 177006 358 Month 12 1.870 Infiguois No No 177006 355 Month 24 1.130 No No No 105002 722 Month 24 1.130 No No No 122002 357 Month 24 1.770 No No No 124003 722 Month 24 1.770 No No No 124013 722 Month 24 1.770</td><td>Treatment Group Positive
Innumber Missy Innumber Stripty Innumber St</td><td>Treatment Group Subject ID Rositive
Innumoreactivity Innumoreactivity Innumoreactivity 170010 365 / Month 1.2 2.770 No 170010 365 / Month 1.2 2.770 No 177006 355 / Month 1.2 2.770 No 177006 355 / Month 1.2 2.800 Infammation Ranibizumab 0.5 mg 102001 715 / Month 2.4 1.130 No 177006 355 / Month 1.2 1.870 Infammation 177006 355 / Month 2.4 1.130 No 122002 719 / Month 2.4 1.130 No 122002 722 / Month 2.4 1.130 No 124003 722 / Month 2.4 1.130 No 124003 722 / Month 2.4 1.770 No</td><td>Treatment Group Evolutive
Intrusocentivity Intrusocentiaty Intransaction Arsay 2.770 No No No 170010 365/Month 12 2.770 No No 177006 355/Month 12 1.870 Intrianation Ranibizumab 0.5 mg 102001 355/Month 24 1.850 No 177006 732/Month 24 1.140 No No 122002 732/Month 24 1.130 No No 122002 732/Month 24 1.130 No No 122002 732/Month 24 1.130 No No 124003 722/Month 24 1.130 No No 124001 174/Month 6 1.770 No No 124003 722/Month 24 1.130 No No 124001 174/Month 6 1.770 No No 124003 722/Month 24 1.940 No No 124001 1.74 0.780 No No <</td></td></td<></td></td<>
 | Treatment Group Subject ID Assry Lurrarectifix Intransition JTeettment Group Subject ID 365 / Month 12 2770 No No 170010 365 / Month 12 2770 No No No 177006 358 / Month 12 1870 Irtitis Diagnoits 177006 358 / Month 12 1870 Irtitis No 177006 358 / Month 12 1870 Irtitis 177006 358 / Month 12 1870 Irtitis 104002 719 / Month 24 1140 No 122002 339 / Month 12 1630 No 122002 722 / Month 24 1770 No 122003 727 / Month 24 1770 No 122003 727 / Month 24 1770 No 122004 537 / Month 24 1700 No 122004 362 / Month 12 1770 No 141008 181 / Month 24 1.570 No 123006 193 0.022

 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID 34sy Assy Assy Assy Diagnois T0010 355 / Month 12 2770 No No No T77066 358 / Month 12 1870 Irtits No T77/Month 24 1.870 Irtits No 106002 719 / Month 24 1.140 No 102001 722 / Month 24 1.130 No 120001 124003 722 / Month 24 1.700 No 12001 174 / Month 6 1.700 No No 12001 722 / Month 24 1.700 No No 12001 174 / Month 6 1.700 No No 122003 722 / Month 12 1.6400 No No 122004 131 / Month 6 1.700 No No 141008 181 / Month 24 1.770 No No

 | Treatment Group Bositre
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity JTeatment Group Subject ID Assy Assy Assy Intrancicular 170010 365/Mouth 12 2770 No No 177006 358/Mouth 12 1870 Intrinsion 177006 358/Mouth 12 1870 Intris 177006 358/Mouth 24 1.140 No 106002 719/Mouth 24 1.130 No 122002 722/Mouth 24 1.130 No 122002 722/Mouth 24 1.700 No 122002 722/Mouth 24 1.700 No 12300 11/4 No No 124003 722/Mouth 24 1.700 No 122004 131/Mouth 6 1.700 No 123006 181/Mouth 64 1.570 No 12400 717/Mouth 24 1.700 No 12400 717/Mouth 64 1.900 No 121003

 | Treatment Group Subject ID Monthize activity Immunoreactivity
 | Treatment Group Bositre
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity JTeatment Group Subject ID Assy Assy Assy Intrancicular 170010 365/Mouth 12 2770 No No 177006 358/Mouth 12 1870 Intrinsion
177006 358/Mouth 12 1870 Intris 177006 358/Mouth 24 1.140 No 106002 719/Mouth 24 1.130 No 122002 722/Mouth 24 1.130 No 122002 722/Mouth 24 1.700 No 122002 722/Mouth 24 1.700 No 12300 11/4 No No 124003 722/Mouth 24 1.700 No 122004 131/Mouth 6 1.700 No 123006 181/Mouth 64 1.570 No 12400 717/Mouth 24 1.700 No 12400 717/Mouth 64 1.900 No 121003
 | Treatment Group Bositre
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity JTeatment Group Subject ID Assy Assy Assy Intrancicular 170010 365/Mouth 12 2770 No No 177006 358/Mouth 12 1870 Intrinsion 177006 358/Mouth 12 1870 Intris 177006 358/Mouth 24 1.140 No 106002 719/Mouth 24 1.130 No 122002 722/Mouth 24 1.130 No 122002 722/Mouth 24 1.700 No 122002 722/Mouth 24 1.700 No 12300 11/4 No No 124003 722/Mouth 24 1.700 No 122004 131/Mouth 6 1.700 No 123006 181/Mouth 64 1.570 No 12400 717/Mouth 24 1.700 No 12400 717/Mouth 64 1.900 No 121003
 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID 34sy Assy Assy Assy Diagnois T0010 355 / Month 12 2770 No No No T77066 358 / Month 12 1870 Irtits No T77/Month 24 1.870 Irtits No 106002 719 / Month 24 1.140 No 102001 722 / Month 24 1.130 No 120001 124003 722 / Month 24 1.700 No
12001 174 / Month 6 1.700 No No 12001 722 / Month 24 1.700 No No 12001 174 / Month 6 1.700 No No 122003 722 / Month 12 1.6400 No No 122004 131 / Month 6 1.700 No No 141008 181 / Month 24 1.770 No No
 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID 34sy Assy Assy Assy Diagnois T0010 355 / Month 12 2770 No No No T77066 358 / Month 12 1870 Irtits No T77/Month 24 1.870 Irtits No 106002 719 / Month 24 1.140 No 102001 722 / Month 24 1.130 No 120001 124003 722 / Month 24 1.700 No 12001 174 / Month 6 1.700 No No 12001 722 / Month 24 1.700 No No 12001 174 / Month 6 1.700 No No 122003 722 / Month 12 1.6400 No No 122004 131 / Month 6 1.700 No No 141008 181 / Month 24 1.770 No No
 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID 34sy Assy Assy Assy Diagnois T0010 355 / Month 12 2770 No No No T77066 358 / Month 12 1870 Irtits No T77/Month 24 1.870 Irtits No 106002 719 / Month 24 1.140 No 102001 722 / Month 24 1.130 No 120001 124003 722 / Month 24 1.700 No 12001 174 / Month 6 1.700 No No 12001 722 / Month 24 1.700 No No 12001 174 / Month 6 1.700 No No 122003 722 / Month 12 1.6400 No No 122004 131 / Month 6 1.700 No No 141008 181 / Month 24 1.770 No No
 | Treatment Group Subject ID Torrative frammoreactivity Intransition Assy Asso Asso <td< td=""><td>Treatment Group Subject ID Terminion factority Intranscrints Intranscrints Assy Jase Month 12 25770 No No No 170010 365 / Month 12 25770 No No No 177006 358 / Month 12 1870 Irtitis Diagnois 177006 358 / Month 12 1870 Irtitis 177006 358 / Month 12 1870 Irtitis 177006 358 / Month 12 1870 Irtitis 177006 358 / Month 24 1130 No 122002 722 / Month 24 1130 No 122002 722 / Month 24 1770 No 122002 727 / Month 24 1770 No 122003 727 / Month 24 1770 No 122004 522 / Month 12 1670 No 141008 181 / Month 6 1940 No 141008 181 / Month 24 2640 No 153006 11750 No No <td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Arise 170010 365 Month 12 2.770 No No 170010 365 Month 12 2.800 Infiguois Assive Log Titer No 170010 355 Month 12 1.870 Infiguois No No 177006 358 Month 12 1.870 Infiguois No No 177006 355 Month 24 1.130 No No No 105002 722 Month 24 1.130 No No No 122002 357 Month 24 1.770 No No No 124003 722 Month 24 1.770 No No No 124013 722 Month 24 1.770</td><td>Treatment Group Positive
Innumber Missy Innumber Stripty Innumber St</td><td>Treatment Group Subject ID Rositive
Innumoreactivity Innumoreactivity Innumoreactivity 170010 365 / Month 1.2 2.770 No 170010 365 / Month 1.2 2.770 No 177006 355 / Month 1.2 2.770 No 177006 355 / Month 1.2 2.800 Infammation Ranibizumab 0.5 mg 102001 715 / Month 2.4 1.130 No 177006 355 / Month 1.2 1.870 Infammation 177006 355 / Month 2.4 1.130 No 122002 719 / Month 2.4 1.130 No 122002 722 / Month 2.4 1.130 No 124003 722 / Month 2.4 1.130 No 124003 722 / Month 2.4 1.770 No</td><td>Treatment Group Evolutive
Intrusocentivity Intrusocentiaty Intransaction Arsay 2.770 No No No 170010 365/Month 12 2.770 No No 177006 355/Month 12 1.870 Intrianation Ranibizumab 0.5 mg 102001 355/Month 24 1.850 No 177006 732/Month 24 1.140 No No 122002 732/Month 24 1.130 No No 122002 732/Month 24 1.130 No No 122002 732/Month 24 1.130 No No 124003 722/Month 24 1.130 No No 124001 174/Month 6 1.770 No No 124003 722/Month 24 1.130 No No 124001 174/Month 6 1.770 No No 124003 722/Month 24 1.940 No No 124001 1.74 0.780 No No <</td></td></td<>
 | Treatment Group Subject ID Terminion factority Intranscrints Intranscrints Assy Jase Month 12 25770 No No No 170010 365 / Month 12 25770 No No No 177006 358 / Month 12 1870 Irtitis Diagnois 177006 358 / Month 12 1870 Irtitis 177006 358 / Month 12 1870 Irtitis 177006 358 / Month 12 1870 Irtitis 177006 358 / Month 24 1130 No 122002 722 / Month 24 1130 No 122002 722 / Month 24 1770 No 122002 727 / Month 24 1770 No 122003 727 / Month 24 1770 No 122004 522 / Month 12 1670 No 141008 181 / Month 6 1940 No 141008 181 / Month 24 2640 No 153006 11750 No No <td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Arise 170010 365 Month 12 2.770 No No 170010 365 Month 12 2.800 Infiguois Assive Log Titer No 170010 355 Month 12 1.870 Infiguois No No 177006 358 Month 12 1.870 Infiguois No No 177006 355 Month 24 1.130 No No No 105002 722 Month 24 1.130 No No No 122002 357 Month 24 1.770 No No No 124003 722 Month 24 1.770 No No No 124013 722 Month 24 1.770</td> <td>Treatment Group Positive
Innumber Missy Innumber Stripty Innumber St</td> <td>Treatment Group Subject ID Rositive
Innumoreactivity Innumoreactivity Innumoreactivity 170010 365 / Month 1.2 2.770 No 170010 365 / Month 1.2 2.770 No 177006 355 / Month 1.2 2.770 No 177006 355 / Month 1.2 2.800 Infammation Ranibizumab 0.5 mg 102001 715 / Month 2.4 1.130 No 177006 355 / Month 1.2 1.870 Infammation 177006 355 / Month 2.4 1.130 No 122002 719 / Month 2.4 1.130 No 122002 722 / Month 2.4 1.130 No 124003 722 / Month 2.4 1.130 No 124003 722 / Month 2.4 1.770 No</td> <td>Treatment Group Evolutive
Intrusocentivity Intrusocentiaty Intransaction Arsay 2.770 No No No 170010 365/Month 12 2.770 No No 177006 355/Month 12 1.870 Intrianation Ranibizumab 0.5 mg 102001 355/Month 24 1.850 No 177006 732/Month 24 1.140 No No 122002 732/Month 24 1.130 No No 122002 732/Month 24 1.130 No No 122002 732/Month 24 1.130 No No 124003 722/Month 24 1.130 No No 124001 174/Month 6 1.770 No No 124003 722/Month 24 1.130 No No 124001 174/Month 6 1.770 No No 124003 722/Month 24 1.940 No No 124001 1.74 0.780 No No <</td> | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Arise 170010 365 Month 12 2.770 No No 170010 365 Month 12 2.800 Infiguois Assive Log Titer No 170010 355 Month 12 1.870 Infiguois No No 177006 358 Month 12 1.870 Infiguois No No 177006 355 Month 24 1.130 No No No 105002 722 Month 24 1.130 No No No 122002 357 Month 24 1.770 No No No 124003 722 Month 24 1.770 No No No 124013 722 Month 24 1.770
 | Treatment Group Positive
Innumber Missy Innumber Stripty Innumber St | Treatment Group Subject ID Rositive
Innumoreactivity Innumoreactivity Innumoreactivity 170010 365 / Month 1.2 2.770 No 170010 365 / Month 1.2 2.770 No 177006 355 / Month 1.2 2.770 No 177006 355 / Month 1.2 2.800 Infammation Ranibizumab 0.5 mg 102001 715 / Month 2.4 1.130 No 177006 355 / Month 1.2 1.870 Infammation 177006 355 / Month 2.4 1.130 No 122002 719 / Month 2.4 1.130 No 122002 722 / Month 2.4 1.130 No 124003 722 / Month 2.4 1.130 No 124003 722 / Month 2.4 1.770 No | Treatment Group Evolutive
Intrusocentivity Intrusocentiaty Intransaction Arsay 2.770 No No No 170010 365/Month 12 2.770 No No 177006 355/Month 12 1.870 Intrianation Ranibizumab 0.5 mg 102001 355/Month 24 1.850 No 177006 732/Month 24 1.140 No No 122002 732/Month 24 1.130 No No 122002 732/Month 24 1.130 No No 122002 732/Month 24 1.130 No No 124003 722/Month 24 1.130 No No 124001 174/Month 6 1.770 No No 124003 722/Month 24 1.130 No No 124001 174/Month 6 1.770 No No 124003 722/Month 24 1.940 No No 124001 1.74 0.780 No No < |
|

 |

 |

 | Treatment Group Intranscriptive Intranscription Arrent/Forup Subject ID Assey Log Titler Intranscription 170010 365 / Month 12 Assey Log Titler Diagnois 177006 358 / Month 12 1870 Irritis 177016 358 / Month 12 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 717 / Month 24 1870 Irritis 117006 359 / Month 24 1130 No 122002 359 / Month 24 1130 No 124001 722 / Month 24 1130 No 124003 727 / Month 24 1630 No 124003 727 / Month 24 1770 No 124003 727 / Month 24 1630 No 124003 727 / Month 24 1630 No 126001 717 / Month 24 1630 No 125004 818 / Month 24 1640 No

 | Treatment Group Subject ID Immunoreactivity Immunoreactivity Immunoreactivity Arrent Group Subject ID 365 / Month 12 Xarsy Log Titer Diagnois 170010 365 / Month 12 1870 No 177006 358 / Month 24 2800 No 177006 358 / Month 24
 1870 Irrits 177006 358 / Month 24 1870 Irrits 177006 358 / Month 24 1130 No 104002 717 / Month 24 1130 No 102001 722 / Month 24 1130 No 122002 359 / Month 24 11700 No 124003 722 / Month 24 17700 No 124003 723 / Month 24 17700 No 124003 723 / Month 24 17700 No 125004 353 / Month 12 1630 No 126001 717 / Month 24 1770 No 126001 722 / Month 24 1940 No 125004 <td< td=""><td>Treatment Group Subject ID Assisty Immunoreactivity <th< td=""><td>Treatment Group Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 Xasy Log Titer Diagnois 170010 365 / Month 24 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 715 / Month 24 1130 No 102002 722 / Month 24 1130 No 122002 359 / Month 24 1130 No 124003 722 / Month 24 1130 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 126001 174 / Month 24 1700 No 126001 722 / Month 24 1700 No 126001 723 / Month 24 1600 No 12</td><td>Treatment Group Runtumoreactivity Immunoreactivity Immunoreactivity<</td><td>Treatment Group Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 Xasy Log Titer Diagnois 170010 365 / Month 24 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 715 / Month 24 1130 No 102002 722 / Month 24 1130 No 122002 359 / Month 24 1130 No 124003 722 / Month 24 1130 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 126001 174 / Month 24 1700 No 126001 722 / Month 24 1700 No 126001 723 / Month 24 1600 No 12</td><td>Treatment Group Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 Xasy Log Titer Diagnois 170010 365 / Month 24 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 715 / Month 24 1130 No 102002 722 / Month 24 1130 No 122002 359 / Month 24 1130 No 124003 722 / Month 24 1130 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 126001 174 / Month 24 1700 No 126001 722 / Month 24 1700 No 126001 723 / Month 24 1600 No 12</td><td>Treatment Group Subject ID Assisty Immunoreactivity <th< td=""><td>Treatment Group Subject ID Assisty Immunoreactivity <th< td=""><td>Treatment Group Subject ID Assisty Immunoreactivity <th< td=""><td>Treatment Group Intranscriptive Intranscription Arrent/Forup Subject ID Assey Log Titler Intranscription 170010 365 / Month 12 Assey Log Titler Diagnois 177006 358 / Month 12 1870 Irritis 177016 358 / Month 12 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 717 / Month 24 1870 Irritis 117006 359 / Month 24 1130 No 122002 359 / Month 24 1130 No 124001 722 / Month 24 1130 No 124003 727 / Month 24 1630 No 124003 727 / Month 24 1770 No 124003 727 / Month 24 1630 No 124003 727 / Month 24 1630 No 126001 717 / Month 24 1630 No 125004 818 / Month 24 1640 No</td><td>Treatment Group Subject ID Tommunoreactivity Intransition Arrentment Group Subject ID Ammunoreactivity Intraminition 170010 365 / Month 12 2800 No 177016 358 / Month 12 2800 No 177016 358 / Month 12 1870 Irritis 177016 358 / Month 24 1130 No 1177006 358 / Month 24 1130 No 1177006 358 / Month 24 1130 No 117700 717 / Month 24 1130 No 122002 359 / Month 24 1130 No 124001 727 / Month 24 1130 No 124003 727 / Month 24 1630 No 124001 727 / Month 24 1640 No 126001 727 / Month 24 1640 No</td><td>Treatment Group Rolitive
Subject ID Rominization
Asiay Intranuoreactivity
Asiay Log Titer Intranuoreactivity
Intramation Intranuoreactivity
Asiay Log Titer Intranuoreactivity
Intramation Ranibizumab 0.5 mg 177006 355 / Month 12 1.870 Intras Ranibizumab 0.5 mg 177006 358 / Month 12 1.870 Intras 170010 355 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 122002 357 / Month 24 1.130 No 124003 723 / Month 24 1.130 No 124003 723 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 125004 357 / Month 24 2.610 Vitritits 12304 715 / Month 24 2.610 No 12400 722 / Month 24 2.610 No 125004 365 / Month 12 1.940</td><td>Treatment Group Positive
served viry Intranuoreactivity Intranuoreactivity Intranuoreactivity Intranustion
Assay 170010 365 / Month 12 2700 No 170010 365 / Month 12 2800 Iritis 170010 365 / Month 12 1870 Iritis 170010 355 / Month 24 1130 No 177 / Month 24 1130 No No 122002 359 / Month 24 1130 No 122002 357 / Month 24 1130 No 124003 722 / Month 24 1130 No 124003 723 / Month 24 1300 No 124003 727 / Month 24 1300 No 124003 727 / Month 24 1300 No 124003 727 / Month 24 1300 No 124013 715 / Month 24 1300 No 12504 357 / Month 24 2610 Virmits 12400 722 / Month 24 1600 No 12400 726</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td><td>Treatment Group Environment of timmunoreactivity Immunoreactivity Im</td></th<></td></th<></td></th<></td></th<></td></td<>
 | Treatment Group Subject ID Assisty Immunoreactivity Immunoreactivity <th< td=""><td>Treatment Group Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 Xasy Log Titer Diagnois 170010 365 / Month 24 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 715 / Month 24 1130 No 102002 722 / Month 24 1130 No 122002 359 / Month 24 1130 No 124003 722 / Month 24 1130 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 126001 174 / Month 24 1700 No 126001 722 / Month 24 1700 No 126001 723 / Month 24 1600 No 12</td><td>Treatment Group Runtumoreactivity Immunoreactivity Immunoreactivity<</td><td>Treatment Group Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 Xasy Log Titer Diagnois 170010 365 / Month 24 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 715 / Month 24 1130 No 102002 722 / Month 24 1130 No 122002 359 / Month 24 1130 No 124003 722 / Month 24 1130 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 126001 174 / Month 24 1700 No 126001 722 / Month 24 1700 No 126001 723 / Month 24 1600 No 12</td><td>Treatment Group Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 Xasy Log Titer Diagnois 170010 365 / Month 24 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 715 / Month 24 1130 No 102002 722 / Month 24 1130 No 122002 359 / Month 24 1130 No 124003 722 / Month 24 1130 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 126001 174 / Month 24 1700 No 126001 722 / Month 24 1700 No 126001 723 / Month 24 1600 No 12</td><td>Treatment Group Subject ID Assisty Immunoreactivity <th< td=""><td>Treatment Group Subject ID Assisty Immunoreactivity <th< td=""><td>Treatment Group Subject ID Assisty Immunoreactivity <th< td=""><td>Treatment Group Intranscriptive Intranscription Arrent/Forup Subject ID Assey Log Titler Intranscription 170010 365 / Month 12 Assey Log Titler Diagnois 177006 358 / Month 12 1870 Irritis 177016 358 / Month 12 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 717 / Month 24 1870 Irritis 117006 359 / Month 24 1130 No 122002 359 / Month 24 1130 No 124001 722 / Month 24 1130 No 124003 727 / Month 24 1630 No 124003 727 / Month 24 1770 No 124003 727 / Month 24 1630 No 124003 727 / Month 24 1630 No 126001 717 / Month 24 1630 No 125004 818 / Month 24 1640 No</td><td>Treatment Group Subject ID Tommunoreactivity Intransition Arrentment Group Subject ID Ammunoreactivity Intraminition 170010 365 / Month 12 2800 No 177016 358 / Month 12 2800 No 177016 358 / Month 12 1870 Irritis 177016 358 / Month 24 1130 No 1177006 358 / Month 24 1130 No 1177006 358 / Month 24 1130 No 117700 717 / Month 24 1130 No 122002 359 / Month 24 1130 No 124001 727 / Month 24 1130 No 124003 727 / Month 24 1630 No 124001 727 / Month 24 1640 No 126001 727 / Month 24 1640 No</td><td>Treatment Group Rolitive
Subject ID Rominization
Asiay Intranuoreactivity
Asiay Log Titer Intranuoreactivity
Intramation Intranuoreactivity
Asiay Log Titer Intranuoreactivity
Intramation Ranibizumab 0.5 mg 177006 355 / Month 12 1.870 Intras Ranibizumab 0.5 mg 177006 358 / Month 12 1.870 Intras 170010 355 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 122002 357 / Month 24 1.130 No 124003 723 / Month 24 1.130 No 124003 723 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 125004 357 / Month 24 2.610 Vitritits 12304 715 / Month 24 2.610 No 12400 722 / Month 24 2.610 No 125004 365 / Month 12 1.940</td><td>Treatment Group Positive
served viry Intranuoreactivity Intranuoreactivity Intranuoreactivity Intranustion
Assay 170010 365 / Month 12 2700 No 170010 365 / Month 12 2800 Iritis 170010 365 / Month 12 1870 Iritis 170010 355 / Month 24 1130 No 177 / Month 24 1130 No No 122002 359 / Month 24 1130 No 122002 357 / Month 24 1130 No 124003 722 / Month 24 1130 No 124003 723 / Month 24 1300 No 124003 727 / Month 24 1300 No 124003 727 / Month 24 1300 No 124003 727 / Month 24 1300
 No 124013 715 / Month 24 1300 No 12504 357 / Month 24 2610 Virmits 12400 722 / Month 24 1600 No 12400 726</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td><td>Treatment Group Environment of timmunoreactivity Immunoreactivity Im</td></th<></td></th<></td></th<></td></th<> | Treatment Group Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 Xasy Log Titer Diagnois 170010 365 / Month 24 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 715 / Month 24 1130 No 102002 722 / Month 24 1130 No 122002 359 / Month 24 1130 No 124003 722 / Month 24 1130 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 126001 174 / Month 24 1700 No 126001 722 / Month 24 1700 No 126001 723 / Month 24 1600 No 12

 | Treatment Group Runtumoreactivity Immunoreactivity Immunoreactivity<
 | Treatment Group Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 Xasy Log Titer Diagnois 170010 365 / Month 24 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 715 / Month 24 1130 No 102002 722 / Month 24 1130 No 122002 359 / Month 24 1130 No 124003 722 / Month 24 1130 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 126001 174 / Month 24 1700 No 126001 722 / Month 24 1700 No 126001 723 / Month 24 1600 No 12

 | Treatment Group Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 Xasy Log Titer Diagnois 170010 365 / Month 24 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 715 / Month 24 1130 No 102002 722 / Month 24 1130 No 122002 359 / Month 24 1130 No 124003 722 / Month 24 1130 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 126001 174 / Month 24 1700 No 126001 722 / Month 24 1700 No 126001 723 / Month 24 1600 No 12
 | Treatment Group Subject ID Assisty Immunoreactivity Immunoreactivity <th< td=""><td>Treatment Group Subject ID Assisty Immunoreactivity <th< td=""><td>Treatment Group Subject ID Assisty Immunoreactivity <th< td=""><td>Treatment Group Intranscriptive Intranscription Arrent/Forup Subject ID Assey Log Titler Intranscription 170010 365 / Month 12 Assey Log Titler Diagnois 177006 358 / Month 12 1870 Irritis 177016 358 / Month 12 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 717 / Month 24 1870 Irritis 117006 359 / Month 24 1130 No 122002 359 / Month 24 1130 No 124001 722 / Month 24 1130 No 124003 727 / Month 24 1630 No 124003 727 / Month 24 1770 No 124003 727 / Month 24 1630 No 124003 727 / Month 24 1630 No 126001 717 / Month 24 1630 No 125004 818 / Month 24 1640 No</td><td>Treatment Group Subject ID Tommunoreactivity Intransition Arrentment Group Subject ID Ammunoreactivity Intraminition 170010 365 / Month 12 2800 No 177016 358 / Month 12 2800 No 177016 358 / Month 12 1870 Irritis 177016 358 / Month 24 1130 No 1177006 358 / Month 24 1130 No 1177006 358 / Month 24 1130 No 117700 717 / Month 24 1130 No 122002 359 / Month 24 1130 No 124001 727 / Month 24 1130 No 124003 727 / Month 24 1630 No 124001 727 / Month 24 1640 No 126001 727 / Month 24 1640 No</td><td>Treatment Group Rolitive
Subject ID Rominization
Asiay Intranuoreactivity
Asiay Log Titer Intranuoreactivity
Intramation Intranuoreactivity
Asiay Log Titer Intranuoreactivity
Intramation Ranibizumab 0.5 mg 177006 355 / Month 12 1.870 Intras Ranibizumab 0.5 mg 177006 358 / Month 12 1.870 Intras 170010 355 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 122002 357 / Month 24 1.130 No 124003 723 / Month 24 1.130 No 124003 723 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 125004 357 / Month 24 2.610 Vitritits 12304 715 / Month 24 2.610 No 12400 722 / Month 24 2.610 No 125004 365 / Month 12 1.940</td><td>Treatment Group Positive
served viry Intranuoreactivity Intranuoreactivity Intranuoreactivity Intranustion
Assay 170010 365 / Month 12 2700 No 170010 365 / Month 12 2800 Iritis 170010 365 / Month 12 1870 Iritis 170010 355 / Month 24 1130 No 177 / Month 24 1130 No No 122002 359 / Month 24 1130 No 122002 357 / Month 24 1130 No 124003 722 / Month 24 1130 No 124003 723 / Month 24 1300 No 124003 727 / Month 24 1300 No 124003 727 / Month 24 1300 No 124003 727 / Month 24 1300 No 124013 715 / Month 24 1300 No 12504 357 / Month 24 2610 Virmits 12400 722 / Month 24 1600 No 12400 726</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td><td>Treatment Group Environment of timmunoreactivity Immunoreactivity Im</td></th<></td></th<></td></th<>
 | Treatment Group Subject ID Assisty Immunoreactivity Immunoreactivity <th< td=""><td>Treatment Group Subject ID Assisty Immunoreactivity <th< td=""><td>Treatment Group Intranscriptive Intranscription Arrent/Forup Subject ID Assey Log Titler Intranscription 170010 365 / Month 12 Assey Log Titler Diagnois 177006 358 / Month 12 1870 Irritis 177016 358 / Month 12 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 717 / Month 24 1870 Irritis 117006 359 / Month 24 1130 No 122002 359 / Month 24 1130 No 124001 722 / Month 24 1130 No 124003 727 / Month 24 1630 No 124003 727 / Month 24 1770 No 124003 727 / Month 24 1630 No 124003 727 / Month 24 1630 No 126001 717 / Month 24 1630 No 125004 818 / Month 24 1640 No</td><td>Treatment Group Subject ID Tommunoreactivity Intransition Arrentment Group Subject ID Ammunoreactivity Intraminition 170010 365 / Month 12 2800 No 177016 358 / Month 12 2800 No 177016 358 / Month 12 1870 Irritis 177016 358 / Month 24 1130 No 1177006 358 / Month 24 1130 No 1177006 358 / Month 24 1130 No 117700 717 / Month 24 1130 No 122002 359 / Month 24 1130 No 124001 727 / Month 24 1130 No 124003 727 / Month 24 1630 No 124001 727 / Month 24 1640 No 126001 727 / Month 24 1640 No</td><td>Treatment Group Rolitive
Subject ID Rominization
Asiay Intranuoreactivity
Asiay Log Titer Intranuoreactivity
Intramation Intranuoreactivity
Asiay Log Titer Intranuoreactivity
Intramation Ranibizumab 0.5 mg 177006 355 / Month 12 1.870 Intras Ranibizumab 0.5 mg 177006 358 / Month 12 1.870 Intras 170010 355 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 122002 357 / Month 24 1.130 No 124003 723 / Month 24 1.130 No 124003 723 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 125004 357 / Month 24 2.610 Vitritits 12304 715 / Month 24 2.610 No 12400 722 / Month 24 2.610 No 125004 365 / Month 12 1.940</td><td>Treatment Group Positive
served viry Intranuoreactivity Intranuoreactivity Intranuoreactivity Intranustion
Assay 170010 365 / Month 12 2700 No 170010 365 / Month 12 2800 Iritis 170010 365 / Month 12 1870 Iritis 170010 355 / Month 24 1130 No 177 / Month 24 1130 No No 122002 359 / Month 24 1130 No 122002 357 / Month 24 1130 No 124003 722 / Month 24 1130 No 124003 723 / Month 24 1300 No 124003 727 / Month 24 1300 No 124003 727 / Month 24 1300 No 124003 727 / Month 24 1300 No 124013 715 / Month 24 1300 No 12504 357 / Month 24 2610 Virmits 12400 722 / Month 24 1600 No 12400 726</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td><td>Treatment Group Environment of timmunoreactivity Immunoreactivity Im</td></th<></td></th<> | Treatment Group Subject ID Assisty Immunoreactivity Immunoreactivity <th< td=""><td>Treatment Group Intranscriptive Intranscription Arrent/Forup Subject ID Assey Log Titler Intranscription 170010 365 / Month 12 Assey Log Titler Diagnois 177006 358 / Month 12 1870 Irritis 177016 358 / Month 12 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 717 / Month 24 1870 Irritis 117006 359 / Month 24 1130 No 122002 359 / Month 24 1130 No 124001 722 / Month 24 1130 No 124003 727 / Month 24 1630 No 124003 727 / Month 24 1770 No 124003 727 / Month 24 1630 No 124003 727 / Month 24 1630 No 126001 717 / Month 24 1630 No 125004 818 / Month 24 1640 No</td><td>Treatment Group Subject ID Tommunoreactivity Intransition Arrentment Group Subject ID Ammunoreactivity Intraminition 170010 365 / Month 12 2800 No 177016 358 / Month 12 2800 No 177016 358 / Month 12 1870 Irritis 177016 358 / Month 24 1130 No 1177006 358 / Month 24 1130 No 1177006 358 / Month 24 1130 No 117700 717 / Month 24 1130 No 122002 359 / Month 24 1130 No 124001 727 / Month 24 1130 No 124003 727 / Month 24 1630 No 124001 727 / Month 24 1640 No 126001 727 / Month 24 1640 No</td><td>Treatment Group Rolitive
Subject ID Rominization
Asiay Intranuoreactivity
Asiay Log Titer Intranuoreactivity
Intramation Intranuoreactivity
Asiay Log Titer Intranuoreactivity
Intramation Ranibizumab 0.5 mg 177006 355 / Month 12 1.870 Intras Ranibizumab 0.5 mg 177006 358 / Month 12 1.870 Intras 170010 355 / Month 24 1.130 No 122002 359 / Month 24 1.130 No
122002 357 / Month 24 1.130 No 124003 723 / Month 24 1.130 No 124003 723 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 125004 357 / Month 24 2.610 Vitritits 12304 715 / Month 24 2.610 No 12400 722 / Month 24 2.610 No 125004 365 / Month 12 1.940</td><td>Treatment Group Positive
served viry Intranuoreactivity Intranuoreactivity Intranuoreactivity Intranustion
Assay 170010 365 / Month 12 2700 No 170010 365 / Month 12 2800 Iritis 170010 365 / Month 12 1870 Iritis 170010 355 / Month 24 1130 No 177 / Month 24 1130 No No 122002 359 / Month 24 1130 No 122002 357 / Month 24 1130 No 124003 722 / Month 24 1130 No 124003 723 / Month 24 1300 No 124003 727 / Month 24 1300 No 124003 727 / Month 24 1300 No 124003 727 / Month 24 1300 No 124013 715 / Month 24 1300 No 12504 357 / Month 24 2610 Virmits 12400 722 / Month 24 1600 No 12400 726</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td><td>Treatment Group Environment of timmunoreactivity Immunoreactivity Im</td></th<> | Treatment Group Intranscriptive Intranscription Arrent/Forup Subject ID Assey Log Titler Intranscription 170010 365 / Month 12 Assey Log Titler Diagnois 177006 358 / Month 12 1870 Irritis 177016 358 / Month 12 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 717 / Month 24 1870 Irritis 117006 359 / Month 24 1130 No 122002 359 / Month 24 1130 No 124001 722 / Month 24 1130 No 124003 727 / Month 24 1630 No 124003 727 / Month 24 1770 No 124003 727 / Month 24 1630 No 124003 727 / Month 24 1630 No 126001 717 / Month 24 1630 No 125004 818 / Month 24 1640 No
 | Treatment Group Subject ID Tommunoreactivity Intransition Arrentment Group Subject ID Ammunoreactivity Intraminition 170010 365 / Month 12 2800 No 177016 358 / Month 12 2800 No 177016 358 / Month 12 1870 Irritis 177016 358 / Month 24 1130 No 1177006 358 / Month 24 1130 No 1177006 358 / Month 24 1130 No 117700 717 / Month 24 1130 No 122002 359 / Month 24 1130 No 124001 727 / Month 24 1130 No 124003 727 / Month 24 1630 No 124001 727 / Month 24 1640 No 126001 727 / Month 24 1640 No | Treatment Group Rolitive
Subject ID Rominization
Asiay Intranuoreactivity
Asiay Log Titer Intranuoreactivity
Intramation Intranuoreactivity
Asiay Log Titer Intranuoreactivity
Intramation Ranibizumab 0.5 mg 177006 355 / Month 12 1.870 Intras Ranibizumab 0.5 mg 177006 358 / Month 12 1.870 Intras 170010 355 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 122002 357 / Month 24 1.130 No 124003 723 / Month 24 1.130 No 124003 723 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 125004 357 / Month 24 2.610 Vitritits 12304 715 / Month 24 2.610 No 12400 722 / Month 24 2.610 No 125004 365 / Month 12 1.940
 | Treatment Group Positive
served viry Intranuoreactivity Intranuoreactivity Intranuoreactivity Intranustion
Assay 170010 365 / Month 12 2700 No 170010 365 / Month 12 2800 Iritis 170010 365 / Month 12 1870 Iritis 170010 355 / Month 24 1130 No 177 / Month 24 1130 No No 122002 359 / Month 24 1130 No 122002 357 / Month 24 1130 No 124003 722 / Month 24 1130 No 124003 723 / Month 24 1300 No 124003 727 / Month 24 1300 No 124003 727 / Month 24 1300 No 124003 727 / Month 24 1300 No 124013 715 / Month 24 1300 No 12504 357 / Month 24 2610 Virmits 12400 722 / Month 24 1600 No 12400 726 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit | Treatment Group Environment of timmunoreactivity Immunoreactivity Im
 |
| Ranibizumab 0.5 mg 507018 357 / Month 12 0.875 No

 | 0.5 mg 507018 357 / Month 12 0.875

 | 0 K mg 507010 367 Mouth 10 0 076

 | Treatment Group Intransition Intransition Arrentment Group Subject ID Intransition Intransition 170010 365 / Month 12 2.77 Or No 170010 365 / Month 24 2.800 Infinimation 170010 365 / Month 24 2.800 No 177006 358 / Month 24 1.870 Infinis 177006 358 / Month 24 1.870 Infinis 102001 722 / Month 24 1.130 No 122002 739 / Month 24 1.770 No 124003 722 / Month 24 1.770 No

 | Treatment Group Intranscriptive Intranscriptive Intranscriptive Affertiment Group Subject ID Subject ID Subject ID Jagrovis I 70010 365 / Month 12 2.800 No I 70010 365 / Month 24 2.800 No I 77016 358 / Month 24 1.870 Iritis I 77006 358 / Month 24 1.870 Iritis I 17006 358 / Month 24 1.130 No I 12002 721 / Month 24 1.130 No I 12002 722 / Month 24 1.1700 No I 12002 722 / Month 24 1.770 No I 12003 717 / Month 24 1.770 No I 141018 11/4 / Month 24
1.770 No I 141013 715 /

 | Treatment Group Subject ID Fositive
Innunoreactivity Innunoreactivity Innunoreactivity Innunoreactivity Treatment Group Subject ID 365 / Month 12 2.800 No 170010 365 / Month 12 2.800 No 177006 358 / Month 24 2.800 No 177006 358 / Month 24 1.870 Iritis 102001 727 / Month 24 1.870 No 112002 739 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 124003 722 / Month 24 1.770 No

 | Treatment Group Subject ID Fositive
Innunoreactivity Innunoreactivity Innunoreactivity Innunoreactivity Areatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 177006 358 / Month 24 1.870 Iritis 177006 358 / Month 24 1.870 Iritis 102001 721 / Month 24 1.870 No 102002 723 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 122002 359 / Month 24 1.770 No 122002 357 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 723 / Month 24 1.770 No
 | Treatment Group Subject ID Fositive
Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity Areatment Group 355 / Month 12 355 / Month 12 357 / Month 24 350 / Month 24 No 170010 355 / Month 12 1870 Irritis No 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1870 No 177006 358 / Month 24 1370 No 102001 717 / Month 24 1370 No 122002 359 / Month 24 1130 No 122002 357 / Month 24 1770 No 122001 717 / Month 24 1770 No 124003 723 / Month 24 1770 No 121000
 174 / Month 24
 | Treatment Group Subject ID Fositive
Innunoreactivity Innunoreactivity Innunoreactivity Innunoreactivity Areatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 177006 358 / Month 24 1.870 Iritis 177006 358 / Month 24 1.870 Iritis 102001 721 / Month 24 1.870 No 102002 723 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 122002 359 / Month 24 1.770 No 122002 357 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 723 / Month 24 1.770 No

 | Treatment Group Subject ID Fositive
Innunoreactivity Innunoreactivity Innunoreactivity Innunoreactivity Areatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 177006 358 / Month 24 1.870 Iritis 177006 358 / Month 24 1.870 Iritis 102001 721 / Month 24 1.870 No 102002 723 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 122002 359 / Month 24 1.770 No 122002 357 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 723 / Month 24 1.770 No
 | Treatment Group Subject ID Fositive
Innunoreactivity Innunoreactivity Innunoreactivity Innunoreactivity Treatment Group Subject ID 365 / Month 12 2.800 No 170010 365 / Month 12 2.800 No 177006 358 / Month 24 2.800 No 177006 358 / Month 24 1.870 Iritis 102001 727 / Month 24 1.870 No 112002 739 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 124003 722 / Month 24 1.770 No
 | Treatment Group Subject ID Fositive
Innunoreactivity Innunoreactivity Innunoreactivity Innunoreactivity Treatment Group Subject ID 365 / Month 12 2.800 No 170010 365 / Month 12 2.800 No 177006 358 / Month 24 2.800 No 177006 358 / Month 24 1.870 Iritis 102001 727 / Month 24 1.870 No 112002 739 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 124003 722 / Month 24 1.770 No
 | Treatment Group Subject ID Fositive
Innunoreactivity Innunoreactivity Innunoreactivity Innunoreactivity Treatment Group Subject ID 365 / Month 12 2.800 No 170010 365 / Month 12 2.800 No 177006 358 / Month 24 2.800 No 177006 358 / Month 24 1.870 Iritis 102001 727 / Month 24 1.870 No 112002 739 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 124003 722 / Month 24 1.770 No
 | Treatment Group Intransition Intransition Arrentment Group Subject ID Intransition Intransition 170010 365 / Month 12 2.77 Or No 170010 365 / Month 24 2.800 Infinimation 170010 365 / Month 24 2.800 No 177006 358 / Month 24 1.870 Infinis 177006 358 / Month 24 1.870 Infinis 102001 722 / Month 24 1.130 No 122002 739 / Month 24 1.770 No 124003 722 / Month 24 1.770 No
 | Treatment Group Intransion Intransition Treatment Group Subject ID Rumunorescrivity Intraminition 170010 365 / Month 12 2.770 No 170010 365 / Month 24 2.800 Initia 170010 365 / Month 24 1.870 Initia 177006 358 / Month 24 1.870 Initia 102001 717 / Month 24 1.870 No 112002 722 / Month 24 1.130 No 106002 722 / Month 24 1.770 No 112002 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124001 174 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124001 174 / Month 24 1.770 No <tr< td=""><td>Treatment Group Doitive Turnoreactivity Intransition Arran Freet Terron Subject ID Assay Log Ther Intransition 170010 365 / Month 12 2.770 No 170010 365 / Month 24 1.850 Intrassociate 170010 365 / Month 24 1.850 No 177006 339 / Month 24 1.130 No 112002 712 / Month 24 1.130 No 106002 722 / Month 24 1.130 No 112002 739 / Month 24 1.770 No 112002 722 / Month 24 1.770 No 112003 722 / Month 24 1.770 No 112003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770</td><td>Treatment Group Positive
Intransectivity Intransective
Infammation Subject ID Subject ID Number expertive
Assay Infammation 170010 365 / Month 12 2.770 No 170010 365 / Month 24 1.850 Infammation 170010 365 / Month 12 1.870 Infam 170010 358 / Month 12 1.870 Infam 117005 358 / Month 24 1.140 No 117001 722 / Month 24 1.130 No 112002 722 / Month 24 1.130 No 112002 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124001 174 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 717 / Month 24 1.770 No 12401 135 / Month 24 0.790 <</td><td>Treatment Group Dositive
Intranscripty Diagnois 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 170010 365 /
Month 12 2.770 No 170010 358 / Month 12 1.870 Irritis 170010 358 / Month 12 1.870 Irritis 177015 717 / Month 24 1.130 No 105002 722 / Month 24 1.130 No 106002 722 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 122002 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 725 / Month 24 1.940 No 12400<!--</td--><td>Treatment Group Display Limit Service Transferrativity Immoveractivity Immoveractivity Immoveractivity 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intrascentar 177006 358 / Month 12 1.870 Intrascentar 177006 359 / Month 24 0.9250 No 104002 719 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 359 / Month 24 0.9250 No 122002 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 717 / Month 6 1.770 No 124003 719 / Month 24 1.700 No 124013 715 / Month 24 1.480 No</td></td></tr<> | Treatment Group Doitive Turnoreactivity Intransition Arran Freet Terron Subject ID Assay Log Ther Intransition 170010 365 / Month 12 2.770 No 170010 365 / Month 24 1.850 Intrassociate 170010 365 / Month 24 1.850 No 177006 339 / Month 24 1.130 No 112002 712 / Month 24 1.130 No 106002 722 / Month 24 1.130 No 112002 739 / Month 24 1.770 No 112002 722 / Month 24 1.770 No 112003 722 / Month 24 1.770 No 112003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 | Treatment Group Positive
Intransectivity Intransective
Infammation Subject ID Subject ID Number expertive
Assay Infammation 170010 365 / Month 12 2.770 No 170010 365 / Month 24 1.850 Infammation 170010 365 / Month 12 1.870 Infam 170010 358 / Month 12 1.870 Infam 117005 358 / Month 24 1.140 No 117001 722 / Month 24 1.130 No 112002 722 / Month 24 1.130 No 112002 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124001 174 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 717 / Month 24 1.770 No 12401 135 / Month 24 0.790 <
 | Treatment Group Dositive
Intranscripty Diagnois 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 170010 358 / Month 12 1.870 Irritis 170010 358 / Month 12 1.870 Irritis 177015 717 / Month 24 1.130 No 105002 722 / Month 24 1.130 No 106002 722 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 122002 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 725 / Month 24 1.940 No 12400 </td <td>Treatment Group Display Limit Service Transferrativity Immoveractivity Immoveractivity Immoveractivity 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intrascentar 177006 358 / Month 12 1.870 Intrascentar 177006 359 / Month 24 0.9250 No 104002 719 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 359 / Month 24 0.9250 No 122002 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 717 / Month 6 1.770 No 124003 719 / Month 24 1.700 No 124013 715 / Month 24 1.480 No</td> | Treatment Group Display Limit Service Transferrativity Immoveractivity Immoveractivity Immoveractivity 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intrascentar 177006 358 / Month 12 1.870 Intrascentar 177006 359 / Month 24 0.9250 No 104002 719 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 359 / Month 24 0.9250 No 122002 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 717 / Month 6 1.770 No 124003 719 / Month 24 1.700 No 124013 715 / Month 24 1.480 No |
| 0.875 Division 12

 | 1 22 0 1 21 400 1 25 1 210/02 1 200 CT

 |

 | Treatment Group Intransition Intransition Arrentment Group Subject ID Intransition Intransition Subject ID Subject ID Subject ID Assey Log Tip Intransition I 70010 365 Month 12 2.770 No No I 70010 365 Month 12 2.800 No No I 70010 365 Month 12 1.870 Intrias No I 70010 353 Month 24 1.130 No No I 17006 359 Month 24 1.130 No No I 12002 717 Month 24 1.1700 No No I 12002 722 Month 24 1.1700 No No I 12002 722 Month 24 1.770 No No I 12001 174 Month 24 1.770 No No I 12002 722 Month 24 1.770 No No I 12001 174 Month 24 1.770 No No I 12001 722 Month 24 1.770 No

 | Treatment Group Subject ID Tommunoreactivity Intransition Affective Subject ID Subject ID Assive the process of the proces of the process of the proces of the process of the p

 | Treatment Group Subject ID Tomunoreactivity Innumoreactivity Innumoreactivity Treatment Group Subject ID 365 / Month 12 2.800 No 170010 365 / Month 12 2.800 No 177010 715 / Month 24 1.870 Irris 177010 358 / Month 24 1.870 Irris 177010 358 / Month 24 1.870 Irris 177 Month 24 1.870 No No 102001 721 / Month 24 1.130 No 122002 739 / Month 24 1.130 No 12001 174 / Month 24 1.770 No 12001 174 / Month 24 1.770 No 12001 722 / Month 24 1.770 No 12001 174 / Month 24<

 | Treatment Group Subject ID Toritive Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity Innuminition 170010 365 / Month 12 X387 / Og Tite No No No No 170010 365 / Month 12 1870 Iritis No No No 177006 358 / Month 24 1.870 Iritis No No No 177006 358 / Month 24 1.130 No No No No 177006 359 / Month 24 1.130 No No </td <td>Treatment Group Bubliert ID
Subject ID Fositree
immunorescrivity Immunorescrivity
immunorescrivity Immunorescrivity Immunorescrivity
immunorescrivity Immunorescrity
immorescrivity</td> <td>Treatment Group Subject ID Toritive Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity Innuminition 170010 365 / Month 12 X387 / Og Tite No No No No 170010 365 / Month 12 1870 Iritis No No No 177006 358 / Month 24 1.870 Iritis No No No 177006 358 / Month 24 1.130 No No No No 177006 359 / Month 24 1.130 No No<!--</td--><td>Treatment Group Subject ID Toritive Innumoreactivity Innumoreactivity
 Innumoreactivity Innumoreactivity Innuminition 170010 365 / Month 12 X387 / Og Tite No No No No 170010 365 / Month 12 1870 Iritis No No No 177006 358 / Month 24 1.870 Iritis No No No 177006 358 / Month 24 1.130 No No No No 177006 359 / Month 24 1.130 No No<!--</td--><td>Treatment Group Subject ID Tomunoreactivity Innumoreactivity Innumoreactivity Treatment Group Subject ID 365 / Month 12 2.800 No 170010 365 / Month 12 2.800 No 177010 715 / Month 24 1.870 Irris 177010 358 / Month 24 1.870 Irris 177010 358 / Month 24 1.870 Irris 177 Month 24 1.870 No No 102001 721 / Month 24 1.130 No 122002 739 / Month 24 1.130 No 12001 174 / Month 24 1.770 No 12001 174 / Month 24 1.770 No 12001 722 / Month 24 1.770 No 12001 174 / Month 24<</td><td>Treatment Group Subject ID Tomunoreactivity Innumoreactivity Innumoreactivity Treatment Group Subject ID 365 / Month 12 2.800 No 170010 365 / Month 12 2.800 No 177010 715 / Month 24 1.870 Irris 177010 358 / Month 24 1.870 Irris 177010 358 / Month 24 1.870 Irris 177 Month 24 1.870 No No 102001 721 / Month 24 1.130 No 122002 739 / Month 24 1.130 No 12001 174 / Month 24 1.770 No 12001 174 / Month 24 1.770 No 12001 722 / Month 24 1.770 No 12001 174 / Month 24<</td><td>Treatment Group Subject ID Tomunoreactivity Innumoreactivity Innumoreactivity Treatment Group Subject ID 365 / Month 12 2.800 No 170010 365 / Month 12 2.800 No 177010 715 / Month 24 1.870 Irris 177010 358 / Month 24 1.870 Irris 177010 358 / Month 24 1.870 Irris 177 Month 24 1.870 No No 102001 721 / Month 24 1.130 No 122002 739 / Month 24 1.130 No 12001 174 / Month 24 1.770 No 12001 174 / Month 24 1.770 No 12001 722 / Month 24 1.770 No 12001 174 / Month 24<</td><td>Treatment Group Intransition Intransition Arrentment Group Subject ID Intransition Intransition Subject ID Subject ID Subject ID Assey Log Tip Intransition I 70010 365 Month 12 2.770 No No I 70010 365 Month 12 2.800 No No I 70010 365 Month 12 1.870 Intrias No I 70010 353 Month 24 1.130 No No I 17006 359 Month 24 1.130 No No I 12002 717 Month 24 1.1700 No No I 12002 722 Month 24 1.1700 No No I 12002 722 Month 24 1.770 No No I 12001 174 Month 24 1.770 No No I 12002 722 Month 24 1.770 No No I 12001 174 Month 24 1.770 No No I 12001 722 Month 24 1.770 No</td><td>Treatment Group Subject ID Positive
Immunorescrivity Immunorescrivity Immunorescrivity Immunorescrivity Areatment Group Subject ID Subject ID Subject ID Assey Log Tity Insposis I 70010 365 / Month 12 2.770 No No I 70010 365 / Month 12 1.870 Intria I 70010 358 / Month 12 1.870 Intria I 70010 715 / Month 24 1.130 No I 10002 712 / Month 24 1.130 No I 106002 722 / Month 24 1.130 No I 106002 722 / Month 24 1.770 No I 12002 735 / Month 24 1.770 No I 12001 174 / Month 24 1.770 No I 12001 725 / Month 24 1.770 No I 12002 731 / Month 24 1.770 No I 141018 181 / Month 24 1.770 No I 12001 715 / Month 24 1.940 No I 141018</td><td>Treatment Group Doitive Turnuoreactivity Intransition Subject ID Assay Log Ther Intransition 170010 365 / Month 12 2.770 No 170010 365 / Month 24 2.800 Intransition 170010 365 / Month 12 1.870 Intris 177006 358 / Month 24 1.870 Intris 117001 717 / Month 24 1.130 No 1122002 722 / Month 24 1.130 No 104002 719 / Month 24 1.130 No 122002 723 / Month 24 1.770 No 122002 723 / Month 24 1.770 No 124003 722 / Month 24 1.480 No <</td><td>Treatment Group Dositive
Intransectivity Intransectivity
Assay Log Titery Intransectivity
Intransation 170010 365 / Month 12 2.770 No 170010 365 / Month 24 2.800 Intransation 170010 365 / Month 24 2.800 Intrasectivity 170010 365 / Month 24 1.870 Intrasectivity 177006 353 / Month 24 1.870 Intrasectivity 105001 712 / Month 24 1.130 No 102001 722 / Month 24 1.130 No 106002 723 / Month 24 1.130 No 122002 357 / Month 24 1.7700 No 124003 722 / Month 24 1.7700 No 124003<td>Treatment Group Dositive
Intransactivity Intransaction
Intransaction Intransaction
Intransaction 170010 365 / Month 12 2.770 No 170010 355 / Month 12 2.770 No 177015 715 / Month 24 2.800 Intransaction 177016 358 / Month 12 1.870 Intris 177016 715 / Month 24 1.870 Intris 105002 722 / Month 24 1.130 No 102001 723 / Month 24 1.130 No 106002 723 / Month 24 1.130 No 122002 357 / Month 24 1.700 No 122002 723 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 141013 722 / Month 24</td><td>Treatment Group District ID Sociative
investoristivity Intransicular
intransicular Treatment Group Subject ID Sesy Top Ther Intransicular 170010 365 / Month 12 2.770 No 177016 355 / Month 12 2.770 No 177016 355 / Month 12 1.870 Littis 177016 715 / Month 24 0.922 No 177016 722 / Month 24 1.140 No 100002 723 / Month 24 1.130 No 122002 357 / Month 24 1.130 No 122002 357 / Month 24 1.700 No 122002 357 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003 725 / Month 24 1.700 No 124003 725 / Month 24 1.700 No 124003 725 / Month 24 1.700 No 141013 726 / Month 24</td></td></td></td>
 | Treatment Group Bubliert ID
Subject ID Fositree
immunorescrivity Immunorescrivity
immunorescrivity Immunorescrivity Immunorescrivity
immunorescrivity Immunorescrity
immorescrivity
 | Treatment Group Subject ID Toritive Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity Innuminition 170010 365 / Month 12 X387 / Og Tite No No No No 170010 365 / Month 12 1870 Iritis No No No 177006 358 / Month 24 1.870 Iritis No No No 177006 358 / Month 24 1.130 No No No No 177006 359 / Month 24 1.130 No No </td <td>Treatment Group Subject ID Toritive Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity Innuminition 170010 365 / Month 12 X387 / Og Tite No No No No 170010 365 / Month 12 1870 Iritis No No No 177006 358 / Month 24 1.870 Iritis No No No 177006 358 / Month 24 1.130 No No No No 177006 359 / Month 24 1.130 No No<!--</td--><td>Treatment Group Subject ID Tomunoreactivity Innumoreactivity Innumoreactivity Treatment Group Subject ID 365 / Month 12 2.800 No 170010 365 / Month 12 2.800 No 177010 715 / Month 24 1.870 Irris 177010 358 / Month 24 1.870 Irris 177010 358 / Month 24 1.870 Irris 177 Month 24 1.870 No No 102001 721 / Month 24 1.130 No 122002 739 / Month 24 1.130 No 12001 174 / Month 24 1.770 No 12001 174 / Month 24 1.770 No 12001 722 / Month 24 1.770 No 12001 174 / Month 24<</td><td>Treatment Group Subject ID Tomunoreactivity Innumoreactivity Innumoreactivity Treatment Group Subject ID 365 / Month 12 2.800 No 170010 365 / Month 12 2.800 No 177010 715 / Month 24 1.870 Irris 177010 358 / Month 24 1.870 Irris 177010 358 / Month 24 1.870 Irris 177 Month 24 1.870 No No 102001 721 / Month 24 1.130 No 122002 739 / Month 24 1.130 No 12001 174 / Month 24 1.770 No 12001 174 / Month 24 1.770 No 12001 722 / Month 24 1.770 No 12001 174 / Month 24<</td><td>Treatment Group Subject ID Tomunoreactivity Innumoreactivity Innumoreactivity Treatment Group Subject ID 365 / Month 12 2.800 No 170010 365 / Month 12 2.800 No 177010 715 / Month 24 1.870 Irris 177010 358 / Month 24 1.870 Irris 177010 358 / Month 24 1.870 Irris 177 Month 24 1.870 No No 102001 721 / Month 24 1.130 No 122002 739 / Month 24 1.130 No 12001 174 /
Month 24 1.770 No 12001 174 / Month 24 1.770 No 12001 722 / Month 24 1.770 No 12001 174 / Month 24<</td><td>Treatment Group Intransition Intransition Arrentment Group Subject ID Intransition Intransition Subject ID Subject ID Subject ID Assey Log Tip Intransition I 70010 365 Month 12 2.770 No No I 70010 365 Month 12 2.800 No No I 70010 365 Month 12 1.870 Intrias No I 70010 353 Month 24 1.130 No No I 17006 359 Month 24 1.130 No No I 12002 717 Month 24 1.1700 No No I 12002 722 Month 24 1.1700 No No I 12002 722 Month 24 1.770 No No I 12001 174 Month 24 1.770 No No I 12002 722 Month 24 1.770 No No I 12001 174 Month 24 1.770 No No I 12001 722 Month 24 1.770 No</td><td>Treatment Group Subject ID Positive
Immunorescrivity Immunorescrivity Immunorescrivity Immunorescrivity Areatment Group Subject ID Subject ID Subject ID Assey Log Tity Insposis I 70010 365 / Month 12 2.770 No No I 70010 365 / Month 12 1.870 Intria I 70010 358 / Month 12 1.870 Intria I 70010 715 / Month 24 1.130 No I 10002 712 / Month 24 1.130 No I 106002 722 / Month 24 1.130 No I 106002 722 / Month 24 1.770 No I 12002 735 / Month 24 1.770 No I 12001 174 / Month 24 1.770 No I 12001 725 / Month 24 1.770 No I 12002 731 / Month 24 1.770 No I 141018 181 / Month 24 1.770 No I 12001 715 / Month 24 1.940 No I 141018</td><td>Treatment Group Doitive Turnuoreactivity Intransition Subject ID Assay Log Ther Intransition 170010 365 / Month 12 2.770 No 170010 365 / Month 24 2.800 Intransition 170010 365 / Month 12 1.870 Intris 177006 358 / Month 24 1.870 Intris 117001 717 / Month 24 1.130 No 1122002 722 / Month 24 1.130 No 104002 719 / Month 24 1.130 No 122002 723 / Month 24 1.770 No 122002 723 / Month 24 1.770 No 124003 722 / Month 24 1.480 No <</td><td>Treatment Group Dositive
Intransectivity Intransectivity
Assay Log Titery Intransectivity
Intransation 170010 365 / Month 12 2.770 No 170010 365 / Month 24 2.800 Intransation 170010 365 / Month 24 2.800 Intrasectivity 170010 365 / Month 24 1.870 Intrasectivity 177006 353 / Month 24 1.870 Intrasectivity 105001 712 / Month 24 1.130 No 102001 722 / Month 24 1.130 No 106002 723 / Month 24 1.130 No 122002 357 / Month 24 1.7700 No 124003 722 / Month 24 1.7700 No 124003<td>Treatment Group Dositive
Intransactivity Intransaction
Intransaction Intransaction
Intransaction 170010 365 / Month 12 2.770 No 170010 355 / Month 12 2.770 No 177015 715 / Month 24 2.800 Intransaction 177016 358 / Month 12 1.870 Intris 177016 715 / Month 24 1.870 Intris 105002 722 / Month 24 1.130 No 102001 723 / Month 24 1.130 No 106002 723 / Month 24 1.130 No 122002 357 / Month 24 1.700 No 122002 723 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 141013 722 / Month 24</td><td>Treatment Group District ID Sociative
investoristivity Intransicular
intransicular Treatment Group Subject ID Sesy Top Ther Intransicular 170010 365 / Month 12 2.770 No 177016 355 / Month 12 2.770 No 177016 355 / Month 12 1.870 Littis 177016 715 / Month 24 0.922 No 177016 722 / Month 24 1.140 No 100002 723 / Month 24 1.130 No 122002 357 / Month 24 1.130 No 122002 357 / Month 24 1.700 No 122002 357 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003 725 / Month 24 1.700 No 124003 725 / Month 24 1.700 No 124003 725 / Month 24 1.700 No 141013 726 / Month 24</td></td></td> | Treatment Group Subject ID Toritive Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity Innuminition 170010 365 / Month 12 X387 / Og Tite No No No No 170010 365 / Month 12 1870 Iritis No No No 177006 358 / Month 24 1.870 Iritis No No No 177006 358 / Month 24 1.130 No No No No 177006 359 / Month 24 1.130 No No </td <td>Treatment Group Subject ID Tomunoreactivity Innumoreactivity Innumoreactivity Treatment Group Subject ID 365 / Month 12 2.800 No 170010 365 / Month 12 2.800 No 177010 715 / Month 24 1.870 Irris 177010 358 / Month 24 1.870 Irris 177010 358 / Month 24
 1.870 Irris 177 Month 24 1.870 No No 102001 721 / Month 24 1.130 No 122002 739 / Month 24 1.130 No 12001 174 / Month 24 1.770 No 12001 174 / Month 24 1.770 No 12001 722 / Month 24 1.770 No 12001 174 / Month 24<</td> <td>Treatment Group Subject ID Tomunoreactivity Innumoreactivity Innumoreactivity Treatment Group Subject ID 365 / Month 12 2.800 No 170010 365 / Month 12 2.800 No 177010 715 / Month 24 1.870 Irris 177010 358 / Month 24 1.870 Irris 177010 358 / Month 24 1.870 Irris 177 Month 24 1.870 No No 102001 721 / Month 24 1.130 No 122002 739 / Month 24 1.130 No 12001 174 / Month 24 1.770 No 12001 174 / Month 24 1.770 No 12001 722 / Month 24 1.770 No 12001 174 / Month 24<</td> <td>Treatment Group Subject ID Tomunoreactivity Innumoreactivity Innumoreactivity Treatment Group Subject ID 365 / Month 12 2.800 No 170010 365 / Month 12 2.800 No 177010 715 / Month 24 1.870 Irris 177010 358 / Month 24 1.870 Irris 177010 358 / Month 24 1.870 Irris 177 Month 24 1.870 No No 102001 721 / Month 24 1.130 No 122002 739 / Month 24 1.130 No 12001 174 / Month 24 1.770 No 12001 174 / Month 24 1.770 No 12001 722 / Month 24 1.770 No 12001 174 / Month 24<</td> <td>Treatment Group Intransition Intransition Arrentment Group Subject ID Intransition Intransition Subject ID Subject ID Subject ID Assey Log Tip Intransition I 70010 365 Month 12 2.770 No No I 70010 365 Month 12 2.800 No No I 70010 365 Month 12 1.870 Intrias No I 70010 353 Month 24 1.130 No No I 17006 359 Month 24 1.130 No No I 12002 717 Month 24 1.1700 No No I 12002 722 Month 24 1.1700 No No I 12002 722 Month 24 1.770 No No I 12001 174 Month 24 1.770 No No I 12002 722 Month 24 1.770 No No I 12001 174 Month 24 1.770 No No I 12001 722 Month 24 1.770 No</td> <td>Treatment Group Subject ID Positive
Immunorescrivity Immunorescrivity Immunorescrivity Immunorescrivity Areatment Group Subject ID Subject ID Subject ID Assey Log Tity Insposis I 70010 365 / Month 12 2.770 No No I 70010 365 / Month 12 1.870 Intria I 70010 358 / Month 12 1.870 Intria I 70010 715 / Month 24 1.130 No I 10002 712 / Month 24 1.130 No I 106002 722 / Month 24 1.130 No I 106002 722 / Month 24 1.770 No I 12002 735 / Month 24 1.770 No I 12001 174 / Month 24 1.770 No I 12001 725 / Month 24 1.770 No I 12002 731 / Month 24 1.770 No I 141018 181 / Month 24 1.770 No I 12001 715 / Month 24 1.940 No I 141018</td> <td>Treatment Group Doitive Turnuoreactivity Intransition Subject ID Assay Log Ther Intransition 170010 365 / Month 12 2.770 No 170010 365 / Month 24 2.800 Intransition 170010 365 / Month 12 1.870 Intris 177006 358 / Month 24 1.870 Intris 117001 717 / Month 24 1.130 No 1122002 722 / Month 24 1.130 No 104002 719 / Month 24 1.130 No 122002 723 / Month 24 1.770 No 122002 723 / Month 24 1.770 No 124003 722 / Month 24 1.480 No <</td> <td>Treatment Group Dositive
Intransectivity Intransectivity
Assay Log Titery Intransectivity
Intransation 170010 365 / Month 12 2.770 No 170010 365 / Month 24 2.800 Intransation 170010 365 / Month 24 2.800 Intrasectivity 170010 365 / Month 24 1.870 Intrasectivity 177006 353 / Month 24 1.870 Intrasectivity 105001 712 / Month 24 1.130 No 102001 722 / Month 24 1.130 No 106002 723 / Month 24 1.130 No 122002 357 / Month 24 1.7700 No 124003 722 / Month 24 1.7700 No 124003<td>Treatment Group Dositive
Intransactivity Intransaction
Intransaction Intransaction
Intransaction 170010 365 / Month 12 2.770 No 170010 355 / Month 12 2.770 No 177015 715 / Month 24 2.800 Intransaction 177016 358 / Month 12 1.870 Intris 177016 715 / Month 24 1.870 Intris 105002 722 / Month 24 1.130 No 102001 723 / Month 24 1.130 No 106002 723 / Month 24 1.130 No 122002 357 / Month 24 1.700 No 122002 723 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 141013 722 / Month 24</td><td>Treatment Group District ID Sociative
investoristivity Intransicular
intransicular Treatment Group Subject ID Sesy Top Ther Intransicular 170010 365 / Month 12 2.770 No 177016 355 / Month 12 2.770 No 177016 355 / Month 12 1.870 Littis 177016 715 / Month 24 0.922 No 177016 722 / Month 24 1.140 No 100002 723 / Month 24 1.130 No 122002 357 / Month 24 1.130 No 122002 357 / Month 24 1.700 No 122002 357 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003 725 / Month 24 1.700 No 124003 725 / Month 24 1.700 No 124003 725 / Month 24 1.700 No 141013 726 / Month 24</td></td>
 | Treatment Group Subject ID Tomunoreactivity Innumoreactivity Innumoreactivity Treatment Group Subject ID 365 / Month 12 2.800 No 170010 365 / Month 12 2.800 No 177010 715 / Month 24 1.870 Irris 177010 358 / Month 24 1.870 Irris 177010 358 / Month 24 1.870 Irris 177 Month 24 1.870 No No 102001 721 / Month 24 1.130 No 122002 739 / Month 24 1.130 No 12001 174 / Month 24 1.770 No 12001 174 / Month 24 1.770 No 12001 722 / Month 24 1.770 No 12001 174 / Month 24<
 | Treatment Group Subject ID Tomunoreactivity Innumoreactivity Innumoreactivity Treatment Group Subject ID 365 / Month 12 2.800 No 170010 365 / Month 12 2.800 No 177010 715 / Month 24 1.870 Irris 177010 358 / Month 24 1.870 Irris 177010 358 / Month 24 1.870 Irris 177 Month 24 1.870 No No 102001 721 / Month 24 1.130 No 122002 739 / Month 24 1.130 No 12001 174 / Month 24 1.770 No 12001 174 / Month 24 1.770 No 12001 722 / Month 24 1.770 No 12001 174 / Month 24<
 | Treatment Group Subject ID Tomunoreactivity Innumoreactivity Innumoreactivity Treatment Group Subject ID 365 / Month 12 2.800 No 170010 365 / Month 12 2.800 No 177010 715 / Month 24 1.870 Irris 177010 358 / Month 24 1.870 Irris 177010 358 / Month 24 1.870 Irris 177 Month 24 1.870 No No 102001 721 / Month 24 1.130 No 122002 739 / Month 24 1.130 No 12001 174 / Month 24 1.770 No 12001 174 / Month 24 1.770 No 12001 722 / Month 24 1.770 No 12001 174 / Month 24<
 | Treatment Group Intransition Intransition Arrentment Group Subject ID Intransition Intransition Subject ID Subject ID Subject ID Assey Log Tip Intransition I 70010 365 Month 12 2.770 No No I 70010 365 Month 12 2.800 No No I 70010 365 Month 12 1.870 Intrias No I 70010 353 Month 24 1.130 No No I 17006 359 Month 24 1.130 No No I 12002 717 Month 24 1.1700 No No I 12002 722 Month 24 1.1700 No No I 12002 722 Month 24 1.770 No No I 12001 174 Month 24 1.770 No No I 12002 722 Month 24 1.770 No No I 12001 174 Month 24 1.770 No No I 12001 722 Month 24 1.770 No
 | Treatment Group Subject ID Positive
Immunorescrivity Immunorescrivity Immunorescrivity Immunorescrivity Areatment Group Subject ID Subject ID Subject ID Assey Log Tity Insposis I 70010 365 / Month 12 2.770 No No I 70010 365 / Month 12 1.870 Intria I 70010 358 / Month 12 1.870 Intria I 70010 715 / Month 24 1.130 No I 10002 712 / Month 24 1.130 No I 106002 722 / Month 24 1.130 No I 106002 722 / Month 24 1.770 No I 12002 735 / Month 24 1.770 No I 12001 174 / Month 24 1.770 No I 12001 725 / Month 24 1.770 No I 12002 731 / Month 24 1.770 No I 141018 181 / Month 24 1.770 No I 12001 715 / Month 24 1.940 No I 141018
 | Treatment Group Doitive Turnuoreactivity Intransition Subject ID Assay Log Ther Intransition 170010 365 / Month 12 2.770 No 170010 365 / Month 24 2.800 Intransition 170010 365 / Month 12 1.870 Intris 177006 358 / Month 24 1.870 Intris 117001 717 / Month 24 1.130 No 1122002 722 / Month 24 1.130 No 104002 719 / Month 24 1.130 No 122002 723 / Month 24 1.770 No 122002 723 / Month 24 1.770 No 124003 722 / Month 24 1.480 No < | Treatment Group Dositive
Intransectivity Intransectivity
Assay Log Titery Intransectivity
Intransation 170010 365 / Month 12 2.770 No 170010 365 / Month 24 2.800 Intransation 170010 365 / Month 24 2.800 Intrasectivity 170010 365 / Month 24 1.870 Intrasectivity 177006 353 / Month 24 1.870 Intrasectivity 105001 712 / Month 24 1.130 No 102001 722 / Month 24 1.130 No 106002 723 / Month 24 1.130 No 122002 357 / Month 24 1.7700 No 124003 722 / Month 24 1.7700 No 124003 <td>Treatment Group Dositive
Intransactivity Intransaction
Intransaction Intransaction
Intransaction 170010 365 / Month 12 2.770 No 170010 355 / Month 12 2.770 No 177015 715 / Month 24 2.800 Intransaction 177016 358 / Month 12 1.870 Intris 177016 715 / Month 24 1.870 Intris 105002 722 / Month 24 1.130 No 102001 723 / Month 24 1.130 No 106002 723 / Month 24 1.130 No 122002 357 / Month 24 1.700 No 122002 723 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 141013 722 / Month 24</td> <td>Treatment Group District ID Sociative
investoristivity Intransicular
intransicular Treatment Group Subject ID Sesy Top Ther Intransicular 170010 365 / Month 12 2.770 No 177016 355 / Month 12 2.770 No 177016 355 / Month 12 1.870 Littis 177016 715 / Month 24 0.922 No 177016 722 / Month 24 1.140 No 100002 723 / Month 24 1.130 No 122002 357 / Month 24 1.130 No 122002 357 / Month 24 1.700 No 122002 357 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003 725 / Month 24 1.700 No 124003 725 / Month 24 1.700 No 124003 725 / Month 24 1.700 No 141013 726 / Month 24</td>
 | Treatment Group Dositive
Intransactivity Intransaction
Intransaction Intransaction
Intransaction 170010 365 / Month 12 2.770 No 170010 355 / Month 12 2.770 No 177015 715 / Month 24 2.800 Intransaction 177016 358 / Month 12 1.870 Intris 177016 715 / Month 24 1.870 Intris 105002 722 / Month 24 1.130 No 102001 723 / Month 24 1.130 No 106002 723 / Month 24 1.130 No 122002 357 / Month 24 1.700 No 122002 723 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 141013 722 / Month 24 | Treatment Group District ID Sociative
investoristivity Intransicular
intransicular Treatment Group Subject ID Sesy Top Ther Intransicular 170010 365 / Month 12 2.770 No 177016 355 / Month 12 2.770 No 177016 355 / Month 12 1.870 Littis 177016 715 / Month 24 0.922 No 177016 722 / Month 24 1.140 No 100002 723 / Month 24 1.130 No 122002 357 / Month 24 1.130 No 122002 357 / Month 24 1.700 No 122002 357 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003 725 / Month 24 1.700 No 124003 725 / Month 24 1.700 No 124003 725 / Month 24 1.700 No 141013 726 / Month 24 |
| 0.5 mg 507018 357 / Month 12 0.875

 | 0.5 mg 507018 357 / Month 12 0.875

 | $15 \text{ m} c$ 1507019 $257 M_{out}$ 10 005

 | Treatment Group Intransion frammation Intransion Intransion Affect Their Group Subject ID Subject ID Assay Lost Intransion 170010 365 / Month 12 2.77 Og No 177010 365 / Month 24 2.800 Intrascutar 177010 358 / Month 24 1.870 Intrascutar 177015 358 / Month 24 1.870 Intrascutar 177006 358 / Month 24 1.130 No 102001 722 / Month 24 1.130 No 122002 739 / Month 24 1.770 No 122002 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124001 174 / Month 24 1.770 No 126001 174 / Month 24 1.770 No 121000 122

 | Treatment Group Intranscriptive Intranscriptive Intranscriptive Affective Subject ID Subject ID Assive furmule reservery Intranscription 170010 365 / Month 12 2.770 No No 177010 355 / Month 24 1.870 Irrinis No 177010 355 / Month 24 1.870 Irrinis No 177010 355 / Month 24 1.130 No No 102001 722 / Month 24 1.130 No
 No 122002 722 / Month 24 1.130 No No No 12001 722 / Month 24 1.770 No No No No 124003 722 / Month 24 1.770 No N

 | Treatment Group Subject ID Fositive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID 365 / Month 12 2.800 No 170010 365 / Month 12 2.800 No 177016 358 / Month 24 2.800 No 177016 358 / Month 24 1.870 Irinis 177006 358 / Month 24 1.870 No 102001 721 / Month 24 1.130 No 102002 722 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 12400 174 / Month 24 1.770 No

 | Treatment Group Subject ID Townuoreactivity Innuuoreactivity Innuuoreactivity 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 24 1.870 Iritis 177006 358 / Month 24 1.870 Iritis 177006 358 / Month 24 1.870 No 102001 721 / Month 24 1.130 No 12202 739 / Month 24 1.130 No 124003 722 / Month 24 1.770 No 124001 174 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 141008 11/4 / Month 24 1.7
 | Treatment Group Subject ID Fositive
Immunorescienting Immunorescienting Immunorescienting Areatment Group Subject ID 365 / Month 12 Xarsy Tog Titer
Diagnois I 10010 365 / Month 12 Xarsy Tog Titer Diagnois I 17006 358 / Month 12 1870 Initia I 17006 358 / Month 24 1870 Initia I 177066 358 / Month 24 1870 Initia I 177006 358 / Month 24 1130 No I 12002 722 / Month 24 1130 No I 12002 722 / Month 24 1130 No I 12003 722 / Month 24 1770 No I 12001 174 / Month 24 1770 No I 12003 722 / Month 24 1770 No I 12001 723 / Month 24 1770 No I 12003 722 / Month 24 1770 No I 12003 723 / Month 24 1770 No I 12003 713 / Month 24 1760 No </th <th>Treatment Group Subject ID Townuoreactivity Innuuoreactivity Innuuoreactivity 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 24 1.870 Iritis 177006 358 / Month 24 1.870 Iritis 177006 358 / Month 24 1.870 No 102001 721 / Month 24 1.130 No 12202 739 / Month 24 1.130 No 124003 722 / Month 24 1.770 No 124001 174 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 141008 11/4 / Month 24 1.7</th> <th>Treatment Group Subject ID Townuoreactivity Innuuoreactivity Innuuoreactivity 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 24 1.870 Iritis 177006 358 / Month 24 1.870 Iritis 177006 358 / Month 24 1.870 No 102001 721 / Month 24 1.130 No 12202 739 / Month 24 1.130 No 124003 722 / Month 24 1.770 No 124001 174 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 141008 11/4 / Month 24 1.7</th> <th>Treatment Group Subject ID Fositive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID 365 / Month 12 2.800 No 170010 365 / Month 12 2.800 No 177016 358 / Month 24 2.800 No 177016 358 / Month 24 1.870 Irinis 177006 358 / Month 24 1.870 No 102001 721 / Month 24 1.130 No 102002 722 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 12400 174 / Month 24 1.770 No</th> <th>Treatment Group Subject ID Fositive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID 365 / Month 12 2.800 No 170010 365 / Month 12 2.800 No 177016 358 / Month 24 2.800 No 177016 358 / Month 24 1.870 Irinis 177006 358 / Month 24 1.870 No 102001 721 / Month 24 1.130 No 102002 722 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 12400 174 / Month 24 1.770 No</th> <th>Treatment Group Subject ID Fositive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID 365 / Month 12 2.800 No 170010 365 / Month 12 2.800 No 177016 358 / Month 24 2.800 No 177016 358 / Month 24 1.870 Irinis 177006 358 / Month 24 1.870 No 102001 721 / Month 24 1.130 No 102002 722 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 12400 174 / Month 24 1.770 No</th> <th>Treatment Group Intransion frammation Intransion Intransion Affect Their Group Subject ID Subject ID Assay Lost Intransion 170010 365 / Month 12 2.77 Og No 177010 365 / Month 24 2.800 Intrascutar 177010 358 / Month 24 1.870 Intrascutar 177015 358 / Month 24 1.870 Intrascutar 177006 358 / Month 24 1.130 No 102001 722 / Month 24 1.130 No 122002 739 / Month 24 1.770 No 122002 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124001 174 / Month 24 1.770 No 126001 174 / Month 24 1.770 No 121000 122</th> <th>Treatment Group Intransion frammation Intransion Intransion Arrentinent Group Subject ID Subject ID Assay Log Tity Intransion 170010 365 Month 12 2.770 No No 170010 365 Month 12 2.800 Inframmation 170010 365 Month 24 1.850 Inframmation 177006 358 Month 24 1.870 Infra 102001 721 Month 24 1.130 No 102002 722 Month 24 1.130 No 102001 722 Month 24 1.130 No 122002 359 Month 24 1.770 No 124003 722 Month 24 1.770 No 124003 724 Month 24 1.770 No 12400 1.14 Month 24<th>Treatment Group Doitive Turnoreactivity Intransition Subject ID Subject ID Assay Log Ther Infamilion 170010 365 / Month 24 2.770 No 170010 365 / Month 24 2.800 Infamilion 170010 365 / Month 24 1.850 No 177006 358 / Month 24 1.140 No 117001 717 / Month 24 1.130 No 105002 722 / Month 24 1.130 No 106002 722 / Month 24 1.130 No 106002 722 / Month 24 1.770 No 1122002 359 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 724 / Month 24 0.790 No</th><th>Treatment Group Dositive
Intransectivity Intransectivity
Assay Log Titer Intransectivity
Inframation 170010 365 / Month 12 2.770 No 170010 365 / Month 24 2.800 Inframation 170010 365 / Month 24 2.800 Inframation 170010 365 / Month 24 1.850 No 177006 358 / Month 24 1.130 No 1170010 717 / Month 24 1.130 No 106002 722 / Month 24 1.130 No 106002 722 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 725 / Month 24 1.940 No 124003 725 / Month 24</th><th>Treatment Group Dositive
Intranscripty
Diagnoist
Intranscripty Intranscripty
Intranscripty Intranscripty
Intranscripty Intranscripty
Intranscripty Intranscripty
Intranscripty Intranscripty
Intranscripty Intranscripty Intranscript 715 715 Month 12 2.770 No No 717006 355 Month 12 1.870 Intra
No No 717 717 Month 24 1.130 No No 105002 722 Month 24 1.130 No No 106002 723 Month 24 1.770 No No 122002 723 Month 24 1.770 No No 122002 723 Month 24 1.770 No No 124003 722 Month 24 1.770 No No 124003 725 Month 24 1.770 No No 124003 725 Month 24 1.770 No No 124003 726 Month 24 1.4</th><th>Treatment Group Display function assistic to the interactivity interactivity interactivity interactivity interactivity interactivity interaction assistic and assisted assistic and assistic and assist</th></th> | Treatment Group Subject ID Townuoreactivity Innuuoreactivity Innuuoreactivity 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 24 1.870 Iritis 177006 358 / Month 24 1.870 Iritis 177006 358 / Month 24 1.870 No 102001 721 / Month 24 1.130 No 12202 739 / Month 24 1.130 No 124003 722 / Month 24 1.770 No 124001 174 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 141008 11/4 / Month 24 1.7
 | Treatment Group Subject ID Townuoreactivity Innuuoreactivity Innuuoreactivity 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 24 1.870 Iritis 177006 358 / Month 24 1.870 Iritis 177006 358 / Month 24 1.870 No 102001 721 / Month 24 1.130 No 12202 739 / Month 24 1.130 No 124003 722 / Month 24 1.770 No 124001 174 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 141008 11/4 / Month 24 1.7

 | Treatment Group Subject ID Fositive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID 365 / Month 12 2.800 No 170010 365 / Month 12 2.800 No 177016 358 / Month 24 2.800 No 177016 358 / Month 24 1.870 Irinis 177006 358 / Month 24 1.870 No 102001 721 / Month 24 1.130 No 102002 722 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 12400 174 / Month 24 1.770 No
 | Treatment Group Subject ID Fositive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID 365 / Month 12 2.800 No 170010 365 / Month 12 2.800 No 177016 358 / Month 24 2.800 No 177016 358 / Month 24 1.870 Irinis 177006 358 / Month 24 1.870 No 102001 721 / Month 24 1.130 No 102002 722 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 12400 174 / Month 24 1.770 No
 | Treatment Group Subject ID Fositive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID 365 / Month 12 2.800 No 170010 365 / Month 12 2.800 No 177016 358 / Month 24 2.800 No 177016 358 / Month 24 1.870 Irinis 177006 358 / Month 24 1.870 No 102001 721 / Month 24 1.130 No 102002 722 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 12400 174 / Month 24 1.770 No
 | Treatment Group Intransion frammation Intransion Intransion Affect Their Group Subject ID Subject ID Assay Lost Intransion 170010 365 / Month 12 2.77 Og No 177010 365 / Month 24 2.800 Intrascutar 177010 358 / Month 24 1.870 Intrascutar 177015 358 / Month 24 1.870 Intrascutar 177006 358 / Month 24 1.130 No 102001 722 / Month 24 1.130 No 122002 739 / Month 24 1.770 No 122002 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124001 174 / Month 24 1.770 No 126001 174 / Month 24 1.770 No 121000 122
 | Treatment Group Intransion frammation Intransion Intransion Arrentinent Group Subject ID Subject ID Assay Log Tity Intransion 170010 365 Month 12 2.770 No No 170010 365 Month 12 2.800 Inframmation 170010 365 Month 24 1.850 Inframmation 177006 358 Month 24 1.870 Infra 102001 721 Month 24 1.130 No 102002 722 Month 24 1.130 No 102001 722 Month 24 1.130 No 122002 359 Month 24 1.770 No 124003 722 Month 24 1.770 No 124003 724 Month 24 1.770 No 12400 1.14 Month 24 <th>Treatment Group Doitive Turnoreactivity Intransition Subject ID Subject ID Assay Log Ther Infamilion 170010 365 / Month 24 2.770 No 170010 365 / Month 24 2.800 Infamilion 170010 365 / Month 24 1.850 No 177006 358 / Month 24 1.140 No 117001 717 / Month 24 1.130 No 105002 722 / Month 24 1.130 No 106002 722 / Month 24 1.130 No 106002 722 / Month 24 1.770 No 1122002 359 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 724 / Month 24 0.790 No</th> <th>Treatment Group Dositive
Intransectivity Intransectivity
Assay Log Titer Intransectivity
Inframation 170010 365 / Month 12 2.770 No 170010 365 / Month 24 2.800 Inframation 170010 365 / Month 24 2.800 Inframation 170010 365 / Month 24 1.850 No 177006 358 / Month 24 1.130 No 1170010 717 / Month 24 1.130 No 106002 722 / Month 24 1.130 No 106002 722 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 725 / Month 24 1.940 No 124003 725 / Month 24</th> <th>Treatment Group Dositive
Intranscripty Diagnoist
Intranscripty Intranscripty
Intranscripty Intranscripty
Intranscripty Intranscripty
Intranscripty Intranscripty
Intranscripty Intranscripty
Intranscripty Intranscripty Intranscript 715 715 Month 12 2.770 No No 717006 355 Month 12 1.870 Intra
No No 717 717 Month 24 1.130 No No 105002 722 Month 24 1.130 No No 106002 723 Month 24 1.770 No No 122002 723 Month 24 1.770 No No 122002 723 Month 24 1.770 No No 124003 722 Month 24 1.770 No No 124003 725 Month 24 1.770 No No 124003 725 Month 24 1.770 No No 124003 726 Month 24 1.4</th> <th>Treatment Group Display function assistic to the interactivity interactivity interactivity interactivity interactivity interactivity interaction assistic and assisted assistic
and assistic and assist</th> | Treatment Group Doitive Turnoreactivity Intransition Subject ID Subject ID Assay Log Ther Infamilion 170010 365 / Month 24 2.770 No 170010 365 / Month 24 2.800 Infamilion 170010 365 / Month 24 1.850 No 177006 358 / Month 24 1.140 No 117001 717 / Month 24 1.130 No 105002 722 / Month 24 1.130 No 106002 722 / Month 24 1.130 No 106002 722 / Month 24 1.770 No 1122002 359 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 724 / Month 24 0.790 No | Treatment Group Dositive
Intransectivity Intransectivity
Assay Log Titer Intransectivity
Inframation 170010 365 / Month 12 2.770 No 170010 365 / Month 24 2.800 Inframation 170010 365 / Month 24 2.800 Inframation 170010 365 / Month 24 1.850 No 177006 358 / Month 24 1.130 No 1170010 717 / Month 24 1.130 No 106002 722 / Month 24 1.130 No 106002 722 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 725 / Month 24 1.940 No 124003 725 / Month 24 | Treatment Group Dositive
Intranscripty Diagnoist
Intranscripty Intranscripty
Intranscripty Intranscripty
Intranscripty Intranscripty
Intranscripty Intranscripty
Intranscripty Intranscripty
Intranscripty Intranscripty Intranscript 715 715 Month 12 2.770 No No 717006 355 Month 12 1.870 Intra
No No 717 717 Month 24 1.130 No No 105002 722 Month 24 1.130 No No 106002 723 Month 24 1.770 No No 122002 723
 Month 24 1.770 No No 122002 723 Month 24 1.770 No No 124003 722 Month 24 1.770 No No 124003 725 Month 24 1.770 No No 124003 725 Month 24 1.770 No No 124003 726 Month 24 1.4 | Treatment Group Display function assistic to the interactivity interactivity interactivity interactivity interactivity interactivity interaction assistic and assisted assistic and assistic and assist |
|

 |

 |

 | Treatment Group Intranscription Intranscription Affect froup Subject ID Intranscription Intranscription 170010 365 / Month 12 2.770 No 177016 355 / Month 12 2.800 No 177016 355 / Month 24 1.870 Iritis 177016 355 / Month 24 1.870 Iritis 177006 355 / Month 24 1.130 No 102001 721 / Month 24 1.130 No 1122002 359 / Month 24 1.1700 No 124003 722 / Month 24 1.770 No 122002 359 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 715 / Month 24 1.770 No 124003 715 / Month 24 1.770 No 124003 725 / Month 24 1.770 No

 | Treatment Group Intranscription Intranscription Affective Subject ID Formunoreactivity Intranscription 170010 365 / Month 12 2.800 No 177016 358 / Month 12 2.800 No 177016 358 / Month 12 1.870 Iritis 177016 358 / Month
24 1.870 Iritis 177006 358 / Month 24 1.870 No 102001 721 / Month 24 1.130 No 1122002 359 / Month 24 1.130 No 124003 723 / Month 24 1.770 No 122002 359 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 715 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 725 / Month 24 1.770 No <

 | Treatment Group Subject ID Townuoreactivity Intransition Arrentment Group Subject ID 365 / Month 12 2.800 No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Initia 177010 358 / Month 24 2.800 No 177006 358 / Month 24 1.870 Initia 177006 358 / Month 24 1.870 No 102001 721 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 122002 357 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 723 / Month 24 0.782 No 124003 715 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 714 / Month 24 0.772 No 124003 715 / Month 24

 | Treatment Group Subject ID Fositive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity 170010 365 / Month 12 2800 No No No 170010 365 / Month 12 2800 No No No 177006 358 / Month 12 1870 Irritis No 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1870 No 102001 717 / Month 24 1870 No 122002 359 / Month 24 1130 No 122003 722 / Month 24 1770 No 124003 717 / Month 24 1770 No 124003 715 / Month 24 1770 No 141018 117 / Month 24

 | Treatment Group Runtumoreactivity Immunoreactivity Immunoreactivity<
 | Treatment Group Subject ID Fositive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity 170010 365 / Month 12 2800 No No No 170010 365 / Month 12 2800 No No No 177006 358 / Month 12 1870 Irritis No 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1870 No 102001 717 / Month 24 1870 No 122002 359 / Month 24 1130 No 122003 722 / Month 24 1770 No 124003 717 / Month 24 1770 No 124003 715 / Month 24 1770 No 141018 117 / Month 24
 | Treatment Group Subject ID
 Fositive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity 170010 365 / Month 12 2800 No No No 170010 365 / Month 12 2800 No No No 177006 358 / Month 12 1870 Irritis No 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1870 No 102001 717 / Month 24 1870 No 122002 359 / Month 24 1130 No 122003 722 / Month 24 1770 No 124003 717 / Month 24 1770 No 124003 715 / Month 24 1770 No 141018 117 / Month 24
 | Treatment Group Subject ID Townuoreactivity Intransition Arrentment Group Subject ID 365 / Month 12 2.800 No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Initia 177010 358 / Month 24 2.800 No 177006 358 / Month 24 1.870 Initia 177006 358 / Month 24 1.870 No 102001 721 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 122002 357 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 723 / Month 24 0.782 No 124003 715 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 714 / Month 24 0.772 No 124003 715 / Month 24
 | Treatment Group Subject ID Townuoreactivity Intransition Arrentment Group Subject ID 365 / Month 12 2.800 No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Initia 177010 358 / Month 24 2.800 No 177006 358 / Month 24 1.870 Initia 177006 358 / Month 24 1.870 No 102001 721 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 122002 357 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 723 / Month 24 0.782 No 124003 715 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 714 / Month 24 0.772 No 124003 715 / Month 24
 | Treatment Group Subject ID Townuoreactivity Intransition Arrentment Group Subject ID 365 / Month 12 2.800 No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Initia 177010 358 / Month 24 2.800 No 177006 358 / Month 24 1.870 Initia 177006 358 / Month 24 1.870 No 102001 721 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 122002 357 / Month 24 1.770 No 124003
 722 / Month 24 1.770 No 124003 723 / Month 24 0.782 No 124003 715 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 714 / Month 24 0.772 No 124003 715 / Month 24 | Treatment Group Intranscription Intranscription Affect froup Subject ID Intranscription Intranscription 170010 365 / Month 12 2.770 No 177016 355 / Month 12 2.800 No 177016 355 / Month 24 1.870 Iritis 177016 355 / Month 24 1.870 Iritis 177006
 355 / Month 24 1.130 No 102001 721 / Month 24 1.130 No 1122002 359 / Month 24 1.1700 No 124003 722 / Month 24 1.770 No 122002 359 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 715 / Month 24 1.770 No 124003 715 / Month 24 1.770 No 124003 725 / Month 24 1.770 No | Treatment Group Rolitive
Immunoreactivity Immunoreactivity Immunoreactivity Arrentment Group Subject ID Subject ID Subject ID Intramistion I 70010 365 / Month 12 2.770 No No I 70010 365 / Month 12 2.800 No No I 70010 365 / Month 24 1.870 Irrins No I 70010 358 / Month 24 1.870 Irrins No I 70001 721 / Month 24 1.300 No No I 12002 739 / Month 24 1.130 No No I 12002 731 / Month 24 1.770 No No I 12002 735 / Month 24 1.770 No No I 12002 735 / Month 24 1.770 No No I 12003 715 / Month 24 1.770 No No I 12003 715 / Month 24 1.770 No No I 12001 714 / Month 24 1.770 No No I 12001
 | Treatment Group Doitive Intransicult Intransicult Areatment Group Subject ID Assay Log Ther Infamilion 170010 365 / Month 12 2.770 No 170010 365 / Month 24 2.800 Infamilion 170010 365 / Month 24 1.850 No 177006 338 / Month 24 1.870 Infamilion 102001 721 / Month 24 1.850 No 102001 722 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 122002 723 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 0.780 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003 725 / Month 24 0.790 No 124003 722 / Month 24 0.700 <td< td=""><td>Treatment Group Positive Positive Intramonentity Intramotion Subject ID Subject ID Assay Log Ther Inflammation 170010 365 / Month 12 2.770 No 170010 365 / Month 24 1.850 Inflammation 170010 358 / Month 12 1.870 Inflammation 170010 358 / Month 24 1.130 No 117005 339 / Month 24 1.130 No 102001 722 / Month 24 1.130 No 112002 739 / Month 24 1.1700 No 122002 739 / Month 24 1.770 No 124003 722 / Month 24</td><td>Treatment Group Districe
Intranscripty Districe
Intranscripty Intranscripty Intranscripty 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 170010 365 / Month 12 1.850 Intrascripty Rantbizumab 0.5 mg 102001 715 / Month 24 1.850 No 117006 353 / Month 12 1.870 Intris Intrascripty 117006 353 / Month 24 1.140 No No 122002 722 / Month 24 1.130 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770</td><td>Treathent Group Fositive
subject ID Fositive
assist and the second second second second and second
and second sec</td></td<> | Treatment Group Positive Positive Intramonentity Intramotion Subject ID Subject ID Assay Log Ther Inflammation 170010 365 / Month 12 2.770 No 170010 365 / Month 24 1.850 Inflammation 170010 358 / Month 12 1.870 Inflammation 170010 358 / Month 24 1.130 No 117005 339 / Month 24 1.130 No 102001 722 / Month 24 1.130 No 112002 739 / Month 24 1.1700 No 122002 739 / Month 24 1.770 No 124003 722 / Month 24
 | Treatment Group Districe
Intranscripty Districe
Intranscripty Intranscripty Intranscripty 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 170010 365 / Month 12 1.850 Intrascripty Rantbizumab 0.5 mg 102001 715 / Month 24 1.850 No 117006 353 / Month 12 1.870 Intris Intrascripty 117006 353 / Month 24 1.140 No No 122002 722 / Month 24 1.130 No No 124003 722 / Month 24 1.770 | Treathent Group Fositive
subject ID Fositive
assist and the second second second second and second
and second sec |
|

 |

 |

 | Treatment Group Intransionesettivity Intransionesettivity Intransionesettivity ITeatment Group Subject ID Subject ID Ammunoresettivity Intransion Introl 355 / Month 12 2.800 No Introl Introl 355 / Month 12 1.870 Intris Introl Introl 358 / Month 24 1.870 Intris Intris Introl 717 / Month 24 1.870 No Intris Introl 722 / Month 24 1.130 No Introl Introl 723 / Month 24 1.1700 No Introl Introl 723 / Month 24 1.770 No No Introl 726 / Month 24 1.770 No No <

 | Treatment Group Intranscription Interment Group Subject ID Formunoreactivity Intranscription Interment Group Subject ID 365 / Month 12 2 sto0 No Intrastructure 117006 358 / Month 12 1 sto0 No Intrastructure 117006 358 / Month 24 2 sto0 No Intrastructure 1177006 358 / Month 24 1 sto0 Intrastructure Intrastructure 102001 717 / Month 24 1 sto0 No Intrastructure 102001 717 / Month 24 1 sto0 No
 Intrastructure 102001 717 / Month 24 1 sto0 No Intrastructure 104002 727 / Month 24 1 sto0 No Intrastructure 124003 727 / Month 24 1 sto0 No Intrastructure 124003 717 / Month 24 1 sto0 No Intrastructure 124003 717 / Month 24 1 sto0 No Intrastructure 126001 174 / Month 24 1 sto0 <td< td=""><td>Treatment Group Subject ID Tomunoreactivity Innunoreactivity Innunoreactivity Arcentment Group Subject ID 365 / Month 12 2 sty Tog Titer Diagnois 170010 365 / Month 12 1870 No 177006 358 / Month 24 2 sty Tog Titer Diagnois 177006 358 / Month 24 1870 Irrits 177006 358 / Month 24 19200 No 177006 358 / Month 24 1130 No 104002 717 / Month 24 1130 No 122002 359 / Month 24 1130 No 122002 359 / Month 24 1130 No 122003 717 / Month 24 1500 No 124003 723 / Month 24 1770 No 126001 174 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001 727 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001<td>Treatment Group Subject ID Assist Immunoreactivity Immunoreactivity</td><td>Treatment Group Runumoreactivity Immunoreactivity Immunoreactivity<!--</td--><td>Treatment Group Subject ID Assist Immunoreactivity Immunoreactivity</td><td>Treatment Group Subject ID Assist Immunoreactivity Immunoreactivity</td><td>Treatment Group Subject ID Tomunoreactivity Innunoreactivity Innunoreactivity Arcentment Group Subject ID 365 / Month 12 2 sty Tog Titer Diagnois 170010 365 / Month 12 1870 No 177006 358 / Month 24 2 sty Tog Titer Diagnois 177006 358 / Month 24 1870 Irrits 177006 358 / Month 24 19200 No 177006 358 / Month 24 1130 No 104002 717 / Month 24 1130 No 122002 359 / Month 24 1130 No 122002 359 / Month 24 1130 No 122003 717 / Month 24 1500 No 124003 723 / Month 24 1770 No 126001 174 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001 727 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001<td>Treatment Group Subject ID Tomunoreactivity Innunoreactivity Innunoreactivity Arcentment Group Subject ID 365 / Month 12 2 sty Tog Titer Diagnois 170010 365 / Month 12 1870 No 177006 358 / Month 24 2 sty Tog Titer Diagnois 177006 358 / Month 24 1870 Irrits 177006 358 / Month 24 19200 No 177006 358 / Month 24 1130 No 104002 717 / Month 24 1130 No 122002 359 / Month 24 1130 No 122002 359 / Month 24 1130 No 122003 717 / Month 24 1500 No 124003 723 / Month 24 1770 No 126001 174 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001 727 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001<td>Treatment Group Subject ID Tomunoreactivity Innunoreactivity Innunoreactivity Arcentment Group Subject ID 365 / Month 12 2 sty Tog Titer Diagnois 170010 365 / Month 12 1870 No 177006 358 / Month 24 2 sty Tog Titer Diagnois 177006 358 / Month 24 1870 Irrits 177006 358 / Month 24 19200 No 177006 358 / Month 24 1130 No 104002 717 / Month 24 1130 No 122002 359 / Month 24 1130 No 122002 359 / Month 24 1130 No 122003 717 / Month 24 1500 No 124003 723 / Month 24 1770 No 126001 174 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001 727 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001<td>Treatment Group Intransionesettivity Intransionesettivity Intransionesettivity ITeatment Group Subject ID Subject ID Ammunoresettivity Intransion Introl 355 / Month 12 2.800 No Introl Introl 355 / Month 12 1.870 Intris Introl Introl 358 / Month 24 1.870 Intris Intris Introl 717 / Month 24 1.870 No Intris Introl 722 / Month 24 1.130 No Introl Introl 723 / Month 24 1.1700 No Introl Introl 723 / Month 24 1.770 No No Introl 726 / Month 24 1.770 No No <</td><td>Treatment Group Rumunoreactivity Intramoreactivity Intraminition Affective Subject ID Assay Log Titer Diagnois 170010 365 / Month 12 2.800 No 177016 358 / Month 12 1.870 Iritis 177016 358 / Month 24 1.870 Iritis 177016 358 / Month 24 1.870 No 102001 721 / Month 24 1.870 No 102002 719 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 122002 359 / Month 24 1.770 No 122002 359 / Month 24 1.770 No 122003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 717 / Month 24 1.770 No 126001 357 / Month 24 1.770 No 126001 714 / Month 24 2.610 <td< td=""><td>Treatment Group Dointive Intransionation Treatment Group Subject ID Assay Log Titer Intransion 170010 365 / Month 12 2.770 No 170010 365 / Month 24 2.800 Iritis 177006 538 / Month 24 1.850 Iritis 177006 538 / Month 24 1.870 Iritis 177006 538 / Month 24 1.130 No 102001 722 / Month 24 1.130 No 102002 723 / Month 24 1.770 No 1122002 359 / Month 24 1.770 No 1224003 723 / Month 24 1.770 No 124003 714 / Month 24 1.770 No 124003 723 / Month 24 1.770 No</td><td>Treatment Group Positive Turnuoreactivity Infammation Areathient Group Subject ID Assay Log Ther Infammation 170010 365 / Month 24 2.770 No 170010 365 / Month 24 2.800 Infammation 170010 365 / Month 24 1.850 Infam 170010 358 / Month 24 1.870 Infam 177 Month 24 1.870 No No 102001 722 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 122002 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 126001 174 / Month 24 1.770 No 126001 725 / Month 24 1.940</td><td>Treatment Group Positive
Intranscripty Intranscripty Intranscripty Areatment Group Subject ID Assay Log Ther Infamoation 170010 365 / Month 12 2.770 No 170010 365 / Month 24 1.850 Infamoation 170010 365 / Month 24 1.850 No 177006 338 / Month 24 1.850 No 102001 722 / Month 24 1.130 No 102002 723 / Month 24 1.770 No
122002 357 / Month 24 1.770 No 124003 723 / Month 24 1.770</td><td>Treatment Group Subject ID Fositive
innumeractivity Innumoractivity
assive Log Titer Innumoractivity
infinitumation 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 170010 355 / Month 12 1.870 Inthia 170010 355 / Month 24 1.300 No 170001 722 / Month 24 1.140 No 122002 723 / Month 24 1.140 No 122002 723 / Month 24 1.140 No 124003 722 / Month 24 1.140 No 124003 722 / Month 24 1.770 No 12400 723 / Month 24 1.770 No 12400 723 / M</td></td<></td></td></td></td></td></td></td<> | Treatment Group Subject ID Tomunoreactivity Innunoreactivity Innunoreactivity Arcentment Group Subject ID 365 / Month 12 2 sty Tog Titer Diagnois 170010 365 / Month 12 1870 No 177006 358 / Month 24 2 sty Tog Titer Diagnois 177006 358 / Month 24 1870 Irrits 177006 358 / Month 24 19200 No 177006 358 / Month 24 1130 No 104002 717 / Month 24 1130 No 122002 359 / Month 24 1130 No 122002 359 / Month 24 1130 No 122003 717 / Month 24 1500 No 124003 723 / Month 24 1770 No 126001 174 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001 727 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001 <td>Treatment Group Subject ID Assist Immunoreactivity Immunoreactivity</td> <td>Treatment Group Runumoreactivity Immunoreactivity Immunoreactivity<!--</td--><td>Treatment Group Subject ID Assist Immunoreactivity Immunoreactivity</td><td>Treatment Group Subject ID Assist Immunoreactivity Immunoreactivity</td><td>Treatment Group Subject ID Tomunoreactivity Innunoreactivity Innunoreactivity Arcentment Group Subject ID 365 / Month 12 2 sty Tog Titer Diagnois 170010 365 / Month 12 1870 No 177006 358 / Month 24 2 sty Tog Titer Diagnois 177006 358 / Month 24 1870 Irrits 177006 358 / Month 24 19200 No 177006 358 / Month 24 1130 No 104002 717 / Month 24 1130 No 122002 359 / Month 24 1130 No 122002 359 / Month 24 1130 No 122003 717 / Month 24 1500 No 124003 723 / Month 24 1770 No 126001 174 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001 727 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001<td>Treatment Group Subject ID Tomunoreactivity Innunoreactivity Innunoreactivity Arcentment Group Subject ID 365 / Month 12 2 sty Tog Titer Diagnois 170010 365 / Month 12 1870 No 177006 358 / Month 24 2 sty Tog Titer Diagnois 177006 358 / Month 24 1870 Irrits 177006 358 / Month 24 19200 No 177006 358 / Month 24 1130 No 104002 717 / Month 24 1130 No 122002 359 / Month 24 1130 No 122002 359 / Month 24 1130 No 122003 717 / Month 24 1500 No 124003 723 / Month 24 1770 No 126001 174 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001 727 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001<td>Treatment Group Subject ID Tomunoreactivity Innunoreactivity Innunoreactivity Arcentment Group Subject ID 365 / Month 12 2 sty Tog Titer Diagnois 170010 365 / Month 12 1870 No 177006 358 / Month 24 2 sty Tog Titer Diagnois 177006 358 / Month 24 1870 Irrits 177006 358 / Month 24 19200 No 177006 358 / Month 24 1130 No 104002 717 / Month 24 1130 No 122002 359 / Month 24 1130 No 122002 359 / Month 24 1130 No 122003 717 / Month 24 1500 No 124003 723 / Month 24 1770 No 126001 174 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001 727 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001<td>Treatment Group Intransionesettivity Intransionesettivity Intransionesettivity ITeatment Group Subject ID Subject ID Ammunoresettivity Intransion Introl 355 / Month 12 2.800 No Introl Introl 355 / Month 12 1.870 Intris Introl Introl 358 / Month 24 1.870 Intris Intris Introl 717 / Month 24 1.870 No Intris Introl 722 / Month 24 1.130 No Introl Introl 723 / Month 24
 1.1700 No Introl Introl 723 / Month 24 1.770 No No Introl 726 / Month 24 1.770 No No <</td><td>Treatment Group Rumunoreactivity Intramoreactivity Intraminition Affective Subject ID Assay Log Titer Diagnois 170010 365 / Month 12 2.800 No 177016 358 / Month 12 1.870 Iritis 177016 358 / Month 24 1.870 Iritis 177016 358 / Month 24 1.870 No 102001 721 / Month 24 1.870 No 102002 719 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 122002 359 / Month 24 1.770 No 122002 359 / Month 24 1.770 No 122003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 717 / Month 24 1.770 No 126001 357 / Month 24 1.770 No 126001 714 / Month 24 2.610 <td< td=""><td>Treatment Group Dointive Intransionation Treatment Group Subject ID Assay Log Titer Intransion 170010 365 / Month 12 2.770 No 170010 365 / Month 24 2.800 Iritis 177006 538 / Month 24 1.850 Iritis 177006 538 / Month 24 1.870 Iritis 177006 538 / Month 24 1.130 No 102001 722 / Month 24 1.130 No 102002 723 / Month 24 1.770 No 1122002 359 / Month 24 1.770 No 1224003 723 / Month 24 1.770 No 124003 714 / Month 24 1.770 No 124003 723 / Month 24 1.770 No</td><td>Treatment Group Positive Turnuoreactivity Infammation Areathient Group Subject ID Assay Log Ther Infammation 170010 365 / Month 24 2.770 No 170010 365 / Month 24 2.800 Infammation 170010 365 / Month 24 1.850 Infam 170010 358 / Month 24 1.870 Infam 177 Month 24 1.870 No No 102001 722 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 122002 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 126001 174 / Month 24 1.770 No 126001 725 / Month 24 1.940</td><td>Treatment Group Positive
Intranscripty Intranscripty Intranscripty Areatment Group Subject ID Assay Log Ther Infamoation 170010 365 / Month 12 2.770 No 170010 365 / Month 24 1.850 Infamoation 170010 365 / Month 24 1.850 No 177006 338 / Month 24 1.850 No 102001 722 / Month 24 1.130 No 102002 723 / Month 24 1.770 No 122002 357 / Month 24 1.770 No 124003 723 / Month 24 1.770</td><td>Treatment Group Subject ID Fositive
innumeractivity Innumoractivity
assive Log Titer Innumoractivity
infinitumation 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 170010 355 / Month 12 1.870 Inthia 170010 355 / Month 24 1.300 No 170001 722 / Month 24 1.140 No 122002 723 / Month 24 1.140 No 122002 723 / Month 24 1.140 No 124003 722 / Month 24 1.140 No 124003 722 / Month 24 1.770 No 12400 723 / Month 24 1.770 No 12400 723 / M</td></td<></td></td></td></td></td> | Treatment Group Subject ID Assist Immunoreactivity

 | Treatment Group Runumoreactivity Immunoreactivity Immunoreactivity </td <td>Treatment Group Subject ID Assist Immunoreactivity Immunoreactivity</td> <td>Treatment Group Subject ID Assist Immunoreactivity Immunoreactivity</td> <td>Treatment Group Subject ID Tomunoreactivity Innunoreactivity Innunoreactivity Arcentment Group Subject ID 365 / Month 12 2 sty Tog Titer Diagnois 170010 365 / Month 12 1870 No 177006 358 / Month 24 2 sty Tog Titer Diagnois 177006 358 / Month 24 1870 Irrits 177006 358 / Month 24 19200 No 177006 358 / Month 24 1130 No 104002 717 / Month 24 1130 No 122002 359 / Month 24 1130 No 122002 359 / Month 24 1130 No 122003 717 / Month 24 1500 No 124003 723 / Month 24 1770 No 126001 174 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001 727 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001<td>Treatment Group Subject ID Tomunoreactivity Innunoreactivity Innunoreactivity Arcentment Group Subject ID 365 / Month 12 2 sty Tog Titer Diagnois 170010 365 / Month 12 1870 No 177006 358 / Month 24 2 sty Tog Titer Diagnois 177006 358 / Month 24 1870 Irrits 177006 358 / Month 24 19200 No 177006 358 / Month 24 1130 No 104002 717 / Month 24 1130 No 122002 359 / Month 24 1130 No 122002 359 / Month 24 1130 No 122003 717 / Month 24 1500 No 124003 723 / Month 24 1770 No 126001 174 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001 727 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001<td>Treatment Group Subject ID Tomunoreactivity Innunoreactivity Innunoreactivity Arcentment Group Subject ID 365 / Month 12 2 sty Tog Titer Diagnois 170010 365 / Month 12 1870 No 177006 358 / Month 24 2 sty Tog Titer Diagnois 177006 358 / Month 24 1870 Irrits 177006 358 / Month 24 19200 No 177006 358 / Month 24 1130 No 104002 717 / Month 24 1130 No 122002 359 / Month 24 1130 No 122002 359 / Month 24 1130 No 122003 717 / Month 24 1500 No 124003 723 / Month 24 1770 No 126001 174 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001 727 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001<td>Treatment Group Intransionesettivity Intransionesettivity Intransionesettivity ITeatment Group Subject ID Subject ID Ammunoresettivity Intransion Introl 355 / Month 12 2.800 No Introl Introl 355 / Month 12 1.870 Intris Introl Introl 358 / Month 24 1.870 Intris Intris Introl 717 / Month 24 1.870 No Intris Introl 722 / Month 24 1.130 No Introl Introl 723 / Month 24 1.1700 No Introl Introl 723 / Month 24 1.770 No No Introl 726 / Month 24 1.770 No No <</td><td>Treatment Group Rumunoreactivity Intramoreactivity Intraminition Affective Subject ID Assay Log Titer Diagnois 170010 365 / Month 12 2.800 No 177016 358 / Month 12 1.870 Iritis 177016 358 / Month 24 1.870 Iritis 177016 358 / Month 24 1.870 No 102001 721 / Month 24 1.870 No 102002 719 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 122002 359 / Month 24 1.770 No 122002 359 / Month 24 1.770 No 122003 723 / Month 24 1.770
 No 124003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 717 / Month 24 1.770 No 126001 357 / Month 24 1.770 No 126001 714 / Month 24 2.610 <td< td=""><td>Treatment Group Dointive Intransionation Treatment Group Subject ID Assay Log Titer Intransion 170010 365 / Month 12 2.770 No 170010 365 / Month 24 2.800 Iritis 177006 538 / Month 24 1.850 Iritis 177006 538 / Month 24 1.870 Iritis 177006 538 / Month 24 1.130 No 102001 722 / Month 24 1.130 No 102002 723 / Month 24 1.770 No 1122002 359 / Month 24 1.770 No 1224003 723 / Month 24 1.770 No 124003 714 / Month 24 1.770 No 124003 723 / Month 24 1.770 No</td><td>Treatment Group Positive Turnuoreactivity Infammation Areathient Group Subject ID Assay Log Ther Infammation 170010 365 / Month 24 2.770 No 170010 365 / Month 24 2.800 Infammation 170010 365 / Month 24 1.850 Infam 170010 358 / Month 24 1.870 Infam 177 Month 24 1.870 No No 102001 722 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 122002 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 126001 174 / Month 24 1.770 No 126001 725 / Month 24 1.940</td><td>Treatment Group Positive
Intranscripty Intranscripty Intranscripty Areatment Group Subject ID Assay Log Ther Infamoation 170010 365 / Month 12 2.770 No 170010 365 / Month 24 1.850 Infamoation 170010 365 / Month 24 1.850 No 177006 338 / Month 24 1.850 No 102001 722 / Month 24 1.130 No 102002 723 / Month 24 1.770 No 122002 357 / Month 24 1.770 No 124003 723 / Month 24 1.770</td><td>Treatment Group Subject ID Fositive
innumeractivity Innumoractivity
assive Log Titer Innumoractivity
infinitumation 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 170010 355 / Month 12 1.870 Inthia 170010 355 / Month 24 1.300 No 170001 722 / Month 24 1.140 No 122002 723 / Month 24 1.140 No 122002 723 / Month 24 1.140 No 124003 722 / Month 24 1.140 No 124003 722 / Month 24 1.770 No 12400 723 / Month 24 1.770 No 12400 723 / M</td></td<></td></td></td></td> | Treatment Group Subject ID Assist Immunoreactivity
 | Treatment Group Subject ID Assist Immunoreactivity

 | Treatment Group Subject ID Tomunoreactivity Innunoreactivity Innunoreactivity Arcentment Group Subject ID 365 / Month 12 2 sty Tog Titer Diagnois 170010 365 / Month 12 1870 No 177006 358 / Month 24 2 sty Tog Titer Diagnois 177006 358 / Month 24 1870 Irrits 177006 358 / Month 24 19200 No 177006 358 / Month 24 1130 No 104002 717 / Month 24 1130 No 122002 359 / Month 24 1130 No 122002 359 / Month 24 1130 No 122003 717 / Month 24 1500 No 124003 723 / Month 24 1770 No 126001 174 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001 727 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001 <td>Treatment Group Subject ID Tomunoreactivity Innunoreactivity Innunoreactivity Arcentment Group Subject ID 365 / Month 12 2 sty Tog Titer Diagnois 170010 365 / Month 12 1870 No 177006 358 / Month 24 2 sty Tog Titer Diagnois 177006 358 / Month 24 1870 Irrits 177006 358 / Month 24 19200 No 177006 358 / Month 24 1130 No 104002 717 / Month 24 1130 No 122002 359 / Month 24 1130 No 122002 359 / Month 24 1130 No 122003 717 / Month 24 1500 No 124003 723 / Month 24 1770 No 126001 174 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001 727 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001<td>Treatment Group Subject ID Tomunoreactivity Innunoreactivity Innunoreactivity Arcentment Group Subject ID 365 / Month 12 2 sty Tog Titer Diagnois 170010 365 / Month 12 1870 No 177006 358 / Month 24 2 sty Tog Titer Diagnois 177006 358 / Month 24 1870 Irrits 177006 358 / Month 24 19200 No 177006 358 / Month 24 1130 No 104002 717 / Month 24 1130 No 122002 359 / Month 24 1130 No 122002 359 / Month 24 1130 No 122003 717 / Month 24 1500 No 124003 723 / Month 24 1770 No 126001 174 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001 727 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001<td>Treatment Group Intransionesettivity Intransionesettivity Intransionesettivity ITeatment Group Subject ID Subject ID Ammunoresettivity Intransion Introl 355 / Month 12 2.800 No Introl Introl 355 / Month 12 1.870 Intris Introl Introl 358 / Month 24 1.870 Intris Intris Introl 717 / Month 24 1.870 No Intris Introl 722 / Month 24 1.130 No Introl Introl 723 / Month 24 1.1700 No Introl Introl 723 / Month 24 1.770 No No Introl 726 / Month 24 1.770 No No <</td><td>Treatment Group Rumunoreactivity Intramoreactivity Intraminition Affective Subject ID Assay Log Titer Diagnois 170010 365 / Month 12 2.800 No 177016 358 / Month 12 1.870 Iritis 177016 358 / Month 24 1.870 Iritis 177016 358 / Month 24 1.870 No 102001 721 / Month 24 1.870 No 102002 719 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 122002 359 / Month 24 1.770 No 122002 359 / Month 24 1.770 No 122003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 717 / Month 24 1.770 No 126001 357 / Month 24 1.770 No 126001 714 / Month 24 2.610 <td< td=""><td>Treatment Group Dointive Intransionation Treatment Group Subject ID Assay Log Titer Intransion 170010 365 / Month 12 2.770 No 170010 365 / Month 24 2.800 Iritis 177006 538 / Month 24 1.850 Iritis 177006 538 / Month 24 1.870 Iritis 177006 538 / Month 24 1.130 No 102001 722 / Month 24 1.130 No 102002 723 / Month 24 1.770 No 1122002 359 / Month 24 1.770 No 1224003 723 / Month 24 1.770 No 124003 714 / Month 24 1.770 No 124003 723 / Month 24 1.770 No</td><td>Treatment Group Positive Turnuoreactivity Infammation Areathient Group Subject ID Assay Log Ther Infammation 170010 365 / Month 24 2.770 No 170010 365 / Month 24 2.800 Infammation 170010 365 / Month 24 1.850 Infam 170010 358 / Month 24 1.870 Infam 177 Month 24 1.870 No No 102001 722 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 122002 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 126001 174 / Month 24 1.770 No 126001 725 / Month 24 1.940</td><td>Treatment Group Positive
Intranscripty Intranscripty Intranscripty Areatment Group Subject ID Assay Log Ther Infamoation 170010 365 / Month 12 2.770 No 170010 365 / Month 24 1.850 Infamoation 170010 365 / Month 24 1.850 No 177006 338 / Month 24 1.850 No 102001 722 / Month 24 1.130 No 102002 723 / Month 24 1.770 No 122002 357 / Month 24 1.770 No 124003 723 / Month 24 1.770</td><td>Treatment Group Subject ID Fositive
innumeractivity Innumoractivity
assive Log Titer Innumoractivity
infinitumation 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 170010 355 / Month 12 1.870 Inthia 170010 355 /
Month 24 1.300 No 170001 722 / Month 24 1.140 No 122002 723 / Month 24 1.140 No 122002 723 / Month 24 1.140 No 124003 722 / Month 24 1.140 No 124003 722 / Month 24 1.770 No 12400 723 / Month 24 1.770 No 12400 723 / M</td></td<></td></td></td> | Treatment Group Subject ID Tomunoreactivity Innunoreactivity Innunoreactivity Arcentment Group Subject ID 365 / Month 12 2 sty Tog Titer Diagnois 170010 365 / Month 12 1870 No 177006 358 / Month 24 2 sty Tog Titer Diagnois 177006 358 / Month 24 1870 Irrits 177006 358 / Month 24 19200 No 177006 358 / Month 24 1130 No 104002 717 / Month 24 1130 No 122002 359 / Month 24 1130 No 122002 359 / Month 24 1130 No 122003 717 / Month 24 1500 No 124003 723 / Month 24 1770 No 126001 174 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001 727 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001 <td>Treatment Group Subject ID Tomunoreactivity Innunoreactivity Innunoreactivity Arcentment Group Subject ID 365 / Month 12 2 sty Tog Titer Diagnois 170010 365 / Month 12 1870 No 177006 358 / Month 24 2 sty Tog Titer Diagnois 177006 358 / Month 24 1870 Irrits 177006 358 / Month 24 19200 No 177006 358 / Month 24 1130 No 104002 717 / Month 24 1130 No 122002 359 / Month 24 1130 No 122002 359 / Month 24 1130 No 122003 717 / Month 24 1500 No 124003 723 / Month 24 1770 No 126001 174 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001 727 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001<td>Treatment Group Intransionesettivity Intransionesettivity Intransionesettivity ITeatment Group Subject ID Subject ID Ammunoresettivity Intransion Introl 355 / Month 12 2.800 No Introl Introl 355 / Month 12 1.870 Intris Introl Introl 358 / Month 24 1.870 Intris Intris Introl 717 / Month 24 1.870 No Intris Introl 722 / Month 24 1.130 No Introl Introl 723 / Month 24 1.1700 No Introl Introl 723 / Month 24 1.770 No No Introl 726 / Month 24 1.770 No No <</td><td>Treatment Group Rumunoreactivity Intramoreactivity Intraminition Affective Subject ID Assay Log Titer Diagnois 170010 365 / Month 12 2.800 No 177016 358 / Month 12 1.870 Iritis 177016 358 / Month 24 1.870 Iritis 177016 358 / Month 24 1.870 No 102001 721 / Month 24 1.870 No 102002 719 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 122002 359 / Month 24 1.770 No 122002 359 / Month 24 1.770 No 122003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 717 / Month 24 1.770 No 126001 357 / Month 24 1.770 No 126001 714 / Month 24 2.610 <td< td=""><td>Treatment Group Dointive Intransionation Treatment Group Subject ID Assay Log Titer Intransion 170010 365 / Month 12 2.770 No 170010 365 / Month 24 2.800 Iritis 177006 538 / Month 24 1.850 Iritis 177006 538 / Month 24 1.870 Iritis 177006 538 / Month 24 1.130 No 102001 722 / Month 24 1.130 No 102002 723 / Month 24 1.770 No 1122002 359 / Month 24 1.770 No 1224003 723 / Month 24 1.770 No 124003 714 / Month 24 1.770 No 124003 723 / Month 24 1.770 No</td><td>Treatment Group Positive Turnuoreactivity Infammation Areathient Group Subject ID Assay Log Ther Infammation 170010 365 / Month 24 2.770 No 170010 365 / Month 24 2.800 Infammation 170010 365 / Month 24 1.850 Infam 170010 358 / Month 24 1.870 Infam 177 Month 24 1.870 No No 102001 722 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 122002 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 126001 174 / Month 24 1.770 No 126001 725 / Month 24 1.940</td><td>Treatment Group Positive
Intranscripty Intranscripty Intranscripty Areatment Group Subject ID Assay Log Ther Infamoation 170010 365 / Month 12 2.770 No 170010 365 / Month 24 1.850 Infamoation 170010 365 / Month 24 1.850 No 177006 338 / Month 24 1.850 No 102001 722 /
Month 24 1.130 No 102002 723 / Month 24 1.770 No 122002 357 / Month 24 1.770 No 124003 723 / Month 24 1.770</td><td>Treatment Group Subject ID Fositive
innumeractivity Innumoractivity
assive Log Titer Innumoractivity
infinitumation 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 170010 355 / Month 12 1.870 Inthia 170010 355 / Month 24 1.300 No 170001 722 / Month 24 1.140 No 122002 723 / Month 24 1.140 No 122002 723 / Month 24 1.140 No 124003 722 / Month 24 1.140 No 124003 722 / Month 24 1.770 No 12400 723 / Month 24 1.770 No 12400 723 / M</td></td<></td></td> | Treatment Group Subject ID Tomunoreactivity Innunoreactivity Innunoreactivity Arcentment Group Subject ID 365 / Month 12 2 sty Tog Titer Diagnois 170010 365 / Month 12 1870 No 177006 358 / Month 24 2 sty Tog Titer Diagnois 177006 358 / Month 24 1870 Irrits 177006 358 / Month 24 19200 No 177006 358 / Month 24 1130 No 104002 717 / Month 24 1130 No 122002 359 / Month 24 1130 No 122002 359 / Month 24 1130 No 122003 717 / Month 24 1500 No 124003 723 / Month 24 1770 No 126001 174 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001 727 / Month 24 1630 No 126001 717 / Month 24 1630 No 126001 <td>Treatment Group Intransionesettivity Intransionesettivity Intransionesettivity ITeatment Group Subject ID Subject ID Ammunoresettivity Intransion Introl 355 / Month 12 2.800 No Introl Introl 355 / Month 12 1.870 Intris Introl Introl 358 / Month 24 1.870 Intris Intris Introl 717 / Month 24 1.870 No Intris Introl 722 / Month 24 1.130 No Introl Introl 723 / Month 24 1.1700 No Introl Introl 723 / Month 24 1.770 No No Introl 726 / Month 24 1.770 No No <</td> <td>Treatment Group Rumunoreactivity Intramoreactivity Intraminition Affective Subject ID Assay Log Titer Diagnois 170010 365 / Month 12 2.800 No 177016 358 / Month 12 1.870 Iritis 177016 358 / Month 24 1.870 Iritis 177016 358 / Month 24 1.870 No 102001 721 / Month 24 1.870 No 102002 719 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 122002 359 / Month 24 1.770 No 122002 359 / Month 24 1.770 No 122003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 717 / Month 24 1.770 No 126001 357 / Month 24 1.770 No 126001 714 / Month 24 2.610 <td< td=""><td>Treatment Group Dointive Intransionation Treatment Group Subject ID Assay Log Titer Intransion 170010 365 / Month 12 2.770 No 170010 365 / Month 24 2.800 Iritis 177006 538 / Month 24 1.850 Iritis 177006 538 / Month 24 1.870 Iritis 177006 538 / Month 24 1.130 No 102001 722 / Month 24 1.130 No 102002 723 / Month 24 1.770 No 1122002 359 / Month 24 1.770 No 1224003 723 / Month 24 1.770 No 124003 714 / Month 24 1.770 No 124003 723 / Month 24 1.770 No</td><td>Treatment Group Positive Turnuoreactivity Infammation Areathient Group Subject ID Assay Log Ther Infammation 170010 365 / Month 24 2.770 No 170010 365 / Month 24 2.800 Infammation 170010 365 / Month 24 1.850 Infam 170010 358 / Month 24 1.870 Infam 177 Month 24 1.870 No No 102001 722 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 122002 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 126001 174 / Month 24 1.770 No 126001 725 / Month 24 1.940</td><td>Treatment Group Positive
Intranscripty Intranscripty Intranscripty Areatment Group Subject ID Assay Log Ther Infamoation 170010 365 / Month 12 2.770 No 170010 365 / Month 24 1.850 Infamoation 170010 365 / Month 24 1.850 No 177006 338 / Month 24 1.850 No 102001 722 / Month 24 1.130 No 102002 723 / Month 24 1.770 No 122002 357 / Month 24 1.770 No 124003 723 / Month 24 1.770</td><td>Treatment Group Subject ID Fositive
innumeractivity Innumoractivity
assive Log Titer Innumoractivity
infinitumation 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 170010 355 / Month 12 1.870 Inthia 170010 355 / Month 24 1.300 No 170001 722 / Month 24 1.140 No 122002 723 / Month 24 1.140 No 122002 723 / Month 24 1.140 No 124003 722 / Month 24
1.140 No 124003 722 / Month 24 1.770 No 12400 723 / Month 24 1.770 No 12400 723 / M</td></td<></td> | Treatment Group Intransionesettivity Intransionesettivity Intransionesettivity ITeatment Group Subject ID Subject ID Ammunoresettivity Intransion Introl 355 / Month 12 2.800 No Introl Introl 355 / Month 12 1.870 Intris Introl Introl 358 / Month 24 1.870 Intris Intris Introl 717 / Month 24 1.870 No Intris Introl 722 / Month 24 1.130 No Introl Introl 723 / Month 24 1.1700 No Introl Introl 723 / Month 24 1.770 No No Introl 726 / Month 24 1.770 No No <
 | Treatment Group Rumunoreactivity Intramoreactivity Intraminition Affective Subject ID Assay Log Titer Diagnois 170010 365 / Month 12 2.800 No 177016 358 / Month 12 1.870 Iritis 177016 358 / Month 24 1.870 Iritis 177016 358 / Month 24 1.870 No 102001 721 / Month 24 1.870 No 102002 719 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 122002 359 / Month 24 1.770 No 122002 359 / Month 24 1.770 No 122003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 717 / Month 24 1.770 No 126001 357 / Month 24 1.770 No 126001 714 / Month 24 2.610 <td< td=""><td>Treatment Group Dointive Intransionation Treatment Group Subject ID Assay Log Titer Intransion 170010 365 / Month 12 2.770 No 170010 365 / Month 24 2.800 Iritis 177006 538 / Month 24 1.850 Iritis 177006 538 / Month 24 1.870 Iritis 177006 538 / Month 24 1.130 No 102001 722 / Month 24 1.130 No 102002 723 / Month 24 1.770 No 1122002 359 / Month 24 1.770 No 1224003 723 / Month 24 1.770 No 124003 714 / Month 24 1.770 No 124003 723 / Month 24 1.770 No</td><td>Treatment Group Positive Turnuoreactivity Infammation Areathient Group Subject ID Assay Log Ther Infammation 170010 365 / Month 24 2.770 No 170010 365 / Month 24 2.800 Infammation 170010 365 / Month 24 1.850 Infam 170010 358 / Month 24 1.870 Infam 177 Month 24 1.870 No No 102001 722 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 122002 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 126001 174 / Month 24 1.770 No 126001 725 / Month 24 1.940</td><td>Treatment Group Positive
Intranscripty Intranscripty Intranscripty Areatment Group Subject ID Assay Log Ther Infamoation 170010 365 / Month 12 2.770 No 170010 365 / Month 24 1.850 Infamoation 170010 365 / Month 24 1.850 No 177006 338 / Month 24 1.850 No 102001 722 / Month 24 1.130 No 102002 723 / Month 24 1.770 No 122002 357 / Month 24 1.770 No 124003 723 / Month 24 1.770</td><td>Treatment Group Subject ID Fositive
innumeractivity Innumoractivity
assive Log Titer Innumoractivity
infinitumation 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 170010 355 / Month 12 1.870 Inthia 170010 355 / Month 24 1.300 No 170001 722 / Month 24 1.140 No 122002 723 / Month 24 1.140 No 122002 723 / Month 24 1.140 No 124003 722 / Month 24 1.140 No 124003 722 / Month 24 1.770 No 12400 723 / Month 24 1.770 No 12400 723 / M</td></td<> | Treatment Group Dointive Intransionation Treatment Group Subject ID Assay Log Titer Intransion 170010 365 / Month 12 2.770 No 170010 365 / Month 24 2.800 Iritis 177006 538 / Month 24 1.850 Iritis 177006 538 / Month 24 1.870 Iritis 177006 538 / Month 24 1.130 No 102001 722 / Month 24 1.130 No 102002 723 / Month 24 1.770 No 1122002 359 / Month 24 1.770 No 1224003 723 / Month 24 1.770 No 124003 714 / Month 24 1.770 No 124003 723 / Month 24 1.770 No
 | Treatment Group Positive Turnuoreactivity Infammation Areathient Group Subject ID Assay Log Ther Infammation 170010 365 / Month 24 2.770 No 170010 365 / Month 24 2.800 Infammation 170010 365 / Month 24 1.850 Infam 170010 358 / Month 24 1.870 Infam 177 Month 24 1.870 No No 102001 722 / Month 24 1.130 No 122002 359 / Month 24 1.770 No 122002 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 126001 174 / Month 24 1.770 No 126001 725 / Month 24 1.940 | Treatment Group Positive
Intranscripty Intranscripty Intranscripty Areatment Group Subject ID Assay Log Ther Infamoation 170010 365 / Month 12 2.770 No 170010 365 / Month 24 1.850 Infamoation 170010 365 / Month 24 1.850 No 177006 338 / Month 24 1.850 No 102001 722 / Month 24 1.130 No 102002 723 / Month 24 1.770 No 122002 357 / Month 24 1.770 No 124003 723 / Month 24 1.770 | Treatment Group Subject ID Fositive
innumeractivity Innumoractivity
assive Log Titer Innumoractivity
infinitumation 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 170010 355 / Month 12 1.870 Inthia 170010 355 / Month 24 1.300 No 170001 722 / Month 24 1.140 No 122002 723 / Month 24 1.140 No 122002 723 / Month 24 1.140 No 124003 722 / Month 24 1.140 No 124003 722 / Month 24 1.770 No 12400 723 / Month 24 1.770 No 12400 723 / M |
|

 |

 |

 | Treatment Group Intranscriptive Intranscription Arrent/Forup Subject ID Assey Log Titler Intranscription 170010 365 / Month 12 Assey Log Titler Diagnois 177006 358 / Month 12 1870 Irritis 177016 358 / Month 12 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 717 / Month 24 1870 Irritis 117006 359 / Month 24 1130 No 122002 359 / Month 24 1130 No 124001 722 / Month 24 1130 No 124003 727 / Month 24 1630 No 124003 727 / Month 24 1770 No 124003 727 / Month 24 1630 No 124003 727 / Month 24 1630 No 126001 717 / Month 24 1630 No 125004 818 / Month 24 1640 No

 | Treatment Group Subject ID Immunoreactivity Immunoreactivity Immunoreactivity Arrent Group Subject ID 365 / Month 12 Xarsy Log Titer Diagnois 170010 365 / Month 12 1870 No 177006 358 / Month 24 2800 No 177006 358 / Month 24
 1870 Irrits 177006 358 / Month 24 1870 Irrits 177006 358 / Month 24 1130 No 104002 717 / Month 24 1130 No 102001 722 / Month 24 1130 No 122002 359 / Month 24 11700 No 124003 722 / Month 24 17700 No 124003 723 / Month 24 17700 No 124003 723 / Month 24 17700 No 125004 353 / Month 12 1630 No 126001 717 / Month 24 1770 No 126001 722 / Month 24 1940 No 125004 <td< td=""><td>Treatment Group Subject ID Assisty Immunoreactivity <th< td=""><td>Treatment Group Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 Xasy Log Titer Diagnois 170010 365 / Month 24 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 715 / Month 24 1130 No 102002 722 / Month 24 1130 No 122002 359 / Month 24 1130 No 124003 722 / Month 24 1130 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 126001 174 / Month 24 1700 No 126001 722 / Month 24 1700 No 126001 723 / Month 24 1600 No 12</td><td>Treatment Group Runtumoreactivity Immunoreactivity Immunoreactivity<</td><td>Treatment Group Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 Xasy Log Titer Diagnois 170010 365 / Month 24 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 715 / Month 24 1130 No 102002 722 / Month 24 1130 No 122002 359 / Month 24 1130 No 124003 722 / Month 24 1130 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 126001 174 / Month 24 1700 No 126001 722 / Month 24 1700 No 126001 723 / Month 24 1600 No 12</td><td>Treatment Group Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 Xasy Log Titer Diagnois 170010 365 / Month 24 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 715 / Month 24 1130 No 102002 722 / Month 24 1130 No 122002 359 / Month 24 1130 No 124003 722 / Month 24 1130 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 126001 174 / Month 24 1700 No 126001 722 / Month 24 1700 No 126001 723 / Month 24 1600 No 12</td><td>Treatment Group Subject ID Assisty Immunoreactivity <th< td=""><td>Treatment Group Subject ID Assisty Immunoreactivity <th< td=""><td>Treatment Group Subject ID Assisty Immunoreactivity <th< td=""><td>Treatment Group Intranscriptive Intranscription Arrent/Forup Subject ID Assey Log Titler Intranscription 170010 365 / Month 12 Assey Log Titler Diagnois 177006 358 / Month 12 1870 Irritis 177016 358 / Month 12 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 717 / Month 24 1870 Irritis 117006 359 / Month 24 1130 No 122002 359 / Month 24 1130 No 124001 722 / Month 24 1130 No 124003 727 / Month 24 1630 No 124003 727 / Month 24 1770 No 124003 727 / Month 24 1630 No 124003 727 / Month 24 1630 No 126001 717 / Month 24 1630 No 125004 818 / Month 24 1640 No</td><td>Treatment Group Subject ID Tommunoreactivity Intransition Arrentment Group Subject ID Ammunoreactivity Intraminition 170010 365 / Month 12 2800 No 177016 358 / Month 12 2800 No 177016 358 / Month 12 1870 Irritis 177016 358 / Month 24 1130 No 1177006 358 / Month 24 1130 No 1177006 358 / Month 24 1130 No 117700 717 / Month 24 1130 No 122002 359 / Month 24 1130 No 124001 727 / Month 24 1130 No 124003 727 / Month 24 1630 No 124001 727 / Month 24 1640 No 126001 727 / Month 24 1640 No</td><td>Treatment Group Rolitive
Subject ID Rominization
Asiay Intranuoreactivity
Asiay Log Titer Intranuoreactivity
Intramation Intranuoreactivity
Asiay Log Titer Intranuoreactivity
Intramation Ranibizumab 0.5 mg 177006 355 / Month 12 1.870 Intras Ranibizumab 0.5 mg 177006 358 / Month 12 1.870 Intras 170010 355 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 122002 357 / Month 24 1.130 No 124003 723 / Month 24 1.130 No 124003 723 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 125004 357 / Month 24 2.610 Vitritits 12304 715 / Month 24 2.610 No 12400 722 / Month 24 2.610 No 125004 365 / Month 12 1.940</td><td>Treatment Group Positive
served viry Intranuoreactivity Intranuoreactivity Intranuoreactivity Intranustion
Assay 170010 365 / Month 12 2700 No 170010 365 / Month 12 2800 Iritis 170010 365 / Month 12 1870 Iritis 170010 355 / Month 24 1130 No 177 / Month 24 1130 No No 122002 359 / Month 24 1130 No 122002 357 / Month 24 1130 No 124003 722 / Month 24 1130 No 124003 723 / Month 24 1300 No 124003 727 / Month 24 1300 No 124003 727 / Month 24 1300 No 124003 727 / Month 24 1300 No 124013 715 / Month 24 1300 No 12504 357 / Month 24 2610 Virmits 12400 722 / Month 24 1600 No 12400 726</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td><td>Treatment Group Environment of timmunoreactivity Immunoreactivity Im</td></th<></td></th<></td></th<></td></th<></td></td<>
 | Treatment Group Subject ID Assisty Immunoreactivity Immunoreactivity <th< td=""><td>Treatment Group Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 Xasy Log Titer Diagnois 170010 365 / Month 24 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 715 / Month 24 1130 No 102002 722 / Month 24 1130 No 122002 359 / Month 24 1130 No 124003 722 / Month 24 1130 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 126001 174 / Month 24 1700 No 126001 722 / Month 24 1700 No 126001 723 / Month 24 1600 No 12</td><td>Treatment Group Runtumoreactivity Immunoreactivity Immunoreactivity<</td><td>Treatment Group Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 Xasy Log Titer Diagnois 170010 365 / Month 24 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 715 / Month 24 1130 No 102002 722 / Month 24 1130 No 122002 359 / Month 24 1130 No 124003 722 / Month 24 1130 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 126001 174 / Month 24 1700 No 126001 722 / Month 24 1700 No 126001 723 / Month 24 1600 No 12</td><td>Treatment Group Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 Xasy Log Titer Diagnois 170010 365 / Month 24 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 715 / Month 24 1130 No 102002 722 / Month 24 1130 No 122002 359 / Month 24 1130 No 124003 722 / Month 24 1130 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 126001 174 / Month 24 1700 No 126001 722 / Month 24 1700 No 126001 723 / Month 24 1600 No 12</td><td>Treatment Group Subject ID Assisty Immunoreactivity <th< td=""><td>Treatment Group Subject ID Assisty Immunoreactivity <th< td=""><td>Treatment Group Subject ID Assisty Immunoreactivity <th< td=""><td>Treatment Group Intranscriptive Intranscription Arrent/Forup Subject ID Assey Log Titler Intranscription 170010 365 / Month 12 Assey Log Titler Diagnois 177006 358 / Month 12 1870 Irritis 177016 358 / Month 12 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 717 / Month 24 1870 Irritis 117006 359 / Month 24 1130 No 122002 359 / Month 24 1130 No 124001 722 / Month 24 1130 No 124003 727 / Month 24 1630 No 124003 727 / Month 24 1770 No 124003 727 / Month 24 1630 No 124003 727 / Month 24 1630 No 126001 717 / Month 24 1630 No 125004 818 / Month 24 1640 No</td><td>Treatment Group Subject ID Tommunoreactivity Intransition Arrentment Group Subject ID Ammunoreactivity Intraminition 170010 365 / Month 12 2800 No 177016 358 / Month 12 2800 No 177016 358 / Month 12 1870 Irritis 177016 358 / Month 24 1130 No 1177006 358 / Month 24 1130 No 1177006 358 / Month 24 1130 No 117700 717 / Month 24 1130 No 122002 359 / Month 24 1130 No 124001 727 / Month 24 1130 No 124003 727 / Month 24 1630 No 124001 727 / Month 24 1640 No 126001 727 / Month 24 1640 No</td><td>Treatment Group Rolitive
Subject ID Rominization
Asiay Intranuoreactivity
Asiay Log Titer Intranuoreactivity
Intramation Intranuoreactivity
Asiay Log Titer Intranuoreactivity
Intramation Ranibizumab 0.5 mg 177006 355 / Month 12 1.870 Intras Ranibizumab 0.5 mg 177006 358 / Month 12 1.870 Intras 170010 355 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 122002 357 / Month 24 1.130 No 124003 723 / Month 24 1.130 No 124003 723 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 125004 357 / Month 24 2.610 Vitritits 12304 715 / Month 24 2.610 No 12400 722 / Month 24 2.610 No 125004 365 / Month 12 1.940</td><td>Treatment Group Positive
served viry Intranuoreactivity Intranuoreactivity Intranuoreactivity Intranustion
Assay 170010 365 / Month 12 2700 No 170010 365 / Month 12 2800 Iritis 170010 365 / Month 12 1870 Iritis 170010 355 / Month 24 1130 No 177 / Month 24 1130 No No 122002 359 / Month 24 1130 No 122002 357 / Month 24 1130 No 124003 722 / Month 24 1130 No 124003 723 / Month 24 1300 No 124003 727 / Month 24 1300 No 124003 727 / Month 24 1300 No 124003 727 / Month 24 1300
 No 124013 715 / Month 24 1300 No 12504 357 / Month 24 2610 Virmits 12400 722 / Month 24 1600 No 12400 726</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td><td>Treatment Group Environment of timmunoreactivity Immunoreactivity Im</td></th<></td></th<></td></th<></td></th<> | Treatment Group Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 Xasy Log Titer Diagnois 170010 365 / Month 24 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 715 / Month 24 1130 No 102002 722 / Month 24 1130 No 122002 359 / Month 24 1130 No 124003 722 / Month 24 1130 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 126001 174 / Month 24 1700 No 126001 722 / Month 24 1700 No 126001 723 / Month 24 1600 No 12

 | Treatment Group Runtumoreactivity Immunoreactivity Immunoreactivity<
 | Treatment Group Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 Xasy Log Titer Diagnois 170010 365 / Month 24 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 715 / Month 24 1130 No 102002 722 / Month 24 1130 No 122002 359 / Month 24 1130 No 124003 722 / Month 24 1130 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 126001 174 / Month 24 1700 No 126001 722 / Month 24 1700 No 126001 723 / Month 24 1600 No 12

 | Treatment Group Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 Xasy Log Titer Diagnois 170010 365 / Month 24 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 715 / Month 24 1130 No 102002 722 / Month 24 1130 No 122002 359 / Month 24 1130 No 124003 722 / Month 24 1130 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 124003 722 / Month 24 1700 No 126001 174 / Month 24 1700 No 126001 722 / Month 24 1700 No 126001 723 / Month 24 1600 No 12
 | Treatment Group Subject ID Assisty Immunoreactivity Immunoreactivity <th< td=""><td>Treatment Group Subject ID Assisty Immunoreactivity <th< td=""><td>Treatment Group Subject ID Assisty Immunoreactivity <th< td=""><td>Treatment Group Intranscriptive Intranscription Arrent/Forup Subject ID Assey Log Titler Intranscription 170010 365 / Month 12 Assey Log Titler Diagnois 177006 358 / Month 12 1870 Irritis 177016 358 / Month 12 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 717 / Month 24 1870 Irritis 117006 359 / Month 24 1130 No 122002 359 / Month 24 1130 No 124001 722 / Month 24 1130 No 124003 727 / Month 24 1630 No 124003 727 / Month 24 1770 No 124003 727 / Month 24 1630 No 124003 727 / Month 24 1630 No 126001 717 / Month 24 1630 No 125004 818 / Month 24 1640 No</td><td>Treatment Group Subject ID Tommunoreactivity Intransition Arrentment Group Subject ID Ammunoreactivity Intraminition 170010 365 / Month 12 2800 No 177016 358 / Month 12 2800 No 177016 358 / Month 12 1870 Irritis 177016 358 / Month 24 1130 No 1177006 358 / Month 24 1130 No 1177006 358 / Month 24 1130 No 117700 717 / Month 24 1130 No 122002 359 / Month 24 1130 No 124001 727 / Month 24 1130 No 124003 727 / Month 24 1630 No 124001 727 / Month 24 1640 No 126001 727 / Month 24 1640 No</td><td>Treatment Group Rolitive
Subject ID Rominization
Asiay Intranuoreactivity
Asiay Log Titer Intranuoreactivity
Intramation Intranuoreactivity
Asiay Log Titer Intranuoreactivity
Intramation Ranibizumab 0.5 mg 177006 355 / Month 12 1.870 Intras Ranibizumab 0.5 mg 177006 358 / Month 12 1.870 Intras 170010 355 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 122002 357 / Month 24 1.130 No 124003 723 / Month 24 1.130 No 124003 723 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 125004 357 / Month 24 2.610 Vitritits 12304 715 / Month 24 2.610 No 12400 722 / Month 24 2.610 No 125004 365 / Month 12 1.940</td><td>Treatment Group Positive
served viry Intranuoreactivity Intranuoreactivity Intranuoreactivity Intranustion
Assay 170010 365 / Month 12 2700 No 170010 365 / Month 12 2800 Iritis 170010 365 / Month 12 1870 Iritis 170010 355 / Month 24 1130 No 177 / Month 24 1130 No No 122002 359 / Month 24 1130 No 122002 357 / Month 24 1130 No 124003 722 / Month 24 1130 No 124003 723 / Month 24 1300 No 124003 727 / Month 24 1300 No 124003 727 / Month 24 1300 No 124003 727 / Month 24 1300 No 124013 715 / Month 24 1300 No 12504 357 / Month 24 2610 Virmits 12400 722 / Month 24 1600 No 12400 726</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td><td>Treatment Group Environment of timmunoreactivity Immunoreactivity Im</td></th<></td></th<></td></th<>
 | Treatment Group Subject ID Assisty Immunoreactivity Immunoreactivity <th< td=""><td>Treatment Group Subject ID Assisty Immunoreactivity <th< td=""><td>Treatment Group Intranscriptive Intranscription Arrent/Forup Subject ID Assey Log Titler Intranscription 170010 365 / Month 12 Assey Log Titler Diagnois 177006 358 / Month 12 1870 Irritis 177016 358 / Month 12 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 717 / Month 24 1870 Irritis 117006 359 / Month 24 1130 No 122002 359 / Month 24 1130 No 124001 722 / Month 24 1130 No 124003 727 / Month 24 1630 No 124003 727 / Month 24 1770 No 124003 727 / Month 24 1630 No 124003 727 / Month 24 1630 No 126001 717 / Month 24 1630 No 125004 818 / Month 24 1640 No</td><td>Treatment Group Subject ID Tommunoreactivity Intransition Arrentment Group Subject ID Ammunoreactivity Intraminition 170010 365 / Month 12 2800 No 177016 358 / Month 12 2800 No 177016 358 / Month 12 1870 Irritis 177016 358 / Month 24 1130 No 1177006 358 / Month 24 1130 No 1177006 358 / Month 24 1130 No 117700 717 / Month 24 1130 No 122002 359 / Month 24 1130 No 124001 727 / Month 24 1130 No 124003 727 / Month 24 1630 No 124001 727 / Month 24 1640 No 126001 727 / Month 24 1640 No</td><td>Treatment Group Rolitive
Subject ID Rominization
Asiay Intranuoreactivity
Asiay Log Titer Intranuoreactivity
Intramation Intranuoreactivity
Asiay Log Titer Intranuoreactivity
Intramation Ranibizumab 0.5 mg 177006 355 / Month 12 1.870 Intras Ranibizumab 0.5 mg 177006 358 / Month 12 1.870 Intras 170010 355 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 122002 357 / Month 24 1.130 No 124003 723 / Month 24 1.130 No 124003 723 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 125004 357 / Month 24 2.610 Vitritits 12304 715 / Month 24 2.610 No 12400 722 / Month 24 2.610 No 125004 365 / Month 12 1.940</td><td>Treatment Group Positive
served viry Intranuoreactivity Intranuoreactivity Intranuoreactivity Intranustion
Assay 170010 365 / Month 12 2700 No 170010 365 / Month 12 2800 Iritis 170010 365 / Month 12 1870 Iritis 170010 355 / Month 24 1130 No 177 / Month 24 1130 No No 122002 359 / Month 24 1130 No 122002 357 / Month 24 1130 No 124003 722 / Month 24 1130 No 124003 723 / Month 24 1300 No 124003 727 / Month 24 1300 No 124003 727 / Month 24 1300 No 124003 727 / Month 24 1300 No 124013 715 / Month 24 1300 No 12504 357 / Month 24 2610 Virmits 12400 722 / Month 24 1600 No 12400 726</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td><td>Treatment Group Environment of timmunoreactivity Immunoreactivity Im</td></th<></td></th<> | Treatment Group Subject ID Assisty Immunoreactivity Immunoreactivity <th< td=""><td>Treatment Group Intranscriptive Intranscription Arrent/Forup Subject ID Assey Log Titler Intranscription 170010 365 / Month 12 Assey Log Titler Diagnois 177006 358 / Month 12 1870 Irritis 177016 358 / Month 12 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 717 / Month 24 1870 Irritis 117006 359 / Month 24 1130 No 122002 359 / Month 24 1130 No 124001 722 / Month 24 1130 No 124003 727 / Month 24 1630 No 124003 727 / Month 24 1770 No 124003 727 / Month 24 1630 No 124003 727 / Month 24 1630 No 126001 717 / Month 24 1630 No 125004 818 / Month 24 1640 No</td><td>Treatment Group Subject ID Tommunoreactivity Intransition Arrentment Group Subject ID Ammunoreactivity Intraminition 170010 365 / Month 12 2800 No 177016 358 / Month 12 2800 No 177016 358 / Month 12 1870 Irritis 177016 358 / Month 24 1130 No 1177006 358 / Month 24 1130 No 1177006 358 / Month 24 1130 No 117700 717 / Month 24 1130 No 122002 359 / Month 24 1130 No 124001 727 / Month 24 1130 No 124003 727 / Month 24 1630 No 124001 727 / Month 24 1640 No 126001 727 / Month 24 1640 No</td><td>Treatment Group Rolitive
Subject ID Rominization
Asiay Intranuoreactivity
Asiay Log Titer Intranuoreactivity
Intramation Intranuoreactivity
Asiay Log Titer Intranuoreactivity
Intramation Ranibizumab 0.5 mg 177006 355 / Month 12 1.870 Intras Ranibizumab 0.5 mg 177006 358 / Month 12 1.870 Intras 170010 355 / Month 24 1.130 No 122002 359 / Month 24 1.130 No
122002 357 / Month 24 1.130 No 124003 723 / Month 24 1.130 No 124003 723 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 125004 357 / Month 24 2.610 Vitritits 12304 715 / Month 24 2.610 No 12400 722 / Month 24 2.610 No 125004 365 / Month 12 1.940</td><td>Treatment Group Positive
served viry Intranuoreactivity Intranuoreactivity Intranuoreactivity Intranustion
Assay 170010 365 / Month 12 2700 No 170010 365 / Month 12 2800 Iritis 170010 365 / Month 12 1870 Iritis 170010 355 / Month 24 1130 No 177 / Month 24 1130 No No 122002 359 / Month 24 1130 No 122002 357 / Month 24 1130 No 124003 722 / Month 24 1130 No 124003 723 / Month 24 1300 No 124003 727 / Month 24 1300 No 124003 727 / Month 24 1300 No 124003 727 / Month 24 1300 No 124013 715 / Month 24 1300 No 12504 357 / Month 24 2610 Virmits 12400 722 / Month 24 1600 No 12400 726</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td><td>Treatment Group Environment of timmunoreactivity Immunoreactivity Im</td></th<> | Treatment Group Intranscriptive Intranscription Arrent/Forup Subject ID Assey Log Titler Intranscription 170010 365 / Month 12 Assey Log Titler Diagnois 177006 358 / Month 12 1870 Irritis 177016 358 / Month 12 1870 Irritis 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1130 No 102001 717 / Month 24 1870 Irritis 117006 359 / Month 24 1130 No 122002 359 / Month 24 1130 No 124001 722 / Month 24 1130 No 124003 727 / Month 24 1630 No 124003 727 / Month 24 1770 No 124003 727 / Month 24 1630 No 124003 727 / Month 24 1630 No 126001 717 / Month 24 1630 No 125004 818 / Month 24 1640 No
 | Treatment Group Subject ID Tommunoreactivity Intransition Arrentment Group Subject ID Ammunoreactivity Intraminition 170010 365 / Month 12 2800 No 177016 358 / Month 12 2800 No 177016 358 / Month 12 1870 Irritis 177016 358 / Month 24 1130 No 1177006 358 / Month 24 1130 No 1177006 358 / Month 24 1130 No 117700 717 / Month 24 1130 No 122002 359 / Month 24 1130 No 124001 727 / Month 24 1130 No 124003 727 / Month 24 1630 No 124001 727 / Month 24 1640 No 126001 727 / Month 24 1640 No | Treatment Group Rolitive
Subject ID Rominization
Asiay Intranuoreactivity
Asiay Log Titer Intranuoreactivity
Intramation Intranuoreactivity
Asiay Log Titer Intranuoreactivity
Intramation Ranibizumab 0.5 mg 177006 355 / Month 12 1.870 Intras Ranibizumab 0.5 mg 177006 358 / Month 12 1.870 Intras 170010 355 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 122002 357 / Month 24 1.130 No 124003 723 / Month 24 1.130 No 124003 723 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 124003 727 / Month 24 1.300 No 125004 357 / Month 24 2.610 Vitritits 12304 715 / Month 24 2.610 No 12400 722 / Month 24 2.610 No 125004 365 / Month 12 1.940
 | Treatment Group Positive
served viry Intranuoreactivity Intranuoreactivity Intranuoreactivity Intranustion
Assay 170010 365 / Month 12 2700 No 170010 365 / Month 12 2800 Iritis 170010 365 / Month 12 1870 Iritis 170010 355 / Month 24 1130 No 177 / Month 24 1130 No No 122002 359 / Month 24 1130 No 122002 357 / Month 24 1130 No 124003 722 / Month 24 1130 No 124003 723 / Month 24 1300 No 124003 727 / Month 24 1300 No 124003 727 / Month 24 1300 No 124003 727 / Month 24 1300 No 124013 715 / Month 24 1300 No 12504 357 / Month 24 2610 Virmits 12400 722 / Month 24 1600 No 12400 726 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit | Treatment Group Environment of timmunoreactivity Immunoreactivity Im
 |
|

 |

 |

 | TreatmentGroup Bubject ID Immunoractivity
Information Internection 170010 365 / Month 12 2770 No 170010 365 / Month 12 2870 Infamination 170010 355 / Month 12 1870 Infamination 170010 355 / Month 12 1870 Infain 170010 355 / Month 12 1870 Infain 170010 717 / Month 24 1870 Infais 106002 722 / Month 24 1140 No 106002 723 / Month 24 11700 No 122002 357 / Month 24 1570 No 122002 357 / Month 24 1570 No 126001 722 / Month 24 1570 No 122002 357 / Month 24 1570 No 122003 357 / Month 24 1570 No 124003 722 / Month 24 1570 No 124003 722 / Month 24 1570 No 126001 181 / Month 6 1570 No </td <td>Treatment Group Innumoreactivity Innumoreactivity<!--</td--><td>Treatment Group Bubljet ID framunoractivity
frammoractivity Intrancition Asiny 2siny Asiny Asiny Intrancition 170010 365 / Month 12 2770 No No 170010 355 / Month 12 1870 Intrancition 170010 355 / Month 12 1870 Intrins 170010 355 / Month 12 1870 Intrins 170010 717 / Month 24 1870 Intrins 104002 713 / Month 24 1140 No 105001 722 / Month 12 1630 No 122002 359 / Month 24 1770 No 124003 722 / Month 24 1770 No 124003 722 / Month 24 1770 No 126001 1357 / Month 6 1770 No 124003 722 / Month 24 1570 No 126001 181 / Month 6 1570 No 126001 725 / Month 24 1570 No 12900 522 / Early Term<</td><td>Treatment Group Subject ID from unoreactivity
from the sary Intrancition
Asay <thintrancition
Asay Intrancition
Asay Intrancition
Asay</thintrancition
</td><td>Treatment Group Subject ID fmmunoreactivity
Asary Innumoreactivity
Asary Innumoreactivity
Asary Intracediat
Innumoreactivity
Asary Intracediat
Asary 170010 365 / Month 12 2770 No 170010 355 / Month 12 2800 No 177006 358 / Month 12 1870 Intracediat Rambizumab 0.5 mg 102001 722 / Month 24 1870 Intris 104002 717 / Month 24 1830 No No Intris 102001 722 / Month 24 1130 No No Intris 122002 359 / Month 24 1130 No No Intris 122002 357 / Month 24 1570 No No Intris 124003 722 / Month 24 1570 No No Intris 124003 722 / Month 24 1570 No No Intris 124003 722 / Month 24 1570 No No Intris 124003 722 / Month 24 1570 No</td><td>Treatment Group Subject ID from unoreactivity
from the sary Intrancition
Asay
<thintrancition
Asay Intrancition
Asay Intrancition
Asay</thintrancition
</td><td>Treatment Group Subject ID from unoreactivity
from the sary Intrancition
Asay <thintrancition
Asay Intrancition
Asay Intrancition
Asay</thintrancition
</td><td>Treatment Group Bubljet ID framunoractivity
frammoractivity Intrancition Asiny 2siny Asiny Asiny Intrancition 170010 365 / Month 12 2770 No No 170010 355 / Month 12 1870 Intrancition 170010 355 / Month 12 1870 Intrins 170010 355 / Month 12 1870 Intrins 170010 717 / Month 24 1870 Intrins 104002 713 / Month 24 1140 No 105001 722 / Month 12 1630 No 122002 359 / Month 24 1770 No 124003 722 / Month 24 1770 No 124003 722 / Month 24 1770 No 126001 1357 / Month 6 1770 No 124003 722 / Month 24 1570 No 126001 181 / Month 6 1570 No 126001 725 / Month 24 1570 No 12900 522 / Early Term<</td><td>Treatment Group Bubljet ID framunoractivity
frammoractivity Intrancition Asiny 2siny Asiny Asiny Intrancition 170010 365 / Month 12 2770 No No 170010 355 / Month 12 1870 Intrancition 170010 355 / Month 12 1870 Intrins 170010 355 / Month 12 1870 Intrins 170010 717 / Month 24 1870 Intrins 104002 713 / Month 24 1140 No 105001 722 / Month 12 1630 No 122002 359 / Month 24 1770 No 124003 722 / Month 24 1770 No 124003 722 / Month 24 1770 No 126001 1357 / Month 6 1770 No 124003 722 / Month 24 1570 No 126001 181 / Month 6 1570 No 126001 725 / Month 24 1570 No 12900 522 / Early Term<</td><td>Treatment Group Bubljet ID framunoractivity
frammoractivity Intrancition Asiny 2siny Asiny Asiny Intrancition 170010 365 / Month 12 2770 No No 170010 355 / Month 12 1870 Intrancition 170010 355 / Month 12 1870 Intrins 170010 355 / Month 12 1870 Intrins 170010 717 / Month 24 1870 Intrins 104002 713 / Month 24 1140 No 105001 722 / Month 12 1630 No 122002 359 / Month 24 1770 No 124003 722 / Month 24 1770 No 124003 722 / Month 24 1770 No 126001 1357 / Month 6 1770 No 124003 722 / Month 24 1570 No 126001 181 / Month 6 1570 No 126001 725 / Month 24 1570 No 12900 522 / Early Term<</td><td>TreatmentGroup Bubject ID Immunoractivity
Information Internection 170010 365 / Month 12 2770 No 170010 365 / Month 12 2870 Infamination 170010 355 / Month 12 1870 Infamination 170010 355 / Month 12 1870 Infain 170010 355 / Month 12 1870 Infain 170010 717 / Month 24 1870 Infais 106002 722 / Month 24 1140 No 106002 723 / Month 24 11700 No 122002 357 / Month 24 1570 No 122002 357 / Month 24 1570 No 126001 722 / Month 24 1570 No 122002 357 / Month 24 1570 No 122003 357 / Month 24 1570 No 124003 722 / Month 24 1570 No 124003 722 / Month 24 1570 No 126001 181 / Month 6 1570 No<!--</td--><td>Treatment Group Bubject ID Rominoceactivity
Innumoceactivity Intransition Affection 365 / Month 12 2770 No No 170010 365 / Month 12 2870 No No 170010 355 / Month 12 1870 Irrins No 170010 355 / Month 12 1870 Irrins No 177006 358 / Month 24 2800 No No 177006 355 / Month 24 1870 Irrins No 106002 722 / Month 24 11340 No No 122002 357 / Month 24 1500 No No 122002 357 / Month 24 1570 No No 122003 357 / Month 24 1570 No No 122004 357 / Month 24 1570</td><td>Treatment Group Bolistive
Innumoreactivity Innumoreactivity Intraminition
Assay Log Titer Intraminition
Infammation Ramibizumab 0.5 mg 170010 355 / Month 12 2700 No 170010 355 / Month 12 1870 Intra No 170010 355 / Month 12 1870 Intris 170010 355 / Month 12 1870 Intris 170010 355 / Month 12 1870 No 106002 712 / Month 24 1140 No 106002 722 / Month 12 1530 No 122002 357 / Month 24 1700 No 124003 722 / Month 24 1570 No 126001 17100 No No No 126001 722 / Month 24 1570 No No 128003 181 / Month 6 17700 No No 128004 181 / Month 24 2340 No No 128004 522 / Early Term 0752 No No 135006<</td><td>Treatment Group Subject ID Positive
Innumerativity Immunoreactivity Immunoreactivity Immunoreactivity 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 170010 365 / Month 12 1.870 Initia No No 170010 358 / Month 24 1.140 No No No 170010 719 / Month 24 1.140 No No No 122002 722 / Month 24 1.130 No No No 124003 722 / Month 24 1.1700 No No No 122002 357 / Month 24 1.1700 No No No 122003 722 / Month 24 1.7700 No No No 122003 723 / Month 24 1.7700 No No No 122004 131 / Month 24 1.7700 No No No 12400 1.17 / Month 24 <</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 170010 365 / Month 12 1.870 Infinametion 170010 351 / Month 24 1.350 No 170010 719 / Month 24 1.140 No 122002 722 / Month 24 1.130 No 124003 722 / Month 24 1.1700 No 122002 735 / Month 24 1.1700 No 124003 722 / Month 24 1.7700 No 124003 722 / Month 24 1.7700 No 122002 357 / Month 24 1.7700 No 122003 725 / Month 24 1.7700 No 123004 181 / Month 24 1.7700 No 12400 726 / Month 24 1.7700 No 125004 181 / Month 24</td><td>Treatment Group Environment of the minumenent of the minumenen</td></td></td>
 | Treatment Group Innumoreactivity Innumoreactivity </td <td>Treatment Group Bubljet ID framunoractivity
frammoractivity Intrancition Asiny 2siny Asiny Asiny Intrancition 170010 365 / Month 12 2770 No No 170010 355 / Month 12 1870 Intrancition 170010 355 / Month 12 1870 Intrins 170010 355 / Month 12 1870 Intrins 170010 717 / Month 24 1870 Intrins 104002 713 / Month 24 1140 No 105001 722 / Month 12 1630 No 122002 359 / Month 24 1770 No 124003 722 / Month 24 1770 No 124003 722 / Month 24 1770 No 126001 1357 / Month 6 1770 No 124003 722 / Month 24 1570 No 126001 181 / Month 6 1570 No 126001 725 / Month 24 1570 No 12900 522 / Early Term<</td> <td>Treatment Group Subject ID from unoreactivity
from the sary Intrancition
Asay <thintrancition
Asay Intrancition
Asay Intrancition
Asay</thintrancition
</td> <td>Treatment Group Subject ID fmmunoreactivity
Asary Innumoreactivity
Asary Innumoreactivity
Asary Intracediat
Innumoreactivity
Asary Intracediat
Asary 170010 365 / Month 12 2770 No 170010 355 / Month 12 2800 No 177006 358 / Month 12 1870 Intracediat Rambizumab 0.5 mg 102001 722 / Month 24 1870 Intris 104002 717 / Month 24 1830 No No Intris 102001 722 / Month 24 1130 No No Intris 122002 359 / Month 24 1130 No No Intris 122002 357 / Month 24 1570 No No Intris 124003 722 / Month 24 1570 No No Intris 124003 722 / Month 24 1570 No No Intris 124003 722 / Month 24 1570 No No Intris 124003 722 / Month 24 1570 No</td> <td>Treatment Group Subject ID from unoreactivity
from the sary Intrancition
Asay <thintrancition
Asay Intrancition
Asay Intrancition
Asay</thintrancition
</td> <td>Treatment Group Subject ID from unoreactivity
from the sary Intrancition
Asay <thintrancition
Asay Intrancition
Asay Intrancition
Asay</thintrancition
</td> <td>Treatment Group Bubljet ID framunoractivity
frammoractivity Intrancition Asiny 2siny Asiny Asiny Intrancition 170010 365 / Month 12 2770 No No 170010 355 / Month 12 1870 Intrancition 170010 355 / Month 12 1870 Intrins 170010 355 / Month 12 1870 Intrins 170010 717 / Month 24 1870 Intrins 104002 713 / Month 24 1140 No 105001 722 / Month 12 1630 No 122002 359 / Month 24 1770 No 124003 722 / Month 24 1770 No 124003 722 / Month 24 1770 No 126001 1357 / Month 6 1770 No 124003 722 / Month 24 1570 No 126001 181 / Month 6 1570 No 126001 725 / Month 24 1570 No 12900 522 / Early Term<</td> <td>Treatment Group Bubljet ID framunoractivity
frammoractivity Intrancition Asiny 2siny Asiny Asiny Intrancition 170010 365 / Month 12 2770 No No 170010 355 / Month 12 1870 Intrancition 170010 355 / Month 12 1870 Intrins 170010 355 / Month 12 1870 Intrins 170010 717 / Month 24 1870 Intrins 104002 713 / Month 24 1140 No 105001 722 / Month 12 1630 No 122002 359 / Month 24 1770 No 124003 722 / Month 24 1770 No 124003 722 / Month 24 1770 No 126001 1357 / Month 6 1770 No 124003 722 / Month 24 1570 No 126001 181 / Month 6 1570 No 126001 725 / Month 24 1570 No 12900 522 / Early Term<</td> <td>Treatment Group Bubljet ID framunoractivity
frammoractivity Intrancition Asiny 2siny Asiny Asiny Intrancition 170010 365 / Month 12 2770 No No 170010 355 / Month 12 1870 Intrancition 170010 355 / Month 12 1870 Intrins 170010 355 / Month 12 1870 Intrins 170010 717 / Month 24 1870 Intrins 104002 713 / Month 24 1140 No 105001 722 / Month 12 1630 No 122002 359 / Month 24 1770 No 124003 722 / Month 24 1770 No 124003 722 / Month 24 1770 No 126001 1357 / Month 6 1770 No 124003 722 / Month 24 1570 No 126001 181 / Month 6 1570 No 126001 725 / Month 24 1570 No 12900 522 / Early Term<</td> <td>TreatmentGroup Bubject ID Immunoractivity
Information Internection 170010 365 / Month 12 2770 No 170010 365 / Month 12 2870 Infamination 170010 355 / Month 12 1870 Infamination 170010 355 / Month 12 1870 Infain 170010 355 / Month 12 1870 Infain 170010 717 / Month 24 1870 Infais 106002 722 / Month 24 1140 No 106002 723 / Month 24 11700 No 122002 357 / Month 24 1570 No 122002 357 / Month 24 1570 No 126001 722 / Month 24 1570 No 122002 357 / Month 24 1570 No 122003 357 / Month 24 1570 No 124003 722 / Month 24 1570 No 124003 722 / Month 24 1570 No 126001 181 / Month 6 1570 No<!--</td--><td>Treatment Group Bubject ID Rominoceactivity
Innumoceactivity Intransition Affection 365 / Month 12 2770 No No 170010 365 / Month 12 2870 No No 170010 355 / Month 12 1870 Irrins No 170010 355 / Month 12 1870 Irrins No 177006 358 / Month 24 2800 No No 177006 355 / Month 24 1870 Irrins No 106002 722 / Month 24 11340 No No 122002 357 / Month 24 1500 No No 122002
 357 / Month 24 1570 No No 122003 357 / Month 24 1570 No No 122004 357 / Month 24 1570</td><td>Treatment Group Bolistive
Innumoreactivity Innumoreactivity Intraminition
Assay Log Titer Intraminition
Infammation Ramibizumab 0.5 mg 170010 355 / Month 12 2700 No 170010 355 / Month 12 1870 Intra No 170010 355 / Month 12 1870 Intris 170010 355 / Month 12 1870 Intris 170010 355 / Month 12 1870 No 106002 712 / Month 24 1140 No 106002 722 / Month 12 1530 No 122002 357 / Month 24 1700 No 124003 722 / Month 24 1570 No 126001 17100 No No No 126001 722 / Month 24 1570 No No 128003 181 / Month 6 17700 No No 128004 181 / Month 24 2340 No No 128004 522 / Early Term 0752 No No 135006<</td><td>Treatment Group Subject ID Positive
Innumerativity Immunoreactivity Immunoreactivity Immunoreactivity 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 170010 365 / Month 12 1.870 Initia No No 170010 358 / Month 24 1.140 No No No 170010 719 / Month 24 1.140 No No No 122002 722 / Month 24 1.130 No No No 124003 722 / Month 24 1.1700 No No No 122002 357 / Month 24 1.1700 No No No 122003 722 / Month 24 1.7700 No No No 122003 723 / Month 24 1.7700 No No No 122004 131 / Month 24 1.7700 No No No 12400 1.17 / Month 24 <</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 170010 365 / Month 12 1.870 Infinametion 170010 351 / Month 24 1.350 No 170010 719 / Month 24 1.140 No 122002 722 / Month 24 1.130 No 124003 722 / Month 24 1.1700 No 122002 735 / Month 24 1.1700 No 124003 722 / Month 24 1.7700 No 124003 722 / Month 24 1.7700 No 122002 357 / Month 24 1.7700 No 122003 725 / Month 24 1.7700 No 123004 181 / Month 24 1.7700 No 12400 726 / Month 24 1.7700 No 125004 181 / Month 24</td><td>Treatment Group Environment of the minumenent of the minumenen</td></td> | Treatment Group Bubljet ID framunoractivity
frammoractivity Intrancition Asiny 2siny Asiny Asiny Intrancition 170010 365 / Month 12 2770 No No 170010 355 / Month 12 1870 Intrancition 170010 355 / Month 12 1870 Intrins 170010 355 / Month 12 1870 Intrins 170010 717 / Month 24 1870 Intrins 104002 713 / Month 24 1140 No 105001 722 / Month 12 1630 No 122002 359 / Month 24 1770 No 124003 722 / Month 24 1770 No 124003 722 / Month 24 1770 No 126001 1357 / Month 6 1770 No 124003 722 / Month 24 1570 No 126001 181 / Month 6 1570 No 126001 725 / Month 24 1570 No 12900 522 / Early Term<

 | Treatment Group Subject ID from unoreactivity
from the sary Intrancition
Asay Intrancition
Asay <thintrancition
Asay Intrancition
Asay Intrancition
Asay</thintrancition

 | Treatment Group Subject ID fmmunoreactivity
Asary Innumoreactivity
Asary Innumoreactivity
Asary Intracediat
Innumoreactivity
Asary Intracediat
Asary 170010 365 / Month 12 2770 No 170010 355 / Month 12 2800 No 177006 358 / Month 12 1870 Intracediat Rambizumab 0.5 mg 102001 722 / Month 24 1870 Intris 104002 717 / Month 24 1830 No No Intris 102001 722 / Month 24 1130 No No Intris 122002 359 / Month 24 1130 No No Intris 122002 357 / Month 24 1570 No No Intris 124003 722 / Month 24 1570 No No Intris 124003 722 / Month 24 1570 No No Intris 124003 722 / Month 24 1570 No No Intris 124003 722 / Month 24 1570 No
 | Treatment Group Subject ID from unoreactivity
from the sary Intrancition
Asay Intrancition
Asay <thintrancition
Asay Intrancition
Asay Intrancition
Asay</thintrancition

 | Treatment Group Subject ID from unoreactivity
from the sary Intrancition
Asay Intrancition
Asay <thintrancition
Asay Intrancition
Asay Intrancition
Asay</thintrancition

 | Treatment Group Bubljet ID framunoractivity
frammoractivity Intrancition Asiny 2siny Asiny Asiny Intrancition 170010 365 / Month 12 2770 No No 170010 355 / Month 12 1870 Intrancition 170010 355 / Month 12 1870 Intrins 170010 355 / Month 12 1870 Intrins 170010 717 / Month 24 1870 Intrins 104002 713 / Month 24 1140 No 105001 722 / Month 12 1630 No 122002 359 / Month 24 1770 No 124003 722 / Month 24 1770 No 124003 722 / Month 24 1770 No 126001 1357 / Month 6 1770 No 124003 722 / Month 24 1570 No 126001 181 / Month 6 1570 No 126001 725 / Month 24 1570 No 12900 522 / Early Term<
 | Treatment Group Bubljet ID framunoractivity
frammoractivity Intrancition Asiny 2siny Asiny Asiny Intrancition 170010 365 / Month 12 2770 No No 170010 355 / Month 12 1870 Intrancition 170010 355 / Month 12 1870 Intrins 170010 355 / Month 12 1870 Intrins 170010 717 / Month 24 1870 Intrins 104002 713 / Month 24 1140 No 105001 722 / Month 12 1630 No 122002 359 / Month 24 1770 No 124003 722 / Month 24 1770 No 124003 722 / Month 24 1770 No 126001 1357 / Month 6 1770 No 124003 722 / Month 24 1570 No 126001 181 / Month 6 1570 No 126001 725 / Month 24 1570 No 12900 522 / Early Term<

 | Treatment Group Bubljet ID framunoractivity
frammoractivity Intrancition Asiny 2siny Asiny Asiny Intrancition 170010 365 / Month 12 2770 No No 170010 355 / Month 12 1870 Intrancition 170010 355 / Month 12 1870 Intrins 170010 355 / Month 12 1870 Intrins 170010 717 / Month 24 1870 Intrins 104002 713 / Month 24 1140 No 105001 722 / Month 12 1630 No 122002 359 / Month 24 1770 No 124003 722 / Month 24 1770 No 124003 722 / Month 24 1770 No 126001 1357 / Month 6 1770 No 124003 722 / Month 24 1570 No 126001 181 / Month 6 1570 No 126001 725 / Month 24 1570 No 12900 522 / Early Term<
 | TreatmentGroup Bubject ID Immunoractivity
Information Internection 170010 365 / Month 12 2770 No 170010 365 / Month 12 2870 Infamination 170010 355 / Month 12 1870 Infamination 170010 355 / Month 12 1870 Infain 170010 355 / Month 12 1870 Infain 170010 717 / Month 24 1870 Infais 106002 722 / Month 24 1140 No 106002 723 / Month 24 11700 No 122002 357 / Month 24 1570 No 122002 357 / Month 24 1570 No 126001 722 / Month 24 1570 No 122002 357 / Month 24 1570 No 122003 357 / Month 24 1570 No 124003 722 / Month 24 1570 No 124003 722 / Month 24 1570 No 126001 181 / Month 6 1570 No </td <td>Treatment Group Bubject ID Rominoceactivity
Innumoceactivity Intransition Affection 365 / Month 12 2770 No No 170010 365 / Month 12 2870 No No 170010 355 / Month 12 1870 Irrins No 170010 355 / Month 12 1870 Irrins No 177006 358 / Month 24 2800 No No 177006 355 / Month 24 1870 Irrins No 106002 722 / Month 24 11340 No No 122002 357 / Month 24 1500 No No 122002 357 / Month 24 1570 No No 122003 357 / Month 24 1570 No No 122004 357 / Month 24 1570</td> <td>Treatment Group Bolistive
Innumoreactivity Innumoreactivity Intraminition
Assay Log Titer Intraminition
Infammation Ramibizumab 0.5 mg 170010 355 / Month 12 2700 No 170010 355 / Month 12 1870 Intra No 170010 355 / Month 12 1870 Intris 170010 355 / Month 12 1870 Intris 170010 355 / Month 12 1870 No 106002 712 / Month 24 1140 No 106002 722 / Month 12 1530 No 122002 357 / Month 24 1700 No 124003 722 / Month 24 1570 No 126001 17100 No No No 126001 722 / Month 24 1570 No No 128003 181 / Month 6 17700 No No 128004 181 / Month 24 2340 No No 128004 522 / Early Term 0752 No No 135006<</td> <td>Treatment Group Subject ID Positive
Innumerativity Immunoreactivity Immunoreactivity Immunoreactivity 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 170010 365 / Month 12 1.870 Initia No No 170010 358 / Month 24 1.140 No No No 170010 719 / Month 24 1.140 No No No 122002 722 / Month 24 1.130 No No No 124003 722 / Month 24 1.1700 No No No 122002 357 / Month 24 1.1700 No No No 122003 722 / Month 24 1.7700 No No No 122003 723 / Month 24 1.7700 No No No 122004 131 / Month 24 1.7700 No No No 12400 1.17 / Month 24 <</td> <td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 170010 365 / Month 12 1.870 Infinametion 170010 351 / Month 24 1.350 No 170010 719 / Month 24 1.140 No 122002 722 / Month 24 1.130 No 124003 722 / Month 24 1.1700 No 122002 735 / Month 24 1.1700 No 124003 722 / Month 24 1.7700 No 124003 722 / Month 24 1.7700 No 122002 357 / Month 24 1.7700 No 122003 725 / Month 24 1.7700 No 123004 181 / Month 24 1.7700 No 12400 726 / Month 24 1.7700 No 125004 181 / Month 24</td> <td>Treatment Group Environment of the minumenent of the minumenen</td> | Treatment Group Bubject ID Rominoceactivity
Innumoceactivity Intransition Affection 365 / Month 12 2770 No No 170010 365 / Month 12 2870 No No 170010 355 / Month 12 1870 Irrins No 170010 355 / Month 12 1870 Irrins No 177006 358 / Month 24 2800 No No 177006 355 / Month 24 1870 Irrins No 106002 722 / Month 24 11340 No No 122002 357 / Month 24 1500 No No 122002 357 / Month 24 1570 No No 122003 357 / Month 24 1570 No No 122004 357 / Month 24 1570
 | Treatment Group Bolistive
Innumoreactivity Innumoreactivity Intraminition
Assay Log Titer Intraminition
Infammation Ramibizumab 0.5 mg 170010 355 / Month 12 2700 No 170010 355 / Month 12 1870 Intra No 170010 355 / Month 12 1870 Intris 170010 355 / Month 12 1870 Intris 170010 355 / Month 12 1870 No 106002 712 / Month 24 1140 No 106002 722 / Month 12 1530 No 122002 357 / Month 24 1700 No 124003 722 / Month 24 1570 No 126001 17100 No No No 126001 722 / Month 24 1570 No No 128003 181 / Month 6 17700 No No 128004 181 / Month 24 2340 No No 128004 522 / Early Term 0752 No No 135006< | Treatment Group Subject ID Positive
Innumerativity Immunoreactivity Immunoreactivity Immunoreactivity 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No
 No 170010 365 / Month 12 1.870 Initia No No 170010 358 / Month 24 1.140 No No No 170010 719 / Month 24 1.140 No No No 122002 722 / Month 24 1.130 No No No 124003 722 / Month 24 1.1700 No No No 122002 357 / Month 24 1.1700 No No No 122003 722 / Month 24 1.7700 No No No 122003 723 / Month 24 1.7700 No No No 122004 131 / Month 24 1.7700 No No No 12400 1.17 / Month 24 < | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 170010 365 / Month 12 1.870 Infinametion 170010 351 / Month 24 1.350 No 170010 719 / Month 24 1.140 No 122002 722 / Month 24 1.130 No 124003 722 / Month 24 1.1700 No 122002 735 / Month 24 1.1700 No 124003 722 / Month 24 1.7700 No 124003 722 / Month 24 1.7700 No 122002 357 / Month 24 1.7700 No 122003 725 / Month 24 1.7700 No 123004 181 / Month 24 1.7700 No 12400 726 / Month 24 1.7700 No 125004 181 / Month 24 | Treatment Group Environment of the minumenent of the minumenen |
| Sham 534001 -7/Screening 2.520 Vitritis

 | Sham 534001 -7 / Screening 2.520 Vitritis

 | Sham 534001 -7 / Screening 2.520 Vitritis

 | Treatment Group Subject ID Assy Lurrarecents Assy Asso Asso <td< td=""><td>Treatment Group Subject ID Assry Lurrarectifity Intransition JTeettment Group Subject ID 365 / Month 12 2770 No 170010 365 / Month 12 2870 Infimination 177006 358 / Month 12 1870 Irtitis 177006 358 / Month 12 1870 Irtitis 177006 358 / Month 12 1850 No 177006 358 / Month 12 1870 Irtitis 177006 358 / Month 12 1140 No 12002 722 / Month 24 1130 No 122002 339 / Month 12 16300 No 122002 722 / Month 24 1770 No 122003 722 / Month 24 1770 No 122003 722 / Month 24 1770 No 122004 522 / Month 24 1770 No 141008 181 / Month 24 1.570 No 141013 715 / Month 24 0.700 No 153006 183 / Month 2<</td><td>Treatment Group Subject ID Assy Lurracellar Interment Group Subject ID Assy Assy Lurracellar Interment Group Subject ID Assy Assy Lurracellar Interment Group 170010 358/Mouth 12 2770 No Interment Group 175/Mouth 24 1.870 Intrinsition Interment Group 715/Mouth 24 1.140 No Interment Group 722/Mouth 24 1.130 No Interment Group 722/Mouth 24 1.700 No Interment Group 722/Mouth 24 1.700 No Interment Group 722/Mouth 24 1.700 No Interment Group 727/Mouth 24 1.700 No Interment Group 362/Mouth 12 1.600 No Interment Group 362/Mouth 24 1.700 No Interment Group 362/Mouth 24 1.700 No Interment Group 362/Mouth 24 1.700 No Interment Group 362/Mouth 24</td><td>Treatment Group Bositre
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity JTeatment Group Subject ID Assy Assy Assy Intrancicular 170010 365/Mouth 12 2770 No No 177006 358/Mouth 12 1870 Intrinsion 177006 358/Mouth 12 1870 Intris 177006 358/Mouth 24 1.140 No 106002 719/Mouth 24 1.130 No 122002 722/Mouth 24 1.700 No 124003 722/Mouth 24 1.700 No 124003 722/Mouth 24 1.700 No 141008 181/Mouth 24 1.700 No 125004 852/Mouth 24 1.700 No 128001 117/Mouth 24 2.540 No <</td><td>Treatment Group Bubject ID Positive
Assay Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactity Immunoreactivity
Immunoreactivity</td><td>Treatment Group Bositre
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity JTeatment Group Subject ID Assy Assy Assy Intrancicular 170010 365/Mouth 12 2770 No No 177006
358/Mouth 12 1870 Intrinsion 177006 358/Mouth 12 1870 Intris 177006 358/Mouth 24 1.140 No 106002 719/Mouth 24 1.130 No 122002 722/Mouth 24 1.700 No 124003 722/Mouth 24 1.700 No 124003 722/Mouth 24 1.700 No 141008 181/Mouth 24 1.700 No 125004 852/Mouth 24 1.700 No 128001 117/Mouth 24 2.540 No <</td><td>Treatment Group Bositre
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity JTeatment Group Subject ID Assy Assy Assy Intrancicular 170010 365/Mouth 12 2770 No No 177006 358/Mouth 12 1870 Intrinsion 177006 358/Mouth 12 1870 Intris 177006 358/Mouth 24 1.140 No 106002 719/Mouth 24 1.130 No 122002 722/Mouth 24 1.700 No 124003 722/Mouth 24 1.700 No 124003 722/Mouth 24 1.700 No 141008 181/Mouth 24 1.700 No 125004 852/Mouth 24 1.700 No 128001 117/Mouth 24 2.540 No <</td><td>Treatment Group Subject ID Assy Lurracellar Interment Group Subject ID Assy Assy Lurracellar Interment Group Subject ID Assy Assy Lurracellar Interment Group 170010 358/Mouth 12 2770 No Interment Group 175/Mouth 24 1.870 Intrinsition Interment Group 715/Mouth 24 1.140 No Interment Group 722/Mouth 24 1.130 No Interment Group 722/Mouth 24 1.700 No Interment Group 722/Mouth 24 1.700 No Interment Group 722/Mouth 24 1.700 No Interment Group 727/Mouth 24 1.700 No Interment Group 362/Mouth 12 1.600 No Interment Group 362/Mouth 24 1.700 No Interment Group 362/Mouth 24 1.700 No Interment Group 362/Mouth 24 1.700 No Interment Group 362/Mouth 24</td><td>Treatment Group Subject ID Assy Lurracellar Interment Group Subject ID Assy Assy Lurracellar Interment Group Subject ID Assy Assy Lurracellar Interment Group 170010 358/Mouth 12 2770 No Interment Group 175/Mouth 24 1.870 Intrinsition Interment Group 715/Mouth 24 1.140 No Interment Group 722/Mouth 24 1.130 No Interment Group 722/Mouth 24 1.700 No Interment Group 722/Mouth 24 1.700 No Interment Group 722/Mouth 24 1.700 No Interment Group 727/Mouth 24 1.700 No Interment Group 362/Mouth 12 1.600 No Interment Group 362/Mouth 24 1.700 No Interment Group 362/Mouth 24 1.700 No Interment Group 362/Mouth 24 1.700 No Interment Group 362/Mouth 24</td><td>Treatment Group Subject ID Assy Lurracellar Interment Group Subject ID Assy Assy Lurracellar Interment Group Subject ID Assy Assy Lurracellar Interment Group 170010 358/Mouth 12 2770 No Interment Group 175/Mouth 24 1.870 Intrinsition Interment Group 715/Mouth 24 1.140 No Interment Group 722/Mouth 24 1.130 No Interment Group 722/Mouth 24 1.700 No Interment Group 722/Mouth 24 1.700 No Interment Group 722/Mouth 24 1.700 No Interment Group 727/Mouth 24 1.700 No Interment Group 362/Mouth 12 1.600 No Interment Group 362/Mouth 24 1.700 No Interment Group 362/Mouth 24 1.700 No Interment Group 362/Mouth 24 1.700 No Interment Group 362/Mouth 24</td><td>Treatment Group Subject ID Assy Lurrarecents Assy Asso <td< td=""><td>Treatment Group Subject ID Terminion for activity Intranscrints Assy Diagnois Assy Asso <t< td=""><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Arisy Arisy</td></t<></td></td<><td>Treatment Group Positive
Innumber Missy Innumber Strivty Innumber Strivty Innumber Strivty Innumber Strivty Innumston 170010 365 / Mouth 12 2.770 No No No 170010 365 / Mouth 12 2.800 Initiamiston No No 170010 355 / Mouth 24 1.870 Initia No No 177006 358 / Mouth 24 1.130 No No No 105002 719 / Mouth 24 1.130 No No No 122002 359 / Mouth 12 1.630 No No No 122002 722 / Mouth 24 1.130 No No No 124003 722 / Mouth 24 1.630 No No No 124003 722 / Mouth 24 1.630 No No No 124003 722 / Mouth 24 1.630 No No No 124003 722 / Mouth 24 1.640 No No No 124003</td><td>Treatment Group Rotitive
Immunoreactivity Immunoreactivity Immunoreactivity Assay 170010 365 / Month 1.2 2.770 No 170010 355 / Month 1.2 2.770 No 177006 355 / Month 1.2 2.800 Infammation 177006 355 / Month 1.2 2.800 No 177006 355 / Month 2.4 1.800 Infammation 177006 355 / Month 2.4 1.130 No 177006 355 / Month 2.4 1.130 No 122002 719 / Month 2.4 1.130 No 122002 722 / Month 2.4 1.130 No 124003 722 / Month 2.4 1.300 No 124003 722 / Month 2.4 0.782 No 124003 722 / Month 2.4 0.780 No 124003 722 / Month 2.4 0.770 No 124003 722 / Month 2.4 0.780 No 124003 722 / Month 2.4 0.770 No 12400 1.770</td><td>Treatment Group Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Asiay Locattive Inflammation 170010 365 / Month 12 2.770 No No 170010 355 / Month 12 1.870 Inflammation 177006 715 / Month 24 1.850 No 177006 732 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 739 / Month 24 1.130 No 124003 722 / Month 24 1.770 No 12400 1.14</td></td></td<>
 | Treatment Group Subject ID Assry Lurrarectifity Intransition JTeettment Group Subject ID 365 / Month 12 2770 No 170010 365 / Month 12 2870 Infimination 177006 358 / Month 12 1870 Irtitis 177006 358 / Month 12 1870 Irtitis 177006 358 / Month 12 1850 No 177006 358 / Month 12 1870 Irtitis 177006 358 / Month 12 1140 No 12002 722 / Month 24 1130 No 122002 339 / Month 12 16300 No 122002 722 / Month 24 1770 No 122003 722 / Month 24 1770 No 122003 722 / Month 24 1770 No 122004 522 / Month 24 1770 No 141008 181 / Month 24 1.570 No 141013 715 / Month 24 0.700 No 153006 183 / Month 2<

 | Treatment Group Subject ID Assy Lurracellar Interment Group Subject ID Assy Assy Lurracellar Interment Group Subject ID Assy Assy Lurracellar Interment Group 170010 358/Mouth 12 2770 No Interment Group 175/Mouth 24 1.870 Intrinsition Interment Group 715/Mouth 24 1.140 No Interment Group 722/Mouth 24 1.130 No Interment Group 722/Mouth 24 1.700 No Interment Group 722/Mouth 24 1.700 No Interment Group 722/Mouth 24 1.700 No Interment Group 727/Mouth 24 1.700 No Interment Group 362/Mouth 12 1.600 No Interment Group 362/Mouth 24 1.700 No Interment Group 362/Mouth 24 1.700 No Interment Group 362/Mouth 24 1.700 No Interment Group 362/Mouth 24

 | Treatment Group Bositre
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity JTeatment Group Subject ID Assy Assy Assy Intrancicular 170010 365/Mouth 12 2770 No No 177006 358/Mouth 12 1870 Intrinsion 177006 358/Mouth 12 1870 Intris 177006 358/Mouth 24 1.140 No 106002 719/Mouth 24 1.130 No 122002 722/Mouth 24 1.700 No 124003 722/Mouth 24 1.700 No 124003 722/Mouth 24 1.700 No 141008 181/Mouth 24 1.700 No 125004 852/Mouth 24 1.700 No 128001 117/Mouth 24 2.540 No <

 | Treatment Group Bubject ID Positive
Assay Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactity Immunoreactivity
Immunoreactivity
 | Treatment Group Bositre
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity JTeatment Group Subject ID Assy Assy Assy Intrancicular 170010 365/Mouth 12 2770 No No 177006 358/Mouth 12 1870 Intrinsion 177006 358/Mouth 12 1870 Intris 177006 358/Mouth 24 1.140 No 106002 719/Mouth 24 1.130 No 122002 722/Mouth 24 1.700 No 124003 722/Mouth 24 1.700 No 124003 722/Mouth 24 1.700 No 141008 181/Mouth 24 1.700 No 125004 852/Mouth 24 1.700 No 128001 117/Mouth 24 2.540 No <

 | Treatment Group Bositre
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity JTeatment Group Subject ID Assy Assy Assy Intrancicular 170010 365/Mouth 12 2770 No No 177006 358/Mouth 12 1870 Intrinsion 177006 358/Mouth 12 1870 Intris 177006 358/Mouth 24 1.140 No 106002 719/Mouth 24 1.130 No 122002 722/Mouth 24 1.700 No 124003 722/Mouth 24 1.700 No 124003 722/Mouth 24 1.700 No 141008 181/Mouth 24 1.700 No 125004 852/Mouth 24 1.700 No 128001 117/Mouth 24 2.540 No <
 | Treatment Group Subject ID Assy Lurracellar Interment Group Subject ID Assy Assy Lurracellar Interment Group Subject ID Assy Assy Lurracellar Interment Group 170010 358/Mouth 12 2770 No Interment Group 175/Mouth 24 1.870 Intrinsition Interment Group 715/Mouth 24 1.140 No Interment Group 722/Mouth 24 1.130 No Interment Group 722/Mouth 24 1.700 No Interment Group 722/Mouth 24 1.700 No Interment Group 722/Mouth 24 1.700 No Interment Group 727/Mouth 24 1.700 No Interment Group 362/Mouth 12 1.600 No Interment Group 362/Mouth 24 1.700 No Interment Group 362/Mouth 24 1.700 No Interment Group 362/Mouth 24 1.700 No Interment Group 362/Mouth 24

 | Treatment Group Subject ID Assy Lurracellar Interment Group Subject ID Assy Assy Lurracellar Interment Group Subject ID Assy Assy Lurracellar Interment Group 170010 358/Mouth 12 2770 No Interment Group 175/Mouth 24 1.870 Intrinsition Interment Group 715/Mouth 24 1.140 No Interment Group 722/Mouth 24 1.130 No Interment Group 722/Mouth 24 1.700 No Interment Group 722/Mouth 24 1.700 No Interment Group 722/Mouth 24 1.700 No Interment Group 727/Mouth 24 1.700 No Interment Group 362/Mouth 12 1.600 No Interment Group 362/Mouth 24 1.700 No Interment Group 362/Mouth 24 1.700 No Interment Group 362/Mouth 24 1.700 No Interment Group 362/Mouth 24
 | Treatment Group Subject ID Assy Lurracellar Interment Group Subject ID Assy Assy Lurracellar Interment Group Subject ID Assy Assy Lurracellar Interment Group 170010 358/Mouth 12 2770 No Interment Group 175/Mouth 24 1.870 Intrinsition Interment Group 715/Mouth 24 1.140 No Interment Group 722/Mouth 24 1.130 No Interment Group 722/Mouth 24 1.700 No Interment Group 722/Mouth 24 1.700 No Interment Group 722/Mouth 24 1.700 No Interment Group 727/Mouth 24 1.700 No Interment Group 362/Mouth 12 1.600 No Interment Group 362/Mouth 24 1.700 No Interment Group 362/Mouth 24 1.700 No Interment Group 362/Mouth 24 1.700 No Interment Group 362/Mouth 24
 | Treatment Group Subject ID Assy Lurrarecents Assy Asso Asso <td< td=""><td>Treatment Group Subject ID Terminion for activity Intranscrints Assy Diagnois Assy Asso <t< td=""><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Arisy Arisy</td></t<></td></td<> <td>Treatment Group Positive
Innumber Missy Innumber Strivty Innumber Strivty Innumber Strivty Innumber Strivty Innumston 170010 365 / Mouth 12 2.770 No No No 170010 365 / Mouth 12 2.800 Initiamiston No No 170010 355 / Mouth 24 1.870 Initia No No 177006 358 / Mouth 24 1.130 No No No 105002 719 / Mouth 24 1.130 No No No 122002 359 / Mouth 12 1.630 No No No 122002 722 / Mouth 24 1.130 No No No 124003 722 / Mouth 24 1.630 No No No 124003 722 / Mouth 24 1.630 No No No 124003 722 / Mouth 24 1.630 No No No 124003 722 / Mouth 24 1.640 No No No 124003</td> <td>Treatment Group Rotitive
Immunoreactivity Immunoreactivity Immunoreactivity Assay 170010 365 / Month 1.2 2.770 No 170010 355 / Month 1.2 2.770 No 177006 355 / Month 1.2 2.800 Infammation 177006 355 / Month 1.2 2.800 No 177006 355 / Month 2.4 1.800 Infammation 177006 355 / Month 2.4 1.130 No 177006 355 / Month 2.4 1.130 No 122002 719 / Month 2.4 1.130 No 122002 722 / Month 2.4 1.130 No 124003 722 / Month 2.4 1.300 No 124003 722 / Month 2.4 0.782 No 124003 722 / Month 2.4 0.780 No 124003 722 / Month 2.4 0.770 No 124003 722 / Month 2.4 0.780 No 124003 722 / Month 2.4 0.770 No 12400 1.770</td> <td>Treatment Group Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Asiay Locattive Inflammation 170010 365 / Month 12 2.770 No No 170010 355 / Month 12 1.870 Inflammation 177006 715 / Month 24 1.850 No 177006 732 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 739 / Month 24 1.130 No 124003 722 / Month 24 1.770 No 12400 1.14</td> | Treatment Group Subject ID Terminion for activity Intranscrints Assy Diagnois Assy Asso Asso <t< td=""><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Arisy Arisy</td></t<>
 | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Arisy | Treatment Group Positive
Innumber Missy Innumber Strivty Innumber Strivty Innumber Strivty Innumber Strivty Innumston 170010 365 / Mouth 12 2.770 No No No 170010 365 / Mouth 12 2.800 Initiamiston No No 170010 355 / Mouth 24 1.870 Initia No No 177006 358 / Mouth 24 1.130 No No No 105002 719 / Mouth 24 1.130 No No No 122002 359 / Mouth 12 1.630 No No No 122002 722 / Mouth 24 1.130 No No No 124003 722 / Mouth 24 1.630 No No No 124003 722 / Mouth 24 1.630 No No No 124003 722 / Mouth 24 1.630 No No No 124003 722 / Mouth 24 1.640 No No No 124003
 | Treatment Group Rotitive
Immunoreactivity Immunoreactivity Immunoreactivity Assay 170010 365 / Month 1.2 2.770 No 170010 355 / Month 1.2 2.770 No 177006 355 / Month 1.2 2.800 Infammation 177006 355 / Month 1.2 2.800 No 177006 355 / Month 2.4 1.800 Infammation 177006 355 / Month 2.4 1.130 No 177006 355 / Month 2.4 1.130 No 122002 719 / Month 2.4 1.130 No 122002 722 / Month 2.4 1.130 No 124003 722 / Month 2.4 1.300 No 124003 722 / Month 2.4 0.782 No 124003 722 / Month 2.4 0.780 No 124003 722 / Month 2.4 0.770 No 124003 722 / Month 2.4 0.780 No 124003 722 / Month 2.4 0.770 No 12400 1.770 | Treatment Group Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Asiay Locattive Inflammation 170010 365 / Month 12 2.770 No No 170010 355 / Month 12 1.870 Inflammation 177006 715 / Month 24 1.850 No 177006 732 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 739 / Month 24 1.130 No 124003 722 / Month 24 1.770 No 12400 1.14 |
| 534001 -7 / Screening 2.520 Vitritis

 | Sham 534001 -7 / Screening 2.520 Vitritis

 | Sham 534001 -7 / Screening 2.520 Vitritis

 | Treatment Group Positive
Innunoreactivity Innunoreactivity
Innunoreactivity Intransition Affection Subject ID 365 / Month 12 2 3770 No 170010 355 / Month 12 2 3870 No No 170010 355 / Month 12 1 3700 Initianisition Ranibizumab 0.5 mg 177006 335 / Month 12 1 8700 Initias 102001 717 / Month 24 1 880 No No 1172002 335 / Month 12 1 140 No No 1222002 335 / Month 12 1 140 No No 122001 722 / Month 24 1 3700 No No 124003 722 / Month 24 1 3700 No No 124003 722 / Month 24 1 3700 No No 122002 357 / Month 24 2 440 No No 122004 717 / Month 24 2 440 No No 122004 722 / Month 24 2 440 No No 123006

 | Treatment Group Subject ID Tommooractivity
innunoractivity Innunoractivity
innunoractivity Innunoractivity
innunoractivity Innunoractivity Innunoractity Innunoractity Innu

 | Treatment Group Subject ID Tammunoractivity
fimmunoractivity Intransition Assy Asso
 | Treatment Group
Bubject ID Assy Lurraceultr Intrunor activity Intrunor activity <td>Treatment Group Subject ID Susty Lurraceular IT0010 365 / Month 12 2770 No I70010 355 / Month 12 2770 No I70010 355 / Month 12 2770 No I77006 358 / Month 12 1870 Irtiis I177006 359 / Month 12 1870 Irtiis I06002 722 / Month 24 1130 No I2200 357 / Month 24 1700 No I24003 722 / Month 24 1700 No I24003 722 / Month 24 1.700 No I24003 717 / Month 24 1.700 No I25004 357 / Month 24 1.700 No I25002 356 / Month 12 1.700 No I22003 722 / Month 24 1.700 No</td> <td>Treatment Group Bubject ID Assy Lurraceultr Intrunor activity Intrunor activity<td>Treatment Group Bubject ID Assy Lurraceultr Intrunor activity Intrunor activity<td>Treatment Group Subject ID Tammunoractivity
fimmunoractivity Intransition Assy Asso Asso</td><td>Treatment Group Subject ID Tammunoractivity
fimmunoractivity Intransition Assy Asso Asso</td><td>Treatment Group Subject ID Tammunoractivity
fimmunoractivity Intransition Assy Asso Asso</td><td>Treatment Group Positive
Innunoreactivity Innunoreactivity
Innunoreactivity Intransition Affection Subject ID 365 / Month 12 2 3770 No 170010 355 / Month 12 2 3870 No No 170010 355 / Month 12 1 3700 Initianisition Ranibizumab 0.5 mg 177006 335 / Month 12 1 8700 Initias 102001 717 / Month 24 1 880 No No 1172002 335 / Month 12 1 140 No No 1222002 335 / Month 12 1 140 No No 122001 722 / Month 24 1 3700 No No 124003 722 / Month 24 1 3700 No No 124003 722 / Month 24 1 3700 No No 122002 357 / Month 24 2 440 No No 122004 717 / Month 24 2 440 No No 122004 722 / Month 24 2 440 No No 123006</td><td>Treatment Group Positives Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity Innumisition 7 170010 365/Month 12 2.2770 No No No No 170010 355/Month 12 1.870 Initiamisition Xassy Log Titer Diagnosis Ranibizumab 0.5 mg 102001 715/Month 2.4 1.870 Initis No 177006 335/Month 12 1.870 Initis No No 122002 335/Month 2.4 1.130 No No No 122002 335/Month 2.4 1.700 No No No 124003 722/Month 2.4 1.700 No No No 124003 727/Month 2.4 1.700 No No No 122002 357/Month 2.4 1.700 No No No 124003 712/Month 2.4 1.700 No No No 123004 181/Month 2.4 2.440 No<</td><td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumorea</td><td>Treatment Group Positive
Innumbered Vity Innumbered Vity I</td><td>Treatment Group Rotitive
Innumber Massy Innumber Strivty Innumber Stripty No No No No No No No Innumber Stripty No No</td><td>Treatment Group Evolutive
Intrusorectivity Intrusorectivity Intrusorectivity Subject ID Subject ID Asiay Local Jagnois 170010 355 / Month 12 2.770 No 170010 355 / Month 12 2.870 Inflammation 170010 355 / Month 12 1.870 Inflammation Ranibizumab 0.5 mg 102001 715 / Month 24 1.850 No 117006 717 / Month 24 1.130 No No 122002 722 / Month 24 1.130 No No 124003 722 / Month 24 1.770 No No 124001 174 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124001 174 / Month 24 0.782 No No 124003 717 / Month 24 1.770 No No 124003 715 / Month 24 1.770 No No 124003 715 / Month 24 2.440 No</td></td></td> | Treatment Group Subject ID Susty Lurraceular IT0010 365 / Month 12 2770 No I70010 355 / Month 12 2770 No I70010 355 / Month 12 2770 No I77006 358 / Month 12 1870 Irtiis I177006 359 / Month 12 1870 Irtiis I06002 722 / Month 24 1130 No I2200 357 / Month 24 1700 No I24003 722 / Month 24 1700 No I24003 722 / Month 24 1.700 No I24003 717 / Month 24 1.700 No I25004 357 / Month 24 1.700 No I25002 356 / Month 12 1.700 No I22003 722 / Month 24 1.700 No

 | Treatment Group Bubject ID Assy Lurraceultr Intrunor activity Intrunor activity <td>Treatment Group Bubject ID Assy Lurraceultr Intrunor activity Intrunor activity<td>Treatment Group Subject ID Tammunoractivity
fimmunoractivity Intransition Assy Asso Asso</td><td>Treatment Group Subject ID Tammunoractivity
fimmunoractivity Intransition Assy Asso Asso</td><td>Treatment Group Subject ID Tammunoractivity
fimmunoractivity Intransition Assy Asso Asso</td><td>Treatment Group Positive
Innunoreactivity Innunoreactivity
Innunoreactivity Intransition Affection Subject ID 365 / Month 12 2 3770 No 170010 355 / Month 12 2 3870 No No 170010 355 / Month 12 1 3700 Initianisition Ranibizumab 0.5 mg 177006 335 / Month 12 1 8700 Initias 102001 717 / Month 24 1 880 No No 1172002 335 / Month 12 1 140 No No 1222002 335 / Month 12 1 140 No No 122001 722 / Month 24 1 3700 No No 124003 722 / Month 24 1 3700 No No 124003 722 / Month 24 1 3700 No No 122002 357 / Month 24 2 440 No No 122004 717 / Month 24 2 440 No No 122004 722 / Month 24 2 440 No No 123006</td><td>Treatment Group Positives Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity Innumisition 7 170010 365/Month 12 2.2770 No No No No 170010 355/Month 12 1.870 Initiamisition Xassy Log Titer Diagnosis Ranibizumab 0.5 mg 102001 715/Month 2.4 1.870 Initis No 177006 335/Month 12 1.870 Initis No No 122002 335/Month 2.4 1.130 No No No 122002 335/Month 2.4 1.700 No No No 124003 722/Month 2.4 1.700 No No No 124003 727/Month 2.4 1.700 No No No 122002 357/Month 2.4 1.700 No No No 124003 712/Month 2.4 1.700 No No No 123004 181/Month 2.4 2.440 No<</td><td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumorea</td><td>Treatment Group Positive
Innumbered Vity Innumbered Vity I</td><td>Treatment Group Rotitive
Innumber Massy Innumber Strivty Innumber Stripty No No No No No No No Innumber Stripty No No</td><td>Treatment Group Evolutive
Intrusorectivity Intrusorectivity Intrusorectivity Subject ID Subject ID Asiay Local Jagnois 170010 355 / Month 12 2.770 No 170010 355 / Month 12 2.870 Inflammation 170010 355 / Month 12 1.870 Inflammation Ranibizumab 0.5 mg 102001 715 / Month 24 1.850 No 117006 717 / Month 24 1.130 No No 122002 722 / Month 24 1.130 No No 124003 722 / Month 24 1.770 No No 124001 174 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124001 174 / Month 24 0.782 No No 124003 717 / Month 24 1.770 No No 124003 715 / Month 24 1.770 No No 124003 715 / Month 24 2.440 No</td></td> | Treatment Group Bubject ID Assy Lurraceultr Intrunor activity Intrunor activity <td>Treatment Group Subject ID Tammunoractivity
fimmunoractivity Intransition Assy Asso Asso</td> <td>Treatment Group Subject ID Tammunoractivity
fimmunoractivity Intransition Assy Asso Asso</td> <td>Treatment Group Subject ID Tammunoractivity
fimmunoractivity Intransition Assy Asso Asso</td> <td>Treatment Group Positive
Innunoreactivity Innunoreactivity
Innunoreactivity Intransition Affection Subject ID 365 / Month 12 2 3770 No 170010 355 / Month 12 2 3870 No No 170010 355 / Month 12 1 3700 Initianisition Ranibizumab 0.5 mg 177006 335 / Month 12 1 8700 Initias 102001 717 / Month 24 1 880 No No 1172002 335 / Month 12 1 140 No No 1222002 335 / Month 12 1 140 No No 122001 722 / Month 24 1 3700 No No 124003 722 / Month 24 1 3700 No No 124003 722 / Month 24 1 3700 No No 122002 357 / Month 24 2 440 No No 122004 717 / Month 24 2 440 No No 122004 722 / Month 24 2 440 No No
123006</td> <td>Treatment Group Positives Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity Innumisition 7 170010 365/Month 12 2.2770 No No No No 170010 355/Month 12 1.870 Initiamisition Xassy Log Titer Diagnosis Ranibizumab 0.5 mg 102001 715/Month 2.4 1.870 Initis No 177006 335/Month 12 1.870 Initis No No 122002 335/Month 2.4 1.130 No No No 122002 335/Month 2.4 1.700 No No No 124003 722/Month 2.4 1.700 No No No 124003 727/Month 2.4 1.700 No No No 122002 357/Month 2.4 1.700 No No No 124003 712/Month 2.4 1.700 No No No 123004 181/Month 2.4 2.440 No<</td> <td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumorea</td> <td>Treatment Group Positive
Innumbered Vity Innumbered Vity I</td> <td>Treatment Group Rotitive
Innumber Massy Innumber Strivty Innumber Stripty No No No No No No No Innumber Stripty No No</td> <td>Treatment Group Evolutive
Intrusorectivity Intrusorectivity Intrusorectivity Subject ID Subject ID Asiay Local Jagnois 170010 355 / Month 12 2.770 No 170010 355 / Month 12 2.870 Inflammation 170010 355 / Month 12 1.870 Inflammation Ranibizumab 0.5 mg 102001 715 / Month 24 1.850 No 117006 717 / Month 24 1.130 No No 122002 722 / Month 24 1.130 No No 124003 722 / Month 24 1.770 No No 124001 174 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124001 174 / Month 24 0.782 No No 124003 717 / Month 24 1.770 No No 124003 715 / Month 24 1.770 No No 124003 715 / Month 24 2.440 No</td> | Treatment Group Subject ID Tammunoractivity
fimmunoractivity Intransition Assy Asso
 | Treatment Group Subject ID Tammunoractivity
fimmunoractivity Intransition Assy Asso
 | Treatment Group Subject ID Tammunoractivity
fimmunoractivity Intransition Assy Asso
 | Treatment Group Positive
Innunoreactivity Innunoreactivity
Innunoreactivity Intransition Affection Subject ID 365 / Month 12 2 3770 No 170010 355 / Month 12 2 3870 No No 170010 355 / Month 12 1 3700 Initianisition Ranibizumab 0.5 mg 177006 335 / Month 12 1 8700 Initias 102001 717 / Month 24 1 880 No No 1172002 335 / Month 12 1 140 No No 1222002 335 / Month 12 1 140 No No 122001 722 / Month 24 1 3700 No No 124003 722 / Month 24 1 3700 No No 124003 722 / Month 24 1 3700 No No 122002 357 / Month 24 2 440 No No 122004 717 / Month 24 2 440 No No 122004 722 / Month 24 2 440 No No 123006
 | Treatment Group Positives Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity Innumisition 7 170010 365/Month 12 2.2770 No No No No 170010 355/Month 12 1.870 Initiamisition Xassy Log Titer Diagnosis Ranibizumab 0.5 mg 102001 715/Month 2.4 1.870 Initis No 177006 335/Month 12 1.870 Initis No No 122002 335/Month 2.4 1.130 No No No 122002 335/Month 2.4 1.700 No No No 124003 722/Month 2.4 1.700 No No No 124003 727/Month 2.4 1.700 No No No 122002 357/Month 2.4 1.700 No No No 124003 712/Month 2.4 1.700 No No No 123004 181/Month 2.4 2.440 No<
 | Treatment Group Positive
Innumoreactivity Innumoreactivity Innumorea | Treatment Group Positive
Innumbered Vity Innumbered Vity I | Treatment Group Rotitive
Innumber Massy Innumber Strivty Innumber Stripty No No No No No No No Innumber Stripty No
 | Treatment Group Evolutive
Intrusorectivity Intrusorectivity Intrusorectivity Subject ID Subject ID Asiay Local Jagnois 170010 355 / Month 12 2.770 No 170010 355 / Month 12 2.870 Inflammation 170010 355 / Month 12 1.870 Inflammation Ranibizumab 0.5 mg 102001 715 / Month 24 1.850 No 117006 717 / Month 24 1.130 No No 122002 722 / Month 24 1.130 No No 124003 722 / Month 24 1.770 No No 124001 174 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124001 174 / Month 24 0.782 No No 124003 717 / Month 24 1.770 No No 124003 715 / Month 24 1.770 No No 124003 715 / Month 24 2.440 No |
| Sham 534001 -7 / Screening 2.520 Vitritis

 | Sham 534001 -7 / Screening 2.520 Vitritis

 | Sham 534001 -7 / Screening 2.520 Virritis

 | Treatment Group Positive
Assist Turnancentivity
Immunoreactivity Intransition
Assist Turnancentiat
Assist Intransition
Assist Intransist Intransist

 | Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity

 | Treatment Group Subject ID Positive
Immunoractivity Immunoractivity Immuno

 | Treatment Group Bositre
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity JTeettment Group Subject ID 365 / Month 12 2770 No 170010 365 / Month 12 2770 No 177006 358 / Month 12 1870 Irtitis 177006 358 / Month 12 1870 Irtitis 177006 358 / Month 12 1850 No 177006 358 / Month 12 1870 Irtitis 104002 711 / Month 24 1140 No 104002 722 / Month 12 1630 No 104002 722 / Month 24 1770 No 126001 181 / Month 6 1.700 No 126001 181 / Month 24 1.940 No 141013 715 / Month 24 1.940 No 143010 722 / Month 24 1.940 No 143010 722 / Month 24 1.940 No 143010 722 / Month 24 1.940 No 143010

 | Treatment Group Bositre
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity JTeatment Group Subject ID 34sy 23770 No 170010 355 / Month 12 2770 No Ingmosis 177006 358 / Month 12 1870 Irritis Ingmosis 177006 358 / Month 12 1850 No Intris 177006 358 / Month 12 1870 Irritis Intris 177006 358 / Month 12 1870 Irritis No 104002 722 / Month 24 1.140 No No 126001 126/001 27 / Month 24 1.700 No 126001 181 / Month 6 1.700 No Irritis 126001 181 / Month 6 1.570 No No 13600 181 / Month 52 1.940 No No 141013 715 / Month 24 1.570 No No 122004 522 / Month 24 1.940 No No

 | Treatment Group Bositre
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity JTeettment Group Subject ID 365 / Month 12 2770 No 170010 365 / Month 12 2770 No 177006 358 / Month 12 1870 Irtitis 177006 358 / Month 12 1870 Irtitis 177006 358 / Month 12 1850 No 177006 358 / Month 12 1870 Irtitis 104002 711 / Month 24 1140 No 104002 722 / Month 12 1630 No 104002 722 / Month 24 1770 No 126001 181 / Month 6 1.700 No 126001 181 / Month 24 1.940 No 141013 715 / Month 24 1.940 No 143010 722 / Month 24 1.940 No 143010 722 / Month 24 1.940 No 143010 722 / Month 24 1.940 No 143010
 | Treatment Group Bositre
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity JTeettment Group Subject ID 365 / Month 12 2770 No 170010 365 / Month 12 2770 No 177006 358 / Month 12 1870 Irtitis 177006 358 / Month 12 1870 Irtitis 177006 358 / Month 12 1850 No 177006 358 / Month 12 1870 Irtitis 104002 711 / Month 24 1140 No 104002 722 / Month 12 1630 No 104002 722 / Month 24 1770 No 126001 181 / Month 6 1.700 No 126001 181 / Month 24 1.940 No 141013 715 / Month 24 1.940 No 143010 722 / Month 24 1.940 No 143010 722 / Month 24 1.940 No 143010 722 / Month 24 1.940 No 143010

 | Treatment Group Subject ID Positive
Immunoractivity Immunoractivity Immuno
 | Treatment Group Subject ID Positive
Immunoractivity Immunoractivity Immuno
 | Treatment Group Subject ID Positive
Immunoractivity Immunoractivity Immuno
 | Treatment Group Positive
Assist Turnancentivity
Immunoreactivity Intransition
Assist Turnancentiat
Assist Intransition
Assist Intransist Intransist
 | Treatment Group Positive
Innunoreactivity Innunoreactivity
Innunoreactivity Intransiction Areatiment Group Subject ID 365 / Month 12 2 sry Log Titer Diagnoits 170010 365 / Month 12 2 sry Log Titer Diagnoits 177006 355 / Month 12 1 sry 0 No 177006 355 / Month 12 1 sry 0 Irris Ranibizumab 0.5 mg 102001 722 / Month 24 1 sry 0 No 102002 722 / Month 12 1 sry 0 No No 122002 359 / Month 12 1 sry 0 No No 122002 722 / Month 24 1 sry 0 No No 126001 722 / Month 24 1 sry 0 No No 126001 727 / Month 24 1 sry 0 No No 126001 715 / Month 24 1 sry 0 No No 128004 181 / Month 24 1 sry 0 No No 139010 722 / Month 24 1 sry 0 No No 141013 | Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity Treatment Group Subject ID 365 / Mouth 12 2.770 No No 170010 365 / Mouth 12 2.770 No No No Ranibizumab 0.5 mg 170010 355 / Mouth 24 2.800 Irritis No 177006 3.55 / Mouth 24 0.922 No No No 102001 772 / Mouth 24 1.870 No No 104002 722 / Mouth 24 1.140 No No 122001 722 / Mouth 24 1.1700 No No 126001 722 / Mouth 24 1.700 No No 126001 722 / Mouth 24 1.700 No No 126001 717 / Mouth 24 1.700 No No 128004 181 / Mouth 24 1.700 No No 128010 715 / Mouth 24 1.940 No No 135004 181 / Mouth 24
 | Treatment Group Positive
Innumoreactivity Innumoreactivity Innumorea | Treatment Group Positive
Innumeredivity Innumeredivity Innumeredivity Innumeredivity Asiay Intracentiat Asiay Innumeredivity Innumeredivity Innumeredivity 170010 365 / Mouth 12 2.770 No No 170010 355 / Mouth 12 2.800 Initia 170010 355 / Mouth 24 1.850 No 177 Month 24 1.870 Initia No 105001 712 / Mouth 24 1.300 No No 105002 712 / Mouth 24 1.300 No No 102001 722 / Mouth 24 1.700 No No 122002 357 / Mouth 24 1.700 No No 124003 712 / Mouth 24 1.700 No No 124003 715 / Mouth 24 1.700 No No 124003 715 / Mouth 24 1.700 No No 124003 715 / Mouth 24 1.940 No No 125004 522 / Mouth 24 | Treatment Group Immunoractivity Immunoractivity Immunoractivity Subject ID Subject ID Asiay Asiay Infammiton I70010 365 Month 12 2.770 No I70010 355 Month 12 2.800 Infammiton Ranibizumab 0.5 mg 170010 355 Month 12 1.870 Infam 177006 355 Month 12 1.870 Infam Infam 102001 722 Month 24 1.130 No No 102002 722 Month 24 1.130 No No 122002 359 Month 12 1.630 No No 122002 357 Month 24 1.700 No No 124003 712 Month 24 1.700 No No 124003 715 Month 24 1.700 No No 124003 715 Month 24 1.700 No No 124003 717 Month 24 1.400 No No 124003 715 Month 24 1.940 No N
 |
| 188005 717 / Month 24 1.250 No No </th <th>188005 717 / Month 24 1.250 No No<!--</th--><td>I88005 717/Month 24 1.250 No No<td>Treatment Group Subject ID Assy Lurrarecular ITreatment Group Subject ID Assy Asso Ass</td><td>Treatment Group Subject ID Towninoreactivity Immunoreactivity Immunoreactivity</td><td>Treatment Group Subject ID Tannunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immuno</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td><td>Treatment Group Subject ID Monthize activity
Subject ID Immunoreactivity
Subject I</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td><td>Treatment Group Subject ID Tannunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immuno</td><td>Treatment Group Subject ID Tannunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immuno</td><td>Treatment Group Subject ID Tannunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immuno</td><td>Treatment Group Subject ID Assy Lurrarecular ITreatment Group Subject ID Assy Asso Ass</td><td>Treatment Group Bubject ID Assiy Assiy Intransocials Assiy Ass</td><td>Treatment Group Positive
Innunoreactivity Innunoreactivity Innunorea</td><td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumorea</td><td>Treatment Group Rotitive
Innumber Aise Province activity
Innumber Aise Innumber Aise Innumber Aise 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 Initiamination 170010 365 / Month 12 2.800 Initia 170010 355 / Month 12 1.870 Initia 177006 3.55 / Month 24 0.922 No 105001 722 / Month 24 1.140 No 104002 722 / Month 24 1.140 No 122001 722 / Month 24 1.1700 No 122002 359 / Month 12 1.700 No 126001 727 / Month 24 1.700 No 126001 727 / Month 24 1.700 No 13600 181 / Month 6 1.700 No 141013 725 / Month 24 1.940 No 143010 722 / Month 24 1.700 No 143010 722 / Month 24 1.940 No 141013<td>Treatment Group Subject ID Positive
Inframineton Intranciular Treatment Group Subject ID Assay Log Tiert Inframineton 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Inframineton Ranibizumab 0.5 mg 177006 358 / Month 24 1.870 Intrus 177006 358 / Month 24 1.870 Nio No 177001 727 / Month 24 1.870 Nio No 104002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.170 No No 124003 722 / Month 24 1.700 No<!--</td--></td></td></td></th> | 188005 717 / Month 24 1.250 No No </th <td>I88005 717/Month 24 1.250 No No<td>Treatment Group Subject ID Assy Lurrarecular ITreatment Group Subject ID Assy Asso Ass</td><td>Treatment Group Subject ID Towninoreactivity Immunoreactivity Immunoreactivity</td><td>Treatment Group Subject ID Tannunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immuno</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td><td>Treatment Group Subject ID Monthize activity
Subject ID Immunoreactivity
Subject I</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td><td>Treatment Group Subject ID Tannunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immuno</td><td>Treatment Group Subject ID Tannunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immuno</td><td>Treatment Group Subject ID Tannunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immuno</td><td>Treatment Group Subject ID Assy Lurrarecular ITreatment Group Subject ID Assy Asso Ass</td><td>Treatment Group Bubject ID Assiy Assiy Intransocials Assiy Ass</td><td>Treatment Group Positive
Innunoreactivity Innunoreactivity Innunorea</td><td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumorea</td><td>Treatment Group Rotitive
Innumber Aise Province activity
Innumber Aise Innumber Aise Innumber Aise 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 Initiamination 170010 365 / Month 12 2.800 Initia 170010 355 / Month 12 1.870 Initia 177006 3.55 / Month 24 0.922 No 105001 722 / Month 24 1.140 No 104002 722 / Month 24 1.140 No 122001 722 / Month 24 1.1700 No 122002 359 / Month 12 1.700 No 126001 727 / Month 24 1.700 No 126001 727 / Month 24 1.700 No 13600 181 / Month 6 1.700 No 141013 725 / Month 24 1.940 No 143010 722 / Month 24 1.700 No 143010 722 / Month 24 1.940 No 141013<td>Treatment Group Subject ID Positive
Inframineton Intranciular Treatment Group Subject ID Assay Log Tiert Inframineton 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Inframineton Ranibizumab 0.5 mg 177006 358 / Month 24 1.870 Intrus 177006 358 / Month 24 1.870 Nio No 177001 727 / Month 24 1.870 Nio No 104002
 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.170 No No 124003 722 / Month 24 1.700 No<!--</td--></td></td></td> | I88005 717/Month 24 1.250 No No <td>Treatment Group Subject ID Assy Lurrarecular ITreatment Group Subject ID Assy Asso Ass</td> <td>Treatment Group Subject ID Towninoreactivity Immunoreactivity Immunoreactivity</td> <td>Treatment Group Subject ID Tannunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immuno</td> <td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td> <td>Treatment Group Subject ID Monthize activity
Subject ID Immunoreactivity
Subject I</td> <td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td> <td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td> <td>Treatment Group Subject ID Tannunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immuno</td> <td>Treatment Group Subject ID Tannunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immuno</td> <td>Treatment Group Subject ID Tannunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immuno</td> <td>Treatment Group Subject ID Assy Lurrarecular ITreatment Group Subject ID Assy Asso Ass</td> <td>Treatment Group Bubject ID Assiy Assiy Intransocials Assiy Ass</td> <td>Treatment Group Positive
Innunoreactivity Innunoreactivity Innunorea</td> <td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumorea</td> <td>Treatment Group Rotitive
Innumber Aise Province activity
Innumber Aise Innumber Aise Innumber Aise 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 Initiamination 170010 365 / Month 12 2.800 Initia 170010 355 / Month 12 1.870 Initia 177006 3.55 / Month 24 0.922 No 105001 722 / Month 24 1.140 No 104002 722 / Month 24 1.140 No 122001 722 / Month 24 1.1700 No 122002 359 / Month 12 1.700 No 126001 727 / Month 24 1.700 No 126001 727 / Month 24 1.700 No 13600 181 / Month 6 1.700 No 141013 725 / Month 24 1.940 No 143010 722 / Month 24 1.700 No 143010 722 / Month 24 1.940 No 141013<td>Treatment Group Subject ID Positive
Inframineton Intranciular Treatment Group Subject ID Assay Log Tiert Inframineton 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Inframineton Ranibizumab 0.5 mg 177006 358 / Month 24 1.870 Intrus 177006 358 / Month 24 1.870 Nio No 177001 727 / Month 24 1.870 Nio No 104002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.170 No No 124003 722 / Month 24 1.700 No<!--</td--></td></td> | Treatment Group Subject ID Assy Lurrarecular ITreatment Group Subject ID Assy Asso Ass

 | Treatment Group Subject ID Towninoreactivity Immunoreactivity

 | Treatment Group Subject ID Tannunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immuno

 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit

 | Treatment Group Subject ID Monthize activity
Subject ID Immunoreactivity
Subject I
 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit

 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit
 | Treatment Group Subject ID Tannunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immuno
 | Treatment Group Subject ID Tannunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immuno
 | Treatment Group Subject ID Tannunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immuno
 | Treatment Group Subject ID Assy Lurrarecular ITreatment Group Subject ID Assy Asso Ass
 | Treatment Group Bubject ID Assiy Assiy Intransocials Assiy Ass
 | Treatment Group Positive
Innunoreactivity Innunoreactivity Innunorea | Treatment Group Positive
Innumoreactivity Innumoreactivity Innumorea | Treatment Group Rotitive
Innumber Aise Province activity
Innumber Aise Innumber Aise Innumber Aise 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 Initiamination 170010 365 / Month 12 2.800 Initia 170010 355 / Month 12 1.870 Initia 177006 3.55 / Month 24 0.922 No 105001 722 / Month 24 1.140 No 104002 722 / Month 24 1.140 No 122001 722 / Month 24 1.1700 No 122002 359 / Month 12 1.700 No 126001 727 / Month 24 1.700 No 126001 727 / Month 24 1.700 No 13600 181 / Month 6 1.700 No 141013 725 / Month 24 1.940 No 143010 722 / Month 24 1.700 No 143010 722 / Month 24 1.940 No 141013 <td>Treatment Group Subject ID Positive
Inframineton Intranciular Treatment Group Subject ID Assay Log Tiert Inframineton 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Inframineton
Ranibizumab 0.5 mg 177006 358 / Month 24 1.870 Intrus 177006 358 / Month 24 1.870 Nio No 177001 727 / Month 24 1.870 Nio No 104002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.170 No No 124003 722 / Month 24 1.700 No<!--</td--></td> | Treatment Group Subject ID Positive
Inframineton Intranciular Treatment Group Subject ID Assay Log Tiert Inframineton 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Inframineton Ranibizumab 0.5 mg 177006 358 / Month 24 1.870 Intrus 177006 358 / Month 24 1.870 Nio No 177001 727 / Month 24 1.870 Nio No 104002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.170 No No 124003 722 / Month 24 1.700 No </td |
| 188005 717 / Month 24 1.250 No Sham 534001 -7 / Screening 2.520 Vitritis

 | 188005 717 / Month 24 1.250 No Sham 534001 -7 / Screening 2.520 Vitritis

 | 188005 717 / Month 24 1.250 No Sham 534001 -7 / Screening 2.520 Vitritis

 | Treatment Group Innumoreactivity Innumoreactivity </td <td>Treatment Group Subject ID Nasy Lurraceular Instruction Subject ID Subject ID Jasay Lurraceular Instruction 170010 365 / Month 12 2770 No Instruction 175006 358 / Month 12 2770 No Instruction 715 / Month 24 1.870 Irtits Instruction 717 / Month 24 1.130 No Instruction 722 / Month 24 1.700 No Instruction 722 / Month 24 1.700 No Instruction 737 / Month 24 1.700 No Instruction 362 / Month 12 1.600 No Instruction 11/4 0.782 No Instruction 12200 1.700 No Instruction 1.140 No No</td> <td>Treatment Group Bubject ID Subject ID Nasty Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group 170010 355 Mouth 12 2770 No Interment Group 175006 358 Mouth 12 1870 Intrins Interment Group 177 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 106002 721 Month 24 1770 No No Interment D 5 mg 120001 174 Month 24 1770 No No Interment D 5 mg 120001 722 Month 24 1770 No No Interment D 6 1770 No No No No Interment D 6 1740 No No No</td> <td>Treatment Group Bositre
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity JTeatment Group Subject ID 3ssy Asay Asay Lugrandia 170010 365/Month 12 2770 No No 170010 358/Month 12 2870 Infrimmation 177006 358/Month 12 1870 Infri 177006 358/Month 24 1.140 No 106002 719/Month 24 1.140 No 122002 339/Month 24 1.1700 No 124003 722/Month 24 1.700 No 122002 339/Month 12 1.690 No 124003 721/Month 24 1.700 No 124003 722/Month 24 1.700 No 124003 722/Month 24 1.700 No 124003 721/Month 24 1.700 No 12400 733/Month 24 1.700 No 12400 131/Month 24 1.700 No 1</td> <td>Treatment Group Bubject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td> <td>Treatment Group Bositre
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity JTeatment Group Subject ID 3ssy Asay Asay Lugrandia 170010 365/Month 12 2770 No No 170010 358/Month 12 2870 Infrimmation 177006 358/Month 12 1870 Infri 177006 358/Month 24 1.140 No
 106002 719/Month 24 1.140 No 122002 339/Month 24 1.1700 No 124003 722/Month 24 1.700 No 122002 339/Month 12 1.690 No 124003 721/Month 24 1.700 No 124003 722/Month 24 1.700 No 124003 722/Month 24 1.700 No 124003 721/Month 24 1.700 No 12400 733/Month 24 1.700 No 12400 131/Month 24 1.700 No 1</td> <td>Treatment Group Bositre
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity JTeatment Group Subject ID 3ssy Asay Asay Lugrandia 170010 365/Month 12 2770 No No 170010 358/Month 12 2870 Infrimmation 177006 358/Month 12 1870 Infri 177006 358/Month 24 1.140 No 106002 719/Month 24 1.140 No 122002 339/Month 24 1.1700 No 124003 722/Month 24 1.700 No 122002 339/Month 12 1.690 No 124003 721/Month 24 1.700 No 124003 722/Month 24 1.700 No 124003 722/Month 24 1.700 No 124003 721/Month 24 1.700 No 12400 733/Month 24 1.700 No 12400 131/Month 24 1.700 No 1</td> <td>Treatment Group Bubject ID Subject ID Nasty Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group 170010 355 Mouth 12 2770 No Interment Group 175006 358 Mouth 12 1870 Intrins Interment Group 177 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 106002 721 Month 24 1770 No No Interment D 5 mg 120001 174 Month 24 1770 No No Interment D 5 mg 120001 722 Month 24 1770 No No Interment D 6 1770 No No No No Interment D 6 1740 No No No</td> <td>Treatment Group Bubject ID Subject ID Nasty Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group 170010 355 Mouth 12 2770 No Interment Group 175006 358 Mouth 12 1870 Intrins Interment Group 177 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 106002 721 Month 24 1770 No No Interment D 5 mg 120001 174 Month 24 1770 No No Interment D 5 mg 120001 722 Month 24 1770 No No Interment D 6 1770 No No No No Interment D 6 1740 No No No</td> <td>Treatment Group Bubject ID Subject ID Nasty Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group 170010 355 Mouth 12 2770 No Interment Group 175006 358 Mouth 12 1870 Intrins Interment Group 177 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 106002 721 Month 24 1770 No No Interment D 5 mg 120001 174 Month 24 1770 No No Interment D 5 mg 120001 722 Month 24 1770 No No Interment D 6 1770 No No No No Interment D 6 1740 No No No</td> <td>Treatment Group Innumoreactivity Innumoreactivity<!--</td--><td>Treatment Group Intranceditive Intranceditie Treatment Group Subject ID Assey Assey Intranceditie 170010 365 / Month 12 2770 No No 170010 365 / Month 12 2770 No No 170010 365 / Month 12 1870 Irrinia Irris 177006 358 / Month 12 1870 Irris No 177006 358 / Month 24 1390 No No 104002 712 / Month 24 1140 No No 124003 722 / Month 24 1330 No No 122002 359 / Month 24 1770 No No 124003 722 / Month 24 1770 No <t< td=""><td>Treatment/Group Intranscription Treatment/Group Innumoreactivity Intranscription 170010 365/Month 12 23700 Nio 170010 365/Month 12 2300 Nio 170010 355/Month 12 1870 Irritis 170010 355/Month 24 1870 Irritis 177006 338/Month 24 1360 Nio 177005 355/Month 24 1370 Nio 104002 712/Month 24 1140 Nio 122002 359/Month 12 1500 Nio 122002 359/Month 12 1500 Nio 122002 359/Month 24 1300 Nio 122002 359/Month 12 1500 Nio 124003 722/Month 24 1300 Nio 124003 722/Month 24 1300 Nio 124003 722/Month 24 1300 Nio 124003 722/Month 24 1700 Nio 124003 722/Month 24 1600</td><td>Treatment Group Politive
Innunoreactivity Intrancentiar
Innunoreactivity Intrancentiar
Infammination Arsay Leg Titer Subject ID Assay Leg Titer Digenosis 170010 365/Month 12 2800 No 177006 338/Month 12 1870 Irritis 177006 338/Month 24 1870 Irritis 104002 717/Month 24 1140 No 104002 722/Month 24 1130 No 122002 359/Month 12 16300 No 124003 722/Month 24 1130 No 122002 359/Month 12 16300 No 124003 722/Month 24 1130 No 124003 722/Month 24 1770 No 124003 722/Month 24 1770 No 124003 722/Month 24 1700 <</td><td>Treatment Group Positive
Innumerativity Lurrancettisty Lurrancettisty Treatment Group Subject ID Assay Log Titer Diagnosis 170010 365 / Month 12 2770 No Diagnosis 170010 365 / Month 12 2800 No Diagnosis 170010 365 / Month 24 1870 Lirtis Diagnosis 177006 338 / Month 24 1870 Lirtis Diagnosis 104002 712 / Month 24 1140 No No 104002 722 / Month 24 1130 No No 122002 359 / Month 24 1170 No No 124003 722 / Month 24 1770 No No 124003 722 / Month 24 1770 No No 12400 722 /</td><td>Treatment Group Routing and the seture of the particular function of the particular function of the particular function of the particular desired by the partin desired by the particular desired by the particular</td></t<></td></td>
 | Treatment Group Subject ID Nasy Lurraceular Instruction Subject ID Subject ID Jasay Lurraceular Instruction 170010 365 / Month 12 2770 No Instruction 175006 358 / Month 12 2770 No Instruction 715 / Month 24 1.870 Irtits Instruction 717 / Month 24 1.130 No Instruction 722 / Month 24 1.700 No Instruction 722 / Month 24 1.700 No Instruction 737 / Month 24 1.700 No Instruction 362 / Month 12 1.600 No Instruction 11/4 0.782 No Instruction 12200 1.700 No Instruction 1.140 No No

 | Treatment Group Bubject ID Subject ID Nasty Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group 170010 355 Mouth 12 2770 No Interment Group 175006 358 Mouth 12 1870 Intrins Interment Group 177 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 106002 721 Month 24 1770 No No Interment D 5 mg 120001 174 Month 24 1770 No No Interment D 5 mg 120001 722 Month 24 1770 No No Interment D 6 1770 No No No No Interment D 6 1740 No No No

 | Treatment Group Bositre
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity JTeatment Group Subject ID 3ssy Asay Asay Lugrandia 170010 365/Month 12 2770 No No 170010 358/Month 12 2870 Infrimmation 177006 358/Month 12 1870 Infri 177006 358/Month 24 1.140 No 106002 719/Month 24 1.140 No 122002 339/Month 24 1.1700 No 124003 722/Month 24 1.700 No 122002 339/Month 12 1.690 No 124003 721/Month 24 1.700 No 124003 722/Month 24 1.700 No 124003 722/Month 24 1.700 No 124003 721/Month 24 1.700 No 12400 733/Month 24 1.700 No 12400 131/Month 24 1.700 No 1

 | Treatment Group Bubject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit
 | Treatment Group Bositre
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity JTeatment Group Subject ID 3ssy Asay Asay Lugrandia 170010 365/Month 12 2770 No No 170010 358/Month 12 2870 Infrimmation 177006 358/Month 12 1870 Infri 177006 358/Month 24 1.140 No 106002 719/Month 24 1.140 No 122002 339/Month 24 1.1700 No 124003 722/Month 24 1.700 No 122002 339/Month 12 1.690 No 124003 721/Month 24 1.700 No 124003 722/Month 24 1.700 No 124003 722/Month 24 1.700 No 124003 721/Month 24 1.700 No 12400 733/Month 24 1.700 No 12400 131/Month 24 1.700 No 1

 | Treatment Group Bositre
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity JTeatment Group Subject ID 3ssy Asay Asay Lugrandia 170010 365/Month 12 2770 No No 170010 358/Month 12 2870 Infrimmation 177006 358/Month 12 1870 Infri 177006 358/Month 24 1.140 No 106002 719/Month 24 1.140 No 122002 339/Month 24 1.1700 No 124003 722/Month 24 1.700 No 122002 339/Month 12 1.690 No 124003 721/Month 24 1.700 No 124003 722/Month 24 1.700 No 124003 722/Month 24 1.700 No 124003 721/Month 24 1.700 No 12400 733/Month 24 1.700 No 12400 131/Month 24 1.700 No 1
 | Treatment Group Bubject ID Subject ID Nasty Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group 170010 355 Mouth 12 2770 No Interment Group 175006 358 Mouth 12 1870 Intrins Interment Group 177 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 106002 721 Month 24 1770 No No Interment D 5 mg 120001 174 Month 24 1770 No No Interment D 5 mg 120001 722 Month 24 1770 No No Interment D 6 1770 No No No No Interment D 6 1740 No No No

 | Treatment Group Bubject ID Subject ID Nasty Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group 170010 355 Mouth 12 2770 No Interment Group 175006 358 Mouth 12 1870 Intrins Interment Group 177 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 106002 721 Month 24 1770 No No Interment D 5 mg 120001 174 Month 24 1770 No No Interment D 5 mg 120001 722 Month 24 1770 No No Interment D 6 1770 No No No No Interment D 6 1740 No No No
 | Treatment Group Bubject ID Subject ID Nasty Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group Subject ID 3454y Assay Lurraceultar Interment Group 170010 355 Mouth 12 2770 No Interment Group 175006 358 Mouth 12 1870 Intrins Interment Group 177 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 102001 722 Month 24 1130 No No Interment D 5 mg 106002 721 Month 24 1770 No No Interment D 5 mg 120001 174 Month 24 1770 No No Interment D 5 mg 120001 722 Month 24 1770 No No Interment D 6 1770 No No No No Interment D 6 1740 No No No
 | Treatment Group Innumoreactivity Innumoreactivity </td <td>Treatment Group Intranceditive Intranceditie Treatment Group Subject ID Assey Assey Intranceditie 170010 365 / Month 12 2770 No No 170010 365 / Month 12 2770 No No 170010 365 / Month 12 1870 Irrinia Irris 177006 358 / Month 12 1870 Irris No 177006 358 / Month 24 1390 No No 104002 712 / Month 24 1140 No No 124003 722 / Month 24 1330 No No 122002 359 / Month 24 1770 No No 124003 722 / Month 24 1770 No <t< td=""><td>Treatment/Group Intranscription Treatment/Group Innumoreactivity Intranscription 170010 365/Month 12 23700 Nio 170010 365/Month 12 2300 Nio 170010 355/Month 12 1870 Irritis 170010 355/Month 24 1870 Irritis 177006 338/Month 24 1360 Nio 177005 355/Month 24 1370 Nio 104002 712/Month 24 1140 Nio 122002 359/Month 12 1500 Nio 122002 359/Month 12 1500 Nio 122002 359/Month 24 1300 Nio 122002 359/Month 12 1500 Nio 124003 722/Month 24 1300 Nio 124003 722/Month 24 1300 Nio 124003 722/Month 24 1300 Nio 124003 722/Month 24 1700 Nio 124003 722/Month 24 1600</td><td>Treatment Group Politive
Innunoreactivity Intrancentiar
Innunoreactivity Intrancentiar
Infammination Arsay Leg Titer Subject ID Assay Leg Titer Digenosis 170010 365/Month 12 2800 No 177006 338/Month 12 1870 Irritis 177006 338/Month 24 1870 Irritis 104002 717/Month 24 1140 No 104002 722/Month 24 1130 No 122002 359/Month 12 16300 No 124003 722/Month 24 1130 No 122002 359/Month 12 16300 No 124003 722/Month 24 1130 No 124003 722/Month 24 1770 No 124003 722/Month 24 1770 No 124003 722/Month 24 1700 <</td><td>Treatment Group Positive
Innumerativity Lurrancettisty Lurrancettisty Treatment Group Subject ID Assay Log Titer Diagnosis 170010 365 / Month 12 2770 No Diagnosis 170010 365 / Month 12 2800 No Diagnosis 170010 365 / Month 24 1870 Lirtis Diagnosis 177006 338 / Month 24 1870 Lirtis Diagnosis 104002 712 / Month 24 1140 No No 104002 722 / Month 24 1130 No No 122002 359 / Month 24 1170 No No 124003 722 / Month 24 1770 No No 124003 722 / Month 24 1770 No No 12400 722 /</td><td>Treatment Group Routing and the seture of the particular function of the particular function of the particular function of the particular desired by the partin desired by the particular desired by the particular</td></t<></td> | Treatment Group Intranceditive Intranceditie Treatment Group Subject ID Assey Assey Intranceditie 170010 365 / Month 12 2770 No No 170010 365 / Month 12 2770 No No 170010 365 / Month 12 1870 Irrinia Irris 177006 358 / Month 12 1870 Irris No 177006 358 / Month 24 1390 No No 104002 712 / Month 24 1140 No No 124003 722 / Month 24 1330 No No 122002 359 / Month 24 1770 No No 124003 722 / Month 24 1770 No <t< td=""><td>Treatment/Group Intranscription Treatment/Group Innumoreactivity Intranscription 170010 365/Month 12 23700 Nio 170010 365/Month 12 2300 Nio 170010 355/Month 12 1870 Irritis 170010 355/Month 24 1870 Irritis 177006 338/Month 24 1360 Nio 177005 355/Month 24 1370 Nio 104002 712/Month 24 1140 Nio 122002 359/Month 12 1500 Nio 122002 359/Month 12 1500 Nio 122002 359/Month 24 1300 Nio 122002 359/Month 12 1500 Nio 124003 722/Month 24 1300 Nio 124003 722/Month 24 1300 Nio 124003 722/Month 24 1300 Nio 124003
722/Month 24 1700 Nio 124003 722/Month 24 1600</td><td>Treatment Group Politive
Innunoreactivity Intrancentiar
Innunoreactivity Intrancentiar
Infammination Arsay Leg Titer Subject ID Assay Leg Titer Digenosis 170010 365/Month 12 2800 No 177006 338/Month 12 1870 Irritis 177006 338/Month 24 1870 Irritis 104002 717/Month 24 1140 No 104002 722/Month 24 1130 No 122002 359/Month 12 16300 No 124003 722/Month 24 1130 No 122002 359/Month 12 16300 No 124003 722/Month 24 1130 No 124003 722/Month 24 1770 No 124003 722/Month 24 1770 No 124003 722/Month 24 1700 <</td><td>Treatment Group Positive
Innumerativity Lurrancettisty Lurrancettisty Treatment Group Subject ID Assay Log Titer Diagnosis 170010 365 / Month 12 2770 No Diagnosis 170010 365 / Month 12 2800 No Diagnosis 170010 365 / Month 24 1870 Lirtis Diagnosis 177006 338 / Month 24 1870 Lirtis Diagnosis 104002 712 / Month 24 1140 No No 104002 722 / Month 24 1130 No No 122002 359 / Month 24 1170 No No 124003 722 / Month 24 1770 No No 124003 722 / Month 24 1770 No No 12400 722 /</td><td>Treatment Group Routing and the seture of the particular function of the particular function of the particular function of the particular desired by the partin desired by the particular desired by the particular</td></t<> | Treatment/Group Intranscription Treatment/Group Innumoreactivity Intranscription 170010 365/Month 12 23700 Nio 170010 365/Month 12 2300 Nio 170010 355/Month 12 1870 Irritis 170010 355/Month 24 1870 Irritis 177006 338/Month 24 1360 Nio 177005 355/Month 24 1370 Nio 104002 712/Month 24 1140 Nio 122002 359/Month 12 1500 Nio 122002 359/Month 12 1500 Nio 122002 359/Month 24 1300 Nio 122002 359/Month 12 1500 Nio 124003 722/Month 24 1300 Nio 124003 722/Month 24 1300 Nio 124003 722/Month 24 1300 Nio 124003 722/Month 24 1700 Nio 124003 722/Month 24 1600 | Treatment Group Politive
Innunoreactivity Intrancentiar
Innunoreactivity Intrancentiar
Infammination Arsay Leg Titer Subject ID Assay Leg Titer Digenosis 170010 365/Month 12 2800 No 177006 338/Month 12 1870 Irritis 177006 338/Month 24 1870 Irritis 104002 717/Month 24 1140 No 104002 722/Month 24 1130 No 122002 359/Month 12 16300 No 124003 722/Month 24 1130 No 122002 359/Month 12 16300 No 124003 722/Month 24 1130 No 124003 722/Month 24 1770 No 124003 722/Month 24 1770 No 124003 722/Month 24 1700 <
 | Treatment Group Positive
Innumerativity Lurrancettisty Lurrancettisty Treatment Group Subject ID Assay Log Titer Diagnosis 170010 365 / Month 12 2770 No Diagnosis 170010 365 / Month 12 2800 No Diagnosis 170010 365 / Month 24 1870 Lirtis Diagnosis 177006 338 / Month 24 1870 Lirtis Diagnosis 104002 712 / Month 24 1140 No No 104002 722 / Month 24 1130 No No 122002 359 / Month 24 1170 No No 124003 722 / Month 24 1770 No No 124003 722 / Month 24 1770 No No 12400 722 / | Treatment Group Routing and the seture of the particular function of the particular function of the particular function of the particular desired by the partin desired by the particular desired by the particular |
| 10/002 71/1/Month 24 1.230 NO NO </th <th>10/002 71/1/Month 24 1.230 NO NO<!--</th--><td>I0/002 $71/7$ Month 24 1.230 NO NO</td><td>Treatment Group Positive
Innunoreactivity Innunoreactivity Innunoreactivity Innunoreactivity Jreatment Group Subject ID 365 / Month 12 2770 No 170010 365 / Month 12 1870 Inflammation 177006 358 / Month 12 1870 Inflammation 104002 717 / Month 24 1140 No 1124003 722 / Month 24 1130 No 122002 359 / Month 12 1630 No 124003 722 / Month 24 1770 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1600 No 124003 722 / Month 24 1600 No</td><td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innemotion Innumoreactivity Innumoreactivit</td><td>Treatment Group Entimunoreactivity
and the properties Positive
Assay Intransitin
Assay Intransitin
Assay Intransitin
Assay Intransitin
Assay JTeettment Group Subject ID 365 / Moath 12 No No 170010 365 / Moath 12 3700 No No 177006 358 / Moath 2 2700 No 177006 358 / Moath 2 2000 No 177006 358 / Moath 1850 Intris No 104002 717 / Moath 1850 Intris No 1177006 358 / Moath 1350 No No 126001 174 / Moath 1130 No No 126001 174 / Moath 1300 No No 126001 174 / Moath 1300 No No 126001 174 / Moath 1300 No No 128001 174 / Moath 1310 722 / Moath No 141013 715 / Moath 1400</td><td>Treatment Group Ensitive
Subject ID Positive
Assay Intrancediat
Assay Intrancediat</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Intrancionation Treatment Group Subject ID Assay Assay Assay Intrancionation 170010 365 / Mouth 12 2770 No Diagnois 170010 355 / Mouth 12 1870 Intrascitian 177006 358 / Mouth 12 1870 No 177001 717 / Month 24 1850 Intits 104002 719 / Month 24 1140 No 120001 722 / Month 24 1300 No 122002 359 / Month 12 1300 No 122002 357 / Month 24 0.782 No 124001 174 / Month 6 1.700 No 124001 174 / Month 6 1.700 No 124001 722 / Month 24 0.782 No 124001 722 / Month 24 1.700 No 125004 362 / Month 24 1.700 No 143010 722 / Month 24</td><td>Treatment Group Ensitive
Subject ID Positive
Assay Intrancediat
Assay Intrancediat</td><td>Treatment Group Ensitive
Subject ID Positive
Assay Intrancediat
Assay Intrancediat</td><td>Treatment Group Entimunoreactivity
and the properties Positive
Assay Intransitin
Assay Intransitin
Assay Intransitin
Assay Intransitin
Assay JTeettment Group Subject ID 365 / Moath 12 No No 170010 365 / Moath 12 3700 No No 177006 358 / Moath 2 2700 No 177006 358 / Moath 2 2000 No 177006 358 / Moath 1850 Intris No 104002 717 / Moath 1850 Intris No 1177006 358 / Moath 1350 No No 126001 174 / Moath 1130 No No 126001 174 / Moath 1300 No No 126001 174 / Moath 1300 No No 126001 174 / Moath 1300 No No 128001 174 / Moath 1310 722 / Moath No 141013 715 / Moath 1400</td><td>Treatment Group Entimunoreactivity
and the properties Positive
Assay Intransitin
Assay Intransitin
Assay Intransitin
Assay Intransitin
Assay JTeettment Group Subject ID 365 / Moath 12 No No 170010 365 / Moath 12 3700 No No 177006 358 / Moath 2 2700 No 177006 358 / Moath 2 2000 No 177006 358 / Moath 1850 Intris No 104002 717 / Moath 1850 Intris No 1177006 358 / Moath 1350 No No 126001 174 / Moath 1130 No No 126001 174 / Moath 1300 No No 126001 174 / Moath 1300 No No 126001 174 / Moath 1300 No No 128001 174 / Moath 1310 722 / Moath No 141013 715 / Moath 1400</td><td>Treatment Group Entimunoreactivity
and the properties Positive
Assay Intransitin
Assay Intransitin
Assay Intransitin
Assay Intransitin
Assay JTeettment Group Subject ID 365 / Moath 12 No No 170010 365 / Moath 12 3700 No No 177006 358 / Moath 2 2700 No 177006 358 / Moath 2 2000 No 177006 358 / Moath 1850 Intris No 104002 717 / Moath 1850 Intris No 1177006 358 / Moath 1350 No No 126001 174 / Moath 1130 No No 126001 174 / Moath 1300 No No 126001 174 / Moath 1300 No No 126001 174 / Moath 1300 No No 128001 174 / Moath 1310 722 / Moath No 141013 715 / Moath 1400</td><td>Treatment Group Positive
Innunoreactivity Innunoreactivity Innunoreactivity Innunoreactivity Jreatment Group Subject ID 365 / Month 12 2770 No 170010 365 / Month 12 1870 Inflammation 177006 358 / Month 12 1870 Inflammation 104002 717 / Month 24 1140 No 1124003 722 / Month 24 1130 No 122002 359 / Month 12 1630 No 124003 722 / Month 24 1770 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1600 No 124003 722 / Month 24 1600 No</td><td>Treatment Group Intranceditive
Intransition Distinve
Ansity Intranceditie Jreatment Group Subject ID Assity Xasu Log Titer Diagnois 170010 365 / Month 12 Xasy Log Titer Diagnois 170010 365 / Month 12 Xasy Log Titer Diagnois 177006 358 / Month 12 1870 Intris 177001 715 / Month 24 1350 No 104002 717 / Month 24 1140 No 112002 722 / Month 24 1130 No 126001 174 / Month 6 1.770 No 124003 722 / Month 24 1.130 No 124001 174 / Month 6 1.770 No 124001 174 / Month 6 1.770 No 124003 722 / Month 24 1.140 No 124001 174 / Month 6 1.770 No 124001 174 / Month 6 1.770 No 141013 715 / Month 24 1.940 No 143010 <td< td=""><td>Treatment/Group Intranscription Treatment/Group Subject ID Ammunoreactivity Intransition 170010 365/Month 12 2770
No 170010 365/Month 12 1870 Irrini 177006 358/Month 12 1870 Irrinis 177006 358/Month 24 2800 No 177006 358/Month 24 13600 No 104002 717/Month 24 1370 Irrinis 104002 722/Month 24 13600 No 126001 174/Month 24 1300 No 122002 359/Month 24 1300 No 124003 722/Month 24 1300 No 124001 174/Month 6 1,700 No 124003 722/Month 24 1,700 No 124003 722/Month 24</td><td>Treatment Group Pointve
Immunoracity is
170010 Pointve
Assay Immunoracity is
Assay Log Titer Intrancitian
Diagnosis 170010 365/Month 12 2770 Nio 177006 358/Month 12 1870 Irritis 177006 358/Month 12 1870 Irritis 177006 358/Month 24 2800 Nio 177006 358/Month 24 1370 Nio 104002 717/Month 24 1390 Nio 104002 722/Month 24 13130 Nio 124003 722/Month 24 13130 Nio 124003 722/Month 24 1300 Nio 124003 772/Month 24 1300 Nio 125004 174/Month 24 1300 Nio 124003 722/Month 24 1300 Nio 141013 715/Month 24 <td< td=""><td>Treatment Group Positive
Intranscription Positive
Intranscription Interactivity
Assay Leg Titer Interactivity
Inflamosition 170010 365/Month 12 2700 No 170010 365/Month 12 2800 Inflamosition 177006 358/Month 12 1870 Intris 177006 358/Month 24 1870 Intris 177006 358/Month 24 1360 No 104002 712/Month 24 1300 No 122002 359/Month 24 13130 No 124003 722/Month 24 1300 No 122002 357/Month 24 1300 No 124003 722/Month 24 1300 No 124003 715/Month 24 1300 No 141013 715/Month 24</td><td>Treatment Group Foulder ID
answitce Positive
Inframineton Intranscutar
Assay Intranscutar
Inframineton 170010 365 / Month 12 2.770 No 177006 385 / Month 12 2.800 Inframineton 177010 365 / Month 12 2.800 Inframosticative Ranibizumab 0.5 mg 177006 385 / Month 24 1.870 Infra 1770002 717 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 359 / Month 24 1.170 No No No 122002 359 / Month 24 1.170 No No No 124003 722 / Month 24 1.700 No No No 124003 722 / Month 24 1.700 No No No 124003 722 / Month 24 1.700 No No No 124003 722 / Month 24 1.700 No No No 124003 174 / Month 24</td></td<></td></td<></td></th> | 10/002 71/1/Month 24 1.230 NO NO </th <td>I0/002 $71/7$ Month 24 1.230 NO NO</td> <td>Treatment Group Positive
Innunoreactivity Innunoreactivity Innunoreactivity Innunoreactivity Jreatment Group Subject ID 365 / Month 12 2770 No 170010 365 / Month 12 1870 Inflammation 177006 358 / Month 12 1870 Inflammation 104002 717 / Month 24 1140 No 1124003 722 / Month 24 1130 No 122002 359 / Month 12 1630 No 124003 722 / Month 24 1770 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1600 No 124003 722 / Month 24 1600 No</td> <td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innemotion Innumoreactivity Innumoreactivit</td> <td>Treatment Group Entimunoreactivity
and the properties Positive
Assay Intransitin
Assay Intransitin
Assay Intransitin
Assay Intransitin
Assay JTeettment Group Subject ID 365 / Moath 12 No No 170010 365 / Moath 12 3700 No No 177006 358 / Moath 2 2700 No 177006 358 / Moath 2 2000 No 177006 358 / Moath 1850 Intris No 104002 717 / Moath 1850 Intris No 1177006 358 / Moath 1350 No No 126001 174 / Moath 1130 No No 126001 174 / Moath 1300 No No 126001 174 / Moath 1300 No No 126001 174 / Moath 1300 No No 128001 174 / Moath 1310 722 / Moath No 141013 715 / Moath 1400</td> <td>Treatment Group Ensitive
Subject ID Positive
Assay Intrancediat
Assay Intrancediat</td> <td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Intrancionation Treatment Group Subject ID Assay Assay Assay Intrancionation 170010 365 / Mouth 12 2770 No Diagnois 170010 355 / Mouth 12 1870 Intrascitian 177006 358 / Mouth 12 1870 No 177001 717 / Month 24 1850 Intits 104002 719 / Month 24 1140 No 120001 722 / Month 24 1300 No 122002 359 / Month 12 1300 No 122002 357 / Month 24 0.782 No 124001 174 / Month 6 1.700 No 124001 174 / Month 6 1.700 No 124001 722 / Month 24 0.782 No 124001 722 / Month 24 1.700 No 125004 362 / Month 24 1.700 No 143010 722 / Month 24</td> <td>Treatment Group Ensitive
Subject ID Positive
Assay Intrancediat
Assay Intrancediat</td> <td>Treatment Group Ensitive
Subject ID
Positive
Assay Intrancediat
Assay Intrancediat</td> <td>Treatment Group Entimunoreactivity
and the properties Positive
Assay Intransitin
Assay Intransitin
Assay Intransitin
Assay Intransitin
Assay JTeettment Group Subject ID 365 / Moath 12 No No 170010 365 / Moath 12 3700 No No 177006 358 / Moath 2 2700 No 177006 358 / Moath 2 2000 No 177006 358 / Moath 1850 Intris No 104002 717 / Moath 1850 Intris No 1177006 358 / Moath 1350 No No 126001 174 / Moath 1130 No No 126001 174 / Moath 1300 No No 126001 174 / Moath 1300 No No 126001 174 / Moath 1300 No No 128001 174 / Moath 1310 722 / Moath No 141013 715 / Moath 1400</td> <td>Treatment Group Entimunoreactivity
and the properties Positive
Assay Intransitin
Assay Intransitin
Assay Intransitin
Assay Intransitin
Assay JTeettment Group Subject ID 365 / Moath 12 No No 170010 365 / Moath 12 3700 No No 177006 358 / Moath 2 2700 No 177006 358 / Moath 2 2000 No 177006 358 / Moath 1850 Intris No 104002 717 / Moath 1850 Intris No 1177006 358 / Moath 1350 No No 126001 174 / Moath 1130 No No 126001 174 / Moath 1300 No No 126001 174 / Moath 1300 No No 126001 174 / Moath 1300 No No 128001 174 / Moath 1310 722 / Moath No 141013 715 / Moath 1400</td> <td>Treatment Group Entimunoreactivity
and the properties Positive
Assay Intransitin
Assay Intransitin
Assay Intransitin
Assay Intransitin
Assay JTeettment Group Subject ID 365 / Moath 12 No No 170010 365 / Moath 12 3700 No No 177006 358 / Moath 2 2700 No 177006 358 / Moath 2 2000 No 177006 358 / Moath 1850 Intris No 104002 717 / Moath 1850 Intris No 1177006 358 / Moath 1350 No No 126001 174 / Moath 1130 No No 126001 174 / Moath 1300 No No 126001 174 / Moath 1300 No No 126001 174 / Moath 1300 No No 128001 174 / Moath 1310 722 / Moath No 141013 715 / Moath 1400</td> <td>Treatment Group Positive
Innunoreactivity Innunoreactivity Innunoreactivity Innunoreactivity Jreatment Group Subject ID 365 / Month 12 2770 No 170010 365 / Month 12 1870 Inflammation 177006 358 / Month 12 1870 Inflammation 104002 717 / Month 24 1140 No 1124003 722 / Month 24 1130 No 122002 359 / Month 12 1630 No 124003 722 / Month 24 1770 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1600 No 124003 722 / Month 24 1600 No</td> <td>Treatment Group Intranceditive
Intransition Distinve
Ansity Intranceditie Jreatment Group Subject ID Assity Xasu Log Titer Diagnois 170010 365 / Month 12 Xasy Log Titer Diagnois 170010 365 / Month 12 Xasy Log Titer Diagnois 177006 358 / Month 12 1870 Intris 177001 715 / Month 24 1350 No 104002 717 / Month 24 1140 No 112002 722 / Month 24 1130 No 126001 174 / Month 6 1.770 No 124003 722 / Month 24 1.130 No 124001 174 / Month 6 1.770 No 124001 174 / Month 6 1.770 No 124003 722 / Month 24 1.140 No 124001 174 / Month 6 1.770 No 124001 174 / Month 6 1.770 No 141013 715 / Month 24 1.940 No 143010 <td< td=""><td>Treatment/Group Intranscription Treatment/Group Subject ID Ammunoreactivity Intransition 170010 365/Month 12 2770 No 170010 365/Month 12 1870 Irrini 177006 358/Month 12 1870 Irrinis 177006 358/Month 24 2800 No 177006 358/Month 24 13600 No 104002 717/Month 24 1370 Irrinis 104002 722/Month 24 13600 No 126001 174/Month 24 1300 No 122002 359/Month 24 1300 No 124003 722/Month 24 1300 No 124001 174/Month 6 1,700 No 124003 722/Month 24 1,700 No 124003 722/Month 24</td><td>Treatment Group Pointve
Immunoracity is
170010 Pointve
Assay Immunoracity is
Assay Log Titer Intrancitian
Diagnosis 170010 365/Month 12 2770 Nio 177006 358/Month 12 1870 Irritis 177006 358/Month 12 1870 Irritis 177006 358/Month 24 2800 Nio 177006 358/Month 24 1370 Nio 104002 717/Month 24 1390 Nio 104002 722/Month 24 13130 Nio 124003 722/Month 24 13130 Nio 124003 722/Month 24 1300 Nio 124003 772/Month 24 1300 Nio 125004 174/Month 24 1300 Nio 124003 722/Month 24 1300 Nio 141013 715/Month 24 <td< td=""><td>Treatment Group Positive
Intranscription Positive
Intranscription Interactivity
Assay Leg Titer Interactivity
Inflamosition 170010 365/Month 12 2700 No 170010 365/Month 12 2800 Inflamosition 177006 358/Month 12 1870 Intris 177006 358/Month 24 1870 Intris 177006 358/Month 24 1360 No 104002 712/Month 24 1300 No 122002 359/Month 24 13130 No 124003 722/Month 24 1300 No 122002 357/Month 24 1300 No 124003 722/Month 24 1300 No 124003 715/Month 24 1300 No 141013 715/Month 24</td><td>Treatment Group Foulder ID
answitce Positive
Inframineton Intranscutar
Assay Intranscutar
Inframineton 170010 365 / Month 12 2.770 No 177006 385 / Month 12 2.800 Inframineton 177010 365 / Month 12 2.800 Inframosticative Ranibizumab 0.5 mg 177006 385 / Month 24 1.870 Infra 1770002 717 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 359 / Month 24 1.170 No No No 122002 359 / Month 24 1.170 No No No 124003 722 / Month 24 1.700 No No No 124003 722 / Month 24 1.700 No No No 124003 722 / Month 24 1.700 No No No 124003 722 / Month 24 1.700 No No No 124003 174 / Month 24</td></td<></td></td<></td>
 | I0/002 $71/7$ Month 24 1.230 NO

 | Treatment Group Positive
Innunoreactivity Innunoreactivity Innunoreactivity Innunoreactivity Jreatment Group Subject ID 365 / Month 12 2770 No 170010 365 / Month 12 1870 Inflammation 177006 358 / Month 12 1870 Inflammation 104002 717 / Month 24 1140 No 1124003 722 / Month 24 1130 No 122002 359 / Month 12 1630 No 124003 722 / Month 24 1770 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1600 No 124003 722 / Month 24 1600 No

 | Treatment Group Positive
Innumoreactivity Innumoreactivity Innemotion Innumoreactivity Innumoreactivit

 | Treatment Group Entimunoreactivity
and the properties Positive
Assay Intransitin
Assay Intransitin
Assay Intransitin
Assay Intransitin
Assay JTeettment Group Subject ID 365 / Moath 12 No No 170010 365 / Moath 12 3700 No No 177006 358 / Moath 2 2700 No 177006 358 / Moath 2 2000 No 177006 358 / Moath 1850 Intris No 104002 717 / Moath 1850 Intris No 1177006 358 / Moath 1350
 No No 126001 174 / Moath 1130 No No 126001 174 / Moath 1300 No No 126001 174 / Moath 1300 No No 126001 174 / Moath 1300 No No 128001 174 / Moath 1310 722 / Moath No 141013 715 / Moath 1400
 | Treatment Group Ensitive
Subject ID Positive
Assay Intrancediat
Assay Intrancediat

 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Intrancionation Treatment Group Subject ID Assay Assay Assay Intrancionation 170010 365 / Mouth 12 2770 No Diagnois 170010 355 / Mouth 12 1870 Intrascitian 177006 358 / Mouth 12 1870 No 177001 717 / Month 24 1850 Intits 104002 719 / Month 24 1140 No 120001 722 / Month 24 1300 No 122002 359 / Month 12 1300 No 122002 357 / Month 24 0.782 No 124001 174 / Month 6 1.700 No 124001 174 / Month 6 1.700 No 124001 722 / Month 24 0.782 No 124001 722 / Month 24 1.700 No 125004 362 / Month 24 1.700 No 143010 722 / Month 24

 | Treatment Group Ensitive
Subject ID Positive
Assay Intrancediat
Assay Intrancediat
 | Treatment Group Ensitive
Subject ID Positive
Assay Intrancediat
Assay Intrancediat
 | Treatment Group Entimunoreactivity
and the properties Positive
Assay Intransitin
Assay Intransitin
Assay Intransitin
Assay Intransitin
Assay JTeettment Group Subject ID 365 / Moath 12 No No 170010 365 / Moath 12 3700 No No 177006 358 / Moath 2 2700 No 177006 358 / Moath 2 2000 No 177006 358 / Moath 1850 Intris No 104002 717 / Moath 1850 Intris No 1177006 358 / Moath 1350 No No 126001 174 / Moath 1130 No No 126001 174 / Moath 1300 No No 126001 174 / Moath 1300 No No 126001
174 / Moath 1300 No No 128001 174 / Moath 1310 722 / Moath No 141013 715 / Moath 1400
 | Treatment Group Entimunoreactivity
and the properties Positive
Assay Intransitin
Assay Intransitin
Assay Intransitin
Assay Intransitin
Assay JTeettment Group Subject ID 365 / Moath 12 No No 170010 365 / Moath 12 3700 No No 177006 358 / Moath 2 2700 No 177006 358 / Moath 2 2000 No 177006 358 / Moath 1850 Intris No 104002 717 / Moath 1850 Intris No 1177006 358 / Moath 1350 No No 126001 174 / Moath 1130 No No 126001 174 / Moath 1300 No No 126001 174 / Moath 1300 No No 126001 174 / Moath 1300 No No 128001 174 / Moath 1310 722 / Moath No 141013 715 / Moath 1400
 | Treatment Group Entimunoreactivity
and the properties Positive
Assay Intransitin
Assay Intransitin
Assay Intransitin
Assay Intransitin
Assay JTeettment Group Subject ID 365 / Moath 12 No No 170010 365 / Moath 12 3700 No No 177006 358 / Moath 2 2700 No 177006 358 / Moath 2 2000 No 177006 358 / Moath 1850 Intris No 104002 717 / Moath 1850 Intris No 1177006 358 / Moath 1350 No No 126001 174 / Moath 1130 No No 126001 174 / Moath 1300 No No 126001 174 / Moath 1300 No No 126001 174 / Moath 1300 No No 128001 174 / Moath 1310 722 / Moath No 141013 715 / Moath 1400
 | Treatment Group Positive
Innunoreactivity Innunoreactivity Innunoreactivity Innunoreactivity Jreatment Group Subject ID 365 / Month 12 2770 No 170010 365 / Month 12 1870 Inflammation 177006 358 / Month 12 1870 Inflammation 104002 717 / Month 24 1140 No 1124003 722 / Month 24 1130 No 122002 359 / Month 12 1630 No 124003 722 / Month 24 1770 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1600 No 124003 722 / Month 24 1600 No
 | Treatment Group Intranceditive
Intransition Distinve
Ansity Intranceditie Jreatment Group Subject ID Assity Xasu Log Titer Diagnois 170010 365 / Month 12 Xasy Log Titer Diagnois 170010 365 / Month 12 Xasy Log Titer Diagnois 177006 358 / Month 12 1870 Intris 177001 715 / Month 24 1350 No 104002 717 / Month 24 1140 No 112002 722 / Month 24 1130 No 126001 174 / Month 6 1.770 No 124003 722 / Month 24 1.130 No 124001 174 / Month 6 1.770 No 124001 174 / Month 6 1.770 No 124003 722 / Month 24 1.140 No 124001 174 / Month 6 1.770 No 124001 174 / Month 6 1.770 No 141013 715 / Month 24 1.940 No 143010 <td< td=""><td>Treatment/Group Intranscription Treatment/Group Subject ID Ammunoreactivity Intransition 170010 365/Month 12 2770 No 170010 365/Month 12 1870 Irrini 177006 358/Month 12 1870 Irrinis 177006 358/Month 24 2800 No 177006 358/Month 24 13600 No 104002 717/Month 24 1370 Irrinis 104002 722/Month 24 13600 No 126001 174/Month 24 1300 No 122002 359/Month 24 1300 No 124003 722/Month 24 1300 No 124001 174/Month 6 1,700 No 124003 722/Month 24 1,700 No 124003 722/Month 24</td><td>Treatment Group Pointve
Immunoracity is
170010 Pointve
Assay Immunoracity is
Assay Log Titer Intrancitian
Diagnosis 170010 365/Month 12 2770 Nio 177006 358/Month 12 1870 Irritis 177006 358/Month 12 1870 Irritis 177006 358/Month 24 2800 Nio 177006 358/Month 24 1370 Nio 104002 717/Month 24 1390 Nio 104002 722/Month 24 13130 Nio 124003 722/Month 24 13130 Nio 124003 722/Month 24 1300 Nio 124003 772/Month 24 1300 Nio 125004 174/Month 24 1300 Nio 124003 722/Month 24 1300 Nio 141013 715/Month 24 <td< td=""><td>Treatment Group Positive
Intranscription Positive
Intranscription Interactivity
Assay Leg Titer Interactivity
Inflamosition 170010 365/Month 12 2700 No 170010 365/Month 12 2800 Inflamosition 177006 358/Month 12 1870 Intris 177006 358/Month 24 1870 Intris 177006 358/Month 24 1360 No 104002 712/Month 24 1300 No 122002 359/Month 24 13130 No 124003 722/Month 24 1300 No 122002 357/Month 24 1300 No 124003 722/Month 24 1300 No 124003 715/Month 24 1300 No 141013 715/Month 24</td><td>Treatment Group Foulder ID
answitce Positive
Inframineton Intranscutar
Assay Intranscutar
Inframineton 170010 365 / Month 12 2.770 No 177006 385 / Month 12 2.800 Inframineton 177010 365 / Month 12 2.800 Inframosticative Ranibizumab 0.5 mg 177006 385 / Month 24 1.870 Infra 1770002 717 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 359 / Month 24 1.170 No No No 122002 359 / Month 24 1.170 No No No 124003 722 / Month 24 1.700 No No No 124003 722 / Month 24 1.700 No No No 124003 722 / Month 24 1.700 No No No 124003 722 / Month 24 1.700 No No No 124003 174 / Month 24</td></td<></td></td<> | Treatment/Group Intranscription Treatment/Group Subject ID Ammunoreactivity Intransition 170010 365/Month 12 2770 No 170010 365/Month 12 1870 Irrini 177006 358/Month 12 1870 Irrinis 177006 358/Month 24 2800 No 177006 358/Month 24 13600 No 104002 717/Month 24 1370 Irrinis 104002 722/Month 24 13600 No 126001 174/Month 24 1300 No 122002
359/Month 24 1300 No 124003 722/Month 24 1300 No 124001 174/Month 6 1,700 No 124003 722/Month 24 | Treatment Group Pointve
Immunoracity is
170010 Pointve
Assay Immunoracity is
Assay Log Titer Intrancitian
Diagnosis 170010 365/Month 12 2770 Nio 177006 358/Month 12 1870 Irritis 177006 358/Month 12 1870 Irritis 177006 358/Month 24 2800 Nio 177006 358/Month 24 1370 Nio 104002 717/Month 24 1390 Nio 104002 722/Month 24 13130 Nio 124003 722/Month 24 13130 Nio 124003 722/Month 24 1300 Nio 124003 772/Month 24 1300 Nio 125004 174/Month 24 1300 Nio 124003 722/Month 24 1300 Nio 141013 715/Month 24 <td< td=""><td>Treatment Group Positive
Intranscription Positive
Intranscription Interactivity
Assay Leg Titer Interactivity
Inflamosition 170010 365/Month 12 2700 No 170010 365/Month 12 2800 Inflamosition 177006 358/Month 12 1870 Intris 177006 358/Month 24 1870 Intris 177006 358/Month 24 1360 No 104002 712/Month 24 1300 No 122002 359/Month 24 13130 No 124003 722/Month 24 1300 No 122002 357/Month 24 1300 No 124003 722/Month 24 1300 No 124003 715/Month 24 1300 No 141013 715/Month 24</td><td>Treatment Group Foulder ID
answitce Positive
Inframineton Intranscutar
Assay Intranscutar
Inframineton 170010 365 / Month 12 2.770 No 177006 385 / Month 12 2.800 Inframineton 177010 365 / Month 12 2.800 Inframosticative Ranibizumab 0.5 mg 177006 385 / Month 24 1.870 Infra 1770002 717 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 359 / Month 24 1.170 No No No 122002 359 / Month 24 1.170 No No No 124003 722 / Month 24 1.700 No No No 124003 722 / Month 24 1.700 No No No 124003 722 / Month 24 1.700 No No No 124003 722 / Month 24 1.700 No No No 124003 174 / Month 24</td></td<> | Treatment Group Positive
Intranscription Positive
Intranscription Interactivity
Assay Leg Titer Interactivity
Inflamosition 170010 365/Month 12 2700 No 170010 365/Month 12 2800 Inflamosition 177006 358/Month 12 1870 Intris 177006 358/Month 24 1870 Intris 177006 358/Month 24 1360 No 104002 712/Month 24 1300 No 122002 359/Month 24 13130 No 124003 722/Month 24 1300 No 122002 357/Month 24 1300 No 124003 722/Month 24 1300 No 124003 715/Month 24 1300 No 141013 715/Month 24
 | Treatment Group Foulder ID
answitce Positive
Inframineton Intranscutar
Assay Intranscutar
Inframineton 170010 365 / Month 12 2.770 No 177006 385 / Month 12 2.800 Inframineton 177010 365 / Month 12 2.800 Inframosticative Ranibizumab 0.5 mg 177006 385 / Month 24 1.870 Infra 1770002 717 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 359 / Month 24 1.170 No No No 122002 359 / Month 24 1.170 No No No 124003 722 / Month 24 1.700 No No No 124003 722 / Month 24 1.700 No No No 124003 722 / Month 24 1.700 No No No 124003 722 / Month 24 1.700 No No No 124003 174 / Month 24 |
| 167002 717 / Mont 24 1.230 No Mont Mont Mont Mont Mont Mont Mont Mont

 | 167002 717 / Mont 24 1.230 No Mont Mont Mont Mont Mont Mont Mont Mont

 | 167002 717 / Mont 24 1.230 No Mont 24 Mont 25

 | Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity Jreatment Group Subject ID 365 / Mostry Assry 2770 No 170010 365 / Mostry Assry Assry Assry Diapnois 170010 365 / Mosth 2700 No No 177006 358 / Month 12 13500 Iritis 177006 358 / Month 12 13500 No 177006 358 / Month 13600 No No 104002 719 / Month 24 1140 No No 122002 355 / Month 1630 No No 122002 357 / Month 24 1.130 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 24 1.940 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No

 | Treatment Group Positive
Assay Positive
Assay Intransition
Assay

 | Treatment Group Positive
Inflammation Positive
Assay Positive
Inflammation Intraocular Treatment Group Subject ID Assay Assay Assay Assay Intraocular Treatment Group Subject ID Assay Assay Assay Assay Assay Assay Assay Dispuosis 170010 365/Mouth 12 15700 Mouth 12 1870 Intraocular 177006 358/Mouth 24 1140 No No 100002 719/Mouth 24 1350 No No 112002 355/Mouth 12 1370 No No 122002 355/Mouth 24 1140 No No 122002 357/Mouth 24 1770 No No 122002 357/Mouth 24 1770 No No 122002 357/Mouth 24 1770 No No 124003 722/Mouth
24 1770 No No 125001 174/Mouth 24 1770 No No </td <td>Treatment Group Ensistee
Subject ID Positive
Assay Intrancediat
Intrancediat Intrancediat Treatment Group Subject ID Assay Assay Assay Intrancediat 170010 365/Mouth 12 2.770 No No 170010 355/Mouth 24 1870 Intris No 177006 355/Mouth 24 1370 No No 177001 722/Mouth 24 1350 No No 100022 717/Month 24 1360 No No 122002 355/Mouth 24 1390 No No 122002 357/Mouth 24 1390 No No 122002 357/Mouth 24 1390 No No 126001 174/Month 6 1,770 No No No 126001 174/Month 24 0,782 No No No 126001 174/Month 24 1,770 No No No 126001 174/Month 24 1,700 No N</td> <td>Treatment Group Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intrancionation 170010 365/ Month 12 2700 No 170010 355/ Month 24 2800 Intraccular 170010 355/ Month 24 1870 Intraccular 177006 355/ Month 24 1870 Intraccular 177001 355/ Month 24 1360 Intraccular 177005 355/ Month 24 1370 No 104002 717 / Month 24 1360 No 122002 355/ Month 24 1330 No 122002 357 / Month 24 1300 No 124003 722 / Month 24 1300 No 126001 174 / Month 6 1,770 No 126001 174 / Month 6 1,690 No 141013 722 / Month 24 0,782 No 15006 181 / Month 6 1,770 No 141013 715 / Month 24 0,782 No 141013 715 / Month 24</td> <td>Treatment Group Ensistee
Subject ID Positive
Assay Intrancediat
Intrancediat Intrancediat Treatment Group Subject ID Assay Assay Assay Intrancediat 170010 365/Mouth 12 2.770 No No 170010 355/Mouth 24 1870 Intris No 177006 355/Mouth 24 1370 No No 177001 722/Mouth 24 1350 No No 100022 717/Month 24 1360 No No 122002 355/Mouth 24 1390 No No 122002 357/Mouth 24 1390 No No 122002 357/Mouth 24 1390 No No 126001 174/Month 6 1,770 No No No 126001 174/Month 24 0,782 No No No 126001 174/Month 24 1,770 No No No 126001 174/Month 24 1,700 No N</td> <td>Treatment Group Ensistee
Subject ID Positive
Assay Intrancediat
Intrancediat Intrancediat Treatment Group Subject ID Assay Assay Assay Intrancediat 170010 365/Mouth 12 2.770 No No 170010 355/Mouth 24 1870 Intris No 177006 355/Mouth 24 1370 No No 177001 722/Mouth 24 1350 No No 100022 717/Month 24 1360 No No 122002 355/Mouth 24 1390 No No 122002 357/Mouth 24 1390 No No 122002 357/Mouth 24 1390 No No 126001 174/Month 6 1,770 No No No 126001 174/Month 24 0,782 No No No 126001 174/Month 24 1,770 No No No 126001 174/Month 24 1,700 No N</td> <td>Treatment Group Positive
Inflammation Positive
Assay Positive
Inflammation Intraocular Treatment Group Subject ID Assay Assay Assay Assay Intraocular Treatment Group Subject ID Assay Assay Assay Assay Assay Assay Assay Dispuosis 170010 365/Mouth 12 15700 Mouth 12 1870 Intraocular 177006 358/Mouth 24 1140 No No 100002 719/Mouth 24 1350 No No 112002 355/Mouth 12 1370 No No 122002 355/Mouth 24 1140 No No 122002 357/Mouth 24 1770 No No 122002 357/Mouth 24 1770 No No 122002 357/Mouth 24 1770 No No 124003 722/Mouth 24 1770 No No 125001 174/Mouth 24 1770 No No <!--</td--><td>Treatment Group Positive
Inflammation Positive
Assay Positive
Inflammation Intraocular Treatment Group Subject ID Assay Assay Assay Assay Intraocular Treatment Group Subject ID Assay Assay Assay Assay Assay Assay Assay Dispuosis 170010 365/Mouth 12 15700 Mouth 12 1870 Intraocular 177006 358/Mouth 24 1140 No No 100002 719/Mouth 24 1350 No No 112002 355/Mouth 12 1370 No No 122002 355/Mouth 24 1140 No No 122002 357/Mouth 24 1770 No No 122002 357/Mouth 24 1770 No No 122002 357/Mouth 24 1770 No No 124003 722/Mouth 24 1770 No No 125001 174/Mouth 24 1770 No No <!--</td--><td>Treatment Group Positive
Inflammation Positive
Assay Positive
Inflammation Intraocular Treatment Group Subject ID Assay Assay Assay Assay Intraocular Treatment Group Subject ID Assay Assay Assay Assay Assay Assay Assay Dispuosis 170010 365/Mouth 12 15700 Mouth 12 1870 Intraocular 177006 358/Mouth 24 1140 No No 100002 719/Mouth 24 1350 No No 112002 355/Mouth 12 1370 No No 122002 355/Mouth 24 1140 No No 122002 357/Mouth 24 1770 No No 122002 357/Mouth 24 1770 No No 122002 357/Mouth 24 1770 No No 124003 722/Mouth 24 1770 No No 125001 174/Mouth 24 1770 No No <!--</td--><td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity Jreatment Group Subject ID 365 / Mostry Assry 2770 No 170010 365 / Mostry Assry Assry Assry Diapnois 170010 365 / Mosth 2700 No No 177006 358 / Month 12 13500 Iritis 177006 358 / Month 12 13500 No 177006 358 / Month 13600 No No 104002 719 / Month 24 1140 No No 122002 355 / Month 1630 No No 122002 357 / Month 24 1.130 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 24 1.940 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No</td><td>Treatment Group Turnunoreactivity
Innunoreactivity Innunoreactivity
Innunoreactivity Innunoreactivity
Infamination Jreatment Group Subject ID 365 / Month 12 2770 No 170010 365 / Month 12 2770 No 177006 358 / Month 12 1870 Irritis 177006 358 / Month 12 1870 Irritis 177006 358 /
Month 24 1140 No 104002 717 / Month 24 1130 No 12001 722 / Month 24 1130 No 122002 359 / Month 12 1300 No 122002 355 / Month 24 1300 No 122002 355 / Month 24 1300 No 124003 722 / Month 24 1300 No 126001 174 / Month 6 1770 No 124003 722 / Month 24 1300 No 126001 174 / Month 6 1770 No 141013 715 / Month 24 1640 No 152016 <t< td=""><td>Treatment/Group Intranscription Intranscription Treatment/Group Subject ID Assay Assay Intranscription 170010 365/Month 12 2770 No Diagnosis 170010 365/Month 12 1870 Intris Diagnosis 177006 358/Month 12 1870 Intris Diagnosis 177006 358/Month 24 13870 Intris Diagnosis 104002 717/Month 24 13870 Intris Diagnosis 12001 722/Month 24 1300 No Diagnosis 12002 722/Month 24 1300 No Diagnosis 124003 722/Month 24 1300 No Diagnosis 141013 71</td><td>Treatment/Group Positive
Innunoreactivity Intrancentiar
Intrancentiar Treatment/Group Subject ID Assay Assay Innunoreactivity Inframination 170010 365/Month 12 2770 No No No 177006 358/Month 12 1870 Irritis No 177006 358/Month 24 1870 Irritis 177006 358/Month 24 1370 No 104002 717/Month 24 1380 No 102001 722/Month 24 1300 No 122002 359/Month 12 1300 No 122002 357/Month 24 0.782 No 124001 174/Month 6 1.770 No 124003 722/Month 24 0.782 No 141013 715/Month 54 0.782 No 143010 722/Month 24 0.782 No 152004 522/Early Term. 0.782 No 153006 133/Month 24 0.790 No 153</td><td>Treatment Group Positive
Innumoracity is Assay Log Titer Inframation
Inframation Areatment Group 365 / Month 12 2570 No 170010 365 / Month 12 2570 No 177006 358 / Month 12 1870 Irritis 177006 358 / Month 12 1870 Irritis 177006 358 / Month 24 1360 No 177001 717 / Month 24 1370 Irritis 104002 712 / Month 24 1360 No 126001 174 / Month 6 1770 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124001 174 / Month 6 1770 No 141008 382 / Month 12 1300 No 152004 527 / Month 54 1770 No 124001 174 / Month 6 1770 No 141013 725 / Month 24 1570 No 152006 181 / Month 6 1770 No</td><td>Treatment Group Animunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Asiav Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 Iritiannition 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 24 1.870 Iritis 104002 717 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 126001 174 / Month 24 1.170 No 122002 353 / Month 12 1.600 No 124003 722 / Month 24 0.782 No 124001 174 / Month 6 1.770 No 124003 722 / Month 24 0.782 No 124001 174 / Month 6 1.770 No 124003 724 / Month 6 1.770 No 124001 724 / Month 6 1.770 No 1410103 <td< td=""></td<></td></t<></td></td></td></td> | Treatment Group Ensistee
Subject ID Positive
Assay Intrancediat
Intrancediat Intrancediat Treatment Group Subject ID Assay Assay Assay Intrancediat 170010 365/Mouth 12 2.770 No No 170010 355/Mouth 24 1870 Intris No 177006 355/Mouth 24 1370 No No 177001 722/Mouth 24 1350 No No 100022 717/Month 24 1360 No No 122002 355/Mouth 24 1390 No No 122002 357/Mouth 24 1390 No No 122002
357/Mouth 24 1390 No No 126001 174/Month 6 1,770 No No No 126001 174/Month 24 0,782 No No No 126001 174/Month 24 1,770 No No No 126001 174/Month 24 1,700 No N
 | Treatment Group Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intrancionation 170010 365/ Month 12 2700 No 170010 355/ Month 24 2800 Intraccular 170010 355/ Month 24 1870 Intraccular 177006 355/ Month 24 1870 Intraccular 177001 355/ Month 24 1360 Intraccular 177005 355/ Month 24 1370 No 104002 717 / Month 24 1360 No 122002 355/ Month 24 1330 No 122002 357 / Month 24 1300 No 124003 722 / Month 24 1300 No 126001 174 / Month 6 1,770 No 126001 174 / Month 6 1,690 No 141013 722 / Month 24 0,782 No 15006 181 / Month 6 1,770 No 141013 715 / Month 24 0,782 No 141013 715 / Month 24

 | Treatment Group Ensistee
Subject ID Positive
Assay Intrancediat
Intrancediat Intrancediat Treatment Group Subject ID Assay Assay Assay Intrancediat 170010 365/Mouth 12 2.770 No No 170010 355/Mouth 24 1870 Intris No 177006 355/Mouth 24 1370 No No 177001 722/Mouth 24 1350 No No 100022 717/Month 24 1360 No No 122002 355/Mouth 24 1390 No No 122002 357/Mouth 24 1390 No No 122002 357/Mouth 24 1390 No No 126001 174/Month 6 1,770 No No No 126001 174/Month 24 0,782 No No No 126001 174/Month 24 1,770 No No No 126001 174/Month 24 1,700 No N
 | Treatment Group Ensistee
Subject ID Positive
Assay Intrancediat
Intrancediat Intrancediat Treatment Group Subject ID Assay Assay Assay Intrancediat 170010 365/Mouth 12 2.770 No No 170010 355/Mouth 24 1870 Intris No 177006 355/Mouth 24 1370 No No 177001 722/Mouth 24 1350 No No 100022 717/Month 24 1360 No No 122002 355/Mouth 24 1390 No No 122002 357/Mouth 24 1390 No No 122002 357/Mouth 24 1390 No No 126001 174/Month 6 1,770 No No No 126001 174/Month 24 0,782 No No No 126001 174/Month 24 1,770 No No No 126001 174/Month 24 1,700 No N

 | Treatment Group Positive
Inflammation Positive
Assay Positive
Inflammation Intraocular Treatment Group Subject ID Assay Assay Assay Assay Intraocular Treatment Group Subject ID Assay Assay Assay Assay Assay Assay Assay Dispuosis 170010 365/Mouth 12 15700 Mouth 12 1870 Intraocular 177006 358/Mouth 24 1140 No No 100002 719/Mouth 24 1350 No No 112002 355/Mouth 12 1370 No No 122002 355/Mouth 24 1140 No No 122002 357/Mouth 24 1770 No No 122002 357/Mouth 24 1770 No No 122002 357/Mouth 24 1770 No No 124003 722/Mouth 24 1770 No No 125001 174/Mouth 24 1770 No No </td <td>Treatment Group Positive
Inflammation Positive
Assay Positive
Inflammation Intraocular Treatment Group Subject ID Assay Assay Assay Assay Intraocular Treatment Group Subject ID Assay Assay Assay Assay Assay Assay Assay Dispuosis 170010 365/Mouth 12 15700 Mouth 12 1870 Intraocular 177006 358/Mouth 24 1140 No No 100002 719/Mouth 24 1350 No No 112002 355/Mouth 12 1370 No No 122002 355/Mouth 24 1140 No No 122002 357/Mouth 24 1770 No No 122002 357/Mouth 24 1770 No No 122002 357/Mouth 24 1770 No No 124003 722/Mouth 24 1770 No No 125001 174/Mouth 24 1770 No No <!--</td--><td>Treatment Group Positive
Inflammation Positive
Assay Positive
Inflammation Intraocular Treatment Group Subject ID Assay Assay Assay Assay Intraocular Treatment Group Subject ID Assay Assay Assay Assay Assay Assay Assay Dispuosis 170010 365/Mouth 12 15700 Mouth 12 1870 Intraocular 177006 358/Mouth 24 1140 No No 100002 719/Mouth 24 1350 No No 112002 355/Mouth 12 1370 No No 122002 355/Mouth 24 1140 No No 122002 357/Mouth 24 1770 No No 122002 357/Mouth 24 1770 No No 122002 357/Mouth 24 1770 No No 124003 722/Mouth 24 1770 No No 125001 174/Mouth 24 1770 No No <!--</td--><td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity Jreatment Group Subject ID 365 / Mostry Assry 2770 No 170010 365 / Mostry Assry Assry Assry Diapnois 170010 365 / Mosth 2700 No No 177006 358 / Month 12 13500 Iritis 177006 358 / Month 12 13500 No 177006 358 / Month 13600 No No 104002 719 / Month 24 1140 No No 122002 355 / Month 1630 No No 122002 357 / Month 24 1.130 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 24 1.940 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No</td><td>Treatment Group Turnunoreactivity
Innunoreactivity Innunoreactivity
Innunoreactivity Innunoreactivity
Infamination Jreatment Group Subject ID 365 / Month 12 2770 No 170010 365 / Month 12 2770 No 177006 358 / Month 12 1870 Irritis 177006 358 / Month 12 1870 Irritis 177006 358 / Month 24 1140 No 104002 717 / Month 24 1130 No 12001 722 / Month 24 1130 No 122002 359 / Month 12 1300 No 122002 355 / Month 24 1300 No 122002 355 / Month 24 1300 No 124003 722 / Month 24 1300 No 126001 174 / Month 6 1770 No 124003 722 / Month 24 1300 No 126001 174 / Month 6 1770 No 141013 715 / Month 24 1640 No 152016 <t< td=""><td>Treatment/Group Intranscription Intranscription Treatment/Group Subject ID Assay Assay Intranscription 170010 365/Month 12 2770 No Diagnosis 170010 365/Month 12 1870 Intris Diagnosis 177006 358/Month 12 1870 Intris Diagnosis 177006 358/Month 24 13870 Intris Diagnosis 104002 717/Month 24 13870 Intris Diagnosis 12001 722/Month 24 1300 No Diagnosis 12002 722/Month 24 1300 No Diagnosis 124003 722/Month 24 1300 No Diagnosis 141013 71</td><td>Treatment/Group Positive
Innunoreactivity Intrancentiar
Intrancentiar Treatment/Group Subject ID Assay Assay Innunoreactivity
 Inframination 170010 365/Month 12 2770 No No No 177006 358/Month 12 1870 Irritis No 177006 358/Month 24 1870 Irritis 177006 358/Month 24 1370 No 104002 717/Month 24 1380 No 102001 722/Month 24 1300 No 122002 359/Month 12 1300 No 122002 357/Month 24 0.782 No 124001 174/Month 6 1.770 No 124003 722/Month 24 0.782 No 141013 715/Month 54 0.782 No 143010 722/Month 24 0.782 No 152004 522/Early Term. 0.782 No 153006 133/Month 24 0.790 No 153</td><td>Treatment Group Positive
Innumoracity is Assay Log Titer Inframation
Inframation Areatment Group 365 / Month 12 2570 No 170010 365 / Month 12 2570 No 177006 358 / Month 12 1870 Irritis 177006 358 / Month 12 1870 Irritis 177006 358 / Month 24 1360 No 177001 717 / Month 24 1370 Irritis 104002 712 / Month 24 1360 No 126001 174 / Month 6 1770 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124001 174 / Month 6 1770 No 141008 382 / Month 12 1300 No 152004 527 / Month 54 1770 No 124001 174 / Month 6 1770 No 141013 725 / Month 24 1570 No 152006 181 / Month 6 1770 No</td><td>Treatment Group Animunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Asiav Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 Iritiannition 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 24 1.870 Iritis 104002 717 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 126001 174 / Month 24 1.170 No 122002 353 / Month 12 1.600 No 124003 722 / Month 24 0.782 No 124001 174 / Month 6 1.770 No 124003 722 / Month 24 0.782 No 124001 174 / Month 6 1.770 No 124003 724 / Month 6 1.770 No 124001 724 / Month 6 1.770 No 1410103 <td< td=""></td<></td></t<></td></td></td> | Treatment Group Positive
Inflammation Positive
Assay Positive
Inflammation Intraocular Treatment Group Subject ID Assay Assay Assay Assay Intraocular Treatment Group Subject ID Assay Assay Assay Assay Assay Assay Assay Dispuosis 170010 365/Mouth 12 15700 Mouth 12 1870 Intraocular 177006 358/Mouth 24 1140 No No 100002 719/Mouth 24 1350 No No 112002 355/Mouth 12 1370 No No 122002 355/Mouth 24 1140 No No 122002 357/Mouth 24 1770 No No 122002 357/Mouth 24 1770 No No 122002 357/Mouth 24 1770 No No 124003 722/Mouth 24 1770 No No 125001 174/Mouth 24 1770 No No </td <td>Treatment Group Positive
Inflammation Positive
Assay Positive
Inflammation Intraocular Treatment Group Subject ID Assay Assay Assay Assay Intraocular Treatment Group Subject ID Assay Assay Assay Assay Assay Assay Assay Dispuosis 170010 365/Mouth 12 15700 Mouth 12 1870 Intraocular 177006 358/Mouth 24 1140 No No 100002 719/Mouth 24 1350 No No 112002 355/Mouth 12 1370 No No 122002 355/Mouth 24 1140 No No 122002 357/Mouth 24 1770 No No 122002 357/Mouth 24 1770 No No 122002 357/Mouth 24 1770 No No 124003 722/Mouth 24 1770 No No 125001 174/Mouth 24 1770 No No <!--</td--><td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity Jreatment Group Subject ID 365 / Mostry Assry 2770 No 170010 365 / Mostry Assry Assry Assry Diapnois 170010 365 / Mosth 2700 No No 177006 358 / Month 12 13500 Iritis 177006 358 / Month 12 13500 No 177006 358 / Month 13600 No No 104002 719 / Month 24 1140 No No 122002 355 / Month 1630 No No 122002 357 / Month 24 1.130 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 24 1.940 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No</td><td>Treatment Group Turnunoreactivity
Innunoreactivity Innunoreactivity
Innunoreactivity Innunoreactivity
Infamination Jreatment Group Subject ID 365 / Month 12 2770 No 170010 365 / Month 12 2770 No 177006 358 / Month 12 1870
Irritis 177006 358 / Month 12 1870 Irritis 177006 358 / Month 24 1140 No 104002 717 / Month 24 1130 No 12001 722 / Month 24 1130 No 122002 359 / Month 12 1300 No 122002 355 / Month 24 1300 No 122002 355 / Month 24 1300 No 124003 722 / Month 24 1300 No 126001 174 / Month 6 1770 No 124003 722 / Month 24 1300 No 126001 174 / Month 6 1770 No 141013 715 / Month 24 1640 No 152016 <t< td=""><td>Treatment/Group Intranscription Intranscription Treatment/Group Subject ID Assay Assay Intranscription 170010 365/Month 12 2770 No Diagnosis 170010 365/Month 12 1870 Intris Diagnosis 177006 358/Month 12 1870 Intris Diagnosis 177006 358/Month 24 13870 Intris Diagnosis 104002 717/Month 24 13870 Intris Diagnosis 12001 722/Month 24 1300 No Diagnosis 12002 722/Month 24 1300 No Diagnosis 124003 722/Month 24 1300 No Diagnosis 141013 71</td><td>Treatment/Group Positive
Innunoreactivity Intrancentiar
Intrancentiar Treatment/Group Subject ID Assay Assay Innunoreactivity Inframination 170010 365/Month 12 2770 No No No 177006 358/Month 12 1870 Irritis No 177006 358/Month 24 1870 Irritis 177006 358/Month 24 1370 No 104002 717/Month 24 1380 No 102001 722/Month 24 1300 No 122002 359/Month 12 1300 No 122002 357/Month 24 0.782 No 124001 174/Month 6 1.770 No 124003 722/Month 24 0.782 No 141013 715/Month 54 0.782 No 143010 722/Month 24 0.782 No 152004 522/Early Term. 0.782 No 153006 133/Month 24 0.790 No 153</td><td>Treatment Group Positive
Innumoracity is Assay Log Titer Inframation
Inframation Areatment Group 365 / Month 12 2570 No 170010 365 / Month 12 2570 No 177006 358 / Month 12 1870 Irritis 177006 358 / Month 12 1870 Irritis 177006 358 / Month 24 1360 No 177001 717 / Month 24 1370 Irritis 104002 712 / Month 24 1360 No 126001 174 / Month 6 1770 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124001 174 / Month 6 1770 No 141008 382 / Month 12 1300 No 152004 527 / Month 54 1770 No 124001 174 / Month 6 1770 No 141013 725 / Month 24 1570 No 152006 181 / Month 6 1770 No</td><td>Treatment Group Animunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Asiav Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 Iritiannition 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 24 1.870 Iritis 104002 717 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 126001 174 / Month 24 1.170 No 122002 353 / Month 12 1.600 No 124003 722 / Month 24 0.782 No 124001 174 / Month 6 1.770 No 124003 722 / Month 24 0.782 No 124001 174 / Month 6 1.770 No 124003 724 / Month 6 1.770 No 124001 724 / Month 6 1.770 No 1410103 <td< td=""></td<></td></t<></td></td> | Treatment Group Positive
Inflammation Positive
Assay Positive
Inflammation Intraocular Treatment Group Subject ID Assay Assay Assay Assay Intraocular Treatment Group Subject ID Assay Assay Assay Assay Assay Assay Assay Dispuosis 170010 365/Mouth 12 15700 Mouth 12 1870 Intraocular 177006 358/Mouth 24 1140 No No 100002 719/Mouth 24 1350 No No 112002 355/Mouth 12 1370 No No 122002 355/Mouth 24 1140 No No 122002 357/Mouth 24 1770 No No 122002 357/Mouth 24 1770 No No 122002 357/Mouth 24 1770 No No 124003 722/Mouth 24 1770 No No 125001 174/Mouth 24 1770 No No </td <td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity Jreatment Group Subject ID 365 / Mostry Assry 2770 No 170010 365 / Mostry Assry Assry Assry Diapnois 170010 365 / Mosth 2700 No No 177006 358 / Month 12 13500 Iritis 177006 358 / Month 12 13500 No 177006 358 / Month 13600 No No 104002 719 / Month 24 1140 No No 122002 355 / Month 1630 No No 122002 357 / Month 24 1.130 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 24 1.940 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No</td> <td>Treatment
Group Turnunoreactivity
Innunoreactivity Innunoreactivity
Innunoreactivity Innunoreactivity
Infamination Jreatment Group Subject ID 365 / Month 12 2770 No 170010 365 / Month 12 2770 No 177006 358 / Month 12 1870 Irritis 177006 358 / Month 12 1870 Irritis 177006 358 / Month 24 1140 No 104002 717 / Month 24 1130 No 12001 722 / Month 24 1130 No 122002 359 / Month 12 1300 No 122002 355 / Month 24 1300 No 122002 355 / Month 24 1300 No 124003 722 / Month 24 1300 No 126001 174 / Month 6 1770 No 124003 722 / Month 24 1300 No 126001 174 / Month 6 1770 No 141013 715 / Month 24 1640 No 152016 <t< td=""><td>Treatment/Group Intranscription Intranscription Treatment/Group Subject ID Assay Assay Intranscription 170010 365/Month 12 2770 No Diagnosis 170010 365/Month 12 1870 Intris Diagnosis 177006 358/Month 12 1870 Intris Diagnosis 177006 358/Month 24 13870 Intris Diagnosis 104002 717/Month 24 13870 Intris Diagnosis 12001 722/Month 24 1300 No Diagnosis 12002 722/Month 24 1300 No Diagnosis 124003 722/Month 24 1300 No Diagnosis 141013 71</td><td>Treatment/Group Positive
Innunoreactivity Intrancentiar
Intrancentiar Treatment/Group Subject ID Assay Assay Innunoreactivity Inframination 170010 365/Month 12 2770 No No No 177006 358/Month 12 1870 Irritis No 177006 358/Month 24 1870 Irritis 177006 358/Month 24 1370 No 104002 717/Month 24 1380 No 102001 722/Month 24 1300 No 122002 359/Month 12 1300 No 122002 357/Month 24 0.782 No 124001 174/Month 6 1.770 No 124003 722/Month 24 0.782 No 141013 715/Month 54 0.782 No 143010 722/Month 24 0.782 No 152004 522/Early Term. 0.782 No 153006 133/Month 24 0.790 No 153</td><td>Treatment Group Positive
Innumoracity is Assay Log Titer Inframation
Inframation Areatment Group 365 / Month 12 2570 No 170010 365 / Month 12 2570 No 177006 358 / Month 12 1870 Irritis 177006 358 / Month 12 1870 Irritis 177006 358 / Month 24 1360 No 177001 717 / Month 24 1370 Irritis 104002 712 / Month 24 1360 No 126001 174 / Month 6 1770 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124001 174 / Month 6 1770 No 141008 382 / Month 12 1300 No 152004 527 / Month 54 1770 No 124001 174 / Month 6 1770 No 141013 725 / Month 24 1570 No 152006 181 / Month 6 1770 No</td><td>Treatment Group Animunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Asiav Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 Iritiannition 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 24 1.870 Iritis 104002 717 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 126001 174 / Month 24 1.170 No 122002 353 / Month 12 1.600 No 124003 722 / Month 24 0.782 No 124001 174 / Month 6 1.770 No 124003 722 / Month 24 0.782 No 124001 174 / Month 6 1.770 No 124003 724 / Month 6 1.770 No 124001 724 / Month 6 1.770 No 1410103 <td< td=""></td<></td></t<></td> | Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity Jreatment Group Subject ID 365 / Mostry Assry 2770 No 170010 365 / Mostry Assry Assry Assry Diapnois 170010 365 / Mosth 2700 No No 177006 358 / Month 12 13500 Iritis 177006 358 / Month 12 13500 No 177006 358 / Month 13600 No No 104002 719 / Month 24 1140 No No 122002 355 / Month 1630 No No 122002 357 / Month 24 1.130 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 24 1.940 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No
 | Treatment Group Turnunoreactivity
Innunoreactivity Innunoreactivity
Innunoreactivity Innunoreactivity
Infamination Jreatment Group Subject ID 365 / Month 12 2770 No 170010 365 / Month 12 2770 No 177006 358 / Month 12 1870 Irritis 177006 358 / Month 12 1870 Irritis 177006 358 / Month 24 1140 No 104002 717 / Month 24 1130 No 12001 722 / Month 24 1130 No 122002 359 / Month 12 1300 No 122002 355 / Month 24 1300 No 122002 355 / Month 24 1300 No 124003 722 / Month 24 1300 No 126001 174 / Month 6 1770 No 124003 722 / Month 24 1300 No 126001 174 / Month 6 1770 No 141013 715 / Month 24 1640 No 152016 <t< td=""><td>Treatment/Group Intranscription Intranscription Treatment/Group Subject ID Assay Assay Intranscription 170010 365/Month 12 2770 No Diagnosis 170010 365/Month 12 1870 Intris Diagnosis 177006 358/Month 12 1870 Intris Diagnosis 177006 358/Month 24 13870 Intris Diagnosis 104002 717/Month 24 13870 Intris Diagnosis 12001 722/Month 24 1300 No Diagnosis 12002 722/Month 24 1300 No Diagnosis 124003 722/Month 24 1300 No Diagnosis 141013 71</td><td>Treatment/Group Positive
Innunoreactivity Intrancentiar
Intrancentiar Treatment/Group Subject ID Assay Assay Innunoreactivity Inframination 170010 365/Month 12 2770 No No No 177006 358/Month 12 1870 Irritis No 177006 358/Month 24 1870 Irritis 177006 358/Month 24 1370 No 104002 717/Month 24 1380 No 102001 722/Month 24 1300 No 122002 359/Month 12 1300 No 122002 357/Month 24 0.782 No 124001 174/Month 6 1.770 No 124003 722/Month 24 0.782 No 141013 715/Month 54 0.782 No 143010 722/Month 24 0.782 No 152004 522/Early Term. 0.782 No 153006 133/Month 24 0.790 No 153</td><td>Treatment Group Positive
Innumoracity is Assay Log Titer Inframation
Inframation Areatment Group 365 / Month 12 2570 No 170010 365 / Month 12 2570 No 177006 358 / Month
12 1870 Irritis 177006 358 / Month 12 1870 Irritis 177006 358 / Month 24 1360 No 177001 717 / Month 24 1370 Irritis 104002 712 / Month 24 1360 No 126001 174 / Month 6 1770 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124001 174 / Month 6 1770 No 141008 382 / Month 12 1300 No 152004 527 / Month 54 1770 No 124001 174 / Month 6 1770 No 141013 725 / Month 24 1570 No 152006 181 / Month 6 1770 No</td><td>Treatment Group Animunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Asiav Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 Iritiannition 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 24 1.870 Iritis 104002 717 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 126001 174 / Month 24 1.170 No 122002 353 / Month 12 1.600 No 124003 722 / Month 24 0.782 No 124001 174 / Month 6 1.770 No 124003 722 / Month 24 0.782 No 124001 174 / Month 6 1.770 No 124003 724 / Month 6 1.770 No 124001 724 / Month 6 1.770 No 1410103 <td< td=""></td<></td></t<> | Treatment/Group Intranscription Intranscription Treatment/Group Subject ID Assay Assay Intranscription 170010 365/Month 12 2770 No Diagnosis 170010 365/Month 12 1870 Intris Diagnosis 177006 358/Month 12 1870 Intris Diagnosis 177006 358/Month 24 13870 Intris Diagnosis 104002 717/Month 24 13870 Intris Diagnosis 12001 722/Month 24 1300 No Diagnosis 12002 722/Month 24 1300 No Diagnosis 124003 722/Month 24 1300 No Diagnosis 141013 71 | Treatment/Group Positive
Innunoreactivity Intrancentiar
Intrancentiar Treatment/Group Subject ID Assay Assay Innunoreactivity Inframination 170010 365/Month 12 2770 No No No 177006 358/Month 12 1870 Irritis No 177006 358/Month 24 1870 Irritis 177006 358/Month 24 1370 No 104002 717/Month 24 1380 No 102001 722/Month 24 1300 No 122002 359/Month 12 1300 No 122002 357/Month 24 0.782 No 124001 174/Month 6 1.770 No 124003 722/Month 24 0.782 No 141013 715/Month 54 0.782 No 143010 722/Month 24 0.782 No 152004 522/Early Term. 0.782 No 153006 133/Month 24 0.790 No 153
 | Treatment Group Positive
Innumoracity is Assay Log Titer Inframation
Inframation Areatment Group 365 / Month 12 2570 No 170010 365 / Month 12 2570 No 177006 358 / Month 12 1870 Irritis 177006 358 / Month 12 1870 Irritis 177006 358 / Month 24 1360 No 177001 717 / Month 24 1370 Irritis 104002 712 / Month 24 1360 No 126001 174 / Month 6 1770 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124001 174 / Month 6 1770 No 141008 382 / Month 12 1300 No 152004 527 / Month 54 1770 No 124001 174 / Month 6 1770 No 141013 725 / Month 24 1570 No 152006 181 / Month 6 1770 No | Treatment Group Animunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Asiav Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 Iritiannition 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 24 1.870 Iritis 104002 717 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 126001 174 / Month 24 1.170 No 122002 353 / Month 12 1.600 No 124003 722 / Month 24 0.782 No 124001 174 / Month 6 1.770 No 124003 722 / Month 24 0.782 No 124001 174 / Month 6 1.770 No 124003 724 / Month 6 1.770 No 124001 724 / Month 6 1.770 No 1410103 <td< td=""></td<> |
| 167002 717 / Mont 24 1.230 No No <th>167002 717 / Mont 24 1.230 No No<td>167002 717/Mont 24 1.230 No Mont 24 1.250 No Mont 24 Mont 250 Mont 250<td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innamion 770010 365 Assay Assay Assay Log Diapnois 170010 355 Month 124 2700 No No 177006 358 Month 24 1370 No No 107002 717 Month 24 1390 No No 1124003 722 Month 24 1390 No No 124003 722 Month 24 1300 No No 124003 722 Month 24 1300 No No 124003 722 Month 12 2040 No No 122002 357 Month 24 1770 No No 124003 722 Month 24 1770 No</td><td>Treatment Group Positive
Inflammation Dispositive
Assay Intraordiat Intraordiat Treatment Group Subject ID Assay Assay Assay Assay Assay Assay Assay Assay Inflammation Treatment Group Subject ID Assay Asad Assay Assay</td><td>Treatment Group Ensistee
Subject ID Positree
Assay Intrancediat
Intranced
Assay Intranced
Assay Intranced
Assay</td><td>Treatment Group Subject ID Positive
Assay Immunoreactivity
Immunoreactivity Immunoreactivity Intraocidiar Treatment Group Subject ID 365 Mouth 12 2.770 No 170010 355 Mouth 24 2.800 Iritis Diagnosis 170010 355 Mouth 24 1870 No No 177006 355 Mouth 24 1870 No No 177006 355 Mouth 24 1370 No No 104002 717 Month 24 1360 No No 102001 722 Month 24 1370 No No 124003 722 Month 24 1300 No No 12400 12001 174 Month 6 1.700 No 125004 5357 Month 12 1600 No No 126001<!--</td--><td>Treatment Group Subject ID Assay Positive
Immunoreactivity Intranscription Treatment Group Subject ID 3650 Mouth 12 2.770 No 170010 355 /Mouth 24 2.800 Irtitis Diagnosis 177006 355 /Mouth 24 1850 Irtitis 177006 355 /Mouth 24 1850 Irtitis 177006 355 /Mouth 24 1360 Irtitis 177006 355 /Mouth 24 1360 No 122002 722 /Mouth 24 1360 No 124003 722 /Mouth 24 1360 No 124003 722 /Mouth 24 1370 No 124003 722 /Mouth 24 1370 No 124003 722 /Mouth 24 1370 No 126001 174 /Mouth 24 1370 No 126001 174 /Mouth 24 1600 No 126001 174 /Mouth 24 1600 No 126001 174 /Mouth 24 1600 No 1</td><td>Treatment Group Subject ID Positive
Assay Immunoreactivity
Immunoreactivity Immunoreactivity Intraocidiar Treatment Group Subject ID 365 Mouth 12 2.770 No 170010 355 Mouth 24 2.800 Iritis Diagnosis 170010 355 Mouth 24 1870 No No 177006 355 Mouth 24 1870 No No 177006 355 Mouth 24 1370 No No 104002 717 Month 24 1360 No No 102001 722 Month 24 1370 No No 124003 722 Month 24 1300 No No 12400 12001 174 Month 6 1.700 No 125004 5357 Month 12 1600 No No 126001<!--</td--><td>Treatment Group Subject ID Positive
Assay Immunoreactivity
Immunoreactivity Immunoreactivity Intraocidiar Treatment Group Subject ID 365 Mouth 12 2.770 No 170010 355 Mouth 24 2.800 Iritis Diagnosis 170010 355 Mouth 24 1870 No No 177006 355 Mouth 24 1870 No No 177006 355 Mouth 24 1370 No No 104002 717 Month 24 1360 No No 102001 722 Month 24 1370 No No 124003 722 Month 24 1300 No No 12400 12001 174 Month 6 1.700 No 125004 5357 Month 12 1600 No No 126001<!--</td--><td>Treatment Group Ensistee
Subject ID Positree
Assay Intrancediat
Intranced
Assay Intranced
Assay Intranced
Assay</td><td>Treatment Group Ensistee
Subject ID Positree
Assay Intrancediat
Intranced
Assay Intranced
Assay Intranced
Assay</td><td>Treatment Group Ensistee
Subject ID Positree
Assay Intrancediat
Intranced
Assay Intranced
Assay Intranced
Assay</td><td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innamion 770010 365 Assay Assay Assay Log Diapnois 170010 355 Month 124 2700 No No 177006 358 Month 24 1370 No No 107002 717 Month 24 1390 No No 1124003 722 Month 24 1390 No No 124003 722 Month 24 1300 No No 124003 722 Month 24 1300 No No 124003 722 Month 12 2040 No No 122002 357 Month 24 1770 No No 124003 722 Month 24 1770 No</td><td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Jreatment Group Subject ID Assay Assay Assay Innumoreactivity Inflammation Jreatment Group Subject ID 365 / Month 12 2.770 No No 170010 355 / Month 12 1870 Intraorchits Diagnois 177006 358 / Month 24 1870 Intits No 177006 358 / Month 24 1140 No No 106002 722 / Month 24 1130 No No 124003 722 / Month 24 1130 No No 126001 174 / Month 24 1300 No No 126001 174 / Month 24 1300 No No 122002 357 / Month 24 1770 No No 123003 357 / Month 24 1770 No No 124003 722 / Month 24 1770 No No 125004 5357 / Month 24 1770 No<</td><td>Treatment Group Intrancettar
Intrancettar Intrancettar
Intrancettar Intrancettar
Intrancettar Intrancettar
Intrancettar Areatment Group 365 / Month 12 Assay Log Titer Diagnosis 170010 365 / Month 12 Assay Log Titer Diagnosis 170010 355 / Month 12 Assay Log Titer No 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1140 No 104002 712 / Month 24 1130 No 104002 722 / Month 24 1130 No 122002 359 / Month 12 1630 No 124003 722 / Month 24 1140 No 124003 722 / Month 24 1130 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1770 No 124003 722 / Month 24 1770 No</td><td>Treatment Group Politive
Innunoreactivity Innunoreactivity Intrancitian
intrancision Areatment Group Skylject ID Assay Log Trest Diagnosis 170010 355 / Month 12 2537 / 00 No Diagnosis 170010 355 / Month 12 2800
 No Diagnosis 170010 355 / Month 24 1870 Irrits Diagnosis 177006 338 / Month 24 1300 No No 104002 712 / Month 24 1140 No No 104002 722 / Month 24 1130 No No 122002 359 / Month 12 1630 No No 124003 722 / Month 24 1130 No No 124003 722 / Month 24 1130 No No 124003 722 / Month 24 1300 No No 124003 722 / Month 24 1300 No No 124003 722 / Month 24 1300 No No 124003</td><td>Treatment Group Rolitive
Innunoreactivity Lurrancettiar Treatment Group Subject ID Routinest Civity Innunoreactivity Innenvation 170010 365 Month 12 2370 No No No 170010 365 Month 12 2870 No No No 170010 365 Month 12 2800 No No No 177006 338 Month 24 1870 Irrits No No 104002 712 Month 24 1140 No No No 104002 722 Month 24 1130 No No No 122002 359 Month 12 1630 No No No 124003 722 Month 24 1130 No No No 124003 722 Month 24 1300 No No No 124003 722 Month 24 1300 No No No 124003 722 Month 24 1300 No No No No No</td><td>Treatment Group Routing and the sective sective sective intermediation and the sective sective and the sective sective and the sective sective and the sective and the sective sective and the sective and</td></td></td></td></td></th> | 167002 717 / Mont 24 1.230 No No <td>167002 717/Mont 24 1.230 No Mont 24 1.250 No Mont 24 Mont 250 Mont 250<td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innamion 770010 365 Assay Assay Assay Log Diapnois 170010 355 Month 124 2700 No No 177006 358 Month 24 1370 No No 107002 717 Month 24 1390 No No 1124003 722 Month 24 1390 No No 124003 722 Month 24 1300 No No 124003 722 Month 24 1300 No No 124003 722 Month 12 2040 No No 122002 357 Month 24 1770 No No 124003 722 Month 24 1770 No</td><td>Treatment Group Positive
Inflammation Dispositive
Assay Intraordiat Intraordiat Treatment Group Subject ID Assay Assay Assay Assay Assay Assay Assay Assay Inflammation Treatment Group Subject ID Assay Asad Assay Assay</td><td>Treatment Group Ensistee
Subject ID Positree
Assay Intrancediat
Intranced
Assay Intranced
Assay Intranced
Assay</td><td>Treatment Group Subject ID Positive
Assay Immunoreactivity
Immunoreactivity Immunoreactivity Intraocidiar Treatment Group Subject ID 365 Mouth 12 2.770 No 170010 355 Mouth 24 2.800 Iritis Diagnosis 170010 355 Mouth 24 1870 No No 177006 355 Mouth 24 1870 No No 177006 355 Mouth 24 1370 No No 104002 717 Month 24 1360 No No 102001 722 Month 24 1370 No No 124003 722 Month 24 1300 No No 12400 12001 174 Month 6 1.700 No 125004 5357 Month 12 1600 No No 126001<!--</td--><td>Treatment Group Subject ID Assay Positive
Immunoreactivity Intranscription Treatment Group Subject ID 3650 Mouth 12 2.770 No 170010 355 /Mouth 24 2.800 Irtitis Diagnosis 177006 355 /Mouth 24 1850 Irtitis 177006 355 /Mouth 24 1850 Irtitis 177006 355 /Mouth 24 1360 Irtitis 177006 355 /Mouth 24 1360 No 122002 722 /Mouth 24 1360 No 124003 722 /Mouth 24 1360 No 124003 722 /Mouth 24 1370 No 124003 722 /Mouth 24 1370 No 124003 722 /Mouth 24 1370 No 126001 174 /Mouth 24 1370 No 126001 174 /Mouth 24 1600 No 126001 174 /Mouth 24 1600 No 126001 174 /Mouth 24 1600 No 1</td><td>Treatment Group Subject ID Positive
Assay Immunoreactivity
Immunoreactivity Immunoreactivity Intraocidiar Treatment Group Subject ID 365 Mouth 12 2.770 No 170010 355 Mouth 24 2.800 Iritis Diagnosis 170010 355 Mouth 24 1870 No No 177006 355 Mouth 24 1870 No No 177006 355 Mouth 24 1370 No No 104002 717 Month 24 1360 No No 102001 722 Month 24 1370 No No 124003 722 Month 24 1300 No No 12400 12001 174 Month 6 1.700 No 125004 5357 Month 12 1600 No No 126001<!--</td--><td>Treatment Group Subject ID Positive
Assay Immunoreactivity
Immunoreactivity Immunoreactivity Intraocidiar Treatment Group Subject ID 365 Mouth 12 2.770 No 170010 355 Mouth 24 2.800 Iritis Diagnosis 170010 355 Mouth 24 1870 No No 177006 355 Mouth 24 1870 No No 177006 355 Mouth 24 1370 No No 104002 717 Month 24 1360 No No 102001 722 Month 24 1370 No No 124003 722 Month 24 1300 No No 12400 12001 174 Month 6 1.700 No 125004 5357 Month 12 1600 No No 126001<!--</td--><td>Treatment Group Ensistee
Subject ID Positree
Assay Intrancediat
Intranced
Assay Intranced
Assay Intranced
Assay</td><td>Treatment Group Ensistee
Subject ID Positree
Assay Intrancediat
Intranced
Assay Intranced
Assay Intranced
Assay</td><td>Treatment Group Ensistee
Subject ID Positree
Assay Intrancediat
Intranced
Assay Intranced
Assay Intranced
Assay</td><td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innamion 770010 365 Assay Assay Assay Log Diapnois 170010 355 Month 124 2700 No No 177006 358 Month 24 1370 No No 107002 717 Month 24 1390 No No 1124003 722 Month 24 1390 No No 124003 722
Month 24 1300 No No 124003 722 Month 24 1300 No No 124003 722 Month 12 2040 No No 122002 357 Month 24 1770 No No 124003 722 Month 24 1770 No</td><td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Jreatment Group Subject ID Assay Assay Assay Innumoreactivity Inflammation Jreatment Group Subject ID 365 / Month 12 2.770 No No 170010 355 / Month 12 1870 Intraorchits Diagnois 177006 358 / Month 24 1870 Intits No 177006 358 / Month 24 1140 No No 106002 722 / Month 24 1130 No No 124003 722 / Month 24 1130 No No 126001 174 / Month 24 1300 No No 126001 174 / Month 24 1300 No No 122002 357 / Month 24 1770 No No 123003 357 / Month 24 1770 No No 124003 722 / Month 24 1770 No No 125004 5357 / Month 24 1770 No<</td><td>Treatment Group Intrancettar
Intrancettar Intrancettar
Intrancettar Intrancettar
Intrancettar Intrancettar
Intrancettar Areatment Group 365 / Month 12 Assay Log Titer Diagnosis 170010 365 / Month 12 Assay Log Titer Diagnosis 170010 355 / Month 12 Assay Log Titer No 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1140 No 104002 712 / Month 24 1130 No 104002 722 / Month 24 1130 No 122002 359 / Month 12 1630 No 124003 722 / Month 24 1140 No 124003 722 / Month 24 1130 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1770 No 124003 722 / Month 24 1770 No</td><td>Treatment Group Politive
Innunoreactivity Innunoreactivity Intrancitian
intrancision Areatment Group Skylject ID Assay Log Trest Diagnosis 170010 355 / Month 12 2537 / 00 No Diagnosis 170010 355 / Month 12 2800 No Diagnosis 170010 355 / Month 24 1870 Irrits Diagnosis 177006 338 / Month 24 1300 No No 104002 712 / Month 24 1140 No No 104002 722 / Month 24 1130 No No 122002 359 / Month 12 1630 No No 124003 722 / Month 24 1130 No No 124003 722 / Month 24 1130 No No 124003 722 / Month 24 1300 No No 124003 722 / Month 24 1300 No No 124003 722 / Month 24 1300 No No 124003</td><td>Treatment Group Rolitive
Innunoreactivity Lurrancettiar Treatment Group Subject ID Routinest Civity Innunoreactivity Innenvation 170010 365 Month 12 2370 No No No 170010 365 Month 12 2870 No No No 170010 365 Month 12 2800 No No No 177006 338 Month 24 1870 Irrits No No 104002 712 Month 24 1140 No No No 104002 722 Month 24 1130 No No No 122002 359 Month 12 1630 No No No 124003 722 Month 24 1130 No No No 124003 722 Month 24 1300 No No No 124003 722 Month 24 1300 No No No 124003 722 Month 24 1300 No No No No No</td><td>Treatment Group Routing and the sective sective sective intermediation and the sective sective and the sective sective and the sective sective and the sective and the sective sective and the sective and</td></td></td></td></td> | 167002 717/Mont 24 1.230 No Mont 24 1.250 No Mont 24 Mont 250 Mont 250 <td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innamion 770010 365 Assay Assay Assay Log Diapnois 170010 355 Month 124 2700 No No 177006 358 Month 24 1370 No No 107002 717 Month 24 1390 No No 1124003 722 Month 24 1390 No No 124003 722 Month 24 1300 No No 124003 722 Month 24 1300 No No 124003 722 Month 12 2040 No No 122002 357 Month 24 1770 No No 124003 722 Month 24 1770 No</td> <td>Treatment Group Positive
Inflammation Dispositive
Assay Intraordiat Intraordiat Treatment Group Subject ID Assay Assay Assay Assay Assay Assay Assay Assay Inflammation Treatment Group Subject ID Assay Asad Assay Assay</td> <td>Treatment Group Ensistee
Subject ID Positree
Assay Intrancediat
Intranced
Assay Intranced
Assay Intranced
Assay</td> <td>Treatment Group Subject ID Positive
Assay Immunoreactivity
Immunoreactivity Immunoreactivity Intraocidiar Treatment Group Subject ID 365 Mouth 12 2.770 No 170010 355 Mouth 24 2.800 Iritis Diagnosis 170010 355 Mouth 24 1870 No No 177006 355 Mouth 24 1870 No No 177006 355 Mouth 24 1370 No No 104002 717 Month 24 1360 No No 102001 722 Month 24 1370 No No 124003 722 Month 24 1300 No No 12400 12001 174 Month 6 1.700 No 125004 5357 Month 12 1600 No No 126001<!--</td--><td>Treatment Group Subject ID Assay Positive
Immunoreactivity Intranscription Treatment Group Subject ID 3650 Mouth 12 2.770 No 170010 355 /Mouth 24 2.800 Irtitis Diagnosis 177006 355 /Mouth 24 1850 Irtitis 177006 355 /Mouth 24 1850 Irtitis 177006 355 /Mouth 24 1360 Irtitis 177006 355 /Mouth 24 1360 No 122002 722 /Mouth 24 1360 No 124003 722 /Mouth 24 1360 No 124003 722 /Mouth 24 1370 No 124003 722 /Mouth 24 1370 No 124003 722 /Mouth 24 1370 No 126001 174 /Mouth 24 1370 No 126001 174 /Mouth 24 1600 No 126001 174 /Mouth 24 1600 No 126001 174 /Mouth 24 1600
 No 1</td><td>Treatment Group Subject ID Positive
Assay Immunoreactivity
Immunoreactivity Immunoreactivity Intraocidiar Treatment Group Subject ID 365 Mouth 12 2.770 No 170010 355 Mouth 24 2.800 Iritis Diagnosis 170010 355 Mouth 24 1870 No No 177006 355 Mouth 24 1870 No No 177006 355 Mouth 24 1370 No No 104002 717 Month 24 1360 No No 102001 722 Month 24 1370 No No 124003 722 Month 24 1300 No No 12400 12001 174 Month 6 1.700 No 125004 5357 Month 12 1600 No No 126001<!--</td--><td>Treatment Group Subject ID Positive
Assay Immunoreactivity
Immunoreactivity Immunoreactivity Intraocidiar Treatment Group Subject ID 365 Mouth 12 2.770 No 170010 355 Mouth 24 2.800 Iritis Diagnosis 170010 355 Mouth 24 1870 No No 177006 355 Mouth 24 1870 No No 177006 355 Mouth 24 1370 No No 104002 717 Month 24 1360 No No 102001 722 Month 24 1370 No No 124003 722 Month 24 1300 No No 12400 12001 174 Month 6 1.700 No 125004 5357 Month 12 1600 No No 126001<!--</td--><td>Treatment Group Ensistee
Subject ID Positree
Assay Intrancediat
Intranced
Assay Intranced
Assay Intranced
Assay</td><td>Treatment Group Ensistee
Subject ID Positree
Assay Intrancediat
Intranced
Assay Intranced
Assay Intranced
Assay</td><td>Treatment Group Ensistee
Subject ID Positree
Assay Intrancediat
Intranced
Assay Intranced
Assay Intranced
Assay</td><td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innamion 770010 365 Assay Assay Assay Log Diapnois 170010 355 Month 124 2700 No No 177006 358 Month 24 1370 No No 107002 717 Month 24 1390 No No 1124003 722 Month 24 1390 No No 124003 722 Month 24 1300 No No 124003 722 Month 24 1300 No No 124003 722 Month 12 2040 No No 122002 357 Month 24 1770 No No 124003 722 Month 24 1770 No</td><td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Jreatment Group Subject ID Assay Assay Assay Innumoreactivity Inflammation Jreatment Group Subject ID 365 / Month 12 2.770 No No 170010 355 / Month 12 1870 Intraorchits Diagnois 177006 358 / Month 24 1870 Intits No 177006 358 / Month 24 1140 No No 106002 722 / Month 24 1130 No No 124003 722 / Month 24 1130 No No 126001 174 / Month 24 1300 No No 126001 174 / Month 24 1300 No No 122002 357 / Month 24 1770 No No 123003 357 / Month 24 1770 No No 124003 722 / Month 24 1770 No No 125004 5357 / Month 24 1770 No<</td><td>Treatment Group Intrancettar
Intrancettar Intrancettar
Intrancettar Intrancettar
Intrancettar Intrancettar
Intrancettar Areatment Group 365 / Month 12 Assay Log Titer Diagnosis 170010 365 / Month 12 Assay Log Titer Diagnosis 170010 355 / Month 12 Assay Log Titer No 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1140 No 104002 712 / Month 24 1130 No 104002 722 / Month 24 1130 No 122002 359 / Month 12 1630 No 124003 722 / Month 24 1140 No 124003 722 / Month 24 1130 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1770 No 124003 722 / Month 24 1770 No</td><td>Treatment Group Politive
Innunoreactivity Innunoreactivity Intrancitian
intrancision Areatment Group Skylject ID Assay Log Trest Diagnosis 170010 355 / Month 12 2537 / 00 No Diagnosis 170010 355 / Month 12 2800 No Diagnosis 170010 355 / Month 24 1870 Irrits Diagnosis 177006 338 / Month 24 1300 No No 104002 712 / Month 24 1140 No No 104002 722 / Month 24 1130 No No 122002 359 / Month 12 1630 No No 124003 722 / Month 24 1130 No No 124003 722 / Month 24 1130 No No 124003 722 / Month 24 1300 No No 124003 722 / Month 24 1300 No No 124003 722 / Month 24 1300 No No 124003</td><td>Treatment Group Rolitive
Innunoreactivity Lurrancettiar Treatment Group Subject ID Routinest Civity Innunoreactivity Innenvation 170010 365 Month 12 2370 No No No 170010 365 Month 12 2870 No No No 170010 365 Month 12 2800 No No No 177006 338 Month 24 1870 Irrits No No 104002 712 Month 24 1140 No No No 104002 722 Month 24 1130 No No No 122002 359 Month 12 1630 No No No 124003 722 Month 24 1130 No No No 124003 722 Month 24 1300 No No No 124003 722 Month 24 1300 No No No 124003 722 Month 24 1300 No No No No No</td><td>Treatment Group Routing and the sective sective sective intermediation and the sective sective and the sective sective and the sective sective and the sective and the sective sective and the sective and</td></td></td></td> | Treatment Group Positive
Innumoreactivity Innumoreactivity Innamion 770010 365 Assay Assay Assay Log Diapnois 170010 355 Month 124 2700 No No 177006 358 Month 24 1370 No No 107002 717 Month 24 1390 No No 1124003 722 Month 24 1390 No No 124003 722 Month 24 1300 No No 124003 722 Month 24 1300 No No 124003 722
 Month 12 2040 No No 122002 357 Month 24 1770 No No 124003 722 Month 24 1770 No

 | Treatment Group Positive
Inflammation Dispositive
Assay Intraordiat Intraordiat Treatment Group Subject ID Assay Assay Assay Assay Assay Assay Assay Assay Inflammation Treatment Group Subject ID Assay Asad Assay Assay

 | Treatment Group Ensistee
Subject ID Positree
Assay Intrancediat
Intranced
Assay Intranced
Assay

 | Treatment Group Subject ID Positive
Assay Immunoreactivity
Immunoreactivity Immunoreactivity Intraocidiar Treatment Group Subject ID 365 Mouth 12 2.770 No 170010 355 Mouth 24 2.800 Iritis Diagnosis 170010 355 Mouth 24 1870 No No 177006 355 Mouth 24 1870 No No 177006 355 Mouth 24 1370 No No 104002 717 Month 24 1360 No No 102001 722 Month 24 1370 No No 124003 722 Month 24 1300 No No 12400 12001 174 Month 6 1.700 No 125004 5357 Month 12 1600 No No 126001 </td <td>Treatment Group Subject ID Assay Positive
Immunoreactivity Intranscription Treatment Group Subject ID 3650 Mouth 12 2.770 No 170010 355 /Mouth 24 2.800 Irtitis Diagnosis 177006 355 /Mouth 24 1850 Irtitis 177006 355 /Mouth 24 1850 Irtitis 177006 355 /Mouth 24 1360 Irtitis 177006 355 /Mouth 24 1360 No 122002 722 /Mouth 24 1360 No 124003 722 /Mouth 24 1360 No 124003 722 /Mouth 24 1370 No 124003 722 /Mouth 24 1370 No 124003 722 /Mouth 24 1370 No 126001 174 /Mouth 24 1370 No 126001 174 /Mouth 24 1600 No 126001 174 /Mouth 24 1600 No 126001 174 /Mouth 24 1600 No 1</td> <td>Treatment Group Subject ID Positive
Assay Immunoreactivity
Immunoreactivity Immunoreactivity Intraocidiar Treatment Group Subject ID 365 Mouth 12 2.770 No 170010 355 Mouth 24 2.800 Iritis Diagnosis 170010 355 Mouth 24 1870 No No 177006 355 Mouth 24 1870 No No 177006 355 Mouth 24 1370 No No 104002 717 Month 24 1360 No No 102001 722 Month 24 1370 No No 124003 722 Month 24 1300 No No 12400 12001 174 Month 6 1.700 No 125004 5357 Month 12 1600 No No 126001<!--</td--><td>Treatment Group Subject ID Positive
Assay Immunoreactivity
Immunoreactivity Immunoreactivity Intraocidiar Treatment Group Subject ID 365 Mouth 12 2.770 No 170010 355 Mouth 24 2.800 Iritis Diagnosis 170010 355 Mouth 24 1870 No No 177006 355 Mouth 24 1870 No No 177006 355 Mouth 24 1370 No No 104002 717 Month 24 1360 No No 102001 722 Month 24 1370 No No 124003 722 Month 24 1300 No No 12400 12001 174 Month 6 1.700 No 125004 5357 Month 12 1600 No No 126001<!--</td--><td>Treatment Group Ensistee
Subject ID Positree
Assay Intrancediat
Intranced
Assay Intranced
Assay Intranced
Assay</td><td>Treatment Group Ensistee
Subject ID Positree
Assay Intrancediat
Intranced
Assay Intranced
Assay Intranced
Assay</td><td>Treatment Group Ensistee
Subject ID Positree
Assay Intrancediat
Intranced
Assay Intranced
Assay Intranced
Assay</td><td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innamion 770010 365 Assay Assay Assay Log Diapnois 170010 355 Month 124 2700 No No 177006 358 Month 24 1370 No No 107002 717 Month 24 1390 No No 1124003 722 Month 24 1390 No No 124003 722 Month 24 1300 No No 124003 722 Month 24 1300 No No 124003 722 Month 12 2040 No No 122002 357 Month 24 1770 No No 124003 722 Month 24 1770 No</td><td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Jreatment Group Subject ID Assay Assay Assay Innumoreactivity Inflammation Jreatment Group Subject ID 365 / Month 12 2.770 No No 170010 355 / Month 12 1870 Intraorchits Diagnois 177006 358 / Month 24 1870 Intits No 177006 358 / Month 24 1140 No No 106002 722 / Month 24 1130 No No 124003 722 / Month 24 1130 No No 126001 174 / Month 24 1300 No No 126001 174 / Month 24 1300 No No 122002 357 / Month 24 1770 No No 123003 357 / Month 24 1770 No No 124003 722 / Month 24 1770 No No 125004 5357 / Month 24 1770 No<</td><td>Treatment Group Intrancettar
Intrancettar Intrancettar
Intrancettar Intrancettar
Intrancettar Intrancettar
Intrancettar Areatment Group 365 / Month 12 Assay Log Titer Diagnosis 170010 365 / Month 12 Assay Log Titer Diagnosis 170010 355 / Month 12 Assay Log Titer
 No 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1140 No 104002 712 / Month 24 1130 No 104002 722 / Month 24 1130 No 122002 359 / Month 12 1630 No 124003 722 / Month 24 1140 No 124003 722 / Month 24 1130 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1770 No 124003 722 / Month 24 1770 No</td><td>Treatment Group Politive
Innunoreactivity Innunoreactivity Intrancitian
intrancision Areatment Group Skylject ID Assay Log Trest Diagnosis 170010 355 / Month 12 2537 / 00 No Diagnosis 170010 355 / Month 12 2800 No Diagnosis 170010 355 / Month 24 1870 Irrits Diagnosis 177006 338 / Month 24 1300 No No 104002 712 / Month 24 1140 No No 104002 722 / Month 24 1130 No No 122002 359 / Month 12 1630 No No 124003 722 / Month 24 1130 No No 124003 722 / Month 24 1130 No No 124003 722 / Month 24 1300 No No 124003 722 / Month 24 1300 No No 124003 722 / Month 24 1300 No No 124003</td><td>Treatment Group Rolitive
Innunoreactivity Lurrancettiar Treatment Group Subject ID Routinest Civity Innunoreactivity Innenvation 170010 365 Month 12 2370 No No No 170010 365 Month 12 2870 No No No 170010 365 Month 12 2800 No No No 177006 338 Month 24 1870 Irrits No No 104002 712 Month 24 1140 No No No 104002 722 Month 24 1130 No No No 122002 359 Month 12 1630 No No No 124003 722 Month 24 1130 No No No 124003 722 Month 24 1300 No No No 124003 722 Month 24 1300 No No No 124003 722 Month 24 1300 No No No No No</td><td>Treatment Group Routing and the sective sective sective intermediation and the sective sective and the sective sective and the sective sective and the sective and the sective sective and the sective and</td></td></td> | Treatment Group Subject ID Assay Positive
Immunoreactivity Intranscription Treatment Group Subject ID 3650 Mouth 12 2.770 No 170010 355 /Mouth 24 2.800 Irtitis Diagnosis 177006 355 /Mouth 24 1850 Irtitis 177006 355 /Mouth 24 1850 Irtitis 177006 355 /Mouth 24 1360 Irtitis 177006 355 /Mouth 24 1360 No 122002 722 /Mouth 24 1360 No 124003 722 /Mouth 24 1360 No 124003 722 /Mouth 24 1370 No 124003 722 /Mouth 24 1370 No 124003 722 /Mouth 24 1370 No 126001 174 /Mouth 24 1370 No 126001 174 /Mouth 24 1600 No 126001 174 /Mouth 24 1600 No 126001 174 /Mouth 24 1600 No 1
 | Treatment Group Subject ID Positive
Assay Immunoreactivity
Immunoreactivity Immunoreactivity Intraocidiar Treatment Group Subject ID 365 Mouth 12 2.770 No 170010
 355 Mouth 24 2.800 Iritis Diagnosis 170010 355 Mouth 24 1870 No No 177006 355 Mouth 24 1870 No No 177006 355 Mouth 24 1370 No No 104002 717 Month 24 1360 No No 102001 722 Month 24 1370 No No 124003 722 Month 24 1300 No No 12400 12001 174 Month 6 1.700 No 125004 5357 Month 12 1600 No No 126001 </td <td>Treatment Group Subject ID Positive
Assay Immunoreactivity
Immunoreactivity Immunoreactivity Intraocidiar Treatment Group Subject ID 365 Mouth 12 2.770 No 170010 355 Mouth 24 2.800 Iritis Diagnosis 170010 355 Mouth 24 1870 No No 177006 355 Mouth 24 1870 No No 177006 355 Mouth 24 1370 No No 104002 717 Month 24 1360 No No 102001 722 Month 24 1370 No No 124003 722 Month 24 1300 No No 12400 12001 174 Month 6 1.700 No 125004 5357 Month 12 1600 No No 126001<!--</td--><td>Treatment Group Ensistee
Subject ID Positree
Assay Intrancediat
Intranced
Assay Intranced
Assay Intranced
Assay</td><td>Treatment Group Ensistee
Subject ID Positree
Assay Intrancediat
Intranced
Assay Intranced
Assay Intranced
Assay</td><td>Treatment Group Ensistee
Subject ID Positree
Assay Intrancediat
Intranced
Assay Intranced
Assay Intranced
Assay</td><td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innamion 770010 365 Assay Assay Assay Log Diapnois 170010 355 Month 124 2700 No No 177006 358 Month 24 1370 No No 107002 717 Month 24 1390 No No 1124003 722 Month 24 1390 No No 124003 722 Month 24 1300 No No 124003 722 Month 24 1300 No No 124003 722 Month 12 2040 No No 122002 357 Month 24 1770 No No 124003 722 Month 24 1770 No</td><td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Jreatment Group Subject ID Assay Assay Assay Innumoreactivity Inflammation Jreatment Group Subject ID 365 / Month 12 2.770 No No 170010 355 / Month 12 1870 Intraorchits Diagnois 177006 358 / Month 24 1870 Intits No 177006 358 / Month 24 1140 No No 106002 722 / Month 24 1130 No No 124003 722 / Month 24 1130 No No 126001 174 / Month 24 1300 No No 126001 174 / Month 24 1300 No No 122002 357 / Month 24 1770 No No 123003 357 / Month 24 1770 No No 124003 722 / Month 24 1770 No No 125004 5357 / Month 24 1770 No<</td><td>Treatment Group Intrancettar
Intrancettar Intrancettar
Intrancettar Intrancettar
Intrancettar Intrancettar
Intrancettar Areatment Group 365 / Month 12 Assay Log Titer Diagnosis 170010 365 / Month 12 Assay Log Titer Diagnosis 170010 355 / Month 12 Assay Log Titer No 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1140 No 104002 712 / Month 24 1130 No 104002 722 / Month 24 1130 No 122002 359 / Month 12 1630 No 124003 722 / Month 24 1140 No 124003 722 / Month 24 1130 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1770 No 124003 722 / Month 24 1770 No</td><td>Treatment Group Politive
Innunoreactivity Innunoreactivity Intrancitian
intrancision Areatment Group Skylject ID Assay Log Trest Diagnosis 170010 355 / Month 12 2537 / 00 No Diagnosis 170010 355 / Month 12 2800 No Diagnosis 170010 355 / Month 24 1870 Irrits Diagnosis 177006 338 / Month 24 1300 No No 104002 712 / Month 24 1140 No No 104002 722 / Month 24 1130 No No 122002 359 / Month 12 1630 No No 124003 722 / Month 24 1130 No No 124003 722 / Month 24 1130 No No 124003 722 / Month 24 1300 No No 124003 722 / Month 24 1300 No No 124003 722 / Month 24 1300 No No 124003</td><td>Treatment Group Rolitive
Innunoreactivity Lurrancettiar Treatment Group Subject ID Routinest Civity Innunoreactivity Innenvation 170010 365 Month 12 2370 No No No 170010 365 Month 12 2870 No No No 170010 365 Month 12 2800 No No No 177006 338 Month 24 1870 Irrits No No 104002 712 Month 24 1140 No No No 104002 722 Month 24 1130 No No No 122002 359 Month 12 1630 No No No 124003 722 Month 24 1130 No No No 124003 722 Month 24 1300 No No No 124003 722 Month 24 1300 No No No 124003 722 Month 24 1300 No No No No No</td><td>Treatment Group Routing and the sective sective sective intermediation and the sective sective and the sective sective and the sective sective and the sective and the sective sective and the sective and</td></td> | Treatment Group Subject ID Positive
Assay Immunoreactivity
Immunoreactivity Immunoreactivity Intraocidiar Treatment Group Subject ID 365 Mouth 12 2.770 No 170010 355 Mouth 24 2.800 Iritis Diagnosis 170010 355 Mouth 24 1870 No No 177006 355 Mouth 24 1870 No No 177006 355 Mouth 24 1370 No No 104002 717 Month 24 1360 No No 102001 722 Month 24 1370 No No 124003 722 Month 24 1300 No No 12400 12001 174 Month 6 1.700 No 125004 5357 Month 12 1600 No No 126001 </td <td>Treatment Group Ensistee
Subject ID Positree
Assay Intrancediat
Intranced
Assay Intranced
Assay Intranced
Assay</td> <td>Treatment Group Ensistee
Subject ID Positree
Assay Intrancediat
Intranced
Assay Intranced
Assay Intranced
Assay</td> <td>Treatment Group Ensistee
Subject ID Positree
Assay Intrancediat
Intranced
Assay Intranced
Assay Intranced
Assay</td> <td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innamion 770010 365 Assay Assay Assay Log Diapnois 170010 355 Month 124 2700 No No 177006 358 Month 24 1370 No No 107002 717 Month 24 1390 No No 1124003 722 Month 24
 1390 No No 124003 722 Month 24 1300 No No 124003 722 Month 24 1300 No No 124003 722 Month 12 2040 No No 122002 357 Month 24 1770 No No 124003 722 Month 24 1770 No</td> <td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Jreatment Group Subject ID Assay Assay Assay Innumoreactivity Inflammation Jreatment Group Subject ID 365 / Month 12 2.770 No No 170010 355 / Month 12 1870 Intraorchits Diagnois 177006 358 / Month 24 1870 Intits No 177006 358 / Month 24 1140 No No 106002 722 / Month 24 1130 No No 124003 722 / Month 24 1130 No No 126001 174 / Month 24 1300 No No 126001 174 / Month 24 1300 No No 122002 357 / Month 24 1770 No No 123003 357 / Month 24 1770 No No 124003 722 / Month 24 1770 No No 125004 5357 / Month 24 1770 No<</td> <td>Treatment Group Intrancettar
Intrancettar Intrancettar
Intrancettar Intrancettar
Intrancettar Intrancettar
Intrancettar Areatment Group 365 / Month 12 Assay Log Titer Diagnosis 170010 365 / Month 12 Assay Log Titer Diagnosis 170010 355 / Month 12 Assay Log Titer No 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1140 No 104002 712 / Month 24 1130 No 104002 722 / Month 24 1130 No 122002 359 / Month 12 1630 No 124003 722 / Month 24 1140 No 124003 722 / Month 24 1130 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1770 No 124003 722 / Month 24 1770 No</td> <td>Treatment Group Politive
Innunoreactivity Innunoreactivity Intrancitian
intrancision Areatment Group Skylject ID Assay Log Trest Diagnosis 170010 355 / Month 12 2537 / 00 No Diagnosis 170010 355 / Month 12 2800 No Diagnosis 170010 355 / Month 24 1870 Irrits Diagnosis 177006 338 / Month 24 1300 No No 104002 712 / Month 24 1140 No No 104002 722 / Month 24 1130 No No 122002 359 / Month 12 1630 No No 124003 722 / Month 24 1130 No No 124003 722 / Month 24 1130 No No 124003 722 / Month 24 1300 No No 124003 722 / Month 24 1300 No No 124003 722 / Month 24 1300 No No 124003</td> <td>Treatment Group Rolitive
Innunoreactivity Lurrancettiar Treatment Group Subject ID Routinest Civity Innunoreactivity Innenvation 170010 365 Month 12 2370 No No No 170010 365 Month 12 2870 No No No 170010 365 Month 12 2800 No No No 177006 338 Month 24 1870 Irrits No No 104002 712 Month 24 1140 No No No 104002 722 Month 24 1130 No No No 122002 359 Month 12 1630 No No No 124003 722 Month 24 1130 No No No 124003 722 Month 24 1300 No No No 124003 722 Month 24 1300 No No No 124003 722 Month 24 1300 No No No No No</td> <td>Treatment Group Routing and the sective sective sective intermediation and the sective sective and the sective sective and the sective sective and the sective and the sective sective and the sective and</td> | Treatment Group Ensistee
Subject ID Positree
Assay Intrancediat
Intranced
Assay Intranced
Assay
 | Treatment Group Ensistee
Subject ID Positree
Assay Intrancediat
Intranced
Assay Intranced
Assay
 | Treatment Group Ensistee
Subject ID Positree
Assay Intrancediat
Intranced
Assay Intranced
Assay
 | Treatment Group Positive
Innumoreactivity Innumoreactivity Innamion 770010 365 Assay Assay Assay Log Diapnois 170010 355 Month 124 2700 No No 177006 358 Month 24 1370 No No 107002 717 Month 24 1390 No No 1124003 722 Month 24 1390 No No 124003 722 Month 24 1300 No No 124003 722 Month 24 1300 No No 124003 722 Month 12 2040 No No 122002 357 Month 24 1770 No No 124003 722 Month 24 1770 No
 | Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Jreatment Group Subject ID Assay Assay Assay Innumoreactivity Inflammation Jreatment Group Subject ID 365 / Month 12 2.770 No No 170010 355 / Month 12 1870 Intraorchits Diagnois 177006 358 / Month 24 1870 Intits No 177006 358 / Month 24 1140 No No 106002 722 / Month 24 1130 No No 124003 722 / Month 24 1130 No No 126001 174 / Month 24 1300 No No 126001 174 / Month 24 1300 No No 122002 357 / Month 24 1770 No No 123003 357 / Month 24 1770 No No 124003 722 / Month 24 1770 No No 125004 5357 / Month 24 1770 No<
 | Treatment Group Intrancettar
Intrancettar Intrancettar
Intrancettar Intrancettar
Intrancettar Intrancettar
Intrancettar Areatment Group 365 / Month 12 Assay Log Titer Diagnosis 170010 365 / Month 12 Assay Log Titer Diagnosis 170010 355 / Month 12 Assay Log Titer No 177006 358 / Month 24 1870 Irritis 177006 358 / Month 24 1140 No 104002 712 / Month 24 1130 No 104002 722 / Month 24 1130 No 122002 359 / Month 12 1630 No 124003 722 / Month 24 1140 No 124003 722 / Month 24 1130 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1300 No 124003 722 / Month 24 1770 No 124003 722 / Month 24 1770 No | Treatment Group Politive
Innunoreactivity Innunoreactivity Intrancitian
intrancision Areatment Group Skylject ID Assay Log Trest Diagnosis 170010 355 / Month 12 2537 / 00 No Diagnosis 170010 355 / Month 12 2800 No Diagnosis 170010 355 / Month 24 1870 Irrits Diagnosis 177006 338 / Month 24 1300 No No 104002 712 / Month 24 1140 No No 104002 722 / Month 24 1130 No No 122002 359 / Month 12 1630 No No 124003 722 / Month 24 1130 No No 124003 722 / Month 24 1130 No No 124003 722 / Month 24 1300 No No 124003 722 / Month 24 1300 No No 124003 722 / Month 24 1300 No No 124003
 | Treatment Group Rolitive
Innunoreactivity Lurrancettiar Treatment Group Subject ID Routinest Civity Innunoreactivity Innenvation 170010 365 Month 12 2370 No No No 170010 365 Month 12 2870 No No No 170010 365 Month 12 2800 No No No 177006 338 Month 24 1870 Irrits No No 104002 712 Month 24 1140 No No No 104002 722 Month 24 1130 No No No 122002 359 Month 12 1630 No No No 124003 722 Month 24 1130 No No No 124003 722 Month 24 1300 No No No 124003 722 Month 24 1300 No No No 124003 722 Month 24 1300 No No No No No | Treatment Group Routing and the sective sective sective intermediation and the sective sective and the sective sective and the sective sective and the sective and the sective sective and the sective and |
| 1.2701 1.0701 1.0701 1.00 1.00 167002 717/Mont 24 1.230 No 1.00 188005 717/Month 24 1.250 No 1.00 Sham 534001 -7/Screening 2.520 Vitritis

 | 15701 10701 10701 100 100 167002 717/Mont 24 1.230 No 100 188005 717/Month 24 1.250 No 100 Sham 534001 -7/Screening 2.520 Vitritis

 | •

 | Treatment Group Positive
Immunoreactivity Intrancitianistion Jreatment Group Subject ID Assay Assay Intrancitianistion 170010 36 / Month 22 2700 No 170010 36 / Month 24 2800 No 170010 36 / Month 22 2000 No 177006 358 / Month 24 1870 Intris 104002 717 / Month 1870 Intris No 1177006 358 / Month 1140 No No 106002 722 / Month 1130 No No 124003 722 / Month 1130 No No 124001 174 / Month 1130 No No 124003 722 / Month 1480 No No 124003 722 / Month 1480 No No 124003 722 / Month 24 1770 No 124003 722 / Month 24 1770 No

 | Treatment Group Positive
Immunoreactivity Intrancitian
Intransition Jreatment Group Subject ID Assity Lurrancitian 170010 365 / Mostry Assity Assity Diagnois 170010 365 / Mostry Assity Assity Diagnois 170010 365 / Mostry
2700 No 177006 358 / Month 12 1870 Irritis 104002 717 / Month 24 1850 Irritis 104002 722 / Month 24 1140 No 122002 359 / Month 12 1630 No 124001 174 / Month 6 1.770 No 124003 722 / Month 24 1.140 No 124001 174 / Month 6 1.770 No 124001 174 / Month 6 1.770 No 124003 722 / Month 24 0.782 No 124001 174 / Month 6 1.770 No 124001 174 / Month 6 1.770 No 141013 715 / Month 24

 | Treatment Group Positive
Immunoreactivity Intransitin
Immunoreactivity Intransitin
Immunoreactivity Intransitin
Immunoreactivity JTeatment Group Subject ID Assay Assay Assay Diagnois I70010 365 / Month 12 2770 No Diagnois I77016 358 / Month 12 1870 Irritis Diagnois I77016 358 / Month 12 1870 Irritis Diagnois I177006 358 / Month 12 1870 Irritis Diagnois I04002 717 / Month 24 1350 No Diagnois I12002 722 / Month 24 1140 No Diagnois I24003 722 / Month 24 1300 No Diagnois I2400 177

 | Treatment Group Positive
Subject ID Positive
Assay Intranciciant
Intransion Treatment Group Subject ID Assay Assay Log Titer Diagnois 170010 36/ Month 12 2770 No No 170010 358 / Month 12 18700 Irritis No 177006 338 / Month 12 18700 Irritis No 177006 338 / Month 12 18700 Irritis No 104002 717 / Month 24 1850 No No 102001 722 / Month 24 11400 No No 122002 335 / Month 12 1630 No No 122002 722 / Month 24 17700 No No 124003 722 / Mo
 | Treatment Group Rolifiere
Subject ID Positive
Assay Intransectivity
Assay Log Titer Intransectina
Diagnois
 Treatment Group Subject ID Assay Assay Assay Log Titer Diagnois 170010 365/Mouth 12 2.770 No No 177006 358/Mouth 12 1.870 Intris No 177006 358/Mouth 12 1.870 No No 177006 358/Mouth 12 1.870 No No 104002 717/Mouth 24 1.870 No No No 102001 722/Mouth 24 1.140 No No No 122002 359/Mouth 12 1.130 No No No 122002 722/Mouth 24 1.130 No No No 124001 174/Mouth 6 1.770 No No No 124003 722/Mouth 24 1.630 No No 124001 174/Mouth 6 1.770 No No 124001 174/M
 | Treatment Group Positive
Subject ID Positive
Assay Intranciciant
Intransion Treatment Group Subject ID Assay Assay Log Titer Diagnois 170010 36/ Month 12 2770 No No 170010 358 / Month 12 18700 Irritis No 177006 338 / Month 12 18700 Irritis No 177006 338 / Month 12 18700 Irritis No 104002 717 / Month 24 1850 No No 102001 722 / Month 24 11400 No No 122002 335 / Month 12 1630 No No 122002 722 / Month 24 17700 No No 124003 722 / Mo

 | Treatment Group Positive
Subject ID Positive
Assay Intranciciant
Intransion Treatment Group Subject ID Assay Assay Log Titer Diagnois 170010 36/ Month 12 2770 No No 170010 358 / Month 12 18700 Irritis No 177006 338 / Month 12 18700 Irritis No 177006 338 / Month 12 18700 Irritis No 104002 717 / Month 24 1850 No No 102001 722 / Month 24 11400 No No 122002 335 / Month 12 1630 No No 122002 722 / Month 24 17700 No No 124003 722 / Mo
 | Treatment Group Positive
Immunoreactivity Intransitin
Immunoreactivity Intransitin
Immunoreactivity Intransitin
Immunoreactivity JTeatment Group Subject ID Assay Assay Assay Diagnois I70010 365 / Month 12 2770 No Diagnois I77016 358 / Month 12 1870 Irritis Diagnois I77016 358 / Month 12 1870 Irritis Diagnois I177006 358 / Month 12 1870 Irritis Diagnois I04002 717 / Month 24 1350 No Diagnois I12002 722 / Month 24 1140 No Diagnois I24003 722 / Month 24 1300 No Diagnois I2400 177
 | Treatment Group Positive
Immunoreactivity Intransitin
Immunoreactivity Intransitin
Immunoreactivity Intransitin
Immunoreactivity JTeatment Group Subject ID Assay Assay Assay Diagnois I70010 365 / Month 12 2770 No Diagnois I77016 358 / Month 12 1870 Irritis Diagnois I77016 358 / Month 12 1870 Irritis Diagnois I177006 358 / Month 12 1870 Irritis Diagnois I04002 717 / Month 24 1350 No Diagnois I12002 722 / Month 24 1140 No Diagnois I24003 722 / Month 24 1300 No Diagnois I2400 177
 | Treatment Group Positive
Immunoreactivity Intransitin
Immunoreactivity Intransitin
Immunoreactivity Intransitin
Immunoreactivity JTeatment Group Subject ID Assay Assay Assay Diagnois I70010 365 / Month 12 2770 No Diagnois I77016 358 / Month 12 1870 Irritis Diagnois I77016 358 / Month 12 1870 Irritis
 Diagnois I177006 358 / Month 12 1870 Irritis Diagnois I04002 717 / Month 24 1350 No Diagnois I12002 722 / Month 24 1140 No Diagnois I24003 722 / Month 24 1300 No Diagnois I2400 177 | Treatment Group Positive
Immunoreactivity Intrancitianistion Jreatment Group Subject ID Assay Assay Intrancitianistion 170010 36 / Month 22 2700 No 170010 36 / Month 24 2800 No 170010 36 / Month 22 2000 No 177006 358 / Month 24 1870 Intris
104002 717 / Month 1870 Intris No 1177006 358 / Month 1140 No No 106002 722 / Month 1130 No No 124003 722 / Month 1130 No No 124001 174 / Month 1130 No No 124003 722 / Month 1480 No No 124003 722 / Month 1480 No No 124003 722 / Month 24 1770 No 124003 722 / Month 24 1770 No | Treatment Group Positive
Innunoreactivity Intrancentiat
Infamination
Assy
170010 Month 12 Lurran
Assy
Assy Assy
Assy Assy
Assy Assy
177006 Intrancentiat
Assy
Assy Month 12 Intrancentiat
Infamination
Assy
Assy Month 12 Intrancentiat
Infamination
Assy
Assy Month 12 Intrancentiat
Assy
Assy Month 12 Intrancentiat
Assy
Assy Month 12 Intrancentiat
Assy
Assy Month 12 Intrancentiat
Assy
Assy Month 12 Intrancentiat
Assy Month 12 Intrancentiat
Assy Month 12 Intrancentiat
Assy Month 12 Intrancentiat
Asso
Assy Month 12 Intrancentiat
Asso
Assy Month 12 Intrancentiat
Asso
Asso
Month 12 Intrancentiat
Asso
Asso
Asso
Asso
Asso
Asso
Asso
Ass
 | Treatment Group Intrancitievely
Intransition Intrancitievely
Assisty Intransitien
Assisty Intransitien
Assisin Int | Treatment GroupPositive
IntrancactivityLutraccitiat
IntrancactivityTreatment GroupSubject IDMonth 12LutractivityLutraccitiat
Intrancactivity170010 365 /Month 12 23770 No170010 365 /Month 12 1870 Intrus177006 358 /Month 12 1870 Intrus177006 358 /Month 12 1870 Intrus177005 358 /Month 24 1.140 No104002 717 /Month 24 1.140 No104002 722 /Month 24 1.140 No122002 339 /Month 24 1.770 No124003 722 /Month 24 1.770 No124003 722 /Month 24 1.700 No124003 725 /Month 24 1.700 No124003 726 /Month 24 2.940 No125004 533 /Month 12 1.940 No125004 533 /Month 24 2.940 No125004 536 /Month 24 2.940 No125004 536 /Month 24 2.940 No153004 533 /Month 24 2.940 No153004 533 /Month 24 2.940 No153004 534 1.940 No153004
 | Treatment GroupPositive
ImmunoractivityImmunoractivity
ImmunoractivityImmunoractivity
ImmunoractivityTreatment GroupSubject IDAssyAssyIsso170010 365 Month 12 2770 Noo170010 365 Month 12 1870 Irritis177006 358 Month 12 1870 Irritis177006 358 Month 12 1870 Irritis177006 358 Month 24 1.140 No104002 717 Month 24 1.140 No104002 722 Month 24 1.140 No122003 339 Month 24 1.770 No124003 722 Month 24 1.700 No124003 725 Month 24 1.700 No124003 725 Month 24 1.700 No125004 535 Month 24 2.940 No125004 535 Month 24 2.940 No125004 532 Month 24 2.940 No153004 533 Month 24 2.940 No153004 536 Month 12 1.570 No153004 536 Month 24 2.940 No153004 536 Month 24 2.940 No153004 533 1.940 No1 | Treatment Group Subject ID Positive
Immunorescivity Immunorescivity Immunorescivity Treatment Group Subject ID Asisy Asisy Asisy Asisy 170010 365/Month 12 2.770 No No 170010 365/Month 12 2.770 No No 177006 338/Month 12 1.870 Irris No 177006 338/Month 12 1.870 Irris No 104002 717/Month 24 1.850 No No 122002 339/Month 12 1.140 No No 122002 339/Month 24 1.130 No No 124003 722/Month 24 1.770 No No 124003 723/Month 24 1.770 No No No 124003 725/Month 24 1.770 No No No No 124003 725/Month 24 1.770 No No No No 125004 174/Month 24 1.770 </td |
| 159017 716 / Month 24 0.780 T No 167002 717 / Month 24 1.230 No 1 188005 717 / Month 24 1.230 No 1 Sham 534001 -7 / Screening 2.520 Vitritis

 | 159017 716 / Month 24 0.780 T No 167002 717 / Month 24 1.230 No Mo 188005 717 / Month 24 1.230 No Mo Sham 534001 -7 / Screening 2.520 Vitritis

 | 159017 716/Month 24 0.780 T No 167002 717/Month 24 1.230 No 1 188005 717/Month 24 1.230 No 1 Sham 534001 -7/Screening 2.520 Virritis

 | Treatment Group Bubject ID Positive
finantion Intranscrattyrity Intranscrattyrity Intranscrattyrity Treatment Group Subject ID Assry Assry Assry Assry 170010 36. Month 12 2.770 No No 170010 35. Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177001 715 / Month 24 1.850 Irritis 100002 719 / Month 24 1.850 No 100002 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 723 / Month 24 0.782 No 122001 174 / Month 6 1.700 No 122002 357 / Month 12 1.700 No 122001 722 / Month 24 0.782 No 124003 722 / Month 24 0.780 No 124003 732 / Month 24 0.790 No 125001 174 / Month 6 1.770

 | Treatment Group Bubject ID Assry Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Infimmination Jreatment Group Subject ID Assry Assry Assry Assry Inframination 170010 36./Month 12 2.770 No No No
 170010 35./Month 12 1.870 Inframination No 177006 358/Month 12 1.870 No No 177001 717/Month 24 1.850 Infra No 106002 719/Month 24 1.140 No No 122002 359/Month 12 1.630 No No 122002 723/Month 24 0.782 No No 124003 722/Month 24 0.782 No No 126001 174/Month 6 1.700 No No 122002 357/Month 24 0.782 No No 124003 722/Month 24 0.790 No No 126001 174/Month 24 </td <td>Treatment Group Bubject ID Positive
inflammation Intranscrittar Treatment Group Subject ID Assay Assay Assay Intranscrittar Treatment Group Subject ID Assay Assay Assay Assay Intranscrittar 170010 36/Month 12 2.770 No No 177006 338/Month 12 1.850 Intris No 177006 338/Month 12 1.850 Intris No 100002 717/Month 24 1.850 No No 106002 722/Month 24 1.140 No No 122002 335/Month 12 1.630 No No 122002 723/Month 24 0.782 No No 124003 722/Month 24 1.700 No No 126001 174/Month 6 1.700 No No 126001 174/Month 24 2.040 No No 126001 174/Month 24 2.440 No No <t< td=""><td>Treatment Group Subject ID Positive
Inflammation Intranceditvity
Assay Intranceditat
Assay Intraceditat
Assay Intraceditat
Assay <th< td=""><td>Treatment Group Subject ID Positive
fimiliarian Intrancedityty
Assay Intrancedityty
Assay Intranceditar
Assay Intraceditar
Assay Intranceditar
Assay <th< td=""><td>Treatment Group Subject ID Positive
Inflammation Intranceditvity
Assay Intranceditat
Assay Intraceditat
Assay Intraceditat
Assay <th< td=""><td>Treatment Group Subject ID Positive
Inflammation Intranceditvity
Assay Intranceditat
Assay Intraceditat
Assay Intraceditat
Assay <th< td=""><td>Treatment Group Bubject ID Positive
inflammation Intranscrittar Treatment Group Subject ID Assay Assay Assay Intranscrittar Treatment Group Subject ID Assay Assay Assay Assay Intranscrittar 170010 36/Month 12 2.770 No No 177006 338/Month 12 1.850 Intris No 177006 338/Month 12 1.850 Intris No 100002 717/Month 24 1.850 No No 106002 722/Month 24 1.140 No No 122002 335/Month 12 1.630 No No 122002 723/Month 24 0.782 No No 124003 722/Month 24 1.700 No No 126001 174/Month 6 1.700 No No 126001 174/Month 24 2.040 No No 126001 174/Month 24 2.440 No No <t< td=""><td>Treatment Group Bubject ID Positive
inflammation Intranscrittar Treatment Group Subject ID Assay Assay Assay Intranscrittar Treatment Group Subject ID Assay Assay Assay Assay Intranscrittar 170010 36/Month 12 2.770 No No 177006 338/Month 12 1.850 Intris No 177006 338/Month 12 1.850 Intris No 100002 717/Month 24 1.850 No No 106002 722/Month 24 1.140 No No 122002 335/Month 12 1.630 No No 122002 723/Month 24 0.782 No No 124003 722/Month 24 1.700 No No 126001 174/Month 6 1.700 No No 126001 174/Month 24 2.040 No No 126001 174/Month 24 2.440 No No <t< td=""><td>Treatment Group Bubject ID Positive
inflammation Intranscrittar Treatment Group Subject ID Assay Assay Assay Intranscrittar Treatment Group Subject ID Assay Assay Assay Assay Intranscrittar 170010 36/Month 12 2.770 No No 177006 338/Month 12 1.850 Intris No 177006 338/Month 12 1.850 Intris No 100002 717/Month 24 1.850 No No 106002 722/Month 24 1.140 No No 122002 335/Month 12 1.630 No No 122002 723/Month 24 0.782 No No 124003 722/Month 24 1.700 No No 126001 174/Month 6 1.700 No No 126001 174/Month 24 2.040 No No 126001 174/Month 24 2.440 No No <t< td=""><td>Treatment Group Bubject ID Positive
finantion Intranscrattyrity Intranscrattyrity Intranscrattyrity Treatment Group Subject ID Assry Assry Assry Assry 170010 36. Month 12 2.770 No No 170010 35. Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177001 715 / Month 24 1.850 Irritis 100002 719 / Month 24 1.850 No 100002 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 723 / Month 24 0.782 No 122001 174 / Month 6 1.700 No 122002 357 / Month 12 1.700 No 122001 722 / Month 24 0.782 No 124003 722 / Month 24 0.780 No 124003 732 / Month 24 0.790 No 125001 174 / Month 6 1.770</td><td>Treatment Group Bubject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assry Assry Assry Disposis 170010 36. Month 12 2.770 No No No 177006 358 / Month 12 1870 Irritis No 177006 358 / Month 12 1870 Irritis No 177006 358 / Month 12 1850 Irritis No 177006 358 / Month 12 1870 No No 177006 37 / Month 24 1930 No No 122002 722 / Month 12 1.130 No No 122002 357 / Month 24 0.782 No No 122001 174 / Month 6 1.700 No No No 122002 357 / Month 12 1.630 No No No 122002 357 / Month 24 0.782 No No No 124003 722 / Month 24 <</td><td>Treatment Group Bublect ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assy 2 370 No 170010 365 / Month 12 2 380 No No 177006 358 / Month 12 1870 Irritis No 104002 722 / Month 24 1.140 No No 122002 359 / Month 12 1.130 No No 122002 357 / Month 24 0.782 No No 122001 174 / Month 6 1.700 No No 122002 357 / Month 24 0.782 No No 122001 174 / Month 6 1.700 No No 122002 357 / Month 24 0.782 No No 12100</td><td>Treatment Group Bublect ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay 23770 No 170010 365 / Month 12 2770 No No 177006 358 / Month 12 1870 Irritis No
104002 722 / Month 24 0.922 No No 122002 393 / Month 12 1.140 No No 122002 323 / Month 24 0.782 No No 124003 722 / Month 24 0.782 No No 124003 732 / Month 24 0.782 No No 124003 732 / Month 24 0.782 No No 124003 732 / Month 24 0.782 No No 124003</td><td>Treatment Group Runinioreactivity Immunoreactivity Treatment Group Subject ID Assay Lug Titer Disprosis 170010 365 / Month 12 2339 / Log Titer No No</td><td>Treatment GroupImmunorescivity
InformationTreatment GroupSubject IDAsiavImmunorescivity
Information170010$365$ Month 12$2.770$No170010$365$ Month 12$2.770$No177006$358$ Month 12$1870$Lirits177006$358$ Month 12$1870$Lirits177006$358$ Month 24$1.870$Lirits177001$722$ Month 24$1.850$No104002$717$ Month 24$1.140$No106002$722$ Month 24$1.130$No122002$329$ Month 24$1.700$No122002$329$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$717$ Month 24$2.940$No125004$522$ Early Term0.752No155004$522$ Month 24$2.940$No155004$527$ Month 24$2.070$No155005$183$ Month 12$1.900$No155005$183$ Month 24$2.940$No155005$183$ Month 24$2.940$No155005$183$ Month 24$2.070$No155005$183$ Month 24$2.075$$No$</td></t<></td></t<></td></t<></td></th<></td></th<></td></th<></td></th<></td></t<></td> | Treatment Group Bubject ID Positive
inflammation Intranscrittar Treatment Group Subject ID Assay Assay Assay Intranscrittar Treatment Group Subject ID Assay Assay Assay Assay Intranscrittar 170010 36/Month 12 2.770 No No 177006 338/Month 12 1.850 Intris No 177006 338/Month 12 1.850 Intris No 100002 717/Month 24 1.850 No No 106002 722/Month 24 1.140 No No 122002 335/Month 12 1.630 No No 122002 723/Month 24 0.782 No No 124003 722/Month 24 1.700 No No 126001 174/Month 6 1.700 No No 126001 174/Month 24 2.040 No No 126001 174/Month 24 2.440 No No <t< td=""><td>Treatment Group Subject ID Positive
Inflammation Intranceditvity
Assay Intranceditat
Assay Intraceditat
Assay Intraceditat
Assay <th< td=""><td>Treatment Group Subject ID Positive
fimiliarian Intrancedityty
Assay Intrancedityty
Assay Intranceditar
Assay Intraceditar
Assay Intranceditar
Assay <th< td=""><td>Treatment Group Subject ID Positive
Inflammation Intranceditvity
Assay Intranceditat
Assay Intraceditat
Assay Intraceditat
Assay <th< td=""><td>Treatment Group Subject ID Positive
Inflammation Intranceditvity
Assay Intranceditat
Assay Intraceditat
Assay Intraceditat
Assay <th< td=""><td>Treatment Group Bubject ID Positive
inflammation Intranscrittar Treatment Group Subject ID Assay Assay Assay Intranscrittar Treatment Group Subject ID Assay Assay Assay Assay Intranscrittar 170010 36/Month 12 2.770 No No 177006 338/Month 12 1.850 Intris No 177006 338/Month 12 1.850 Intris No 100002 717/Month 24 1.850 No No 106002 722/Month 24 1.140 No No 122002 335/Month 12 1.630 No No 122002 723/Month 24 0.782 No No 124003 722/Month 24 1.700 No No 126001 174/Month 6 1.700 No No 126001 174/Month 24 2.040 No No 126001 174/Month 24 2.440 No No <t< td=""><td>Treatment Group Bubject ID Positive
inflammation Intranscrittar Treatment Group Subject ID Assay Assay Assay Intranscrittar Treatment Group Subject ID Assay Assay Assay Assay Intranscrittar 170010 36/Month 12 2.770 No No 177006 338/Month 12 1.850 Intris No 177006 338/Month 12 1.850 Intris No 100002 717/Month 24 1.850 No No 106002 722/Month 24 1.140 No No 122002 335/Month 12 1.630 No No 122002 723/Month 24 0.782 No No 124003 722/Month 24 1.700 No No 126001 174/Month 6 1.700 No No 126001 174/Month 24 2.040 No No 126001 174/Month 24 2.440 No No <t< td=""><td>Treatment Group Bubject ID Positive
inflammation Intranscrittar Treatment Group Subject ID Assay Assay Assay Intranscrittar Treatment Group Subject ID Assay Assay Assay Assay Intranscrittar 170010 36/Month 12 2.770 No No 177006 338/Month 12 1.850 Intris No 177006 338/Month 12 1.850 Intris No 100002 717/Month 24 1.850 No No 106002 722/Month 24 1.140 No No 122002 335/Month 12 1.630 No No 122002 723/Month 24 0.782 No No 124003 722/Month 24 1.700 No No 126001 174/Month 6 1.700 No No 126001 174/Month 24 2.040 No No 126001 174/Month 24 2.440 No No <t< td=""><td>Treatment Group Bubject ID Positive
finantion Intranscrattyrity Intranscrattyrity Intranscrattyrity Treatment Group Subject ID Assry Assry Assry Assry 170010 36. Month 12 2.770 No No 170010 35. Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177001 715 / Month 24 1.850 Irritis 100002 719 / Month 24 1.850 No 100002 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 723 / Month 24 0.782
 No 122001 174 / Month 6 1.700 No 122002 357 / Month 12 1.700 No 122001 722 / Month 24 0.782 No 124003 722 / Month 24 0.780 No 124003 732 / Month 24 0.790 No 125001 174 / Month 6 1.770</td><td>Treatment Group Bubject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assry Assry Assry Disposis 170010 36. Month 12 2.770 No No No 177006 358 / Month 12 1870 Irritis No 177006 358 / Month 12 1870 Irritis No 177006 358 / Month 12 1850 Irritis No 177006 358 / Month 12 1870 No No 177006 37 / Month 24 1930 No No 122002 722 / Month 12 1.130 No No 122002 357 / Month 24 0.782 No No 122001 174 / Month 6 1.700 No No No 122002 357 / Month 12 1.630 No No No 122002 357 / Month 24 0.782 No No No 124003 722 / Month 24 <</td><td>Treatment Group Bublect ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assy 2 370 No 170010 365 / Month 12 2 380 No No 177006 358 / Month 12 1870 Irritis No 104002 722 / Month 24 1.140 No No 122002 359 / Month 12 1.130 No No 122002 357 / Month 24 0.782 No No 122001 174 / Month 6 1.700 No No 122002 357 / Month 24 0.782 No No 122001 174 / Month 6 1.700 No No 122002 357 / Month 24 0.782 No No 12100</td><td>Treatment Group Bublect ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay 23770 No 170010 365 / Month 12 2770 No No 177006 358 / Month 12 1870 Irritis No 104002 722 / Month 24 0.922 No No 122002 393 / Month 12 1.140 No No 122002 323 / Month 24 0.782 No No 124003 722 / Month 24 0.782 No No 124003 732 / Month 24 0.782 No No 124003 732 / Month 24 0.782 No No 124003 732 / Month 24 0.782 No No 124003</td><td>Treatment Group Runinioreactivity Immunoreactivity Treatment Group Subject ID Assay Lug Titer Disprosis 170010 365 / Month 12 2339 / Log Titer No No</td><td>Treatment GroupImmunorescivity
InformationTreatment GroupSubject IDAsiavImmunorescivity
Information170010$365$ Month 12$2.770$No170010$365$ Month 12$2.770$No177006$358$ Month 12$1870$Lirits177006$358$ Month 12$1870$Lirits177006$358$ Month 24$1.870$Lirits177001$722$ Month 24$1.850$No104002$717$ Month 24$1.140$No106002$722$ Month 24$1.130$No122002$329$ Month 24$1.700$No122002$329$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$717$ Month 24$2.940$No125004$522$ Early Term0.752No155004$522$ Month 24$2.940$No155004$527$ Month 24$2.070$No155005$183$ Month 12$1.900$No155005$183$ Month 24$2.940$No155005$183$ Month 24$2.940$No155005$183$ Month 24$2.070$No155005$183$ Month 24$2.075$$No$</td></t<></td></t<></td></t<></td></th<></td></th<></td></th<></td></th<></td></t<> | Treatment Group Subject ID Positive
Inflammation Intranceditvity
Assay Intranceditat
Assay Intraceditat
Assay Intraceditat
Assay <th< td=""><td>Treatment Group Subject ID Positive
fimiliarian Intrancedityty
Assay Intrancedityty
Assay Intranceditar
Assay Intraceditar
Assay Intranceditar
Assay <th< td=""><td>Treatment Group Subject ID Positive
Inflammation Intranceditvity
Assay Intranceditat
Assay Intraceditat
Assay Intraceditat
Assay <th< td=""><td>Treatment Group Subject ID Positive
Inflammation Intranceditvity
Assay Intranceditat
Assay Intraceditat
Assay Intraceditat
Assay <th< td=""><td>Treatment Group Bubject ID Positive
inflammation Intranscrittar Treatment Group Subject ID Assay Assay Assay Intranscrittar Treatment Group Subject ID Assay Assay Assay Assay Intranscrittar 170010 36/Month 12 2.770 No No 177006 338/Month 12 1.850 Intris No 177006 338/Month 12 1.850 Intris No 100002 717/Month 24 1.850 No No 106002 722/Month 24 1.140 No No 122002 335/Month 12 1.630 No No 122002 723/Month 24 0.782 No No 124003 722/Month 24 1.700 No No 126001 174/Month 6 1.700 No No 126001 174/Month 24 2.040 No No 126001 174/Month 24 2.440 No No <t< td=""><td>Treatment Group Bubject ID Positive
inflammation Intranscrittar Treatment Group Subject ID Assay Assay Assay Intranscrittar Treatment Group Subject ID Assay Assay Assay Assay Intranscrittar 170010 36/Month 12 2.770 No No 177006 338/Month 12 1.850 Intris No 177006 338/Month 12 1.850 Intris No 100002 717/Month 24 1.850 No No 106002 722/Month 24 1.140 No No 122002 335/Month 12 1.630 No No 122002 723/Month 24 0.782 No No 124003 722/Month 24 1.700 No No 126001 174/Month 6 1.700 No No 126001 174/Month 24 2.040 No No 126001 174/Month 24 2.440 No No <t< td=""><td>Treatment Group Bubject ID Positive
inflammation Intranscrittar Treatment Group Subject ID Assay Assay Assay Intranscrittar Treatment Group Subject ID Assay Assay Assay Assay Intranscrittar 170010 36/Month 12 2.770 No No 177006 338/Month 12 1.850 Intris No 177006 338/Month 12 1.850 Intris No
 100002 717/Month 24 1.850 No No 106002 722/Month 24 1.140 No No 122002 335/Month 12 1.630 No No 122002 723/Month 24 0.782 No No 124003 722/Month 24 1.700 No No 126001 174/Month 6 1.700 No No 126001 174/Month 24 2.040 No No 126001 174/Month 24 2.440 No No <t< td=""><td>Treatment Group Bubject ID Positive
finantion Intranscrattyrity Intranscrattyrity Intranscrattyrity Treatment Group Subject ID Assry Assry Assry Assry 170010 36. Month 12 2.770 No No 170010 35. Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177001 715 / Month 24 1.850 Irritis 100002 719 / Month 24 1.850 No 100002 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 723 / Month 24 0.782 No 122001 174 / Month 6 1.700 No 122002 357 / Month 12 1.700 No 122001 722 / Month 24 0.782 No 124003 722 / Month 24 0.780 No 124003 732 / Month 24 0.790 No 125001 174 / Month 6 1.770</td><td>Treatment Group Bubject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assry Assry Assry Disposis 170010 36. Month 12 2.770 No No No 177006 358 / Month 12 1870 Irritis No 177006 358 / Month 12 1870 Irritis No 177006 358 / Month 12 1850 Irritis No 177006 358 / Month 12 1870 No No 177006 37 / Month 24 1930 No No 122002 722 / Month 12 1.130 No No 122002 357 / Month 24 0.782 No No 122001 174 / Month 6 1.700 No No No 122002 357 / Month 12 1.630 No No No 122002 357 / Month 24 0.782 No No No 124003 722 / Month 24 <</td><td>Treatment Group Bublect ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assy 2 370 No 170010 365 / Month 12 2 380 No No 177006 358 / Month 12 1870 Irritis No 104002 722 / Month 24 1.140 No No 122002 359 / Month 12 1.130 No No 122002 357 / Month 24 0.782 No No 122001 174 / Month 6 1.700 No No 122002 357 / Month 24 0.782 No No 122001 174 / Month 6 1.700 No No 122002 357 / Month 24 0.782 No No 12100</td><td>Treatment Group Bublect ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay 23770 No 170010 365 / Month 12 2770 No No 177006 358 / Month 12 1870 Irritis No 104002 722 / Month 24 0.922 No No 122002 393 / Month 12 1.140 No No 122002 323 / Month 24 0.782 No No 124003 722 / Month 24 0.782 No No 124003 732 / Month 24 0.782 No No 124003 732 / Month 24 0.782 No No 124003 732 / Month 24 0.782 No No 124003</td><td>Treatment Group Runinioreactivity Immunoreactivity Treatment Group Subject ID Assay Lug Titer Disprosis 170010 365 / Month 12 2339 / Log Titer No No</td><td>Treatment GroupImmunorescivity
InformationTreatment GroupSubject IDAsiavImmunorescivity
Information170010$365$ Month 12$2.770$No170010$365$ Month 12$2.770$No177006$358$ Month 12$1870$Lirits177006$358$ Month 12$1870$Lirits177006$358$ Month 24$1.870$Lirits177001$722$ Month 24$1.850$No104002$717$ Month 24$1.140$No106002$722$ Month 24$1.130$No122002$329$ Month 24$1.700$No122002$329$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$717$ Month 24$2.940$No125004$522$ Early Term0.752No155004$522$ Month 24$2.940$No155004$527$ Month 24$2.070$No155005$183$ Month 12$1.900$No155005$183$ Month 24$2.940$No155005$183$ Month 24$2.940$No155005$183$ Month 24$2.070$No155005$183$ Month 24$2.075$$No$</td></t<></td></t<></td></t<></td></th<></td></th<></td></th<></td></th<> | Treatment Group Subject ID Positive
fimiliarian Intrancedityty
Assay Intrancedityty
Assay Intranceditar
Assay Intraceditar
Assay Intranceditar
Assay <th< td=""><td>Treatment Group Subject ID Positive
Inflammation Intranceditvity
Assay Intranceditat
Assay Intraceditat
Assay Intraceditat
Assay <th< td=""><td>Treatment Group Subject ID Positive
Inflammation Intranceditvity
Assay Intranceditat
Assay Intraceditat
Assay Intraceditat
Assay <th< td=""><td>Treatment Group Bubject ID Positive
inflammation Intranscrittar Treatment Group Subject ID Assay Assay Assay Intranscrittar Treatment Group Subject ID Assay Assay Assay Assay Intranscrittar 170010 36/Month 12 2.770 No No 177006 338/Month 12 1.850 Intris No 177006 338/Month 12 1.850 Intris No 100002 717/Month 24 1.850 No No 106002 722/Month 24 1.140 No No 122002 335/Month 12 1.630 No No 122002 723/Month 24 0.782 No No 124003 722/Month 24 1.700 No No 126001 174/Month 6 1.700 No No 126001 174/Month 24 2.040 No No 126001 174/Month 24 2.440 No No <t< td=""><td>Treatment Group Bubject ID Positive
inflammation Intranscrittar Treatment Group Subject ID Assay Assay Assay Intranscrittar Treatment Group Subject ID Assay Assay Assay Assay Intranscrittar 170010 36/Month 12 2.770 No No 177006 338/Month 12 1.850 Intris No 177006 338/Month 12 1.850 Intris No 100002 717/Month 24 1.850 No No 106002 722/Month 24 1.140 No No 122002 335/Month 12 1.630 No No 122002 723/Month 24 0.782 No No 124003 722/Month 24 1.700 No No 126001 174/Month 6 1.700 No No 126001 174/Month 24 2.040 No No 126001 174/Month 24 2.440 No No <t< td=""><td>Treatment Group Bubject ID Positive
inflammation Intranscrittar Treatment Group Subject ID Assay Assay Assay Intranscrittar Treatment Group Subject ID Assay Assay Assay Assay Intranscrittar 170010 36/Month 12 2.770 No No 177006 338/Month 12 1.850 Intris No 177006 338/Month 12 1.850 Intris No 100002 717/Month 24
1.850 No No 106002 722/Month 24 1.140 No No 122002 335/Month 12 1.630 No No 122002 723/Month 24 0.782 No No 124003 722/Month 24 1.700 No No 126001 174/Month 6 1.700 No No 126001 174/Month 24 2.040 No No 126001 174/Month 24 2.440 No No <t< td=""><td>Treatment Group Bubject ID Positive
finantion Intranscrattyrity Intranscrattyrity Intranscrattyrity Treatment Group Subject ID Assry Assry Assry Assry 170010 36. Month 12 2.770 No No 170010 35. Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177001 715 / Month 24 1.850 Irritis 100002 719 / Month 24 1.850 No 100002 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 723 / Month 24 0.782 No 122001 174 / Month 6 1.700 No 122002 357 / Month 12 1.700 No 122001 722 / Month 24 0.782 No 124003 722 / Month 24 0.780 No 124003 732 / Month 24 0.790 No 125001 174 / Month 6 1.770</td><td>Treatment Group Bubject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assry Assry Assry Disposis 170010 36. Month 12 2.770 No No No 177006 358 / Month 12 1870 Irritis No 177006 358 / Month 12 1870 Irritis No 177006 358 / Month 12 1850 Irritis No 177006 358 / Month 12 1870 No No 177006 37 / Month 24 1930 No No 122002 722 / Month 12 1.130 No No 122002 357 / Month 24 0.782 No No 122001 174 / Month 6 1.700 No No No 122002 357 / Month 12 1.630 No No No 122002 357 / Month 24 0.782 No No No 124003 722 / Month 24 <</td><td>Treatment Group Bublect ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assy 2 370 No 170010 365 / Month 12 2 380 No No 177006 358 / Month 12 1870 Irritis No 104002 722 / Month 24 1.140 No No 122002 359 / Month 12 1.130 No No 122002 357 / Month 24 0.782 No No 122001 174 / Month 6 1.700 No No 122002 357 / Month 24 0.782 No No 122001 174 / Month 6 1.700 No No 122002 357 / Month 24 0.782 No No 12100</td><td>Treatment Group Bublect ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay 23770 No 170010 365 / Month 12 2770 No No 177006 358 / Month 12 1870 Irritis No 104002 722 / Month 24 0.922 No No 122002 393 / Month 12 1.140 No No 122002 323 / Month 24 0.782 No No 124003 722 / Month 24 0.782 No No 124003 732 / Month 24 0.782 No No 124003 732 / Month 24 0.782 No No 124003 732 / Month 24 0.782 No No 124003</td><td>Treatment Group Runinioreactivity Immunoreactivity Treatment Group Subject ID Assay Lug Titer Disprosis 170010 365 / Month 12 2339 / Log Titer No No</td><td>Treatment GroupImmunorescivity
InformationTreatment GroupSubject IDAsiavImmunorescivity
Information170010$365$ Month 12$2.770$No170010$365$ Month 12$2.770$No177006$358$ Month 12$1870$Lirits177006$358$ Month 12$1870$Lirits177006$358$ Month 24$1.870$Lirits177001$722$ Month 24$1.850$No104002$717$ Month 24$1.140$No106002$722$ Month 24$1.130$No122002$329$ Month 24$1.700$No122002$329$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$717$ Month 24$2.940$No125004$522$ Early Term0.752No155004$522$ Month 24$2.940$No155004$527$ Month 24$2.070$No155005$183$ Month 12$1.900$No155005$183$ Month 24$2.940$No155005$183$ Month 24$2.940$No155005$183$ Month 24$2.070$No155005$183$ Month 24$2.075$$No$</td></t<></td></t<></td></t<></td></th<></td></th<></td></th<> | Treatment Group Subject ID Positive
Inflammation Intranceditvity
Assay Intranceditat
Assay Intraceditat
Assay Intraceditat
Assay <th< td=""><td>Treatment Group Subject ID Positive
Inflammation Intranceditvity
Assay Intranceditat
Assay Intraceditat
Assay Intraceditat
Assay <th< td=""><td>Treatment Group Bubject ID Positive
inflammation Intranscrittar Treatment Group Subject ID Assay Assay Assay Intranscrittar Treatment Group Subject ID Assay Assay Assay Assay Intranscrittar 170010 36/Month 12 2.770 No No 177006 338/Month 12 1.850 Intris No 177006 338/Month 12 1.850 Intris No 100002 717/Month 24 1.850 No No 106002 722/Month 24 1.140 No No 122002 335/Month 12 1.630 No No 122002 723/Month 24 0.782 No No 124003 722/Month 24 1.700 No No 126001 174/Month 6 1.700 No No 126001 174/Month 24 2.040 No No 126001 174/Month 24 2.440 No No <t< td=""><td>Treatment Group Bubject ID Positive
inflammation Intranscrittar Treatment Group Subject ID Assay Assay Assay Intranscrittar Treatment Group Subject ID Assay Assay Assay Assay Intranscrittar 170010 36/Month 12 2.770 No No 177006 338/Month 12 1.850 Intris No 177006 338/Month 12 1.850 Intris No 100002 717/Month 24 1.850 No No 106002 722/Month 24 1.140 No No 122002 335/Month 12 1.630 No No 122002 723/Month 24 0.782 No No 124003 722/Month 24 1.700 No No 126001 174/Month 6 1.700 No No 126001 174/Month 24 2.040 No No 126001 174/Month 24 2.440 No No <t< td=""><td>Treatment Group Bubject ID Positive
inflammation Intranscrittar Treatment Group Subject ID Assay Assay Assay Intranscrittar Treatment Group Subject ID Assay Assay Assay Assay Intranscrittar 170010 36/Month 12 2.770 No No 177006 338/Month 12 1.850 Intris No 177006 338/Month 12 1.850 Intris No 100002 717/Month 24 1.850 No No 106002 722/Month 24 1.140 No No 122002 335/Month 12 1.630 No No 122002 723/Month 24 0.782 No No 124003 722/Month 24 1.700 No No 126001 174/Month 6 1.700 No No 126001 174/Month 24 2.040 No No 126001 174/Month 24 2.440 No No <t< td=""><td>Treatment Group Bubject ID Positive
finantion Intranscrattyrity Intranscrattyrity Intranscrattyrity Treatment
Group Subject ID Assry Assry Assry Assry 170010 36. Month 12 2.770 No No 170010 35. Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177001 715 / Month 24 1.850 Irritis 100002 719 / Month 24 1.850 No 100002 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 723 / Month 24 0.782 No 122001 174 / Month 6 1.700 No 122002 357 / Month 12 1.700 No 122001 722 / Month 24 0.782 No 124003 722 / Month 24 0.780 No 124003 732 / Month 24 0.790 No 125001 174 / Month 6 1.770</td><td>Treatment Group Bubject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assry Assry Assry Disposis 170010 36. Month 12 2.770 No No No 177006 358 / Month 12 1870 Irritis No 177006 358 / Month 12 1870 Irritis No 177006 358 / Month 12 1850 Irritis No 177006 358 / Month 12 1870 No No 177006 37 / Month 24 1930 No No 122002 722 / Month 12 1.130 No No 122002 357 / Month 24 0.782 No No 122001 174 / Month 6 1.700 No No No 122002 357 / Month 12 1.630 No No No 122002 357 / Month 24 0.782 No No No 124003 722 / Month 24 <</td><td>Treatment Group Bublect ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assy 2 370 No 170010 365 / Month 12 2 380 No No 177006 358 / Month 12 1870 Irritis No 104002 722 / Month 24 1.140 No No 122002 359 / Month 12 1.130 No No 122002 357 / Month 24 0.782 No No 122001 174 / Month 6 1.700 No No 122002 357 / Month 24 0.782 No No 122001 174 / Month 6 1.700 No No 122002 357 / Month 24 0.782 No No 12100</td><td>Treatment Group Bublect ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay 23770 No 170010 365 / Month 12 2770 No No 177006 358 / Month 12 1870 Irritis No 104002 722 / Month 24 0.922 No No 122002 393 / Month 12 1.140 No No 122002 323 / Month 24 0.782 No No 124003 722 / Month 24 0.782 No No 124003 732 / Month 24 0.782 No No 124003 732 / Month 24 0.782 No No 124003 732 / Month 24 0.782 No No 124003</td><td>Treatment Group Runinioreactivity Immunoreactivity Treatment Group Subject ID Assay Lug Titer Disprosis 170010 365 / Month 12 2339 / Log Titer No No</td><td>Treatment GroupImmunorescivity
InformationTreatment GroupSubject IDAsiavImmunorescivity
Information170010$365$ Month 12$2.770$No170010$365$ Month 12$2.770$No177006$358$ Month 12$1870$Lirits177006$358$ Month 12$1870$Lirits177006$358$ Month 24$1.870$Lirits177001$722$ Month 24$1.850$No104002$717$ Month 24$1.140$No106002$722$ Month 24$1.130$No122002$329$ Month 24$1.700$No122002$329$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$717$ Month 24$2.940$No125004$522$ Early Term0.752No155004$522$ Month 24$2.940$No155004$527$ Month 24$2.070$No155005$183$ Month 12$1.900$No155005$183$ Month 24$2.940$No155005$183$ Month 24$2.940$No155005$183$ Month 24$2.070$No155005$183$ Month 24$2.075$$No$</td></t<></td></t<></td></t<></td></th<></td></th<> | Treatment Group Subject ID Positive
Inflammation Intranceditvity
Assay Intranceditat
Assay Intraceditat
Assay Intraceditat
Assay <th< td=""><td>Treatment Group Bubject ID Positive
inflammation Intranscrittar Treatment Group Subject ID Assay Assay Assay Intranscrittar Treatment Group Subject ID Assay Assay Assay Assay Intranscrittar 170010 36/Month 12 2.770 No No 177006 338/Month 12 1.850 Intris No 177006 338/Month 12 1.850 Intris No 100002 717/Month 24 1.850 No No 106002 722/Month 24 1.140 No No 122002 335/Month 12 1.630 No No 122002 723/Month 24 0.782 No No 124003 722/Month 24 1.700 No No 126001 174/Month 6 1.700 No No 126001 174/Month 24 2.040 No No 126001 174/Month 24 2.440 No No <t< td=""><td>Treatment Group Bubject ID Positive
inflammation Intranscrittar Treatment Group Subject ID Assay Assay Assay Intranscrittar Treatment Group Subject ID Assay Assay Assay Assay Intranscrittar 170010 36/Month 12 2.770 No No 177006 338/Month 12 1.850 Intris No 177006 338/Month 12 1.850 Intris No 100002 717/Month 24 1.850 No No 106002 722/Month 24 1.140 No No 122002 335/Month 12 1.630 No No 122002 723/Month 24 0.782 No No 124003 722/Month 24 1.700 No No 126001 174/Month 6 1.700 No No 126001 174/Month 24 2.040 No No 126001 174/Month 24 2.440 No No <t< td=""><td>Treatment Group Bubject ID Positive
inflammation Intranscrittar Treatment Group Subject ID Assay Assay Assay Intranscrittar Treatment Group Subject ID Assay Assay Assay Assay Intranscrittar 170010 36/Month 12 2.770 No No 177006 338/Month 12 1.850 Intris No 177006 338/Month 12 1.850 Intris No 100002 717/Month 24 1.850 No No 106002 722/Month 24 1.140 No No 122002 335/Month 12 1.630 No No 122002 723/Month 24 0.782 No No 124003 722/Month 24 1.700 No No 126001 174/Month 6 1.700 No No 126001 174/Month 24 2.040 No No
126001 174/Month 24 2.440 No No <t< td=""><td>Treatment Group Bubject ID Positive
finantion Intranscrattyrity Intranscrattyrity Intranscrattyrity Treatment Group Subject ID Assry Assry Assry Assry 170010 36. Month 12 2.770 No No 170010 35. Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177001 715 / Month 24 1.850 Irritis 100002 719 / Month 24 1.850 No 100002 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 723 / Month 24 0.782 No 122001 174 / Month 6 1.700 No 122002 357 / Month 12 1.700 No 122001 722 / Month 24 0.782 No 124003 722 / Month 24 0.780 No 124003 732 / Month 24 0.790 No 125001 174 / Month 6 1.770</td><td>Treatment Group Bubject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assry Assry Assry Disposis 170010 36. Month 12 2.770 No No No 177006 358 / Month 12 1870 Irritis No 177006 358 / Month 12 1870 Irritis No 177006 358 / Month 12 1850 Irritis No 177006 358 / Month 12 1870 No No 177006 37 / Month 24 1930 No No 122002 722 / Month 12 1.130 No No 122002 357 / Month 24 0.782 No No 122001 174 / Month 6 1.700 No No No 122002 357 / Month 12 1.630 No No No 122002 357 / Month 24 0.782 No No No 124003 722 / Month 24 <</td><td>Treatment Group Bublect ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assy 2 370 No 170010 365 / Month 12 2 380 No No 177006 358 / Month 12 1870 Irritis No 104002 722 / Month 24 1.140 No No 122002 359 / Month 12 1.130 No No 122002 357 / Month 24 0.782 No No 122001 174 / Month 6 1.700 No No 122002 357 / Month 24 0.782 No No 122001 174 / Month 6 1.700 No No 122002 357 / Month 24 0.782 No No 12100</td><td>Treatment Group Bublect ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay 23770 No 170010 365 / Month 12 2770 No No 177006 358 / Month 12 1870 Irritis No 104002 722 / Month 24 0.922 No No 122002 393 / Month 12 1.140 No No 122002 323 / Month 24 0.782 No No 124003 722 / Month 24 0.782 No No 124003 732 / Month 24 0.782 No No 124003 732 / Month 24 0.782 No No 124003 732 / Month 24 0.782 No No 124003</td><td>Treatment Group Runinioreactivity Immunoreactivity Treatment Group Subject ID Assay Lug Titer Disprosis 170010 365 / Month 12 2339 / Log Titer No No</td><td>Treatment GroupImmunorescivity
InformationTreatment GroupSubject IDAsiavImmunorescivity
Information170010$365$ Month 12$2.770$No170010$365$ Month 12$2.770$No177006$358$ Month 12$1870$Lirits177006$358$ Month 12$1870$Lirits177006$358$ Month 24$1.870$Lirits177001$722$ Month 24$1.850$No104002$717$ Month 24$1.140$No106002$722$ Month 24$1.130$No122002$329$ Month 24$1.700$No122002$329$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$717$ Month 24$2.940$No125004$522$ Early Term0.752No155004$522$ Month 24$2.940$No155004$527$ Month 24$2.070$No155005$183$ Month 12$1.900$No155005$183$ Month 24$2.940$No155005$183$ Month 24$2.940$No155005$183$ Month 24$2.070$No155005$183$ Month 24$2.075$$No$</td></t<></td></t<></td></t<></td></th<> | Treatment Group Bubject ID Positive
inflammation Intranscrittar Treatment Group Subject ID Assay Assay Assay Intranscrittar Treatment Group Subject ID Assay Assay Assay Assay Intranscrittar 170010 36/Month 12 2.770 No No 177006 338/Month 12 1.850 Intris No 177006 338/Month 12 1.850 Intris No 100002 717/Month 24 1.850 No No 106002 722/Month 24 1.140 No No 122002 335/Month 12 1.630 No No 122002 723/Month 24 0.782 No No 124003 722/Month 24 1.700 No No 126001 174/Month 6 1.700 No No 126001 174/Month 24 2.040 No No 126001 174/Month 24 2.440 No No <t< td=""><td>Treatment Group Bubject ID Positive
inflammation Intranscrittar Treatment Group Subject ID Assay Assay Assay Intranscrittar Treatment Group Subject ID Assay Assay Assay Assay Intranscrittar 170010 36/Month 12 2.770 No No 177006 338/Month 12 1.850 Intris No 177006 338/Month 12 1.850 Intris No 100002 717/Month 24 1.850 No No 106002 722/Month 24 1.140 No No 122002 335/Month 12 1.630 No No 122002 723/Month 24 0.782 No No 124003 722/Month 24 1.700 No No 126001 174/Month 6 1.700 No No 126001 174/Month 24 2.040 No No 126001 174/Month 24 2.440 No No <t< td=""><td>Treatment Group Bubject ID Positive
inflammation Intranscrittar Treatment Group Subject ID Assay Assay Assay Intranscrittar Treatment Group Subject ID Assay Assay Assay Assay Intranscrittar 170010 36/Month 12 2.770 No No 177006 338/Month 12 1.850
Intris No 177006 338/Month 12 1.850 Intris No 100002 717/Month 24 1.850 No No 106002 722/Month 24 1.140 No No 122002 335/Month 12 1.630 No No 122002 723/Month 24 0.782 No No 124003 722/Month 24 1.700 No No 126001 174/Month 6 1.700 No No 126001 174/Month 24 2.040 No No 126001 174/Month 24 2.440 No No <t< td=""><td>Treatment Group Bubject ID Positive
finantion Intranscrattyrity Intranscrattyrity Intranscrattyrity Treatment Group Subject ID Assry Assry Assry Assry 170010 36. Month 12 2.770 No No 170010 35. Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177001 715 / Month 24 1.850 Irritis 100002 719 / Month 24 1.850 No 100002 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 723 / Month 24 0.782 No 122001 174 / Month 6 1.700 No 122002 357 / Month 12 1.700 No 122001 722 / Month 24 0.782 No 124003 722 / Month 24 0.780 No 124003 732 / Month 24 0.790 No 125001 174 / Month 6 1.770</td><td>Treatment Group Bubject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assry Assry Assry Disposis 170010 36. Month 12 2.770 No No No 177006 358 / Month 12 1870 Irritis No 177006 358 / Month 12 1870 Irritis No 177006 358 / Month 12 1850 Irritis No 177006 358 / Month 12 1870 No No 177006 37 / Month 24 1930 No No 122002 722 / Month 12 1.130 No No 122002 357 / Month 24 0.782 No No 122001 174 / Month 6 1.700 No No No 122002 357 / Month 12 1.630 No No No 122002 357 / Month 24 0.782 No No No 124003 722 / Month 24 <</td><td>Treatment Group Bublect ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assy 2 370 No 170010 365 / Month 12 2 380 No No 177006 358 / Month 12 1870 Irritis No 104002 722 / Month 24 1.140 No No 122002 359 / Month 12 1.130 No No 122002 357 / Month 24 0.782 No No 122001 174 / Month 6 1.700 No No 122002 357 / Month 24 0.782 No No 122001 174 / Month 6 1.700 No No 122002 357 / Month 24 0.782 No No 12100</td><td>Treatment Group Bublect ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay 23770 No 170010 365 / Month 12 2770 No No 177006 358 / Month 12 1870 Irritis No 104002 722 / Month 24 0.922 No No 122002 393 / Month 12 1.140 No No 122002 323 / Month 24 0.782 No No 124003 722 / Month 24 0.782 No No 124003 732 / Month 24 0.782 No No 124003 732 / Month 24 0.782 No No 124003 732 / Month 24 0.782 No No 124003</td><td>Treatment Group Runinioreactivity Immunoreactivity Treatment Group Subject ID Assay Lug Titer Disprosis 170010 365 / Month 12 2339 / Log Titer No No</td><td>Treatment GroupImmunorescivity
InformationTreatment GroupSubject IDAsiavImmunorescivity
Information170010$365$ Month 12$2.770$No170010$365$ Month 12$2.770$No177006$358$ Month 12$1870$Lirits177006$358$ Month 12$1870$Lirits177006$358$ Month 24$1.870$Lirits177001$722$ Month 24$1.850$No104002$717$ Month 24$1.140$No106002$722$ Month 24$1.130$No122002$329$ Month 24$1.700$No122002$329$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$717$ Month 24$2.940$No125004$522$ Early Term0.752No155004$522$ Month 24$2.940$No155004$527$ Month 24$2.070$No155005$183$ Month 12$1.900$No155005$183$ Month 24$2.940$No155005$183$ Month 24$2.940$No155005$183$ Month 24$2.070$No155005$183$ Month 24$2.075$$No$</td></t<></td></t<></td></t<> | Treatment Group Bubject ID Positive
inflammation Intranscrittar Treatment Group Subject ID Assay Assay Assay Intranscrittar Treatment Group Subject ID Assay Assay Assay Assay Intranscrittar 170010 36/Month 12 2.770 No No 177006 338/Month 12 1.850 Intris No 177006 338/Month 12 1.850 Intris No 100002 717/Month 24 1.850 No No 106002 722/Month 24 1.140 No No 122002 335/Month 12 1.630 No No 122002 723/Month 24 0.782 No No 124003 722/Month 24 1.700 No No 126001 174/Month 6 1.700 No No 126001 174/Month 24 2.040 No No 126001 174/Month 24 2.440 No No <t< td=""><td>Treatment Group Bubject ID Positive
inflammation Intranscrittar Treatment Group Subject ID Assay Assay Assay
 Intranscrittar Treatment Group Subject ID Assay Assay Assay Assay Intranscrittar 170010 36/Month 12 2.770 No No 177006 338/Month 12 1.850 Intris No 177006 338/Month 12 1.850 Intris No 100002 717/Month 24 1.850 No No 106002 722/Month 24 1.140 No No 122002 335/Month 12 1.630 No No 122002 723/Month 24 0.782 No No 124003 722/Month 24 1.700 No No 126001 174/Month 6 1.700 No No 126001 174/Month 24 2.040 No No 126001 174/Month 24 2.440 No No <t< td=""><td>Treatment Group Bubject ID Positive
finantion Intranscrattyrity Intranscrattyrity Intranscrattyrity Treatment Group Subject ID Assry Assry Assry Assry 170010 36. Month 12 2.770 No No 170010 35. Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177001 715 / Month 24 1.850 Irritis 100002 719 / Month 24 1.850 No 100002 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 723 / Month 24 0.782 No 122001 174 / Month 6 1.700 No 122002 357 / Month 12 1.700 No 122001 722 / Month 24 0.782 No 124003 722 / Month 24 0.780 No 124003 732 / Month 24 0.790 No 125001 174 / Month 6 1.770</td><td>Treatment Group Bubject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assry Assry Assry Disposis 170010 36. Month 12 2.770 No No No 177006 358 / Month 12 1870 Irritis No 177006 358 / Month 12 1870 Irritis No 177006 358 / Month 12 1850 Irritis No 177006 358 / Month 12 1870 No No 177006 37 / Month 24 1930 No No 122002 722 / Month 12 1.130 No No 122002 357 / Month 24 0.782 No No 122001 174 / Month 6 1.700 No No No 122002 357 / Month 12 1.630 No No No 122002 357 / Month 24 0.782 No No No 124003 722 / Month 24 <</td><td>Treatment Group Bublect ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assy 2 370 No 170010 365 / Month 12 2 380 No No 177006 358 / Month 12 1870 Irritis No 104002 722 / Month 24 1.140 No No 122002 359 / Month 12 1.130 No No 122002 357 / Month 24 0.782 No No 122001 174 / Month 6 1.700 No No 122002 357 / Month 24 0.782 No No 122001 174 / Month 6 1.700 No No 122002 357 / Month 24 0.782 No No 12100</td><td>Treatment Group Bublect ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay 23770 No 170010 365 / Month 12 2770 No No 177006 358 / Month 12 1870 Irritis No 104002 722 / Month 24 0.922 No No 122002 393 / Month 12 1.140 No No 122002 323 / Month 24 0.782 No No 124003 722 / Month 24 0.782 No No 124003 732 / Month 24 0.782 No No 124003 732 / Month 24 0.782 No No 124003 732 / Month 24 0.782 No No 124003</td><td>Treatment Group Runinioreactivity Immunoreactivity Treatment Group Subject ID Assay Lug Titer Disprosis 170010 365 / Month 12 2339 / Log Titer No No</td><td>Treatment GroupImmunorescivity
InformationTreatment GroupSubject IDAsiavImmunorescivity
Information170010$365$ Month 12$2.770$No170010$365$ Month 12$2.770$No177006$358$ Month 12$1870$Lirits177006$358$ Month 12$1870$Lirits177006$358$ Month 24$1.870$Lirits177001$722$ Month 24$1.850$No104002$717$ Month 24$1.140$No106002$722$ Month 24$1.130$No122002$329$ Month 24$1.700$No122002$329$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$717$ Month 24$2.940$No125004$522$ Early Term0.752No155004$522$ Month 24$2.940$No155004$527$ Month 24$2.070$No155005$183$ Month 12$1.900$No155005$183$ Month 24$2.940$No155005$183$ Month 24$2.940$No155005$183$ Month 24$2.070$No155005$183$ Month 24$2.075$$No$</td></t<></td></t<> | Treatment Group Bubject ID Positive
inflammation Intranscrittar Treatment Group Subject ID Assay Assay Assay Intranscrittar Treatment Group Subject ID Assay Assay Assay Assay Intranscrittar 170010 36/Month 12 2.770 No No 177006 338/Month 12 1.850 Intris No 177006 338/Month 12 1.850 Intris No 100002 717/Month 24 1.850 No No 106002 722/Month 24 1.140 No No 122002 335/Month 12 1.630 No No 122002 723/Month 24 0.782 No No 124003 722/Month 24 1.700 No No 126001 174/Month 6 1.700 No No 126001 174/Month 24 2.040 No No 126001 174/Month 24 2.440 No No <t< td=""><td>Treatment Group Bubject ID Positive
finantion Intranscrattyrity Intranscrattyrity Intranscrattyrity Treatment Group Subject ID Assry Assry Assry Assry
 170010 36. Month 12 2.770 No No 170010 35. Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177001 715 / Month 24 1.850 Irritis 100002 719 / Month 24 1.850 No 100002 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 723 / Month 24 0.782 No 122001 174 / Month 6 1.700 No 122002 357 / Month 12 1.700 No 122001 722 / Month 24 0.782 No 124003 722 / Month 24 0.780 No 124003 732 / Month 24 0.790 No 125001 174 / Month 6 1.770</td><td>Treatment Group Bubject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assry Assry Assry Disposis 170010 36. Month 12 2.770 No No No 177006 358 / Month 12 1870 Irritis No 177006 358 / Month 12 1870 Irritis No 177006 358 / Month 12 1850 Irritis No 177006 358 / Month 12 1870 No No 177006 37 / Month 24 1930 No No 122002 722 / Month 12 1.130 No No 122002 357 / Month 24 0.782 No No 122001 174 / Month 6 1.700 No No No 122002 357 / Month 12 1.630 No No No 122002 357 / Month 24 0.782 No No No 124003 722 / Month 24 <</td><td>Treatment Group Bublect ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assy 2 370 No 170010 365 / Month 12 2 380 No No 177006 358 / Month 12 1870 Irritis No 104002 722 / Month 24 1.140 No No 122002 359 / Month 12 1.130 No No 122002 357 / Month 24 0.782 No No 122001 174 / Month 6 1.700 No No 122002 357 / Month 24 0.782 No No 122001 174 / Month 6 1.700 No No 122002 357 / Month 24 0.782 No No 12100</td><td>Treatment Group Bublect ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay 23770 No 170010 365 / Month 12 2770 No No 177006 358 / Month 12 1870 Irritis No 104002 722 / Month 24 0.922 No No 122002 393 / Month 12 1.140 No No 122002 323 / Month 24 0.782 No No 124003 722 / Month 24 0.782 No No 124003 732 / Month 24 0.782 No No 124003 732 / Month 24 0.782 No No 124003 732 / Month 24 0.782 No No 124003</td><td>Treatment Group Runinioreactivity Immunoreactivity Treatment Group Subject ID Assay Lug Titer Disprosis 170010 365 / Month 12 2339 / Log Titer No No</td><td>Treatment GroupImmunorescivity
InformationTreatment GroupSubject IDAsiavImmunorescivity
Information170010$365$ Month 12$2.770$No170010$365$ Month 12$2.770$No177006$358$ Month 12$1870$Lirits177006$358$ Month 12$1870$Lirits177006$358$ Month 24$1.870$Lirits177001$722$ Month 24$1.850$No104002$717$ Month 24$1.140$No106002$722$ Month 24$1.130$No122002$329$ Month 24$1.700$No122002$329$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$722$ Month 24$1.700$No124003$717$ Month 24$2.940$No125004$522$ Early Term0.752No155004$522$ Month 24$2.940$No155004$527$ Month 24$2.070$No155005$183$ Month 12$1.900$No155005$183$ Month 24$2.940$No155005$183$ Month 24$2.940$No155005$183$ Month 24$2.070$No155005$183$ Month 24$2.075$$No$</td></t<> | Treatment Group Bubject ID Positive
finantion Intranscrattyrity Intranscrattyrity Intranscrattyrity Treatment Group Subject ID Assry Assry Assry Assry 170010 36. Month 12 2.770 No No 170010 35. Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177001 715 / Month 24 1.850 Irritis 100002 719 / Month 24 1.850 No 100002 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 723 / Month 24 0.782 No 122001 174 / Month 6 1.700 No 122002 357 / Month 12 1.700 No 122001 722 / Month 24 0.782 No 124003 722 / Month 24 0.780 No 124003 732 / Month 24 0.790 No 125001 174 / Month 6 1.770
 | Treatment Group Bubject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assry Assry Assry Disposis 170010 36. Month 12 2.770 No No No 177006 358 / Month 12 1870 Irritis No 177006 358 / Month 12 1870 Irritis No 177006 358 / Month 12 1850 Irritis No 177006 358 / Month 12 1870 No No 177006 37 / Month 24 1930 No No 122002 722 / Month 12 1.130 No No 122002 357 / Month 24 0.782 No No 122001 174 / Month 6 1.700 No No No 122002 357 / Month 12 1.630 No No No 122002 357 / Month 24 0.782 No No No 124003 722 / Month 24 <
 | Treatment Group Bublect ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assy 2 370 No 170010 365 / Month 12 2 380 No No 177006 358 / Month 12 1870 Irritis No 104002 722 / Month 24 1.140 No No 122002 359 / Month 12 1.130 No No 122002 357 / Month 24 0.782 No No 122001 174 / Month 6 1.700 No No 122002 357 / Month 24 0.782 No No 122001 174 / Month 6 1.700 No No 122002 357 / Month 24 0.782 No No 12100 | Treatment Group Bublect ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay 23770 No 170010 365 / Month 12 2770 No No 177006 358 / Month 12 1870 Irritis No 104002 722 / Month 24 0.922 No No 122002 393 / Month 12 1.140 No No 122002 323 / Month 24 0.782 No No 124003 722 / Month 24 0.782 No No 124003 732 / Month 24 0.782 No No 124003 732 / Month 24 0.782 No No 124003 732 / Month 24 0.782 No No 124003
 | Treatment Group Runinioreactivity Immunoreactivity Treatment Group Subject ID Assay Lug Titer Disprosis 170010 365 / Month 12 2339 / Log Titer No | Treatment GroupImmunorescivity
InformationTreatment GroupSubject IDAsiavImmunorescivity
Information170010 365 Month 12 2.770 No170010 365 Month 12 2.770 No177006 358 Month 12 1870 Lirits177006 358 Month 12 1870 Lirits177006 358 Month 24 1.870 Lirits177001 722 Month 24 1.850 No104002 717 Month 24 1.140 No106002 722 Month 24 1.130 No122002 329 Month 24 1.700 No122002 329 Month 24 1.700 No124003 722 Month 24 1.700 No124003 717 Month 24 2.940 No125004 522 Early Term 0.752 No155004 522 Month 24 2.940 No155004 527 Month 24 2.070 No155005 183 Month 12 1.900 No155005 183 Month 24 2.940 No155005 183 Month 24 2.940 No155005 183 Month 24 2.070 No155005 183 Month 24 2.075 No |
| 159017 716 / Month 24 0.780 7 No 167002 717 / Mont 24 1.230 No 188005 717 / Month 24 1.250 No Sham 534001 -7 / Screening 2.520 Vitritis

 | 159017 716 / Month 24 0.780 7 No 167002 717 / Mont 24 1.230 No 188005 717 / Month 24 1.250 No 534001 -7 / Screening 2.520 Vitritis

 | 159017 716 / Month 24 0.780 No No </td <td>Treatment Group Bubject ID Positive
Assay Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea</td> <td>Treatment Group Bubject ID Positive
Infimumoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Infimumation Treatment Group Subject ID Assay Assay Assay Inframmation 170010 35/Month 12 2.770 No No 177006 358/Month 24 1870 Intrus 177005 358/Month 24 1870 No 177005 358/Month 24 13670 No 106002 717/Month 24 1870 No 106002 722/Month 24 0.922 No 106002 723/Month 24 1.300 No 124003 722/Month 24 0.922 No 124003 722/Month 24 0.770 No 124003 722/Month 24 0.700 No <td>Treatment Group Bubject ID Positive
fimiliariation Intransition
Assay Intransition</td><td>Treatment Group Bubject ID Positive
fimumoreactivity Immunoreactivity
manunoreactivity Immunoreactivity
manunoreactivity Intrancitian
mation Treatment Group 365/Month 12 2.770 No Diagnosis 170010 355/Month 24 2.870 No No 177006 358/Month 24 1870 Irritis No 177005 358/Month 24 1870 No No 177005 358/Month 24 1870 No No 106002 717/Month 24 1870 No No 124003 722/Month 24 1330 No No 124003 722/Month 24 1330 No No 124003 722/Month 24 1330 No No 124003 722/Month 24 1770 No No</td><td>Treatment Group Subject ID Positive
fimmunoreactivity Intranscitiat
fimmunoreactivity Intranscitiat
figuois Ranibizumab 0.5 mg 170010 365/Month 24 1.870 No No 177005 715/Month 24 1.130 No No No 124003 722/Month 24 1.300 No No No 124003 722/Month 24 1.770 No No No 124003 722/Month 24 1.770 No No No 124003 722/Month 24 1.770 No No No 124003 72</td><td>Treatment Group Bubject ID Positive
fimumoreactivity Immunoreactivity
manunoreactivity Immunoreactivity
manunoreactivity Intrancitian
mation Treatment Group 365/Month 12 2.770 No Diagnosis 170010 355/Month 24 2.870 No No 177006 358/Month 24 1870 Irritis No 177005 358/Month 24 1870 No No 177005 358/Month 24 1870 No No 106002 717/Month 24 1870 No No 124003 722/Month 24 1330 No No 124003 722/Month 24 1330 No No 124003 722/Month 24 1330 No No 124003 722/Month 24 1770 No No</td><td>Treatment Group Bubject ID Positive
fimumoreactivity Immunoreactivity
manunoreactivity Immunoreactivity
manunoreactivity Intrancitian
mation Treatment Group 365/Month 12 2.770 No Diagnosis 170010 355/Month 24 2.870 No No 177006 358/Month 24 1870 Irritis No 177005 358/Month 24 1870 No No 177005 358/Month 24 1870 No No 106002 717/Month 24 1870 No No 124003 722/Month 24 1330 No No 124003 722/Month 24 1330 No No 124003 722/Month 24 1330 No No 124003 722/Month 24 1770 No No</td><td>Treatment Group Bubject ID Positive
fimiliariation Intransition
Assay Intransition</td><td>Treatment Group Bubject ID Positive
fimiliariation Intransition
Assay Intransition</td><td>Treatment Group Bubject ID Positive
fimiliariation Intransition
Assay Intransition</td><td>Treatment Group Bubject ID Positive
Assay Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea</td><td>Treatment Group Bubject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td><td>Treatment Group Positive
Innunoreactivity Innercentiation Treatment Group Subject ID Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 No 17700 717 / Month 24 1.850 No 106002 719 / Month 24 1.140 No 124003 722 / Month 12 1.630 No 124003 723 / Month 12 1.630 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124013 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No</td><td>Treatment Group Bublect ID
Intraocritist Positive
Intramiation Intraocritist
Assay Log Titer Intraocritist
Intramiation Treatment Group 345 / Month 12 Xasy Log Titer Diagnosis 170010 355 / Month 12 Xasy Log Titer Diagnosis 177006 358 / Month 12 Xasy Log Titer No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis 100002 717 / Month 24 1.850 No 100002 722 / Month 12 1.630 No 124003 722 / Month 12 1.630 No 124003 722 / Month 12 1.770 No 124003 722 / Month 12 2.040 No 126001 174 / Month 6 1.770 No 126001 174 / Month 6 1.770 No 126001 722 / Month 12 2.040 No 126001 174 / Month 6
1.770 No 126001 175 / Month 24 2.040 No</td><td>Treatment Group Runninoreactivity Intranscritisty Treatment Group Subject ID Assay Log Titer Diagnosis 170010 365 / Month 12 2370 No No 177006 358 / Month 12 1870 Irritis No 106002 717 / Month 24 1870 Irritis No 106002 722 / Month 12 1.630 No No 122002 357 / Month 12 1.140 No No 124003 722 / Month 12 2.040 No No 124003 722 / Month 12 2.040 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 126001 174 / Month 6 1.770</td><td>Treatment Group Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group 170010 365 / Month 12 2 370 No 170010 365 / Month 12 2 370 No No 177006 358 / Month 12 1 870 Irrinis No 177006 358 / Month 12 1 870 Irrinis No 177006 358 / Month 12 1 870 Irrinis No 177006 358 / Month 12 1 870 Irrinis No 100002 722 / Month 24 1 140 No No 122002 339 / Month 12 1 630 No No 122002 337 / Month 24 0 782 No No 124003 722 / Month 24 1 480 No No 124003 722 / Month 24 1 480 No No 124003 722 / Month 24 1 480 No No 124003 722 / Month 24 1 480 No No 126001<!--</td--></td></td> | Treatment Group Bubject ID Positive
Assay Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea

 | Treatment Group Bubject ID Positive
Infimumoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Infimumation Treatment Group Subject ID Assay Assay Assay Inframmation 170010 35/Month 12 2.770 No No 177006 358/Month 24 1870 Intrus 177005 358/Month 24 1870 No 177005 358/Month 24 13670 No 106002 717/Month 24 1870 No 106002 722/Month 24 0.922 No 106002 723/Month 24 1.300 No 124003 722/Month 24 0.922 No 124003 722/Month 24 0.770 No 124003 722/Month 24 0.700 No <td>Treatment Group Bubject ID Positive
fimiliariation Intransition
Assay Intransition</td> <td>Treatment Group Bubject ID Positive
fimumoreactivity Immunoreactivity
manunoreactivity Immunoreactivity
manunoreactivity Intrancitian
mation Treatment Group 365/Month 12 2.770 No Diagnosis 170010 355/Month 24 2.870 No No 177006 358/Month 24 1870 Irritis No 177005 358/Month 24 1870 No No 177005 358/Month 24 1870 No No 106002 717/Month 24 1870 No No 124003 722/Month 24 1330 No No 124003 722/Month 24 1330 No No 124003 722/Month 24 1330 No No 124003 722/Month 24 1770 No No</td> <td>Treatment Group Subject ID Positive
fimmunoreactivity Intranscitiat
fimmunoreactivity Intranscitiat
figuois Ranibizumab 0.5 mg 170010 365/Month 24 1.870 No No 177005 715/Month 24 1.130 No No No 124003 722/Month 24 1.300 No No No 124003 722/Month 24 1.770 No No No 124003 722/Month 24 1.770 No No No 124003 722/Month 24 1.770 No No No 124003 72</td> <td>Treatment Group Bubject ID Positive
fimumoreactivity Immunoreactivity
manunoreactivity Immunoreactivity
manunoreactivity Intrancitian
mation Treatment Group 365/Month 12 2.770 No Diagnosis 170010 355/Month 24 2.870 No No 177006 358/Month 24 1870 Irritis No 177005 358/Month 24 1870 No No 177005 358/Month 24 1870 No No 106002 717/Month 24 1870 No No 124003 722/Month 24 1330 No No 124003 722/Month 24 1330 No No 124003 722/Month 24 1330 No No 124003 722/Month 24 1770 No No</td> <td>Treatment Group Bubject ID Positive
fimumoreactivity Immunoreactivity
manunoreactivity Immunoreactivity
manunoreactivity Intrancitian
mation Treatment Group 365/Month 12 2.770 No Diagnosis 170010 355/Month 24 2.870 No No 177006 358/Month 24 1870 Irritis No 177005 358/Month 24 1870 No No 177005 358/Month 24 1870 No No 106002 717/Month 24 1870 No No 124003 722/Month 24 1330 No No 124003 722/Month 24 1330 No No 124003 722/Month 24 1330 No No 124003 722/Month 24 1770 No No</td> <td>Treatment Group Bubject ID Positive
fimiliariation Intransition
Assay
Intransition</td> <td>Treatment Group Bubject ID Positive
fimiliariation Intransition
Assay Intransition</td> <td>Treatment Group Bubject ID Positive
fimiliariation Intransition
Assay Intransition</td> <td>Treatment Group Bubject ID Positive
Assay Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea</td> <td>Treatment Group Bubject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td> <td>Treatment Group Positive
Innunoreactivity Innercentiation Treatment Group Subject ID Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 No 17700 717 / Month 24 1.850 No 106002 719 / Month 24 1.140 No 124003 722 / Month 12 1.630 No 124003 723 / Month 12 1.630 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124013 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No</td> <td>Treatment Group Bublect ID
Intraocritist Positive
Intramiation Intraocritist
Assay Log Titer Intraocritist
Intramiation Treatment Group 345 / Month 12 Xasy Log Titer Diagnosis 170010 355 / Month 12 Xasy Log Titer Diagnosis 177006 358 / Month 12 Xasy Log Titer No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis 100002 717 / Month 24 1.850 No 100002 722 / Month 12 1.630 No 124003 722 / Month 12 1.630 No 124003 722 / Month 12 1.770 No 124003 722 / Month 12 2.040 No 126001 174 / Month 6 1.770 No 126001 174 / Month 6 1.770 No 126001 722 / Month 12 2.040 No 126001 174 / Month 6 1.770 No 126001 175 / Month 24 2.040 No</td> <td>Treatment Group Runninoreactivity Intranscritisty Treatment Group Subject ID Assay Log Titer Diagnosis 170010 365 / Month 12 2370 No No 177006 358 / Month 12 1870 Irritis No 106002 717 / Month 24 1870 Irritis No 106002 722 / Month 12 1.630 No No 122002 357 / Month 12 1.140 No No 124003 722 / Month 12 2.040 No No 124003 722 / Month 12 2.040 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 126001 174 / Month 6 1.770</td> <td>Treatment Group Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group 170010 365 / Month 12 2 370 No 170010 365 / Month 12 2 370 No No 177006 358 / Month 12 1 870 Irrinis No 177006 358 / Month 12 1 870 Irrinis No 177006 358 / Month 12 1 870 Irrinis No 177006 358 / Month 12 1 870 Irrinis No 100002 722 / Month 24 1 140 No No 122002 339 / Month 12 1 630 No No 122002 337 / Month 24 0 782 No No 124003 722 / Month 24 1 480 No No 124003 722 / Month 24 1 480 No No 124003 722 / Month 24 1 480 No No 124003 722 / Month 24 1 480 No No 126001<!--</td--></td> | Treatment Group Bubject ID Positive
fimiliariation Intransition
Assay Intransition

 | Treatment Group Bubject ID Positive
fimumoreactivity Immunoreactivity
manunoreactivity Immunoreactivity
manunoreactivity Intrancitian
mation Treatment Group 365/Month 12 2.770 No Diagnosis 170010 355/Month 24 2.870 No No 177006 358/Month 24 1870 Irritis No 177005 358/Month 24 1870 No No 177005 358/Month 24 1870 No No 106002 717/Month 24 1870 No No 124003 722/Month 24 1330 No No 124003 722/Month 24 1330 No No 124003 722/Month 24 1330 No No 124003 722/Month 24 1770 No No

 | Treatment Group Subject ID Positive
fimmunoreactivity Intranscitiat
fimmunoreactivity Intranscitiat
figuois Ranibizumab 0.5 mg 170010 365/Month 24 1.870 No No 177005 715/Month 24 1.130 No No No 124003 722/Month 24 1.300 No No No 124003 722/Month 24 1.770 No No No 124003 722/Month 24 1.770 No No No 124003 722/Month 24 1.770 No No No 124003 72
 | Treatment Group Bubject ID Positive
fimumoreactivity Immunoreactivity
manunoreactivity Immunoreactivity
manunoreactivity Intrancitian
mation Treatment Group 365/Month 12 2.770 No Diagnosis 170010 355/Month 24 2.870 No No 177006 358/Month 24 1870 Irritis No 177005 358/Month 24 1870 No No 177005 358/Month 24 1870 No No 106002 717/Month 24 1870 No No 124003 722/Month 24 1330 No No 124003 722/Month 24 1330 No No 124003 722/Month 24 1330 No No 124003 722/Month 24 1770 No No

 | Treatment Group Bubject ID Positive
fimumoreactivity Immunoreactivity
manunoreactivity Immunoreactivity
manunoreactivity Intrancitian
mation Treatment Group 365/Month 12 2.770 No Diagnosis 170010 355/Month 24 2.870 No No 177006 358/Month 24 1870 Irritis No 177005 358/Month 24 1870 No No 177005 358/Month 24 1870 No No 106002 717/Month 24 1870 No No 124003 722/Month 24 1330 No No 124003 722/Month 24 1330 No No 124003 722/Month 24 1330 No No 124003 722/Month 24 1770 No No
 | Treatment Group Bubject ID Positive
fimiliariation Intransition
Assay Intransition
 | Treatment Group Bubject ID Positive
fimiliariation Intransition
Assay Intransition

 | Treatment Group Bubject ID Positive
fimiliariation Intransition
Assay Intransition | Treatment Group Bubject ID Positive
Assay Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea
 | Treatment Group Bubject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit
 | Treatment Group Positive
Innunoreactivity Innercentiation Treatment Group Subject ID Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 No 17700 717 / Month 24 1.850 No 106002 719 / Month 24 1.140 No 124003 722 / Month 12 1.630 No 124003 723 / Month 12 1.630 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124013 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No | Treatment Group Bublect ID
Intraocritist Positive
Intramiation Intraocritist
Assay Log Titer Intraocritist
Intramiation Treatment Group 345 / Month 12 Xasy Log Titer Diagnosis 170010 355 / Month 12 Xasy Log Titer Diagnosis 177006 358 / Month 12 Xasy Log Titer No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis 100002 717 / Month 24 1.850 No 100002 722 / Month 12 1.630 No 124003 722 / Month 12 1.630 No 124003 722 / Month 12 1.770 No 124003 722 / Month 12 2.040 No 126001 174 / Month 6 1.770 No 126001 174 / Month 6 1.770 No 126001 722 / Month 12 2.040 No 126001 174 / Month 6 1.770 No 126001 175 / Month 24 2.040 No
 | Treatment Group Runninoreactivity Intranscritisty Treatment Group Subject ID Assay Log Titer Diagnosis 170010 365 / Month 12 2370 No No 177006 358 / Month 12 1870 Irritis No 106002 717 / Month 24 1870 Irritis No 106002 722 / Month 12 1.630 No No 122002 357 / Month 12 1.140 No No 124003 722 / Month 12 2.040 No No 124003 722 / Month 12 2.040 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 126001 174 / Month 6 1.770 | Treatment Group Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group 170010 365 / Month 12 2 370 No 170010 365 / Month 12 2 370 No No 177006 358 / Month 12 1 870 Irrinis No 177006 358 / Month 12 1 870 Irrinis No 177006 358 / Month 12 1 870 Irrinis No 177006 358 / Month 12 1 870 Irrinis No 100002 722 / Month 24 1 140 No No 122002 339 / Month 12 1 630 No No 122002 337 / Month 24 0 782 No No 124003 722 / Month 24 1 480 No No 124003 722 / Month 24 1 480 No No 124003 722 / Month 24 1 480 No No 124003 722 / Month 24 1 480 No No 126001 </td |
| 718 / Month 24 2.070 No 159017 716 / Month 24 0.780 No 167002 717 / Mont 24 1.230 No 188005 717 / Month 24 1.250 No 534001 -7 / Screening 2.520 Vitritis

 | 718 / Month 24 2.070 No 159017 716 / Month 24 0.780 No 167002 717 / Month 24 1.230 No 188005 717 / Month 24 1.250 No 534001 -7 / Screening 2.520 Vitritis

 | 718 / Month 24 2.070 No 159017 716 / Month 24 0.780 No 167002 717 / Month 24 1.230 No 188005 717 / Month 24 1.250 No 534001 -7 / Screening 2.520 Vintits

 | Treatment Group Bubject ID Positive
Inflammation Intranscription Treatment Group Subject ID Assay Assay Assay Intranscription Treatment Group Subject ID Assay Assay Assay Intranscription 170010 355/Month 12 2.770 No No 177006 358/Month 24 1870 Intris 177006 358/Month 24 1870 No 177005 719/Month 24 1870 No 104002 719/Month 24 1.870 No 124001 722/Month 24 1.130 No 124003 722/Month 24 1.770 No 124003 722/Month 24 1.770 No 124001 721/Month 6 1.770 No 124003 722/Month 24 1.940 No 124003 722/Month 24 1.770 No 124003 721/Month 24 1.770 No 124003 721/Month 24 1.770 No

 | Treatment Group Bubject ID Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivit

 | Treatment Group Subject ID Positive
fimiliarian Intranscrittyric
Assay Intranscrittyr
Assay Intranscrittyr
Assay Intranscrittyr
Assay Intranscrittyr
Assay Intranscrittry
Assay Intranstry
Assay Intranstry
Assay
 | Treatment Group Subject ID Positive
fimmunoreactivity Intrancedutity Intrancedutity Treatment Group Subject ID Assay Assay Assay
 Assay Intrancedutity Intrancedutity 170010 365/Month 12 2.770 No Diagnosis 177006 355/Month 12 2.800 Irttis Diagnosis 177006 358/Month 12 1.850 No No 177005 358/Month 24 1.140 No No 124002 719/Month 24 1.130 No No 124003 722/Month 24 1.130 No No 124003 722/Month 24 1.700 No
 | Treatment Group Bositry
Immunoreactivity Immunoreactivity
Immunoreactivity Intrancitian
Assay Latrancitian
Assay Latrancitian
Assay Intrancitian
Assay Intranccutan
Assay Intrancutan
Assay Intrancutan
Assay

 | Treatment Group Subject ID Positive
fimmunoreactivity Intrancedutity Intrancedutity Treatment Group Subject ID Assay Assay Assay Assay Intrancedutity Intrancedutity 170010 365/Month 12 2.770 No Diagnosis 177006 355/Month 12 2.800 Irttis Diagnosis 177006 358/Month 12 1.850 No No 177005 358/Month 24 1.140 No No 124002 719/Month 24 1.130 No No 124003 722/Month 24 1.130 No No 124003 722/Month 24 1.700 No
 | Treatment Group Subject ID Positive
fimmunoreactivity Intrancedutity Intrancedutity Treatment Group Subject ID Assay Assay Assay Assay Intrancedutity Intrancedutity 170010 365/Month 12 2.770 No Diagnosis 177006 355/Month 12 2.800 Irttis Diagnosis 177006 358/Month 12 1.850 No No 177005 358/Month 24 1.140 No No 124002 719/Month 24 1.130 No No 124003 722/Month 24 1.130 No No 124003 722/Month 24 1.700 No

 | Treatment Group Subject ID Positive
fimiliarian Intranscrittyric
Assay Intranscrittyr
Assay Intranscrittyr
Assay Intranscrittyr
Assay Intranscrittyr
Assay Intranscrittry
Assay Intranstry
Assay Intranstry
Assay
 | Treatment Group Subject ID Positive
fimiliarian Intranscrittyric
Assay Intranscrittyr
Assay Intranscrittyr
Assay Intranscrittyr
Assay Intranscrittyr
Assay Intranscrittry
Assay Intranstry
Assay Intranstry
Assay
 | Treatment Group Subject ID Positive
fimiliarian Intranscrittyric
Assay Intranscrittyr
Assay Intranscrittyr
Assay Intranscrittyr
Assay Intranscrittyr
Assay Intranscrittry
Assay Intranstry
Assay Intranstry
Assay
 | Treatment Group Bubject ID Positive
Inflammation Intranscription Treatment Group Subject ID Assay Assay Assay Intranscription Treatment Group Subject ID Assay Assay Assay Intranscription 170010 355/Month 12 2.770 No No 177006 358/Month 24 1870 Intris 177006 358/Month 24 1870 No 177005 719/Month 24 1870 No 104002 719/Month 24 1.870 No 124001 722/Month 24 1.130 No 124003 722/Month 24 1.770 No 124003 722/Month 24 1.770 No 124001 721/Month 6 1.770 No 124003 722/Month 24 1.940 No 124003 722/Month 24 1.770 No 124003 721/Month 24 1.770 No 124003 721/Month 24 1.770 No
 | Treatment Group Bubject ID Positive
Assay Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity | Treatment Group Bubject ID
Intranceditive
Infimumoreactivity Intranceditie
Infimumation Assay Assay Assay Infimumoreactivity Infimumation I70010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Infimumation Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 No 177005 358 / Month 12 1.870 No No 100002 717 / Month 24 1.870 No No 104002 719 / Month 24 1.870 No No 124003 722 / Month 24 1.130 No No 124003 722 / Month 24 1.770 No No 124001 722 / Month 24
 | Treatment Group Runifier Biolistics Positive immunoreactivity immunoreactivity immunoreactivity immunoreactivity immunoreactivity immunoreactivity immunoreactivity Intrancitian Treatment Group Subject ID Assy Assy Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 338 / Month 12 1.870 Intrascotiar 177005 338 / Month 12 1.870 No 177006 338 / Month 24 1.870 No 106002 717 / Month 24 1.850 No 106002 722 / Month 24 1.140 No 124003 722 / Month 24 1.130 No 124003 722 / Month 24 1.300 No 124003 722 / Month 24 1.770 No 124003 722 / Mont | Treatment Group Rositive
Innunoreactivity Innunoreactivity
Innunoreactivity Innunoreactivity
Innunoreactivity Innunoreactivity
Innunoreactivity Innunoreactivity
Innunoreactivity Innunoreactivity
Innunoreactivity Innunoreactivity
Innunoreactivity Innunoreactivity
Innunoreactivity Innunoreactivity
Innunoreactivity Innunoreactivity Innuno No | Treatment Group Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group 365 / Month 12 2 370 No |
| 718 / Month 24 2.070 No 159017 716 / Month 24 0.780 No 167002 717 / Mont 24 1.230 No 188005 717 / Month 24 1.250 No 534001 -7 / Screening 2.520 Vitritis

 | 718 / Month 24 2.070 Month 24 2.070 Month 24 159017 716 / Month 24 0.780 No 167002 717 / Mont 24 1.230 No 188005 717 / Month 24 1.250 No 534001 -7 / Screening 2.520 Vitritis

 | 718 / Month 24 2.070 Month 24 2.070 Month 24 159017 716 / Month 24 0.780 No 167002 717 / Month 24 1.230 No 188005 717 / Month 24 1.250 No 534001 -7 / Screening 2.520 Vitritis

 | Treatment Group Evolution Framminic activity immunor activity in the

 | Treatment Group Bositive
Innumoreactivity Innumoreactivity
Innumoreactivity Inneocutat
Innumoreactivity Inneocutat
Innumoreactivity Inneocutat
Innumoreactivity Inneocutat
Innumoreactivity Inneocutat
Innumoreactivity Inneocutat
Innumoreactivity Inneocutat
Innumoreactivity Inneocutat
Innumoreactivity Inneocutat
Inneocutat Inneocutat Inneocutat <td>Treatment Group Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intraocutat
Diagnosis Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 1.870 Intraocutat 177006 358 / Month 12 1.870 Intraocutat 177006 358 / Month 12 1.870 Intraocutat 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 177001 722 / Month 24 1.130 No 122002 359 / Month 12 1.300 No 124003 722 / Month 24 1.130 No 124003 722 / Month 24 1.700 No 124001 174 / Month 24 1.770 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 125004 532 / Month 24 1.700 No</td> <td>Treatment GroupPositive
InnumoreactivityInnumoreactivity
InnumoreactivityIntrancitian
InnumoreactivityTreatment GroupSubject IDAsisyAsisyLog170010365 Month 122.770No177006358 Month 121.870Iritis177006358 Month 121.870Iritis177006358 Month 121.870Iritis177006358 Month 121.870Iritis177006717 Month 241.130No106002722 Month 241.130No122002359 Month 121.630No124003722 Month 241.770No124003722 Month 241.770No124003722 Month 241.770No124003723 Month 241.630No124003722 Month 241.630No124003722 Month 241.630No124003715 Month 242.040No124003715 Month 242.040No124003715 Month 242.040No124003715 Month 242.040No125004522 Month
242.340Vitritis141013715 Month 242.610Vitritis152004522 Month 242.340No15305522 Month 542.340No153061900722 Month 542.0401530619000.752No15306183 Month 540.752No15306</td> <td>Treatment GroupSubject IDPositive
ImmunoreactivityIntranscitiat
ImmunoreactivityIntranscitiat
InflammetidaTreatment GroupSubject ID365 Month 12$2.770$No170010$365$ Month 12$2.770$No177006$355$ Month 12$1.870$Iritis177006$355$ Month 24$1.870$Iritis177006$712$ Month 24$1.870$Iritis104002$719$ Month 24$1.140$No122002$359$ Month 12$1.630$No122002$359$ Month 12$1.630$No124003$722$ Month 24$1.770$No124003$722$ Month 24$1.770$No124003$722$ Month 24$1.770$No124003$722$ Month 24$1.770$No124003$722$ Month 24$1.770$No124003$722$ Month 24$0.782$No124003$722$ Month 24$0.782$No124003$725$ Month 24$0.782$No124003$725$ Month 24$0.782$No124003$715$ Month 24$2.040$No124003$715$ Month 24$2.040$No124003$715$ Month 24$2.040$No124003$715$ Month 24$2.040$No124003$715$ Month 24$2.040$No124003$725$ Month 24$2.040$No124003$715$ Month 24$2.040$No12504$522$ Month 24$2.9$</td> <td>Treatment GroupPositive
InnumoreactivityInnumoreactivity
InnumoreactivityIntrancitian
InnumoreactivityTreatment GroupSubject IDAsisyAsisyLog170010365 Month 122.770No177006358 Month 121.870Iritis177006358 Month 121.870Iritis177006358 Month 121.870Iritis177006358 Month 121.870Iritis177006717 Month 241.130No106002722 Month 241.130No122002359 Month 121.630No124003722 Month 241.770No124003722 Month 241.770No124003722 Month 241.770No124003723 Month 241.630No124003722 Month 241.630No124003722 Month 241.630No124003715 Month 242.040No124003715 Month 242.040No124003715 Month 242.040No124003715 Month 242.040No125004522 Month 242.340Vitritis141013715 Month 242.610Vitritis152004522 Month 242.340No15305522 Month 542.340No153061900722 Month 542.0401530619000.752No15306183 Month 540.752No15306</td> <td>Treatment GroupPositive
InnumoreactivityInnumoreactivity
InnumoreactivityIntrancitian
InnumoreactivityTreatment GroupSubject IDAsisyAsisyLog170010365 Month 122.770No177006358 Month 121.870Iritis177006358 Month 121.870Iritis177006358 Month 121.870Iritis177006358 Month 121.870Iritis177006717 Month 241.130No106002722 Month 241.130No122002359 Month 121.630No124003722 Month 241.770No124003722 Month 241.770No124003722 Month 241.770No124003723 Month 241.630No124003722 Month 241.630No124003722 Month 241.630No124003715 Month 242.040No124003715 Month 242.040No124003715 Month 242.040No124003715 Month 242.040No125004522 Month 242.340Vitritis141013715 Month 242.610Vitritis152004522 Month 242.340No15305522 Month 542.340No153061900722 Month 542.0401530619000.752No15306183 Month 540.752No15306</td> <td>Treatment Group Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intraocutat
Diagnosis Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 1.870 Intraocutat 177006 358 / Month 12 1.870 Intraocutat 177006 358 / Month 12 1.870 Intraocutat 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 177001 722 / Month 24 1.130 No 122002 359 / Month 12 1.300 No 124003 722 / Month 24 1.130 No 124003 722 / Month 24 1.700 No 124001 174 / Month 24 1.770 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 125004 532 / Month 24 1.700 No</td> <td>Treatment Group Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intraocutat
Diagnosis Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 1.870 Intraocutat 177006 358 / Month 12 1.870 Intraocutat 177006 358 / Month 12 1.870 Intraocutat 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 177001 722 / Month 24 1.130 No 122002 359 / Month 12 1.300 No 124003 722 / Month 24 1.130 No 124003 722 / Month 24 1.700 No 124001 174 / Month 24 1.770 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 125004 532 / Month 24 1.700 No</td> <td>Treatment Group Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intraocutat
Diagnosis Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 1.870 Intraocutat 177006 358 / Month 12 1.870 Intraocutat 177006 358 / Month 12 1.870 Intraocutat 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 177001 722 / Month 24 1.130 No 122002 359 / Month 12 1.300 No 124003 722 / Month 24 1.130 No 124003 722 / Month 24 1.700 No 124001 174 / Month 24 1.770 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 125004 532 / Month 24 1.700 No</td> <td>Treatment Group Evolution Framminic activity immunor activity in the activity in the</td> <td>Treatment Group Positive
Immunoractivity Immunoractivity
Immunoractivity Immunoractivity
Immunoractivity Immunoractivity Treatment Group 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 Iritis 177006 358 / Month 12 1.870 Iritis 717/ Month 24 1.870 Iritis No 717/ Month 24 1.140 No No 7122002 359 / Month 12 1.300 No No 122002 722 / Month 24 1.140 No No 124003 722 / Month 24 1.1700 No No 124003 722 / Month 24 1.770 No No 125004 181 / Month 24 1.770 No</td> <td>Treatment Group Positive
Immunoreactivity Intransition
Intransition Treatment Group Subject ID Assay Assay Intransition 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.850 No 177006 358 / Month 24 1.850 No 177006 358 / Month 24 1.140 No 177001 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 359 / Month 24 1.1700 No 124003 722 / Month 24 1.770 No 126001 174 / Month 6 1.770 No 124003 722 / Month 24 1.770 No 126001 174 / Month 6 1.770 No 126001 174 / Month 24 1.770 No 125002 352 / Month 12 1.870 No 126001 174 / Month 24 1.770 No 126001 174 0.782 No</td> <td>Treatment Group Positive
Innunoreactivity Innunoreactivity Innunoreactivity Innunoreactivity Innunition Arbitet ID 3ubject ID Assay Assay Log Titer Diagnosis 170010 358/Month 12 2.770 No No 177006 358/Month 24 1.850 No No 177005 358/Month 24 1.300 No No 177005 358/Month 24 1.300 No No 177005 358/Month 24 1.140 No No 122002 359/Month 24 1.140 No No 122002 359/Month 24 1.770 No No 124003 722/Month 24 1.770 No No 124003<!--</td--><td>Treatment Group Rolitive Positive Intranocativity Intranocativity Treatment Group Subject ID Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No 177006 358 / Month 24 1.850 Intrius 177006 358 / Month 24 1.870 Intrius 177005 358 / Month 24 1.870 No 177006 358 / Month 24 1.140 No 122002 717 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 359 / Month 12 1.630 No 124003 722 / Month
24 1.130 No 124003 722 / Month 24 1.700 No 126001 174 / Month 6 1.770 No 124003 722 / Month 24 1.800 No 141018 181 / Month 6 1.770 No 125004 532 / Month 24 1.940 No 141013 715 / Month 24 <</td><td>Treatment Group Intransocativity
Intransocativity Intransocativity
Intransocativity Intransocativity
Intransocativity Intransocativity Subject ID Sol Month 12 2:370 No No 170010 365 / Month 12 2:870 No No 177006 358 / Month 12 1:870 Irtitis No 177005 358 / Month 12 1:870 Irtitis No 177006 358 / Month 24 1:870 Irtitis No 106002 712 / Month 24 1:870 No No 1122002 359 / Month 12 1:870 No No 122002 359 / Month 24 1:300 No No 122002 359 / Month 24 1:300 No No 126001 174 / Month 6 1:700 No No 126001 174 / Month 24 1:700 No No 126001 174 / Month 6 1:700 No No 126001 174 / Month 6 1:770 No No <!--</td--></td></td> | Treatment Group Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intraocutat
Diagnosis Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 1.870 Intraocutat 177006 358 / Month 12 1.870 Intraocutat 177006 358 / Month 12 1.870 Intraocutat 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 177001 722 / Month 24 1.130 No 122002 359 / Month 12 1.300 No 124003 722 / Month 24 1.130 No 124003 722 / Month 24 1.700 No 124001 174 / Month 24 1.770 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 125004 532 / Month 24 1.700 No

 | Treatment GroupPositive
InnumoreactivityInnumoreactivity
InnumoreactivityIntrancitian
InnumoreactivityTreatment GroupSubject IDAsisyAsisyLog170010365 Month 122.770No177006358 Month 121.870Iritis177006358 Month 121.870Iritis177006358 Month 121.870Iritis177006358 Month 121.870Iritis177006717 Month 241.130No106002722 Month 241.130No122002359 Month 121.630No124003722 Month 241.770No124003722 Month 241.770No124003722 Month 241.770No124003723 Month 241.630No124003722 Month 241.630No124003722 Month 241.630No124003715 Month 242.040No124003715 Month 242.040No124003715 Month 242.040No124003715 Month 242.040No125004522 Month 242.340Vitritis141013715 Month 242.610Vitritis152004522 Month 242.340No15305522 Month 542.340No153061900722 Month 542.0401530619000.752No15306183 Month 540.752No15306

 | Treatment GroupSubject IDPositive
ImmunoreactivityIntranscitiat
ImmunoreactivityIntranscitiat
InflammetidaTreatment GroupSubject ID 365 Month 12 2.770 No170010 365 Month 12 2.770 No177006 355 Month 12 1.870 Iritis177006 355 Month 24 1.870 Iritis177006 712 Month 24 1.870 Iritis104002 719 Month 24 1.140 No122002 359 Month 12 1.630 No122002 359 Month 12 1.630 No124003 722 Month 24 1.770 No124003 722 Month 24 0.782 No124003 722 Month 24 0.782 No124003 725 Month 24 0.782 No124003 725 Month 24 0.782 No124003 715 Month 24 2.040 No124003 725 Month 24 2.040 No124003 715 Month 24 2.040 No12504 522 Month 24 2.9

 | Treatment GroupPositive
InnumoreactivityInnumoreactivity
InnumoreactivityIntrancitian
InnumoreactivityTreatment GroupSubject IDAsisyAsisyLog170010365 Month 122.770No177006358 Month 121.870Iritis177006358 Month 121.870Iritis177006358 Month 121.870Iritis177006358 Month 121.870Iritis177006717 Month 241.130No106002722 Month 241.130No122002359 Month 121.630No124003722 Month 241.770No124003722 Month 241.770No124003722 Month 241.770No124003723 Month 241.630No124003722 Month 241.630No124003722 Month 241.630No124003715 Month 242.040No124003715 Month 242.040No124003715 Month 242.040No124003715 Month 242.040No125004522 Month 242.340Vitritis141013715 Month 242.610Vitritis152004522 Month 242.340No15305522 Month 542.340No153061900722 Month 542.0401530619000.752No15306183 Month 540.752No15306
 | Treatment GroupPositive
InnumoreactivityInnumoreactivity
InnumoreactivityIntrancitian
InnumoreactivityTreatment GroupSubject IDAsisyAsisyLog170010365 Month 122.770No177006358 Month 121.870Iritis177006358 Month 121.870Iritis177006358 Month 121.870Iritis177006358 Month 121.870Iritis177006717 Month 241.130No106002722 Month 241.130No122002359 Month 121.630No124003722 Month 241.770No124003722 Month 241.770No124003722 Month 241.770No124003723 Month 241.630No124003722 Month 241.630No124003722 Month 241.630No124003715 Month 242.040No124003715 Month 242.040No124003715 Month 242.040No124003715 Month 242.040No125004522 Month 242.340Vitritis141013715 Month 242.610Vitritis152004522 Month 242.340No15305522 Month 542.340No153061900722 Month 542.0401530619000.752No15306183 Month 540.752No15306
 | Treatment Group Subject ID Positive
Assay Immunoreactivity
Assay Log Titer
 Intraocutat
Diagnosis Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 1.870 Intraocutat 177006 358 / Month 12 1.870 Intraocutat 177006 358 / Month 12 1.870 Intraocutat 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 177001 722 / Month 24 1.130 No 122002 359 / Month 12 1.300 No 124003 722 / Month 24 1.130 No 124003 722 / Month 24 1.700 No 124001 174 / Month 24 1.770 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 125004 532 / Month 24 1.700 No
 | Treatment Group Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intraocutat
Diagnosis Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 1.870 Intraocutat 177006 358 / Month 12 1.870 Intraocutat 177006 358 / Month 12 1.870 Intraocutat 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 177001 722 / Month 24 1.130 No 122002 359 / Month 12 1.300 No 124003 722 / Month 24 1.130 No 124003 722 / Month 24 1.700 No 124001 174 / Month 24 1.770 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 125004 532 / Month 24 1.700 No
 | Treatment Group Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intraocutat
Diagnosis Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 1.870 Intraocutat 177006 358 / Month 12 1.870 Intraocutat 177006 358 / Month 12 1.870 Intraocutat 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 177001 722 / Month 24 1.130 No 122002 359 / Month 12 1.300 No 124003 722 / Month 24 1.130 No 124003 722 / Month 24 1.700 No 124001 174 / Month 24 1.770 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 125004 532 / Month 24 1.700 No
 | Treatment Group Evolution Framminic activity immunor activity in the
 | Treatment Group Positive
Immunoractivity Immunoractivity
Immunoractivity Immunoractivity
Immunoractivity Immunoractivity Treatment Group 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 Iritis 177006 358 / Month 12 1.870 Iritis 717/ Month 24 1.870 Iritis No 717/ Month 24 1.140 No No 7122002 359 / Month 12 1.300 No No 122002 722 / Month 24 1.140 No No 124003 722 / Month 24 1.1700 No No 124003 722 / Month 24 1.770 No No 125004 181 / Month 24 1.770 No | Treatment Group Positive
Immunoreactivity Intransition
Intransition Treatment Group Subject ID Assay Assay Intransition 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.850 No 177006 358 / Month 24 1.850 No 177006 358 / Month 24 1.140 No 177001 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 359 / Month 24 1.1700 No 124003 722 / Month 24 1.770 No 126001 174 / Month 6 1.770 No 124003 722 / Month 24 1.770 No 126001 174 / Month 6 1.770 No 126001 174 / Month 24 1.770 No 125002 352 / Month 12 1.870 No 126001 174 / Month 24 1.770 No 126001 174 0.782 No
 | Treatment Group Positive
Innunoreactivity Innunoreactivity Innunoreactivity Innunoreactivity Innunition Arbitet ID 3ubject ID Assay Assay Log Titer Diagnosis 170010 358/Month 12 2.770 No No 177006 358/Month 24 1.850 No No 177005 358/Month 24 1.300 No No 177005 358/Month 24 1.300 No No 177005 358/Month 24 1.140 No No 122002 359/Month 24 1.140 No No 122002 359/Month 24 1.770 No No 124003 722/Month 24 1.770 No No 124003 </td <td>Treatment Group Rolitive Positive Intranocativity Intranocativity Treatment Group Subject ID Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No 177006 358 / Month 24 1.850 Intrius 177006 358 / Month 24 1.870 Intrius 177005 358 / Month 24 1.870 No 177006 358 / Month 24 1.140 No 122002 717 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 359 / Month 12 1.630 No 124003 722 / Month 24 1.130 No 124003 722 / Month 24 1.700 No 126001 174 / Month 6 1.770 No 124003 722 / Month 24 1.800 No 141018 181 / Month 6 1.770 No 125004 532 / Month 24 1.940 No 141013 715 / Month 24 <</td> <td>Treatment Group Intransocativity
Intransocativity Intransocativity
Intransocativity Intransocativity
Intransocativity Intransocativity Subject ID Sol Month 12 2:370 No No 170010 365 / Month 12 2:870 No No 177006 358 / Month 12 1:870 Irtitis No 177005 358 / Month 12 1:870 Irtitis No 177006 358 / Month 24 1:870 Irtitis No 106002 712 / Month 24 1:870 No No 1122002 359 / Month 12 1:870 No No 122002 359 / Month 24 1:300 No No 122002 359 / Month 24 1:300 No No 126001 174 / Month 6 1:700 No No 126001 174 / Month 24 1:700 No No 126001 174 / Month 6 1:700 No No 126001 174 / Month 6 1:770 No No <!--</td--></td> | Treatment Group Rolitive Positive Intranocativity Intranocativity Treatment Group Subject ID Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No 177006 358 / Month 24 1.850 Intrius 177006 358 / Month 24 1.870 Intrius 177005 358 / Month 24 1.870 No 177006 358 / Month 24 1.140 No 122002 717 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 359 / Month 12 1.630 No 124003 722 / Month 24 1.130 No 124003 722 / Month 24 1.700 No 126001 174 / Month 6 1.770 No 124003 722 / Month 24 1.800 No 141018 181 / Month 6 1.770 No 125004 532 / Month 24 1.940 No 141013 715 / Month 24 <
 | Treatment Group Intransocativity
Intransocativity Intransocativity
Intransocativity Intransocativity
Intransocativity Intransocativity Subject ID Sol Month 12 2:370 No No 170010 365 / Month 12 2:870 No No 177006 358 / Month 12 1:870 Irtitis No 177005 358 / Month 12 1:870 Irtitis No 177006 358 / Month 24 1:870 Irtitis No 106002 712 / Month 24 1:870 No No 1122002 359 / Month 12 1:870 No No 122002 359 / Month 24 1:300 No No 122002 359 / Month 24 1:300 No No 126001 174 / Month 6 1:700 No No 126001 174 / Month 24 1:700 No No 126001 174 / Month 6 1:700 No No 126001 174 / Month 6 1:770 No No </td |
| Sham 533/00000000000000000000000000000000000

 | Sham 533/0011 1230 718/Month 24 2.070 159017 716/Month 24 167002 717/Mont 24 167002 717/Month 24 188005 717/Month 24 11230 No 188005 717/Month 24 11230 No 188005 717/Month 24 11250 No 11250 No 11250 No

 | Sham S34001 718 / Month 24 2.070 No 159017 718 / Month 24 0.780 No 167002 717 / Month 24 0.780 No 188005 717 / Month 24 1.230 No 188005 717 / Month 24 1.250 No 188005 717 / Month 24 1.250 No 188005 717 / Month 24 1.250 No

 | Treatment Group Bositive
Immunoreactivity Immunoreactivity Immunorea

 | Treatment Group Evolution Subject ID Positive Assay Intranscription Intranscription Treatment Group Subject ID Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis No 177006 358 / Month 12 1.870 Irritis No 177006 358 / Month 24 1.870 Irritis No 177006 358 / Month 24 1.130 No No 122002 359 / Month 24 1.130 No No 124003 722 / Month 24 1.130 No No 124003 722 / Month 24 1.170 No No 126001 174 / Month 6 1.700 No No 126001 174 / Month 6 1.700 No No 126001 174 / Month 6 1.700 No No 136001 174 / Month 6 1.700 No No 1410103 722

 | Tratment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immention
Diagnosis Tratment Group Subject ID Assy Assy Information Subject ID 365 Month 12 2.770 No 177006 355 Month 12 2.770 No 177006 355 Month 12 1.870 Irritis 177006 355 Month 24 1.870 Irritis 177006 355 Month 24 1.870 No 177005 722 Month 24 1.130 No 106002 722 Month 24 1.130 No 120001 174 Month 6 1.700 No 120001 722 Month 12 1.630 No 124003 722 Month 24 1.700 No 126001 174 Month 6 1.700 No 126001 174 Month 6 1.700 No 126001 174 Month 6 1.700 No 136001 174 Month 6 1.700 No 141013 722 Month 24 2.

 | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunorea
 | Treatment Group Positive
Innunoreactivity Innunoreactivity Innunorea

 | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunorea
 | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunorea
 | Tratment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immention
Diagnosis Tratment Group Subject ID Assy Assy Information Subject ID 365 Month 12 2.770 No 177006 355 Month 12 2.770 No 177006 355 Month 12 1.870 Irritis 177006 355 Month 24 1.870 Irritis 177006 355 Month 24 1.870 No 177005 722 Month 24 1.130 No 106002 722 Month 24 1.130 No 120001 174 Month 6 1.700 No 120001 722 Month 12 1.630 No 124003 722 Month 24 1.700 No
126001 174 Month 6 1.700 No 126001 174 Month 6 1.700 No 126001 174 Month 6 1.700 No 136001 174 Month 6 1.700 No 141013 722 Month 24 2.
 | Tratment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immention
Diagnosis Tratment Group Subject ID Assy Assy Information Subject ID 365 Month 12 2.770 No 177006 355 Month 12 2.770 No 177006 355 Month 12 1.870 Irritis 177006 355 Month 24 1.870 Irritis 177006 355 Month 24 1.870 No 177005 722 Month 24 1.130 No 106002 722 Month 24 1.130 No 120001 174 Month 6 1.700 No 120001 722 Month 12 1.630 No 124003 722 Month 24 1.700 No 126001 174 Month 6 1.700 No 126001 174 Month 6 1.700 No 126001 174 Month 6 1.700 No 136001 174 Month 6 1.700 No 141013 722 Month 24 2.
 | Tratment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immention
Diagnosis Tratment Group Subject ID Assy Assy Information Subject ID 365 Month 12 2.770 No 177006 355 Month 12 2.770 No 177006 355 Month 12 1.870 Irritis 177006 355 Month 24 1.870 Irritis 177006 355 Month 24 1.870 No 177005 722 Month 24 1.130 No 106002 722 Month 24 1.130 No 120001 174 Month 6 1.700 No 120001 722 Month 12 1.630 No 124003 722 Month 24 1.700 No 126001 174 Month 6 1.700 No 126001 174 Month 6 1.700 No 126001 174 Month 6 1.700 No 136001 174 Month 6 1.700 No 141013 722 Month 24 2.
 | Treatment Group Bositive
Immunoreactivity Immunoreactivity Immunorea
 | Treatment Group Positive
Immunoractivity Intractuation
Intractivity Intractuation
Intractivity Intractuation
Intractivity Areatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 355/Month 24 2.770 No No 177006 358/Month 24 1.870 Irritis 177006 358/Month 24 1.870 No 177006 358/Month 24 1.140 No 106002 722/Month 24 1.130 No 106002 723/Month 24 1.170 No 122002 335/Month 24 1.770 No 124003 723/Month 24 1.770 No <t< td=""><td>Treatment Group Positive
Inframoreactivity Intranciation
Inframoreactivity Intranciation
Inframoreactivity Intranciation
Inframoreactivity Intranciation
Inframoreactivity Intranciation Rainbizumab 0.5 mg 170010 365 / Month 12 2770 No No 177006 338 / Month 12 1870 Irritis No 177006 338 / Month 24 1.870 Irritis No 177006 338 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 1122002 359 / Month 24 1.170 No No 124003 722 / Month 24 1.170 No No 124003 723 / Month 12 1.630 No No 124003 357 / Month 24 1.770 No No 124003 723 / Month 24 1.770 No No 124003 723 / Month 24 1.770 No No 124003 723 / Month 24 1.940 No No <td< td=""><td>Treatment Group Positive
Inframination Intrancediar Intransition Areatment Group Subject ID Assay Log Titer Diagnosis 170010 365 / Month 12 Xssay Log Titer Diagnosis 170010 365 / Month 12 Xssay Log Titer Diagnosis 170010 365 / Month 12 1870 Irritis 177006 338 / Month 24 1.870 Irritis 177006 338 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 106002 722 / Month 24 1.170 No 1122002 359 / Month 24 1.1710 No 124003 723 / Month 24 1.1700 No 124003 723 / Month 24 1.770 No 124003 357 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 724 / Mon</td><td>Treatment Group Positive
Infamuation Protect ID Amnunoreactivity
Infammation Inframation Treatment Group Subject ID 365 / Month 12 23770 No 170010 365 / Month 12 2800 No 177006 358 / Month 12 1.870 Irrits 177006 358 / Month 12 1.870 Irrits 177006 358 / Month 24 1.870 Irrits 1777 / Month 24 1.870 Irrits 106002 722 / Month 24 1.140 No 122002 359 / Month 12 1.130 No 122002 359 / Month 24 1.170 No 124003 722 / Month 24 1.170 No 124003 357 / Month 24 1.770 No 124003 357 / Month 24 1.770 No 124003 357 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 12400 1.171</td></td<></td></t<> <td>Treatment Group Fositive
Innunorescrivity Innunorescrivity Innunition
Innunition Subject ID Subject ID Assy Log Titer No 170010 365 / Month 12 25800 No 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 24 1.870 Iritis 104002 717 / Month 24 1.870 Iritis 1122002 359 / Month 12 1.870 No 122002 722 / Month 24 1.140 No 122002 723 / Month 24 1.170 No 124003 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.900 No 124003 722 / Month 24 1.900 No 124003 722 / Month 24 1.900 No 12400 1.174 / Month 6 <td< td=""></td<></td> | Treatment Group Positive
Inframoreactivity Intranciation
Inframoreactivity Intranciation
Inframoreactivity Intranciation
Inframoreactivity Intranciation
Inframoreactivity Intranciation Rainbizumab 0.5 mg 170010 365 / Month 12 2770 No No 177006 338 / Month 12 1870 Irritis No 177006 338 / Month 24 1.870 Irritis No 177006 338 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 1122002 359 / Month 24 1.170 No No 124003 722 / Month 24 1.170 No No 124003 723 / Month 12 1.630 No No 124003 357 / Month 24 1.770 No No 124003 723 / Month 24 1.770 No No 124003 723 / Month 24 1.770 No No 124003 723 / Month 24 1.940 No No <td< td=""><td>Treatment Group Positive
Inframination Intrancediar Intransition Areatment Group Subject ID Assay Log Titer Diagnosis 170010 365 / Month 12 Xssay Log Titer Diagnosis
 170010 365 / Month 12 Xssay Log Titer Diagnosis 170010 365 / Month 12 1870 Irritis 177006 338 / Month 24 1.870 Irritis 177006 338 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 106002 722 / Month 24 1.170 No 1122002 359 / Month 24 1.1710 No 124003 723 / Month 24 1.1700 No 124003 723 / Month 24 1.770 No 124003 357 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 724 / Mon</td><td>Treatment Group Positive
Infamuation Protect ID Amnunoreactivity
Infammation Inframation Treatment Group Subject ID 365 / Month 12 23770 No 170010 365 / Month 12 2800 No 177006 358 / Month 12 1.870 Irrits 177006 358 / Month 12 1.870 Irrits 177006 358 / Month 24 1.870 Irrits 1777 / Month 24 1.870 Irrits 106002 722 / Month 24 1.140 No 122002 359 / Month 12 1.130 No 122002 359 / Month 24 1.170 No 124003 722 / Month 24 1.170 No 124003 357 / Month 24 1.770 No 124003 357 / Month 24 1.770 No 124003 357 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 12400 1.171</td></td<> | Treatment Group Positive
Inframination Intrancediar Intransition Areatment Group Subject ID Assay Log Titer Diagnosis 170010 365 / Month 12 Xssay Log Titer Diagnosis 170010 365 / Month 12 Xssay Log Titer Diagnosis 170010 365 / Month 12 1870 Irritis 177006 338 / Month 24 1.870 Irritis 177006 338 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 106002 722 / Month 24 1.170 No 1122002 359 / Month 24 1.1710 No 124003 723 / Month 24 1.1700 No 124003 723 / Month 24 1.770 No 124003 357 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 724 / Mon | Treatment Group Positive
Infamuation Protect ID Amnunoreactivity
Infammation Inframation Treatment Group Subject ID 365 / Month 12 23770 No 170010 365 / Month 12 2800 No 177006 358 / Month 12 1.870 Irrits 177006 358 / Month 12 1.870 Irrits 177006 358 / Month 24 1.870 Irrits 1777 / Month 24 1.870 Irrits 106002 722 / Month 24 1.140 No 122002 359 / Month 12 1.130 No 122002 359 / Month 24 1.170 No 124003 722 / Month 24 1.170 No 124003 357 / Month 24 1.770 No 124003 357 / Month 24 1.770 No 124003 357 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 12400 1.171
 | Treatment Group Fositive
Innunorescrivity Innunorescrivity Innunition
Innunition Subject ID Subject ID Assy Log Titer No 170010 365 / Month 12 25800 No 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 24 1.870 Iritis 104002 717 / Month 24 1.870 Iritis 1122002 359 / Month 12 1.870 No 122002 722 / Month 24 1.140 No 122002 723 / Month 24 1.170 No 124003 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.900 No 124003 722 / Month 24 1.900 No 124003 722 / Month 24 1.900 No 12400 1.174 / Month 6 <td< td=""></td<> |
| 365 / Month 12 1.530 1.530 $718 / Month 24$ 2.070 No 159017 $716 / Month 24$ 0.780 No 167002 $717 / Mont 24$ 1.230 No 188005 $717 / Month 24$ 1.230 No 188005 $717 / Month 24$ 1.230 No 1.230 No No No 1.250 No No No 1.250 No No No 1.250 No No No

 | 365 / Month 12 1.530 1.530 $718 / Month 24$ 2.070 No 159017 $716 / Month 24$ 0.780 No 167002 $717 / Mont 24$ 1.230 No 188005 $717 / Month 24$ 1.230 No 188005 $717 / Month 24$ 1.230 No 1.230 No No No 1.250 No No No 1.250 No No No

 | 365 / Month 12 1.530 1.530 718 / Month 24 2.070 No 159017 716 / Month 24 0.780 No 167002 717 / Month 24 1.230 No 188005 717 / Month 24 1.230 No 188005 717 / Month 24 1.250 No 188005 717 / Month 24 1.250 No 1001 $-7 / Screening$ 2.520 Vitritis

 | Treatment Group Positive
fimmunoractivity Intranciation
fimmunoractivity Intranciation
fimmunoractivity Intranciation Treatment Group Subject ID Assay Assay Assay Intranciation 170010 365 / Month 12 2.770 No No 177006 355 / Month 12 2.800 Intris No 177006 358 / Month 12 1.850 No No 177005 358 / Month 12 1.800 Intris No 177006 358 / Month 24 1.140 No No 122002 722 / Month 24 1.130 No No 124003 722 / Month 24 1.770 No No 126001 174 Month 6 1.770 No No 126001 174 Month 24 1.460 No No 126001 174 Month 24 1.770 No No 126001 174 Month 24 1.650 No No 126001 174 Month 6 1.770 No No

 | Treatment Group Evolution Framminic activity immunor activity intermediate intermed

 | Treatment Group Rubject ID Positive
Assay Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea

 | Treatment Group Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Immunoreactivity
Diagnosis Treatment Group Subject ID Assay Assay Assay Intraocutat 170010 365 / Mouth 12 2.700 No No 177006 355 / Mouth 24 1.870 Iritis 177006 358 / Mouth 24 1.870 Iritis 177006 358 / Mouth 24 1.140 No 177001 722 / Mouth 24 1.140 No 122002 359 / Mouth 24 1.140 No 124003 722 / Mouth 24 1.770 No 12400 17000 No No

 | Treatment Group Subject ID Assay Log Intrancentativity Intrancentation Treatment Group Subject ID Assay Assay Intrancentation Intrancentation Intransition 365 / Month 12 2.770 No Intrancentation Intransition 365 / Month 12 1.7700 $365 / Month 12$ 1.870 Intrancentation Intransition $355 / Month 12$ 1.870 Intrins No Intransition $715 / Month 24$ 1.870 Intrins No Intransition $722 / Month 24$ 1.140 No No Intransition $722 / Month 24$ 1.130 No No Intransition $722 / Month 24$ 1.700 No No Intransition $352 / Month 24$ 1.570 <

 | Treatment Group Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Immunoreactivity
Diagnosis Treatment Group Subject ID Assay Assay Assay Intraocutat 170010 365 / Mouth 12 2.700 No No 177006 355 / Mouth 24 1.870 Iritis 177006 358 / Mouth 24 1.870 Iritis 177006 358 / Mouth 24 1.140 No 177001 722 / Mouth 24 1.140 No 122002 359 / Mouth 24 1.140 No 124003 722 / Mouth 24 1.770 No 12400 17000 No No
 | Treatment Group Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Immunoreactivity
Diagnosis Treatment Group Subject ID Assay Assay Assay Intraocutat 170010 365 / Mouth 12 2.700 No No 177006 355 / Mouth 24 1.870 Iritis 177006 358 / Mouth 24 1.870 Iritis 177006 358 / Mouth 24 1.140 No 177001 722 / Mouth 24 1.140 No 122002 359 / Mouth 24 1.140 No 124003 722 / Mouth 24 1.770 No 12400 17000 No No

 | Treatment Group Rubject ID Positive
Assay Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea
 | Treatment Group Rubject ID Positive
Assay Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea
 | Treatment Group Rubject ID Positive
Assay Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea
 | Treatment Group Positive
fimmunoractivity Intranciation
fimmunoractivity Intranciation
fimmunoractivity Intranciation Treatment Group Subject ID Assay Assay Assay Intranciation 170010 365 / Month 12 2.770 No No 177006 355 / Month 12 2.800 Intris No 177006 358 / Month 12 1.850 No No 177005 358 / Month 12 1.800 Intris No 177006 358 / Month 24 1.140 No No 122002 722 / Month 24 1.130 No No 124003 722 / Month 24 1.770 No No 126001 174 Month 6 1.770 No No 126001 174 Month 24 1.460 No No 126001 174 Month 24 1.770 No No 126001 174 Month 24 1.650 No No 126001 174 Month 6 1.770 No No
 | Treatment Group Positive
Immunoractivity Intrancial
Intransition Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 355 / Month 12 2.800 Iritis No No 177006 358 / Month 24 1.870 Iritis No No 177005 358 / Month 12 1.870 No No No 177005 358 / Month 12 1.130 No No No 122002 722 / Month 24 1.140 No No No 122002 722 / Month 24 1.130 No No No 124003 722 / Month 24 1.770 No No No 124003 357 / Month 24 1.640 No No No 124003 722 / Month 24 1.640 No No No 124003 722 / Month 24 1.640 No No No | Treatment Group Positive
Immunoreactivity Intranciation
Intransition Treatment Group Subject ID Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No 177006 358 / Month 24 1.870 Irritis 177006 358 / Month 24 1.870 Irritis 177005 358 / Month 24 1.870 Irritis 177006 358 / Month 24 1.870 No 177005 358 / Month 24 1.140 No 122002 722 / Month 24 1.130 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 357 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 357 / Month 24 1.770 No 124003 357 / Month 24 1.770 No 124003 357 / Month 24 1.770 No 12400 357 / Month 24 1.770 <td< td=""><td>Treatment Group Rolitive
Inframmation Positive
Inframmation Intraocular
Assay Log Titer Intraocular
Inframmation
 Treatment Group Subject ID 365 / Month 12 23770 Nio 170010 365 / Month 12 2300 Intraocular Diagnosis 177006 338 / Month 24 1870 Intris 177005 338 / Month 24 1360 Nio 177 / Month 24 1130 Nio Nio 106002 722 / Month 24 1140 Nio 122002 339 / Month 24 1.770 Nio 124003 722 / Month 24 1.770 Nio 124003 722 / Month 24 1.770 Nio 124003 357 / Month 24 1.770 Nio 124003 722 / Month 24 1.770 Nio 124003 357 / Month 24 1.770 Nio 124003 722 / Month 24 1.770 Nio 124003 722 / Month 24 1.770 Nio 12400 1700 Nio Nio</td></td<> <td>Treatment Group Rositive Innumoreactivity Innumoreactivity Innumition Treatment Group Subject ID Assay Log Titer Diagnosis Jiagnosis 170010 365 / Month 12 Xssy Log Titer Diagnosis Jiagnosis 170010 365 / Month 12 1870 Irritis No 177006 338 / Month 24 1870 Irritis 177005 338 / Month 24 1140 No 105002 722 / Month 24 1130 No 122002 339 / Month 24 1130 No 124003 722 / Month 24 11700 No 124003 722 / Month 24 11700 No 124003 722 / Month 24 17700 No 124003 722 / Month 24 1770 No 124003 722 / Month 24 17700 No 124003 722 / Month 24 1770 No 124003 722 / Month 24 1770 No 12400 722 / Month 24 10700 No<td>Treatment Group Foilive Intransectivity Intransion Treatment Group Subject ID Assy Log Titer Diagnosis 170010 365 / Month 12 Assy Log Titer Diagnosis 170010 365 / Month 12 Assy Log Titer Diagnosis 177006 338 / Month 12 1.870 Intrimmation 177006 338 / Month 24 1.870 Intris 177006 338 / Month 24 1.870 Intris 177006 338 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 335 / Month 12 1.650 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 357 / Month 24 1.770 No 124003 357 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 357 / Month 24 1.770 No 12400 1.1400 <</td></td> | Treatment Group Rolitive
Inframmation Positive
Inframmation Intraocular
Assay Log Titer Intraocular
Inframmation Treatment Group Subject ID 365 / Month 12 23770 Nio 170010 365 / Month 12 2300 Intraocular Diagnosis 177006 338 / Month 24 1870 Intris 177005 338 / Month 24 1360 Nio 177 / Month 24 1130 Nio Nio 106002 722 / Month 24 1140 Nio 122002 339 / Month 24 1.770 Nio 124003 722 / Month 24 1.770 Nio 124003 722 / Month 24 1.770 Nio 124003 357 / Month 24 1.770 Nio 124003 722 / Month 24 1.770 Nio 124003 357 / Month 24 1.770 Nio 124003 722 / Month 24 1.770 Nio 124003 722 / Month 24 1.770 Nio 12400 1700 Nio Nio | Treatment Group Rositive Innumoreactivity Innumoreactivity Innumition Treatment Group Subject ID Assay Log Titer Diagnosis Jiagnosis 170010 365 / Month 12 Xssy Log Titer Diagnosis Jiagnosis 170010 365 / Month 12 1870 Irritis No 177006 338 / Month 24 1870 Irritis 177005 338 / Month 24 1140 No 105002 722 / Month 24 1130 No 122002 339 / Month 24 1130 No 124003 722 / Month 24 11700 No 124003 722 / Month 24 11700 No 124003 722 / Month 24 17700 No 124003 722 / Month 24 1770 No 124003 722 / Month 24 17700 No 124003 722 / Month 24 1770 No 124003 722 / Month 24 1770 No 12400 722 / Month 24 10700 No <td>Treatment Group Foilive Intransectivity Intransion Treatment Group Subject ID Assy Log Titer Diagnosis 170010 365 / Month 12 Assy Log Titer Diagnosis 170010 365 / Month 12 Assy Log Titer Diagnosis 177006 338 / Month 12 1.870 Intrimmation 177006 338 / Month 24 1.870 Intris 177006 338 / Month 24
 1.870 Intris 177006 338 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 335 / Month 12 1.650 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 357 / Month 24 1.770 No 124003 357 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 357 / Month 24 1.770 No 12400 1.1400 <</td> | Treatment Group Foilive Intransectivity Intransion Treatment Group Subject ID Assy Log Titer Diagnosis 170010 365 / Month 12 Assy Log Titer Diagnosis 170010 365 / Month 12 Assy Log Titer Diagnosis 177006 338 / Month 12 1.870 Intrimmation 177006 338 / Month 24 1.870 Intris 177006 338 / Month 24 1.870 Intris 177006 338 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 335 / Month 12 1.650 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 357 / Month 24 1.770 No 124003 357 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 357 / Month 24 1.770 No 12400 1.1400 < |
| 365 / Month 12 1.530 365 / Month 12 1.530 159017 716 / Month 24 2.070 167002 717 / Mont 24 0.780 188005 717 / Month 24 1.230 188005 717 / Month 24 1.250 188005 717 / Month 24 1.250 1001 -7 / Screening 2.520 1001 -7 / Screening 2.520

 | 365 / Month 12 1.530 718 / Month 24 2.070 159017 716 / Month 24 167002 717 / Mont 24 167002 717 / Month 24 188005 717 / Month 24 117 / Month 24 1.230 1000 No 117 / Month 24 1.250 1000 No 117 / Month 24 1.250 1000 717 / Month 24

 | 365 / Month 12 1.530 No 718 / Month 24 2.070 No 159017 716 / Month 24 0.780 No 167002 717 / Month 24 0.780 No No 188005 717 / Month 24 1.230 No No Sham 534001 -7 / Screening 2.520 Vintitis

 | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunorea

 | Treatment Group Bositive
Immunoreactivity Immunoreactivity
Immunoreactivity Immenoreactivity
Immunoreactivity Immenoreactivity
Immunoreactivity Immenoreactivity
Immenoreactivity Immenoreactivity Immenorea

 | Tratment Group Exolite Positive Intrancentiat Tratment Group Subject ID Assay Log Intrancentiat Tratment Group Subject ID Assay Log Timunoreactivity Intrancentiat 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intracentiat No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 24 1.130 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.700 No No 124003 722
/ Month 24 1.700 No No 124001 174 / Month 6 1.770 No No 124003 722 / Month 24 1.9480 No No
 | Tratment.Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunor Immunoreactivity Immunoreactivity <td>Tratment Group Positive
Immunoreactivity
Immunoreactivity Immunoreac</td> <td>Tratment.Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunor Immunoreactivity Immunoreactivity<td>Tratment.Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunor Immunoreactivity Immunoreactivity<td>Tratment Group Exolite Positive Intrancentiat Tratment Group Subject ID Assay Log Intrancentiat Tratment Group Subject ID Assay Log Timunoreactivity Intrancentiat 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intracentiat No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 24 1.130 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.700 No No 124003 722 / Month 24 1.700 No No 124001 174 / Month 6 1.770 No No 124003 722 / Month 24 1.9480 No No</td><td>Tratment Group Exolite Positive Intrancentiat Tratment Group Subject ID Assay Log Intrancentiat Tratment Group Subject ID Assay Log Timunoreactivity Intrancentiat 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intracentiat No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 24 1.130 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.700 No No 124003 722 / Month 24 1.700 No No 124001 174 / Month 6 1.770 No No 124003 722 / Month 24 1.9480 No No</td><td>Tratment Group Exolite Positive Intrancentiat Tratment Group Subject ID Assay Log Intrancentiat Tratment Group Subject ID Assay Log Timunoreactivity Intrancentiat 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intracentiat No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 24 1.130 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.700 No No 124003 722 / Month 24 1.700 No No 124001 174 / Month 6 1.770 No No 124003 722 / Month 24 1.9480 No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunorea</td><td>Treatment Group Positive
Immunoreactivity Intrancitien
Infimmention Arsay Litent Group Subject ID Assay Litent Group Intrancitien 170010 365 / Month 12 2.770 No No 177006 355 / Month 24 1.870 Litits No 177006 358 / Month 24 1.870 Litits No 177006 358 / Month 24 0.922 No No 177006 358 / Month 24 1.140 No No 122002 717 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 124003 722 / Month 24 1.1700 No No 124003 722 / Month 24 1.700 No No 141013 722 / Month 2</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td><td>Treatment Group Subject ID Positive
Immunoreactivity Intracondiat
Immunoreactivity Intracondiation Ranthizumab 0.5 mg 105001 171/Month 24 1300 No No No No No Immunoreac</td><td>Treatment Group Rubject ID Positive
Innunoreactivity Innunoreactivity Innunoreactivit</td><td>Treatment Group Evolutive
Inframonation Prostitive
Inframonation Inframonation Areatment Group Subject ID xsrv log Tier Diagnosis 170010 365 / Month 12 2srv log Tier Diagnosis 170010 365 / Month 12 18700 Inframonation 177006 338 / Month 12 18700 Inframonation 177005 338 / Month 12 18700 Inframonation 177006 338 / Month 12 18700 Inframonation 177005 338 / Month 12 18700 Inframonation 177006 338 / Month 24 11400 No 122002 359 / Month 12 16500 No 122003 712 / Month 24 17700 No 124003 722 / Month 24 17700 No 124003 714 / Month 24 17000 No <</td></td></td> | Tratment Group Positive
Immunoreactivity Immunoreactivity Immunoreac

 | Tratment.Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunor Immunoreactivity Immunoreactivity <td>Tratment.Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunor Immunoreactivity Immunoreactivity<td>Tratment Group Exolite Positive Intrancentiat Tratment Group Subject ID Assay Log Intrancentiat Tratment Group Subject ID Assay Log Timunoreactivity Intrancentiat 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intracentiat No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 24 1.130 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.700 No No 124003 722 / Month 24 1.700 No No 124001 174 / Month 6 1.770 No No 124003 722 / Month 24 1.9480 No No</td><td>Tratment Group Exolite Positive Intrancentiat Tratment Group Subject ID Assay Log Intrancentiat Tratment Group Subject ID Assay Log Timunoreactivity Intrancentiat 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intracentiat No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 24 1.130 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.700 No No 124003 722 / Month 24 1.700 No No 124001 174 / Month 6 1.770 No No 124003 722 / Month 24 1.9480 No No</td><td>Tratment Group Exolite Positive Intrancentiat Tratment Group Subject ID Assay Log Intrancentiat Tratment Group Subject ID Assay Log Timunoreactivity Intrancentiat 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intracentiat No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 24 1.130 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.700 No No 124003 722 / Month 24 1.700 No No 124001 174 / Month 6 1.770 No No 124003 722 / Month 24 1.9480 No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunorea</td><td>Treatment Group Positive
Immunoreactivity Intrancitien
Infimmention Arsay Litent Group Subject ID Assay Litent Group Intrancitien 170010 365 / Month 12 2.770 No No 177006 355 / Month 24 1.870 Litits No 177006 358 / Month 24 1.870 Litits No 177006 358 / Month 24 0.922 No No 177006 358 / Month 24 1.140 No No 122002 717 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 124003 722 / Month 24 1.1700 No No 124003 722 / Month 24 1.700 No No 141013 722 / Month 2</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td><td>Treatment Group Subject ID Positive
Immunoreactivity Intracondiat
Immunoreactivity Intracondiation Ranthizumab 0.5 mg 105001 171/Month 24 1300 No No No No No Immunoreac</td><td>Treatment Group Rubject ID Positive
Innunoreactivity Innunoreactivity Innunoreactivit</td><td>Treatment Group Evolutive
Inframonation Prostitive
Inframonation Inframonation Areatment Group Subject ID xsrv log Tier Diagnosis 170010 365 / Month 12 2srv log Tier Diagnosis 170010 365 / Month 12 18700 Inframonation 177006 338 / Month 12 18700 Inframonation 177005 338 / Month 12 18700 Inframonation 177006 338 / Month 12 18700 Inframonation 177005 338 / Month 12 18700 Inframonation 177006 338 / Month 24 11400 No 122002 359 / Month 12 16500 No 122003 712 / Month 24 17700 No 124003 722 / Month 24 17700 No 124003 714 / Month 24 17000 No <</td></td> | Tratment.Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunor Immunoreactivity Immunoreactivity <td>Tratment Group Exolite Positive Intrancentiat Tratment Group Subject ID Assay Log Intrancentiat Tratment Group Subject ID Assay Log Timunoreactivity Intrancentiat 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intracentiat No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 24 1.130 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.700 No No 124003 722 / Month 24 1.700 No No 124001 174 / Month 6 1.770 No No 124003 722 / Month 24 1.9480 No No</td> <td>Tratment Group Exolite Positive Intrancentiat Tratment Group Subject ID Assay Log Intrancentiat Tratment Group Subject ID Assay Log Timunoreactivity Intrancentiat 170010 365 / Month 12 2.770 No No No 177006
 358 / Month 12 1.870 Intracentiat No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 24 1.130 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.700 No No 124003 722 / Month 24 1.700 No No 124001 174 / Month 6 1.770 No No 124003 722 / Month 24 1.9480 No No</td> <td>Tratment Group Exolite Positive Intrancentiat Tratment Group Subject ID Assay Log Intrancentiat Tratment Group Subject ID Assay Log Timunoreactivity Intrancentiat 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intracentiat No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 24 1.130 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.700 No No 124003 722 / Month 24 1.700 No No 124001 174 / Month 6 1.770 No No 124003 722 / Month 24 1.9480 No No</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunorea</td> <td>Treatment Group Positive
Immunoreactivity Intrancitien
Infimmention Arsay Litent Group Subject ID Assay Litent Group Intrancitien 170010 365 / Month 12 2.770 No No 177006 355 / Month 24 1.870 Litits No 177006 358 / Month 24 1.870 Litits No 177006 358 / Month 24 0.922 No No 177006 358 / Month 24 1.140 No No 122002 717 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 124003 722 / Month 24 1.1700 No No 124003 722 / Month 24 1.700 No No 141013 722 / Month 2</td> <td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td> <td>Treatment Group Subject ID Positive
Immunoreactivity Intracondiat
Immunoreactivity Intracondiation Ranthizumab 0.5 mg 105001 171/Month 24 1300 No No No No No Immunoreac</td> <td>Treatment Group Rubject ID Positive
Innunoreactivity Innunoreactivity Innunoreactivit</td> <td>Treatment Group Evolutive
Inframonation Prostitive
Inframonation Inframonation Areatment Group Subject ID xsrv log Tier Diagnosis 170010 365 / Month 12 2srv log Tier Diagnosis 170010 365 / Month 12 18700 Inframonation 177006 338 / Month 12 18700 Inframonation 177005 338 / Month 12 18700 Inframonation 177006 338 / Month 12 18700 Inframonation 177005 338 / Month 12 18700 Inframonation 177006 338 / Month 24 11400 No 122002 359 / Month 12 16500 No 122003 712 / Month 24 17700 No 124003 722 / Month 24 17700 No 124003 714 / Month 24 17000 No <</td> | Tratment Group Exolite Positive Intrancentiat Tratment Group Subject ID Assay Log Intrancentiat Tratment Group Subject ID Assay Log Timunoreactivity Intrancentiat 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intracentiat No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 24 1.130 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.700 No No 124003 722 / Month 24 1.700 No No 124001 174 / Month 6 1.770 No No 124003 722 / Month 24 1.9480 No No
 | Tratment Group Exolite Positive Intrancentiat Tratment Group Subject ID Assay Log Intrancentiat Tratment Group Subject ID Assay Log Timunoreactivity Intrancentiat 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intracentiat No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 24 1.130 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.700 No No 124003 722 / Month 24 1.700 No No 124001 174 / Month 6 1.770 No No 124003 722 / Month 24 1.9480 No No

 | Tratment Group Exolite Positive Intrancentiat Tratment Group Subject ID Assay Log Intrancentiat Tratment Group Subject ID Assay Log Timunoreactivity Intrancentiat 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intracentiat No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 24 1.130 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.700 No No 124003 722 / Month 24 1.700 No No 124001 174 / Month 6 1.770 No No 124003 722 / Month 24 1.9480 No No
 | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunorea | Treatment Group Positive
Immunoreactivity Intrancitien
Infimmention Arsay Litent Group Subject ID Assay Litent Group Intrancitien 170010 365 / Month 12 2.770 No No 177006 355 / Month 24 1.870 Litits No 177006 358 / Month 24 1.870 Litits No 177006 358 / Month 24 0.922 No No 177006 358 / Month 24 1.140 No No 122002 717 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 124003 722 / Month 24 1.1700 No No 124003 722 / Month 24 1.700 No No 141013 722 / Month 2
 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit | Treatment Group Subject ID Positive
Immunoreactivity Intracondiat
Immunoreactivity Intracondiation Ranthizumab 0.5 mg 105001 171/Month 24 1300 No No No No No Immunoreac
 | Treatment Group Rubject ID Positive
Innunoreactivity Innunoreactivity Innunoreactivit | Treatment Group Evolutive
Inframonation Prostitive
Inframonation Inframonation Areatment Group Subject ID xsrv log Tier Diagnosis 170010 365 / Month 12 2srv log Tier Diagnosis 170010 365 / Month 12 18700 Inframonation 177006 338 / Month 12 18700 Inframonation 177005 338 / Month 12 18700 Inframonation 177006 338 / Month 12 18700 Inframonation 177005 338 / Month 12 18700 Inframonation 177006 338 / Month 24 11400 No 122002 359 / Month 12 16500 No 122003 712 / Month 24 17700 No 124003 722 / Month 24 17700 No 124003 714 / Month 24 17000 No < |
| I53006 183 / Month 6 1.900 No $365 / Month 12$ 1.530 No $365 / Month 12$ 1.530 No 159017 $716 / Month 24$ 2.070 No 167002 $717 / Mont 24$ 0.780 No 167002 $717 / Mont 24$ 1.230 No 188005 $717 / Month 24$ 1.230 No 88005 $717 / Month 24$ 1.250 No 88005 $717 / Month 24$ 1.250 No 7.520 No No

 | I53006 183/Month 6 1.900 No $365/Month 12$ 1.530 No $365/Month 24$ 0.780^{10} No 159017 $716/Month 24$ 0.780^{10} No 167002 $717/Mont 24$ 1.230^{10} No 188005 $717/Month 24$ 1.230^{10} No 88005 $717/Month 24$ 1.250^{10} No 88005 $717/Month 24$ 1.250^{10} No 7.520^{10} No 1.250^{10} No

 | I33006 183/Month 6 1.900 No $365/Month 12$ 1.530 No $365/Month 24$ 2.070 No 159017 $716/Month 24$ 0.780 No 167002 $717/Month 24$ 0.780 No 188005 $717/Month 24$ 1.230 No 188005 $717/Month 24$ 1.250 No 834001 $-7/Screening$ 2.520 Vitritis

 | Treatment Group Subject ID Positive
firminioreactivity Immunoreactivity Immunoreactiv

 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit

 | Treatment Group Subject ID Positive
Asiay Immunoreactivity
Asiay Log Titer Immunoreactivity
Diagnosis Treatment Group Subject ID 365 Month 12 2.770 No 177006 358 Month 12 2.870 Infammation Ranibizumab 0.5 mg 177006 358 Month 12 1.870 Infitis 177006 358 Month 12 1.870 Infitis No 177006 358 Month 12 1.870 Infitis 107001 722 Month 24 1.140 No 106002 722 Month 24 1.140 No 122002 339 Month 12 1.630 No 122002 335 Month 24 1.770 No 122003 722 Month 24 1.700 No 124003 722 Month 24 1.770 No 124003 722 Month 24 1.700 No 124003 722 Month 24 1.770
 No 124003 722 Month 24 1.770 No 141013 725 Month 24 1.770 <td< td=""><td>Treatment Group Subject ID Fositive
Asiay Immunoreactivity
Assay Log Titer Immunoreactivity
Diagnosis Treatment Group Subject ID 365 Month 12 2.770 No 177006 358 Month 12 2.800 Infinimistion 717 Month 24 1.870 Intitis 177006 735 Month 12 1.870 Intitis 177006 717 Month 24 1.870 No 102001 722 Month 24 1.140 No 106002 722 Month 24 1.140 No 122002 339 Month 12 1.630 No 122002 339 Month 12 1.630 No 122002 339 Month 12 1.630 No 122003 722 Month 24 1.140 No 126001 174 Month 6 1.770 No 124003 722 Month 12 2.040 No 124003 722 Month 24 1.770 No 124003 722 Month 24 1.770 No 141013 725 Month 24</td><td>Treatment Group Subject ID Assay Positive
Immunoreactivity Immunoreactivity Immunoreactivity</td><td>Treatment Group Subject ID Fositive
Asiay Immunoreactivity
Assay Log Titer Immunoreactivity
Diagnosis Treatment Group Subject ID 365 Month 12 2.770 No 177006 358 Month 12 2.800 Infinimistion 717 Month 24 1.870 Intitis 177006 735 Month 12 1.870 Intitis 177006 717 Month 24 1.870 No 102001 722 Month 24 1.140 No 106002 722 Month 24 1.140 No 122002 339 Month 12 1.630 No 122002 339 Month 12 1.630 No 122002 339 Month 12 1.630 No 122003 722 Month 24 1.140 No 126001 174 Month 6 1.770 No 124003 722 Month 12 2.040 No 124003 722 Month 24 1.770 No 124003 722 Month 24 1.770 No 141013 725 Month 24</td><td>Treatment Group Subject ID Fositive
Asiay Immunoreactivity
Assay Log Titer Immunoreactivity
Diagnosis Treatment Group Subject ID 365 Month 12 2.770 No 177006 358 Month 12 2.800 Infinimistion 717 Month 24 1.870 Intitis 177006 735 Month 12 1.870 Intitis 177006 717 Month 24 1.870 No 102001 722 Month 24 1.140 No 106002 722 Month 24 1.140 No 122002 339 Month 12 1.630 No 122002 339 Month 12 1.630 No 122002 339 Month 12 1.630 No 122003 722 Month 24 1.140 No 126001 174 Month 6 1.770 No 124003 722 Month 12 2.040 No 124003 722 Month 24 1.770 No 124003 722 Month 24 1.770 No 141013 725 Month 24</td><td>Treatment Group Subject ID Positive
Asiay Immunoreactivity
Asiay Log Titer Immunoreactivity
Diagnosis Treatment Group Subject ID 365 Month 12 2.770 No 177006 358 Month 12 2.870 Infammation Ranibizumab 0.5 mg 177006 358 Month 12 1.870 Infitis 177006 358 Month 12 1.870 Infitis No 177006 358 Month 12 1.870 Infitis 107001 722 Month 24 1.140 No 106002 722 Month 24 1.140 No 122002 339 Month 12 1.630 No 122002 335 Month 24 1.770 No 122003 722 Month 24 1.700 No 124003 722 Month 24 1.770 No 124003 722 Month 24 1.700 No 124003 722 Month 24 1.770 No 124003 722 Month 24 1.770 No 141013 725 Month 24 1.770 <td< td=""><td>Treatment Group Subject ID Positive
Asiay Immunoreactivity
Asiay Log Titer Immunoreactivity
Diagnosis Treatment Group Subject ID 365 Month 12 2.770 No 177006 358 Month 12 2.870 Infammation Ranibizumab 0.5 mg 177006 358 Month 12 1.870 Infitis 177006 358 Month 12 1.870 Infitis No 177006 358 Month 12 1.870 Infitis 107001 722 Month 24 1.140 No 106002 722 Month 24 1.140 No 122002 339 Month 12 1.630 No 122002 335 Month 24 1.770 No 122003 722 Month 24 1.700 No 124003 722 Month 24 1.770 No 124003 722 Month 24 1.700 No 124003 722 Month 24 1.770 No 124003 722 Month 24 1.770 No 141013 725 Month 24 1.770 <td< td=""><td>Treatment Group Subject ID Positive
Asiay Immunoreactivity
Asiay Log Titer Immunoreactivity
Diagnosis Treatment Group Subject ID 365 Month 12 2.770 No 177006 358 Month 12 2.870 Infammation Ranibizumab 0.5 mg 177006 358 Month 12 1.870 Infitis 177006 358 Month 12 1.870 Infitis No 177006 358 Month 12 1.870 Infitis 107001 722 Month 24 1.140 No 106002 722 Month 24 1.140 No 122002 339 Month 12 1.630 No 122002 335 Month 24 1.770 No 122003 722 Month 24 1.700 No 124003 722 Month 24 1.770 No 124003 722 Month 24 1.700 No 124003 722 Month 24 1.770 No 124003 722 Month 24 1.770 No 141013 725 Month 24 1.770 <td< td=""><td>Treatment Group Subject ID Positive
firminioreactivity Immunoreactivity Immunoreactiv</td><td>Treatment Group Subject ID Positive
firminioreactivity Intrancentivity Intracentity Intrancentivity Intran</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Intracondiation Treatment Group Subject ID Assay Assay Assay Intracondiation 170010 365/Month 12 2.770 No No 177006 371/Month 24 1.870 Irtitis 177006 378/Month 12 1.870 Irtitis 177006 378/Month 24 1.140 No 177006 717/Month 24 1.300 No 122002 722/Month 24 1.130 No 122002 359/Month 12 1.630 No 124003 722/Month 24 1.130 No 124003 722/Month 24 1.1700 No 124003 722/Month 24 1.770 No</td><td>Treatment Group Bubject ID Positive
Assry Innumoreactivity
Innumoreactivity Intraoodilar
Infammition Treatment Group Subject ID Assry Assry Assry Assry Assry Intraoodilar 170010 365/Month 12 2.770 No No 177006 358/Month 24 1.870 Irritis 177006 358/Month 24 0.922 No 177006 359/Month 12 1.870 Irritis 104002 717/Month 24 0.922 No 122002 359/Month 12 1.300 No 122002 359/Month 12 1.630 No 124003 722/Month 24 1.170 No 124003 722/Month 24 1.770 No 124003 722/Month 24 1.770 No 124003 722/Month 24 1.700 No 124003 722/Month 24 1.700 No 124003 722/Month 24 1.700 No 124001 174/Month 24 1</td><td>Treatment Group Subject ID Positive
Inframoractivity Inframoractivity Inframoractivity
Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 24 1.870 Irritis 177006 358 / Month 24 1.870 Irritis 177006 358 / Month 24 1.870 Irritis 177005 358 / Month 24 1.140 No 104002 722 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 124003 722 / Month 24 1.170 No 124003 722 / Month 24 1.170 No 124003 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 141013</td></td<></td></td<></td></td<></td></td<> | Treatment Group Subject ID Fositive
Asiay Immunoreactivity
Assay Log Titer Immunoreactivity
Diagnosis Treatment Group Subject ID 365 Month 12 2.770 No 177006 358 Month 12 2.800 Infinimistion 717 Month 24 1.870 Intitis 177006 735 Month 12 1.870 Intitis 177006 717 Month 24 1.870 No 102001 722 Month 24 1.140 No 106002 722 Month 24 1.140 No 122002 339 Month 12 1.630 No 122002 339 Month 12 1.630 No 122002 339 Month 12 1.630 No 122003 722 Month 24 1.140 No 126001 174 Month 6 1.770 No 124003 722 Month 12 2.040 No 124003 722 Month 24 1.770 No 124003 722 Month 24 1.770 No 141013 725 Month 24

 | Treatment Group Subject ID Assay Positive
Immunoreactivity Immunoreactivity
 | Treatment Group Subject ID Fositive
Asiay Immunoreactivity
Assay Log Titer Immunoreactivity
Diagnosis Treatment Group Subject ID 365 Month 12 2.770 No 177006 358 Month 12 2.800 Infinimistion 717 Month 24 1.870 Intitis 177006 735 Month 12 1.870 Intitis 177006 717 Month 24 1.870 No 102001 722 Month 24 1.140 No 106002 722 Month 24 1.140 No 122002 339 Month 12 1.630 No 122002 339 Month 12 1.630 No 122002 339 Month 12 1.630 No 122003 722 Month 24 1.140 No 126001 174 Month 6 1.770 No 124003 722 Month 12 2.040 No 124003 722 Month 24 1.770 No 124003 722 Month 24 1.770 No 141013 725 Month 24

 | Treatment Group Subject ID Fositive
Asiay Immunoreactivity
Assay Log Titer Immunoreactivity
Diagnosis Treatment Group Subject ID 365 Month 12 2.770 No 177006 358 Month 12 2.800 Infinimistion 717 Month 24 1.870 Intitis 177006 735 Month 12 1.870 Intitis 177006 717 Month 24 1.870 No 102001 722 Month 24 1.140 No 106002 722 Month 24 1.140 No 122002 339 Month 12 1.630 No 122002 339 Month 12 1.630 No 122002 339 Month 12 1.630 No 122003 722 Month 24 1.140 No 126001 174 Month 6 1.770 No 124003 722 Month 12 2.040 No 124003 722 Month 24 1.770 No 124003 722 Month 24 1.770 No 141013 725 Month 24
 | Treatment Group Subject ID Positive
Asiay Immunoreactivity
Asiay Log Titer Immunoreactivity
Diagnosis Treatment Group Subject ID 365 Month 12 2.770 No 177006 358 Month 12 2.870 Infammation Ranibizumab 0.5 mg 177006 358 Month 12 1.870 Infitis 177006 358 Month 12 1.870 Infitis No 177006 358 Month 12 1.870 Infitis 107001 722 Month 24 1.140 No 106002 722 Month 24 1.140 No 122002 339 Month 12 1.630 No 122002 335 Month 24 1.770 No 122003 722 Month 24 1.700 No 124003 722 Month 24 1.770 No 124003 722 Month 24 1.700 No 124003 722 Month 24 1.770 No 124003 722 Month 24 1.770 No 141013 725 Month 24 1.770 <td< td=""><td>Treatment Group Subject ID Positive
Asiay Immunoreactivity
Asiay Log Titer Immunoreactivity
Diagnosis Treatment Group Subject ID 365 Month 12 2.770 No 177006 358 Month 12 2.870 Infammation Ranibizumab 0.5 mg 177006 358 Month 12 1.870 Infitis 177006 358 Month 12 1.870 Infitis No 177006 358 Month 12 1.870 Infitis 107001 722 Month 24 1.140 No 106002 722 Month 24 1.140 No 122002 339 Month 12 1.630 No 122002 335 Month 24 1.770 No 122003 722 Month 24 1.700 No 124003 722 Month 24 1.770 No 124003 722 Month 24 1.700 No 124003 722 Month 24 1.770 No 124003 722 Month 24 1.770 No 141013 725 Month 24 1.770 <td< td=""><td>Treatment Group Subject ID Positive
Asiay Immunoreactivity
Asiay Log Titer Immunoreactivity
Diagnosis Treatment Group Subject ID 365 Month 12 2.770 No 177006 358 Month 12 2.870 Infammation Ranibizumab 0.5 mg 177006 358 Month 12 1.870 Infitis 177006 358 Month 12 1.870 Infitis No 177006 358 Month 12 1.870 Infitis 107001 722 Month 24 1.140 No 106002 722 Month 24 1.140 No 122002 339 Month 12 1.630 No 122002 335 Month 24 1.770 No 122003 722 Month 24 1.700 No 124003 722 Month 24 1.770 No 124003 722 Month 24 1.700 No 124003 722 Month 24 1.770 No 124003 722 Month 24 1.770 No 141013 725 Month 24 1.770 <td< td=""><td>Treatment Group Subject ID Positive
firminioreactivity Immunoreactivity
 Immunoreactiv</td><td>Treatment Group Subject ID Positive
firminioreactivity Intrancentivity Intracentity Intrancentivity Intran</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Intracondiation Treatment Group Subject ID Assay Assay Assay Intracondiation 170010 365/Month 12 2.770 No No 177006 371/Month 24 1.870 Irtitis 177006 378/Month 12 1.870 Irtitis 177006 378/Month 24 1.140 No 177006 717/Month 24 1.300 No 122002 722/Month 24 1.130 No 122002 359/Month 12 1.630 No 124003 722/Month 24 1.130 No 124003 722/Month 24 1.1700 No 124003 722/Month 24 1.770 No</td><td>Treatment Group Bubject ID Positive
Assry Innumoreactivity
Innumoreactivity Intraoodilar
Infammition Treatment Group Subject ID Assry Assry Assry Assry Assry Intraoodilar 170010 365/Month 12 2.770 No No 177006 358/Month 24 1.870 Irritis 177006 358/Month 24 0.922 No 177006 359/Month 12 1.870 Irritis 104002 717/Month 24 0.922 No 122002 359/Month 12 1.300 No 122002 359/Month 12 1.630 No 124003 722/Month 24 1.170 No 124003 722/Month 24 1.770 No 124003 722/Month 24 1.770 No 124003 722/Month 24 1.700 No 124003 722/Month 24 1.700 No 124003 722/Month 24 1.700 No 124001 174/Month 24 1</td><td>Treatment Group Subject ID Positive
Inframoractivity Inframoractivity Inframoractivity Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 24 1.870 Irritis 177006 358 / Month 24 1.870 Irritis 177006 358 / Month 24 1.870 Irritis 177005 358 / Month 24 1.140 No 104002 722 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 124003 722 / Month 24 1.170 No 124003 722 / Month 24 1.170 No 124003 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 141013</td></td<></td></td<></td></td<> | Treatment Group Subject ID Positive
Asiay Immunoreactivity
Asiay Log Titer Immunoreactivity
Diagnosis Treatment Group Subject ID 365 Month 12 2.770 No 177006 358 Month 12 2.870 Infammation Ranibizumab 0.5 mg 177006 358 Month 12 1.870 Infitis 177006 358 Month 12 1.870 Infitis No 177006 358 Month 12 1.870 Infitis 107001 722 Month 24 1.140 No 106002 722 Month 24 1.140 No 122002 339 Month 12 1.630 No 122002 335 Month 24 1.770 No 122003 722 Month 24 1.700 No 124003 722 Month 24 1.770 No 124003 722 Month 24 1.700 No 124003 722 Month 24 1.770 No 124003 722 Month 24 1.770 No 141013 725 Month 24 1.770 <td< td=""><td>Treatment Group Subject ID Positive
Asiay Immunoreactivity
Asiay Log Titer Immunoreactivity
Diagnosis Treatment Group Subject ID 365 Month 12 2.770 No 177006 358 Month 12 2.870 Infammation Ranibizumab 0.5 mg 177006 358 Month 12 1.870 Infitis 177006 358 Month 12 1.870 Infitis No 177006 358 Month 12 1.870 Infitis 107001 722 Month 24 1.140 No 106002 722 Month 24 1.140 No 122002 339 Month 12 1.630 No 122002 335 Month 24 1.770 No 122003 722 Month 24 1.700 No 124003 722 Month 24 1.770 No 124003 722 Month 24 1.700 No 124003 722 Month 24 1.770 No 124003 722 Month 24 1.770 No 141013 725 Month 24 1.770 <td< td=""><td>Treatment Group Subject ID Positive
firminioreactivity Immunoreactivity Immunoreactiv</td><td>Treatment Group Subject ID Positive
firminioreactivity Intrancentivity Intracentity Intrancentivity Intran</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Intracondiation Treatment Group Subject ID Assay Assay Assay Intracondiation 170010 365/Month 12 2.770 No No 177006 371/Month 24 1.870 Irtitis 177006 378/Month 12 1.870 Irtitis 177006 378/Month 24 1.140 No 177006 717/Month 24 1.300 No 122002 722/Month 24 1.130 No 122002 359/Month 12 1.630 No 124003 722/Month 24 1.130 No 124003 722/Month 24 1.1700 No 124003 722/Month 24 1.770 No</td><td>Treatment Group Bubject ID Positive
Assry Innumoreactivity
Innumoreactivity Intraoodilar
Infammition Treatment Group Subject ID Assry Assry Assry Assry Assry Intraoodilar 170010 365/Month 12 2.770 No No 177006 358/Month 24 1.870 Irritis 177006 358/Month 24 0.922 No 177006 359/Month 12 1.870 Irritis 104002 717/Month 24 0.922 No 122002 359/Month 12 1.300 No 122002 359/Month 12 1.630 No 124003 722/Month 24 1.170 No 124003 722/Month 24 1.770 No 124003 722/Month 24 1.770
 No 124003 722/Month 24 1.700 No 124003 722/Month 24 1.700 No 124003 722/Month 24 1.700 No 124001 174/Month 24 1</td><td>Treatment Group Subject ID Positive
Inframoractivity Inframoractivity Inframoractivity Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 24 1.870 Irritis 177006 358 / Month 24 1.870 Irritis 177006 358 / Month 24 1.870 Irritis 177005 358 / Month 24 1.140 No 104002 722 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 124003 722 / Month 24 1.170 No 124003 722 / Month 24 1.170 No 124003 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 141013</td></td<></td></td<> | Treatment Group Subject ID Positive
Asiay Immunoreactivity
Asiay Log Titer Immunoreactivity
Diagnosis Treatment Group Subject ID 365 Month 12 2.770 No 177006 358 Month 12 2.870 Infammation Ranibizumab 0.5 mg 177006 358 Month 12 1.870 Infitis 177006 358 Month 12 1.870 Infitis No 177006 358 Month 12 1.870 Infitis 107001 722 Month 24 1.140 No 106002 722 Month 24 1.140 No 122002 339 Month 12 1.630 No 122002 335 Month 24 1.770 No 122003 722 Month 24 1.700 No 124003 722 Month 24 1.770 No 124003 722 Month 24 1.700 No 124003 722 Month 24 1.770 No 124003 722 Month 24 1.770 No 141013 725 Month 24 1.770 <td< td=""><td>Treatment Group Subject ID Positive
firminioreactivity Immunoreactivity Immunoreactiv</td><td>Treatment Group Subject ID Positive
firminioreactivity Intrancentivity Intracentity Intrancentivity Intran</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Intracondiation Treatment Group Subject ID Assay Assay Assay Intracondiation 170010 365/Month 12 2.770 No No 177006 371/Month 24 1.870 Irtitis 177006 378/Month 12 1.870 Irtitis 177006 378/Month 24 1.140 No 177006 717/Month 24 1.300 No 122002 722/Month 24 1.130 No 122002 359/Month 12 1.630 No 124003 722/Month 24 1.130 No 124003 722/Month 24 1.1700 No 124003 722/Month 24 1.770 No</td><td>Treatment Group Bubject ID Positive
Assry Innumoreactivity
Innumoreactivity Intraoodilar
Infammition Treatment Group Subject ID Assry Assry Assry Assry Assry Intraoodilar 170010 365/Month 12 2.770 No No 177006 358/Month 24 1.870 Irritis 177006 358/Month 24 0.922 No 177006 359/Month 12 1.870 Irritis 104002 717/Month 24 0.922 No 122002 359/Month 12 1.300 No 122002 359/Month 12 1.630 No 124003 722/Month 24 1.170 No 124003 722/Month 24 1.770 No 124003 722/Month 24 1.770 No 124003 722/Month 24 1.700 No 124003 722/Month 24 1.700 No 124003 722/Month 24 1.700 No 124001 174/Month 24 1</td><td>Treatment Group Subject ID Positive
Inframoractivity Inframoractivity Inframoractivity Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 24 1.870 Irritis 177006 358 / Month 24 1.870 Irritis 177006 358 / Month 24 1.870 Irritis 177005 358 / Month 24 1.140 No 104002 722 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 124003 722 / Month 24 1.170 No 124003 722 / Month 24 1.170 No 124003 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 141013</td></td<> | Treatment Group Subject ID Positive
firminioreactivity Immunoreactivity Immunoreactiv
 | Treatment Group Subject ID Positive
firminioreactivity Intrancentivity Intracentity Intrancentivity Intran
 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Intracondiation Treatment Group Subject ID Assay Assay Assay Intracondiation 170010 365/Month 12 2.770 No No 177006 371/Month 24 1.870 Irtitis 177006 378/Month 12 1.870 Irtitis 177006 378/Month 24 1.140 No 177006 717/Month 24 1.300 No 122002 722/Month 24 1.130 No 122002 359/Month 12 1.630 No 124003 722/Month 24 1.130 No 124003 722/Month 24 1.1700 No 124003 722/Month 24 1.770 No | Treatment Group Bubject ID Positive
Assry Innumoreactivity
Innumoreactivity
Intraoodilar
Infammition Treatment Group Subject ID Assry Assry Assry Assry Assry Intraoodilar 170010 365/Month 12 2.770 No No 177006 358/Month 24 1.870 Irritis 177006 358/Month 24 0.922 No 177006 359/Month 12 1.870 Irritis 104002 717/Month 24 0.922 No 122002 359/Month 12 1.300 No 122002 359/Month 12 1.630 No 124003 722/Month 24 1.170 No 124003 722/Month 24 1.770 No 124003 722/Month 24 1.770 No 124003 722/Month 24 1.700 No 124003 722/Month 24 1.700 No 124003 722/Month 24 1.700 No 124001 174/Month 24 1 | Treatment Group Subject ID Positive
Inframoractivity Inframoractivity Inframoractivity Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 24 1.870 Irritis 177006 358 / Month 24 1.870 Irritis 177006 358 / Month 24 1.870 Irritis 177005 358 / Month 24 1.140 No 104002 722 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 124003 722 / Month 24 1.170 No 124003 722 / Month 24 1.170 No 124003 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 141013 |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $

 | I53006 I83/Month 6 1.900 No $365/Month 12$ 1.530 No $365/Month 12$ 1.530 No 159017 $716/Month 24$ 2.070 No 167002 $717/Month 24$ 0.780^{10} No 167002 $717/Month 24$ 1.230 No 188005 $717/Month 24$ 1.230 No 534001 $-7/Screening$ 2.520 Vitritis

 | I53006 I83/Month 6 I.900 No $365/Month 12$ 1.530 No No $718/Month 24$ 2.070 No No 159017 $716/Month 24$ 0.780 No 167002 $715/Month 24$ 0.780 No 167002 $717/Month 24$ 1.230 No 188005 $717/Month 24$ 1.230 No 834001 $-7/Screening$ 2.520 Vitritis

 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit

 | Treatment Group Subject ID Positive
Asiay Immunoreactivity
Asiay Log Titer Immunoreactivity
Diagnosis Treatment Group Subject ID 365/Month 12 2.770 No 177006 355/Month 12 2.800 Inflammation Ranibizumab 0.5 mg 177006 355/Month 12 1.870 Inflammation Ranibizumab 0.5 mg 102001 722/Month 24 1.920 No 127002 723/Month 24 1.130 No 122002 722/Month 24 1.130 No 124003 722/Month 24 1.770 No 141013 181/Month 6 1.770

 | Treatment Group Subject ID Positive
Asiay Immunoreactivity
Assay Log Titer
 Immunoreactivity
Diagnosis Treatment Group Subject ID Asiay Asiay Asiay Asiay I70010 365/Month 12 2.770 No No 177005 338/Month 12 2.870 No No 177005 338/Month 12 1.870 Intriso No 177005 338/Month 24 0.922 No No 104002 717/Month 24 1.870 Intriso No 102001 722/Month 24 1.130 No No 122002 339/Month 24 1.130 No No 122003 722/Month 24 1.130 No No 124003 722/Month 24 0.782 No No 126001 174/Month 52 1.140 No No 122002 335/Month 12 1.630 No No 124003 722/Month 24 0.782 No No 141

 | Treatment GroupSubject IDPositive
ImmunoreactivityImmunoreactivity
ImmunoreactivityImmunoreactivity
ImmunoreactivityImmunoreactivity
ImmunoreactivityTreatment GroupSubject ID 365 /Month 12 2.770 No177006 355 /Month 12 2.770 No177005 338 /Month 12 1.870 Intits177005 338 /Month 24 1.870 Intits177005 335 /Month 24 1.870 No104002 722 /Month 24 1.140 No122002 339 /Month 24 1.140 No122002 335 /Month 24 1.130 No122002 335 /Month 24 1.770 No122002 335 /Month 24 1.770 No124003 722 /Month 24 1.700 No124003 357 /Month 24 1.700 No124003 377 /Month 24 1.700 No124013 722 /Month 24 1.940 No124013 722 /Month 24 2.340 No124013 722 /Month 24 2.440 No124013 722 /Month 24 2.440 No124013 722 /Month 24
 | Treatment GroupSubject IDPositive
ImmunoreactivityImmunoreactivity
ImmunoreactivityImmunoreactivity
ImmunoreactivityTreatment GroupSubject IDAsiayAssay Log TiterDiagnosis170010 365 /Month 12 2.770 NoNo177006 338 /Month 24 1.870 Infia177005 338 /Month 24 1.870 Intits177005 722 /Month 24 1.870 No104002 722 /Month 24 1.140 No105002 722 /Month 24 1.140 No122002 339 /Month 24 1.770 No122002 357 /Month 24 1.770 No122003 357 /Month 24 1.770 No126001 174 /Month 6 1.700 No126001 174 /Month 6 1.700 No121002 357 /Month 12 2.040 No121003 357 /Month 24 1.940 No12103 357 /Month 24 1.700 No12103 174 /Month 6 1.700 No12103 357 /Month 24 2.340 No12103 357 /Month 24 2.340 No12103 357 /Month 24 2.340 No12103 174 /Month 24 1.940 No12103 $322/Month 242.340No12103322/Month 242.340No12103322/Month 242.340No12103322/Month 242.340No12113722/Month 24$

 | Treatment GroupSubject IDPositive
ImmunoreactivityImmunoreactivity
ImmunoreactivityImmunoreactivity
ImmunoreactivityImmunoreactivity
ImmunoreactivityTreatment GroupSubject ID 365 /Month 12 2.770 No177006 355 /Month 12 2.770 No177005 338 /Month 12 1.870 Intits177005 338 /Month 24 1.870 Intits177005 335 /Month 24 1.870 No104002 722 /Month 24 1.140 No122002 339 /Month 24 1.140 No122002 335 /Month 24 1.130 No122002 335 /Month 24 1.770 No122002 335 /Month 24 1.770 No124003 722 /Month 24 1.700 No124003 357 /Month 24 1.700 No124003 377 /Month 24 1.700 No124013 722 /Month 24 1.940 No124013 722 /Month 24 2.340 No124013 722 /Month 24 2.440 No124013 722 /Month 24 2.440 No124013 722 /Month 24
 | Treatment GroupSubject IDPositive
ImmunoreactivityImmunoreactivity
ImmunoreactivityImmunoreactivity
ImmunoreactivityImmunoreactivity
ImmunoreactivityTreatment GroupSubject ID 365 /Month 12 2.770 No177006 355 /Month 12 2.770 No177005 338 /Month 12 1.870 Intits177005 338 /Month 24 1.870 Intits177005 335 /Month 24
1.870 No104002 722 /Month 24 1.140 No122002 339 /Month 24 1.140 No122002 335 /Month 24 1.130 No122002 335 /Month 24 1.770 No122002 335 /Month 24 1.770 No124003 722 /Month 24 1.700 No124003 357 /Month 24 1.700 No124003 377 /Month 24 1.700 No124013 722 /Month 24 1.940 No124013 722 /Month 24 2.340 No124013 722 /Month 24 2.440 No124013 722 /Month 24 2.440 No124013 722 /Month 24
 | Treatment Group Subject ID Positive
Asiay Immunoreactivity
Assay Log Titer Immunoreactivity
Diagnosis Treatment Group Subject ID Asiay Asiay Asiay Asiay I70010 365/Month 12 2.770 No No 177005 338/Month 12 2.870 No No 177005 338/Month 12 1.870 Intriso No 177005 338/Month 24 0.922 No No 104002 717/Month 24 1.870 Intriso No 102001 722/Month 24 1.130 No No 122002 339/Month 24 1.130 No No 122003 722/Month 24 1.130 No No 124003 722/Month 24 0.782 No No 126001 174/Month 52 1.140 No No 122002 335/Month 12 1.630 No No 124003 722/Month 24 0.782 No No 141
 | Treatment Group Subject ID Positive
Asiay Immunoreactivity
Assay Log Titer Immunoreactivity
Diagnosis Treatment Group Subject ID Asiay Asiay Asiay Asiay I70010 365/Month 12 2.770 No No 177005 338/Month 12 2.870 No No 177005 338/Month 12 1.870 Intriso No 177005 338/Month 24 0.922 No No 104002 717/Month 24 1.870 Intriso No 102001 722/Month 24 1.130 No No 122002 339/Month 24 1.130 No No 122003 722/Month 24 1.130 No No 124003 722/Month 24 0.782 No No 126001 174/Month 52 1.140 No No 122002 335/Month 12 1.630 No No 124003 722/Month 24 0.782 No No 141
 | Treatment Group Subject ID Positive
Asiay Immunoreactivity
Assay Log Titer Immunoreactivity
Diagnosis Treatment Group Subject ID Asiay Asiay Asiay Asiay I70010 365/Month 12 2.770 No No 177005 338/Month 12 2.870 No No 177005 338/Month 12 1.870 Intriso No 177005 338/Month 24 0.922 No No 104002 717/Month 24 1.870 Intriso No 102001 722/Month 24 1.130 No No 122002 339/Month 24 1.130 No No 122003 722/Month 24 1.130 No No 124003 722/Month 24 0.782 No No 126001 174/Month 52 1.140 No No 122002 335/Month 12
1.630 No No 124003 722/Month 24 0.782 No No 141 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit
 | Treatment Group Subject ID Positive
firminioreactivity Immunoreactivity Immunoreactiv
 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit | Treatment Group Subject ID Positive
Immunoreactivity Intraoordiar
Immunoreactivity Intraoordiar
Inflammation Treatment Group Subject ID Assay Assay Assay Intraoordiar 170010 365/Month 12 2.770 No No 177006 375/Month 12 1.870 Irtits No 177006 375/Month 12 1.870 Irtits No 177006 375/Month 12 1.870 Irtits No 104002 712/Month 24 1.140 No No 122002 339/Month 12 1.630 No No 122002 335/Month 24 1.140 No No 122002 335/Month 24 1.770 No No 124003 722/Month 24 1.770 No No
 | Treatment Group Bubject ID Assy Positive
Inframunoreactivity Inframonation Jreatment Group Subject ID Assy Assy Assy Assy Inframonation 170010 365/Month 12 2.770 No No 177006 358/Month 12 1.870 Irrits No 177006 358/Month 12 1.870 Irrits No 177006 358/Month 12 1.870 No No 177006 358/Month 24 1.140 No No No 122002 722/Month 24 1.130 No No No No 122002 359/Month 24 1.170 No No </td |
| I53006 I83/Month 6 1.900 No 153006 183/Month 12 1.530 No 718/Month 24 2.070 No No 159017 716/Month 24 0.780 No 167002 717/Mont 24 1.230 No 188005 717/Mont 24 1.230 No 534001 -7/Screening 2.520 Vitritis

 | IS3006 I83/Month 6 1.900 No 153006 183/Month 6 1.900 No 365/Month 12 1.530 No 159017 718/Month 24 2.070 No 159017 716/Month 24 0.780 No 167002 717/Month 24 1.230 No 188005 717/Month 24 1.250 No 534001 -7/Screening 2.520 Vitritis

 | IS3006 I83/Month 6 1.900 No 153006 183/Month 6 1.900 No 365/Month 12 1.530 No 718/Month 24 2.070 No 159017 716/Month 24 0.780 No 167002 717/Month 24 1.230 No 188005 717/Month 24 1.230 No 534001 -7/Screening 2.520 Virritis

 | Treatment Group Boliett ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit

 | Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea

 | Treatment Group Subject ID Positive
Asiay Immunoreactivity
Assay Log Titer Immunoreactivity
Infimumation Ariay Subject ID Asiay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 338/Month 12 1.870 Infimumation Rantbizumab 0.5 mg 102001 715/Month 24 1.870 Infits 177006 338/Month 12 1.870 Infits No 100002 722/Month 24 1.870 No No 122002 339/Month 12 1.140 No No 122002 359/Month 12 1.170 No No 122002 359/Month 12 1.170 No No 122002 359/Month 12 1.770 No
 No 122002 359/Month 12 1.770 No No 124003 722/Month 24 1.770 No No 124001 170/Month 24 1.770 No No 126001
 | Treatment Group Subject ID Positive
Asiay Immunoreactivity
Asiay Immunoreactivity
Immunoreactivity Immunation
Immunation Ariay Ses V Log Titer Diagnosis Diagnosis 170010 365/Month 12 2.770 No
177006 338/Month 12 1.870 Infia 177006 338/Month 12 1.870 Infia 177005 338/Month 12 1.870 Infia 17700 722/Month 24 1.140 No 122002 359/Month 12 1.1700 No 122002 359/Month 12 1.770 No 124003 722/Month 24 1.770 No 126001 17/Month 6 1.770 No 126001 17/Month 24 1.770 No 126001 17/Month 24 1.770 No 126001 17/Month 24 1.770 No 127/Month 24 1.770 No No 128/Month 12 1.770 No No 128/Month 24 1.
 | Treatment/Group Exitive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment/Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 338/Month 12 1.870 Infiammation Rantbizumab 0.5 mg 107001 325/Month 24 1.870 Intits 177006 338/Month 12 1.870 Intits No 106002 717/Month 24 1.870 No No 122002 359/Month 12 1.140 No No 122002 359/Month 12 1.1700 No No 122002 359/Month 12 1.1700 No No 122002 359/Month 24 1.1700 No No 122002 359/Month 12 1.1700 No No 122003 359/Month 12 1.1700 No No 124003 722/Month 24 1.7700 No No

 | Treatment Group Subject ID Positive
Asiay Immunoreactivity
Asiay Immunoreactivity
Immunoreactivity Immunation
Immunation Ariay Ses V Log Titer Diagnosis Diagnosis 170010 365/Month 12 2.770 No 177006 338/Month 12 1.870 Infia 177006 338/Month 12 1.870 Infia 177005 338/Month 12 1.870 Infia 17700 722/Month 24 1.140 No 122002 359/Month 12 1.1700 No 122002 359/Month 12 1.770 No 124003 722/Month 24 1.770 No 126001 17/Month 6 1.770 No 126001 17/Month 24 1.770 No 126001 17/Month 24 1.770 No 126001 17/Month 24 1.770 No 127/Month 24 1.770 No No 128/Month 12 1.770 No No 128/Month 24 1.
 | Treatment Group Subject ID Positive
Asiay Immunoreactivity
Asiay Immunoreactivity
Immunoreactivity Immunation
Immunation Ariay Ses V Log Titer Diagnosis Diagnosis 170010 365/Month 12 2.770 No 177006 338/Month 12 1.870 Infia 177006 338/Month 12 1.870 Infia 177005 338/Month 12 1.870 Infia 17700 722/Month 24 1.140 No 122002 359/Month 12 1.1700 No 122002 359/Month 12 1.770 No 124003 722/Month 24 1.770
 No 126001 17/Month 6 1.770 No 126001 17/Month 24 1.770 No 126001 17/Month 24 1.770 No 126001 17/Month 24 1.770 No 127/Month 24 1.770 No No 128/Month 12 1.770 No No 128/Month 24 1.
 | Treatment Group Subject ID Positive
Asiay Immunoreactivity
Assay Log Titer Immunoreactivity
Infimumation Ariay Subject ID Asiay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 338/Month 12 1.870 Infimumation Rantbizumab 0.5 mg 102001 715/Month 24 1.870 Infits 177006 338/Month 12 1.870 Infits No 100002 722/Month 24 1.870 No No 122002 339/Month 12 1.140 No No 122002 359/Month 12 1.170 No No 122002 359/Month 12 1.170 No No 122002 359/Month 12 1.770 No No 122002 359/Month 12 1.770 No No 124003 722/Month 24 1.770 No No 124001 170/Month 24 1.770 No No 126001
 | Treatment Group Subject ID Positive
Asiay Immunoreactivity
Assay Log Titer Immunoreactivity
Infimumation Ariay Subject ID Asiay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 338/Month 12 1.870 Infimumation Rantbizumab 0.5 mg 102001 715/Month 24 1.870 Infits 177006 338/Month 12 1.870 Infits No 100002 722/Month 24 1.870 No No 122002 339/Month 12 1.140 No No 122002 359/Month 12 1.170 No No 122002 359/Month 12 1.170 No No 122002 359/Month 12 1.770 No No 122002 359/Month 12 1.770 No No 124003 722/Month 24 1.770 No No 124001 170/Month 24 1.770 No No 126001
 | Treatment Group Subject ID Positive
Asiay Immunoreactivity
Assay Log Titer Immunoreactivity
Infimumation Ariay Subject ID Asiay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 338/Month 12 1.870 Infimumation Rantbizumab 0.5 mg 102001 715/Month 24 1.870 Infits 177006 338/Month 12 1.870 Infits No 100002 722/Month 24 1.870 No No 122002 339/Month 12 1.140 No No 122002 359/Month 12 1.170 No No 122002 359/Month 12 1.170 No No 122002 359/Month 12 1.770 No No 122002 359/Month 12 1.770 No No 124003 722/Month 24 1.770 No No 124001 170/Month 24 1.770 No No 126001
 | Treatment Group Boliett ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit
 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit
 | Treatment Group Subject ID Positive
immunoreactivity Intracentiar
immunoreactivity Intracentiar
inflammation Treatment Group Subject ID Assay Assay Assay Inflammation 170010 365/Month 12 2.770 No No No 177006 358/Month 12 1.870 Intracentiar No 177006 717/Month 24 1.870 Intris No 177006 722/Month 24 1.870 Intris No 104002 722/Month 24 1.140 No No 120001 722/Month 24 1.130 No No 120002 722/Month 24 1.1700 No No 120003 722/Month 24 1.1700 No No 126001 174/Month 66 1.7700 No No 126001 174/Month 67 1.1700 No No 126001 174/Month 24 1.7700 No No 126001 174/Month 6 1.7700 No | Treatment Group Subject ID Positive
immunoreactivity Intracentiar
immunoreactivity Intracentiar
inflammation Treatment Group Subject ID Assay Assay Assay Inflammation 170010 365/Month 12 2.770 Noo Noo 177006 358/Month 12 1.870 Intris 177006 358/Month 24 0.922 No 177000 717/Month 24 1.870 Intris 104002 719/Month 24 1.870 No 102001 722/Month 24 1.140 No 102002 723/Month 24 1.130 No 122002 353/Month 24 1.770 No 122002 722/Month 24 1.170 No 124003 722/Month 24 1.770 No 126001 174/Month 66 1.770 No 126001 174/Month 6 1.770 No 126001 174/Month 24 1.630 No 126001 174/Month 24 1.770 No
 | Treatment Group Subject ID Positive
Innunoreactivity Innunoreactivity Innon Ranibizumab 0.5 mg 177006 355/Month 24 1.870 Initias Initias Ranibizumab 0.5 mg 102001 722/Month 24 1.130 No No Initias Ranibizumab 0.5 mg 102002 722/Month 24 1.130 No No Initias Ranibizumab 0.5 mg 122002 353/Month 24 1.130 No No Initias 122002 722/Month 12 | Treatment Group Intrancolar Intrancolar Treatment Group Subject ID Solitive Intrancolar 170010 365 / Month 12 2.3770 No 170010 365 / Month 12 2.3770 No 177006 358 / Month 12 1.870 Intris 177005 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 177005 358 / Month 24 1.870 Intris 104002 717 / Month 24 1.870 No 122002 359 / Month 12 1.870 No 122002 359 / Month 24 1.140 No 122002 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No |
| I52004 522/Early Term. 0.752, No 153006 183/Month 6 1.900 No 153005 183/Month 12 1.530 No 153006 183/Month 24 2.070 No 159017 716/Month 24 0.780 No 167002 717/Month 24 1.230 No 188005 717/Month 24 1.250 No 534001 -7/Screening 2.520 Vitritis

 | I52004 522/Early Term. 0.752, No 153006 183/Month 6 1.900 No 153005 183/Month 12 1.530 No 153006 183/Month 12 1.530 No 159017 716/Month 24 2.070 No 167002 717/Month 24 0.780 No 188005 717/Month 24 1.230 No 534001 -7/Screening 2.520 Vitritis

 | IS2004 522/Early Term. 0.752, No 153006 183/Month 6 1.900 No 153005 183/Month 12 1.530 No 718/Month 24 2.070 No 159017 716/Month 24 0.780 No 167002 717/Month 24 0.780 No 188005 717/Month 24 1.250 No

 | Treatment GroupPositive
fimmunoractivityIntransition
AssayPositive
inflammationTreatment GroupSubject IDAssayAssay Log TiterDiagnosis170010365 / Month 122.770NoNo177006383 / Month 121.870IrritisIrritis177006338 / Month 121.870IrritisNo177006338 / Month 121.870IrritisNo177006338 / Month 241.140NoNo106002722 / Month 241.130NoNo124003722 / Month 241.130NoNo124003722 / Month 241.770NoNo124003722 / Month 241.770NoNo124003722 / Month 241.770NoNo124003722 / Month 241.770No124003722 / Month 241.630No124003722 / Month 241.640No124003722 / Month 241.770No124003722 / Month 241.770No124003722 / Month 241.770No124003722 / Month 241.770No124003722 / Month 241.770No12400722 / Month 241.770No

 | Treatment Group Positive
fimmunoreactivity Intranumation Treatment Group Subject ID Assay Taravian Intrancention 170010 365 / Month 12 2.770 No No No No 170010 365 / Month 12 2.770 No No <td< td=""><td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innamiation Arisy Subject ID Asisy Asisy Asisy Asisy Innamiation Arish J15 / Month 12
 2.770 No No No 170010 365 / Month 12 2.800 Intraocedian No 177006 338 / Month 12 1.870 Intris No 177006 338 / Month 12 1.870 Intris No 177006 338 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 24 1.170 No No 124003 722 / Month 24 1.770 No</td></td<> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay Assay Diagnosis 170010 365 / Month 12 2.770 No No No 177006 338 / Month 12 1.870 Irritis No 177006 338 / Month 12 1.870 Irritis 177006 338 / Month 12 1.870 Irritis 17700 772 / Month 24 1.140 No 104002 722 / Month 12 1.630 No 124003 722 / Month 24 1.140 No 124003 722 / Month 24 1.770 No 12400</td> <td>Treatment Group Exite Fositive Immunoreactivity Imm</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay Assay Diagnosis 170010 365 / Month 12 2.770 No No No 177006 338 / Month 12 1.870 Irritis No 177006 338 / Month 12 1.870 Irritis 177006 338 / Month 12 1.870 Irritis 17700 772 / Month 24 1.140 No 104002 722 / Month 12 1.630 No 124003 722 / Month 24 1.140 No 124003 722 / Month 24 1.770 No 12400</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay Assay Diagnosis 170010 365 / Month 12 2.770 No No No 177006 338 / Month 12 1.870 Irritis No 177006 338 / Month 12 1.870 Irritis 177006 338 / Month 12 1.870 Irritis 17700 772 / Month 24 1.140 No 104002 722 / Month 12 1.630 No 124003 722 / Month 24 1.140 No 124003 722 / Month 24 1.770 No 12400</td> <td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innamiation Arisy Subject ID Asisy Asisy Asisy Asisy Innamiation Arish J15 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 Intraocedian No 177006 338 / Month 12 1.870 Intris No 177006 338 / Month 12 1.870 Intris No 177006 338 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 24 1.170 No No 124003 722 / Month 24 1.770 No<td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innamiation Arisy Subject ID Asisy Asisy Asisy Asisy Innamiation Arish J15 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 Intraocedian No 177006 338 / Month 12 1.870 Intris No 177006 338 / Month 12 1.870 Intris No 177006 338 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 24 1.170 No No 124003 722 / Month 24 1.770 No<td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innamiation Arisy Subject ID Asisy Asisy Asisy Asisy Innamiation Arish J15 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 Intraocedian No 177006 338 / Month 12 1.870 Intris No 177006 338 / Month 12 1.870 Intris No 177006 338 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 24 1.170 No No 124003 722 / Month 24 1.770 No<td>Treatment GroupPositive
fimmunoractivityIntransition
AssayPositive
inflammationTreatment GroupSubject IDAssayAssay Log TiterDiagnosis170010365 / Month 122.770NoNo177006383 / Month 121.870IrritisIrritis177006338 / Month 121.870IrritisNo177006338 / Month 121.870IrritisNo177006338 / Month 241.140NoNo106002722 / Month 241.130NoNo124003722 / Month 241.130NoNo124003722 / Month 241.770NoNo124003722 / Month 241.770NoNo124003722 / Month 241.770NoNo124003722 / Month 241.770No124003722 / Month 241.630No124003722 / Month 241.640No124003722 / Month 241.770No124003722 / Month 241.770No124003722 / Month 241.770No124003722 / Month 241.770No124003722 / Month 241.770No12400722 / Month 241.770No</td><td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity Innanation Treatment Group Subject ID Assy Assy Assy Innumoreactivity Innanation 365 / Month 12 2.770 No 177006 338 / Month 24 1.870 Innus Innus</td><td>Treatment Group Positive
Inmunoreactivity Immunoreactivity Immunorea</td><td>Treatment Group Positive
Innumoreactivity Innumoreactivity
Innumoreactivity Innumoreactivity
Innumoreactivity Innamiation
Infiammation 170010 365 / Month 12 2.770 No 170010 355 / Month 24 2.800 Irtits 177006 355 / Month 24 1.870 No 177006 355 / Month 24 1.870 No 177006 355 / Month 24 1.140 No 17700 722 / Month 24 1.140 No 122002 723 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 359 / Month 24 1.130 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.630 No 124003 722 / Month 24 1.770 No 12400</td><td>Treatment Group Positive Intransition Treatment Group Subject ID Assay Log Titer Inframmation 170010 365 / Month 12 2.770 No No 170010 355 / Month 24 2.870 No 177006 358 / Month 24 1.870 No 177006 358 / Month 24 1.870 No 177006 358 / Month 24 1.870 No 17700 722 / Month 24 1.870 No 122002 723 / Month 24 1.140 No 122002 359 / Month 24 1.140 No 122002 359 / Month 24 1.770 No 124003 722 / Month 24 1.770 No<td>Treatment Group Noitive
Inframoracity in the inframmation Treatment Group Subject ID South 12 Asset Jog Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.870 No No 177006 358 / Month 12 1.870 Intrins No 177005 358 / Month 12 1.870 Intrits No 17700 358 / Month 24 1.870 No No 17700 102001 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.130 No
No 122002 359 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 174 / Month 6 1.770</td></td></td></td></td> | Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innamiation Arisy Subject ID Asisy Asisy Asisy Asisy Innamiation Arish J15 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 Intraocedian No 177006 338 / Month 12 1.870 Intris No 177006 338 / Month 12 1.870 Intris No 177006 338 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 24 1.170 No No 124003 722 / Month 24 1.770 No

 | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay Assay Diagnosis 170010 365 / Month 12 2.770 No No No 177006 338 / Month 12 1.870 Irritis No 177006 338 / Month 12 1.870 Irritis 177006 338 / Month 12 1.870 Irritis 17700 772 / Month 24 1.140 No 104002 722 / Month 12 1.630 No 124003 722 / Month 24 1.140 No 124003 722 / Month 24 1.770 No 12400

 | Treatment Group Exite Fositive Immunoreactivity Imm
 | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay Assay Diagnosis 170010 365 / Month 12 2.770 No No No 177006 338 / Month 12 1.870 Irritis No 177006 338 / Month 12 1.870 Irritis 177006 338 / Month 12 1.870 Irritis 17700 772 / Month 24 1.140 No 104002 722 / Month 12 1.630 No 124003 722 / Month 24 1.140 No 124003 722 / Month 24 1.770 No 12400

 | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay Assay Diagnosis 170010 365 / Month 12 2.770 No No No 177006 338 / Month 12 1.870 Irritis No 177006 338 / Month 12 1.870 Irritis 177006 338 / Month 12 1.870 Irritis 17700 772 / Month 24 1.140 No 104002 722 / Month 12 1.630 No 124003 722 / Month 24 1.140 No 124003 722 / Month 24 1.770 No 12400
 | Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innamiation Arisy Subject ID Asisy Asisy Asisy Asisy Innamiation Arish J15 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 Intraocedian No 177006 338 / Month 12 1.870 Intris No 177006 338 / Month 12 1.870 Intris No 177006 338 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 24 1.170 No No 124003 722 / Month 24 1.770 No <td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innamiation Arisy Subject ID Asisy Asisy Asisy Asisy Innamiation Arish J15 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 Intraocedian No 177006 338 / Month 12 1.870 Intris No 177006 338 / Month 12 1.870 Intris No 177006 338 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 24 1.170 No No 124003 722 / Month 24 1.770 No<td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innamiation Arisy Subject ID Asisy Asisy Asisy Asisy Innamiation Arish J15 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 Intraocedian No 177006 338 / Month 12 1.870 Intris No 177006 338 / Month 12 1.870 Intris No 177006 338 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 24 1.170 No No 124003 722 / Month 24 1.770 No<td>Treatment GroupPositive
fimmunoractivityIntransition
AssayPositive
inflammationTreatment GroupSubject IDAssayAssay Log TiterDiagnosis170010365 / Month 122.770NoNo177006383 / Month 121.870IrritisIrritis177006338 / Month 121.870IrritisNo177006338 / Month 121.870IrritisNo177006338 / Month 241.140NoNo106002722 / Month 241.130NoNo124003722 / Month 241.130NoNo124003722 / Month 241.770NoNo124003722 / Month 241.770NoNo124003722 / Month 241.770NoNo124003722 / Month 241.770No124003722 / Month 241.630No124003722 / Month 241.640No124003722 / Month 241.770No124003722 / Month 241.770No124003722 / Month 241.770No124003722 / Month 241.770No124003722 / Month 241.770No12400722 / Month 241.770No</td><td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity Innanation Treatment Group Subject ID Assy Assy Assy
Innumoreactivity Innanation 365 / Month 12 2.770 No 177006 338 / Month 24 1.870 Innus Innus</td><td>Treatment Group Positive
Inmunoreactivity Immunoreactivity Immunorea</td><td>Treatment Group Positive
Innumoreactivity Innumoreactivity
Innumoreactivity Innumoreactivity
Innumoreactivity Innamiation
Infiammation 170010 365 / Month 12 2.770 No 170010 355 / Month 24 2.800 Irtits 177006 355 / Month 24 1.870 No 177006 355 / Month 24 1.870 No 177006 355 / Month 24 1.140 No 17700 722 / Month 24 1.140 No 122002 723 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 359 / Month 24 1.130 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.630 No 124003 722 / Month 24 1.770 No 12400</td><td>Treatment Group Positive Intransition Treatment Group Subject ID Assay Log Titer Inframmation 170010 365 / Month 12 2.770 No No 170010 355 / Month 24 2.870 No 177006 358 / Month 24 1.870 No 177006 358 / Month 24 1.870 No 177006 358 / Month 24 1.870 No 17700 722 / Month 24 1.870 No 122002 723 / Month 24 1.140 No 122002 359 / Month 24 1.140 No 122002 359 / Month 24 1.770 No 124003 722 / Month 24 1.770 No<td>Treatment Group Noitive
Inframoracity in the inframmation Treatment Group Subject ID South 12 Asset Jog Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.870 No No 177006 358 / Month 12 1.870 Intrins No 177005 358 / Month 12 1.870 Intrits No 17700 358 / Month 24 1.870 No No 17700 102001 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 174 / Month 6 1.770</td></td></td></td> | Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innamiation Arisy Subject ID Asisy Asisy Asisy Asisy Innamiation Arish J15 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 Intraocedian No 177006 338 / Month 12 1.870 Intris No 177006 338 / Month 12 1.870 Intris No 177006 338 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 24 1.170 No No 124003 722 / Month 24 1.770 No <td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innamiation Arisy Subject ID Asisy Asisy Asisy Asisy Innamiation Arish J15 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 Intraocedian No 177006 338 / Month 12 1.870 Intris No 177006 338 / Month 12 1.870 Intris No 177006 338 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 24 1.170 No No 124003 722 / Month 24 1.770 No<td>Treatment GroupPositive
fimmunoractivityIntransition
AssayPositive
inflammationTreatment GroupSubject IDAssayAssay Log TiterDiagnosis170010365 / Month 122.770NoNo177006383 / Month 121.870IrritisIrritis177006338 / Month 121.870IrritisNo177006338 / Month 121.870IrritisNo177006338 / Month 241.140NoNo106002722 / Month 241.130NoNo124003722 / Month 241.130NoNo124003722 / Month 241.770NoNo124003722 / Month 241.770NoNo124003722 / Month 241.770NoNo124003722 / Month 241.770No124003722 / Month 241.630No124003722 / Month 241.640No124003722 / Month 241.770No124003722 / Month 241.770No124003722 / Month 241.770No124003722 / Month 241.770No124003722 / Month 241.770No12400722 / Month 241.770No</td><td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity Innanation Treatment Group Subject ID Assy Assy Assy Innumoreactivity Innanation 365 / Month 12 2.770 No 177006 338 / Month 24 1.870 Innus Innus</td><td>Treatment Group Positive
Inmunoreactivity Immunoreactivity Immunorea</td><td>Treatment Group Positive
Innumoreactivity Innumoreactivity
Innumoreactivity Innumoreactivity
Innumoreactivity Innamiation
Infiammation 170010 365 / Month 12 2.770 No 170010 355 / Month 24 2.800 Irtits 177006 355 / Month 24 1.870 No 177006 355 / Month 24 1.870 No 177006 355 / Month 24 1.140 No 17700 722 / Month 24 1.140 No 122002 723 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 359 / Month 24 1.130 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.630 No 124003 722
/ Month 24 1.770 No 12400</td><td>Treatment Group Positive Intransition Treatment Group Subject ID Assay Log Titer Inframmation 170010 365 / Month 12 2.770 No No 170010 355 / Month 24 2.870 No 177006 358 / Month 24 1.870 No 177006 358 / Month 24 1.870 No 177006 358 / Month 24 1.870 No 17700 722 / Month 24 1.870 No 122002 723 / Month 24 1.140 No 122002 359 / Month 24 1.140 No 122002 359 / Month 24 1.770 No 124003 722 / Month 24 1.770 No<td>Treatment Group Noitive
Inframoracity in the inframmation Treatment Group Subject ID South 12 Asset Jog Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.870 No No 177006 358 / Month 12 1.870 Intrins No 177005 358 / Month 12 1.870 Intrits No 17700 358 / Month 24 1.870 No No 17700 102001 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 174 / Month 6 1.770</td></td></td> | Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innamiation Arisy Subject ID Asisy Asisy Asisy Asisy Innamiation Arish J15 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 Intraocedian No 177006 338 / Month 12 1.870 Intris No 177006 338 / Month 12 1.870 Intris No 177006 338 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 24 1.170 No No 124003 722 / Month 24 1.770 No <td>Treatment GroupPositive
fimmunoractivityIntransition
AssayPositive
inflammationTreatment GroupSubject IDAssayAssay Log TiterDiagnosis170010365 / Month 122.770NoNo177006383 / Month 121.870IrritisIrritis177006338 / Month 121.870IrritisNo177006338 / Month 121.870IrritisNo177006338 / Month 241.140NoNo106002722 / Month 241.130NoNo124003722 / Month 241.130NoNo124003722 / Month 241.770NoNo124003722 / Month 241.770NoNo124003722 / Month 241.770NoNo124003722 / Month 241.770No124003722 / Month 241.630No124003722 / Month 241.640No124003722 / Month 241.770No124003722 / Month 241.770No124003722 / Month 241.770No124003722 / Month 241.770No124003722 / Month 241.770No12400722 / Month 241.770No</td> <td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity Innanation Treatment Group Subject ID Assy Assy Assy Innumoreactivity Innanation 365 / Month 12 2.770 No 177006 338 / Month 24 1.870 Innus Innus</td> <td>Treatment Group Positive
Inmunoreactivity Immunoreactivity Immunorea</td> <td>Treatment Group Positive
Innumoreactivity Innumoreactivity
Innumoreactivity Innumoreactivity
Innumoreactivity Innamiation
Infiammation 170010 365 / Month 12 2.770 No 170010 355 / Month 24 2.800 Irtits 177006 355 / Month 24 1.870 No 177006 355 / Month 24 1.870 No 177006 355 / Month 24 1.140 No 17700 722 / Month 24 1.140 No 122002 723 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 359 / Month 24 1.130 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.630 No 124003 722 / Month 24 1.770 No 12400</td> <td>Treatment Group Positive Intransition Treatment Group Subject ID Assay Log Titer Inframmation 170010 365 / Month 12 2.770 No No 170010 355 / Month 24 2.870 No 177006 358 / Month 24 1.870 No 177006 358 / Month 24 1.870 No 177006 358 / Month 24 1.870 No 17700 722 / Month 24 1.870 No 122002 723 / Month 24 1.140 No 122002 359 / Month 24 1.140 No 122002 359 / Month 24 1.770 No 124003 722 / Month 24 1.770 No<td>Treatment Group Noitive
Inframoracity in the inframmation Treatment Group Subject ID South 12 Asset Jog Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.870 No No 177006 358 / Month 12 1.870 Intrins No 177005 358 / Month 12 1.870 Intrits No 17700 358 / Month 24 1.870 No No 17700 102001 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 174 / Month 6 1.770</td></td>
 | Treatment GroupPositive
fimmunoractivityIntransition
AssayPositive
inflammationTreatment GroupSubject IDAssayAssay Log TiterDiagnosis170010365 / Month 122.770NoNo177006383 / Month 121.870IrritisIrritis177006338 / Month 121.870IrritisNo177006338 / Month 121.870IrritisNo177006338 / Month 241.140NoNo106002722 / Month 241.130NoNo124003722 / Month 241.130NoNo124003722 / Month 241.770NoNo124003722 / Month 241.770NoNo124003722 / Month 241.770NoNo124003722 / Month 241.770No124003722 / Month 241.630No124003722 / Month 241.640No124003722 / Month 241.770No124003722 / Month 241.770No124003722 / Month 241.770No124003722 / Month 241.770No124003722 / Month 241.770No12400722 / Month 241.770No
 | Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity Innanation Treatment Group Subject ID Assy Assy Assy Innumoreactivity Innanation 365 / Month 12 2.770 No 177006 338 / Month 24 1.870 Innus | Treatment Group Positive
Inmunoreactivity Immunoreactivity Immunorea
 | Treatment Group Positive
Innumoreactivity Innumoreactivity
Innumoreactivity Innumoreactivity
Innumoreactivity Innamiation
Infiammation 170010 365 / Month 12 2.770 No 170010 355 / Month 24 2.800 Irtits 177006 355 / Month 24 1.870 No 177006 355 / Month 24 1.870 No 177006 355 / Month 24 1.140 No 17700 722 / Month 24 1.140 No 122002 723 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 359 / Month 24 1.130 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.630 No 124003 722 / Month 24 1.770 No 12400 | Treatment Group Positive Intransition Treatment Group Subject ID Assay Log Titer Inframmation 170010 365 / Month 12 2.770 No No 170010 355 / Month 24 2.870 No 177006 358 / Month 24 1.870 No 177006 358 / Month 24 1.870 No 177006 358 / Month 24 1.870 No 17700 722 / Month 24 1.870 No 122002 723 / Month 24 1.140 No 122002 359 / Month 24 1.140 No 122002 359 / Month 24 1.770 No 124003 722 / Month 24 1.770 No <td>Treatment Group Noitive
Inframoracity in the inframmation Treatment Group Subject ID South 12 Asset Jog Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.870 No No 177006 358 / Month 12 1.870 Intrins No 177005 358 / Month 12 1.870 Intrits No 17700 358 / Month 24 1.870 No No 17700 102001 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 174 / Month 6 1.770</td> | Treatment Group Noitive
Inframoracity in the inframmation Treatment Group Subject ID South 12 Asset Jog Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.870 No No 177006 358 / Month 12 1.870 Intrins No 177005 358 / Month 12 1.870 Intrits No 17700 358 / Month 24 1.870 No No 17700 102001 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 174 / Month 6 1.770 |
| I52004 522 / Early Term. 0.752 / No I53006 183 / Month 6 1.900 No 718 / Month 12 1.530 No No 718 / Month 24 2.070 No No 159017 716 / Month 24 2.070 No No 167002 717 / Mont 24 1.230 No No No 188005 717 / Month 24 1.230 No No No 534001 -7 / Screening 2.520 No No No

 | I52004 522 / Early Term. 0.752 / No 153006 183 / Month 6 1.900 No 718 / Month 12 1.530 No 718 / Month 24 2.070 No 159017 716 / Month 24 2.070 167002 717 / Mont 24 1.230 167002 717 / Month 24 1.230 188005 717 / Month 24 1.230 188005 717 / Month 24 1.250 105017 716 / Month 24 1.250 10000 1.250 No 10000 2.520 Vitritis

 | I52004 522 / Early Term. 0.752 / No 153006 183 / Month 6 1.900 No 365 / Month 12 1.530 No 718 / Month 24 2.070 No 159017 716 / Month 24 0.780 No 167002 717 / Month 24 1.230 No 188005 717 / Month 24 1.230 No 188005 717 / Month 24 1.230 No 188005 717 / Month 24 1.250 No 188005 717 / Month 24 1.250 No

 | Treatment Group Positive
fiminific ractivity Intransition
Assay Positive
Assay Intransition
Assay Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intrasocidiar Ranibizumab 0.5 mg 102001 715 / Month 24 1.870 Intris 177006 358 / Month 12 1.870 Intris No 102001 712 / Month 24 1.140 No No 102002 722 / Month 24 1.130 No No 122002 359 / Month 24 1.130 No No 122002 722 / Month 24 1.130 No No 122003 723 / Month 24 1.1700 No No 122003 357 / Month 24 1.1700 No No 124003 722 / Month 24 1.700 No No 124003 725 / Month 24 1.700 No No 124003

 | Treatment Group Positive
Innunioreactivity Innunioreactivity Innunioreactivity Innanition Assay Subject ID Assay Assay Assay Assay Innunioreactivity Innanition I 170010 365 / Month 12 2.770 No No No I 170010 355 / Month
12 1.870 Intia No I 17006 358 / Month 24 1.870 Intia No I 17006 717 / Month 24 1.870 Intia No I 104002 712 / Month 24 1.130 No No I 104002 722 / Month 24 1.130 No No I 122002 359 / Month 24 1.130 No No I 122002 359 / Month 24 1.1700 No No I 124003 722 / Month 24 1.1700 No No I 124003 723 / Month 24 1.700 No No I 1400 170 0.782 No No I 124003 723 / Month 24

 | Treatment Group Positive
Innunioreactivity Innunioreactivity Innunioreactivity Innaniation Assay Subject ID Assay Assay Assay Assay Innunioreactivity Innaniation I 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Inflammation No No 177006 358 / Month 24 1.870 Intitis No No 177006 359 / Month 24 1.870 Intitis No No 104002 719 / Month 24 1.140 No No No 104002 722 / Month 24 1.130 No No No 122003 359 / Month 24 1.1700 No No No 122003 722 / Month 24 1.1700 No No No No 124003 722 / Month 24 1.700 No No No No 124003 725 / Month 24 1.700 No No <

 | Treatment Group Positive
Innunsoreactivity Intransition
Assy Positive
Assy Intransition Areatment Group Subject ID Assy Assay Intransition I 70010 365 / Month 12 2.770 No No I 77006 358 / Month 12 2.770 No No I 77006 358 / Month 24 1.870 Intrias No I 77006 358 / Month 24 1.870 Intrias No I 102001 722 / Month 24 1.870 Intrias No I 104002 719 / Month 24 1.140 No No I 106002 722 / Month 24 1.130 No No I 122002 359 / Month 24 1.130 No No I 124003 722 / Month 24 1.1700 No No I 124003 722 / Month 24 1.1700 No No I 124003 723 / Month 24 1.700 No No I 124003 724 / Month 24 1.700 No No

 | Treatment Group Subject ID Asiay Positive
Innumoreactivity Innamiaton Aready Subject ID Asiay Asiay Innamiaton I 170010 365 / Month 12 2.770 Nio I 170010 365 / Month 12 2.770 Nio I 170010 365 / Month 12 2.770 Nio I 170010 355 / Month 24 1.870 Intrias I 170010 358 / Month 24 1.850 Nio I 102001 722 / Month 24 1.870 Nio I 104002 719 / Month 24 1.140 Nio I 106002 722 / Month 24 1.130 Nio I 22003 359 / Month 24 1.130 Nio I 24003 722 / Month 24 1.1700 Nio I 24003 722 / Month 24 1.700 Nio I 24003 722 / Month 24 1.700 Nio I 24003 723 / Month 24 1.700 Nio I 140 1.700 Nio Nio I 14008 <td< td=""><td>Treatment Group Positive
Innunsoreactivity Intransition
Assy Positive
Assy Intransition Areatment Group Subject ID Assy Assay Intransition I 70010 365 / Month 12 2.770 No No I 77006 358 / Month 12 2.770 No No I 77006 358 / Month 24 1.870 Intrias No I 77006 358 / Month 24 1.870 Intrias No I 102001 722 / Month 24 1.870 Intrias No I 104002 719 / Month 24 1.140 No No I 106002 722 / Month 24 1.130 No No I 122002 359 / Month 24 1.130 No No I 124003 722 / Month 24 1.1700 No No I 124003 722 / Month 24 1.1700 No No I 124003 723 / Month 24 1.700 No No I 124003 724 / Month 24 1.700 No No</td><td>Treatment Group Positive
Innunsoreactivity Intransition
Assy Positive
Assy Intransition Areatment Group Subject ID Assy Assay Intransition I 70010 365 / Month 12 2.770 No No I 77006 358 / Month 12 2.770 No No I 77006 358 / Month 24 1.870 Intrias No I 77006 358 / Month 24 1.870 Intrias No I 102001 722 / Month 24 1.870 Intrias No I 104002 719 / Month 24 1.140 No No I 106002 722 / Month 24 1.130 No No I 122002 359 / Month 24 1.130 No No I 124003 722 / Month 24 1.1700 No No I 124003 722 / Month 24 1.1700 No No I 124003 723 / Month 24 1.700 No No I 124003 724 / Month 24 1.700 No No</td><td>Treatment Group Positive
Innunioreactivity Innunioreactivity Innunioreactivity Innaniation Assay Subject ID Assay Assay Assay Assay Innunioreactivity Innaniation I 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Inflammation No No 177006 358 / Month 24 1.870 Intitis No No 177006 359 / Month 24 1.870 Intitis No No 104002 719 / Month 24 1.140 No No No 104002 722 / Month 24 1.130 No No No 122003 359 / Month 24 1.1700 No No No 122003 722 / Month 24 1.1700 No No No No 124003 722 / Month 24 1.700 No No No No 124003 725 / Month 24 1.700 No No <</td><td>Treatment Group Positive
Innunioreactivity Innunioreactivity Innunioreactivity Innaniation Assay Subject ID Assay Assay Assay Assay Innunioreactivity Innaniation I 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Inflammation No No 177006 358 / Month 24 1.870 Intitis No No 177006 359 / Month 24 1.870 Intitis No No 104002 719 / Month 24 1.140 No No No 104002 722 / Month 24 1.130 No No No 122003 359 / Month 24 1.1700 No No No 122003 722 / Month 24 1.1700 No No No No 124003 722 / Month 24 1.700 No No No No 124003 725 / Month 24 1.700 No No <</td><td>Treatment Group Positive
Innunioreactivity Innunioreactivity Innunioreactivity Innaniation Assay Subject ID Assay Assay Assay Assay Innunioreactivity Innaniation I 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Inflammation No No 177006 358 / Month 24 1.870 Intitis No No 177006 359 / Month 24 1.870 Intitis No No 104002 719 / Month 24 1.140 No No No 104002 722 / Month 24 1.130 No No No 122003 359 / Month 24 1.1700 No No No 122003 722 / Month 24 1.1700 No No No No 124003 722 / Month 24 1.700 No No No No 124003 725 / Month 24 1.700 No No <</td><td>Treatment Group Positive
fiminific ractivity Intransition
Assay Positive
Assay Intransition
Assay Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intrasocidiar Ranibizumab 0.5 mg 102001 715 / Month 24 1.870 Intris 177006 358 / Month 12 1.870 Intris No 102001 712 / Month 24 1.140 No No 102002 722 / Month 24 1.130 No No 122002 359 / Month 24 1.130 No No 122002 722 / Month 24 1.130 No No 122003 723 / Month 24 1.1700 No No 122003 357 / Month 24 1.1700 No No 124003 722 / Month 24 1.700 No No 124003 725 / Month 24 1.700 No No 124003</td><td>Treatment Group Positive
fiminior eactivity Intransition
Assay Positive
Assay Intransition
Assay Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intrasocular 177006 358 / Month 24 1.850 No 177006 717 / Month 24 1.850 No 102001 722 / Month 24 1.140 No 102002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 722 / Month 24 1.130 No 122003 722 / Month 24 1.1700 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 724 / Month 6 1.770 No 12400</td><td>Treatment Group Positive
Innumoreactivity
Immunoreactivity Innamination
Inframmation Assay Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.850 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 24 1.140 No 17700 717 / Month 24 1.140 No 104002 719 / Month 24 1.140 No 122002 339 / Month 12 1.630 No 122002 357 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 726/ Month 24</td><td>Treatment Group Positive
Inmunoreactivity Immunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 24 1.140 No 102001 722 / Month 24 1.140 No 104002 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 359 / Month 12 1.630 No 122002 357 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003<!--</td--><td>Treatment Group Positive Intransition Treatment Group Subject ID Assay Assay Intransition 170010 365 / Month 12 2.770 No 170010 355 / Month 12 2.770 No 177006 358 / Month 12 2.800 Irtits 177006 358 / Month 12 1.870 Irtits 177006 358 / Month 12 1.870 No 17700 358 / Month 24 0.922 No 100001 722 / Month 24 1.140 No 104002 719 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 124003 722 / Month 24 1.1700 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 723 / Month 24 0.782 No 124003 726 / Month 24 1.770 No</td><td>Treatment Group Noitive
Assist Fourinoreactivity
Assist Intrancoular
Assist Intrancoular
Assist</td></td></td<> | Treatment Group Positive
Innunsoreactivity Intransition
Assy Positive
Assy Intransition Areatment Group Subject ID Assy Assay Intransition I 70010 365 / Month 12 2.770 No No I 77006 358 / Month 12 2.770 No No I 77006 358 / Month 24 1.870 Intrias No I 77006 358 / Month 24 1.870 Intrias No I 102001 722 / Month 24 1.870 Intrias No I 104002 719 / Month 24 1.140 No No I 106002 722 / Month 24 1.130 No No I 122002 359 / Month 24 1.130 No No I 124003 722 / Month 24 1.1700 No No I 124003 722 / Month 24 1.1700 No No I 124003 723 / Month 24 1.700 No No I 124003 724 / Month 24 1.700 No No

 | Treatment Group Positive
Innunsoreactivity Intransition
Assy Positive
Assy Intransition Areatment Group Subject ID Assy Assay Intransition I 70010 365 / Month 12 2.770 No No I 77006 358 / Month 12 2.770 No No I 77006 358 / Month 24 1.870 Intrias No I 77006 358 / Month 24 1.870 Intrias No I 102001 722 / Month 24 1.870 Intrias No I 104002 719 / Month 24 1.140 No No I 106002 722 / Month 24 1.130 No No I 122002 359 / Month 24 1.130 No No I 124003 722 / Month 24 1.1700 No No I 124003 722 / Month 24 1.1700 No No I 124003 723 / Month 24 1.700 No No I 124003 724 / Month 24 1.700 No No
 | Treatment Group Positive
Innunioreactivity Innunioreactivity Innunioreactivity Innaniation Assay Subject ID Assay Assay Assay Assay Innunioreactivity Innaniation I 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Inflammation No No 177006 358 / Month 24 1.870 Intitis No No 177006 359 / Month 24 1.870 Intitis No No 104002 719 / Month 24 1.140 No No No 104002 722 / Month 24 1.130 No No No 122003 359 / Month 24 1.1700 No No No 122003 722 / Month 24 1.1700 No No No No 124003 722 / Month 24 1.700 No No No No 124003 725 / Month 24 1.700 No No <
 | Treatment Group Positive
Innunioreactivity Innunioreactivity Innunioreactivity Innaniation Assay Subject ID Assay Assay Assay Assay Innunioreactivity Innaniation I 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Inflammation No No 177006 358 / Month 24 1.870 Intitis No No 177006 359 / Month 24 1.870 Intitis No No 104002 719 / Month 24 1.140 No No No 104002 722 / Month 24 1.130 No No No 122003 359 / Month 24 1.1700 No No No 122003 722 / Month 24 1.1700 No No No No 124003 722 / Month 24 1.700 No No No No 124003 725 / Month 24 1.700 No No <
 | Treatment Group Positive
Innunioreactivity Innunioreactivity Innunioreactivity Innaniation Assay Subject ID Assay Assay Assay Assay
Innunioreactivity Innaniation I 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Inflammation No No 177006 358 / Month 24 1.870 Intitis No No 177006 359 / Month 24 1.870 Intitis No No 104002 719 / Month 24 1.140 No No No 104002 722 / Month 24 1.130 No No No 122003 359 / Month 24 1.1700 No No No 122003 722 / Month 24 1.1700 No No No No 124003 722 / Month 24 1.700 No No No No 124003 725 / Month 24 1.700 No No <
 | Treatment Group Positive
fiminific ractivity Intransition
Assay Positive
Assay Intransition
Assay Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intrasocidiar Ranibizumab 0.5 mg 102001 715 / Month 24 1.870 Intris 177006 358 / Month 12 1.870 Intris No 102001 712 / Month 24 1.140 No No 102002 722 / Month 24 1.130 No No 122002 359 / Month 24 1.130 No No 122002 722 / Month 24 1.130 No No 122003 723 / Month 24 1.1700 No No 122003 357 / Month 24 1.1700 No No 124003 722 / Month 24 1.700 No No 124003 725 / Month 24 1.700 No No 124003 | Treatment Group Positive
fiminior eactivity Intransition
Assay Positive
Assay Intransition
Assay Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intrasocular 177006 358 / Month 24 1.850 No 177006 717 / Month 24 1.850 No 102001 722 / Month 24 1.140 No 102002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 722 / Month 24 1.130 No 122003 722 / Month 24 1.1700 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770
 No 124003 723 / Month 24 1.770 No 124003 724 / Month 6 1.770 No 12400 | Treatment Group Positive
Innumoreactivity Immunoreactivity Innamination
Inframmation Assay Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.850 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 24 1.140 No 17700 717 / Month 24 1.140 No 104002 719 / Month 24 1.140 No 122002 339 / Month 12 1.630 No 122002 357 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 726/ Month 24
 | Treatment Group Positive
Inmunoreactivity Immunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 24 1.140 No 102001 722 / Month 24 1.140 No 104002 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 359 / Month 12 1.630 No 122002 357 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 </td <td>Treatment Group Positive Intransition Treatment Group Subject ID Assay Assay Intransition 170010 365 / Month 12 2.770 No 170010 355 / Month 12 2.770 No 177006 358 / Month 12 2.800 Irtits 177006 358 / Month 12 1.870 Irtits 177006 358 / Month 12 1.870 No 17700 358 / Month 24 0.922 No 100001 722 / Month 24 1.140 No 104002 719 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 124003 722 / Month 24 1.1700 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 723 / Month 24 0.782 No 124003 726 / Month 24 1.770 No</td> <td>Treatment Group Noitive
Assist Fourinoreactivity
Assist Intrancoular
Assist Intrancoular
Assist</td> | Treatment Group Positive Intransition Treatment Group Subject ID Assay Assay Intransition 170010 365 / Month 12 2.770 No 170010 355 / Month 12 2.770 No 177006 358 / Month 12 2.800 Irtits 177006 358 / Month 12 1.870 Irtits 177006 358 / Month 12 1.870 No 17700 358 / Month 24 0.922 No 100001 722 / Month 24 1.140 No 104002 719 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 124003 722 / Month 24 1.1700 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 723 / Month 24 0.782 No 124003 726 / Month 24 1.770 No | Treatment Group Noitive
Assist Fourinoreactivity
Assist Intrancoular
Assist |
| I52004 522/Early Term. 0.752 No 152006 183/Month 6 1.900 No 153006 183/Month 12 1.530 No 153007 718/Month 24 0.780 No 159017 716/Month 24 0.780 No 167002 717/Mont 24 1.230 No 188005 717/Month 24 1.230 No 188005 717/Month 24 1.230 No 1000 7360 No No

 | State State <t< th=""><td>Sham 534001 522/Early Term. 2.770 $N0$ 152004 522/Early Term. 0.752 No 153006 183/Month 6 1.900 No 153007 $365/Month 12$ 1.530 No 159017 $716/Month 24$ 2.070 No 167002 $717/Month 24$ 0.780 No 188005 $717/Month 24$ 1.230 No 188005 $717/Month 24$ 1.250 No 188005 $717/Month 24$ 1.250 No 117/Month 24 1.250 No No</td><td>Treatment Group Positive
Innunior activity Innunior activity Innunior
Assay Positive
Assay Innunior
Assay Innation Ranibizumab 0.5 mg 177006 358 / Month 12 1.870 Intus No Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No No 124003 722 / Month 12 1.630 No No No 124003 722 / Month 24 1.770 No No No No 124003 722 / Month 24 1.770 No No No No No 124003 722 / Month 24 1.770 No No No No No No No</td><td>Treatment Group Positive
fimmunoreactivity Intransition Treatment Group Subject ID Assay Intransition Assay Assay Assay Assay Intransition I 170010 365 / Month 12 2.770 No No 1 170010 365 / Month 12 2.770 No No 1 17006 338 / Month 12 1.870 Intrascentistical 1 17006 338 / Month 12 1.870 Intris 1 17006 338 / Month 12 1.870 Intris 1 10002 712 / Month 24 1.870 Intris 1 10002 722 / Month 12 1.140 No 1 12002 357 / Month 24 1.130 No 1 22002 357 / Month 24 1.770 No 1 24003 722 / Month 24 1.770 No 1 24003 723 / Month 24 1.770 No 1 24003 723 / Month 24 1.770 No 1 24003 720 / Month 24 1.940 No 1 24003</td><td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innamation Ariany Subject ID Asiay Asiay Innumoreactivity Innamation Ariany Innumoreactivity Asiay Innumoreactivity Innamation Introduction 365 / Month 12 2.770 No No Introduction 715 / Month 24 2.800 Intris No Introduction 717 / Month 24 1.870 Intris No Introduction 717 / Month 24 1.870 Intris No Introduction 722 / Month 24 1.140 No No Intervine 120002 722 / Month 24 1.130 No Intervine
120002 722 / Month 24 1.140 No Intervine 120003 723 / Month 24 1.770 No Intervine 124003 722 / Month 24 1.770 No Intervine 357 / Month 24 1.770 No No Intervine 1.770</td><td>Treatment Group Positive
Innunoreactivity Innunoreactivity Innaniation Assay Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 338 / Month 12 1.870 Irritis No 177006 338 / Month 12 1.870 Irritis No 177006 338 / Month 12 1.870 Irritis No 100002 722 / Month 24 1.140 No No 126001 722 / Month 12 1.630 No No 122002 723 / Month 12 1.630 No No 124003 722 / Month 24 1.140 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24</td></t<> <td>Treatment Group Positive
Innunoreactivity Innunoreactivity Innaniation Assay Subject ID Assay Assay Innaniation I70010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 383 / Month 12 1.870 Irritis No Rantibizumab 0.5 mg 102001 722 / Month 24 1.870 Irritis 104002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 124003 722 / Month 24 1.130 No No 124003 722 / Month 24 1.130 No No 124003 722 / Month 24 1.140 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 2</td> <td>Treatment Group Positive
Innunoreactivity Innunoreactivity Innaniation Assay Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 338 / Month 12 1.870 Irritis No 177006 338 / Month 12 1.870 Irritis No 177006 338 / Month 12 1.870 Irritis No 100002 722 / Month 24 1.140 No No 126001 722 / Month 12 1.630 No No 122002 723 / Month 12 1.630 No No 124003 722 / Month 24 1.140 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24<td>Treatment Group Positive
Innunoreactivity Innunoreactivity Innaniation Assay Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 338 / Month 12 1.870 Irritis No 177006 338 / Month 12 1.870 Irritis No 177006 338 / Month 12 1.870 Irritis No 100002 722 / Month 24 1.140 No No 126001 722 / Month 12 1.630 No No 122002 723 / Month 12 1.630 No No 124003 722 / Month 24 1.140 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24<td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innamation Ariany Subject ID Asiay Asiay Innumoreactivity Innamation Ariany Innumoreactivity Asiay Innumoreactivity Innamation Introduction 365 / Month 12 2.770 No No Introduction 715 / Month 24 2.800 Intris No Introduction 717 / Month 24 1.870 Intris No Introduction 717 / Month 24 1.870 Intris No Introduction 722 / Month 24 1.140 No No Intervine 120002 722 / Month 24 1.130 No Intervine 120002 722 / Month 24 1.140 No Intervine 120003 723 / Month 24 1.770 No Intervine 124003 722 / Month 24 1.770 No Intervine 357 / Month 24 1.770 No No Intervine 1.770</td><td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innamation Ariany Subject ID Asiay Asiay Innumoreactivity Innamation Ariany Innumoreactivity Asiay Innumoreactivity Innamation Introduction 365 / Month 12 2.770 No No Introduction 715 / Month 24 2.800 Intris No Introduction 717 / Month 24 1.870 Intris No Introduction 717 / Month 24 1.870 Intris No Introduction 722 / Month 24 1.140 No No Intervine 120002 722 / Month 24 1.130 No Intervine 120002 722 / Month 24 1.140 No Intervine 120003 723 / Month 24 1.770 No Intervine 124003 722 / Month 24 1.770 No Intervine 357 / Month 24 1.770 No No Intervine 1.770</td><td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innamation Ariany Subject ID Asiay Asiay Innumoreactivity Innamation Ariany Innumoreactivity Asiay Innumoreactivity Innamation Introduction 365 / Month 12 2.770 No No Introduction 715 / Month 24 2.800 Intris No Introduction 717 / Month 24 1.870 Intris No Introduction 717 / Month 24 1.870 Intris No Introduction 722 / Month 24 1.140 No No Intervine 120002 722 / Month 24 1.130 No Intervine 120002 722 / Month 24 1.140 No Intervine 120003 723 / Month 24 1.770 No Intervine 124003 722 / Month 24 1.770 No Intervine 357 / Month 24 1.770 No No Intervine 1.770</td><td>Treatment Group Positive
Innunior activity Innunior activity Innunior
Assay Positive
Assay Innunior
Assay Innation Ranibizumab 0.5 mg 177006 358 / Month 12 1.870 Intus No Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No No 124003 722 / Month 12 1.630 No No No 124003 722 / Month 24 1.770 No No No No 124003 722 / Month 24 1.770 No No No No No 124003 722 / Month 24 1.770 No No No No No No No</td><td>Treatment Group Bosityte
fiminificractivity Intransition
Assay Positive
Assay Intransition
Assay Intrasov
Assay Intrasov</td><td>Treatment Group Positive
Innumoreactivity Immunoreactivity Innumoreactivity Innumorea</td><td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity
Innamiation Treatment Group Subject ID 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 Inflammation 177006 715 / Month 24 1.870 Inflammation 104002 719 / Month 24 1.870 Inflammation 104002 719 / Month 24 1.130 No 104002 722 / Month 24 1.130 No 122003 359 / Month 24 1.130 No 124003 722 / Month 24 1.130 No 124003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 126001 174 / Month 6 1.770 No 126001 174 / Month 24 1.480 No 126001 172 / Month 24</td><td>Treatment Group Positive
Innunoreactivity Innunoreactivity
Innunoreactivity Innautooreactivity
Innunoreactivity Innautooreactivity
Infiammation 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 24 1.870 Irritis 177006 358 / Month 24 1.870 Irritis 104002 719 / Month 24 1.870 Irritis 104002 722 / Month 24 1.130 No 122003 359 / Month 24 1.130 No 122003 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 126001 174 / Month 6 1.700 No 126001 174 / Month 6 1.700 No 126001 174 / Month 24 1.700 No 12601 174 / Month 24 1.700 No</td><td>Treatment Group Fositive
Intranuoreactivity Intranuoreactivity Intranocular Assay Assay Assay Intranocular Intranocular ITreatment Group 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 24 1.870 Irritis No Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No 104002 719 / Month 24 1.130 No No 104002 722 / Month 24 1.170 No No 122002 359 / Month 24 1.170 No No 122002 357 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 726 / Month 24 1.770 No No 124003 7</td></td></td> | Sham 534001 522/Early Term. 2.770 $N0$ 152004 522/Early Term. 0.752 No 153006 183/Month 6 1.900 No 153007 $365/Month 12$ 1.530 No 159017 $716/Month 24$ 2.070 No 167002 $717/Month 24$ 0.780 No 188005 $717/Month 24$ 1.230 No 188005 $717/Month 24$ 1.250 No 188005 $717/Month 24$ 1.250 No 117/Month 24 1.250 No No

 | Treatment Group Positive
Innunior activity Innunior activity Innunior
Assay Positive
Assay Innunior
Assay Innation Ranibizumab 0.5 mg 177006 358 / Month 12 1.870 Intus No Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No No 124003 722 / Month 12 1.630 No No No 124003 722 / Month 24 1.770 No No No No 124003 722 / Month 24 1.770 No No No No No 124003 722 / Month 24 1.770 No No No No No No No

 | Treatment Group Positive
fimmunoreactivity Intransition Treatment Group Subject ID Assay Intransition Assay Assay Assay Assay Intransition I 170010 365 / Month 12 2.770 No No 1 170010 365 / Month 12 2.770 No No 1 17006 338 / Month 12 1.870 Intrascentistical 1 17006 338 / Month 12 1.870 Intris 1 17006 338 / Month 12 1.870 Intris 1 10002 712 / Month 24 1.870 Intris 1 10002 722 / Month 12 1.140 No 1 12002 357 / Month 24 1.130 No 1 22002 357 / Month 24 1.770 No 1 24003 722 / Month 24 1.770 No 1 24003 723 / Month 24 1.770 No 1 24003 723 / Month 24 1.770 No 1 24003 720 / Month 24 1.940 No 1 24003

 | Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innamation Ariany Subject ID Asiay Asiay Innumoreactivity Innamation Ariany Innumoreactivity Asiay Innumoreactivity Innamation Introduction 365 / Month 12 2.770 No No Introduction 715 / Month 24 2.800 Intris No Introduction 717 / Month 24 1.870 Intris No Introduction 717 / Month 24 1.870 Intris No Introduction 722 / Month 24 1.140 No No Intervine 120002 722 / Month 24 1.130 No Intervine 120002 722 / Month 24 1.140 No Intervine 120003 723 / Month 24 1.770 No Intervine 124003 722 / Month 24 1.770 No Intervine 357 / Month 24 1.770 No No Intervine 1.770

 | Treatment Group Positive
Innunoreactivity Innunoreactivity Innaniation Assay Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 338 / Month 12 1.870 Irritis No 177006 338 / Month 12 1.870 Irritis No 177006 338 / Month 12 1.870 Irritis No 100002 722 / Month 24 1.140 No No 126001 722 / Month 12 1.630 No No 122002 723 / Month 12 1.630 No No 124003 722 / Month 24 1.140 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24

 | Treatment Group Positive
Innunoreactivity Innunoreactivity Innaniation Assay Subject ID Assay Assay Innaniation I70010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 383 / Month 12 1.870 Irritis No Rantibizumab 0.5 mg 102001 722 / Month 24 1.870 Irritis 104002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 124003 722 / Month 24 1.130 No No 124003 722 / Month 24 1.130 No No 124003 722 / Month 24 1.140 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 2

 | Treatment Group Positive
Innunoreactivity Innunoreactivity Innaniation Assay Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 338 / Month 12 1.870 Irritis No 177006 338 / Month 12 1.870 Irritis No 177006 338 / Month 12 1.870 Irritis No 100002 722 / Month 24 1.140 No No 126001 722 / Month 12 1.630 No No 122002 723 / Month 12 1.630 No No 124003 722 / Month 24 1.140 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 <td>Treatment Group Positive
Innunoreactivity Innunoreactivity Innaniation Assay Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 338 / Month 12 1.870 Irritis No 177006 338 / Month 12 1.870 Irritis No 177006 338 / Month 12 1.870 Irritis No 100002 722 / Month 24 1.140 No No 126001 722 / Month 12 1.630 No No 122002 723 / Month 12 1.630 No No 124003 722 / Month 24 1.140 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24<td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innamation Ariany Subject ID Asiay Asiay Innumoreactivity Innamation Ariany Innumoreactivity Asiay Innumoreactivity Innamation Introduction 365 / Month 12 2.770 No No Introduction 715 / Month 24 2.800 Intris No Introduction 717 / Month 24 1.870 Intris No Introduction 717 / Month 24 1.870 Intris No Introduction 722 / Month 24 1.140 No No Intervine 120002 722 / Month 24 1.130 No Intervine 120002 722 / Month 24 1.140 No Intervine 120003 723 / Month 24 1.770 No Intervine 124003 722 / Month 24 1.770 No Intervine 357 / Month 24 1.770 No No Intervine 1.770</td><td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innamation Ariany Subject ID Asiay Asiay Innumoreactivity Innamation Ariany Innumoreactivity Asiay Innumoreactivity Innamation Introduction 365 / Month 12 2.770 No No Introduction 715 / Month 24 2.800 Intris No Introduction 717 / Month 24 1.870 Intris No Introduction 717 / Month 24 1.870 Intris No Introduction 722 / Month 24 1.140 No No Intervine 120002 722 / Month 24 1.130 No Intervine 120002 722 / Month 24 1.140 No Intervine 120003 723 / Month 24 1.770 No Intervine 124003 722 / Month 24 1.770 No Intervine 357 / Month 24 1.770 No No Intervine 1.770</td><td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innamation Ariany Subject ID Asiay Asiay Innumoreactivity Innamation Ariany Innumoreactivity Asiay Innumoreactivity Innamation Introduction 365 / Month 12 2.770 No No Introduction 715 / Month 24 2.800 Intris No Introduction 717 / Month 24 1.870 Intris No Introduction 717 / Month 24 1.870 Intris No Introduction 722 / Month 24 1.140 No No Intervine 120002 722 / Month 24 1.130 No Intervine 120002 722 / Month 24 1.140 No Intervine 120003 723 / Month 24 1.770 No Intervine 124003 722 / Month 24 1.770 No Intervine 357 / Month 24 1.770 No No Intervine 1.770</td><td>Treatment Group Positive
Innunior activity Innunior activity Innunior
Assay Positive
Assay Innunior
Assay Innation Ranibizumab 0.5 mg 177006 358 / Month 12 1.870 Intus No Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No No 124003 722 / Month 12 1.630 No No No 124003 722 / Month 24 1.770 No No No No 124003 722 / Month 24 1.770 No No No No No 124003 722 / Month 24 1.770 No No No No No No No</td><td>Treatment Group Bosityte
fiminificractivity Intransition
Assay Positive
Assay Intransition
Assay Intrasov
Assay Intrasov</td><td>Treatment Group Positive
Innumoreactivity Immunoreactivity Innumoreactivity Innumorea</td><td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity Innamiation Treatment Group Subject ID 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 Inflammation 177006 715 / Month 24 1.870 Inflammation 104002 719 / Month 24 1.870 Inflammation 104002 719 / Month 24 1.130 No 104002 722 / Month 24 1.130 No 122003 359 / Month 24 1.130 No 124003 722 / Month 24 1.130 No 124003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 126001 174 / Month 6 1.770 No 126001 174 / Month 24 1.480 No 126001 172 / Month 24</td><td>Treatment Group Positive
Innunoreactivity Innunoreactivity
Innunoreactivity Innautooreactivity
Innunoreactivity Innautooreactivity
Infiammation 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 24 1.870 Irritis 177006 358 / Month 24 1.870 Irritis 104002 719 / Month 24 1.870 Irritis 104002 722 / Month 24 1.130 No 122003 359 / Month
24 1.130 No 122003 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 126001 174 / Month 6 1.700 No 126001 174 / Month 6 1.700 No 126001 174 / Month 24 1.700 No 12601 174 / Month 24 1.700 No</td><td>Treatment Group Fositive
Intranuoreactivity Intranuoreactivity Intranocular Assay Assay Assay Intranocular Intranocular ITreatment Group 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 24 1.870 Irritis No Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No 104002 719 / Month 24 1.130 No No 104002 722 / Month 24 1.170 No No 122002 359 / Month 24 1.170 No No 122002 357 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 726 / Month 24 1.770 No No 124003 7</td></td> | Treatment Group Positive
Innunoreactivity Innunoreactivity Innaniation Assay Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 338 / Month 12 1.870 Irritis No 177006 338 / Month 12 1.870 Irritis No 177006 338 / Month 12 1.870 Irritis No 100002 722 / Month 24 1.140 No No 126001 722 / Month 12 1.630 No No 122002 723 / Month 12 1.630 No No 124003 722 / Month 24 1.140 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 <td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innamation Ariany Subject ID Asiay Asiay Innumoreactivity Innamation Ariany Innumoreactivity Asiay Innumoreactivity Innamation Introduction 365 / Month 12 2.770 No No Introduction 715 / Month 24 2.800 Intris No Introduction 717 / Month 24 1.870 Intris No Introduction 717 / Month 24 1.870 Intris No Introduction 722 / Month 24 1.140 No No Intervine 120002 722 / Month 24 1.130 No Intervine 120002 722 / Month 24 1.140 No Intervine 120003 723 / Month 24 1.770 No Intervine 124003 722 / Month 24 1.770 No Intervine 357 / Month 24 1.770 No No Intervine 1.770</td> <td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innamation Ariany Subject ID Asiay Asiay Innumoreactivity Innamation Ariany Innumoreactivity Asiay Innumoreactivity Innamation Introduction 365 / Month 12 2.770 No No Introduction 715 / Month 24 2.800 Intris No Introduction 717 / Month 24 1.870 Intris No Introduction 717 / Month 24 1.870 Intris No Introduction 722 / Month 24 1.140 No No Intervine 120002 722 / Month 24 1.130 No Intervine 120002 722 / Month 24 1.140 No Intervine 120003 723 / Month 24 1.770 No Intervine 124003 722 / Month 24 1.770 No Intervine 357 / Month 24 1.770 No No Intervine 1.770</td> <td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innamation Ariany Subject ID Asiay Asiay Innumoreactivity Innamation Ariany Innumoreactivity Asiay Innumoreactivity Innamation Introduction 365 / Month 12 2.770 No No Introduction 715 / Month 24 2.800 Intris No Introduction 717 / Month 24 1.870 Intris No Introduction 717 / Month 24 1.870 Intris No Introduction 722 / Month 24 1.140 No No Intervine 120002 722 / Month 24 1.130 No Intervine 120002 722 / Month 24 1.140 No Intervine 120003 723 / Month 24 1.770 No Intervine 124003 722 / Month 24 1.770 No Intervine 357 / Month 24 1.770 No No Intervine 1.770</td> <td>Treatment Group Positive
Innunior activity Innunior activity Innunior
Assay Positive
Assay Innunior
Assay Innation Ranibizumab 0.5 mg 177006 358 / Month 12 1.870 Intus No Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No No 124003 722 / Month 12 1.630 No No No 124003 722 / Month 24 1.770 No No No No 124003 722 / Month 24 1.770 No No No No No 124003 722 / Month 24 1.770 No No No No No No No</td> <td>Treatment Group Bosityte
fiminificractivity Intransition
Assay Positive
Assay Intransition
Assay Intrasov
Assay Intrasov</td> <td>Treatment Group Positive
Innumoreactivity Immunoreactivity Innumoreactivity Innumorea</td> <td>Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity Innamiation Treatment Group Subject ID 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 Inflammation 177006 715 / Month 24 1.870 Inflammation 104002 719 / Month 24 1.870 Inflammation 104002 719 / Month 24 1.130 No 104002 722 / Month 24 1.130 No 122003 359 / Month 24 1.130 No 124003 722 / Month 24 1.130 No 124003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 723 / Month
24 1.770 No 126001 174 / Month 6 1.770 No 126001 174 / Month 24 1.480 No 126001 172 / Month 24</td> <td>Treatment Group Positive
Innunoreactivity Innunoreactivity
Innunoreactivity Innautooreactivity
Innunoreactivity Innautooreactivity
Infiammation 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 24 1.870 Irritis 177006 358 / Month 24 1.870 Irritis 104002 719 / Month 24 1.870 Irritis 104002 722 / Month 24 1.130 No 122003 359 / Month 24 1.130 No 122003 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 126001 174 / Month 6 1.700 No 126001 174 / Month 6 1.700 No 126001 174 / Month 24 1.700 No 12601 174 / Month 24 1.700 No</td> <td>Treatment Group Fositive
Intranuoreactivity Intranuoreactivity Intranocular Assay Assay Assay Intranocular Intranocular ITreatment Group 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 24 1.870 Irritis No Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No 104002 719 / Month 24 1.130 No No 104002 722 / Month 24 1.170 No No 122002 359 / Month 24 1.170 No No 122002 357 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 726 / Month 24 1.770 No No 124003 7</td> | Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innamation Ariany Subject ID Asiay Asiay Innumoreactivity Innamation Ariany Innumoreactivity Asiay Innumoreactivity Innamation Introduction 365 / Month 12 2.770 No No Introduction 715 / Month 24 2.800 Intris No Introduction 717 / Month 24 1.870 Intris No Introduction 717 / Month 24 1.870 Intris No Introduction 722 / Month 24 1.140 No No Intervine 120002 722 / Month 24 1.130 No Intervine 120002 722 / Month 24 1.140 No Intervine 120003 723 / Month 24 1.770 No Intervine 124003 722 / Month 24 1.770 No Intervine 357 / Month 24 1.770 No No Intervine 1.770
 | Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innamation Ariany Subject ID Asiay Asiay Innumoreactivity Innamation Ariany Innumoreactivity Asiay Innumoreactivity Innamation Introduction 365 / Month 12 2.770 No No Introduction 715 / Month 24 2.800 Intris No Introduction 717 / Month 24 1.870 Intris No Introduction 717 / Month 24 1.870 Intris No Introduction 722 / Month 24 1.140 No No Intervine 120002 722 / Month 24 1.130 No Intervine 120002 722 / Month 24 1.140 No Intervine 120003 723 / Month 24 1.770 No Intervine 124003 722 / Month 24 1.770 No Intervine 357 / Month 24 1.770 No No Intervine 1.770
 | Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innamation Ariany Subject ID Asiay Asiay Innumoreactivity Innamation Ariany Innumoreactivity Asiay Innumoreactivity Innamation Introduction 365 / Month 12 2.770 No No Introduction 715 / Month 24 2.800 Intris No Introduction 717 / Month 24 1.870 Intris No Introduction 717 / Month 24 1.870 Intris No Introduction 722 / Month 24 1.140 No No Intervine 120002 722 / Month 24 1.130 No Intervine
 120002 722 / Month 24 1.140 No Intervine 120003 723 / Month 24 1.770 No Intervine 124003 722 / Month 24 1.770 No Intervine 357 / Month 24 1.770 No No Intervine 1.770 | Treatment Group Positive
Innunior activity Innunior activity Innunior
Assay Positive
Assay Innunior
Assay Innation Ranibizumab 0.5 mg 177006 358 / Month 12 1.870 Intus No Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No No 124003 722 /
Month 12 1.630 No No No 124003 722 / Month 24 1.770 No No No No 124003 722 / Month 24 1.770 No No No No No 124003 722 / Month 24 1.770 No No No No No No No | Treatment Group Bosityte
fiminificractivity Intransition
Assay Positive
Assay Intransition
Assay Intrasov
Assay Intrasov
 | Treatment Group Positive
Innumoreactivity Immunoreactivity Innumoreactivity Innumorea | Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity Innamiation Treatment Group Subject ID 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 Inflammation 177006 715 / Month 24 1.870 Inflammation 104002 719 / Month 24 1.870 Inflammation 104002 719 / Month 24 1.130 No 104002 722 / Month 24 1.130 No 122003 359 / Month 24 1.130 No 124003 722 / Month 24 1.130 No 124003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 126001 174 / Month 6 1.770 No 126001 174 / Month 24 1.480 No 126001 172 / Month 24
 | Treatment Group Positive
Innunoreactivity Innunoreactivity
Innunoreactivity Innautooreactivity
Innunoreactivity Innautooreactivity
Infiammation 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 24 1.870 Irritis 177006 358 / Month 24 1.870 Irritis 104002 719 / Month 24 1.870 Irritis 104002 722 / Month 24 1.130 No 122003 359 / Month 24 1.130 No 122003 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 723 / Month 24 1.770 No 126001 174 / Month 6 1.700 No 126001 174 / Month 6 1.700 No 126001 174 / Month 24 1.700 No 12601 174 / Month 24 1.700 No | Treatment Group Fositive
Intranuoreactivity Intranuoreactivity Intranocular Assay Assay Assay Intranocular Intranocular ITreatment Group 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 24 1.870 Irritis No Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No 104002 719 / Month 24 1.130 No No 104002 722 / Month 24 1.170 No No 122002 359 / Month 24 1.170 No No 122002 357 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 726 / Month 24 1.770 No No 124003 7 |
| 143010 722 / Month 24 2.440 No 152004 522 / Early Term. 0.752 No 153006 183 / Month 6 1.900 No 153017 718 / Month 12 1.530 No 718 / Month 24 2.070 No 159017 716 / Month 24 2.070 No 159017 716 / Month 24 0.780 No 167002 717 / Mont 24 1.230 No 188005 717 / Month 24 1.230 No 534001 -7 / Screening 2.520 No

 | 143010 722 / Month 24 2.440 No 152004 522 / Early Term. 0.752 No 153006 183 / Month 6 1.900 No 153017 718 / Month 12 1.530 No 718 / Month 24 2.070 No 159017 716 / Month 24 2.070 No 167002 717 / Month 24 0.780 No 188005 717 / Month 24 1.230 No 188005 717 / Month 24 1.250 No 1000 2.520 No No

 | I43010 722 / Month 24 2.440 No 152004 522 / Early Term. 0.752 No 153006 183 / Month 6 1.900 No 718 / Month 12 1.530 No 718 / Month 24 2.070 No 159017 716 / Month 24 0.780 No 167002 717 / Month 24 0.780 No 188005 717 / Month 24 1.230 No 188005 717 / Month 24 1.230 No 188005 717 / Month 24 1.250 No 188005 717 / Month 24 1.250 No

 | Treatment GroupPositive
InframmationInframmation
AssyInframmation
AssyInframmation
AssyTreatment GroupSubject IDAssyAssayInframmationSubject ID365 / Month 122.770No170010365 / Month 122.770No177006388 / Month 121.870Intris177006388 / Month 121.870IntrisRantbizumab 0.5 mg102001722 / Month 241.140No106002722 / Month 241.130No124003722 / Month 241.170No124003722 / Month 241.770No124003722 / Month 241.770No124003726 / Month 241.770No124003726 / Month 241.770No124003727 / Month 241.770No124003727 / Month 241.770No124003726 / Month 241.770No124003727 / Month 241.770No124003726 / Month 241.770No124003727 / Month 241.770No124003726 / Month 241.770No14101

 | Treatment Group Positive
Innunioreactivity Innunioreactivity Innunioreactivity Innunioreactivity Innanition Asiay Subject ID Asiay Asiay Innunioreactivity Innunioreactivity Innunioreactivity Innunioreactivity Innunioreactivity Innunivoireactivity Innaination 3 Innoi Innoit Inno

 | Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innamiation Asiay Subject ID Asiay Asiay Asiay Innamiation I70010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No 177006 338 / Month 12 1.870 Intria 177006 338 / Month 12 1.870 Intris 177006 338 / Month 24 1.140 No 104002 719 / Month 24 1.130 No 106002 722 / Month 24 1.140 No 124001 722 / Month 24 1.770 No 124001 174 / Month 12 2.040 No 124001 174 / Month 24 1.770 No 126001 174 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 352 / Month 24 1.770 No 124001 174 / Month 24 1.770 No

 | Treatment Group Positive
Innunoreactivity Innunoreactivity Innunoreactivity Innamiation Assay Subject ID Assay Assay Assay Assay Innamiation Assay 170010 365 / Month 12 2.770 Nio Nio 170010 365 / Month 12 2.800 Nio Nio 177006 338 / Month 12 1.870 Iritis Nio 177006 338 / Month 24 1.870 Iritis Nio 100001 722 / Month 24 1.140 Nio Nio 106002 722 / Month 24 1.130 Nio Nio 124003 722 / Month 24 1.770 Nio Nio 124003 174 / Month 24 1.770
 | Treatment Group Positive Innumoreactivity Innumoreactivity Innumoreactivity Innamiation Treatment Group Subject ID Assay Assay Assay Assay Innamiation Treatment Group Subject ID Assay Assay Assay Assay Assay Assay Innamiation Toolio 365 / Month 12 2.770 No

 | Treatment Group Positive
Innunoreactivity Innunoreactivity Innunoreactivity Innamiation Assay Subject ID Assay Assay Assay Assay Innamiation Assay 170010 365 / Month 12 2.770 Nio Nio 170010 365 / Month 12 2.800 Nio Nio 177006 338 / Month 12 1.870 Iritis Nio 177006 338 / Month 24 1.870 Iritis Nio 100001 722 / Month 24 1.140 Nio Nio 106002 722 / Month 24 1.130 Nio Nio 124003 722 / Month 24 1.770 Nio Nio 124003 174 / Month 24 1.770
 | Treatment Group Positive
Innunoreactivity Innunoreactivity Innunoreactivity Innamiation Assay Subject ID Assay Assay Assay Assay Innamiation Assay 170010 365 / Month 12 2.770 Nio Nio 170010 365 / Month 12 2.800 Nio Nio 177006 338 / Month 12 1.870 Iritis Nio 177006 338 / Month 24 1.870 Iritis Nio
 100001 722 / Month 24 1.140 Nio Nio 106002 722 / Month 24 1.130 Nio Nio 124003 722 / Month 24 1.770 Nio Nio 124003 174 / Month 24 1.770
 | Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innamiation Asiay Subject ID Asiay Asiay Asiay Innamiation I70010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No 177006 338 / Month 12 1.870 Intria 177006 338 / Month 12 1.870 Intris 177006 338 / Month 24 1.140 No 104002 719 / Month 24 1.130 No 106002 722 / Month 24 1.140 No 124001 722 / Month 24 1.770 No 124001 174 / Month 12 2.040 No 124001 174 / Month 24 1.770 No 126001 174 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 352 / Month 24 1.770 No 124001 174 / Month 24 1.770 No
 | Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innamiation Asiay Subject ID Asiay Asiay Asiay Innamiation I70010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No 177006 338 / Month 12 1.870 Intria 177006 338 / Month 12 1.870 Intris 177006 338 / Month 24 1.140 No 104002 719 / Month 24 1.130 No 106002 722 / Month 24 1.140 No 124001 722 / Month 24 1.770 No 124001 174 / Month 12 2.040 No 124001 174 / Month 24 1.770 No 126001 174 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 352 / Month 24 1.770 No 124001 174 / Month 24 1.770 No
 | Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innamiation Asiay Subject ID Asiay Asiay Asiay Innamiation I70010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No 177006 338 / Month 12 1.870 Intria 177006 338 / Month 12 1.870 Intris 177006 338 / Month 24 1.140 No 104002 719 / Month 24 1.130 No 106002 722 / Month 24 1.140 No 124001 722 / Month 24 1.770 No 124001 174 / Month 12 2.040 No 124001 174 / Month 24 1.770 No 126001 174 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 352 / Month 24 1.770 No 124001 174 / Month 24 1.770 No
 | Treatment GroupPositive
InframmationInframmation
AssyInframmation
AssyInframmation
AssyTreatment GroupSubject IDAssyAssayInframmationSubject ID365 / Month 122.770No170010365 / Month 122.770No177006388 / Month 121.870Intris177006388 / Month 121.870IntrisRantbizumab 0.5 mg102001722 / Month 241.140No106002722 / Month 241.130No124003722 / Month 241.170No124003722 / Month 241.770No124003722 / Month 241.770No124003726 / Month 241.770No124003726 / Month 241.770No124003727 / Month 241.770No124003727 / Month 241.770No124003726 / Month 241.770No124003727 / Month 241.770No124003726 / Month 241.770No124003727 / Month 241.770No124003726 / Month 241.770No14101
 | Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity Innanation Assay Subject ID Assay Assay Assay Diagnosis Innanation I 170010 365 / Month 12 2.770 No No No 177006 338 / Month 12 1.870 Intits No 177006 338 / Month 24 1.870 Intits No 177006 338 / Month 24 1.870 Intits No 100002 722 / Month 24 1.140 No No 124003 722 / Month 24 1.130 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24
 | Treatment Group Subject ID Positive
fiminumoreactivity Inframmation Treatment Group Subject ID Assay Assay Inframmation Introduction 365 / Month 12 2.770 No No Introduction 365 / Month 12 2.770 No No Introduction 365 / Month 12 2.770 No No Introduction 365 / Month 12 1.870 Intrins No Introduction 717 / Month 24 1.870 Intris No Introduction 717 / Month 24 1.850 No No Introduction 722 / Month 24 1.140 No No Introduction 722 / Month 24 1.170 No No Introduction 722 / Month 24 1.770 No No Internation 723 / Month 24 1.770 No No Internation 723 / Month 24 1.770 No No Internation 723 / Month 24 1.770 No No | Treatment Group Subject ID Positive
Assay Inframmation Treatment Group Subject ID Assay Assay Inframmation I70010 365 / Month 12 2.770 No No 17006 358 / Month 12 2.800 Iritis No 177006 358 / Month 12 1.870 Iritis
 No 177006 358 / Month 12 1.870 Iritis No 17700 717 / Month 24 1.870 Iritis No 104002 719 / Month 24 1.140 No No 102001 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 722 / Month 24 1.130 No No 124003 722 / Month 24 1.130 No No 126001 1720 / Month 24 1.170 No No 124003 722 / Month 24 1.700 No No 126001 17000001 1.77 | Treatment Group Subject ID Positive Intrancontactivity | Treatment Group Positive
Innumoreactivity Innumoreactivity Innumoreactivity Innumoreactivity Innumation Treatment Group Subject ID Assay Assay Assay Assay Assay Inframmation 170010 365 / Month 12 2.770 No No No 177006 355 / Month 12 1.870 Irrius No 177006 358 / Month 12 1.870 Irrius No 17700 358 / Month 12 1.870 Irrius No 104002 719 / Month 24 1.870 Irrius No 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.130 No No 122002 357 / Month 24 1.1770 No No 124003 722 / Month 24 1.130 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 |
| I43010722 / Month 24 2.440 No152004 $522 / Early Term.$ 0.752 ,No153006 $183 / Month 6$ 1.900 No $365 / Month 12$ 1.530 No $718 / Month 24$ 2.070 No 159017 $716 / Month 24$ 2.070 No 167002 $717 / Month 24$ 0.780 No 188005 $717 / Month 24$ 1.230 No 88005 $717 / Month 24$ 1.230 No 88005 $717 / Month 24$ 1.250 No

 | 143010 722 / Month 24 2.440 No 152004 522 / Early Term. 0.752 , No 153006 183 / Month 6 1.900 No 153005 183 / Month 12 1.530 No 718 / Month 24 2.070 No 159017 716 / Month 24 0.780 No 167002 717 / Month 24 0.780 No 188005 717 / Month 24 1.230 No 534001 -7 / Screening 2.520 No

 | Id=100 722 / Month 24 2.440 No 152004 522 / Early Term. 0.752 No 153006 183 / Month 6 1.900 No 153006 183 / Month 12 1.530 No 718 / Month 24 2.070 No 159017 716 / Month 24 2.070 No 167002 717 / Mont 24 1.230 No 188005 717 / Month 24 1.230 No 534001 -7 / Screening 2.520 No

 | Treatment Group Positive
Innunoreactivity Innunoreactivity Innamation Asiay Subject ID Asiay Asiay Innunoreactivity Innamation IToblect ID 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis No No 177006 358 / Month 24 1.870 Irritis No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No No 104002 719 / Month 24 1.130 No No No 122002 359 / Month 12 1.630 No No No 122002 359 / Month 12 1.630 No No No No 122002 359 / Month 12 1.630 No No No No 124003 722 / Month 12 2.040 No No No No No <

 | Treatment Group Positive
Innunoreactivity Innamination
Assay Diagnosis 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Iritis 177005 358 / Month 12 1.870 Iritis 177006 358 / Month 24 1.870 Iritis 102001 722 / Month 24 1.870 No 102002 719 / Month 24 1.140 No 1122002 359 / Month 12 1.630 No 122002 359 / Month 12
1.630 No 124003 722 / Month 24 1.770 No 126001 1.74 0.782 No 126001 1.74 0.782 No <

 | Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Atsay Subject ID Assay Assay Assay Assay Assay Infammation 170010 365 / Month 12 2.770 No No No 170010 358 / Month 12 2.800 Infammation 177006 358 / Month 12 1.870 Infammation Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Infaitis 104002 719 / Month 24 1.870 Infaitis No 122002 359 / Month 12 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 124003 722 / Month 12 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 6 1.770 No

 | Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Atsay Subject ID Sasy Jog Diagnosis 170010 365 / Month 12 2.770 No 170010 355 / Month 12 2.800 Infammation 177006 358 / Month 12 1.870 Infammation Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Initis 104002 719 / Month 24 1.870 Initis No 102001 722 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.1700 No No 122002 359 / Month 12 1.630 No No 122003 359 / Month 12 1.630 No No 124003 722 / Month 24 1.770 No No 126001 1.74 / Month 6 1.770 <td>Treatment Group Positive Positive Intranceutar Intranceutar Areatment Group Subject ID Assay Assay Assay Intranceutar IT0010 365/Month 12 2.770 No No IT70016 358/Month 12 1.870 Intraceutar IT70010 358/Month 12 1.870 Intraceutar Ranibizumab 0.5 mg 102001 715/Month 24 1.870 Intraceutar Ranibizumab 0.5 mg 102001 722/Month 24 1.140 No Intraceutar 102001 722/Month 24 1.130 No Intraceutar 1.130 No No No Intraceutar 722/Month 12 1.630 No No Intraceutar 722/Month 24 1.1700 No No Intraceutar 723/Month 12 2.040 No No Intraceutar 723/Month 24 1.700 No No Intraceutar 723/Month 24 1.700 No No <</td> <td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Atsay Subject ID Sasy Jog Diagnosis 170010 365 / Month 12 2.770 No 170010 355 / Month 12 2.800 Infammation 177006 358 / Month 12 1.870 Infammation Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Initis 104002 719 / Month 24 1.870 Initis No 102001 722 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.1700 No No 122002 359 / Month 12 1.630 No No 122003 359 / Month 12 1.630 No No 124003 722 / Month 24 1.770 No No 126001 1.74 / Month 6 1.770<td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Atsay Subject ID Sasy Jog Diagnosis 170010 365 / Month 12 2.770 No 170010 355 / Month 12 2.800 Infammation 177006 358 / Month 12 1.870 Infammation Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Initis 104002 719 / Month 24 1.870 Initis No 102001 722 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.1700 No No 122002 359 / Month 12 1.630 No No 122003 359 / Month 12 1.630 No No 124003 722 / Month 24 1.770 No No 126001 1.74 / Month 6 1.770<td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Atsay Subject ID Assay Assay Assay Assay Assay Infammation 170010 365 / Month 12 2.770 No No No 170010 358 / Month 12 2.800 Infammation 177006 358 / Month 12 1.870 Infammation Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Infaitis 104002 719 / Month 24 1.870 Infaitis No 122002 359 / Month 12 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 124003 722 / Month 12 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 6 1.770 No</td><td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Atsay Subject ID Assay Assay Assay Assay Assay Infammation 170010 365 / Month 12 2.770 No No No 170010 358 / Month 12 2.800 Infammation 177006 358 / Month 12 1.870 Infammation Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Infaitis 104002 719 / Month 24 1.870 Infaitis No 122002 359 / Month 12 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 124003 722 / Month 12 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 6 1.770 No</td><td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Atsay Subject ID Assay Assay Assay Assay Assay Infammation 170010 365 / Month 12 2.770 No No No 170010 358 / Month 12 2.800 Infammation 177006 358 / Month 12 1.870 Infammation Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Infaitis 104002 719 / Month 24 1.870 Infaitis No 122002 359 / Month 12 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 124003 722 / Month 12 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 6 1.770 No</td><td>Treatment Group
Positive
Innunoreactivity Innunoreactivity Innamation Asiay Subject ID Asiay Asiay Innunoreactivity Innamation IToblect ID 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis No No 177006 358 / Month 24 1.870 Irritis No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No No 104002 719 / Month 24 1.130 No No No 122002 359 / Month 12 1.630 No No No 122002 359 / Month 12 1.630 No No No No 122002 359 / Month 12 1.630 No No No No 124003 722 / Month 12 2.040 No No No No No <</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immation Assay Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 358 / Month 12 1.870 Intraotion 177006 358 / Month 12 1.870 Intraotion 177001 717 / Month 24 1.870 Intris 104002 719 / Month 24 1.140 No 102001 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 359 / Month 12 1.630 No 122002 359 / Month 12 1.630 No 124003 722 / Month 12 1.630 No 126001 174 / Month 6 1.770 No 126001 174 / Month 6 1.770 No 126001 174 1.480 No <td< td=""><td>Treatment Group Bubject ID Positive
Assay Inframmation
Assay Inframmation
Assay Inframmation Treatment Group Subject ID Assay Assay Assay Inframmation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 104002 719 / Month 24 1.870 No 104002 719 / Month 24 1.140 No 1122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 124003 722 / Month 12 1.770 No No 126001 174 / Month 6 1.770</td><td>Treatment Group Subject ID Positive
Assay Intranocractivity
Assay Log Titer Intranocriat
Inflammation 170010 365 / Month 12 2.770 No 177006 385 / Month 12 2.770 No 177006 385 / Month 12 1.870 Inflammation Rantbizumab 0.5 mg 102001 715 / Month 24 1.870 Inflam 177006 388 / Month 12 1.870 Inflam No 104002 719 / Month 24 1.870 Inflam No 102001 722 / Month 24 1.140 No No 1122002 359 / Month 12 1.630 No No 1124003 722 / Month 24 1.130 No No 1126001 174 / Month 6 1.770 No No 1126001 174 / Month 6<!--</td--><td>Treatment Group Subject ID Positive
Assay Intranscription
Assay Intranscription
Ass</td><td>Treatment Group Subject ID Fositive
Assay Immunoreactivity
Assay Log Titer Intranocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Iritis Ranibizumab 0.5 mg 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 17700 722 / Month 24 1.140 No No 106002 722 / Month 12 1.650 No No 122002 359 / Month 12 1.650 No No 122002 359 / Month 12 1.650 No No 122002 359 / Month 12 1.650 No No 124003 722 / Month 24 1.170 No No 126001 174 / Month 6 1.700 No No 1210008 181 / Month 6 1.7</td></td></td<></td></td></td> | Treatment Group Positive Positive Intranceutar Intranceutar Areatment Group Subject ID Assay Assay Assay Intranceutar IT0010 365/Month 12 2.770 No No IT70016 358/Month 12 1.870 Intraceutar IT70010 358/Month 12 1.870 Intraceutar Ranibizumab 0.5 mg 102001 715/Month 24 1.870 Intraceutar Ranibizumab 0.5 mg 102001 722/Month 24 1.140 No Intraceutar 102001 722/Month 24 1.130 No Intraceutar 1.130 No No No Intraceutar 722/Month 12 1.630 No No Intraceutar 722/Month 24 1.1700 No No Intraceutar 723/Month 12 2.040 No No Intraceutar 723/Month 24 1.700 No No Intraceutar 723/Month 24 1.700 No No <

 | Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Atsay Subject ID Sasy Jog Diagnosis 170010 365 / Month 12 2.770 No 170010 355 / Month 12 2.800 Infammation 177006 358 / Month 12 1.870 Infammation Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Initis 104002 719 / Month 24 1.870 Initis No 102001 722 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.1700 No No 122002 359 / Month 12 1.630 No No 122003 359 / Month 12 1.630 No No 124003 722 / Month 24 1.770 No No 126001 1.74 / Month 6 1.770 <td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Atsay Subject ID Sasy Jog Diagnosis 170010 365 / Month 12 2.770 No 170010 355 / Month 12 2.800 Infammation 177006 358 / Month 12 1.870 Infammation Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Initis 104002 719 / Month 24 1.870 Initis No 102001 722 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.1700 No No 122002 359 / Month 12 1.630 No No 122003 359 / Month 12 1.630 No No 124003 722 / Month 24 1.770 No No 126001 1.74 / Month 6 1.770<td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Atsay Subject ID Assay Assay Assay Assay Assay Infammation 170010 365 / Month 12 2.770 No No No 170010 358 / Month 12 2.800 Infammation 177006 358 / Month 12 1.870 Infammation Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Infaitis 104002 719 / Month 24 1.870 Infaitis No 122002 359 / Month 12 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 124003 722 / Month 12 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 6 1.770 No</td><td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Atsay Subject ID Assay Assay Assay Assay Assay Infammation 170010 365 / Month 12 2.770 No No No 170010 358 / Month 12 2.800 Infammation 177006 358 / Month 12 1.870 Infammation Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Infaitis 104002 719 / Month 24 1.870 Infaitis No 122002 359 / Month 12 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 124003 722 / Month 12 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 6 1.770 No</td><td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Atsay Subject ID Assay Assay Assay Assay Assay Infammation 170010 365 / Month 12 2.770 No No No 170010 358 / Month 12 2.800 Infammation 177006 358 / Month 12 1.870 Infammation Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Infaitis 104002 719 / Month 24 1.870 Infaitis No 122002 359 / Month 12 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 124003 722 / Month 12 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 6 1.770 No</td><td>Treatment Group Positive
Innunoreactivity Innunoreactivity Innamation Asiay Subject ID Asiay Asiay Innunoreactivity Innamation IToblect ID 365 / Month 12 2.770 No No No
170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis No No 177006 358 / Month 24 1.870 Irritis No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No No 104002 719 / Month 24 1.130 No No No 122002 359 / Month 12 1.630 No No No 122002 359 / Month 12 1.630 No No No No 122002 359 / Month 12 1.630 No No No No 124003 722 / Month 12 2.040 No No No No No <</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immation Assay Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 358 / Month 12 1.870 Intraotion 177006 358 / Month 12 1.870 Intraotion 177001 717 / Month 24 1.870 Intris 104002 719 / Month 24 1.140 No 102001 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 359 / Month 12 1.630 No 122002 359 / Month 12 1.630 No 124003 722 / Month 12 1.630 No 126001 174 / Month 6 1.770 No 126001 174 / Month 6 1.770 No 126001 174 1.480 No <td< td=""><td>Treatment Group Bubject ID Positive
Assay Inframmation
Assay Inframmation
Assay Inframmation Treatment Group Subject ID Assay Assay Assay Inframmation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 104002 719 / Month 24 1.870 No 104002 719 / Month 24 1.140 No 1122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 124003 722 / Month 12 1.770 No No 126001 174 / Month 6 1.770</td><td>Treatment Group Subject ID Positive
Assay Intranocractivity
Assay Log Titer Intranocriat
Inflammation 170010 365 / Month 12 2.770 No 177006 385 / Month 12 2.770 No 177006 385 / Month 12 1.870 Inflammation Rantbizumab 0.5 mg 102001 715 / Month 24 1.870 Inflam 177006 388 / Month 12 1.870 Inflam No 104002 719 / Month 24 1.870 Inflam No 102001 722 / Month 24 1.140 No No 1122002 359 / Month 12 1.630 No No 1124003 722 / Month 24 1.130 No No 1126001 174 / Month 6 1.770 No No 1126001 174 / Month 6<!--</td--><td>Treatment Group Subject ID Positive
Assay Intranscription
Assay Intranscription
Ass</td><td>Treatment Group Subject ID Fositive
Assay Immunoreactivity
Assay Log Titer Intranocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Iritis Ranibizumab 0.5 mg 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 17700 722 / Month 24 1.140 No No 106002 722 / Month 12 1.650 No No 122002 359 / Month 12 1.650 No No 122002 359 / Month 12 1.650 No No 122002 359 / Month 12 1.650 No No 124003 722 / Month 24 1.170 No No 126001 174 / Month 6 1.700 No No 1210008 181 / Month 6 1.7</td></td></td<></td></td> | Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Atsay Subject ID Sasy Jog Diagnosis 170010 365 / Month 12 2.770 No 170010 355 / Month 12 2.800 Infammation 177006 358 / Month 12 1.870 Infammation Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Initis 104002 719 / Month 24 1.870 Initis No 102001 722 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.1700 No No 122002 359 / Month 12 1.630 No No 122003 359 / Month 12 1.630 No No 124003 722 / Month 24 1.770 No No 126001 1.74 / Month 6 1.770 <td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Atsay Subject ID Assay Assay Assay Assay Assay Infammation 170010 365 / Month 12 2.770 No No No 170010 358 / Month 12 2.800 Infammation 177006 358 / Month 12 1.870 Infammation Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Infaitis 104002 719 / Month 24 1.870 Infaitis No 122002 359 / Month 12 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 124003 722 / Month 12 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 6 1.770 No</td> <td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Atsay Subject ID Assay Assay Assay Assay Assay Infammation 170010 365 / Month 12 2.770 No No No 170010 358 / Month 12 2.800 Infammation 177006 358 / Month 12 1.870 Infammation Ranibizumab
0.5 mg 102001 722 / Month 24 1.870 Infaitis 104002 719 / Month 24 1.870 Infaitis No 122002 359 / Month 12 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 124003 722 / Month 12 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 6 1.770 No</td> <td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Atsay Subject ID Assay Assay Assay Assay Assay Infammation 170010 365 / Month 12 2.770 No No No 170010 358 / Month 12 2.800 Infammation 177006 358 / Month 12 1.870 Infammation Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Infaitis 104002 719 / Month 24 1.870 Infaitis No 122002 359 / Month 12 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 124003 722 / Month 12 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 6 1.770 No</td> <td>Treatment Group Positive
Innunoreactivity Innunoreactivity Innamation Asiay Subject ID Asiay Asiay Innunoreactivity Innamation IToblect ID 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis No No 177006 358 / Month 24 1.870 Irritis No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No No 104002 719 / Month 24 1.130 No No No 122002 359 / Month 12 1.630 No No No 122002 359 / Month 12 1.630 No No No No 122002 359 / Month 12 1.630 No No No No 124003 722 / Month 12 2.040 No No No No No <</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immation Assay Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 358 / Month 12 1.870 Intraotion 177006 358 / Month 12 1.870 Intraotion 177001 717 / Month 24 1.870 Intris 104002 719 / Month 24 1.140 No 102001 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 359 / Month 12 1.630 No 122002 359 / Month 12 1.630 No 124003 722 / Month 12 1.630 No 126001 174 / Month 6 1.770 No 126001 174 / Month 6 1.770 No 126001 174 1.480 No <td< td=""><td>Treatment Group Bubject ID Positive
Assay Inframmation
Assay Inframmation
Assay Inframmation Treatment Group Subject ID Assay Assay Assay Inframmation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 104002 719 / Month 24 1.870 No 104002 719 / Month 24 1.140 No 1122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 124003 722 / Month 12 1.770 No No 126001 174 / Month 6 1.770</td><td>Treatment Group Subject ID Positive
Assay Intranocractivity
Assay Log Titer Intranocriat
Inflammation 170010 365 / Month 12 2.770 No 177006 385 / Month 12 2.770 No 177006 385 / Month 12 1.870 Inflammation Rantbizumab 0.5 mg 102001 715 / Month 24 1.870 Inflam 177006 388 / Month 12 1.870 Inflam No 104002 719 / Month 24 1.870 Inflam No 102001 722 / Month 24 1.140 No No 1122002 359 / Month 12 1.630 No No 1124003 722 / Month 24 1.130 No No 1126001 174 / Month 6 1.770 No No 1126001 174 / Month 6<!--</td--><td>Treatment Group Subject ID Positive
Assay Intranscription
Assay Intranscription
Ass</td><td>Treatment Group Subject ID Fositive
Assay Immunoreactivity
Assay Log Titer Intranocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Iritis Ranibizumab 0.5 mg 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 17700 722 / Month 24 1.140 No No 106002 722 / Month 12 1.650 No No 122002 359 / Month 12 1.650 No No 122002 359 / Month 12 1.650 No No 122002 359 / Month 12 1.650 No No 124003 722 / Month 24 1.170 No No 126001 174 / Month 6 1.700 No No 1210008 181 / Month 6 1.7</td></td></td<></td> | Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Atsay Subject ID Assay Assay Assay Assay Assay Infammation 170010 365 / Month 12 2.770 No No No 170010 358 / Month 12 2.800 Infammation 177006 358 / Month 12 1.870 Infammation Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Infaitis 104002 719 / Month 24 1.870 Infaitis No 122002
 359 / Month 12 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 124003 722 / Month 12 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 6 1.770 No
 | Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Atsay Subject ID Assay Assay Assay Assay Assay Infammation 170010 365 / Month 12 2.770 No No No 170010 358 / Month 12 2.800 Infammation 177006 358 / Month 12 1.870 Infammation Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Infaitis 104002 719 / Month 24 1.870 Infaitis No 122002 359 / Month 12 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 124003 722 / Month 12 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 6 1.770 No
 | Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Atsay Subject ID Assay Assay Assay Assay Assay Infammation 170010 365 / Month 12 2.770 No No No 170010 358 / Month 12 2.800 Infammation 177006 358 / Month 12 1.870 Infammation Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Infaitis 104002 719 / Month 24 1.870 Infaitis No 122002 359 / Month 12 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 124003 722 / Month 12 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 6 1.770 No
 | Treatment Group Positive
Innunoreactivity Innunoreactivity Innamation Asiay Subject ID Asiay Asiay Innunoreactivity Innamation IToblect ID 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis No No 177006 358 / Month 24 1.870 Irritis No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No No 104002 719 / Month 24 1.130 No No No 122002 359 / Month 12 1.630 No No No 122002 359 / Month 12 1.630 No No No No 122002 359 / Month 12 1.630 No No No No 124003 722 / Month 12 2.040 No No No No No <
 | Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immation Assay Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 358 / Month 12 1.870 Intraotion 177006 358 / Month 12 1.870 Intraotion 177001 717 / Month 24 1.870 Intris 104002 719 / Month 24 1.140 No 102001 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 359 / Month 12 1.630 No 122002 359 / Month 12 1.630 No 124003 722 / Month 12 1.630 No 126001 174 / Month 6 1.770 No 126001 174 / Month 6 1.770 No 126001 174 1.480 No <td< td=""><td>Treatment Group Bubject ID Positive
Assay Inframmation
Assay Inframmation
Assay Inframmation Treatment Group Subject ID Assay Assay Assay Inframmation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 104002 719 / Month 24 1.870 No 104002 719 / Month 24 1.140 No 1122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 124003 722 / Month 12 1.770 No No 126001 174 / Month 6 1.770</td><td>Treatment Group Subject ID Positive
Assay Intranocractivity
Assay Log Titer Intranocriat
Inflammation 170010 365 / Month 12 2.770 No 177006 385 / Month 12 2.770 No 177006 385 / Month 12 1.870 Inflammation Rantbizumab 0.5 mg 102001 715 / Month 24 1.870 Inflam 177006 388 / Month 12 1.870 Inflam No 104002 719 / Month 24 1.870 Inflam No 102001 722 / Month 24 1.140 No No 1122002 359 / Month 12 1.630 No No 1124003 722 / Month 24 1.130 No No 1126001 174 / Month 6 1.770 No No 1126001 174 / Month 6<!--</td--><td>Treatment Group Subject ID Positive
Assay Intranscription
Assay Intranscription
Ass</td><td>Treatment Group Subject ID Fositive
Assay Immunoreactivity
Assay Log Titer Intranocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Iritis Ranibizumab 0.5 mg 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 17700 722 / Month 24 1.140 No No 106002 722 / Month 12 1.650 No No 122002 359 / Month 12 1.650 No No 122002 359 / Month 12 1.650 No No 122002 359 / Month 12 1.650 No No 124003 722 / Month 24 1.170 No No 126001 174 / Month 6 1.700 No No 1210008 181 / Month 6 1.7</td></td></td<> | Treatment Group Bubject ID Positive
Assay Inframmation
Assay Inframmation
Assay Inframmation Treatment Group Subject ID Assay Assay Assay Inframmation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 104002 719 / Month 24 1.870 No 104002 719 / Month 24 1.140 No 1122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 124003 722 / Month 12 1.770 No No 126001 174 / Month 6 1.770
 | Treatment Group Subject ID Positive
Assay Intranocractivity
Assay Log Titer Intranocriat
Inflammation 170010 365 / Month 12 2.770 No 177006 385 / Month 12 2.770 No 177006 385 / Month 12 1.870 Inflammation Rantbizumab 0.5 mg 102001 715 / Month 24 1.870 Inflam 177006 388 / Month 12 1.870 Inflam No 104002 719 / Month 24 1.870 Inflam No 102001 722 / Month 24 1.140 No No 1122002 359 / Month 12 1.630 No No 1124003 722 / Month 24 1.130 No No 1126001 174 / Month 6 1.770 No No 1126001 174 / Month 6 </td <td>Treatment Group Subject ID Positive
Assay Intranscription
Assay Intranscription
Ass</td> <td>Treatment Group Subject ID Fositive
Assay Immunoreactivity
Assay Log Titer Intranocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Iritis Ranibizumab 0.5 mg 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 17700 722 / Month 24 1.140 No No 106002 722 / Month 12 1.650 No No 122002 359 / Month 12 1.650 No No 122002 359 / Month 12 1.650 No No 122002 359 / Month 12 1.650 No No 124003 722 / Month 24 1.170 No No 126001 174 / Month 6 1.700 No No 1210008 181 / Month 6 1.7</td> | Treatment Group Subject ID Positive
Assay Intranscription
Assay Intranscription
Ass | Treatment Group Subject ID Fositive
Assay Immunoreactivity
Assay Log Titer Intranocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Iritis Ranibizumab 0.5 mg 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 17700 722 / Month 24 1.140 No No 106002 722 / Month 12 1.650 No No 122002 359 / Month 12 1.650 No No 122002 359 / Month 12 1.650 No No 122002 359 / Month 12 1.650 No No 124003 722 / Month 24 1.170 No No 126001 174 / Month 6 1.700 No No 1210008 181 / Month 6 1.7 |
| I41013 /12 / Month 24 2.610 Vitnits 143010 722 / Month 24 2.440 Nio 152004 $522 / Early Term$ 0.752 Nio 153006 $183 / Month 6$ 1.900 Nio 153017 $718 / Month 24$ 2.070 Nio 159017 $718 / Month 24$ 2.070 Nio 159017 $716 / Month 24$ 2.070 Nio 167002 $717 / Mont 24$ 0.780 Nio 188005 $717 / Mont 24$ 1.230 Nio 188005 $717 / Mont 24$ 1.250 Nio 188005 $717 / Month 24$ 1.250 Nio

 | I41013 715 / Month 24 2.610 Vitnitis 143010 722 / Month 24 2.440 Nio 152004 $522 / Early Term.$ 0.752 , Nio 153006 $183 / Month 6$ 1.900 Nio 153017 $718 / Month 24$ 2.070 Nio 159017 $716 / Month 24$ 2.070 Nio 159017 $716 / Month 24$ 2.070 Nio 167002 $717 / Mont 24$ 0.780 Nio 188005 $717 / Mont 24$ 1.230 Nio 188005 $717 / Mont 24$ 1.250 Nio 188005 $717 / Month 24$ 1.250 Nio

 | I41013 /12 / Month 24 2.610 Vitnits 143010 722 / Month 24 2.440 Nio 153006 183 / Month 6 1.900 Nio 153006 183 / Month 12 1.530 Nio 153006 183 / Month 12 1.900 Nio 153006 183 / Month 12 1.530 Nio 153006 183 / Month 12 1.530 Nio 153007 718 / Month 24 2.070 Nio 159017 716 / Month 24 0.780 Nio 167002 717 / Mont 24 1.230 Nio 188005 717 / Month 24 1.230 Nio Sham 534001 -7 / Screening 2.520 Vitritis

 | Treatment Group Dositive
Immunoreactivity Immunoreactivity Immunoreactivity Areatment Group Subject ID Assay Assay Assay Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 Inframmation 177006 358 / Month 12 1.870 Inframmation Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.1700 No No 124003 722 / Month 24 1.7700 No No 126001 174 / Month 24 1.7700 No No 126001 17

 | Treatment Group Positive Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 170010 355/Month 12 1.870 Inframmation 177006 358/Month 12 1.870 Inframmation Ranibizumab 0.5 mg 102001 722/Month 24 1.870 Infrais 122002 359/Month 12 1.870 Infrais No 122002 719/Month 24
1.140 No No 122002 722/Month 24 1.130 No No 122002 722/Month 24 1.1700 No No 124003 722/Month 24 1.1700 No No 126001 174/Month 24 1.7700 No No 126001 174/Month 24 1.7700 No No 126001 174/Month 24 1.7700 No No 126001 172/Month 24 1.7700 <td< td=""><td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Areatment Group Subject ID Assay Assay</td><td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Jreatment Group Subject ID Assay Assay Assay Iog 170010 365/Month 12 2.770 No No 177006 358/Month 12 1.870 Irritis 177006 358/Month 12 1.870 Irritis Ranibizumab 0.5 mg 102001 722/Month 24 1.870 Irritis 177006 359/Month 12 1.870 Irritis No 104002 719/Month 24 1.140 No No 122002 359/Month 24 1.130 No No 122002 722/Month 24 1.1700 No No 124003 722/Month 24 1.7700 No No 126001 174/Month 24</td></td<> <td>Treatment Group Positive
Subject ID Positive
Assay Intranceutar Intraceutar 176attment Group Subject ID Assay Assay Assay Intraceutar 170010 365/Month 12 2.770 No No 177006 358/Month 12 1.870 Intraceutar 177006 358/Month 12 1.870 Intraceutar Ranibizumab 0.5 mg 102001 722/Month 24 1.870 Intraceutar 104002 719/Month 24 1.140 No No No 102001 722/Month 24 1.130 No No No 122002 359/Month 12 1.630 No No No 122002 722/Month 24 1.1700 No No No 124003 722/Month 24 1.7700 No No No 126001 174/Month 6 1.7700 No No No 126001 174/Month 24 1.700 No No No 126001 <td< td=""><td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Jreatment Group Subject ID Assay Assay Assay Iog 170010 365/Month 12 2.770 No No 177006 358/Month 12 1.870 Irritis 177006 358/Month 12 1.870 Irritis Ranibizumab 0.5 mg 102001 722/Month 24 1.870 Irritis 177006 359/Month 12 1.870 Irritis No 104002 719/Month 24 1.140 No No 122002 359/Month 24 1.130 No No 122002 722/Month 24 1.1700 No No 124003 722/Month 24 1.7700 No No 126001 174/Month 24</td></td<><td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Jreatment Group Subject ID Assay Assay Assay Iog 170010 365/Month 12 2.770 No No 177006 358/Month 12 1.870 Irritis 177006 358/Month 12 1.870 Irritis Ranibizumab 0.5 mg 102001 722/Month 24 1.870 Irritis 177006 359/Month 12 1.870 Irritis No 104002 719/Month 24 1.140 No No 122002 359/Month 24 1.130 No No 122002 722/Month 24 1.1700 No No 124003 722/Month 24 1.7700 No No 126001 174/Month 24<td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Areatment Group Subject ID Assay Assay</td><td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Areatment Group Subject ID Assay Assay</td><td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Areatment Group Subject ID Assay Assay</td><td>Treatment Group Dositive
Immunoreactivity Immunoreactivity Immunoreactivity Areatment Group Subject ID Assay Assay Assay Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 Inframmation 177006 358 / Month 12 1.870 Inframmation Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.1700 No No 124003 722 / Month 24 1.7700 No No 126001 174 / Month 24 1.7700 No No 126001 17</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Areatment Group Subject ID Assay Assay Assay Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 Inframmation 177006 358 / Month 12 1.870 Inframmation Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Infraitis 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.1700 No No 124003 722 / Month 24 1.7700 No No 126001 174 / Month 2 1.630 No No 126001 174 / Month 2 1.770 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 6 1.770 No No 126001 174</td><td>Treatment Group Positive
Innunoreactivity Innunoreactivity
Innunoreactivity Innantion
Innunoreactivity Treatment Group Subject ID Assay Assay Innunoreactivity Innunoreactivity 170010 365/Month 12 2770 No No No 170010 365/Month 12 2800 Innunoreactivity Innunoreactivity Innunoreactivity Ranibizumab 0.5 mg 102001 715/Month 24 1870 Intitis No 102001 722/Month 24 1130 No No No No 122002 359/Month 12 1630 No No No No 122002 359/Month 24 1.1700 No No No No 122002 359/Month 12 1.630 No No No No 122002 359/Month 24 1.1700 No No No No 122002 359/Month 12 1.630 No No No No 124003 722/Month 24 1</td><td>Treatment Group Positive
Subject ID Positive
Assay Inframmation
Assay Inframmation
Assay ITool10 365 / Month 12 2.770 No 170015 358 / Month 12 2.800 No 177006 358 / Month 12 1.870 Irritis Ranibizumab 0.5 mg 102001 715 / Month 24 1.870 No 107005 358 / Month 12 1.870 Irritis No 1177006 358 / Month 12 1.870 Irritis No 102001 722 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.770 No No 122002 359 / Month 12 1.630 No No 122003 359 / Month 12 1.630 No No 124003 722 / Month 24 1.770 No No 126001 174 / Month 6 1.770<td>Treatment Group Positive
Subject ID Positive
Assay Inframmation
Assay Inframmation
Assay 170010 365 / Month 12 2.770
 No 170015 358 / Month 12 2.800 Inframmation 177006 358 / Month 12 1.870 Infra 177006 358 / Month 12 1.870 Infra 177006 358 / Month 12 1.870 Infra 177005 358 / Month 24 1.140 No 102001 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 359 / Month 24 1.170 No 124003 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 126001 174 / Month 6 1.770 No 126001 174 / Month 24 1.700 No 126001 174 / Month 6 1.700 No 141008 181 / Month 6 1.700 No 141008 161 / 000</td><td>Treatment Group Fositive Intranocentivity Intranocentivity Assay Assay Assay Assay Intranocentivity Intranocentivity 170010 365 / Month 12 2.770 No No No 177006 355 / Month 12 1.870 Irritis No 177006 355 / Month 12 1.870 Irritis No Raribizumab 0.5 mg 102001 715 / Month 24 1.870 Irritis 17002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 359 / Month 24 1.130 No No 122002 722 / Month 24 1.130 No No 122002 357 / Month 24 1.130 No No No 122003 722 / Month 24 1.130 No No No No 124003 722 / Month 24 1.1770 No No No No No No</td></td></td></td> | Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Areatment Group Subject ID Assay

 | Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Jreatment Group Subject ID Assay Assay Assay Iog 170010 365/Month 12 2.770 No No 177006 358/Month 12 1.870 Irritis 177006 358/Month 12 1.870 Irritis Ranibizumab 0.5 mg 102001 722/Month 24 1.870 Irritis 177006 359/Month 12 1.870 Irritis No 104002 719/Month 24 1.140 No No 122002 359/Month 24 1.130 No No 122002 722/Month 24 1.1700 No No 124003 722/Month 24 1.7700 No No 126001 174/Month 24

 | Treatment Group Positive
Subject ID Positive
Assay Intranceutar Intraceutar 176attment Group Subject ID Assay Assay Assay Intraceutar 170010 365/Month 12 2.770 No No 177006 358/Month 12 1.870 Intraceutar 177006 358/Month 12 1.870 Intraceutar Ranibizumab 0.5 mg 102001 722/Month 24 1.870 Intraceutar 104002 719/Month 24 1.140 No No No 102001 722/Month 24 1.130 No No No 122002 359/Month 12 1.630 No No No 122002 722/Month 24 1.1700 No No No 124003 722/Month 24 1.7700 No No No 126001 174/Month 6 1.7700 No No No 126001 174/Month 24 1.700 No No No 126001 <td< td=""><td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Jreatment Group Subject ID Assay Assay Assay Iog 170010 365/Month 12 2.770 No No 177006 358/Month 12 1.870 Irritis 177006 358/Month 12 1.870 Irritis Ranibizumab 0.5 mg 102001 722/Month 24 1.870 Irritis 177006 359/Month 12 1.870 Irritis No 104002 719/Month 24 1.140 No No 122002 359/Month 24 1.130 No No 122002 722/Month 24 1.1700 No No 124003 722/Month 24 1.7700 No No 126001 174/Month 24</td></td<> <td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Jreatment Group Subject ID Assay Assay Assay Iog 170010 365/Month 12 2.770 No No 177006 358/Month 12 1.870 Irritis 177006 358/Month 12 1.870 Irritis Ranibizumab 0.5 mg 102001 722/Month 24 1.870 Irritis 177006 359/Month 12 1.870 Irritis No 104002 719/Month 24 1.140 No No 122002 359/Month 24 1.130 No No 122002 722/Month 24 1.1700 No No 124003 722/Month 24 1.7700 No No 126001 174/Month 24<td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Areatment Group Subject ID Assay Assay</td><td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Areatment Group Subject ID Assay Assay</td><td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Areatment Group Subject ID Assay Assay</td><td>Treatment Group Dositive
Immunoreactivity Immunoreactivity Immunoreactivity Areatment Group Subject ID Assay Assay Assay Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 Inframmation 177006 358 / Month 12 1.870 Inframmation Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.1700 No No 124003 722 / Month 24 1.7700 No No 126001 174 / Month 24 1.7700 No No 126001 17</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Areatment Group Subject ID Assay Assay Assay Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 Inframmation 177006 358 / Month 12 1.870 Inframmation Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Infraitis 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.1700 No No 124003 722 / Month 24 1.7700 No No 126001 174 / Month 2 1.630 No No 126001 174 / Month 2 1.770 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 6 1.770 No No 126001 174</td><td>Treatment Group Positive
Innunoreactivity Innunoreactivity
Innunoreactivity Innantion
Innunoreactivity Treatment Group Subject ID Assay Assay Innunoreactivity Innunoreactivity 170010 365/Month 12 2770 No No No 170010 365/Month 12 2800 Innunoreactivity Innunoreactivity Innunoreactivity
Ranibizumab 0.5 mg 102001 715/Month 24 1870 Intitis No 102001 722/Month 24 1130 No No No No 122002 359/Month 12 1630 No No No No 122002 359/Month 24 1.1700 No No No No 122002 359/Month 12 1.630 No No No No 122002 359/Month 24 1.1700 No No No No 122002 359/Month 12 1.630 No No No No 124003 722/Month 24 1</td><td>Treatment Group Positive
Subject ID Positive
Assay Inframmation
Assay Inframmation
Assay ITool10 365 / Month 12 2.770 No 170015 358 / Month 12 2.800 No 177006 358 / Month 12 1.870 Irritis Ranibizumab 0.5 mg 102001 715 / Month 24 1.870 No 107005 358 / Month 12 1.870 Irritis No 1177006 358 / Month 12 1.870 Irritis No 102001 722 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.770 No No 122002 359 / Month 12 1.630 No No 122003 359 / Month 12 1.630 No No 124003 722 / Month 24 1.770 No No 126001 174 / Month 6 1.770<td>Treatment Group Positive
Subject ID Positive
Assay Inframmation
Assay Inframmation
Assay 170010 365 / Month 12 2.770 No 170015 358 / Month 12 2.800 Inframmation 177006 358 / Month 12 1.870 Infra 177006 358 / Month 12 1.870 Infra 177006 358 / Month 12 1.870 Infra 177005 358 / Month 24 1.140 No 102001 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 359 / Month 24 1.170 No 124003 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 126001 174 / Month 6 1.770 No 126001 174 / Month 24 1.700 No 126001 174 / Month 6 1.700 No 141008 181 / Month 6 1.700 No 141008 161 / 000</td><td>Treatment Group Fositive Intranocentivity Intranocentivity Assay Assay Assay Assay Intranocentivity Intranocentivity 170010 365 / Month 12 2.770 No No No 177006 355 / Month 12 1.870 Irritis No 177006 355 / Month 12 1.870 Irritis No Raribizumab 0.5 mg 102001 715 / Month 24 1.870 Irritis 17002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 359 / Month 24 1.130 No No 122002 722 / Month 24 1.130 No No 122002 357 / Month 24 1.130 No No No 122003 722 / Month 24 1.130 No No No No 124003 722 / Month 24 1.1770 No No No No No No</td></td></td> | Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Jreatment Group Subject ID Assay Assay Assay Iog 170010 365/Month 12 2.770 No No 177006 358/Month 12 1.870 Irritis 177006 358/Month 12 1.870 Irritis Ranibizumab 0.5 mg 102001 722/Month 24 1.870 Irritis 177006 359/Month 12 1.870 Irritis No 104002 719/Month 24 1.140 No No 122002 359/Month 24 1.130 No No 122002 722/Month 24 1.1700 No No 124003 722/Month 24 1.7700 No No 126001 174/Month 24

 | Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Jreatment Group Subject ID Assay Assay Assay Iog 170010 365/Month 12 2.770 No No 177006 358/Month 12 1.870 Irritis 177006 358/Month 12 1.870 Irritis Ranibizumab 0.5 mg 102001 722/Month 24 1.870 Irritis 177006 359/Month 12 1.870 Irritis No 104002 719/Month 24 1.140 No No 122002 359/Month 24 1.130 No No 122002 722/Month 24 1.1700 No No 124003 722/Month 24 1.7700 No No 126001 174/Month 24 <td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Areatment Group Subject ID Assay Assay</td> <td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Areatment Group Subject ID Assay Assay</td> <td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Areatment Group Subject ID Assay Assay</td> <td>Treatment Group Dositive
Immunoreactivity Immunoreactivity Immunoreactivity Areatment Group Subject ID Assay Assay Assay Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 Inframmation 177006 358 / Month 12 1.870 Inframmation Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.1700 No No 124003 722 / Month 24 1.7700 No No 126001 174 / Month 24 1.7700 No No 126001 17</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Areatment Group Subject ID Assay Assay Assay Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 Inframmation 177006 358 / Month 12 1.870 Inframmation Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Infraitis 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.1700 No No 124003 722 / Month 24 1.7700 No No 126001 174 / Month 2 1.630 No No 126001 174 / Month 2 1.770 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 6 1.770 No No 126001 174</td> <td>Treatment Group Positive
Innunoreactivity Innunoreactivity
Innunoreactivity Innantion
Innunoreactivity Treatment Group Subject ID Assay Assay Innunoreactivity Innunoreactivity 170010 365/Month 12 2770 No No No 170010 365/Month 12 2800 Innunoreactivity Innunoreactivity Innunoreactivity Ranibizumab 0.5 mg 102001 715/Month 24 1870 Intitis No 102001 722/Month 24 1130 No No No No 122002 359/Month 12 1630 No No No No 122002 359/Month 24 1.1700 No No No No 122002 359/Month 12 1.630 No No No No 122002 359/Month 24 1.1700 No No No No 122002 359/Month 12 1.630 No No No No 124003 722/Month 24 1</td> <td>Treatment Group Positive
Subject ID Positive
Assay Inframmation
Assay Inframmation
Assay ITool10 365 / Month 12 2.770 No 170015 358 / Month 12 2.800 No 177006 358 / Month 12 1.870 Irritis Ranibizumab 0.5 mg 102001 715 / Month 24 1.870 No 107005 358 / Month 12 1.870 Irritis No 1177006 358 / Month 12 1.870 Irritis No 102001 722 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.770 No No 122002 359 / Month 12 1.630 No No 122003 359 / Month 12 1.630 No No 124003 722 / Month 24 1.770 No No 126001 174 / Month 6 1.770<td>Treatment Group Positive
Subject ID Positive
Assay Inframmation
Assay Inframmation
Assay 170010 365 / Month 12 2.770 No 170015 358 / Month 12 2.800 Inframmation 177006 358 / Month 12 1.870 Infra 177006 358 / Month 12 1.870 Infra 177006 358 / Month 12 1.870 Infra 177005 358 / Month 24 1.140 No 102001 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 359 / Month 24 1.170 No 124003 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 126001 174 / Month 6 1.770 No 126001 174 / Month 24 1.700 No 126001 174 / Month 6 1.700 No 141008 181 / Month 6 1.700 No 141008 161 / 000</td><td>Treatment Group Fositive Intranocentivity Intranocentivity Assay Assay Assay Assay Intranocentivity Intranocentivity 170010 365 / Month 12 2.770 No No No 177006 355 / Month 12 1.870 Irritis No 177006 355 / Month 12 1.870 Irritis No Raribizumab 0.5 mg 102001 715 / Month 24 1.870 Irritis 17002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 359 / Month 24 1.130 No No 122002 722 / Month 24 1.130 No No 122002 357 / Month 24 1.130 No No No 122003 722 / Month 24 1.130 No No No No 124003 722 / Month 24 1.1770 No No No No No No</td></td>
 | Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Areatment Group Subject ID Assay
 | Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Areatment Group Subject ID Assay
 | Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Areatment Group Subject ID Assay
 | Treatment Group Dositive
Immunoreactivity Immunoreactivity Immunoreactivity Areatment Group Subject ID Assay Assay Assay Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 Inframmation 177006 358 / Month 12 1.870 Inframmation Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.1700 No No 124003 722 / Month 24 1.7700 No No 126001 174 / Month 24 1.7700 No No 126001 17
 | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Areatment Group Subject ID Assay Assay Assay Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 Inframmation 177006 358 / Month 12 1.870 Inframmation Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Infraitis 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.1700 No No 124003 722 / Month 24 1.7700 No No 126001 174 / Month 2 1.630 No No 126001 174 / Month 2 1.770 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 6 1.770 No No 126001 174 | Treatment Group Positive
Innunoreactivity Innunoreactivity
Innunoreactivity Innantion
Innunoreactivity Treatment Group Subject ID Assay Assay Innunoreactivity Innunoreactivity 170010 365/Month 12 2770 No No No 170010 365/Month 12 2800 Innunoreactivity Innunoreactivity Innunoreactivity Ranibizumab 0.5 mg 102001 715/Month 24 1870 Intitis No 102001
 722/Month 24 1130 No No No No 122002 359/Month 12 1630 No No No No 122002 359/Month 24 1.1700 No No No No 122002 359/Month 12 1.630 No No No No 122002 359/Month 24 1.1700 No No No No 122002 359/Month 12 1.630 No No No No 124003 722/Month 24 1 | Treatment Group Positive
Subject ID Positive
Assay Inframmation
Assay Inframmation
Assay ITool10 365 / Month 12 2.770 No 170015 358 / Month 12 2.800 No 177006 358 / Month 12 1.870 Irritis Ranibizumab 0.5 mg 102001 715 / Month 24 1.870 No 107005 358 / Month 12 1.870 Irritis No 1177006 358 / Month 12 1.870 Irritis No 102001 722 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.770 No No 122002 359 / Month 12 1.630 No No 122003 359 / Month 12 1.630 No No 124003 722 / Month 24 1.770 No No 126001 174 / Month 6 1.770 <td>Treatment Group Positive
Subject ID Positive
Assay Inframmation
Assay Inframmation
Assay 170010 365 / Month 12 2.770 No 170015 358 / Month 12 2.800 Inframmation 177006 358 / Month 12 1.870 Infra 177006 358 / Month 12 1.870 Infra 177006 358 / Month 12 1.870 Infra 177005 358 / Month 24 1.140 No 102001 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 359 / Month 24 1.170 No 124003 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 126001 174 / Month 6 1.770 No 126001 174 / Month 24 1.700 No 126001 174 / Month 6 1.700 No 141008 181 / Month 6 1.700 No 141008 161 / 000</td> <td>Treatment Group Fositive Intranocentivity Intranocentivity Assay Assay Assay Assay Intranocentivity Intranocentivity 170010 365 / Month 12 2.770 No No No 177006 355 / Month 12 1.870 Irritis No 177006 355 / Month 12 1.870 Irritis No Raribizumab 0.5 mg 102001 715 / Month 24 1.870 Irritis 17002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 359 / Month 24 1.130 No No 122002 722 / Month 24 1.130 No No 122002 357 / Month 24 1.130 No No No 122003 722 / Month 24 1.130 No No No No 124003 722 / Month 24 1.1770 No No No No No No</td> | Treatment Group Positive
Subject ID Positive
Assay Inframmation
Assay Inframmation
Assay 170010 365 / Month 12 2.770 No 170015 358 / Month 12 2.800 Inframmation 177006 358 / Month 12 1.870 Infra 177006 358 / Month 12 1.870 Infra 177006 358 / Month 12 1.870 Infra 177005 358 / Month 24 1.140 No 102001 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 359 / Month 24 1.170 No 124003 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 126001 174 / Month 6 1.770 No
 126001 174 / Month 24 1.700 No 126001 174 / Month 6 1.700 No 141008 181 / Month 6 1.700 No 141008 161 / 000 | Treatment Group Fositive Intranocentivity Intranocentivity Assay Assay Assay Assay Intranocentivity Intranocentivity 170010 365 / Month 12 2.770 No No No 177006 355 / Month 12 1.870 Irritis No 177006 355 / Month 12 1.870 Irritis No Raribizumab 0.5 mg 102001 715 / Month 24 1.870 Irritis 17002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 359 / Month 24 1.130 No No 122002 722 / Month 24 1.130 No No 122002 357 / Month 24 1.130 No No No 122003 722 / Month 24 1.130 No No No No 124003 722 / Month 24 1.1770 No No No No No No |
| I41013 715 / Month 24 2.610 Vitritis 143010 722 / Month 24 2.440 No 152004 522 / Early Term. 0.752 , No 153006 183 / Month 6 1.900 No 153006 183 / Month 12 0.752 , No 153006 183 / Month 24 2.070 No 718 / Month 24 0.780 No No 159017 716 / Month 24 2.070 No No 167002 717 / Mont 24 0.780 No No 188005 717 / Mont 24 1.230 No No 188005 717 / Mont 24 1.250 No No 1 534001 -7 / Screening 2.520 Vitritis No

 | I41013 715 / Month 24 2.610 Vitritis 143010 722 / Month 24 2.440 No 152004 522 / Early Term. 0.752 , No 153006 183 / Month 6 1.900 No 153006 183 / Month 12 0.752 , No 153006 183 / Month 24 2.070 No 718 / Month 24 0.780 No No 159017 716 / Month 24 2.070 No No 167002 717 / Mont 24 0.780 No No 188005 717 / Mont 24 1.230 No No 188005 717 / Mont 24 1.250 No No 534001 -7 / Screening 2.520 Vitritis No

 | I41013 715 / Month 24 2.610 Vitritis 143010 722 / Month 24 2.440 No 152004 522 / Early Term. 0.752 No 153006 183 / Month 6 1.900 No 153005 183 / Month 24 2.070 No 718 / Month 24 0.780 No No 159017 716 / Month 24 0.780 No 167002 717 / Mont 24 1.230 No 188005 717 / Month 24 1.250 No 534001 -7 / Screening 2.520 No No

 | TreatmentGroup Existion Positive
Immunoreactivity Immunoreactivity Immunoreactivity </td <td>TreatmentGroup Enninoreactivity Immunoreactivity Immunoreactivity<td>Treatment Group Immunoreactivity Immunoreactivity<!--</td--><td>Treatment Group Linnunoreactivity Immunoreactivity Immunoreactivity<</td><td>Treatment Group Existive
Subject ID Fositive
Assay Immunoreactivity
Assay Log Titer Immunoreactivity
Diagnosis 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Immunoreactivity Ranibizumab 0.5 mg 177 / Month 24 2.800 Irritis 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis 17700 717 / Month 24 1.870 Irritis 104002 719 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 359 / Month 12 1.630 No 124003 722 / Month 24 1.700 No 124003 722 / Month 12 1.630 No 124003 722 / Month 12 1.700 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No</td><td>Treatment Group Linnunoreactivity Immunoreactivity Immunoreactivity<</td><td>Treatment Group Linnunoreactivity Immunoreactivity Immunoreactivity<</td><td>Treatment Group Immunoreactivity Immunoreactivity<!--</td--><td>Treatment Group Immunoreactivity Immunoreactivity<!--</td--><td>Treatment Group Immunoreactivity Immunoreactivity<!--</td--><td>TreatmentGroup Existion Positive
Immunoreactivity Immunoreactivity Immunoreactivity<!--</td--><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunorea</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea</td><td>Treatment Group Subject ID Positive
Innumoreactivity Intraocular
Immunoreactivity Intraocular
Immunoreactivity Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 717 / Month 24 1.870 Lintis Intraocular Rantibizumab 0.5 mg 102001 722 / Month 24 1.870 Lintis 107002 722 / Month 24 1.870 No No 102002 722 / Month 24 1.140 No No 122002 359 / Month 24 1.140 No No 124003 722 / Month 24 1.130 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.700 No</td><td>Treatment Group Subject ID Positive Innunoreactivity Innanoreactivity Ireatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 717 / Month 24 1.870 Iritis No 8 717 / Month 24 1.870 Iritis 177005
358 / Month 12 1.870 Iritis 177005 358 / Month 24 1.870 Iritis 104002 719 / Month 24 1.870 No 12001 722 / Month 24 1.140 No 12002 723 / Month 24 1.130 No 124003 723 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003</td></td></td></td></td></td></td> | TreatmentGroup Enninoreactivity Immunoreactivity Immunoreactivity <td>Treatment Group Immunoreactivity Immunoreactivity<!--</td--><td>Treatment Group Linnunoreactivity Immunoreactivity Immunoreactivity<</td><td>Treatment Group Existive
Subject ID Fositive
Assay Immunoreactivity
Assay Log Titer Immunoreactivity
Diagnosis 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Immunoreactivity Ranibizumab 0.5 mg 177 / Month 24 2.800 Irritis 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis 17700 717 / Month 24 1.870 Irritis 104002 719 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 359 / Month 12 1.630 No 124003 722 / Month 24 1.700 No 124003 722 / Month 12 1.630 No 124003 722 / Month 12 1.700 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No</td><td>Treatment Group Linnunoreactivity Immunoreactivity Immunoreactivity<</td><td>Treatment Group Linnunoreactivity Immunoreactivity Immunoreactivity<</td><td>Treatment Group Immunoreactivity Immunoreactivity<!--</td--><td>Treatment Group Immunoreactivity Immunoreactivity<!--</td--><td>Treatment Group Immunoreactivity Immunoreactivity<!--</td--><td>TreatmentGroup Existion Positive
Immunoreactivity Immunoreactivity Immunoreactivity<!--</td--><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunorea</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea</td><td>Treatment Group Subject ID Positive
Innumoreactivity Intraocular
Immunoreactivity Intraocular
Immunoreactivity Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 717 / Month 24 1.870 Lintis Intraocular Rantibizumab 0.5 mg 102001 722 / Month 24 1.870 Lintis 107002 722 / Month 24 1.870 No No 102002 722 / Month 24 1.140 No No 122002 359 / Month 24 1.140 No No 124003 722 / Month 24 1.130 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.700 No</td><td>Treatment Group Subject ID Positive Innunoreactivity Innanoreactivity Ireatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 717 / Month 24 1.870 Iritis No 8 717 / Month 24 1.870 Iritis 177005 358 / Month 12 1.870 Iritis 177005 358 / Month 24 1.870 Iritis 104002 719 / Month 24 1.870 No 12001 722 / Month 24 1.140 No 12002 723 / Month 24 1.130 No 124003 723 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003</td></td></td></td></td></td> | Treatment Group Immunoreactivity Immunoreactivity </td <td>Treatment Group Linnunoreactivity Immunoreactivity Immunoreactivity<</td> <td>Treatment Group Existive
Subject ID Fositive
Assay Immunoreactivity
Assay Log Titer Immunoreactivity
Diagnosis 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Immunoreactivity Ranibizumab 0.5 mg 177 / Month 24 2.800 Irritis 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis 17700 717 / Month 24 1.870 Irritis 104002 719 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 359 / Month 12 1.630 No 124003 722 / Month 24 1.700 No 124003 722 / Month 12 1.630 No 124003 722 / Month 12 1.700 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No</td> <td>Treatment Group Linnunoreactivity Immunoreactivity Immunoreactivity<</td> <td>Treatment Group Linnunoreactivity Immunoreactivity Immunoreactivity<</td> <td>Treatment Group Immunoreactivity Immunoreactivity<!--</td--><td>Treatment Group Immunoreactivity Immunoreactivity<!--</td--><td>Treatment Group Immunoreactivity Immunoreactivity<!--</td--><td>TreatmentGroup Existion Positive
Immunoreactivity Immunoreactivity Immunoreactivity<!--</td--><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunorea</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea</td><td>Treatment Group Subject ID Positive
Innumoreactivity Intraocular
Immunoreactivity Intraocular
Immunoreactivity Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 717 / Month 24 1.870 Lintis Intraocular Rantibizumab 0.5 mg 102001 722 / Month 24 1.870 Lintis 107002 722 / Month 24 1.870 No No 102002 722 / Month 24 1.140 No No 122002 359 / Month 24 1.140 No No 124003 722 / Month 24 1.130 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.700 No</td><td>Treatment Group Subject ID Positive Innunoreactivity Innanoreactivity Ireatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 717 / Month 24 1.870 Iritis No 8 717 / Month 24 1.870 Iritis 177005 358 / Month 12 1.870 Iritis 177005 358 / Month 24 1.870 Iritis 104002 719 / Month 24 1.870 No 12001 722 / Month 24 1.140 No 12002 723 / Month 24 1.130 No 124003 723 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003</td></td></td></td></td> | Treatment Group Linnunoreactivity Immunoreactivity Immunoreactivity<

 | Treatment Group Existive
Subject ID Fositive
Assay Immunoreactivity
Assay Log Titer Immunoreactivity
Diagnosis 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Immunoreactivity Ranibizumab 0.5 mg 177 / Month 24 2.800 Irritis 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis 17700 717 / Month 24 1.870 Irritis 104002 719 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 359 / Month 12 1.630 No 124003 722 / Month 24 1.700 No 124003 722 / Month 12 1.630 No 124003 722 / Month 12 1.700 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No

 | Treatment Group Linnunoreactivity Immunoreactivity Immunoreactivity<
 | Treatment Group Linnunoreactivity Immunoreactivity Immunoreactivity<
 | Treatment Group Immunoreactivity Immunoreactivity </td <td>Treatment Group Immunoreactivity Immunoreactivity<!--</td--><td>Treatment Group Immunoreactivity Immunoreactivity<!--</td--><td>TreatmentGroup Existion Positive
Immunoreactivity Immunoreactivity Immunoreactivity<!--</td--><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunorea</td><td>Treatment Group
Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea</td><td>Treatment Group Subject ID Positive
Innumoreactivity Intraocular
Immunoreactivity Intraocular
Immunoreactivity Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 717 / Month 24 1.870 Lintis Intraocular Rantibizumab 0.5 mg 102001 722 / Month 24 1.870 Lintis 107002 722 / Month 24 1.870 No No 102002 722 / Month 24 1.140 No No 122002 359 / Month 24 1.140 No No 124003 722 / Month 24 1.130 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.700 No</td><td>Treatment Group Subject ID Positive Innunoreactivity Innanoreactivity Ireatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 717 / Month 24 1.870 Iritis No 8 717 / Month 24 1.870 Iritis 177005 358 / Month 12 1.870 Iritis 177005 358 / Month 24 1.870 Iritis 104002 719 / Month 24 1.870 No 12001 722 / Month 24 1.140 No 12002 723 / Month 24 1.130 No 124003 723 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003</td></td></td></td> | Treatment Group Immunoreactivity Immunoreactivity </td <td>Treatment Group Immunoreactivity Immunoreactivity<!--</td--><td>TreatmentGroup Existion Positive
Immunoreactivity Immunoreactivity Immunoreactivity<!--</td--><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunorea</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea</td><td>Treatment Group Subject ID Positive
Innumoreactivity Intraocular
Immunoreactivity Intraocular
Immunoreactivity Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 717 / Month 24 1.870 Lintis Intraocular Rantibizumab 0.5 mg 102001 722 / Month 24 1.870 Lintis 107002 722 / Month 24 1.870 No No 102002 722 / Month 24 1.140 No No 122002 359 / Month 24 1.140 No No 124003 722 / Month 24 1.130 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.700 No</td><td>Treatment Group Subject ID Positive Innunoreactivity Innanoreactivity Ireatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 717 / Month 24 1.870 Iritis No 8 717 / Month 24 1.870 Iritis 177005 358 / Month 12 1.870 Iritis 177005 358 / Month 24 1.870 Iritis 104002 719 / Month 24 1.870 No 12001 722 / Month 24 1.140 No 12002 723 / Month 24 1.130 No 124003 723 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003</td></td></td> | Treatment Group Immunoreactivity Immunoreactivity </td <td>TreatmentGroup Existion Positive
Immunoreactivity Immunoreactivity Immunoreactivity<!--</td--><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunorea</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea</td><td>Treatment Group Subject ID Positive
Innumoreactivity Intraocular
Immunoreactivity Intraocular
Immunoreactivity Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 717 / Month 24 1.870 Lintis Intraocular Rantibizumab 0.5 mg 102001 722 / Month 24 1.870 Lintis 107002 722 / Month 24 1.870 No No 102002 722 / Month 24 1.140 No No 122002 359 / Month 24 1.140 No No 124003 722 / Month 24 1.130 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.700 No</td><td>Treatment Group Subject ID Positive Innunoreactivity Innanoreactivity Ireatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 717 / Month 24 1.870 Iritis No 8 717 / Month 24 1.870 Iritis 177005 358 / Month 12 1.870 Iritis 177005 358 / Month 24 1.870 Iritis 104002 719 / Month 24 1.870 No 12001 722 / Month 24 1.140 No 12002 723 / Month 24 1.130 No 124003 723 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003</td></td> | TreatmentGroup Existion Positive
Immunoreactivity Immunoreactivity Immunoreactivity </td <td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunorea</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea</td> <td>Treatment Group Subject ID Positive
Innumoreactivity Intraocular
Immunoreactivity Intraocular
Immunoreactivity Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 717 / Month 24 1.870 Lintis Intraocular Rantibizumab 0.5 mg 102001 722 / Month 24 1.870 Lintis 107002 722 / Month 24 1.870 No No 102002 722 / Month 24 1.140 No No 122002 359 / Month 24 1.140 No No 124003 722 / Month 24 1.130 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.700 No</td> <td>Treatment Group Subject ID Positive Innunoreactivity Innanoreactivity Ireatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 717 / Month 24 1.870 Iritis No 8 717 / Month 24 1.870 Iritis 177005 358 / Month 12 1.870 Iritis 177005
358 / Month 24 1.870 Iritis 104002 719 / Month 24 1.870 No 12001 722 / Month 24 1.140 No 12002 723 / Month 24 1.130 No 124003 723 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003</td> | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunorea | Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea | Treatment Group Positive
Immunoreactivity
Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea | Treatment Group Subject ID Positive
Innumoreactivity Intraocular
Immunoreactivity Intraocular
Immunoreactivity Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 717 / Month 24 1.870 Lintis Intraocular Rantibizumab 0.5 mg 102001 722 / Month 24 1.870 Lintis 107002 722 / Month 24 1.870 No No 102002 722 / Month 24 1.140 No No 122002 359 / Month 24 1.140 No No 124003 722 / Month 24 1.130 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.700 No | Treatment Group Subject ID Positive Innunoreactivity Innanoreactivity Ireatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 717 / Month 24 1.870 Iritis No 8 717 / Month 24 1.870 Iritis 177005 358 / Month 12 1.870 Iritis 177005 358 / Month 24 1.870 Iritis 104002 719 / Month 24 1.870 No 12001 722 / Month 24 1.140 No 12002 723 / Month 24 1.130 No 124003 723 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003 |
| Norm 715 Month 24 2.340 141013 715 Month 24 2.440 143010 722 Month 24 2.440 152004 522 Early Term. 0.752 , 153006 183 Month 6 1.900 153006 183 Month 24 2.070 153007 718 Month 24 2.070 159017 716 Month 24 2.070 159017 716 Month 24 0.780 167002 717 Month 24 1.230 167002 717 Month 24 1.230 167002 717 Month 24 1.230 167002 717 Month 24 1.250 167002 717 Month 24 1.250 188005 717 Month 24 1.250 1000 No

 | Sham -715 Month 24 2.340 Vitritis 141013 715 Month 24 2.610 Vitritis 152004 522 / Early Term. 0.752 , No 153006 183 / Month 6 1.900 No 153006 183 / Month 24 2.610 Nin 153006 183 / Month 24 2.070 No 159017 718 / Month 24 2.070 No 159017 716 / Month 24 2.070 No 167002 717 / Mont 24 1.230 No 188005 717 / Mont 24 1.230 No 188005 717 / Mont 24 1.250 No 188005 717 / Month 24 1.250 No 188005 717 / Month 24 1.250 No

 | Name Name 2.340 Nitritis 141013 715 / Month 24 2.510 Vitritis 143010 722 / Month 24 2.440 No 153006 183 / Month 6 1.900 No 153006 183 / Month 12 1.900 No 153006 183 / Month 12 1.900 No 153006 183 / Month 12 1.900 No 153006 183 / Month 24 2.070 No 159017 718 / Month 24 2.070 No 159017 716 / Month 24 1.230 No 167002 717 / Mont 24 1.230 No 188005 717 / Month 24 1.250 No 188005 717 / Month 24 1.250 No

 | Treatment Group Immunoreactivity Immunoreactivity </td <td>Treatment Group Immunoreactivity Immunoreactivity<!--</td--><td>Treatment GroupPositivePositiveImmunoreactivityImmunoreactivityIncreationSubject IDAssayAssay Log TiterDiagnosis170010$365 / Month 12$$2.770$No177006$358 / Month 12$$2.800$Infiammation177006$358 / Month 12$$1.870$InfiaRanibizumab 0.5 mg$102001$$715 / Month 24$$1.870$InfiaRanibizumab 0.5 mg$102001$$722 / Month 24$$1.870$Infia100002$719 / Month 24$$1.140$NoNo102001$722 / Month 24$$1.130$NoNo102001$722 / Month 24$$1.130$NoNo102002$722 / Month 24$$1.130$NoNo102001$722 / Month 24$$1.770$NoNo102001$722 / Month 24$$1.130$NoNo102001$722 / Month 24$$1.170$NoNo102001$174 / Month 6$$1.700$NoNo122002$357 / Month 24$$1.170$NoNo124003$722 / Month 24$$1.700$NoNo124003$357 / Month 24$$1.700$NoNo124003$1.74 / Month 6$$1.790$<</td><td>Treatment GroupNoitree
SasyFosityeImmunoreactivityImmunoreactivityIncreationSubject IDAssayAssay L og TiterDiagnosis170010$365 / Month 12$$2.770$No177006$358 / Month 12$$2.800$Irritis177006$358 / Month 12$$1.870$IrritisRanibizumab 0.5 mg$102001$$715 / Month 24$$1.870$IrritisRanibizumab 0.5 mg$102001$$722 / Month 24$$1.800$No106002$719 / Month 24$$1.140$No102001$722 / Month 24$$1.130$No102002$722 / Month 24$$1.130$No102001$722 / Month 24$$1.130$No102002$722 / Month 24$$1.770$No122002$357 / Month 24$$1.770$No124003$722 / Month 24$$1.700$No124003$722 / Month 24$$1.700$No124003$722 / Month 24$$1.700$No124003$722 / Month 24$$1.700$No124003$357 / Month 24$$1.700$No124003$1.74 / Month 6$$1.700$</td><td>Treatment GroupPositive
ImmunoreactivityFositive
ImmunoreactivityImmunoreactivity
ImmunoreactivityImmunoreactivity
ImmunoreactivityTreatment GroupSubject IDAssayAssay Log TiterDiagnosis170010365 / Month 122.770No177006358 / Month 121.870Irritis177006358 / Month 121.870IrritisRanibizumab 0.5 mg102001722 / Month 241.870Irritis104002719 / Month 241.140No106002722 / Month 241.130No122002359 / Month 121.630No124003722 / Month 241.770No126001174 / Month 61.700No126001174 / Month 61.700No141008181 / Month 61.700No141008181 / Month 61.570No141008181 / Month 61.570No141008181 / Month 61.940No</td><td>Treatment GroupNoitree
SasyFosityeImmunoreactivityImmunoreactivityIncreationSubject IDAssayAssay L og TiterDiagnosis170010$365 / Month 12$$2.770$No177006$358 / Month 12$$2.800$Irritis177006$358 / Month 12$$1.870$IrritisRanibizumab 0.5 mg$102001$$715 / Month 24$$1.870$IrritisRanibizumab 0.5 mg$102001$$722 / Month 24$$1.800$No106002$719 / Month 24$$1.140$No102001$722 / Month 24$$1.130$No102002$722 / Month 24$$1.130$No102001$722 / Month 24$$1.130$No102002$722 / Month 24$$1.770$No122002$357 / Month 24$$1.770$No124003$722 / Month 24$$1.700$No124003$722 / Month 24$$1.700$No124003$722 / Month 24$$1.700$No124003$722 / Month 24$$1.700$No124003$357 / Month 24$$1.700$No124003$1.74 / Month 6$$1.700$</td><td>Treatment GroupNoitree
SasyFosityeImmunoreactivityImmunoreactivityIncreationSubject IDAssayAssay L og TiterDiagnosis170010$365 / Month 12$$2.770$No177006$358 / Month 12$$2.800$Irritis177006$358 / Month 12$$1.870$IrritisRanibizumab 0.5 mg$102001$$715 / Month 24$$1.870$IrritisRanibizumab 0.5 mg$102001$$722 / Month 24$$1.800$No106002$719 / Month 24$$1.140$No102001$722 / Month 24$$1.130$No102002$722 / Month 24$$1.130$No102001$722 / Month 24$$1.130$No102002$722 / Month 24$$1.770$No122002$357 / Month 24$$1.770$No124003$722 / Month 24$$1.700$No124003$722 / Month 24$$1.700$No124003$722 / Month 24$$1.700$No124003$722 / Month 24$$1.700$No124003$357 / Month 24$$1.700$No124003$1.74 / Month 6$$1.700$</td><td>Treatment GroupPositivePositiveImmunoreactivityImmunoreactivityIncreationSubject IDAssayAssay Log TiterDiagnosis170010$365 / Month 12$$2.770$No177006$358 / Month 12$$2.800$Infiammation177006$358 / Month 12$$1.870$InfiaRanibizumab 0.5 mg$102001$$715 / Month 24$$1.870$InfiaRanibizumab 0.5 mg$102001$$722 / Month 24$$1.870$Infia100002$719 / Month
24$$1.140$NoNo102001$722 / Month 24$$1.130$NoNo102001$722 / Month 24$$1.130$NoNo102002$722 / Month 24$$1.130$NoNo102001$722 / Month 24$$1.770$NoNo102001$722 / Month 24$$1.130$NoNo102001$722 / Month 24$$1.170$NoNo102001$174 / Month 6$$1.700$NoNo122002$357 / Month 24$$1.170$NoNo124003$722 / Month 24$$1.700$NoNo124003$357 / Month 24$$1.700$NoNo124003$1.74 / Month 6$$1.790$<</td><td>Treatment GroupPositivePositiveImmunoreactivityImmunoreactivityIncreationSubject IDAssayAssay Log TiterDiagnosis170010$365 / Month 12$$2.770$No177006$358 / Month 12$$2.800$Infiammation177006$358 / Month 12$$1.870$InfiaRanibizumab 0.5 mg$102001$$715 / Month 24$$1.870$InfiaRanibizumab 0.5 mg$102001$$722 / Month 24$$1.870$Infia100002$719 / Month 24$$1.140$NoNo102001$722 / Month 24$$1.130$NoNo102001$722 / Month 24$$1.130$NoNo102002$722 / Month 24$$1.130$NoNo102001$722 / Month 24$$1.770$NoNo102001$722 / Month 24$$1.130$NoNo102001$722 / Month 24$$1.170$NoNo102001$174 / Month 6$$1.700$NoNo122002$357 / Month 24$$1.170$NoNo124003$722 / Month 24$$1.700$NoNo124003$357 / Month 24$$1.700$NoNo124003$1.74 / Month 6$$1.790$<</td><td>Treatment GroupPositivePositiveImmunoreactivityImmunoreactivityIncreationSubject IDAssayAssay Log TiterDiagnosis170010$365 / Month 12$$2.770$No177006$358 / Month 12$$2.800$Infiammation177006$358 / Month 12$$1.870$InfiaRanibizumab 0.5 mg$102001$$715 / Month 24$$1.870$InfiaRanibizumab 0.5 mg$102001$$722 / Month 24$$1.870$Infia100002$719 / Month 24$$1.140$NoNo102001$722 / Month 24$$1.130$NoNo102001$722 / Month 24$$1.130$NoNo102002$722 / Month 24$$1.130$NoNo102001$722 / Month 24$$1.770$NoNo102001$722 / Month 24$$1.130$NoNo102001$722 / Month 24$$1.170$NoNo102001$174 / Month 6$$1.700$NoNo122002$357 / Month 24$$1.170$NoNo124003$722 / Month 24$$1.700$NoNo124003$357 / Month 24$$1.700$NoNo124003$1.74 / Month 6$$1.790$<</td><td>Treatment Group Immunoreactivity Immunoreactivity<!--</td--><td>TreatmentGroup Distince Positive Immunoreactivity I</td><td>Treatment Group Subject ID Assay Intrancentisty Intrancentisty Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Irritis 104002 719 / Month 24 1.870 Irritis No 122002 359 / Month 12 1.870 No No 122002 723 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.170 No No 122002 357 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea</td><td>Treatment Group Subject ID Positive
immunoreactivity Immunoreactivity
immunoreactivity Immunoreactivity
immunoreactivity Intraocular
immarion No 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intria No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Intris 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.170 No No 124003 722 / Month 24 1.770 No<td>Treatment Group Positive Innunoreactivity Innunoreactivity</td></td></td></td> | Treatment Group Immunoreactivity Immunoreactivity </td <td>Treatment GroupPositivePositiveImmunoreactivityImmunoreactivityIncreationSubject IDAssayAssay Log TiterDiagnosis170010$365 / Month 12$$2.770$No177006$358 / Month 12$$2.800$Infiammation177006$358 / Month 12$$1.870$InfiaRanibizumab 0.5 mg$102001$$715 / Month 24$$1.870$InfiaRanibizumab 0.5 mg$102001$$722 / Month 24$$1.870$Infia100002$719 / Month 24$$1.140$NoNo102001$722 / Month 24$$1.130$NoNo102001$722 / Month 24$$1.130$NoNo102002$722 / Month 24$$1.130$NoNo102001$722 / Month 24$$1.770$NoNo102001$722 / Month 24$$1.130$NoNo102001$722 / Month 24$$1.170$NoNo102001$174 / Month 6$$1.700$NoNo122002$357 / Month 24$$1.170$NoNo124003$722 / Month 24$$1.700$NoNo124003$357 / Month 24$$1.700$NoNo124003$1.74 / Month 6$$1.790$<</td> <td>Treatment GroupNoitree
SasyFosityeImmunoreactivityImmunoreactivityIncreationSubject IDAssayAssay L og TiterDiagnosis170010$365 / Month 12$$2.770$No177006$358 / Month 12$$2.800$Irritis177006$358 / Month 12$$1.870$IrritisRanibizumab 0.5 mg$102001$$715 / Month 24$$1.870$IrritisRanibizumab 0.5 mg$102001$$722 / Month 24$$1.800$No106002$719 / Month 24$$1.140$No102001$722 / Month 24$$1.130$No102002$722 / Month 24$$1.130$No102001$722 / Month 24$$1.130$No102002$722 / Month 24$$1.770$No122002$357 / Month 24$$1.770$No124003$722 / Month 24$$1.700$No124003$722 / Month 24$$1.700$No124003$722 / Month 24$$1.700$No124003$722 / Month 24$$1.700$No124003$357 / Month 24$$1.700$No124003$1.74 / Month 6$$1.700$</td> <td>Treatment GroupPositive
ImmunoreactivityFositive
ImmunoreactivityImmunoreactivity
ImmunoreactivityImmunoreactivity
ImmunoreactivityTreatment GroupSubject IDAssayAssay Log TiterDiagnosis170010365 / Month 122.770No177006358 / Month 121.870Irritis177006358 / Month 121.870IrritisRanibizumab 0.5 mg102001722 / Month 241.870Irritis104002719 / Month 241.140No106002722 / Month 241.130No122002359 / Month 121.630No124003722 / Month 241.770No126001174 / Month 61.700No126001174 / Month 61.700No141008181 / Month 61.700No141008181 / Month 61.570No141008181 / Month 61.570No141008181 / Month 61.940No</td> <td>Treatment GroupNoitree
SasyFosityeImmunoreactivityImmunoreactivityIncreationSubject IDAssayAssay L og TiterDiagnosis170010$365 / Month 12$$2.770$No177006$358 / Month 12$$2.800$Irritis177006$358 / Month 12$$1.870$IrritisRanibizumab 0.5 mg$102001$$715 / Month 24$$1.870$IrritisRanibizumab 0.5 mg$102001$$722 / Month 24$$1.800$No106002$719 / Month 24$$1.140$No102001$722 / Month 24$$1.130$No102002$722 / Month 24$$1.130$No102001$722 / Month 24$$1.130$No102002$722 / Month 24$$1.770$No122002$357 / Month 24$$1.770$No124003$722 / Month 24$$1.700$No124003$722 / Month 24$$1.700$No124003$722 / Month 24$$1.700$No124003$722 / Month 24$$1.700$No124003$357 / Month 24$$1.700$No124003$1.74 / Month 6$$1.700$</td> <td>Treatment GroupNoitree
SasyFosityeImmunoreactivityImmunoreactivityIncreationSubject IDAssayAssay L og TiterDiagnosis170010$365 / Month 12$$2.770$No177006$358 / Month 12$$2.800$Irritis177006$358 / Month 12$$1.870$IrritisRanibizumab 0.5 mg$102001$$715 / Month 24$$1.870$IrritisRanibizumab 0.5 mg$102001$$722 / Month 24$$1.800$No106002$719 / Month 24$$1.140$No102001$722 / Month 24$$1.130$No102002$722 / Month 24$$1.130$No102001$722 / Month 24$$1.130$No102002$722 / Month 24$$1.770$No122002$357 / Month 24$$1.770$No124003$722 / Month
24$$1.700$No124003$722 / Month 24$$1.700$No124003$722 / Month 24$$1.700$No124003$722 / Month 24$$1.700$No124003$357 / Month 24$$1.700$No124003$1.74 / Month 6$$1.700$</td> <td>Treatment GroupPositivePositiveImmunoreactivityImmunoreactivityIncreationSubject IDAssayAssay Log TiterDiagnosis170010$365 / Month 12$$2.770$No177006$358 / Month 12$$2.800$Infiammation177006$358 / Month 12$$1.870$InfiaRanibizumab 0.5 mg$102001$$715 / Month 24$$1.870$InfiaRanibizumab 0.5 mg$102001$$722 / Month 24$$1.870$Infia100002$719 / Month 24$$1.140$NoNo102001$722 / Month 24$$1.130$NoNo102001$722 / Month 24$$1.130$NoNo102002$722 / Month 24$$1.130$NoNo102001$722 / Month 24$$1.770$NoNo102001$722 / Month 24$$1.130$NoNo102001$722 / Month 24$$1.170$NoNo102001$174 / Month 6$$1.700$NoNo122002$357 / Month 24$$1.170$NoNo124003$722 / Month 24$$1.700$NoNo124003$357 / Month 24$$1.700$NoNo124003$1.74 / Month 6$$1.790$<</td> <td>Treatment GroupPositivePositiveImmunoreactivityImmunoreactivityIncreationSubject IDAssayAssay Log TiterDiagnosis170010$365 / Month 12$$2.770$No177006$358 / Month 12$$2.800$Infiammation177006$358 / Month 12$$1.870$InfiaRanibizumab 0.5 mg$102001$$715 / Month 24$$1.870$InfiaRanibizumab 0.5 mg$102001$$722 / Month 24$$1.870$Infia100002$719 / Month 24$$1.140$NoNo102001$722 / Month 24$$1.130$NoNo102001$722 / Month 24$$1.130$NoNo102002$722 / Month 24$$1.130$NoNo102001$722 / Month 24$$1.770$NoNo102001$722 / Month 24$$1.130$NoNo102001$722 / Month 24$$1.170$NoNo102001$174 / Month 6$$1.700$NoNo122002$357 / Month 24$$1.170$NoNo124003$722 / Month 24$$1.700$NoNo124003$357 / Month 24$$1.700$NoNo124003$1.74 / Month 6$$1.790$<</td> <td>Treatment GroupPositivePositiveImmunoreactivityImmunoreactivityIncreationSubject IDAssayAssay Log TiterDiagnosis170010$365 / Month 12$$2.770$No177006$358 / Month 12$$2.800$Infiammation177006$358 / Month 12$$1.870$InfiaRanibizumab 0.5 mg$102001$$715 / Month 24$$1.870$InfiaRanibizumab 0.5 mg$102001$$722 / Month 24$$1.870$Infia100002$719 / Month 24$$1.140$NoNo102001$722 / Month 24$$1.130$NoNo102001$722 / Month 24$$1.130$NoNo102002$722 / Month 24$$1.130$NoNo102001$722 / Month 24$$1.770$NoNo102001$722 / Month 24$$1.130$NoNo102001$722 / Month 24$$1.170$NoNo102001$174 / Month 6$$1.700$NoNo122002$357 / Month 24$$1.170$NoNo124003$722 / Month 24$$1.700$NoNo124003$357 / Month 24$$1.700$NoNo124003$1.74 / Month 6$$1.790$<</td> <td>Treatment Group Immunoreactivity Immunoreactivity<!--</td--><td>TreatmentGroup Distince Positive Immunoreactivity I</td><td>Treatment Group Subject ID Assay Intrancentisty Intrancentisty Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Irritis 104002 719 / Month 24 1.870 Irritis No 122002 359 / Month 12 1.870 No No 122002 723 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.170 No No 122002 357 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea</td><td>Treatment Group Subject ID Positive
immunoreactivity Immunoreactivity
immunoreactivity Immunoreactivity
immunoreactivity Intraocular
immarion No 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intria No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Intris 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.170 No No 124003 722 / Month 24 1.770 No<td>Treatment Group Positive Innunoreactivity Innunoreactivity</td></td></td> | Treatment GroupPositivePositiveImmunoreactivityImmunoreactivityIncreationSubject IDAssayAssay Log TiterDiagnosis170010 $365 / Month 12$ 2.770 No177006 $358 / Month 12$ 2.800 Infiammation177006 $358 / Month 12$ 1.870 InfiaRanibizumab 0.5 mg 102001 $715 / Month 24$ 1.870 InfiaRanibizumab 0.5 mg 102001 $722 / Month 24$ 1.870 Infia100002 $719 / Month 24$ 1.140 NoNo102001 $722 / Month 24$ 1.130 NoNo102001 $722 / Month 24$ 1.130 NoNo102002 $722 / Month 24$ 1.130 NoNo102001 $722 / Month 24$ 1.770 NoNo102001 $722 / Month 24$ 1.130 NoNo102001 $722 / Month 24$ 1.170 NoNo102001 $174 / Month 6$ 1.700 NoNo122002 $357 / Month 24$ 1.170 NoNo124003 $722 / Month 24$ 1.700 NoNo124003 $357 / Month 24$ 1.700 NoNo124003 $1.74 / Month 6$ 1.790 <

 | Treatment GroupNoitree
SasyFosityeImmunoreactivityImmunoreactivityIncreationSubject IDAssayAssay L og TiterDiagnosis170010 $365 / Month 12$ 2.770 No177006 $358 / Month 12$ 2.800 Irritis177006 $358 / Month 12$ 1.870 IrritisRanibizumab 0.5 mg 102001 $715 / Month 24$ 1.870 IrritisRanibizumab 0.5 mg 102001 $722 / Month 24$ 1.800 No106002 $719 / Month 24$ 1.140 No102001 $722 / Month 24$ 1.130 No102002 $722 / Month 24$ 1.130 No102001 $722 / Month 24$ 1.130 No102002 $722 / Month 24$ 1.770 No122002 $357 / Month 24$ 1.770 No124003 $722 / Month 24$ 1.700 No124003 $357 / Month 24$ 1.700 No124003 $1.74 / Month 6$ 1.700

 | Treatment GroupPositive
ImmunoreactivityFositive
ImmunoreactivityImmunoreactivity
ImmunoreactivityImmunoreactivity
ImmunoreactivityTreatment GroupSubject IDAssayAssay Log TiterDiagnosis170010365 / Month 122.770No177006358 / Month 121.870Irritis177006358 / Month 121.870IrritisRanibizumab 0.5 mg102001722 / Month 241.870Irritis104002719 / Month 241.140No106002722 / Month 241.130No122002359 / Month 121.630No124003722 / Month 241.770No126001174 / Month 61.700No126001174 / Month 61.700No141008181 / Month 61.700No141008181 / Month 61.570No141008181 / Month 61.570No141008181 / Month 61.940No

 | Treatment GroupNoitree
SasyFosityeImmunoreactivityImmunoreactivityIncreationSubject IDAssayAssay L og TiterDiagnosis170010 $365 / Month 12$ 2.770 No177006 $358 / Month 12$ 2.800 Irritis177006 $358 / Month 12$ 1.870 IrritisRanibizumab 0.5 mg 102001 $715 / Month 24$ 1.870 IrritisRanibizumab 0.5 mg 102001 $722 / Month 24$ 1.800 No106002 $719 / Month 24$ 1.140 No102001 $722 / Month 24$ 1.130 No102002 $722 / Month 24$ 1.130 No102001 $722 / Month 24$ 1.130 No102002 $722 / Month 24$ 1.770 No122002 $357 / Month 24$ 1.770 No124003 $722 / Month 24$ 1.700 No124003 $357 / Month 24$ 1.700 No124003 $1.74 / Month 6$ 1.700
 | Treatment GroupNoitree
SasyFosityeImmunoreactivityImmunoreactivityIncreationSubject IDAssayAssay L og TiterDiagnosis170010 $365 / Month 12$ 2.770 No177006 $358 / Month 12$ 2.800 Irritis177006 $358 / Month 12$ 1.870 IrritisRanibizumab 0.5 mg 102001 $715 / Month 24$ 1.870 IrritisRanibizumab 0.5 mg 102001 $722 / Month 24$ 1.800 No106002 $719 / Month 24$ 1.140 No102001 $722 / Month 24$ 1.130 No102002 $722 / Month 24$ 1.130 No102001 $722 / Month 24$ 1.130 No102002 $722 / Month 24$ 1.770 No122002 $357 / Month 24$ 1.770 No124003 $722 / Month 24$ 1.700 No124003 $357 / Month 24$ 1.700 No124003 $1.74 / Month 6$ 1.700

 | Treatment GroupPositivePositiveImmunoreactivityImmunoreactivityIncreationSubject IDAssayAssay Log TiterDiagnosis170010 $365 / Month 12$ 2.770 No177006 $358 / Month 12$ 2.800 Infiammation177006 $358 / Month 12$ 1.870 InfiaRanibizumab 0.5 mg 102001 $715 / Month 24$ 1.870 InfiaRanibizumab 0.5 mg 102001 $722 / Month 24$ 1.870 Infia100002 $719 / Month 24$ 1.140 NoNo102001 $722 / Month 24$ 1.130 NoNo102001 $722 / Month 24$ 1.130 NoNo102002 $722 / Month 24$ 1.130 NoNo102001 $722 / Month 24$ 1.770 NoNo102001 $722 / Month 24$ 1.130 NoNo102001 $722 / Month 24$ 1.170 NoNo102001 $174 / Month 6$ 1.700 NoNo122002 $357 / Month 24$ 1.170 NoNo124003 $722 / Month 24$ 1.700 NoNo124003 $357 / Month 24$ 1.700 NoNo124003 $1.74 / Month 6$ 1.790 <
 | Treatment GroupPositivePositiveImmunoreactivityImmunoreactivityIncreationSubject IDAssayAssay Log TiterDiagnosis170010 $365 / Month 12$ 2.770 No177006 $358 / Month 12$ 2.800 Infiammation177006 $358 / Month 12$ 1.870 InfiaRanibizumab 0.5 mg 102001 $715 / Month 24$ 1.870 InfiaRanibizumab 0.5 mg 102001 $722 / Month 24$ 1.870 Infia100002 $719 / Month 24$ 1.140 NoNo102001 $722 / Month 24$ 1.130 NoNo102001 $722 / Month 24$ 1.130 NoNo102002 $722 / Month 24$ 1.130 NoNo102001 $722 / Month 24$ 1.770 NoNo102001 $722 / Month 24$ 1.130 NoNo102001 $722 / Month 24$ 1.170 NoNo102001 $174 / Month 6$ 1.700 NoNo122002 $357 / Month 24$ 1.170 NoNo124003 $722 / Month 24$ 1.700 NoNo124003 $357 / Month 24$ 1.700 NoNo124003 $1.74 / Month 6$ 1.790 <
 | Treatment GroupPositivePositiveImmunoreactivityImmunoreactivityIncreationSubject IDAssayAssay Log TiterDiagnosis170010 $365 / Month 12$ 2.770 No177006 $358 / Month 12$ 2.800 Infiammation177006 $358 / Month 12$ 1.870 InfiaRanibizumab 0.5 mg 102001 $715 / Month 24$ 1.870 InfiaRanibizumab 0.5 mg 102001 $722 / Month 24$ 1.870 Infia100002 $719 / Month 24$ 1.140 NoNo102001 $722 / Month 24$ 1.130 NoNo102001 $722 / Month 24$ 1.130 NoNo102002 $722 / Month 24$ 1.130 NoNo102001 $722 / Month 24$ 1.770 NoNo102001 $722 / Month 24$ 1.130 NoNo102001 $722 / Month 24$ 1.170 NoNo102001 $174 / Month 6$ 1.700 NoNo122002 $357 / Month 24$ 1.170 NoNo124003 $722 / Month 24$ 1.700 NoNo124003 $357 / Month 24$ 1.700 NoNo124003 $1.74 / Month 6$ 1.790 <
 | Treatment Group Immunoreactivity Immunoreactivity </td <td>TreatmentGroup Distince Positive Immunoreactivity I</td> <td>Treatment Group Subject ID Assay Intrancentisty Intrancentisty Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Irritis 104002 719 / Month 24 1.870 Irritis No 122002 359 / Month 12 1.870 No No 122002 723 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.170 No No 122002 357 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea</td> <td>Treatment Group Subject ID Positive
immunoreactivity Immunoreactivity
immunoreactivity Immunoreactivity
immunoreactivity Intraocular
immarion No 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intria No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Intris 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.170 No No 124003 722 / Month 24 1.770 No<td>Treatment Group Positive Innunoreactivity Innunoreactivity</td></td> | TreatmentGroup Distince Positive Immunoreactivity I
 | Treatment Group Subject ID Assay Intrancentisty Intrancentisty Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Irritis 104002 719 / Month 24 1.870 Irritis No 122002 359 / Month 12 1.870 No No 122002 723 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.170 No No 122002 357 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No | Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity
Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea | Treatment Group Subject ID Positive
immunoreactivity Immunoreactivity
immunoreactivity Immunoreactivity
immunoreactivity Intraocular
immarion No 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intria No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Intris 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.170 No No 124003 722 / Month 24 1.770 No <td>Treatment Group Positive Innunoreactivity Innunoreactivity</td> | Treatment Group Positive Innunoreactivity |
| 726 / Month 24 2.340 Vitritis 141013 715 / Month 24 2.340 Nicritis 143010 722 / Month 24 2.610 Vitritis 152004 522 / Early Term. 0.752 , No 153006 183 / Month 24 2.440 No 153006 183 / Month 24 2.440 No 153006 183 / Month 24 0.752 , No 153007 365 / Month 12 1.900 No 153007 718 / Month 24 0.730 No 167002 711 / Mont 24 0.780 No 167002 717 / Mont 24 1.230 No 188005 717 / Mont 24 1.230 No 188005 717 / Mont 24 1.250 No 188005 717 / Mont 24 1.250 No 188005 717 / Mont 24 1.250 No

 | 726 / Month 24 2.340 Vitritis 141013 715 / Month 24 2.610 Vitritis 143010 722 / Month 24 2.610 Nin 152004 $522 / Early Term.$ 0.752 , No 153006 $183 / Month 24$ 2.440 No 153006 $183 / Month 24$ 2.440 No 153006 $183 / Month 24$ 2.070 No 15300 $183 / Month 12$ 1.530 No 15300 $718 / Month 24$ 2.070 No 167002 $717 / Mont 24$ 0.780 No 167002 $717 / Mont 24$ 1.230 No 188005 $717 / Mont 24$ 1.230 No 188005 $717 / Mont 24$ 1.250 No 188005 $717 / Month 24$ 1.250 No 188005 $717 / Month 24$ 1.250 No

 | 726 / Month 24 2.340 vitritis 141013 715 / Month 24 2.610 Vitritis 143010 722 / Month 24 2.610 Vitritis 152004 522 / Early Term. 0.752 , No 153006 183 / Month 6 1.900 No 153006 183 / Month 24 2.070 No 718 / Month 24 0.780 No No 159017 716 / Month 24 0.780 No No 167002 717 / Mont 24 1.230 No No 188005 717 / Mont 24 1.230 No No 188005 717 / Mont 24 1.250 No No 534001 -7 / Screening 2.520 No No

 | Treatment Group Positive Inmunoreactivity Intraocular Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Irritis 177006 358 / Month 12 1.870 Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Irritis 177006 358 / Month 12 1.870 Irritis Irritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No 104002 719 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.1700 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 24 1.700 No No 124003 722 / Month 24 1.700 No No 124003 723 / Month 12 2.040

 | Treatment Group Positive Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Inflammation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 No 177006 358 / Month
12 1.870 No 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 No 17700 177 Month 24 1.870 No 104002 719 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 124003 722 / Month 24 1.1700 No 124003 722 / Month 12 1.630 No 124003 722 / Month 12 1.630 No 124003 722 / Month 24 1.700 No 124003 722 / Month 12 1.630 No 124003 722 / Month 24 1.700 No <td< td=""><td>Treatment GroupPositive
ImmunoreactivityImmunoreactivityImmunoreactivityIntraocularSasyAssayLog TiterDiagnosis170010365 / Month 122.770NoNo177006358 / Month 121.870IntriaIntris177006358 / Month 121.870IntrisNo177006358 / Month 121.870IntrisNoRantbizumab 0.5 mg102001722 / Month 241.870No104002719 / Month 241.870NoNo122002359 / Month 121.630NoNo122002359 / Month 121.630NoNo122002359 / Month 121.630NoNo122002359 / Month 121.630NoNo124003722 / Month 241.170NoNo126001174 / Month 61.700NoNo126001174 / Month 61.700No126001174 / Month 61.700No126001174 / Month 61.700No12</td><td>Treatment Group Evailation Fosilation Immunoreactivity Immunoreatiotity Immunoreatiotity</td><td>Treatment Group Event of the control of t</td><td>Treatment Group Evailation Fosilation Immunoreactivity Immunoreatiotity Immunoreatiotity</td><td>Treatment Group Evailation Fosilation Immunoreactivity Immunoreatiotity Immunoreatiotity</td><td>Treatment GroupPositive
ImmunoreactivityImmunoreactivityImmunoreactivityIntraocularSasyAssayLog TiterDiagnosis170010365 / Month 122.770NoNo177006358 / Month 121.870IntriaIntris177006358 / Month 121.870IntrisNo177006358 / Month 121.870IntrisNoRantbizumab 0.5 mg102001722 / Month 241.870No104002719 / Month 241.870NoNo122002359 / Month 121.630NoNo122002359 / Month 121.630NoNo122002359 / Month 121.630NoNo122002359 / Month 121.630NoNo124003722 / Month 241.170NoNo126001174 / Month 61.700NoNo126001174 / Month 61.700No126001174 / Month 61.700No126001174 / Month 61.700No12</td><td>Treatment GroupPositive
ImmunoreactivityImmunoreactivityImmunoreactivityIntraocularSasyAssayLog TiterDiagnosis170010365 / Month 122.770NoNo177006358 / Month 121.870IntriaIntris177006358 / Month 121.870IntrisNo177006358 / Month 121.870IntrisNoRantbizumab 0.5 mg102001722 / Month 241.870No104002719 / Month 241.870NoNo122002359 / Month 121.630NoNo122002359 / Month 121.630NoNo122002359 / Month 121.630NoNo122002359 / Month 121.630NoNo124003722 / Month 241.170NoNo126001174 / Month 61.700NoNo126001174 / Month 61.700No126001174 / Month 61.700No126001174 / Month 61.700No12</td><td>Treatment GroupPositive
ImmunoreactivityImmunoreactivityImmunoreactivityIntraocularSasyAssayLog TiterDiagnosis170010365 / Month 122.770NoNo177006358 / Month 121.870IntriaIntris177006358 / Month 121.870IntrisNo177006358 / Month 121.870IntrisNoRantbizumab 0.5 mg102001722 / Month 241.870No104002719 / Month 241.870NoNo122002359 / Month 121.630NoNo122002359 / Month 121.630NoNo122002359 / Month 121.630NoNo122002359 / Month 121.630NoNo124003722 / Month 241.170NoNo126001174 / Month 61.700NoNo126001174 / Month 61.700No126001174 / Month 61.700No126001174 / Month 61.700No12</td><td>Treatment Group Positive Inmunoreactivity Intraocular Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Irritis 177006 358 / Month 12 1.870 Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Irritis 177006 358 / Month 12 1.870 Irritis Irritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No 104002 719 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.1700 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 24 1.700 No No 124003 722 / Month 24 1.700 No No 124003 723 / Month 12 2.040</td><td>Treatment Group Dositive Innunoreactivity Innunoreactivity Innunoreactivity Innaniation Treatment Group Subject ID 365 / Month 12 2.770 Nio Nio 170010 365 / Month 12 2.770 Nio Nio Nio Nio 177006 358 / Month 12 1.870 Irritis Nio Nio</td></td<> <td>Treatment Group Positive
Immunoreactivity Intranceular Treatment Group Subject ID Assay Intranceular Intranceular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intriaceular Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Intris 177005 358 / Month 12 1.870 Intis Intis 104002 717 / Month 24 1.870 Intis Intis 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.770 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No <t< td=""><td>Treatment Group Positive
Innunoreactivity Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No 170010 355 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intriacular Ranibizumab 0.5 mg 102001 715 / Month 24 2.800 Intitis 177006 358 / Month 12 1.870 Intitis Intitis 102001 722 / Month 24 1.870 Intitis Intitis 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.770 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 12 1.770 No <td< td=""><td>Treatment Group Positive
Innunioreactivity Innunioreactivity Innunioreactivity Innunioreactivity Innuniation Assay Subject ID 365 / Month 12 2.770 No No 170010 355 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 12 1.870 Intris No Ranibizumab 0.5 mg 102001 712 / Month 24 1.870 Intris 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.170 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 12 1.770<</td><td>Treatment Group Positive Innunoreactivity Innunoreactivity</td></td<></td></t<></td>
 | Treatment GroupPositive
ImmunoreactivityImmunoreactivityImmunoreactivityIntraocularSasyAssayLog TiterDiagnosis170010365 / Month 122.770NoNo177006358 / Month 121.870IntriaIntris177006358 / Month 121.870IntrisNo177006358 / Month 121.870IntrisNoRantbizumab 0.5 mg102001722 / Month 241.870No104002719 / Month 241.870NoNo122002359 / Month 121.630NoNo122002359 / Month 121.630NoNo122002359 / Month 121.630NoNo122002359 / Month 121.630NoNo124003722 / Month 241.170NoNo126001174 / Month 61.700NoNo126001174 / Month 61.700No126001174 / Month 61.700No126001174 / Month 61.700No12

 | Treatment Group Evailation Fosilation Immunoreactivity Immunoreatiotity Immunoreatiotity
 | Treatment Group
Event of the control of t
 | Treatment Group Evailation Fosilation Immunoreactivity Immunoreatiotity Immunoreatiotity
 | Treatment Group Evailation Fosilation Immunoreactivity Immunoreatiotity Immunoreatiotity

 | Treatment GroupPositive
ImmunoreactivityImmunoreactivityImmunoreactivityIntraocularSasyAssayLog TiterDiagnosis170010365 / Month 122.770NoNo177006358 / Month 121.870IntriaIntris177006358 / Month 121.870IntrisNo177006358 / Month 121.870IntrisNoRantbizumab 0.5 mg102001722 / Month 241.870No104002719 / Month 241.870NoNo122002359 / Month 121.630NoNo122002359 / Month 121.630NoNo122002359 / Month 121.630NoNo122002359 / Month 121.630NoNo124003722 / Month 241.170NoNo126001174 / Month 61.700NoNo126001174 / Month 61.700No126001174 / Month 61.700No126001174 / Month 61.700No12
 | Treatment GroupPositive
ImmunoreactivityImmunoreactivityImmunoreactivityIntraocularSasyAssayLog TiterDiagnosis170010365 / Month 122.770NoNo177006358 / Month 121.870IntriaIntris177006358 / Month 121.870IntrisNo177006358 / Month 121.870IntrisNoRantbizumab 0.5 mg102001722 / Month 241.870No104002719 / Month 241.870NoNo122002359 / Month 121.630NoNo122002359 / Month 121.630NoNo122002359 / Month 121.630NoNo122002359 / Month 121.630NoNo124003722 / Month 241.170NoNo126001174 / Month 61.700NoNo126001174 / Month 61.700No126001174 / Month 61.700No126001174 / Month 61.700No12
 | Treatment GroupPositive
ImmunoreactivityImmunoreactivityImmunoreactivityIntraocularSasyAssayLog TiterDiagnosis170010365 / Month 122.770NoNo177006358 / Month 121.870IntriaIntris177006358 / Month 121.870IntrisNo177006358 / Month 121.870IntrisNoRantbizumab 0.5 mg102001722 / Month 241.870No104002719 / Month 241.870NoNo122002359 / Month 121.630NoNo122002359 / Month 121.630NoNo122002359 / Month 121.630NoNo122002359 / Month 121.630NoNo124003722 / Month 241.170NoNo126001174 / Month 61.700NoNo126001174 / Month 61.700No126001174 / Month 61.700No126001174 / Month 61.700No12
 | Treatment Group Positive Inmunoreactivity Intraocular Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Irritis 177006 358 / Month 12 1.870 Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Irritis 177006 358 / Month 12 1.870 Irritis Irritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No 104002 719 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.1700 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 24 1.700 No No 124003 722 / Month 24 1.700 No No 124003 723 / Month 12 2.040
 | Treatment Group Dositive Innunoreactivity Innunoreactivity Innunoreactivity Innaniation Treatment Group Subject ID 365 / Month 12 2.770 Nio Nio 170010 365 / Month 12 2.770 Nio Nio Nio Nio 177006 358 / Month 12 1.870 Irritis Nio
 | Treatment Group Positive
Immunoreactivity Intranceular Treatment Group Subject ID Assay Intranceular Intranceular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intriaceular Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Intris 177005 358 / Month 12 1.870 Intis Intis 104002 717 / Month 24 1.870 Intis Intis 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.770 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No <t< td=""><td>Treatment Group Positive
Innunoreactivity Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No 170010 355 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intriacular Ranibizumab 0.5 mg 102001 715 / Month 24 2.800 Intitis 177006 358 / Month 12 1.870 Intitis Intitis 102001 722 / Month 24 1.870 Intitis Intitis 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.770 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 12 1.770 No <td< td=""><td>Treatment Group Positive
Innunioreactivity Innunioreactivity Innunioreactivity Innunioreactivity Innuniation Assay Subject ID 365 / Month 12 2.770 No No 170010 355 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 12 1.870 Intris No Ranibizumab 0.5 mg 102001 712 / Month 24 1.870 Intris 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.170 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 12 1.770<</td><td>Treatment Group Positive Innunoreactivity Innunoreactivity</td></td<></td></t<> | Treatment Group Positive
Innunoreactivity Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No 170010 355 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intriacular Ranibizumab 0.5 mg 102001 715 / Month 24 2.800 Intitis 177006 358 / Month 12 1.870 Intitis Intitis 102001 722 / Month 24 1.870 Intitis Intitis 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.770 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 12 1.770 No <td< td=""><td>Treatment Group Positive
Innunioreactivity Innunioreactivity Innunioreactivity Innunioreactivity Innuniation Assay Subject ID 365 / Month 12 2.770 No No 170010 355 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 12 1.870 Intris No Ranibizumab 0.5 mg 102001 712 / Month 24 1.870 Intris 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.170 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 12 1.770<</td><td>Treatment Group Positive Innunoreactivity Innunoreactivity</td></td<> | Treatment Group Positive
Innunioreactivity Innunioreactivity Innunioreactivity Innunioreactivity Innuniation Assay Subject ID 365 / Month 12 2.770 No No 170010 355 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 12 1.870 Intris No Ranibizumab 0.5 mg 102001 712 / Month 24 1.870 Intris 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.170 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 12 1.770<
 | Treatment Group Positive Innunoreactivity |
| 726 / Month 24 2.340 141013 715 / Month 24 2.340 143010 722 / Month 24 2.610 Vitritis 152004 522 / Early Term. 0.752 No 152004 522 / Early Term. 0.752 No 153006 183 / Month 12 1.900 No 153006 183 / Month 12 1.530 No 153007 718 / Month 24 2.070 No 159017 716 / Month 24 2.070 No 167002 717 / Month 24 0.780 No 188005 717 / Month 24 1.230 No 188005 717 / Month 24 1.250 No 188005 717 / Month 24 1.250 No

 | 726 / Month 24 2.340 141013 715 / Month 24 2.340 143010 722 / Month 24 2.610 Vitritis 152004 522 / Early Term. 0.752 No 152004 522 / Early Term. 0.752 No 153006 183 / Month 6 1.900 No 153006 183 / Month 12 1.530 No 153007 718 / Month 24 2.070 No 159017 716 / Month 24 0.780 No 167002 717 / Month 24 1.230 No 188005 717 / Month 24 1.230 No 188005 717 / Month 24 1.250 No 188005 717 / Month 24 1.250 No

 | Name $726 / Month 24$ 2.340 Vitritis141013715 / Month 24 2.340 Nio143010722 / Month 24 2.610 Vitritis152004 $522 / Early Term.0.752,Nio153006183 / Month 61.900Nio153006183 / Month 121.900Nio153007718 / Month 240.780Nio159017716 / Month 240.780Nio159017717 / Month 241.230Nio167002717 / Month 241.230Nio188005717 / Month 241.250Nio188005717 / Month 241.250Nio188005717 / Month 241.250Nio188005717 / Month 241.250Nio188005717 / Month 241.250Nio$

 | Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intraocular Diagnosis Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Intris 107002 719 / Month 24 1.870 Intris No 106002 722 / Month 24 1.140 No No 122002 359 / Month 12 1.140 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.140 No No 124003 722 / Month 12 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770

 | Treatment Group Positive Immunoreactivity

 | Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No 177005 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 No 17700 717 / Month 24 1.870 No 104002 719 / Month 24 1.870 No 106002 722 / Month 24 1.140 No 126001 126001 722 / Month 24 1.130 No 124003 722 / Month 24 1.770 No No 126001 174 / Month 24 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 12 2.040 No No 141008 181 / Month 6 <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 No No 177005 358 / Month 124 1.870 No No 177006 358 / Month 124 1.870 Intris No 177006 358 / Month 124 1.870 No No 177006 358 / Month 124 1.870 No No 104002 717 / Month 24 1.870 No No 104002 722 / Month 24 1.140 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 12 1.770 No No 124003 722 / Month 24 1.770 No No 124003 723 / Month 24 1.770<td>Treatment Group Subject ID Fositive Intraocular Intraocular Treatment Group Subject ID Assay Assay Intraocular Intraocular Treatment Group Subject ID 365 / Month 12 2.770 No No 170010 365 / Month 12 1.870 No No No 177006 358 / Month 124 2.800 No No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Irritis No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 No No 104002 719 / Month 24 1.870 No No No 104002 722 / Month 24 1.140 No No No 124003 722 / Month 12 1.630 No No No 126001 174 / Month 6 1.770 No No No 126001 174 / Month 6 1.770 No No No 126001 174 / Month 6</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 No No 177005 358 / Month 124 1.870 No No 177006 358 / Month 124 1.870 Intris No 177006 358 / Month 124 1.870 No No 177006 358 / Month 124 1.870 No No 104002 717 / Month 24 1.870 No No 104002 722 / Month 24 1.140 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 12 1.770 No No 124003 722 / Month 24 1.770 No No 124003 723 / Month 24 1.770<td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 No No 177005 358 / Month 124 1.870 No No 177006 358 / Month 124 1.870 Intris No 177006 358 / Month 124 1.870 No No 177006 358 / Month 124 1.870 No No 104002 717 / Month 24 1.870 No No 104002 722 / Month 24 1.140 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 12 1.770 No No 124003 722 / Month 24 1.770 No No 124003 723 / Month 24 1.770<td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No 177005 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 No 17700 717 / Month 24 1.870 No 104002 719 / Month 24 1.870 No 106002 722 / Month 24 1.140 No 126001 126001 722 / Month 24 1.130 No 124003 722 / Month 24 1.770 No No 126001 174 / Month 24 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 12 2.040 No No 141008 181 / Month 6<td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No 177005 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 No 17700 717 / Month 24 1.870 No 104002 719 / Month 24 1.870 No 106002 722 / Month 24 1.140 No 126001 126001 722 / Month 24 1.130 No 124003 722 / Month 24 1.770 No No 126001 174 / Month 24 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 12 2.040 No No 141008 181 / Month 6<td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No 177005 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 No 17700 717 / Month 24 1.870 No 104002 719 / Month 24 1.870 No 106002 722 / Month 24 1.140 No 126001 126001 722 / Month 24 1.130 No 124003 722 / Month 24 1.770 No No 126001 174 / Month 24 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 12 2.040 No No 141008 181 / Month 6<td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intraocular Diagnosis Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Intris 107002 719 / Month 24 1.870 Intris No 106002 722 / Month 24
 1.140 No No 122002 359 / Month 12 1.140 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.140 No No 124003 722 / Month 12 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770</td><td>Treatment Group Dositive Staty Intranceutar Intranction Treatment Group Subject ID Assay Intranceutar Intranceutar 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intranceutar Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Intris 104002 719 / Month 24 1.870 Intris No 106002 722 / Month 12 1.870 No No 122002 359 / Month 12 1.140 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.140 No No 122002 357 / Month 24 1.1770 No No 124003 722 / Month 12 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No<!--</td--><td>Treatment Group Positive Function Intraocular Intrancement Intransition Intraocular Intransition Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 2.800 No No 177006 358/Month 12 1.870 No No Ranibizumab 0.5 mg 102001 717/Month 24 0.922 No 106002 719/Month 24 1.870 Intris No 106002 722/Month 24 1.140 No No 122002 359/Month 12 1.630 No No 124003 722/Month 24 0.782 No No 124003 722/Month 24 0.782 No No No 124003 722/Month 24 0.782 No No No 124003 722/Month 24 0.782 No No No 124003 723/Month 24 0.782 No No</td><td>Treatment Group Positive Sisty Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 36 / Month 12 2.770 Nio 177006 358 / Month 12 2.770 Nio 177006 358 / Month 12 1.870 Intriacular Ranibizumab 0.5 mg 102001 715 / Month 24 0.922 Nio 177006 358 / Month 12 1.870 Intriacular 177006 358 / Month 24 0.922 Nio 106002 719 / Month 24 1.870 Nio 122002 359 / Month 12 1.140 Nio 122002 359 / Month 12 1.130 Nio 122002 357 / Month 24 0.782 Nio 124003 722 / Month 12 1.770 Nio 124003 722 / Month 24 0.782 Nio 124003 722 / Month 24 1.770 Nio 124003 722 / Month 24 1.770 Nio 124003 722 / Mo</td><td>Treatment Group Positive
Immunoreactivity Intranocular Treatment Group Subject ID Assay Assay Intranocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 24 1.870 Irritis 104002 719 / Month 24 1.870 Irritis 106002 722 / Month 24 1.140 No 122002 359 / Month 24 1.170 No 122002 359 / Month 24 1.170 No 122002 722 / Month 24 1.170 No 124003 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 723 / Month 24 1.770</td><td>Treatment Group Bubject ID Positive Intrancitiat Intrancitiat Treatment Group Subject ID Assay Assay Intrancitiat Intrancitiat Treatment Group Subject ID 365 / Month 12 2.770 No No 170010 365 / Month 12 2.870 No No No 177006 358 / Month 12 1.870 Irritis No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Irritis No Iot002 722 / Month 24 1.140 No No No 104002 723 / Month 24 1.130 No No No 122002 359 / Month 12 1.630 No No No 122002 359 / Month 24 1.130 No No No No 122002 359 / Month 24 1.130 No No No No No 124003 722 / Month 24 1.770 No No No No</td></td></td></td></td></td></td></td>
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 No No 177005 358 / Month 124 1.870 No No 177006 358 / Month 124 1.870 Intris No 177006 358 / Month 124 1.870 No No 177006 358 / Month 124 1.870 No No 104002 717 / Month 24 1.870 No No 104002 722 / Month 24 1.140 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 12 1.770 No No 124003 722 / Month 24 1.770 No No 124003 723 / Month 24 1.770 <td>Treatment Group Subject ID Fositive Intraocular Intraocular Treatment Group Subject ID Assay Assay Intraocular Intraocular Treatment Group Subject ID 365 / Month 12 2.770 No No 170010 365 / Month 12 1.870 No No No 177006 358 / Month 124 2.800 No No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Irritis No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 No No 104002 719 / Month 24 1.870 No No No 104002 722 / Month 24 1.140 No No No 124003 722 / Month 12 1.630 No No No 126001 174 / Month 6 1.770 No No No 126001 174 / Month 6 1.770 No No No 126001 174 / Month 6</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 No No 177005 358 / Month 124 1.870 No No 177006 358 / Month 124 1.870 Intris No 177006 358 / Month 124 1.870 No No 177006 358 / Month 124 1.870 No No 104002 717 / Month 24 1.870 No No 104002 722 / Month 24 1.140 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 12 1.770 No No 124003 722 / Month 24 1.770 No No 124003 723 / Month 24 1.770<td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 No No 177005 358 / Month 124 1.870 No No 177006 358 / Month 124 1.870 Intris No 177006 358 / Month 124 1.870 No No 177006 358 / Month 124 1.870 No No 104002 717 / Month 24 1.870 No No 104002 722 / Month 24 1.140 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 12 1.770 No No 124003 722 / Month 24 1.770 No No 124003 723 / Month 24 1.770<td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No 177005 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 No 17700 717 / Month 24 1.870 No 104002 719 / Month 24 1.870 No 106002 722 / Month 24 1.140 No 126001 126001 722 / Month 24 1.130 No 124003 722 / Month 24 1.770 No No 126001 174 / Month 24 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 12 2.040 No No 141008 181 / Month 6<td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No 177005 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 No 17700 717 / Month 24 1.870 No 104002 719 / Month 24 1.870 No 106002 722 / Month 24 1.140 No 126001 126001 722 / Month 24 1.130 No 124003 722 / Month 24 1.770 No No 126001 174 / Month 24 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 12 2.040 No No 141008 181 / Month 6<td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No 177005 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 No 17700 717 / Month 24 1.870 No 104002 719 / Month 24 1.870 No 106002 722 / Month 24 1.140 No 126001 126001 722 / Month 24 1.130 No 124003 722 / Month 24 1.770 No No 126001 174 / Month 24 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 12 2.040 No No 141008 181 / Month 6<td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intraocular Diagnosis Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Intris 107002 719 / Month 24 1.870 Intris No 106002 722 / Month 24 1.140 No No 122002 359 / Month 12 1.140 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.140 No No 124003 722 / Month 12 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770</td><td>Treatment
Group Dositive Staty Intranceutar Intranction Treatment Group Subject ID Assay Intranceutar Intranceutar 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intranceutar Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Intris 104002 719 / Month 24 1.870 Intris No 106002 722 / Month 12 1.870 No No 122002 359 / Month 12 1.140 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.140 No No 122002 357 / Month 24 1.1770 No No 124003 722 / Month 12 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No<!--</td--><td>Treatment Group Positive Function Intraocular Intrancement Intransition Intraocular Intransition Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 2.800 No No 177006 358/Month 12 1.870 No No Ranibizumab 0.5 mg 102001 717/Month 24 0.922 No 106002 719/Month 24 1.870 Intris No 106002 722/Month 24 1.140 No No 122002 359/Month 12 1.630 No No 124003 722/Month 24 0.782 No No 124003 722/Month 24 0.782 No No No 124003 722/Month 24 0.782 No No No 124003 722/Month 24 0.782 No No No 124003 723/Month 24 0.782 No No</td><td>Treatment Group Positive Sisty Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 36 / Month 12 2.770 Nio 177006 358 / Month 12 2.770 Nio 177006 358 / Month 12 1.870 Intriacular Ranibizumab 0.5 mg 102001 715 / Month 24 0.922 Nio 177006 358 / Month 12 1.870 Intriacular 177006 358 / Month 24 0.922 Nio 106002 719 / Month 24 1.870 Nio 122002 359 / Month 12 1.140 Nio 122002 359 / Month 12 1.130 Nio 122002 357 / Month 24 0.782 Nio 124003 722 / Month 12 1.770 Nio 124003 722 / Month 24 0.782 Nio 124003 722 / Month 24 1.770 Nio 124003 722 / Month 24 1.770 Nio 124003 722 / Mo</td><td>Treatment Group Positive
Immunoreactivity Intranocular Treatment Group Subject ID Assay Assay Intranocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 24 1.870 Irritis 104002 719 / Month 24 1.870 Irritis 106002 722 / Month 24 1.140 No 122002 359 / Month 24 1.170 No 122002 359 / Month 24 1.170 No 122002 722 / Month 24 1.170 No 124003 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 723 / Month 24 1.770</td><td>Treatment Group Bubject ID Positive Intrancitiat Intrancitiat Treatment Group Subject ID Assay Assay Intrancitiat Intrancitiat Treatment Group Subject ID 365 / Month 12 2.770 No No 170010 365 / Month 12 2.870 No No No 177006 358 / Month 12 1.870 Irritis No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Irritis No Iot002 722 / Month 24 1.140 No No No 104002 723 / Month 24 1.130 No No No 122002 359 / Month 12 1.630 No No No 122002 359 / Month 24 1.130 No No No No 122002 359 / Month 24 1.130 No No No No No 124003 722 / Month 24 1.770 No No No No</td></td></td></td></td></td></td> | Treatment Group Subject ID Fositive Intraocular Intraocular Treatment Group Subject ID Assay Assay Intraocular Intraocular Treatment Group Subject ID 365 / Month 12 2.770 No No 170010 365 / Month 12 1.870 No No No 177006 358 / Month 124 2.800 No No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Irritis No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 No No 104002 719 / Month 24 1.870 No No No 104002 722 / Month 24 1.140 No No No 124003 722 / Month 12 1.630 No No No 126001 174 / Month 6 1.770 No No No 126001 174 / Month 6
1.770 No No No 126001 174 / Month 6
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 No No 177005 358 / Month 124 1.870 No No 177006 358 / Month 124 1.870 Intris No 177006 358 / Month 124 1.870 No No 177006 358 / Month 124 1.870 No No 104002 717 / Month 24 1.870 No No 104002 722 / Month 24 1.140 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 12 1.770 No No 124003 722 / Month 24 1.770 No No 124003 723 / Month 24 1.770 <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 No No 177005 358 / Month 124 1.870 No No 177006 358 / Month 124 1.870 Intris No 177006 358 / Month 124 1.870 No No 177006 358 / Month 124 1.870 No No 104002 717 / Month 24 1.870 No No 104002 722 / Month 24 1.140 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 12 1.770 No No 124003 722 / Month 24 1.770 No No 124003 723 / Month 24 1.770<td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No 177005 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 No 17700 717 / Month 24 1.870 No 104002 719 / Month 24 1.870 No 106002 722 / Month 24 1.140 No 126001 126001 722 / Month 24 1.130 No 124003 722 / Month 24 1.770 No No 126001 174 / Month 24 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 12 2.040 No No 141008 181 / Month 6<td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No 177005 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 No 17700 717 / Month 24 1.870 No 104002 719 / Month 24 1.870 No 106002 722 / Month 24 1.140 No 126001 126001 722 / Month 24 1.130 No 124003 722 / Month 24 1.770 No No 126001 174 / Month 24 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 12 2.040 No No 141008 181 / Month 6<td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No 177005 358 / Month 12 1.870 No 177006 358 /
Month 12 1.870 No 17700 717 / Month 24 1.870 No 104002 719 / Month 24 1.870 No 106002 722 / Month 24 1.140 No 126001 126001 722 / Month 24 1.130 No 124003 722 / Month 24 1.770 No No 126001 174 / Month 24 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 12 2.040 No No 141008 181 / Month 6<td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intraocular Diagnosis Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Intris 107002 719 / Month 24 1.870 Intris No 106002 722 / Month 24 1.140 No No 122002 359 / Month 12 1.140 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.140 No No 124003 722 / Month 12 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770</td><td>Treatment Group Dositive Staty Intranceutar Intranction Treatment Group Subject ID Assay Intranceutar Intranceutar 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intranceutar Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Intris 104002 719 / Month 24 1.870 Intris No 106002 722 / Month 12 1.870 No No 122002 359 / Month 12 1.140 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.140 No No 122002 357 / Month 24 1.1770 No No 124003 722 / Month 12 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No<!--</td--><td>Treatment Group Positive Function Intraocular Intrancement Intransition Intraocular Intransition Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 2.800 No No 177006 358/Month 12 1.870 No No Ranibizumab 0.5 mg 102001 717/Month 24 0.922 No 106002 719/Month 24 1.870 Intris No 106002 722/Month 24 1.140 No No 122002 359/Month 12 1.630 No No 124003 722/Month 24 0.782 No No 124003 722/Month 24 0.782 No No No 124003 722/Month 24 0.782 No No No 124003 722/Month 24 0.782 No No No 124003 723/Month 24 0.782 No No</td><td>Treatment Group Positive Sisty Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 36 / Month 12 2.770 Nio 177006 358 / Month 12 2.770 Nio 177006 358 / Month 12 1.870 Intriacular Ranibizumab 0.5 mg 102001 715 / Month 24 0.922 Nio 177006 358 / Month 12 1.870 Intriacular 177006 358 / Month 24 0.922 Nio 106002 719 / Month 24 1.870 Nio 122002 359 / Month 12 1.140 Nio 122002 359 / Month 12 1.130 Nio 122002 357 / Month 24 0.782 Nio 124003 722 / Month 12 1.770 Nio 124003 722 / Month 24 0.782 Nio 124003 722 / Month 24 1.770 Nio 124003 722 / Month 24 1.770 Nio 124003 722 / Mo</td><td>Treatment Group Positive
Immunoreactivity Intranocular Treatment Group Subject ID Assay Assay Intranocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 24 1.870 Irritis 104002 719 / Month 24 1.870 Irritis 106002 722 / Month 24 1.140 No 122002 359 / Month 24 1.170 No 122002 359 / Month 24 1.170 No 122002 722 / Month 24 1.170 No 124003 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 723 / Month 24 1.770</td><td>Treatment Group Bubject ID Positive Intrancitiat Intrancitiat Treatment Group Subject ID Assay Assay Intrancitiat Intrancitiat Treatment Group Subject ID 365 / Month 12 2.770 No No 170010 365 / Month 12 2.870 No No No 177006 358 / Month 12 1.870 Irritis No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Irritis No Iot002 722 / Month 24 1.140 No No No 104002 723 / Month 24 1.130 No No No 122002 359 / Month 12 1.630 No No No 122002 359 / Month 24 1.130 No No No No 122002 359 / Month 24 1.130 No No No No No 124003 722 / Month 24 1.770 No No No No</td></td></td></td></td></td>
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 No No 177005 358 / Month 124 1.870 No No 177006 358 / Month 124 1.870 Intris No 177006 358 / Month 124 1.870 No No 177006 358 / Month 124 1.870 No No 104002 717 / Month 24 1.870 No No 104002 722 / Month 24 1.140 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 12 1.770 No No 124003 722 / Month 24 1.770 No No 124003 723 / Month 24 1.770 <td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No 177005 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 No 17700 717 / Month 24 1.870 No 104002 719 / Month 24 1.870 No 106002 722 / Month 24 1.140 No 126001 126001 722 / Month 24 1.130 No 124003 722 / Month 24 1.770 No No 126001 174 / Month 24 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 12 2.040 No No 141008 181 / Month 6<td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No 177005 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 No 17700 717 / Month 24 1.870 No 104002 719 / Month 24 1.870 No 106002 722 / Month 24 1.140 No 126001 126001 722 / Month 24 1.130 No 124003 722 / Month 24 1.770 No No 126001 174 / Month 24 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 12 2.040 No No 141008 181 / Month 6<td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No 177005 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 No 17700 717 / Month 24 1.870 No 104002 719 / Month 24 1.870 No 106002 722 / Month 24 1.140 No 126001 126001 722 / Month 24 1.130 No 124003 722 / Month 24 1.770 No No 126001 174 / Month 24 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 12 2.040 No No 141008 181 / Month 6<td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intraocular Diagnosis Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Intris 107002 719 / Month 24 1.870 Intris No 106002 722 / Month 24 1.140 No No 122002 359 / Month 12 1.140 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.140 No No 124003 722 / Month 12 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770</td><td>Treatment Group Dositive Staty Intranceutar Intranction Treatment Group Subject ID Assay Intranceutar Intranceutar 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intranceutar Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Intris 104002 719 / Month 24 1.870 Intris No 106002 722 / Month 12 1.870 No No 122002 359 / Month 12 1.140 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.140 No No 122002 357 / Month 24 1.1770 No No 124003 722 / Month 12 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No<!--</td--><td>Treatment Group Positive Function Intraocular Intrancement Intransition Intraocular Intransition Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 2.800 No No 177006 358/Month 12 1.870 No No Ranibizumab 0.5 mg 102001 717/Month 24 0.922 No 106002 719/Month 24 1.870 Intris No 106002 722/Month 24 1.140 No No 122002 359/Month 12 1.630 No No 124003 722/Month 24 0.782 No No 124003 722/Month 24 0.782 No No No 124003 722/Month 24 0.782 No No No 124003 722/Month 24 0.782 No No No 124003 723/Month 24 0.782 No No</td><td>Treatment Group Positive Sisty Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 36 / Month 12 2.770 Nio 177006 358 / Month 12 2.770 Nio 177006 358 / Month 12 1.870 Intriacular Ranibizumab 0.5 mg 102001 715 / Month 24 0.922 Nio 177006 358 / Month 12 1.870 Intriacular 177006 358 / Month 24 0.922 Nio 106002 719 / Month 24 1.870 Nio 122002 359 / Month 12 1.140 Nio 122002 359 / Month 12 1.130 Nio 122002 357 / Month 24 0.782 Nio 124003 722 / Month 12 1.770 Nio 124003 722 / Month 24 0.782 Nio 124003 722 / Month 24 1.770 Nio 124003 722 / Month 24 1.770 Nio 124003 722 / Mo</td><td>Treatment Group Positive
Immunoreactivity Intranocular Treatment Group Subject ID Assay Assay Intranocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177006
358 / Month 12 1.870 Irritis 177006 358 / Month 24 1.870 Irritis 104002 719 / Month 24 1.870 Irritis 106002 722 / Month 24 1.140 No 122002 359 / Month 24 1.170 No 122002 359 / Month 24 1.170 No 122002 722 / Month 24 1.170 No 124003 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 723 / Month 24 1.770</td><td>Treatment Group Bubject ID Positive Intrancitiat Intrancitiat Treatment Group Subject ID Assay Assay Intrancitiat Intrancitiat Treatment Group Subject ID 365 / Month 12 2.770 No No 170010 365 / Month 12 2.870 No No No 177006 358 / Month 12 1.870 Irritis No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Irritis No Iot002 722 / Month 24 1.140 No No No 104002 723 / Month 24 1.130 No No No 122002 359 / Month 12 1.630 No No No 122002 359 / Month 24 1.130 No No No No 122002 359 / Month 24 1.130 No No No No No 124003 722 / Month 24 1.770 No No No No</td></td></td></td></td> | Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No 177005 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 No 17700 717 / Month 24 1.870 No 104002 719 / Month 24 1.870 No 106002 722 / Month 24 1.140 No 126001 126001 722 / Month 24 1.130 No 124003 722 / Month 24 1.770 No No 126001 174 / Month 24 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 12 2.040 No No 141008 181 / Month 6 <td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No 177005 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 No 17700 717 / Month 24 1.870 No 104002 719 / Month 24 1.870 No 106002 722 / Month 24 1.140 No 126001 126001 722 / Month 24 1.130 No 124003 722 / Month 24 1.770 No No 126001 174 / Month 24 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 12 2.040 No No 141008 181 / Month 6<td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No 177005 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 No 17700 717 / Month 24 1.870 No 104002 719 / Month 24 1.870 No 106002 722 / Month 24 1.140 No 126001 126001 722 / Month 24 1.130 No 124003 722 / Month 24 1.770 No No 126001 174 / Month 24 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 12 2.040 No No 141008 181 / Month 6<td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intraocular Diagnosis Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Intris 107002 719 / Month 24 1.870 Intris No 106002 722 / Month 24 1.140 No No 122002 359 / Month 12 1.140 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.140 No No 124003 722 / Month 12 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770</td><td>Treatment Group Dositive Staty Intranceutar Intranction Treatment Group Subject ID Assay Intranceutar Intranceutar 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intranceutar Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Intris 104002 719 / Month 24 1.870 Intris No 106002 722 / Month 12 1.870 No No 122002 359 / Month 12 1.140 No No 122002 722 / Month 24 1.130 No No
 122002 359 / Month 12 1.140 No No 122002 357 / Month 24 1.1770 No No 124003 722 / Month 12 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No<!--</td--><td>Treatment Group Positive Function Intraocular Intrancement Intransition Intraocular Intransition Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 2.800 No No 177006 358/Month 12 1.870 No No Ranibizumab 0.5 mg 102001 717/Month 24 0.922 No 106002 719/Month 24 1.870 Intris No 106002 722/Month 24 1.140 No No 122002 359/Month 12 1.630 No No 124003 722/Month 24 0.782 No No 124003 722/Month 24 0.782 No No No 124003 722/Month 24 0.782 No No No 124003 722/Month 24 0.782 No No No 124003 723/Month 24 0.782 No No</td><td>Treatment Group Positive Sisty Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 36 / Month 12 2.770 Nio 177006 358 / Month 12 2.770 Nio 177006 358 / Month 12 1.870 Intriacular Ranibizumab 0.5 mg 102001 715 / Month 24 0.922 Nio 177006 358 / Month 12 1.870 Intriacular 177006 358 / Month 24 0.922 Nio 106002 719 / Month 24 1.870 Nio 122002 359 / Month 12 1.140 Nio 122002 359 / Month 12 1.130 Nio 122002 357 / Month 24 0.782 Nio 124003 722 / Month 12 1.770 Nio 124003 722 / Month 24 0.782 Nio 124003 722 / Month 24 1.770 Nio 124003 722 / Month 24 1.770 Nio 124003 722 / Mo</td><td>Treatment Group Positive
Immunoreactivity Intranocular Treatment Group Subject ID Assay Assay Intranocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 24 1.870 Irritis 104002 719 / Month 24 1.870 Irritis 106002 722 / Month 24 1.140 No 122002 359 / Month 24 1.170 No 122002 359 / Month 24 1.170 No 122002 722 / Month 24 1.170 No 124003 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 723 / Month 24 1.770</td><td>Treatment Group Bubject ID Positive Intrancitiat Intrancitiat Treatment Group Subject ID Assay Assay Intrancitiat Intrancitiat Treatment Group Subject ID 365 / Month 12 2.770 No No 170010 365 / Month 12 2.870 No No No 177006 358 / Month 12 1.870 Irritis No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Irritis No Iot002 722 / Month 24 1.140 No No No 104002 723 / Month 24 1.130 No No No 122002 359 / Month 12 1.630 No No No 122002 359 / Month 24 1.130 No No No No 122002 359 / Month 24 1.130 No No No No No 124003 722 / Month 24 1.770 No No No No</td></td></td></td> | Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No 177005 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 No 17700 717 / Month 24 1.870 No 104002 719 / Month 24 1.870 No 106002 722 / Month 24 1.140 No 126001 126001 722 / Month 24 1.130 No 124003 722 / Month 24 1.770 No No 126001 174 / Month 24 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 12 2.040 No No 141008 181 / Month 6 <td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No 177005 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 No 17700 717 / Month 24 1.870 No 104002 719 / Month 24 1.870 No 106002 722 / Month 24 1.140 No 126001 126001 722 / Month 24 1.130 No 124003 722 / Month 24 1.770 No No
126001 174 / Month 24 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 12 2.040 No No 141008 181 / Month 6<td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intraocular Diagnosis Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Intris 107002 719 / Month 24 1.870 Intris No 106002 722 / Month 24 1.140 No No 122002 359 / Month 12 1.140 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.140 No No 124003 722 / Month 12 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770</td><td>Treatment Group Dositive Staty Intranceutar Intranction Treatment Group Subject ID Assay Intranceutar Intranceutar 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intranceutar Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Intris 104002 719 / Month 24 1.870 Intris No 106002 722 / Month 12 1.870 No No 122002 359 / Month 12 1.140 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.140 No No 122002 357 / Month 24 1.1770 No No 124003 722 / Month 12 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No<!--</td--><td>Treatment Group Positive Function Intraocular Intrancement Intransition Intraocular Intransition Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 2.800 No No 177006 358/Month 12 1.870 No No Ranibizumab 0.5 mg 102001 717/Month 24 0.922 No 106002 719/Month 24 1.870 Intris No 106002 722/Month 24 1.140 No No 122002 359/Month 12 1.630 No No 124003 722/Month 24 0.782 No No 124003 722/Month 24 0.782 No No No 124003 722/Month 24 0.782 No No No 124003 722/Month 24 0.782 No No No 124003 723/Month 24 0.782 No No</td><td>Treatment Group Positive Sisty Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 36 / Month 12 2.770 Nio 177006 358 / Month 12 2.770 Nio 177006 358 / Month 12 1.870 Intriacular Ranibizumab 0.5 mg 102001 715 / Month 24 0.922 Nio 177006 358 / Month 12 1.870 Intriacular 177006 358 / Month 24 0.922 Nio 106002 719 / Month 24 1.870 Nio 122002 359 / Month 12 1.140 Nio 122002 359 / Month 12 1.130 Nio 122002 357 / Month 24 0.782 Nio 124003 722 / Month 12 1.770 Nio 124003 722 / Month 24 0.782 Nio 124003 722 / Month 24 1.770 Nio 124003 722 / Month 24 1.770 Nio 124003 722 / Mo</td><td>Treatment Group Positive
Immunoreactivity Intranocular Treatment Group Subject ID Assay Assay Intranocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 24 1.870 Irritis 104002 719 / Month 24 1.870 Irritis 106002 722 / Month 24 1.140 No 122002 359 / Month 24 1.170 No 122002 359 / Month 24 1.170 No 122002 722 / Month 24 1.170 No 124003 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 723 / Month 24 1.770</td><td>Treatment Group Bubject ID Positive Intrancitiat Intrancitiat Treatment Group Subject ID Assay Assay Intrancitiat Intrancitiat Treatment Group Subject ID 365 / Month 12 2.770 No No 170010 365 / Month 12 2.870 No No No 177006 358 / Month 12 1.870 Irritis No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Irritis No Iot002 722 / Month 24 1.140 No No No 104002 723 / Month 24 1.130 No No No 122002 359 / Month 12 1.630 No No No 122002 359 / Month 24 1.130 No No No No 122002 359 / Month 24 1.130 No No No No No 124003 722 / Month 24 1.770 No No No No</td></td></td> | Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay
 Inflammation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No 177005 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 No 17700 717 / Month 24 1.870 No 104002 719 / Month 24 1.870 No 106002 722 / Month 24 1.140 No 126001 126001 722 / Month 24 1.130 No 124003 722 / Month 24 1.770 No No 126001 174 / Month 24 1.630 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 12 2.040 No No 141008 181 / Month 6 <td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intraocular Diagnosis Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Intris 107002 719 / Month 24 1.870 Intris No 106002 722 / Month 24 1.140 No No 122002 359 / Month 12 1.140 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.140 No No 124003 722 / Month 12 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770</td> <td>Treatment Group Dositive Staty Intranceutar Intranction Treatment Group Subject ID Assay Intranceutar Intranceutar 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intranceutar Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Intris 104002 719 / Month 24 1.870 Intris No 106002 722 / Month 12 1.870 No No 122002 359 / Month 12 1.140 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.140 No No 122002 357 / Month 24 1.1770 No No 124003 722 / Month 12 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No<!--</td--><td>Treatment Group Positive Function Intraocular Intrancement Intransition Intraocular Intransition Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 2.800 No No 177006 358/Month 12 1.870 No No Ranibizumab 0.5 mg 102001 717/Month 24 0.922 No 106002 719/Month 24 1.870 Intris No 106002 722/Month 24 1.140 No No 122002 359/Month 12 1.630 No No 124003 722/Month 24 0.782 No No 124003 722/Month 24 0.782 No No No 124003 722/Month 24 0.782 No No No 124003 722/Month 24 0.782 No No No 124003 723/Month 24 0.782 No No</td><td>Treatment Group Positive Sisty Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 36 / Month 12 2.770 Nio 177006 358 / Month 12 2.770 Nio 177006 358 / Month 12 1.870 Intriacular Ranibizumab 0.5 mg 102001 715 / Month 24 0.922 Nio 177006 358 / Month 12 1.870 Intriacular 177006 358 / Month 24 0.922 Nio 106002 719 / Month 24 1.870 Nio 122002 359 / Month 12 1.140 Nio 122002 359 / Month 12 1.130 Nio 122002 357 / Month 24 0.782 Nio 124003 722 / Month 12 1.770 Nio 124003 722 / Month 24 0.782 Nio 124003 722 / Month 24 1.770 Nio 124003 722 / Month 24 1.770 Nio 124003 722 / Mo</td><td>Treatment Group Positive
Immunoreactivity Intranocular Treatment Group Subject ID Assay Assay Intranocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 24 1.870 Irritis 104002 719 / Month 24 1.870 Irritis 106002 722 / Month 24 1.140 No 122002 359 / Month 24 1.170 No 122002 359 / Month 24 1.170 No 122002 722 / Month 24 1.170 No 124003 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 723 / Month 24 1.770</td><td>Treatment Group Bubject ID Positive Intrancitiat Intrancitiat Treatment Group Subject ID Assay Assay Intrancitiat Intrancitiat Treatment Group Subject ID 365 / Month 12 2.770 No No 170010 365 / Month 12 2.870 No No No 177006 358 / Month 12 1.870 Irritis No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Irritis No Iot002 722 / Month 24 1.140 No No No 104002 723 / Month 24 1.130 No No No 122002 359 / Month 12 1.630 No No No 122002 359 / Month 24 1.130 No No No No 122002 359 / Month 24 1.130 No No No No No 124003 722 / Month 24 1.770 No No No No</td></td>
 | Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intraocular Diagnosis Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Intris 107002 719 / Month 24 1.870 Intris No 106002 722 / Month 24 1.140 No No 122002 359 / Month 12 1.140 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.140 No No 124003 722 / Month 12 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 | Treatment Group Dositive Staty Intranceutar Intranction Treatment Group Subject ID Assay Intranceutar Intranceutar 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intranceutar Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Intris 104002 719 / Month 24 1.870 Intris No 106002 722 / Month 12 1.870 No No 122002 359 / Month 12 1.140 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.140 No No 122002 357 / Month 24 1.1770 No No 124003 722 / Month 12
1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No </td <td>Treatment Group Positive Function Intraocular Intrancement Intransition Intraocular Intransition Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 2.800 No No 177006 358/Month 12 1.870 No No Ranibizumab 0.5 mg 102001 717/Month 24 0.922 No 106002 719/Month 24 1.870 Intris No 106002 722/Month 24 1.140 No No 122002 359/Month 12 1.630 No No 124003 722/Month 24 0.782 No No 124003 722/Month 24 0.782 No No No 124003 722/Month 24 0.782 No No No 124003 722/Month 24 0.782 No No No 124003 723/Month 24 0.782 No No</td> <td>Treatment Group Positive Sisty Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 36 / Month 12 2.770 Nio 177006 358 / Month 12 2.770 Nio 177006 358 / Month 12 1.870 Intriacular Ranibizumab 0.5 mg 102001 715 / Month 24 0.922 Nio 177006 358 / Month 12 1.870 Intriacular 177006 358 / Month 24 0.922 Nio 106002 719 / Month 24 1.870 Nio 122002 359 / Month 12 1.140 Nio 122002 359 / Month 12 1.130 Nio 122002 357 / Month 24 0.782 Nio 124003 722 / Month 12 1.770 Nio 124003 722 / Month 24 0.782 Nio 124003 722 / Month 24 1.770 Nio 124003 722 / Month 24 1.770 Nio 124003 722 / Mo</td> <td>Treatment Group Positive
Immunoreactivity Intranocular Treatment Group Subject ID Assay Assay Intranocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 24 1.870 Irritis 104002 719 / Month 24 1.870 Irritis 106002 722 / Month 24 1.140 No 122002 359 / Month 24 1.170 No 122002 359 / Month 24 1.170 No 122002 722 / Month 24 1.170 No 124003 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 723 / Month 24 1.770</td> <td>Treatment Group Bubject ID Positive Intrancitiat Intrancitiat Treatment Group Subject ID Assay Assay Intrancitiat Intrancitiat Treatment Group Subject ID 365 / Month 12 2.770 No No 170010 365 / Month 12 2.870 No No No 177006 358 / Month 12 1.870 Irritis No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Irritis No Iot002 722 / Month 24 1.140 No No No 104002 723 / Month 24 1.130 No No No 122002 359 / Month 12 1.630 No No No 122002 359 / Month 24 1.130 No No No No 122002 359 / Month 24 1.130 No No No No No 124003 722 / Month 24 1.770 No No No No</td> | Treatment Group Positive Function Intraocular Intrancement Intransition Intraocular Intransition Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 2.800 No No 177006 358/Month 12 1.870 No No Ranibizumab 0.5 mg 102001 717/Month 24 0.922 No 106002 719/Month 24 1.870 Intris No 106002 722/Month 24 1.140 No No 122002 359/Month 12 1.630 No No 124003 722/Month 24 0.782 No No 124003 722/Month 24 0.782 No No No 124003 722/Month 24 0.782 No No No 124003 722/Month 24 0.782 No No No 124003 723/Month 24 0.782 No No
 | Treatment Group Positive Sisty Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 36 / Month 12 2.770 Nio 177006 358 / Month 12 2.770 Nio 177006 358 / Month 12 1.870 Intriacular Ranibizumab 0.5 mg 102001 715 / Month 24 0.922 Nio 177006 358 / Month 12 1.870 Intriacular 177006 358 / Month 24 0.922 Nio 106002 719 / Month 24 1.870 Nio 122002 359 / Month 12 1.140 Nio 122002 359 / Month 12 1.130 Nio 122002 357 / Month 24 0.782 Nio 124003 722 / Month 12 1.770 Nio 124003 722 / Month 24 0.782 Nio 124003 722 / Month 24 1.770 Nio 124003 722 / Month 24 1.770 Nio 124003 722 / Mo | Treatment Group Positive
Immunoreactivity Intranocular Treatment Group Subject ID Assay Assay Intranocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 24 1.870 Irritis 104002 719 / Month 24 1.870 Irritis 106002 722 / Month 24 1.140 No 122002 359 / Month 24 1.170 No 122002 359 / Month 24 1.170 No 122002 722 / Month 24 1.170 No 124003 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 723 / Month 24 1.770 | Treatment Group Bubject ID Positive Intrancitiat Intrancitiat Treatment Group Subject ID Assay Assay Intrancitiat Intrancitiat Treatment Group Subject ID 365 / Month 12 2.770 No No 170010 365 / Month 12 2.870 No No No 177006 358 / Month 12 1.870 Irritis No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Irritis No Iot002 722 / Month 24 1.140 No No No 104002 723 / Month 24 1.130 No No No 122002 359 / Month 12 1.630 No No No 122002 359 / Month 24 1.130 No No No No 122002 359 / Month 24 1.130 No No No No No 124003 722 / Month 24 1.770 No No No No
 |
| 362 / Month 12 1.940 $726 / Month 24$ 2.340 141013 $715 / Month 24$ 2.340 143010 $722 / Month 24$ 2.440 Nio 152004 $522 / Early Term$ 0.752 , Nio 153006 $183 / Month 6$ 1.900 Nio 153006 $183 / Month 12$ 1.900 Nio 153006 $183 / Month 12$ 1.900 Nio 153006 $183 / Month 24$ 2.070 Nio 159017 $718 / Month 24$ 2.070 Nio 167002 $717 / Mont 24$ 1.230 Nio 167002 $717 / Mont 24$ 1.230 Nio 188005 $717 / Mont 24$ 1.250 Nio 188005 $717 / Mont 24$ 1.250 Nio

 | Share $362 / Month 12$ 1.940 $726 / Month 24$ 2.340 141013 $715 / Month 24$ 2.340 141013 $715 / Month 24$ 2.610 Vitritis 143010 $722 / Month 24$ 2.440 No 153006 $183 / Month 6$ 1.900 No 153006 $183 / Month 12$ 1.900 No 153006 $183 / Month 12$ 1.900 No 153006 $183 / Month 24$ 2.070 No 159017 $718 / Month 24$ 2.070 No 167002 $717 / Mont 24$ 1.230 No 167002 $717 / Mont 24$ 1.230 No 188005 $717 / Mont 24$ 1.250 No 188005 $717 / Mont 24$ 1.250 No 1000 No No No 1000 No No No 10000 No No No 10000 No No No 100000 No No

 | Sham S62 / Month 12 1.940 362 / Month 24 2.340 Vitritis 141013 715 / Month 24 2.340 Nic 143010 722 / Month 24 2.610 Vitritis 152004 522 / Early Term. 0.752 , Nio 153006 183 / Month 6 1.900 Nio 153006 183 / Month 24 2.070 Nio 153006 183 / Month 24 0.752 , Nio 15300 167002 717 / Month 24 0.780 Nio 167002 717 / Month 24 1.230 Nio Nio 188005 717 / Month 24 1.250 Nio Nio 534001 -7 / Screening 2.520 Nio Nio

 | Treatment Group Positive Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 170010 355 / Month 12 1.870 No 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 No 17700 717 / Month 24 1.870 Irritis 102001 722 / Month 12 1.870 No 104002 719 / Month 24 1.870 No 104002 722 / Month 24 1.140 No 120001 722 / Month 24 1.130 No 124003 722 / Month 24 1.130 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 126001 174 / Month 6 1.700 No 126001 174 / Month 6 1.700 No

 | Treatment Group Positive Innunoreactivity Intraocular Treatment Group Subject ID Assay Innunoreactivity Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870
 Intraocular 177006 358 / Month 12 1.870 No 17700 717 / Month 24 1.870 Intraocular 104002 719 / Month 24 1.870 Intraocular 104002 722 / Month 24 1.870 No 120001 722 / Month 24 1.630 No 12002 723 / Month 24 1.140 No 12002 723 / Month 24 1.630 No 124003 722 / Month 24 1.630 No 124003 722 / Month 24 1.770 No 126001 174 / Month 6 1.700 No 126001 174 / Month 6 1.700 No 14

 | Treatment GroupPositive
IntraocularIntraocular
InflammationTreatment GroupSubject IDAssayIoan
AssayIntraocular
Inflammation170010 $365 / Month 12$ 2.770 No170010 $365 / Month 12$ 2.800 No177006 $358 / Month 12$ 1.870 Iritis177006 $358 / Month 12$ 1.870 Iritis177006 $358 / Month 12$ 1.870 Iritis177006 $358 / Month 12$ 1.870 No104002 $717 / Month 24$ 1.870 No104002 $722 / Month 24$ 1.870 No104002 $722 / Month 24$ 1.140 No122002 $359 / Month 12$ 1.630 No124003 $722 / Month 24$ 1.700 No124003 $722 / Month 12$ 1.630 No126001 $174 / Month 6$ 1.700 No126001 $174 / Month 6$ 1.700 No121008 $357 / Month 12$ 2.040 No126001 $174 / Month 6$ 1.700 No121008 $181 / Month 6$ 1.770 No121000 $172 / Month 6$ 1.700 No121000 $172 / Month 12$ 2.040 No121000 $174 / Month 6$ 1.700 No121000 $174 / Month 6$ 1.700 No121000 $172 / Month 6$ 1.700 No121000 $174 / Month 6$ 1.770 No121000 $172 / Month 6$ 1.700 <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 17700 717 / Month 24 1.870 No No 104002 719 / Month 24 1.140 No No 120001 722 / Month 12 1.630 No No 12002 359 / Month 12 1.630 No No 12003 722 / Month 24 1.140 No No 124003 722 / Month 24 1.770 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 6 1.770 <t< td=""><td>Treatment Group Fositive Inmunoreactivity Immunoreactivity Immunoreactivity</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 17700 717 / Month 24 1.870 No No 104002 719 / Month 24 1.140 No No 120001 722 / Month 12 1.630 No No 12002 359 / Month 12 1.630 No No 12003 722 / Month 24 1.140 No No 124003 722 / Month 24 1.770 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 6 1.770 <t< td=""><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 17700 717 / Month 24 1.870 No No 104002 719 / Month 24 1.140 No No 120001 722 / Month 12 1.630 No No 12002 359 / Month 12 1.630 No No 12003 722 / Month 24 1.140 No No 124003 722 / Month 24 1.770 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 6 1.770 <t< td=""><td>Treatment GroupPositive
IntraocularIntraocular
InflammationTreatment GroupSubject IDAssayIoan
AssayIntraocular
Inflammation170010$365 / Month 12$$2.770$No170010$365 / Month 12$$2.800$No177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$No104002$717 / Month 24$$1.870$No104002$722 / Month 24$$1.870$No104002$722 / Month 24$$1.140$No122002$359 / Month 12$$1.630$No124003$722 / Month 24$$1.700$No124003$722 / Month 12$$1.630$No126001$174 / Month 6$$1.700$No126001$174 / Month 6$$1.700$No121008$357 / Month 12$$2.040$No126001$174 / Month 6$$1.700$No121008$181 / Month 6$$1.770$No121000$172 / Month 6$$1.700$No121000$172 / Month 12$$2.040$No121000$174 / Month 6$$1.700$No121000$174 / Month 6$$1.700$No121000$172 / Month 6$$1.700$No121000$174 / Month 6$$1.770$No121000$172 / Month 6$$1.700$</td></t<><td>Treatment GroupPositive
IntraocularIntraocular
InflammationTreatment GroupSubject IDAssayIoan
AssayIntraocular
Inflammation170010$365 / Month 12$$2.770$No170010$365 / Month 12$$2.800$No177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$No104002$717 / Month 24$$1.870$No104002$722 / Month 24$$1.870$No104002$722 / Month 24$$1.140$No122002$359 / Month 12$$1.630$No124003$722 / Month 24$$1.700$No124003$722 / Month 12$$1.630$No126001$174 / Month 6$$1.700$No126001$174 / Month 6$$1.700$No121002$357 / Month 12$$2.040$No126001$174 / Month 6$$1.700$No126001$174 / Month 6$$1.700$No126001$174 / Month 6$$1.700$No121008$357 / Month 24$$1.800$No121008$357 / Month 6$$1.700$No121000$174 / Month 6$$1.700$No121000$174 / Month 6$$1.700$No121000$174 / Month 6$$1.700$No121000$172 / Month 6$$1.700$</td></td></t<><td>Treatment GroupPositive
IntraocularIntraocular
InflammationTreatment GroupSubject IDAssayIoan
AssayIntraocular
Inflammation170010$365 / Month 12$$2.770$No170010$365 / Month 12$$2.800$No177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$No104002$717 / Month 24$$1.870$No104002$722 / Month 24$$1.870$No104002$722 / Month 24$$1.140$No122002$359 / Month 12$$1.630$No124003$722 / Month 24$$1.700$No124003$722 / Month 12$$1.630$No126001$174 / Month 6$$1.700$No126001$174 / Month 6$$1.700$No121002$357 / Month 12$$2.040$No126001$174 / Month 6$$1.700$No126001$174 / Month 6$$1.700$No126001$174 / Month 6$$1.700$No121008$357 / Month 24$$1.800$No121008$357 / Month 6$$1.700$No121000$174 / Month 6$$1.700$No121000$174 / Month 6$$1.700$No121000$174 / Month 6$$1.700$No121000$172 / Month 6$$1.700$</td></td></t<><td>Treatment Group Positive Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 170010 355 / Month 12 1.870 No 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 No 17700 717 / Month 24 1.870 Irritis 102001 722 / Month 12 1.870 No 104002 719 / Month 24 1.870 No 104002 722 / Month 24 1.140 No 120001 722 / Month 24 1.130 No 124003 722 / Month 24 1.130 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 126001 174 / Month 6 1.700
No 126001 174 / Month 6 1.700 No</td><td>Treatment Group Positive Inmunoreactivity Intraocular Treatment Group Subject ID Assay Assay Inmunoreactivity 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 No 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 715 / Month 24 1.870 No 177006 358 / Month 12 1.870 No No 102001 722 / Month 24 1.870 Intris No 104002 722 / Month 24 1.140 No No 124003 722 / Month 24 1.130 No No 124003 722 / Month 24 1.140 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 6 1.770 No No 124003 722 / Month 12 2.040 No</td><td>Treatment GroupPositive
ImmunoreactivityImmunoreactivityImmunoreactivityImmunoreactivityTreatment GroupSubject IDAssayAssayAssayInflammationSubject IDSubject ID365 / Month 122.770No170010365 / Month 122.770No177006358 / Month 121.870Intitis177006358 / Month 121.870Intitis177006358 / Month 241.870Intitis104002719 / Month 241.870No104002722 / Month 241.140No104002723 / Month 121.630No105001722 / Month 121.630No106002723 / Month 121.630No122002359 / Month 121.630No122002357 / Month 241.770No124003722 / Month 241.770No126001174 / Month 61.700No126001174 / Month 61.700No126001174 / Month 61.700No141008181 / Month 61.570No141008181 / Month 61.570No</td><td>Treatment GroupPositive
ImmunoreactivityImmunoreactivityImmunoreactivityTreatment GroupSubject IDAssayAssay Log TiterDiagnosis170010$365$ Month 12$2.770$No177006$358$ Month 12$2.770$No177006$358$ Month 24$1870$Initis177006$358$ Month 24$1870$Initis177005$358$ Month 24$1870$Initis177006$358$ Month 24$1870$No104002$712$ Month 24$1870$No104002$712$ Month 24$1140$No104002$722$ Month 24$1140$No102001$722$ Month 24$1140$No104002$722$ Month 24$1140$No105002$359$ Month 12$1630$No106002$722$ Month 24$1170$No122002$357$ Month 24$1170$No124003$722$ Month 24$1770$No126001$174$ Month 6$1770$No126001$174$ Month 6$1770$No124003$727$ Month 24$181$ Month 6$1770$124003$727$ Month 24$180$No124003$727$ Month 24$10700$No126001$174$ Month 6$1770$No126001$174$ Month 6$1770$No124008$181$ Month 6$1.770$No</td><td>Treatment Group Positive
Immunoreactivity Intracediat Treatment Group Subject ID Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intracediat Ranibizumab 0.5 mg 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 1.870 Intris No 102001 722 / Month 24 1.870 No No 104002 719 / Month 24 1.140 No No 102001 722 / Month 24 1.140 No No 122002 359 / Month 24 1.140 No No 122002 357 / Month 24 1.140 No No 122003 723 / Month 24 1.170 No No 124003 727 / Month 24 1.770 No No 126001 174 / Month 6 1.770</td><td>Treatment Group Positive Intrancitiar Treatment Group Subject ID Assay Intrancitiar Intrancitiar 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 12 1.870 Intris No 107001 722 / Month 24 1.870 Intris No 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 124003 722 / Month 24 1.170 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 6 1.770 No No 121000 357 / Month 24 1.700 No No</td></td> | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 17700 717 / Month 24 1.870 No No 104002 719 / Month 24 1.140 No No 120001 722 / Month 12 1.630 No No 12002 359 / Month 12 1.630 No No 12003 722 / Month 24 1.140 No No 124003 722 / Month 24 1.770 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 6 1.770 <t< td=""><td>Treatment Group
Fositive Inmunoreactivity Immunoreactivity Immunoreactivity</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 17700 717 / Month 24 1.870 No No 104002 719 / Month 24 1.140 No No 120001 722 / Month 12 1.630 No No 12002 359 / Month 12 1.630 No No 12003 722 / Month 24 1.140 No No 124003 722 / Month 24 1.770 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 6 1.770 <t< td=""><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 17700 717 / Month 24 1.870 No No 104002 719 / Month 24 1.140 No No 120001 722 / Month 12 1.630 No No 12002 359 / Month 12 1.630 No No 12003 722 / Month 24 1.140 No No 124003 722 / Month 24 1.770 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 6 1.770 <t< td=""><td>Treatment GroupPositive
IntraocularIntraocular
InflammationTreatment GroupSubject IDAssayIoan
AssayIntraocular
Inflammation170010$365 / Month 12$$2.770$No170010$365 / Month 12$$2.800$No177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$No104002$717 / Month 24$$1.870$No104002$722 / Month 24$$1.870$No104002$722 / Month 24$$1.140$No122002$359 / Month 12$$1.630$No124003$722 / Month 24$$1.700$No124003$722 / Month 12$$1.630$No126001$174 / Month 6$$1.700$No126001$174 / Month 6$$1.700$No121008$357 / Month 12$$2.040$No126001$174 / Month 6$$1.700$No121008$181 / Month 6$$1.770$No121000$172 / Month 6$$1.700$No121000$172 / Month 12$$2.040$No121000$174 / Month 6$$1.700$No121000$174 / Month 6$$1.700$No121000$172 / Month 6$$1.700$No121000$174 / Month 6$$1.770$No121000$172 / Month 6$$1.700$</td></t<><td>Treatment GroupPositive
IntraocularIntraocular
InflammationTreatment GroupSubject IDAssayIoan
AssayIntraocular
Inflammation170010$365 / Month 12$$2.770$No170010$365 / Month 12$$2.800$No177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$No104002$717 / Month 24$$1.870$No104002$722 / Month 24$$1.870$No104002$722 / Month 24$$1.140$No122002$359 / Month 12$$1.630$No124003$722 / Month 24$$1.700$No124003$722 / Month 12$$1.630$No126001$174 / Month 6$$1.700$No126001$174 / Month 6$$1.700$No121002$357 / Month 12$$2.040$No126001$174 / Month 6$$1.700$No126001$174 / Month 6$$1.700$No126001$174 / Month 6$$1.700$No121008$357 / Month 24$$1.800$No121008$357 / Month 6$$1.700$No121000$174 / Month 6$$1.700$No121000$174 / Month 6$$1.700$No121000$174 / Month 6$$1.700$No121000$172 / Month 6$$1.700$</td></td></t<><td>Treatment GroupPositive
IntraocularIntraocular
InflammationTreatment GroupSubject IDAssayIoan
AssayIntraocular
Inflammation170010$365 / Month 12$$2.770$No170010$365 / Month 12$$2.800$No177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$No104002$717 / Month 24$$1.870$No104002$722 / Month 24$$1.870$No104002$722 / Month 24$$1.140$No122002$359 / Month 12$$1.630$No124003$722 / Month 24$$1.700$No124003$722 / Month 12$$1.630$No126001$174 / Month 6$$1.700$No126001$174 / Month 6$$1.700$No121002$357 / Month 12$$2.040$No126001$174 / Month 6$$1.700$No126001$174 / Month 6$$1.700$No126001$174 / Month 6$$1.700$No121008$357 / Month 24$$1.800$No121008$357 / Month 6$$1.700$No121000$174 / Month 6$$1.700$No121000$174 / Month 6$$1.700$No121000$174 / Month 6$$1.700$No121000$172 / Month 6$$1.700$</td></td></t<> <td>Treatment Group Positive Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 170010 355 / Month 12 1.870 No 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 No 17700 717 / Month 24 1.870 Irritis 102001 722 / Month 12 1.870 No 104002 719 / Month 24 1.870 No 104002 722 / Month 24 1.140 No 120001 722 / Month 24 1.130 No 124003 722 / Month 24 1.130 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 126001 174 / Month 6 1.700 No 126001 174 / Month 6 1.700 No</td> <td>Treatment Group Positive Inmunoreactivity Intraocular Treatment Group Subject ID Assay Assay Inmunoreactivity 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 No 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 715 / Month 24 1.870 No 177006 358 / Month 12 1.870 No No 102001 722 / Month 24 1.870 Intris No 104002 722 / Month 24 1.140 No No 124003 722 / Month 24 1.130 No No 124003 722 / Month 24 1.140 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 6 1.770 No No 124003 722 / Month 12 2.040 No</td> <td>Treatment GroupPositive
ImmunoreactivityImmunoreactivityImmunoreactivityImmunoreactivityTreatment GroupSubject IDAssayAssayAssayInflammationSubject IDSubject ID365 / Month 122.770No170010365 / Month 122.770No177006358 / Month 121.870Intitis177006358 / Month 121.870Intitis177006358 / Month 241.870Intitis104002719 / Month 241.870No104002722 / Month 241.140No104002723 / Month 121.630No105001722 / Month 121.630No106002723 / Month 121.630No122002359 / Month 121.630No122002357 / Month 241.770No124003722 / Month 241.770No126001174 / Month 61.700No126001174 / Month 61.700No126001174 / Month 61.700No141008181 / Month 61.570No141008181 / Month 61.570No</td> <td>Treatment GroupPositive
ImmunoreactivityImmunoreactivityImmunoreactivityTreatment GroupSubject IDAssayAssay Log TiterDiagnosis170010$365$ Month 12$2.770$No177006$358$ Month 12$2.770$No177006$358$ Month 24$1870$Initis177006$358$ Month 24$1870$Initis177005$358$ Month 24$1870$Initis177006$358$ Month 24$1870$No104002$712$ Month 24$1870$No104002$712$ Month 24$1140$No104002$722$ Month 24$1140$No102001$722$ Month 24$1140$No104002$722$ Month 24$1140$No105002$359$ Month 12$1630$No106002$722$ Month 24$1170$No122002$357$ Month 24$1170$No124003$722$ Month 24$1770$No126001$174$ Month 6$1770$No126001$174$ Month 6$1770$No124003$727$ Month 24$181$ Month 6$1770$124003$727$ Month 24$180$No124003$727$ Month 24$10700$No126001$174$ Month 6$1770$No126001$174$ Month 6$1770$No124008$181$ Month 6$1.770$No</td> <td>Treatment Group Positive
Immunoreactivity Intracediat Treatment Group Subject ID Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intracediat Ranibizumab 0.5 mg 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 1.870 Intris No 102001 722 / Month 24 1.870 No No 104002 719 / Month 24 1.140 No No 102001 722 / Month 24 1.140 No No 122002 359 / Month 24 1.140 No No 122002 357 / Month 24 1.140 No No 122003 723 / Month 24 1.170 No No 124003 727 / Month 24 1.770 No No 126001 174 /
Month 6 1.770</td> <td>Treatment Group Positive Intrancitiar Treatment Group Subject ID Assay Intrancitiar Intrancitiar 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 12 1.870 Intris No 107001 722 / Month 24 1.870 Intris No 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 124003 722 / Month 24 1.170 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 6 1.770 No No 121000 357 / Month 24 1.700 No No</td> | Treatment Group Fositive Inmunoreactivity Immunoreactivity
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 17700 717 / Month 24 1.870 No No 104002 719 / Month 24 1.140 No No 120001 722 / Month 12 1.630 No No 12002 359 / Month 12 1.630 No No 12003 722 / Month 24 1.140 No No 124003 722 / Month 24 1.770 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 6 1.770 <t< td=""><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 17700 717 / Month 24 1.870 No No 104002 719 / Month 24 1.140 No No 120001 722 / Month 12
 1.630 No No 12002 359 / Month 12 1.630 No No 12003 722 / Month 24 1.140 No No 124003 722 / Month 24 1.770 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 6 1.770 <t< td=""><td>Treatment GroupPositive
IntraocularIntraocular
InflammationTreatment GroupSubject IDAssayIoan
AssayIntraocular
Inflammation170010$365 / Month 12$$2.770$No170010$365 / Month 12$$2.800$No177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$No104002$717 / Month 24$$1.870$No104002$722 / Month 24$$1.870$No104002$722 / Month 24$$1.140$No122002$359 / Month 12$$1.630$No124003$722 / Month 24$$1.700$No124003$722 / Month 12$$1.630$No126001$174 / Month 6$$1.700$No126001$174 / Month 6$$1.700$No121008$357 / Month 12$$2.040$No126001$174 / Month 6$$1.700$No121008$181 / Month 6$$1.770$No121000$172 / Month 6$$1.700$No121000$172 / Month 12$$2.040$No121000$174 / Month 6$$1.700$No121000$174 / Month 6$$1.700$No121000$172 / Month 6$$1.700$No121000$174 / Month 6$$1.770$No121000$172 / Month 6$$1.700$</td></t<><td>Treatment GroupPositive
IntraocularIntraocular
InflammationTreatment GroupSubject IDAssayIoan
AssayIntraocular
Inflammation170010$365 / Month 12$$2.770$No170010$365 / Month 12$$2.800$No177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$No104002$717 / Month 24$$1.870$No104002$722 / Month 24$$1.870$No104002$722 / Month 24$$1.140$No122002$359 / Month 12$$1.630$No124003$722 / Month 24$$1.700$No124003$722 / Month 12$$1.630$No126001$174 / Month 6$$1.700$No126001$174 / Month 6$$1.700$No121002$357 / Month 12$$2.040$No126001$174 / Month 6$$1.700$No126001$174 / Month 6$$1.700$No126001$174 / Month 6$$1.700$No121008$357 / Month 24$$1.800$No121008$357 / Month 6$$1.700$No121000$174 / Month 6$$1.700$No121000$174 / Month 6$$1.700$No121000$174 / Month 6$$1.700$No121000$172 / Month 6$$1.700$</td></td></t<> <td>Treatment GroupPositive
IntraocularIntraocular
InflammationTreatment GroupSubject IDAssayIoan
AssayIntraocular
Inflammation170010$365 / Month 12$$2.770$No170010$365 / Month 12$$2.800$No177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$No104002$717 / Month 24$$1.870$No104002$722 / Month 24$$1.870$No104002$722 / Month 24$$1.140$No122002$359 / Month 12$$1.630$No124003$722 / Month 24$$1.700$No124003$722 / Month 12$$1.630$No126001$174 / Month 6$$1.700$No126001$174 / Month 6$$1.700$No121002$357 / Month 12$$2.040$No126001$174 / Month 6$$1.700$No126001$174 / Month 6$$1.700$No126001$174 / Month 6$$1.700$No121008$357 / Month 24$$1.800$No121008$357 / Month 6$$1.700$No121000$174 / Month 6$$1.700$No121000$174 / Month 6$$1.700$No121000$174 / Month 6$$1.700$No121000$172 / Month 6$$1.700$</td>
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 17700 717 / Month 24 1.870 No No 104002 719 / Month 24 1.140 No No 120001 722 / Month 12 1.630 No No 12002 359 / Month 12 1.630 No No 12003 722 / Month 24 1.140 No No 124003 722 / Month 24 1.770 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 6 1.770 <t< td=""><td>Treatment GroupPositive
IntraocularIntraocular
InflammationTreatment GroupSubject IDAssayIoan
AssayIntraocular
Inflammation170010$365 / Month 12$$2.770$No170010$365 / Month 12$$2.800$No177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$No104002$717 / Month 24$$1.870$No104002$722 / Month 24$$1.870$No104002$722 / Month 24$$1.140$No122002$359 / Month 12$$1.630$No124003$722 / Month 24$$1.700$No124003$722 / Month 12$$1.630$No126001$174 / Month 6$$1.700$No126001$174 / Month 6$$1.700$No121008$357 / Month 12$$2.040$No126001$174 / Month 6$$1.700$No121008$181 / Month 6$$1.770$No121000$172 / Month 6$$1.700$No121000$172 / Month 12$$2.040$No121000$174 / Month 6$$1.700$No121000$174 / Month 6$$1.700$No121000$172 / Month 6$$1.700$No121000$174 / Month 6$$1.770$No121000$172 / Month 6$$1.700$</td></t<> <td>Treatment GroupPositive
IntraocularIntraocular
InflammationTreatment GroupSubject IDAssayIoan
AssayIntraocular
Inflammation170010$365 / Month 12$$2.770$No170010$365 / Month 12$$2.800$No177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$Iritis177006$358 / Month 12$$1.870$No104002$717 / Month 24$$1.870$No104002$722 / Month 24$$1.870$No104002$722 / Month 24$$1.140$No122002$359 / Month 12$$1.630$No124003$722 / Month 24$$1.700$No124003$722 / Month 12$$1.630$No126001$174 / Month 6$$1.700$No126001$174 / Month 6$$1.700$No121002$357 / Month 12$$2.040$No126001$174 / Month 6$$1.700$No126001$174 / Month 6$$1.700$No126001$174 / Month 6$$1.700$No121008$357 / Month 24$$1.800$No121008$357 / Month 6$$1.700$No121000$174 / Month 6$$1.700$No121000$174 / Month 6$$1.700$No121000$174 / Month 6$$1.700$No121000$172 / Month 6$$1.700$</td>
 | Treatment GroupPositive
IntraocularIntraocular
InflammationTreatment GroupSubject IDAssayIoan
AssayIntraocular
Inflammation170010 $365 / Month 12$ 2.770 No170010 $365 / Month 12$ 2.800 No177006 $358 / Month 12$ 1.870 Iritis177006 $358 / Month 12$ 1.870 Iritis177006 $358 / Month 12$ 1.870 Iritis177006 $358 / Month 12$ 1.870 No104002 $717 / Month 24$ 1.870 No104002 $722 / Month 24$ 1.870 No104002 $722 / Month 24$ 1.140 No122002 $359 / Month 12$ 1.630 No124003 $722 / Month 24$ 1.700 No124003 $722 / Month 12$ 1.630 No126001 $174 / Month 6$ 1.700 No126001 $174 / Month 6$ 1.700 No121008 $357 / Month 12$ 2.040 No126001 $174 / Month 6$ 1.700 No121008 $181 / Month 6$ 1.770 No121000 $172 / Month 6$ 1.700 No121000 $172 / Month 12$ 2.040 No121000 $174 / Month 6$ 1.700 No121000 $174 / Month 6$ 1.700 No121000 $172 / Month 6$ 1.700 No121000 $174 / Month 6$ 1.770 No121000 $172 / Month 6$ 1.700
 | Treatment GroupPositive
IntraocularIntraocular
InflammationTreatment GroupSubject IDAssayIoan
AssayIntraocular
Inflammation170010 $365 / Month 12$ 2.770 No170010 $365 / Month 12$ 2.800 No177006 $358 / Month 12$ 1.870 Iritis177006 $358 / Month 12$ 1.870 Iritis177006 $358 / Month 12$ 1.870 Iritis177006 $358 / Month 12$ 1.870 No104002 $717 / Month 24$ 1.870 No104002 $722 / Month 24$ 1.870 No104002 $722 / Month 24$ 1.140 No122002 $359 / Month 12$ 1.630 No124003 $722 / Month 24$ 1.700 No124003 $722 / Month 12$ 1.630 No126001 $174 / Month 6$ 1.700 No126001 $174 / Month 6$ 1.700 No121002 $357 / Month 12$ 2.040 No126001 $174 / Month 6$ 1.700 No126001 $174 / Month 6$ 1.700 No126001 $174 / Month 6$ 1.700 No121008 $357 / Month 24$ 1.800 No121008 $357 / Month 6$ 1.700 No121000 $174 / Month 6$ 1.700 No121000 $174 / Month 6$ 1.700 No121000 $174 / Month 6$ 1.700 No121000 $172 / Month 6$ 1.700

 | Treatment GroupPositive
IntraocularIntraocular
InflammationTreatment GroupSubject IDAssayIoan
AssayIntraocular
Inflammation170010 $365 / Month 12$ 2.770 No170010 $365 / Month 12$ 2.800 No177006 $358 / Month 12$ 1.870 Iritis177006 $358 / Month 12$ 1.870 Iritis177006 $358 / Month 12$ 1.870 Iritis177006 $358 / Month 12$ 1.870 No104002 $717 / Month 24$ 1.870 No104002 $722 / Month 24$ 1.870 No104002 $722 / Month 24$ 1.140 No122002 $359 / Month 12$ 1.630 No124003 $722 / Month 24$ 1.700 No124003 $722 / Month 12$ 1.630 No126001 $174 / Month 6$ 1.700 No126001 $174 / Month 6$ 1.700 No121002 $357 / Month 12$ 2.040 No126001 $174 / Month 6$ 1.700 No126001 $174 / Month 6$ 1.700 No126001 $174 / Month 6$ 1.700 No121008 $357 / Month 24$ 1.800 No121008 $357 / Month 6$ 1.700 No121000 $174 / Month 6$ 1.700 No121000 $174 / Month 6$ 1.700 No121000 $174 / Month 6$ 1.700 No121000 $172 / Month 6$ 1.700
 | Treatment Group Positive Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 170010 355 / Month 12 1.870 No 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 No 17700 717 / Month 24 1.870 Irritis 102001 722 / Month 12 1.870 No 104002 719 / Month 24 1.870 No 104002 722 / Month 24 1.140 No 120001 722 / Month 24 1.130 No 124003 722 / Month 24 1.130 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 126001 174 / Month 6 1.700 No 126001 174 / Month 6 1.700 No | Treatment Group Positive Inmunoreactivity Intraocular Treatment Group Subject ID Assay Assay Inmunoreactivity 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 No 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg
 102001 715 / Month 24 1.870 No 177006 358 / Month 12 1.870 No No 102001 722 / Month 24 1.870 Intris No 104002 722 / Month 24 1.140 No No 124003 722 / Month 24 1.130 No No 124003 722 / Month 24 1.140 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 6 1.770 No No 124003 722 / Month 12 2.040 No | Treatment GroupPositive
ImmunoreactivityImmunoreactivityImmunoreactivityImmunoreactivityTreatment GroupSubject IDAssayAssayAssayInflammationSubject IDSubject ID365 / Month 122.770No170010365 / Month 122.770No177006358 / Month 121.870Intitis177006358 / Month 121.870Intitis177006358 / Month 241.870Intitis104002719 / Month 241.870No104002722 / Month 241.140No104002723 / Month 121.630No105001722 / Month 121.630No106002723 / Month 121.630No122002359 / Month 121.630No122002357 / Month 241.770No124003722 / Month 241.770No126001174 / Month 61.700No126001174 / Month 61.700No126001174 / Month 61.700No141008181 / Month 61.570No141008181 / Month 61.570No
 | Treatment GroupPositive
ImmunoreactivityImmunoreactivityImmunoreactivityTreatment GroupSubject IDAssayAssay Log TiterDiagnosis170010 365 Month 12 2.770 No177006 358 Month 12 2.770 No177006 358 Month 24 1870 Initis177006 358 Month 24 1870 Initis177005 358 Month 24 1870 Initis177006 358 Month 24 1870 No104002 712 Month 24 1870 No104002 712 Month 24 1140 No104002 722 Month 24 1140 No102001 722 Month 24 1140 No104002 722 Month 24 1140 No105002 359 Month 12 1630 No106002 722 Month 24 1170 No122002 357 Month 24 1170 No124003 722 Month 24 1770 No126001 174 Month 6 1770 No126001 174 Month 6 1770 No124003 727 Month 24 181 Month 6 1770 124003 727 Month 24 180 No124003 727 Month 24 10700 No126001 174 Month 6 1770 No126001 174 Month 6 1770 No124008 181 Month 6 1.770 No | Treatment Group Positive
Immunoreactivity Intracediat Treatment Group Subject ID Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intracediat Ranibizumab 0.5 mg 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 1.870 Intris No 102001 722 / Month 24 1.870 No No 104002 719 / Month 24 1.140 No No 102001 722 / Month 24 1.140 No No 122002 359 / Month 24 1.140 No No 122002 357 / Month 24 1.140 No No 122003 723 / Month 24 1.170 No No 124003 727 / Month 24 1.770 No No 126001 174 / Month 6 1.770 | Treatment Group Positive Intrancitiar Treatment Group Subject ID Assay Intrancitiar Intrancitiar 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 12 1.870 Intris No 107001 722 / Month 24 1.870 Intris No 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 124003 722 / Month 24 1.170 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 6 1.770 No No 121000 357 / Month 24 1.700 No No
 |
| S62 / Month 12 1.940 726 / Month 24 2.340 141013 715 / Month 24 2.340 143010 722 / Month 24 2.610 Vitritis 152004 522 / Month 24 2.440 No 153006 183 / Month 6 1.900 No 153006 183 / Month 12 1.530 No 153007 718 / Month 24 2.070 No 153007 718 / Month 24 2.070 No 153007 716 / Month 24 2.070 No 167002 717 / Mont 24 0.780 No 188005 717 / Month 24 1.250 No 188005 717 / Month 24 1.250 No 1000 No No No 11230 No No No

 | S62 / Month 12 1.940 726 / Month 24 2.340 141013 715 / Month 24 2.340 143010 722 / Month 24 2.610 Vitritis 152004 522 / Early Term. 0.752 , No No 153006 183 / Month 6 1.900 No 153006 183 / Month 12 1.530 No 153007 718 / Month 24 2.070 No 153007 718 / Month 24 2.070 No 153007 716 / Month 24 2.070 No 165007 717 / Mont 24 1.230 No 165002 717 / Mont 24 1.250 No 188005 717 / Month 24 1.250 No 534001 $-7/Screening$ 2.520 Vitritis

 | Sham 362 / Month 12 1.940 Vitritis 726 / Month 24 2.340 Vitritis 141013 715 / Month 24 2.340 Vitritis 143010 722 / Month 24 2.610 Vitritis 153004 522 / Early Term. 0.752 / No 153006 183 / Month 6 1.900 No 153006 183 / Month 24 2.070 No 153006 183 / Month 24 0.752 / No 153006 183 / Month 24 0.780 No 153007 718 / Month 24 0.780 No 159017 716 / Month 24 1.530 No 167002 717 / Mont 24 1.230 No 188005 717 / Month 24 1.250 No 188005 717 / Month 24 1.250 No 188005 717 / Month 24 1.250 No

 | Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea

 | Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea

 | Treatment Group Positive
Innunoreactivity Innunoreactivity Innunorea

 | Treatment Group Bubject ID Fositive
Assay Innunoreactivity
Assay Log Titer Innunoreactivity
Infimmation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intitis 177006 358 / Month 12 1.870 No Ranibizumab 0.5 mg 102001 715 / Month 24 1.870 No 177006 358 / Month 12 1.870 No No 104002 719 / Month 24 1.870 No No 102001 722 / Month 24 1.140 No No 104002 723 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.170 No No 122002 359 / Month 12 1.630 No No 122003 359 / Month 12 1.770 No No 122003 357 / Month 24 1.770 No No 124003 722 / Month 24 1.77

 | Treatment Group Bubject ID Fositive
Assay Innumoreactivity
Assay Log Titer Innumoreactivity
Diagnosis 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 No 104002 719 / Month 24 1.870 No 104002 722 / Month 24 1.140 No 102001 722 / Month 24 1.130 No 122002 359 / Month 12 1.130 No 122002 359 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 359 / Month 12 1.630 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24

 | Treatment Group Bubject ID Fositive
Assay Innunoreactivity
Assay Log Titer Innunoreactivity
Infimmation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intitis 177006 358 / Month 12 1.870 No Ranibizumab 0.5 mg 102001 715 / Month 24 1.870 No 177006 358 / Month 12 1.870 No No 104002 719 / Month 24 1.870 No No 102001 722 / Month 24 1.140 No No 104002 723 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.170 No No 122002 359 / Month 12 1.630 No No 122003 359 / Month 12 1.770 No No 122003 357 / Month 24 1.770 No No 124003 722 / Month 24 1.77
 | Treatment Group Bubject ID Fositive
Assay Innunoreactivity
Assay Log Titer Innunoreactivity
Infimmation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intitis 177006 358 / Month 12 1.870 No Ranibizumab 0.5 mg 102001 715 / Month 24 1.870 No 177006 358 / Month 12 1.870 No No 104002 719 / Month 24 1.870 No No 102001 722 / Month 24 1.140 No No 104002 723 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.170 No No 122002 359 / Month 12 1.630 No No 122003 359 / Month 12 1.770 No No 122003 359 / Month 12 1.770 No No 124003 722 / Month 24 0.78

 | Treatment Group Positive
Innunoreactivity Innunoreactivity Innunorea
 | Treatment Group Positive
Innunoreactivity Innunoreactivity Innunorea
 | Treatment Group Positive
Innunoreactivity Innunoreactivity Innunorea
 | Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea
 | Treatment Group Bubject ID Positive
Assay Immunoreactivity
Assay Immunoreactivity
Infimumation Intraocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Infimumation Ranibizumab 0.5 mg 102001 715 / Month 24 2.800 No 177006 358 / Month 12 1.870 No No 104002 719 / Month 24 1.870 No No 102001 722 / Month 24 1.870 No No 102002 722 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 24 1.170 No No 122003 357 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 126001 | Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 No Ranibizumab 0.5 mg 102001 715 / Month 24 1.870 Intris 106002 722 / Month 24 1.870 No No 122002 359 / Month 12 1.630 No No 122002 723 / Month 24 1.140 No No 122003 723 / Month 24 1.1700 No No 124003 723 / Month 24 1.1700 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Mo
 | Treatment Group Bubject ID Positive
Assay Immunoreactivity
Assay Immunoreactivity
Inflammation Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Intris 104002 719 / Month 24 1.870 Intris No 1122002 359 / Month 12 1.870 No No 1222002 722 / Month 24 1.140 No No 122003 723 / Month 24 1.1700 No No 122003 359 / Month 12 1.630 No No 122003 357 / Month 24 1.1700 No No 124003 723 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No <t< td=""><td>Treatment Group Subject ID Positive
Immunoreactivity Intracediat Treatment Group Subject ID Assay Assay Intracediat 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 102001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122003 722 / Month 24 1.130 No 122003 723 / Month 12 1.630 No 122003 359 / Month 12 1.630 No 122003 723 / Month 24 1.140 No 126001 174 / Month 24 1.770 No 126001 174 / Month 24 1.700 No 126001 174 / Month 24</td><td>Treatment Group Bubject ID Positive Intrancitiat Treatment Group Subject ID Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intractination Ranibizumab 0.5 mg 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 1.870 Intris No 102001 722 / Month 24 1.850 No No 102002 722 / Month 24 1.140 No No 1122002 359 / Month 12 1.630 No No 122003 722 / Month 24 1.130 No No 122003 723 / Month 24 1.770 No No 122003 723 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1</td></t<> | Treatment Group Subject ID Positive
Immunoreactivity Intracediat Treatment Group Subject ID Assay Assay Intracediat 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 102001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122003 722 / Month 24 1.130 No 122003 723 / Month 12 1.630 No 122003 359 / Month 12 1.630 No 122003 723 / Month 24 1.140 No 126001 174 / Month 24 1.770 No 126001 174 / Month 24 1.700 No 126001 174 / Month 24 | Treatment Group Bubject ID Positive Intrancitiat Treatment Group Subject ID Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intractination Ranibizumab 0.5 mg 102001
 715 / Month 24 1.870 Intris 104002 719 / Month 24 1.870 Intris No 102001 722 / Month 24 1.850 No No 102002 722 / Month 24 1.140 No No 1122002 359 / Month 12 1.630 No No 122003 722 / Month 24 1.130 No No 122003 723 / Month 24 1.770 No No 122003 723 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1 |
| Name Nonth 12 1.570 1.570 1.00 1.00 362 / Month 12 1.940 1.940 1.00 141013 715 / Month 24 2.340 1.00 143010 722 / Month 24 2.610 V itritis 153006 183 / Month 6 1.900 No 153006 183 / Month 24 2.440 No 153006 183 / Month 24 2.700 No 153006 183 / Month 24 2.070 No 15300 715 / Month 24 2.070 No 159017 716 / Month 24 1.230 No 167002 717 / Mont 24 1.230 No 188005 717 / Month 24 1.250 No 88005 717 / Month 24 1.250 No 88005 717 / Month 24 1.250 No 834001 -7 / Screening 2.520 $Vitritis$ No

 | Sham Sol Month 12 1.570 1.570 1.00 726 / Month 12 1.940 1.900 1.00 141013 715 / Month 24 2.510 $Vitritis$ 143010 722 / Month 24 2.440 No 153006 183 / Month 6 1.900 No 153006 183 / Month 24 2.440 No 153006 183 / Month 24 2.740 No 153006 183 / Month 24 2.070 No 153007 718 / Month 24 2.070 No 159017 716 / Month 24 2.070 No 167002 717 / Mont 24 1.230 No 188005 717 / Mont 24 1.230 No 188005 717 / Month 24 1.250 No 188005 717 / Month 24 1.250 No

 | Name Nonth 12 1.570 1.570 1.0

 | Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea

 | Treatment Group Positive
Innunoreactivity Innunoreactivity Innunorea

 | Treatment Group Positive
Innuutoreactivity Innuutoreactivity
Innuutoreactivity Innuutoreactivity
Innuutoreactivity Innuutoreactivity Innutreactivity Innut

 | Treatment Group Bolityte
Innuutoreactivity Fosityte
Innuutoreactivity Innuutoreactivity
Assay Innuutoreactivity
Infammation 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis 104002 717 / Month 24 1.870 Irritis 104002 719 / Month 24 1.140 No 106002 722 / Month 12 1.140 No 105001 723 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 357 / Month 24 1.170 No 124003 722 / Month 24 1.700 No 126001 174 / Month 6 1.700 No 126001 174 / Month 24 1.700 No 126001

 | Treatment Group Bubject ID Fositive
Assay Innunoreactivity
Assay Log Titer Innamiation 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 Iritis 104002 717 / Month 24 0.922 No 104002 719 / Month 24 1.140 No 106002 722 / Month 12 1.630 No 106002 722 / Month 24 1.140 No 1122002 359 / Month 12 1.630 No 122002 357 / Month 24 1.170 No 124003 722 / Month 24 1.700 No 126001 174 / Month 6 1.700 No 126001 174 / Month 24 1.700 No 126001 357 / Month 12

 | Treatment Group Bolityte
Innuutoreactivity Fosityte
Innuutoreactivity Innuutoreactivity
Assay Innuutoreactivity
Infammation 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis 104002 717 / Month 24 1.870 Irritis 104002 719 / Month 24 1.140 No 106002 722 / Month 12 1.140 No 105001 723 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 357 / Month 24 1.170 No 124003 722 / Month 24 1.700 No 126001 174 / Month 6 1.700 No 126001 174 / Month 24 1.700 No 126001
 | Treatment Group Bolityte
Innuutoreactivity Fosityte
Innuutoreactivity Innuutoreactivity
Assay Innuutoreactivity
Infammation 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis 104002 717 / Month 24 1.870 Irritis 104002 719 / Month 24 1.140 No 106002 722 / Month 12 1.140 No 105001 723 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 357 / Month 24 1.170 No 124003 722 / Month 24 1.700 No 126001 174 / Month 6 1.700 No 126001 174 / Month 24 1.700 No 126001

 | Treatment Group Positive
Innuutoreactivity Innuutoreactivity
Innuutoreactivity Innuutoreactivity
Innuutoreactivity Innuutoreactivity Innutreactivity Innut
 | Treatment Group Positive
Innuutoreactivity Innuutoreactivity
Innuutoreactivity Innuutoreactivity
Innuutoreactivity Innuutoreactivity Innutreactivity Innut
 | Treatment Group Positive
Innuutoreactivity Innuutoreactivity
Innuutoreactivity Innuutoreactivity
Innuutoreactivity Innuutoreactivity Innutreactivity Innut
 | Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea
 | Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunorea | Treatment Group Positive
Inmunoreactivity Intraocular Intertment Group Subject ID Assay Assay Log Titer Intraocular 170010 365/Month 12 2.770 Nio Nio 177006 358/Month 12 2.800 Nio Nio 177006 358/Month 12 1.870 Nio Nio 177005 358/Month 12 1.870 Nio Nio Ranibizumab 0.5 mg 102001 722/Month 24 0.922 Nio Nio 104002 719/Month 24 1.140 Nio Nio <td>Treatment Group Positive
Subject ID Positive
Assay Intrancentar
Assay Intrancentar</td> <td>Treatment Group Positive
Subject ID Positive
Assay Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365/Month 12 2.770 No 177006 358/Month 12 2.800 No 177006 358/Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 722/Month 24 1.870 Intitis 104002 719/Month 24 1.870 Intitis No 102001 722/Month 24 1.140 No No 122002 359/Month 24 1.140 No No 122002 722/Month 24 1.130 No No 122002 359/Month 12 1.630 No No 122003 359/Month 24 1.170 No No 124003 722/Month 24 1.700 No No 126001 174/Month 6 1.700 No No 122002 357/Month 24 1.700 No No <td>Treatment Group Positive Intrancial Treatment Group Subject ID Assay Assay Intrancial 170010 365/Month 12 2.770 No 177006 358/Month 12 2.800 No 177006 358/Month 12 1.870 Irritis 177006 358/Month 12 1.870 No 177006 358/Month 12 1.870 Irritis 104002 719/Month 24 1.870 Irritis 104002 719/Month 24 1.140 No 122002 359/Month 12 1.140 No 122002 359/Month 12 1.170 No 122002 359/Month 12 1.070 No 122003 359/Month 12 1.070 No 124003 722/Month 24 1.700 No 124003 723/Month 24 1.700 No 124003 723/Month 24 1.700 No 124003 723/Month 24 1.700 No 124003<!--</td--></td></td>
 | Treatment Group Positive
Subject ID Positive
Assay Intrancentar
Assay Intrancentar | Treatment Group Positive
Subject ID Positive
Assay Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365/Month 12 2.770 No 177006 358/Month 12 2.800 No 177006 358/Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 722/Month 24 1.870 Intitis 104002 719/Month 24 1.870 Intitis No 102001 722/Month 24 1.140 No No 122002 359/Month 24 1.140 No No 122002 722/Month 24 1.130 No No 122002 359/Month 12 1.630 No No 122003 359/Month 24 1.170 No No 124003 722/Month 24 1.700 No No 126001 174/Month 6 1.700 No No 122002 357/Month 24 1.700 No No <td>Treatment Group Positive Intrancial Treatment Group Subject ID Assay Assay Intrancial 170010 365/Month 12 2.770 No 177006 358/Month 12 2.800 No 177006 358/Month 12 1.870 Irritis 177006 358/Month 12 1.870 No 177006 358/Month 12 1.870 Irritis 104002 719/Month 24 1.870 Irritis 104002 719/Month 24 1.140 No 122002 359/Month 12 1.140 No 122002 359/Month 12 1.170 No 122002 359/Month 12 1.070 No 122003 359/Month 12 1.070 No 124003 722/Month 24 1.700 No 124003 723/Month 24 1.700 No 124003 723/Month 24 1.700 No 124003 723/Month 24 1.700 No 124003<!--</td--></td> | Treatment Group Positive Intrancial Treatment Group Subject ID Assay Assay Intrancial 170010 365/Month 12 2.770 No 177006 358/Month 12 2.800 No 177006 358/Month 12 1.870 Irritis 177006 358/Month 12 1.870 No 177006 358/Month 12 1.870 Irritis 104002 719/Month 24 1.870 Irritis 104002 719/Month 24 1.140 No 122002 359/Month 12 1.140 No 122002 359/Month 12 1.170 No 122002 359/Month 12 1.070 No 122003 359/Month 12 1.070 No 124003 722/Month 24 1.700 No 124003 723/Month 24 1.700 No 124003 723/Month 24 1.700 No 124003 723/Month 24 1.700 No 124003 </td |
| I41008 181/Month 6 1.570 No 362/Month 12 1.940 No 726/Month 24 2.340 Vitritis 141013 715/Month 24 2.610 Vitritis 143010 722/Month 24 2.610 No 152004 522/Early Term. 0.752, No 153006 183/Month 6 1.900 No 153006 183/Month 24 2.610 No 153006 183/Month 24 2.610 No 153006 183/Month 24 2.070 No 15300 183/Month 24 1.530 No 15300 715/Month 24 1.530 No 167002 717/Mont 24 1.230 No 188005 717/Mont 24 1.250 No 534001 -7/Screening 2.522 No

 | I41008 181/Month 6 1.570 No 362/Month 12 1.940 No 726/Month 24 2.340 Vitritis 143010 722/Month 24 2.610 Vitritis 143010 722/Month 24 2.610 No 152004 522/Early Term. 0.752, No 153006 183/Month 6 1.900 No 153006 183/Month 24 2.610 No 153006 183/Month 24 2.610 No 153006 183/Month 24 2.070 No 153007 718/Month 24 1.530 No 167002 717/Month 24 1.230 No 188005 717/Month 24 1.230 No 188005 717/Month 24 1.250 No 534001 -7/Screening 2.522 No

 | I41008 I81/Month 6 1.570 No 362/Month 12 1.940 No 141013 715/Month 24 2.340 Nintitis 143010 722/Month 24 2.340 No 152004 522/Early Term. 0.752 , No No 153006 183/Month 24 2.610 No 153006 183/Month 24 2.610 No 153006 183/Month 24 2.700 No 159017 718/Month 24 0.752 , No No 159017 716/Month 24 0.780° No 167002 717/Month 24 0.780° No 188005 717/Month 24 1.250° No 534001 $-7/Screening$ 2.520° No

 | Treatment Group Positive
Subject ID Positive
Assay Intrancontactivity
Infimumation Intrancontactivity
Infimumation Intrancontactivity
Assay Log Titer Intrancontactivity
Diagnosis 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 Iritis 177005 358 / Month 24 1.870 Iritis 177006 358 / Month 24 1.870 No 104002 717 / Month 24 1.870 No 104002 722 / Month 24 1.140 No 122002 359 / Month 24 1.130 No 122002 359 / Month 24 1.170 No 122003 357 / Month 24 1.770 No 122003 357 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 126001 174 / Month 6 1.700 No 126001 174 / Month 12 2.040 No

 | Treatment Group Positive
Subject ID Positive
Assay Intrancentist
Assay <

 | Treatment Group Positive
Subject ID Positive
Assay Intrancentar
Intrancentary Intrancentar
Intrancentary Intrancentar
Intrancentary Treatment Group Subject ID Assay Assay Assay Assay No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 I.ritis No 177006 358 / Month 24 1.870 Iritis No Ranibizumab 0.5 mg 102001 722 / Month 24 1.130 No 104002 719 / Month 24 1.140 No No 102001 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122003 722 / Month 24 1.770 No No 122003 359 / Month 12 1.630 No No 122003 357 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 126001

 | Treatment Group Positive Intrancion Assay Assay Log Titer Inframmation Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 I.ritis Iritis Iritis 177006 358 / Month 24 1.870 Iritis No Iritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 No No 104002 719 / Month 24 1.140 No No Iritis No 122002 359 / Month 12 1.630 No No Iritis No No Iritis
 | Treatment Group Positive Intrancion Assay Intrancion Treatment Group Subject ID Subject ID Assay Assay Log Titer Diagnosis 170010 355 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 24 1.870 Iritis Iritis 177006 358 / Month 24 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No Iritis Iritis 102001 722 / Month 24 1.130 No No Iritis Iritis Iritis 122002 359 / Month 12 1.630 No No Iritis No Iritis 122003 357 / Month 24 1.130 No Iritis No Iritis Iritis Iritis Iritis Iritis Iritis Iritis Iritis

 | Treatment Group Positive Intrancion Assay Assay Log Titer Inframmation Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 I.ritis Iritis Iritis 177006 358 / Month 24 1.870 Iritis No Iritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 No No 104002 719 / Month 24 1.140 No No Iritis No 122002 359 / Month 12 1.630 No No Iritis No No Iritis
 | Treatment Group Positive Intrancion Assay Assay Log Titer Inframmation Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 I.ritis Iritis Iritis 177006 358 / Month 24
1.870 Iritis No Iritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 No No 104002 719 / Month 24 1.140 No No Iritis No 122002 359 / Month 12 1.630 No No Iritis No No Iritis
 | Treatment Group Positive
Subject ID Positive
Assay Intrancentar
Intrancentary Intrancentar
Intrancentary Intrancentar
Intrancentary Treatment Group Subject ID Assay Assay Assay Assay No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 I.ritis No 177006 358 / Month 24 1.870 Iritis No Ranibizumab 0.5 mg 102001 722 / Month 24 1.130 No 104002 719 / Month 24 1.140 No No 102001 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122003 722 / Month 24 1.770 No No 122003 359 / Month 12 1.630 No No 122003 357 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 126001
 | Treatment Group Positive
Subject ID Positive
Assay Intrancentar
Intrancentary Intrancentar
Intrancentary Intrancentar
Intrancentary Treatment Group Subject ID Assay Assay Assay Assay No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 I.ritis No 177006 358 / Month 24 1.870 Iritis No Ranibizumab 0.5 mg 102001 722 / Month 24 1.130 No 104002 719 / Month 24 1.140 No No 102001 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122003 722 / Month 24 1.770 No No 122003 359 / Month 12 1.630 No No 122003 357 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 126001
 | Treatment Group Positive
Subject ID Positive
Assay Intrancentar
Intrancentary Intrancentar
Intrancentary Intrancentar
Intrancentary Treatment Group Subject ID Assay Assay Assay Assay No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 I.ritis No 177006 358 / Month 24 1.870 Iritis No Ranibizumab 0.5 mg 102001 722 / Month 24 1.130 No 104002 719 / Month 24 1.140 No No 102001 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122003 722 / Month 24 1.770 No No 122003 359 / Month 12 1.630 No No 122003 357 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 126001
 | Treatment Group Positive
Subject ID Positive
Assay Intrancontactivity
Infimumation Intrancontactivity
Infimumation Intrancontactivity
Assay Log Titer Intrancontactivity
Diagnosis 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 Iritis 177005 358 / Month 24 1.870 Iritis 177006 358 / Month 24 1.870 No 104002 717 / Month 24 1.870 No 104002 722 / Month 24 1.140 No 122002 359 / Month 24 1.130 No 122002 359 / Month 24 1.170 No 122003 357 / Month 24 1.770 No 122003 357 / Month 24 1.770 No
124003 722 / Month 24 1.770 No 126001 174 / Month 6 1.700 No 126001 174 / Month 12 2.040 No | Treatment Group Positive
Innunoreactivity Innunoreactivity Innamiation Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2770 No No 177006 358 / Month 12 1.870 No Iritis 177006 358 / Month 12 1.870 No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Iritis 104002 719 / Month 24 1.870 No No 104002 722 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122003 359 / Month 24 1.170 No No 122003 359 / Month 24 1.130 No No 122003 359 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No
 | Treatment Group Positive
Inmunoreactivity Intrancentar Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 Nio Nio Nio 177006 358 / Month 12 1.870 Nio Nio 177006 358 / Month 24 1.870 Nio 177005 358 / Month 24 1.870 Nio 177006 358 / Month 24 1.870 Nio 102001 722 / Month 24 1.870 Nio 104002 719 / Month 24 1.140 Nio 122002 359 / Month 12 1.630 Nio 122002 359 / Month 24 1.130 Nio 122003 722 / Month 24 1.170 Nio 122003 357 / Month 24 1.770 Nio 122003 357 / Month 12 1.630 Nio 124003 722 / Month 24 1.770 Nio 126001 1.74 / Month 6 1.770 Nio
 | Treatment Group Positive
Innunoreactivity Innunoreactivity Intraochiat 17eatment Group Subject ID Assay | Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 Nio 177006 358 / Month 12 2.800 Nio 177006 358 / Month 12 1.870 Initia 177006 358 / Month 12 1.870 Nio 177006 358 / Month 12 1.870 Nio 17700 358 / Month 12 1.870 Nio 102001 722 / Month 24 1.870 Nio 104002 719 / Month 24 1.870 Nio 104002 722 / Month 24 1.140 Nio 122002 359 / Month 12 1.630 Nio 122003 722 / Month 24 1.170 Nio 124003 722 / Month 24 1.770 Nio 124003 722 / Month 24 1.770 Nio 126001 174 / Month 6 1.770 Nio 126001 174 / Month 12 2.040 Nio </td <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 12 1.870 Initia No 177005 358/Month 12 1.870 No No 177006 358/Month 24 1.870 Initia No 107001 722/Month 24 1.870 Initia No No 104002 719/Month 24 1.140 No No No No 102001 722/Month 24 1.130 No <td< td=""></td<></td> | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 12 1.870 Initia No 177005 358/Month 12 1.870 No No 177006 358/Month 24 1.870 Initia No 107001 722/Month 24 1.870 Initia No No 104002 719/Month 24 1.140 No No No No 102001 722/Month 24 1.130 No No <td< td=""></td<> |
| 141008181/Month 6 1.570 No362/Month 12 1.940 No726/Month 24 2.340 No141013 $715/Month 24$ 2.340 Nimitis143010 $722/Month 24$ 2.610 Nimitis152004 $522/Early Term.0.752,No152004522/Early Term.0.752,No153006183/Month 61.900No153006183/Month 121.530No153006183/Month 121.530No153007718/Month 241.530No159017716/Month 241.230No159017716/Month 241.230No159017717/Mont 241.230No15002717/Month 241.230No188005717/Month 241.230No188005717/Month 241.250No188005717/Month 241.250No188005717/Month 241.250No188005717/Month 241.250No188005717/Month 241.250No188005717/Month 241.250No188005717/Month 241.250No188005717/Month 241.250No188005717/Month 241.250No188005717/Month 241.2501.01$

 | 141008181/Month 6 1.570 No362/Month 12 1.940 No726/Month 24 2.340 Nimitis141013 $715/Month 24$ 2.340 Nimitis143010 $722/Month 24$ 2.610 Nimitis152004 $522/Early Term.0.752,No152004522/Early Term.0.752,No153006183/Month 641.900No153006183/Month 121.530No153007718/Month 241.530No159017716/Month 241.230No159017716/Month 241.230No159017717/Month 241.230No159017717/Month 241.230No159017717/Month 241.230No159017717/Month 241.230No159017717/Month 241.230No15002717/Month 241.230No15003717/Month 241.250No150047.7/Streening2.520Vintits150057707.7201.1250$

 | I41008I81/Month 6 1.570 No141008362/Month 12 1.940 No726/Month 24 2.340 Nitritis141013715/Month 24 2.610 Vitritis143010722/Month 24 2.610 Nitritis153006183/Month 6 1.900 No153006183/Month 12 1.530 No153006183/Month 12 1.530 No153007718/Month 24 0.780 No159017716/Month 24 0.780 No167002717/Month 24 0.780 No188005717/Month 24 1.230 No188005717/Month 24 1.250 No188005<

 | Treatment Group Positive
Innunoreactivity Innunoreactivity Innamiation Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Liritis No 177006 358 / Month 24 1.870 Liritis No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Liritis 106002 719 / Month 24 1.850 No No 106002 722 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.140 No No 122002 359 / Month 24 1.770 No No 124003 722 / Month 24 1.700 No No 126001 174 / Month 64 1.770 No No 126001 174 / Month 6 1.7700 No No

 | Treatment Group Positive Intrancicular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intrancicular 177006 358 / Month 12 1.870 Intra 177006 358 / Month 12 1.870 Intris 177006 358 / Month 24 1.870 Intits 104002 717 / Month 24 1.870 Intits 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 122002 359 / Month 24 1.130 No 124003 722 / Month 24
 1.770 No 126001 174 / Month 6 1.700 No 126001 174 / Month 6 1.700 No 126001 174 / Month 6 1.700 No

 | Treatment Group Positive Positive Intrancicular Treatment Group Subject ID Assay Assay Log Titer Inflammation 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Intraccular Diagnosis 177006 358 / Month 12 1.870 Intraccular No 177006 358 / Month 12 1.870 Intris Intris Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Intits No Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No No 106002 722 / Month 24 1.140 No No No No 122002 359 / Month 12 1.630 No No No No No No 124003 722 / Month 24 1.700 No No No No No No 126001 174 / Month 60 1.700 No No No No

 | Treatment Group Positive Intrancion Intrancion Treatment Group Subject ID Assay Assay Log Titer Inframation Subject ID 365 / Month 12 2.770 No No 170010 355 / Month 12 2.800 Intraocidiar 177006 358 / Month 12 1.870 Intraocidiar 177005 358 / Month 12 1.870 Intris 177006 358 / Month 24 1.870 Intits 104002 717 / Month 24 1.870 Intits 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 124003 722 / Month 24 1.770 No 126001 174 / Month 6 1.700 No 126001 174 / Month 6 1.700 No 126001 174 / Month 6 1.700 No

 | Treatment Group Positive Intrancion Intrancion Treatment Group Subject ID Assay Intrancion Intrancion 170010 365/Month 12 2.770 No No 177006 358/Month 12 2.800 Intrancion 177006 358/Month 12 1.870 Intrascina 177005 358/Month 12 1.870 Intits 177006 358/Month 24 1.870 Intits 107001 717/Month 24 1.870 Intits 104002 719/Month 24 1.140 No 106002 722/Month 24 1.140 No 122002 359/Month 24 1.140 No 122002 359/Month 24 1.770 No 124003 722/Month 24 0.782 No 124003 723/Month 24 0.782 No 126001 174/Month 6 1.700 No 126001 174/Month 6 1.700 No
 | Treatment Group Positive Intrancion Intrancion Treatment Group Subject ID Assay Assay Log Titer Inframation Subject ID 365 / Month 12 2.770 No No 170010 355 / Month 12 2.800 Intraocidiar 177006 358 / Month 12 1.870 Intraocidiar 177005 358 / Month 12 1.870 Intris 177006 358 / Month 24 1.870 Intits 104002 717 / Month 24 1.870 Intits 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 124003 722 / Month 24 1.770 No 126001 174 / Month 6 1.700 No 126001 174 / Month 6 1.700 No 126001 174 / Month 6 1.700 No

 | Treatment Group Positive Intrancion Intrancion Treatment Group Subject ID Assay Assay Log Titer Inframation Subject ID 365 / Month 12 2.770 No No 170010 355 / Month 12 2.800 Intraocidiar 177006 358 / Month 12 1.870 Intraocidiar 177005 358 / Month 12 1.870 Intris 177006 358 / Month 24 1.870 Intits 104002 717 / Month 24 1.870 Intits 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 124003 722 / Month 24 1.770 No 126001 174 / Month 6 1.700 No 126001 174 / Month 6 1.700 No 126001 174 / Month 6 1.700 No
 | Treatment Group Positive Positive Intrancicular Treatment Group Subject ID Assay Assay Log Titer Inflammation 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Intraccular Diagnosis 177006 358 / Month 12 1.870 Intraccular No 177006 358 / Month 12 1.870 Intris Intris Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Intits No Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No No 106002 722 / Month 24 1.140 No No No No 122002 359 / Month 12 1.630 No No No No No No 124003 722 / Month 24 1.700 No No No No No No 126001 174 / Month 60 1.700 No No No No
 | Treatment Group Positive Positive Intrancicular Treatment Group Subject ID Assay Assay Log Titer Inflammation 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Intraccular Diagnosis 177006 358 / Month 12 1.870 Intraccular No 177006 358 / Month 12 1.870 Intris Intris Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Intits No Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No No 106002 722 / Month 24 1.140 No No No No 122002 359 / Month 12 1.630 No No No No
 No No 124003 722 / Month 24 1.700 No No No No No No 126001 174 / Month 60 1.700 No No No No
 | Treatment Group Positive Positive Intrancicular Treatment Group Subject ID Assay Assay Log Titer Inflammation 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Intraccular Diagnosis 177006 358 / Month 12 1.870 Intraccular No 177006 358 / Month 12 1.870 Intris Intris Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Intits No Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No No 106002 722 / Month 24 1.140 No No No No 122002 359 / Month 12 1.630 No No No No No No 124003 722 / Month 24 1.700 No No No No No No 126001 174 / Month 60 1.700 No No No No
 | Treatment Group Positive
Innunoreactivity Innunoreactivity Innamiation Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Liritis No 177006 358 / Month 24 1.870 Liritis No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Liritis 106002 719 / Month 24 1.850 No No 106002 722 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.140 No No 122002 359 / Month 24 1.770 No No 124003 722 / Month 24 1.700 No No 126001 174 / Month 64 1.770 No No 126001 174 / Month 6 1.7700 No No
 | Treatment Group Positive
Subject ID Positive
Assay Intrancontactivity
Assay Intrancontivity
Assay Intrancontactivity
Assay Intrancontactivity
Assay Intrancontivity
Assay Intrancontivity
Assay Intrancontivity
Assay I | Treatment Group Positive
Inmunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay | Treatment Group Positive
Inmunoreactivity Intrancentar
Inmunoreactivity
Intrancentar
Inmunoreactivity Intrancentar
Inframmation 170010 365 / Month 12 2800 No 177006 358 / Month 24 2800 No 177006 358 / Month 12 1.870 Initanmation Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Initis 107002 719 / Month 24 1.870 Initis Initis 102001 722 / Month 24 1.870 Initis Initis 102002 722 / Month 24 1.140 No No 102003 722 / Month 24 1.130 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.770 No No 122003 357 / Month 24 1.700 No No 126001 174 / Month 64 1.700 No No 126001 174 / Month 62 1.700 No No | Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunor Immunoreactivity Immunoreactivity </td <td>Treatment Group Subject ID Positive Intraocular Intraocular Treatment Group Subject ID Assay Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 No 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Intitis 10001 722 / Month 12 1.870 No No 106002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 722 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.770 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 1</td> | Treatment Group Subject ID Positive Intraocular Intraocular Treatment Group Subject ID Assay Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 No 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Intitis 10001 722 / Month 12 1.870 No No 106002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 722 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.770 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 1 |
| Sham 5340 1.400 No 141008 181/Month 6 1.570 No 362/Month 24 3.340 No 141013 715/Month 24 2.340 143010 722/Month 24 2.440 152004 522/Early Term. 0.752, 153006 183/Month 12 1.900 153006 183/Month 12 1.530 153006 183/Month 24 2.070 153007 718/Month 24 2.070 158005 717/Mont 24 1.530 167002 717/Mont 24 1.230 167002 717/Mont 24 1.230 188005 717/Mont 24 1.230 167002 717/Mont 24 1.230 167002 717/Mont 24 1.250 188005 717/Mont 24 1.250 167002 717/Mont 24 1.250 167002 717/Mont 24 1.250 No

 | Interview Interview Interview 141008 181/Month 6 1.570 No 362/Month 24 3.340 No No 141013 715/Month 24 2.340 No 143010 722/Month 24 2.610 Vitritis 152004 522/Early Term. 0.752, No 153006 183/Month 12 1.900 No 153005 183/Month 12 1.530 No 153006 183/Month 24 2.070 No 153007 718/Month 24 1.900 No 158005 717/Mont 24 1.530 No 167002 717/Mont 24 1.230 No 188005 717/Mont 24 1.230 No 188005 717/Mont 24 1.250 No 167002 717/Mont 24 1.250 No

 | Interpret <

 | Treatment Group Positive
Subject ID Positive
Assay Intranciant
Intranciant Intranciant Treatment Group Subject ID Assay Assay Intrance activity Intranciant 170010 365/Month 12 2.770 No No No 177006 358/Month 12 1.870 Intraso Intraso 177006 358/Month 24 1.870 Intrus Intrus 107001 717/Month 24 1.870 Intrus Intrus 102001 722/Month 24 1.140 No No 104002 719/Month 24 1.130 No No 122002 359/Month 12 1.630 No No 122002 722/Month 24 1.140 No No 124003 722/Month 24 1.130 No No No 124003 723/Month 12 1.630 No No No No 126001 174/Month 6 1.770 No No No No No

 | Tratment Group Positive
Subject ID Positive
Assay Intranoreactivity
Assay Log Titer Intraocular 170010 365/Month 12 2.770 No 177006 358/Month 12 2.800 Iritis 177006 358/Month 12 1.870 Iritis 177005 358/Month 24 1.870 Iritis 177005 358/Month 24 1.870 Iritis 102001 722/Month 24 1.870 No 104002 719/Month 24 1.140 No 102002 722/Month 24 1.130 No 122002 359/Month 12 1.630 No 122002 723/Month 24 1.170 No 124003 722/Month 24 1.170 No 124003 723/Month 12 1.630 No 124003 723/Month 12 1.770 No 126001 174/Month 6 1.770 No 126001 174/Month 6 1.770 No

 | Tratment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immonoreactivity Immunoreactivity
Immonoreactivity Immunoreactivity
Immonoreactivity Immunoreactivity
Immonoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immonoreactivity Immonoreac
 | Tratment Group Subject ID Fositive Intraoctian Intraoctian Treatment Group Subject ID Assay Assay Log Titer Intraoctian 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraoctian
 177006 358 / Month 24 1.870 Intraoctian 177006 358 / Month 24 1.870 Intris 177006 358 / Month 24 1.870 Intris 102001 722 / Month 24 1.140 No 104002 719 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 722 / Month 24 1.140 No 124003 722 / Month 12 1.630 No 124003 723 / Month 12 1.770 No 126001 174 / Month 6 1.770 No 126001 174 / Month 12 2.040 No
 | Tratment Group Nubject ID Positive Intraoctian Tratment Group Subject ID Assay Assay Log Titer Intraoctian 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.770 No No No 177006 358 / Month 24 1.870 Irritis Irritis Irritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Irritis No 102002 722 / Month 24 1.140 No No No Irritis

 | Tratment Group Subject ID Fositive Intraoctian Intraoctian Treatment Group Subject ID Assay Assay Log Titer Intraoctian 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraoctian 177006 358 / Month 24 1.870 Intraoctian 177006 358 / Month 24 1.870 Intris 177006 358 / Month 24 1.870 Intris 102001 722 / Month 24 1.140 No 104002 719 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 722 / Month 24 1.140 No 124003 722 / Month 12 1.630 No 124003 723 / Month 12 1.770 No 126001 174 / Month 6 1.770 No 126001 174 / Month 12 2.040 No
 | Tratment Group Subject ID Fositive Intraoctian Intraoctian Treatment Group Subject ID Assay Assay Log Titer Intraoctian 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraoctian 177006 358 / Month 24 1.870 Intraoctian 177006 358 / Month 24 1.870 Intris 177006 358 / Month 24 1.870 Intris 102001 722 / Month 24 1.140 No 104002 719 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 722 / Month 24 1.140 No 124003 722 / Month 12 1.630 No 124003 723 / Month 12 1.770 No 126001 174 / Month 6 1.770 No 126001 174 / Month 12 2.040 No

 | Tratment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immonoreactivity Immunoreactivity
Immonoreactivity Immunoreactivity
Immonoreactivity Immunoreactivity
Immonoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immonoreactivity Immonoreac
 | Tratment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immonoreactivity Immunoreactivity
Immonoreactivity Immunoreactivity
Immonoreactivity Immunoreactivity
Immonoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immonoreactivity Immonoreac
 | Tratment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immonoreactivity Immunoreactivity
Immonoreactivity Immunoreactivity
Immonoreactivity Immunoreactivity
Immonoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immonoreactivity Immonoreac
 | Treatment Group Positive
Subject ID Positive
Assay Intranciant
Intranciant Intranciant Treatment Group Subject ID Assay Assay Intrance activity Intranciant 170010 365/Month 12 2.770 No No No 177006 358/Month 12 1.870 Intraso Intraso 177006 358/Month 24 1.870 Intrus Intrus 107001 717/Month 24 1.870 Intrus Intrus 102001 722/Month 24 1.140 No No 104002 719/Month 24 1.130 No No 122002 359/Month 12 1.630 No No 122002 722/Month 24 1.140 No No 124003 722/Month 24 1.130 No No No 124003 723/Month 12 1.630 No No No No 126001 174/Month 6 1.770 No No No No No
 | Treatment Group Positive
Subject ID Positive
Assay Intranction
Intrancentivity Intranction
Intrancention Treatment Group Subject ID Assay Assay Intrancentivity Intrancention 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intrascuar Intrasc 177006 358 / Month 12 1.870 Intrus Intrus 177006 358 / Month 12 1.870 Intrus Intrus 102001 722 / Month 24 1.140 No No 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 722 / Month 24 1.140 No No 124003 722 / Month 12 1.630 No No No 124003 723 / Month 12 1.770 No No No No 124003 722 / Month 12 2.040 No No No
 | Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immunorea | Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Intrancitiat Treatment Group Subject ID Assay Assay Intrancitat 170010 365 / Month 12 2.300 No No 177006 358 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Irritis Irritis Rantbizumab 0.5 mg 102001 722 / Month 24 1.870 No 104002 719 / Month 24 1.140 No No 104002 722 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 722 / Month 24 1.130 No No 124003 722 / Month 12 1.630 No No 124003 723 / Month 12 1.770 No No 124003 723 / Month 12 1.770 No No 124003 723 / Month 12 2.040 No No | Treatment Group Positive
Innunoreactivity Innunoreactivity
Innunoreactivity Intraoctilat
Innamation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 No 102001 722 / Month 24 1.870 Irritis 104002 719 / Month 24 1.140 No 104002 722 / Month 12 1.630 No 122002 359 / Month 12 1.630 No 122002 722 / Month 24 1.130 No 124003 722 / Month 12 1.630 No 124003 722 / Month 12 1.770 No 126001 174 / Month 6 1.770 No 126001 174 / Month 6 1.700 No
 | Treatment Group Subject ID Positive Inframoreactivity Inframmation Treatment Group Subject ID Assay Assay Assay Inframoreactivity Inframmation 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 12 1.870 Intris No 177001 717 / Month 24 1.870 Intris No 104002 719 / Month 24 1.140 No No 104002 722 / Month 24 1.140 No No 12002 359 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.140 No No No 126001 123 / Month 12 1.770 No No No No 124003 722 / Month 12 2.040 No No No No |
| 727/Month 241.480141008181/Month 61.570No362/Month 121.940No362/Month 242.340Vitritis143010722/Month 242.610Vitritis153006183/Month 242.440No153006183/Month 121.900No153006183/Month 242.070No153005183/Month 242.070No153005183/Month 242.070No158005717/Month 241.330No167002717/Month 241.230No188005717/Month 241.230No188005717/Month 241.250No188005717/Month 241.250No188005717/Month 241.250No188005717/Month 241.250No188005717/Month 241.250No188005717/Month 241.250No

 | No727/Month 24 1.480 141008181/Month 6 1.570 No362/Month 12 1.570 No362/Month 24 2.340 Nitritis143010722/Month 24 2.610 Nitritis153006183/Month 24 2.440 No153006183/Month 12 1.900 No153005183/Month 24 2.740 No153006183/Month 24 2.740 No153005183/Month 24 0.752 ,No153005718/Month 24 1.900 No167002717/Month 24 1.230 No188005717/Month 24 1.230 No188005717/Month 24 1.250 No188005717/Month 24 1.230 No188005717/Month 24 1.230 No188005717/Month 24 1.230 No188005717/Month 24 1.250 No

 | Name $727/Month 24$ 1.480 141008 $181/Month 6$ 1.570 No $362/Month 12$ 1.570 No $362/Month 24$ 2.340 No 141013 $715/Month 24$ 2.340 No 143010 $722/Month 24$ 2.610 No 152004 $522/Early Term.$ 0.752 ,No 153006 $183/Month 24$ 2.440 No 153006 $183/Month 24$ 2.740 No 153006 $183/Month 24$ 0.752 ,No 153007 $718/Month 24$ 0.780 No 159017 $716/Month 24$ 0.780 No 167002 $717/Month 24$ 1.230 No 188005 $717/Month 24$ 1.250 No 11000 1.250 1.1250 No

 | Treatment Group Positive
Subject ID Positive
Assay Intranction
Intrance
Assay Intrance
Intrance Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 2.800 Irritis Irritis 177006 358/Month 24 1.870 Irritis Irritis Ranibizumab 0.5 mg 102001 722/Month 24 1.870 No 106002 719/Month 24 1.140 No No 122002 359/Month 24 1.140 No No 122002 722/Month 24 1.130 No No 124003 722/Month 24 1.140 No No 124003 722/Month 24 1.170 No No No 124003 722/Month 24 1.700 No No No 124003 722/Month 24 1.700 No No No 124003 722/Month 24 1.700

 | Treatment Group Positive
Subject ID Positive
Assay Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.770 No No 177006 358 / Month 24 2.800 Irritis Irritis Ranibizumab 0.5 mg 102001 719 / Month 24 1.870 Irritis 102002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.140 No No 122002 719 / Month 24 1.140 No No 122002 359 / Month 12
 1.630 No No 124003 722 / Month 24 1.140 No No 124003 722 / Month 24 1.130 No No 124003 722 / Month 24 1.770 No No 124003 723 / Month 12 0.782 No No

 | Tratment Group Subject ID Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Irritis Irritis No Ranibizumab 0.5 mg 107000 358 / Month 24 0.922 No No 127006 358 / Month 24 1.870 Irritis Irrit

 | Treatment Group Subject ID Positive
Immunoreactivity Intranciant Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No 122002 359 / Month 12 1.870 Irritis Irritis Irritis Irritis 104002 719 / Month 24 1.140 No No Irritis No 122002 359 / Month 12 1.630 No No Irritis No 124003 722 / Month 24 1.140 No No Irritis No Irritis
 | Treatment Group Subject ID Positive
Immunoreactivity Intrancentarion Treatment Group Subject ID Assay Assay Intrancentarion 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No 106002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.140 No No 122002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 722 / Month 24 1.140 No No No 124003
722 / Month 24 1.130 No No No No 124003 722 / Month 24 1.700 No No No No 124003 722 / Month 24 <t< td=""><td>Treatment Group Subject ID Positive
Immunoreactivity Intranciant Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No 122002 359 / Month 12 1.870 Irritis Irritis Irritis Irritis 104002 719 / Month 24 1.140 No No Irritis No 122002 359 / Month 12 1.630 No No Irritis No 124003 722 / Month 24 1.140 No No Irritis No Irritis Irritis</td><td>Treatment Group Subject ID Positive
Immunoreactivity Intranciant Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No 122002 359 / Month 12 1.870 Irritis Irritis Irritis Irritis 104002 719 / Month 24 1.140 No No Irritis No 122002 359 / Month 12 1.630 No No Irritis No 124003 722 / Month 24 1.140 No No Irritis No Irritis Irritis</td><td>Tratment Group Subject ID Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Irritis Irritis No Ranibizumab 0.5 mg 107000 358 / Month 24 0.922 No No 127006 358 / Month 24 1.870 Irritis Irrit</td><td>Tratment Group Subject ID Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Irritis Irritis No Ranibizumab 0.5 mg 107000 358 / Month 24 0.922 No No 127006 358 / Month 24 1.870 Irritis Irrit</td><td>Tratment Group Subject ID Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Irritis Irritis No Ranibizumab 0.5 mg 107000 358 / Month 24 0.922 No No 127006 358 / Month 24 1.870 Irritis Irrit</td><td>Treatment Group Positive
Subject ID Positive
Assay Intranction
Intrance
Assay Intrance
Intrance Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 2.800 Irritis Irritis 177006 358/Month 24 1.870 Irritis Irritis Ranibizumab 0.5 mg 102001 722/Month 24 1.870 No 106002 719/Month 24 1.140 No No 122002 359/Month 24 1.140 No No 122002 722/Month 24 1.130 No No 124003 722/Month 24 1.140 No No 124003 722/Month 24 1.170 No No No 124003 722/Month 24 1.700 No No No 124003 722/Month 24 1.700 No No No 124003 722/Month 24 1.700</td><td>Treatment Group Positive
Subject ID Positive
Assay Intranceactivity
Assay Intranction
Intranceactivity Intranction
Intranceactivity Treatment Group Subject ID Assay Assay Intranceactivity Intranceactivity 170010 365/Month 12 2.770 No No No 177006 358/Month 24 2.800 Irritis Irritis 177006 358/Month 24 1.870 Irritis Irritis 102001 722/Month 24 1.140 No No 106002 722/Month 24 1.140 No No 122002 359/Month 24 1.140 No No 122002 722/Month 24 1.170 No No 124003 722/Month 24 1.170 No No 124003 723/Month 24 1.770 No No 124003 723/Month 24 1.770 No No 124003 723/Month 24 1.770 No No 124003 723/Month 54<td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Intrancitiat Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis 177005 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 No Irritis 102001 722 / Month 24 1.870 No Irritis 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 722 / Month 24 1.170 No No No 124003 722 / Month 24 0.782 No No No No 124003 722 / Month 24 0.782 No No No No 124003 722 / Month</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Intrancitiat Treatment Group Subject ID Assay Assay Assay Infammation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Irritis 100002 717 / Month 24 1.870 No No 102001 722 / Month 24 1.360 No No 102002 722 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.170 No No No 124003 722 / Month 24 0.782 No No No 124003 722 / Month 24 0.782 No No No 124003 722 / Month 24 0.78</td><td>Treatment Group Positive
Subject ID Positive
Assay Innumoreactivity
Assay Log Titer Inframation
Diagnosis 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 No 177001 715 / Month 24 2.800 Irritis 177005 358 / Month 12 1.870 No 177006 358 / Month 24 1.870 No 177001 717 / Month 24 1.870 Irritis 104002 719 / Month 24 1.870 No 104002 719 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 722 / Month 24 1.130 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 0.782 No 124003 722 / Month 24 0.782 No 126001 174 / Month 6 1.700 No</td><td>Treatment Group Positive Positive Intrancediat Treatment Group Subject ID Assay Assay Intrancediat 170010 365 / Month 12 2.770 No 170010 355 / Month 12 2.800 No
 177006 358 / Month 12 1.870 Intracediat Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Intitis 104002 719 / Month 24 1.870 No No 104002 719 / Month 24 1.130 No No 102001 722 / Month 24 1.140 No No 102002 723 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 124003 722 / Month 24 1.130 No No 124003 722 / Month 24 1.770 No No</td></td></t<> | Treatment Group Subject ID Positive
Immunoreactivity Intranciant Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No 122002 359 / Month 12 1.870 Irritis Irritis Irritis Irritis 104002 719 / Month 24 1.140 No No Irritis No 122002 359 / Month 12 1.630 No No Irritis No 124003 722 / Month 24 1.140 No No Irritis No Irritis
 | Treatment Group Subject ID Positive
Immunoreactivity Intranciant Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No 122002 359 / Month 12 1.870 Irritis Irritis Irritis Irritis 104002 719 / Month 24 1.140 No No Irritis No 122002 359 / Month 12 1.630 No No Irritis No 124003 722 / Month 24 1.140 No No Irritis No Irritis

 | Tratment Group Subject ID Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Irritis Irritis No Ranibizumab 0.5 mg 107000 358 / Month 24 0.922 No No 127006 358 / Month 24 1.870 Irritis Irrit
 | Tratment Group Subject ID Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Irritis Irritis No Ranibizumab 0.5 mg 107000 358 / Month 24 0.922 No No 127006 358 / Month 24 1.870 Irritis Irrit
 | Tratment Group Subject ID Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Irritis Irritis No Ranibizumab 0.5 mg 107000 358 / Month 24 0.922 No No 127006 358 / Month 24 1.870 Irritis Irrit
 | Treatment Group Positive
Subject ID Positive
Assay Intranction
Intrance
Assay Intrance
Intrance Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 2.800 Irritis Irritis 177006 358/Month 24 1.870 Irritis Irritis Ranibizumab 0.5 mg 102001 722/Month 24 1.870 No 106002 719/Month 24 1.140 No No 122002 359/Month 24 1.140 No No 122002 722/Month 24 1.130 No No 124003 722/Month 24 1.140 No No 124003 722/Month 24 1.170 No No No 124003 722/Month 24 1.700 No No No 124003 722/Month 24 1.700 No No No 124003 722/Month 24 1.700
 | Treatment Group Positive
Subject ID Positive
Assay Intranceactivity
Assay Intranction
Intranceactivity Intranction
Intranceactivity Treatment Group Subject ID Assay Assay Intranceactivity Intranceactivity 170010 365/Month 12 2.770 No No No 177006 358/Month 24 2.800 Irritis Irritis 177006 358/Month 24 1.870 Irritis Irritis 102001 722/Month 24 1.140 No No 106002 722/Month 24 1.140 No No 122002 359/Month 24 1.140 No No 122002 722/Month 24 1.170 No No 124003 722/Month 24 1.170 No No 124003 723/Month 24 1.770 No No 124003 723/Month 24 1.770 No No 124003 723/Month 24 1.770 No No 124003 723/Month 54 <td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Intrancitiat Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis 177005 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 No Irritis 102001 722 / Month 24 1.870 No Irritis 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 722 / Month 24 1.170 No No No 124003 722 / Month 24 0.782 No No No No 124003 722 / Month 24 0.782 No No No No 124003 722 / Month</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Intrancitiat Treatment Group Subject ID Assay Assay Assay Infammation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Irritis 100002 717 / Month 24 1.870 No No 102001 722 / Month 24 1.360 No No 102002 722 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.170 No No No 124003 722 / Month 24 0.782 No No No 124003 722 / Month 24 0.782 No No No 124003 722 / Month 24 0.78</td> <td>Treatment Group Positive
Subject ID Positive
Assay Innumoreactivity
Assay Log Titer Inframation
Diagnosis 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 No 177001 715 / Month 24 2.800 Irritis 177005 358 / Month 12 1.870 No 177006 358 / Month 24 1.870 No 177001 717 / Month 24 1.870 Irritis 104002 719 / Month 24 1.870 No 104002 719 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 722 / Month 24 1.130 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 0.782 No 124003 722 / Month 24 0.782 No 126001 174 / Month 6 1.700 No</td> <td>Treatment Group Positive Positive Intrancediat Treatment Group Subject ID Assay Assay Intrancediat 170010 365 / Month 12 2.770 No 170010 355 / Month 12 2.800 No 177006 358 / Month 12 1.870 Intracediat Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Intitis 104002 719 / Month 24 1.870 No No 104002 719 / Month 24 1.130 No No 102001 722 / Month 24 1.140 No No 102002 723 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 124003 722 / Month 24 1.130 No No 124003 722 / Month 24 1.770 No No</td>
 | Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Intrancitiat Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis 177005 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 No Irritis 102001 722 / Month 24 1.870 No Irritis 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 722 / Month 24 1.170 No No No 124003 722 / Month 24 0.782 No No No No 124003 722 / Month 24 0.782 No No No No 124003 722 / Month | Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Intrancitiat Treatment Group Subject ID Assay Assay Assay Infammation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Irritis 100002 717 / Month 24 1.870 No No 102001 722 / Month 24 1.360 No No 102002 722 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 357 / Month 24 1.170 No No No 124003 722 / Month 24 0.782 No No No 124003 722 / Month 24 0.782 No No No 124003 722 / Month 24 0.78
 | Treatment Group Positive
Subject ID Positive
Assay Innumoreactivity
Assay Log Titer Inframation
Diagnosis 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 No 177001 715 / Month 24 2.800 Irritis 177005 358 / Month 12 1.870 No 177006 358 / Month 24 1.870 No 177001 717 / Month 24 1.870 Irritis 104002 719 / Month 24 1.870 No 104002 719 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 722 / Month 24 1.130 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 0.782 No 124003 722 / Month 24 0.782 No 126001 174 / Month 6 1.700 No | Treatment Group Positive Positive Intrancediat Treatment Group Subject ID Assay Assay Intrancediat 170010 365 / Month 12 2.770 No 170010 355 / Month 12 2.800 No 177006 358 / Month 12 1.870 Intracediat Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Intitis 104002 719 / Month 24 1.870 No No 104002 719 / Month 24 1.130 No No 102001 722 / Month 24 1.140 No No 102002 723 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 124003 722 / Month 24 1.130 No No 124003 722 / Month 24 1.770 No No |
| 727/ Month 24 1.480 No 141008 181/ Month 6 1.570 No 362 / Month 12 1.940 No 726 / Month 24 2.340 Vitritis 141013 715 / Month 24 2.340 Nin 143010 722 / Month 24 2.440 No 153006 183 / Month 6 1.900 No 153006 183 / Month 6 1.900 No 153005 183 / Month 24 2.070 No 153005 183 / Month 24 2.070 No 153005 183 / Month 24 0.780 No 153005 183 / Month 24 1.530 No 153005 183 / Month 24 0.780 No 153005 718 / Month 24 0.780 No 153005 715 / Month 24 1.230 No 153005 717 / Month 24 1.230 No 167002 717 / Month 24 1.250 No 188005 717 / Month 24 1.250 No

 | 727/Month 24 1.480 No141008181/Month 6 1.570 No $362/Month 12$ 1.570 No $726/Month 24$ 2.340 Vitritis 141013 $715/Month 24$ 2.340 No 143010 $722/Month 24$ 2.440 No 153006 $183/Month 6$ 1.900 No 153006 $183/Month 6$ 1.900 No 153006 $183/Month 6$ 1.900 No 153006 $183/Month 24$ 2.070 No 153006 $183/Month 24$ 2.070 No 153005 $183/Month 24$ 0.780 No 153005 $183/Month 24$ 0.780 No 153005 $365/Month 12$ 1.530 No 153005 $183/Month 24$ 0.780 No 167002 $717/Month 24$ 0.780 No 167002 $717/Month 24$ 1.250 No 188005 $717/Month 24$ 1.250 No 2.4401 1.250 NoNo 1.5305 $717/Month 24$ 1.250 No 1.5305 $717/Month 24$ 1.250 No 1.5305 $717/Month 24$ 1.250 No 1.5305 1.7500 1.2500 No 1.5305 1.7500 1.1250 1.1250

 | Name 727/Month 24 1.480 No 141008 181/Month 6 1.570 No 362/Month 12 1.940 No 141013 $726/Month 24$ 2.340 Nicritis 143010 $722/Month 24$ 2.340 Nicritis 143010 $722/Month 24$ 2.440 No 152004 $522/Early Term.$ 0.752 , No 153006 183/Month 6 1.900 No 153006 183/Month 24 2.070 No 153006 183/Month 24 0.752 , No 153007 $718/Month 24$ 0.780 No 167002 $717/Mont 24$ 0.780 No 167002 $717/Mont 24$ 1.250 No 188005 $717/Mont 24$ 1.250 No 534001 $-7/Screening$ 2.520 $Vitritis$

 | Treatment Group Positive
Intrancentivity Intrancentivity Intrancentivity Intrancentivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 Irritis Irritis 102001 722 / Month 24 1.870 No No 104002 719 / Month 24 1.140 No No 102001 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122003 722 / Month 24 1.170 No No 122003 722 / Month 24 1.770 No No 122003 722 / Month 24 1.770 No No 124003 722 / Month 24 0.782 No No

 | Treatment Group Positive Immunoreactivity Immanition Set of the set of t

 | Treatment Group Positive Immunoreactivity
 | Treatment Group Positive Positive Immunoreactivity Immunoreactivity Immanition Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 102001 717 / Month 24 1.870 Intris 104002 719 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122003
 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 0.782 No 124003 722 / Month 24 1.770 No <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 102001 712 / Month 24 1.870 Intris 104002 719 / Month 24 1.850 No 106002 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 722 / Month 24 1.130 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 0.782 No 124003 722</td> <td>Treatment Group Positive Positive Immunoreactivity Immunoreactivity Immanition Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 102001 717 / Month 24 1.870 Intris 104002 719 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122003 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 0.782 No 124003 722 / Month 24 1.770 No<td>Treatment Group Positive Positive Immunoreactivity Immunoreactivity Immanition Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 102001 717 / Month 24 1.870 Intris 104002 719 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122003 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 0.782 No 124003 722 / Month 24 1.770 No<td>Treatment Group Positive Immunoreactivity Immunoreactivity</td><td>Treatment Group Positive Immunoreactivity Immunoreactivity</td><td>Treatment Group Positive Immunoreactivity Immunoreactivity</td><td>Treatment Group Positive
Intrancentivity Intrancentivity Intrancentivity Intrancentivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 Irritis Irritis 102001 722 / Month 24 1.870 No No 104002 719 / Month 24 1.140 No No 102001 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122003 722 / Month 24 1.170 No No 122003 722 / Month 24 1.770 No No 122003 722 / Month 24 1.770 No No 124003 722 / Month 24 0.782 No No</td><td>Treatment Group Positive
Innunoreactivity Innunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irtius Irtius 177006 358 / Month 12 1.870 Irtius Irtius 177006 358 / Month 12 1.870 Irtius Irtius 102001 722 / Month 24 1.870 No No 104002 719 / Month 24 1.140 No No 102001 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 722 / Month 24 1.1770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 0.782 No No 124003 <</td><td>Treatment Group Positive
Innunoreactivity Innunoreactivity Innunoreactivity Innamnation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 24 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.1770 No No 124003 722 / Month 24 1.630 No No 124003 722 / Month 24 0.782 No No 124003 722 / Month 24 0.782 No No</td><td>Treatment Group Positive
Innunoreactivity Innunoreactivity
Innunoreactivity Intraocular
Infammation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 24 1.870 Iritis Iritis 177006 358 / Month 24 1.870 Iritis Iritis 104002 717 / Month 24 1.870 No No 106002 722 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 0.782 No No <t< td=""><td>Treatment Group Bubject ID Positive Intrancedivity Intrancediat Treatment Group Subject ID Assay Assay Assay Assay Intrancediat 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intraoculat No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 Intuis No 102001 722 / Month 24 1.870 Intuis No 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.170 No No 124003 722 / Month 24 1.630 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24
 1.770 No <td< td=""><td>Treatment Group Positive
Inframunoreactivity Inframmation Treatment Group Subject ID Assay Assay Intranoreactivity Inframmation 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 1.870 No No No 177006 358 / Month 12 1.870 No No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Intitis No 104002 719 / Month 24 1.860 No No No No 102001 722 / Month 24 1.140 No No</td></td<></td></t<></td></td></td> | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 102001 712 / Month 24 1.870 Intris 104002 719 / Month 24 1.850 No 106002 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 722 / Month 24 1.130 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 0.782 No 124003 722
 | Treatment Group Positive Positive Immunoreactivity Immunoreactivity Immanition Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 102001 717 / Month 24 1.870 Intris 104002 719 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122003 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 0.782 No 124003 722 / Month 24 1.770 No <td>Treatment Group Positive Positive Immunoreactivity
Immunoreactivity Immanition Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 102001 717 / Month 24 1.870 Intris 104002 719 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122003 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 0.782 No 124003 722 / Month 24 1.770 No<td>Treatment Group Positive Immunoreactivity Immunoreactivity</td><td>Treatment Group Positive Immunoreactivity Immunoreactivity</td><td>Treatment Group Positive Immunoreactivity Immunoreactivity</td><td>Treatment Group Positive
Intrancentivity Intrancentivity Intrancentivity Intrancentivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 Irritis Irritis 102001 722 / Month 24 1.870 No No 104002 719 / Month 24 1.140 No No 102001 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122003 722 / Month 24 1.170 No No 122003 722 / Month 24 1.770 No No 122003 722 / Month 24 1.770 No No 124003 722 / Month 24 0.782 No No</td><td>Treatment Group Positive
Innunoreactivity Innunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irtius Irtius 177006 358 / Month 12 1.870 Irtius Irtius 177006 358 / Month 12 1.870 Irtius Irtius 102001 722 / Month 24 1.870 No No 104002 719 / Month 24 1.140 No No 102001 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 722 / Month 24 1.1770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 0.782 No No 124003 <</td><td>Treatment Group Positive
Innunoreactivity Innunoreactivity Innunoreactivity Innamnation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 24 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.1770 No No 124003 722 / Month 24 1.630 No No 124003 722 / Month 24 0.782 No No 124003 722 / Month 24 0.782 No No</td><td>Treatment Group Positive
Innunoreactivity Innunoreactivity
Innunoreactivity Intraocular
Infammation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 24 1.870 Iritis Iritis 177006 358 / Month 24 1.870 Iritis Iritis 104002 717 / Month 24 1.870 No No 106002 722 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 0.782 No No <t< td=""><td>Treatment Group Bubject ID Positive Intrancedivity Intrancediat Treatment Group Subject ID Assay Assay Assay Assay Intrancediat 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intraoculat No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 Intuis No 102001 722 / Month 24 1.870 Intuis No 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.170 No No 124003 722 / Month 24 1.630 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No <td< td=""><td>Treatment Group Positive
Inframunoreactivity Inframmation Treatment Group Subject ID Assay Assay Intranoreactivity Inframmation 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 1.870 No No No 177006 358 / Month 12 1.870 No No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Intitis No 104002 719 / Month 24 1.860 No No No No 102001 722 / Month 24 1.140 No No</td></td<></td></t<></td></td> | Treatment Group Positive Positive Immunoreactivity Immunoreactivity Immanition Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris
 177006 358 / Month 12 1.870 Intris 102001 717 / Month 24 1.870 Intris 104002 719 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122003 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 0.782 No 124003 722 / Month 24 1.770 No <td>Treatment Group Positive Immunoreactivity Immunoreactivity</td> <td>Treatment Group Positive Immunoreactivity Immunoreactivity</td> <td>Treatment Group Positive Immunoreactivity Immunoreactivity</td> <td>Treatment Group Positive
Intrancentivity Intrancentivity Intrancentivity Intrancentivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 Irritis Irritis 102001 722 / Month 24 1.870 No No 104002 719 / Month 24 1.140 No No 102001 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122003 722 / Month 24 1.170 No No 122003 722 / Month 24 1.770 No No 122003 722 / Month 24 1.770 No No 124003 722 / Month 24 0.782 No No</td> <td>Treatment Group Positive
Innunoreactivity Innunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irtius Irtius 177006 358 / Month 12 1.870 Irtius Irtius 177006 358 / Month 12 1.870 Irtius Irtius 102001 722 / Month 24 1.870 No No 104002 719 / Month 24 1.140 No No 102001 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 722 / Month 24 1.1770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 0.782 No No 124003 <</td> <td>Treatment Group Positive
Innunoreactivity Innunoreactivity Innunoreactivity Innamnation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 24 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.1770 No No 124003 722 / Month 24 1.630 No No 124003 722 / Month 24 0.782 No No 124003 722 / Month 24 0.782 No No</td> <td>Treatment Group Positive
Innunoreactivity Innunoreactivity
Innunoreactivity Intraocular
Infammation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 24 1.870 Iritis Iritis 177006 358 / Month 24 1.870 Iritis Iritis 104002 717 / Month 24 1.870 No No 106002 722 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 0.782 No No <t< td=""><td>Treatment Group Bubject ID Positive Intrancedivity Intrancediat Treatment Group Subject ID Assay Assay Assay Assay Intrancediat 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intraoculat No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 Intuis No 102001 722 / Month 24 1.870 Intuis No 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.170 No No 124003 722 / Month 24 1.630 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No <td< td=""><td>Treatment Group Positive
Inframunoreactivity Inframmation Treatment Group Subject ID Assay Assay Intranoreactivity Inframmation 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 1.870 No No No 177006 358 / Month 12 1.870 No No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Intitis No 104002 719 / Month 24 1.860 No No No No 102001 722 / Month 24 1.140 No No</td></td<></td></t<></td> | Treatment Group Positive Immunoreactivity

 | Treatment Group Positive Immunoreactivity
 | Treatment Group Positive Immunoreactivity
 | Treatment Group Positive
Intrancentivity Intrancentivity Intrancentivity Intrancentivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 Irritis Irritis 102001 722 / Month 24 1.870 No No 104002 719 / Month 24 1.140 No No 102001 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122003 722 / Month 24 1.170 No No 122003 722 / Month 24 1.770 No No 122003 722 / Month 24 1.770 No No 124003 722 / Month 24 0.782 No No | Treatment Group Positive
Innunoreactivity Innunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irtius Irtius 177006 358 / Month 12 1.870 Irtius Irtius 177006 358 / Month 12 1.870 Irtius Irtius 102001 722 / Month 24 1.870 No No 104002 719 /
Month 24 1.140 No No 102001 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 722 / Month 24 1.1770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 0.782 No No 124003 < | Treatment Group Positive
Innunoreactivity Innunoreactivity Innunoreactivity Innamnation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 24 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.1770 No No 124003 722 / Month 24 1.630 No No 124003 722 / Month 24 0.782 No No 124003 722 / Month 24 0.782 No No
 | Treatment Group Positive
Innunoreactivity Innunoreactivity
Innunoreactivity Intraocular
Infammation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 24 1.870 Iritis Iritis 177006 358 / Month 24 1.870 Iritis Iritis 104002 717 / Month 24 1.870 No No 106002 722 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 0.782 No No <t< td=""><td>Treatment Group Bubject ID Positive Intrancedivity Intrancediat Treatment Group Subject ID Assay Assay Assay Assay Intrancediat 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intraoculat No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 Intuis No 102001 722 / Month 24 1.870 Intuis No 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.170 No No 124003 722 / Month 24 1.630 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No <td< td=""><td>Treatment Group Positive
Inframunoreactivity Inframmation Treatment Group Subject ID Assay Assay Intranoreactivity Inframmation 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 1.870 No No No 177006 358 / Month 12 1.870 No No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Intitis No 104002 719 / Month 24 1.860 No No No No 102001 722 / Month 24 1.140 No No</td></td<></td></t<> | Treatment Group Bubject ID Positive Intrancedivity Intrancediat Treatment Group Subject ID Assay Assay Assay Assay Intrancediat 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intraoculat No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 Intuis No 102001 722 / Month 24 1.870 Intuis No 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.170 No No 124003 722 / Month 24 1.630 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No <td< td=""><td>Treatment Group Positive
Inframunoreactivity Inframmation Treatment Group Subject ID Assay Assay Intranoreactivity Inframmation 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 1.870 No No No 177006 358 / Month 12 1.870 No No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Intitis No 104002 719 / Month 24 1.860 No No No No 102001 722 / Month 24 1.140 No No</td></td<> | Treatment Group Positive
Inframunoreactivity Inframmation Treatment Group Subject ID Assay Assay Intranoreactivity Inframmation 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 1.870 No No No 177006 358 / Month 12 1.870 No No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Intitis No 104002 719 / Month 24 1.860 No No No No 102001 722 / Month 24 1.140 No |
| 53// Month 12 2.040 727/ Month 24 1.480 141008 181/ Month 6 362 / Month 12 1.940 726 / Month 24 2.340 143010 722 / Month 24 143010 722 / Month 24 143010 722 / Month 24 153006 183 / Month 24 153006 183 / Month 24 153006 183 / Month 24 153007 718 / Month 24 153007 717 / Month 24 153007 100 153007 717 / Month 24

 | 53// Month 12 2.040 727/ Month 24 1.480 141008 181/ Month 6 1.570 726/ Month 24 2.340 715/ Month 24 2.340 143010 722 / Month 24 2.440 7204 522 / Month 24 2.440 152004 522 / Month 24 2.440 153006 183 / Month 24 2.440 153006 183 / Month 24 0.752, 153007 718 / Month 24 0.780 153007 717 / Month 24 1.900 167002 717 / Month 24 0.780 167002 717 / Month 24 1.230 167002 717 / Month 24 1.250

 | 55// Month 12 2.040 727 / Month 24 1.480 141008 181 / Month 6 726 / Month 12 1.940 726 / Month 24 2.340 143010 722 / Month 24 725 / Month 24 2.440 152004 522 / Early Term. 0.752 No 153006 183 / Month 6 153006 183 / Month 6 153006 183 / Month 24 2.070 No 153005 176 / Month 24 2.070 No 153005 183 / Month 24 2.070 No 153005 176 / Month 24 153005 176 / Month 24 167002 717 / Mont 24 15300 1.530 167002 717 / Mont 24 15300 1.250 188005 717 / Mont 24 1.250 No

 | Treatment Group Positive Immunoreactivity

 | Freatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immanition Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Inframmation 717 / Month 24 1.870 Infra No 102001 722 / Month 24 1.870 Infra No 106002 719 / Month 24 1.140 No No No 106002 722 / Month 24 1.130 No No No No 122002 359 / Month 24 1.140 No No No No 122002 359 / Month 24 1.140 No No No No 122002 359 / Month 24 1.140 No No No No 124003 722 / Month 24 1.630 No No No No 126001 174 / Month 6 0.782 No <td< td=""><td>Treatment Group Positive Positive Immunoreactivity Immunoreactivity Immanition Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 24 1.870 Irritis Irritis 102001 712 / Month 24 1.870 Irritis Irritis 106002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 359 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 126001 1.74 / Month 6 0.782 No No<</td><td>Treatment Group
Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis 177006 358 / Month 24 1.870 Irritis No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Irritis No 106002 719 / Month 24 1.140 No No No 106002 722 / Month 24 1.130 No No No 122002 359 / Month 24 1.130 No No No 122002 359 / Month 24 1.140 No No No No 122002 722 / Month 24 1.130 No No No No No 122002 723 / Month 24 1.770 No No No No 124003</td><td>Treatment Group Positive Positive Intraociliar Treatment Group Subject ID Assay Assay Log Titer Intraociliar 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis Ranibizumab 0.5 mg 102001 712 / Month 24 1.870 Irritis No Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No No 106002 719 / Month 24 1.130 No No No No 122002 359 / Month 24 1.130 No No No No 122002 722 / Month 24 1.130 No No No No 122002 359 / Month 24 1.130 No No</td></td<> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis 177006 358 / Month 24 1.870 Irritis No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Irritis No 106002 719 / Month 24 1.140 No No No 106002 722 / Month 24 1.130 No No No 122002 359 / Month 24 1.130 No No No 122002 359 / Month 24 1.140 No No No No 122002 722 / Month 24 1.130 No No No No No 122002 723 / Month 24 1.770 No No No No 124003</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis 177006 358 / Month 24 1.870 Irritis No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Irritis No 106002 719 / Month 24 1.140 No No No 106002 722 / Month 24 1.130 No No No 122002 359 / Month 24 1.130 No No No 122002 359 / Month 24 1.140 No No No No 122002 722 / Month 24 1.130 No No No No No 122002 723 / Month 24 1.770 No No No No 124003</td> <td>Treatment Group Positive Positive Immunoreactivity Immunoreactivity Immanition Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 24 1.870 Irritis Irritis 102001 712 / Month 24 1.870 Irritis Irritis 106002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 359 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 126001 1.74 / Month 6 0.782 No No<</td> <td>Treatment Group Positive Positive Immunoreactivity Immunoreactivity Immanition Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 24 1.870 Irritis Irritis 102001 712 / Month 24 1.870 Irritis Irritis 106002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 359 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 126001 1.74 / Month 6 0.782 No No<</td> <td>Treatment Group Positive Positive Immunoreactivity Immunoreactivity Immanition Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 24 1.870 Irritis Irritis 102001 712 / Month 24 1.870 Irritis Irritis 106002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 359 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 126001 1.74 / Month 6 0.782 No No<</td> <td>Treatment Group Positive Immunoreactivity Immunoreactivity</td> <td>Treatment Group Positive Immunoreactivity Immunoreactivity</td> <td>Treatment GroupPositive
InnunoreactivityInnunoreactivityInnunoreactivityTreatment GroupSubject IDAssayAssay Log TiterDiagnosis170010$365 / Month 12$$2.770$No177006$358 / Month 12$$2.800$Irritis177006$358 / Month 12$$1.870$Irritis177006$358 / Month 12$$1.870$Irritis177006$358 / Month 12$$1.870$Irritis177006$358 / Month 24$$1.870$Irritis102001$722 / Month 24$$1.140$No106002$712 / Month 24$$1.140$No106002$722 / Month 24$$1.140$No122002$359 / Month 24$$1.700$No122002$359 / Month 24$$1.700$No122002$359 / Month 24$$1.700$No122002$174 / Month 24$$1.700$No126001$1.74 / Month 6$$1.700$No</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Treatment Group Subject ID 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Iritis No 177006 358 / Month 12 1.870 No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No 122002 359 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.170 No No 122001 723 / Month 24 1.770 No No 122002 359 / Month 24 1.770 No No 122001 723 / Month 24 1.770 No No</td> <td>Treatment Group Positive
Subject ID Positive
Assay
Intrunoreactivity
Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intra 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intits 177006 358 / Month 12 1.870 Intits 10001 717 / Month 24 1.870 Intits 102001 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 723 / Month 24 1.130 No 122002 723 / Month 24 1.170 No 122002 359 / Month 24 1.770 No 122002 723 / Month 24 1.770 No 122003 723 / Month 24 1.770 No</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immation 170010 365 / Month 12 2.800 No No</td> | Treatment Group Positive Positive Immunoreactivity Immunoreactivity Immanition Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 24 1.870 Irritis Irritis 102001 712 / Month 24 1.870 Irritis Irritis 106002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 359 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 126001 1.74 / Month 6 0.782 No No<

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis 177006 358 / Month 24 1.870 Irritis No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Irritis No 106002 719 / Month 24 1.140 No No No 106002 722 / Month 24 1.130 No No No 122002 359 / Month 24 1.130 No No No 122002 359 / Month 24 1.140 No No No No 122002 722 / Month 24 1.130 No No No No No 122002 723 / Month 24 1.770 No No No No 124003

 | Treatment Group Positive Positive Intraociliar Treatment Group Subject ID Assay Assay Log Titer Intraociliar 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis Ranibizumab 0.5 mg 102001 712 / Month 24 1.870 Irritis No Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No No 106002 719 / Month 24 1.130 No No No No 122002 359 / Month 24 1.130 No No No No 122002 722 / Month 24 1.130 No No No No 122002 359 / Month 24 1.130 No
 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular
 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis 177006 358 / Month 24 1.870 Irritis No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Irritis No 106002 719 / Month 24 1.140 No No No 106002 722 / Month 24 1.130 No No No 122002 359 / Month 24 1.130 No No No 122002 359 / Month 24 1.140 No No No No 122002 722 / Month 24 1.130 No No No No No 122002 723 / Month 24 1.770 No No No No 124003
 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis 177006 358 / Month 24 1.870 Irritis No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Irritis No 106002 719 / Month 24 1.140 No No No 106002 722 / Month 24 1.130 No No No 122002 359 / Month 24 1.130 No No No 122002 359 / Month 24 1.140 No No No No 122002 722 / Month 24 1.130 No No No No No 122002 723 / Month 24 1.770 No No No No 124003
 | Treatment Group Positive Positive Immunoreactivity Immunoreactivity Immanition Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 24
 1.870 Irritis Irritis 102001 712 / Month 24 1.870 Irritis Irritis 106002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 359 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 126001 1.74 / Month 6 0.782 No No<
 | Treatment Group Positive Positive Immunoreactivity Immunoreactivity Immanition Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 24 1.870 Irritis Irritis 102001 712 / Month 24 1.870 Irritis Irritis 106002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 359 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 126001 1.74 / Month 6 0.782 No No<
 | Treatment Group Positive Positive Immunoreactivity Immunoreactivity Immanition Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 24 1.870 Irritis Irritis 102001 712 / Month 24 1.870 Irritis Irritis 106002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 359 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 126001 1.74 / Month 6 0.782 No No<
 | Treatment Group Positive Immunoreactivity
 | Treatment Group Positive Immunoreactivity | Treatment GroupPositive
InnunoreactivityInnunoreactivityInnunoreactivityTreatment GroupSubject IDAssayAssay Log TiterDiagnosis170010 $365 / Month 12$ 2.770 No177006 $358 / Month 12$ 2.800 Irritis177006 $358 / Month 12$ 1.870 Irritis177006 $358 / Month 12$ 1.870 Irritis177006 $358 / Month 12$ 1.870 Irritis177006 $358 / Month 24$ 1.870 Irritis102001 $722 / Month 24$ 1.140 No106002 $712 / Month 24$ 1.140 No106002 $722 / Month 24$ 1.140 No122002 $359 / Month 24$ 1.700 No122002 $359 / Month 24$ 1.700 No122002 $359 / Month 24$ 1.700 No122002 $174 / Month 24$ 1.700 No126001 $1.74 / Month 6$ 1.700 No
 | Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Treatment Group Subject ID 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Iritis No 177006 358 / Month 12 1.870 No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No 122002 359 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.170 No No 122001 723 / Month 24 1.770 No No 122002 359 / Month 24 1.770 No No 122001 723 / Month 24 1.770 No No | Treatment Group Positive
Subject ID Positive
Assay Intrunoreactivity
Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intra 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intits 177006 358 / Month 12 1.870 Intits 10001 717 / Month 24 1.870 Intits 102001 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 723 / Month 24 1.130 No 122002 723 / Month 24 1.170 No 122002 359 / Month 24 1.770 No 122002 723 / Month 24 1.770 No 122003 723 / Month 24 1.770 No
 | Treatment Group Positive
Immunoreactivity Immunoreactivity Immation 170010 365 / Month 12 2.800 No |
| S57/Month 12 2.040 No 727/Month 24 1.480 No 141008 181/Month 6 1.570 No 362/Month 12 1.940 No No 141013 $715/Month 24$ 2.340 Nitritis 143010 $725/Month 24$ 2.610 Vitritis 143010 $722/Month 24$ 2.610 Ni 153006 183/Month 24 2.440 No 153006 183/Month 24 2.610 Ni 153007 $715/Month 24$ 2.610 No 153006 183/Month 24 0.752 , No No 153006 183/Month 24 0.780 No 153007 $718/Month 24$ 0.780 No 153007 $715/Month 24$ 1.230 No 153008 $717/Mont 24$ 1.230 No 167002 $717/Mont 24$ 1.230 No 15300 $717/Mont 24$ 1.250 No

 | S57/Month 12 2.040 No 141008 181/Month 6 1.570 No 141013 727/Month 24 1.480 No 362/Month 12 1.940 No No 141013 715/Month 24 2.610 Vitritis 143010 722/Month 24 2.610 Nitritis 153006 183/Month 24 2.610 No 153006 183/Month 24 2.610 No 153006 183/Month 24 2.610 No 153007 715/Month 24 2.610 No 153006 183/Month 24 1.900 No 153007 183/Month 24 1.900 No 153007 716/Month 24 1.300 No 15300 715/Month 24 1.230 No 15300 715/Month 24 1.230 No 15300 717/Mont 24 1.230 No 1530 717/Mont 24 1.250 No

 | S57/Month 12 2.040 No 141008 181/Month 6 1.570 No 141003 181/Month 6 1.570 No 362/Month 12 1.940 No No 141013 715/Month 24 2.340 No 143010 722/Month 24 2.440 No 143010 722/Month 24 2.440 No 152004 522/Early Term. 0.752, No 153006 183/Month 6 1.900 No 153006 183/Month 24 2.610 No 153006 183/Month 24 2.070 No 153006 183/Month 24 2.070 No 15500 717/Mont 24 1.230 No 1667002 717/Mont 24 1.230 No 188005 717/Mont 24 1.250 N

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Formunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular 177001 717 / Month 24 1.870 Intris 104002 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 104002 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 722 / Month 24 1.170 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 0.782 No 126001 1.74 / Month 6 1.770 No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Intraocular No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No
 No No No 122002 359 / Month 12 1.140 No No No No 122002 359 / Month 24 1.140 No No No No 122002 359 / Month 12 1.630 No No No No No No 124003 722 / Month 24 0.782 No No No No 126001 174 / Month 54 0.782 No No No No

 | Treatment Group Fositive Finaminoreactivity Intraocular Treatment Group Subject ID Finaminoreactivity Intraocular 170010 365 / Month 12 2.770 Nio 170010 365 / Month 12 2.800 Nio 177006 358 / Month 12 1.870 Nio 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Nio 102001 717 / Month 24 0.922 Nio 104002 719 / Month 24 1.140 Nio 104002 722 / Month 24 1.130 Nio 122002 359 / Month 12 1.630 Nio 122002 359 / Month 24 1.170 Nio 124003 722 / Month 24 0.782 Nio 124003 722 / Month 24 0.782 Nio 105001 722 / Month 24 0.782 Nio

 | Treatment Group Fositive Finamination Treatment Group Subject ID Finamination Intraocular 170010 365 / Month 12 2.770 Nio 170010 365 / Month 12 2.770 Nio 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Nio 177006 358 / Month 24 1.870 Intris 102001 717 / Month 24 1.850 Nio 104002 719 / Month 24 1.140 Nio 104002 722 / Month 24 1.130 Nio 122002 359 / Month 24 1.140 Nio 122002 359 / Month 24 1.170 Nio 122002 722 / Month 24 1.630 Nio 124003 722 / Month 24 1.770 Nio 124003 722 / Month 24 1.770 Nio

 | Treatment Group Subject ID Positive
Innunoreactivity Innunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 Intraocular 177001 717 / Month 24 1.870 Intris 102001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 104002 722 / Month 24 1.130 No 104002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 359 / Month 24 1.770 No 122002 722 / Month 24 1.770 No 104003 722 / Month 24 1.770 No
 | Treatment Group Fositive Finamination Treatment Group Subject ID Finamination Intraocular 170010 365 / Month 12 2.770 Nio 170010 365 / Month 12 2.770 Nio 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Nio 177006 358 / Month 24 1.870 Intris 102001 717 / Month 24 1.850 Nio 104002 719 / Month 24 1.140 Nio 104002 722 / Month 24 1.130 Nio 122002 359 / Month 24 1.140 Nio 122002 359 / Month 24 1.170 Nio 122002 722 / Month 24 1.630 Nio 124003 722 / Month 24 1.770 Nio 124003 722 / Month 24 1.770 Nio

 | Treatment Group Subject ID Positive Intraocular Treatment Group Subject ID Tranunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 102001 717 / Month 24 0.922 No 104002 719 / Month 24 1.140 No 104002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 359 / Month 24 1.170 No 124003 722 / Month 24 0.782 No 124003 722 / Month 24 1.770 No 106002 723 / Month 24 1.770 No
 | Treatment Group Fositive Finaminoreactivity Intraocular Treatment Group Subject ID Finaminoreactivity Intraocular 170010 365 / Month 12 2.770 Nio 170010 365 / Month 12 2.800 Nio 177006 358 / Month 12 1.870 Nio 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Nio 102001 717 / Month 24 0.922 Nio 104002 719 / Month 24 1.140 Nio 104002 722 / Month 24 1.130 Nio 122002 359 / Month 12 1.630 Nio 122002 359 / Month 24 1.170 Nio 124003 722 / Month 24 0.782 Nio 124003 722 / Month 24 0.782 Nio 105001 722 / Month 24 0.782 Nio
 | Treatment Group Fositive Finaminoreactivity Intraocular Treatment Group Subject ID Finaminoreactivity Intraocular 170010 365 / Month 12 2.770 Nio 170010 365 / Month 12 2.800 Nio 177006 358 / Month 12 1.870 Nio 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Nio 102001 717 / Month 24 0.922 Nio 104002 719 / Month 24 1.140 Nio 104002 722 / Month 24
 1.130 Nio 122002 359 / Month 12 1.630 Nio 122002 359 / Month 24 1.170 Nio 124003 722 / Month 24 0.782 Nio 124003 722 / Month 24 0.782 Nio 105001 722 / Month 24 0.782 Nio
 | Treatment Group Fositive Finaminoreactivity Intraocular Treatment Group Subject ID Finaminoreactivity Intraocular 170010 365 / Month 12 2.770 Nio 170010 365 / Month 12 2.800 Nio 177006 358 / Month 12 1.870 Nio 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Nio 102001 717 / Month 24 0.922 Nio 104002 719 / Month 24 1.140 Nio 104002 722 / Month 24 1.130 Nio 122002 359 / Month 12 1.630 Nio 122002 359 / Month 24 1.170 Nio 124003 722 / Month 24 0.782 Nio 124003 722 / Month 24 0.782 Nio 105001 722 / Month 24 0.782 Nio
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No No 170010 365 / Month 12 2.800 No No No No 177006 358 / Month 12 1.870 I.ritis No No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Iritis No N | Treatment Group Positive Innunoreactivity Innraocular Treatment Group Subject ID Assay Assay Log Titer
 Inraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 Inframmation No No 177006 358 / Month 12 1.870 I.ritis No No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 I.ritis No | Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 I.ritis No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No No No 122002 359 / Month 12 1.130 No No No No 122002 359 / Month 24 1.130 No No No No 122002 359 / Month 12 1.630 No No No No 122001 722 / Month 24 0.782 No No No No 124003 722 / Month 24 0.782 No No No No
 | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 12 2.800 Inflammation 717/Month 24 1.870 I.ritis 104002 719/Month 24 0.922 No 104002 719/Month 24 1.140 No 106002 722/Month 24 1.130 No 122002 359/Month 24 1.130 No 122002 359/Month 24 1.130 No 122002 722/Month 24 1.170 No 122003 722/Month 24 1.050 No 122003 722/Month 24 1.000 No 124003 722/Month 24 0.782 No 126001 1.74/Month 6 1.770 No | Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 715/Month 24 2.800 Intraocular Intraocular Ranibizumab 0.5 mg 177/Month 24 1.850 No 104002 719/Month 24 0.922 No 106002 722/Month 24 0.922 No 106002 722/Month 24 1.140 No 122002 359/Month 24 1.130 No 122002 359/Month 24 1.130 No 122003 722/Month 24 1.1600 No 122003 722/Month 24 1.050 No 122003 722/Month 24 0.782 No 124003 722/Month 24 0.782 No 126001 1.74/Month 6 1.700 No | Treatment Group Evention From Subject ID Positive frammoreactivity frammoreactivity frammation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Inframmation 717 / Month 24 0.922 No No 104002 719 / Month 24 0.922 No 106002 722 / Month 24 0.922 No No 106002 722 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.630 No No 122002 359 / Month 24 1.770 No No 122003 722 / Month 24 0.782 No No No 122003 723 / Month 24 0.782 No No No No 124003 722 / Month 24 0.782 No No No No
 |
| Sham 357 / Month 12 2.040 357 / Month 12 1.480 No 141008 181 / Month 6 1.570 No 362 / Month 12 1.940 No 362 / Month 24 2.340 Nitritis 143010 722 / Month 24 2.610 Vitritis 143010 722 / Month 24 2.610 Nic 153006 183 / Month 6 1.900 No 153005 183 / Month 24 2.610 Nic 153005 183 / Month 24 0.752 No 153005 183 / Month 24 0.730 No 153005 715 / Month 24 1.530 No 153005 717 / Mont 24 1.200 No 167002 717 / Mont 24 1.230 No 167002 717 / Mont 24 1.250 No 167002 717 / Mont 24 1.250 No

 | Sham 557/Month 12 2.040 727/Month 24 1.480 No 727/Month 5 1.570 No 141008 181/Month 6 1.570 No 726/Month 24 2.340 Vitritis 143010 722/Month 24 2.610 Vitritis 143010 722/Month 24 2.610 Nio 153006 183/Month 6 1.900 No 153005 183/Month 24 2.610 Nin 153005 183/Month 24 2.610 Nin 153005 183/Month 24 0.752, No 153005 183/Month 24 0.780 No 153005 715/Month 24 1.530 No 153005 717/Month 24 1.230 No 167002 717/Month 24 1.230 No 188005 717/Month 24 1.250 No 188005 717/Month 24 1.250 No

 | Sham 357/Month 12 2.040 141008 181/Month 5 1.480 725/Month 24 1.570 No 362/Month 24 2.340 No 141013 715/Month 24 2.340 Nitritis 141013 715/Month 24 2.610 Nitritis 143010 722/Month 24 2.440 No 152004 522/Early Term. 0.752, No 153006 183/Month 6 1.900 No 153006 183/Month 24 2.070 No 153006 183/Month 24 1.530 No 153007 717/Mont 24 0.780 No 167002 717/Mont 24 1.230 No 188005 717/Mont 24 1.250 No 188005 717/Mont 24 1.250 No

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365/Month 12 2.770 No No No 177006 358/Month 12 2.800 Intraocular No No 177006 358/Month 24 1.870 Intris No No No Ranibizumab 0.5 mg 102001 722/Month 24 1.850 No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular No Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Intritis Intritis Ranibizumab 0.5 mg 102001 722 / Month 12 1.870 No No 106002 719 / Month 24 1.140 No No No 106002 722 / Month 12 1.130 No No No 122002 359 / Month 12 1.130 No No No 122002 359 / Month 12 1.630 No No No 124003
 722 / Month 24 1.130 No No No 124003 723 / Month 24 0.782 No No No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Sosay Assay Intraocular 170010 365 / Month 12 2.770 No 17010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 10001 717 / Month 24 1.870 Intitis 102001 722 / Month 24 1.870 Intitis 104002 719 / Month 24 1.140 No 106002 722 / Month 12 1.630 No 122002 359 / Month 12 1.630 No 122002 722 / Month 24 1.140 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No

 | Treatment Group Entitie Finaminoreactivity Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 102001 717 / Month 24 1.870 Intris 104002 719 / Month 24 1.870 No 106002 722 / Month 12 1.140 No 106002 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 722 / Month 24 1.130 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No
 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Ses/ Month
12 2.770 No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Inflammation Ranibizumab 0.5 mg 102001 715 / Month 24 1.870 Infision 102002 719 / Month 24 1.870 Intitis Intitis 102001 722 / Month 24 1.140 No No 102002 722 / Month 12 1.140 No No 106002 722 / Month 12 1.140 No No 122002 359 / Month 12 1.630 No No 122002 722 / Month 24 1.140 No No 122003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No
 | Treatment Group Entitie Finaminoreactivity Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 102001 717 / Month 24 1.870 Intris 104002 719 / Month 24 1.870 No 106002 722 / Month 12 1.140 No 106002 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 722 / Month 24 1.130 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No

 | Treatment Group Entitie Finaminoreactivity Intraocular Treatment Group Subject ID Sasy Intraocular Intraocular 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Inflammation No No Ranibizumab 0.5 mg 102001 715 / Month 24 1.870 Intris No Ranibizumab 0.5 mg 102001 722 / Month 12 1.870 Intris No 106002 722 / Month 12 1.140 No No No No 106002 722 / Month 12 1.140 No No No No 122002 359 / Month 12 1.130 No No No No 124003 722 / Month 24 1.130 No No No No 124003 722 / Month 24 1.770 No No No No 124003 722 / Month 24 1.770 No No No No
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Sosay Assay Intraocular 170010 365 / Month 12 2.770 No 17010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 10001 717 / Month 24 1.870 Intitis 102001 722 / Month 24 1.870 Intitis 104002 719 / Month 24 1.140 No 106002 722 / Month 12 1.630 No 122002 359 / Month 12 1.630 No 122002 722 / Month 24 1.140 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Sosay Assay Intraocular 170010 365 / Month 12 2.770 No 17010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 10001 717 / Month 24 1.870 Intitis 102001 722 / Month 24 1.870 Intitis 104002 719 / Month 24 1.140 No 106002 722 / Month 12 1.630 No 122002 359 / Month 12 1.630 No 122002 722 / Month 24 1.140 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Sosay Assay Intraocular 170010 365 / Month 12 2.770 No 17010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 10001 717 / Month 24 1.870 Intitis 102001 722 / Month 24 1.870 Intitis 104002 719 / Month 24 1.140 No 106002 722 / Month 12 1.630 No 122002 359 / Month 12 1.630 No 122002 722 / Month 24 1.140 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No
 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365/Month 12 2.770 No No No 177006 358/Month 12 2.800 Intraocular No No 177006 358/Month 24 1.870 Intris No No No Ranibizumab 0.5 mg 102001 722/Month 24 1.850 No | Treatment Group Positive Positive Intranocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365/Month 12 2.770 No No No 170010 365/Month 12 2.770 No No No 177006 358/Month 12 1.870 Iritias Iritias Iritias 177006 358/Month 24 1.870 No No No Iritias Ranibizumab 0.5 mg 102001 722/Month 24 1.850 No
 No Iritias 106002 722/Month 24 1.140 No No Iritias | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis 177006 358 / Month 12 1.870 No No Irritis Irritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No Irritis 106002 722 / Month 24 1.140 No No Irritis Irritis <td>Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intranocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Irritis Irritis 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 Irritis Irritis 10001 715 / Month 24 1.870 Irritis Irritis 102001 722 / Month 24 1.850 No No 106002 722 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 723 / Month 24 1.170 No No 124003 723 / Month 24 1.770 No No 124003 723 / Month 24 1.770 No No</td> <td>Treatment Group Positive
Subject ID Positive
Assay Intrunoreactivity
Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intitis 10001 717 / Month 24 1.850 No 102001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 12 1.630 No 122002 359 / Month 12 1.630 No 122002 723 / Month 24 1.170 No 124003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immation Treatment Group Subject ID Assay Assay Assay to g Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 104002 717 / Month 24 1.870 No No 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 719 / Month 24 1.140 No No 122002 722 / Month 24 1.130 No No No 122003 723 / Month 24 1.770 No No No 124003 722 / Month 24 1.770 No No No </td>
 | Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intranocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Irritis Irritis 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 Irritis Irritis 10001 715 / Month 24 1.870 Irritis Irritis 102001 722 / Month 24 1.850 No No 106002 722 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 723 / Month 24 1.170 No No 124003 723 / Month 24 1.770 No No 124003 723 / Month 24 1.770 No No | Treatment Group Positive
Subject ID Positive
Assay Intrunoreactivity
Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intitis 10001 717 / Month 24 1.850 No 102001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 12 1.630 No 122002 359 / Month 12 1.630 No 122002 723 / Month 24 1.170 No 124003 723 / Month 24 1.770 No 124003 723 / Month 24 1.770 No | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immation Treatment Group Subject ID Assay Assay Assay to g Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 104002 717 / Month 24 1.870 No No 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 719 / Month 24 1.140 No No 122002 722 / Month 24 1.130 No No No 122003 723 / Month 24 1.770 No No No 124003 722 / Month 24 1.770 No No No |
| Izeboli 1/4 / Month 6 1.700 No 357 / Month 12 2.040 No 141008 181 / Month 6 1.570 No 726 / Month 12 1.940 No 141013 715 / Month 24 2.340 Nitritis 143010 722 / Month 24 2.610 Vitritis 143010 722 / Month 24 2.610 Nio 152004 522 / Early Term. 0.752 No 153006 183 / Month 6 1.900 No 153005 183 / Month 24 2.610 Nio 153006 183 / Month 24 2.700 No 153006 183 / Month 24 1.900 No 15300 15300 No No 15300 15300 No No 15300 15300 1.530 No 159017 716 / Month 24 1.530 No 167002 717 / Month 24 1.250 No 167002 717 / Month 24 1.250 No 167002 717 / Month 24 1.250 No

 | Sham 537 / Month 6 1.700 No 141008 181 / Month 6 1.570 No 727 / Month 12 1.940 No 141013 715 / Month 24 2.340 Nitritis 143010 726 / Month 24 2.610 Vitritis 143010 722 / Month 24 2.610 Nitritis 152004 522 / Month 24 2.440 No 153006 183 / Month 6 1.900 No 153005 183 / Month 24 2.610 Nitritis 153006 183 / Month 24 2.610 No 153006 183 / Month 24 1.900 No 153005 183 / Month 24 1.900 No 153006 183 / Month 24 1.530 No 15300 718 / Month 24 1.530 No 159017 716 / Month 24 1.530 No 167002 717 / Month 24 1.250 No 158005 717 / Month 24 1.250 No

 | Izeboli 1.4 / Month 6 1.700 No 141008 181 / Month 24 2.040 No 141013 726 / Month 24 1.940 No 726 / Month 24 2.340 Vitritis 143010 722 / Month 24 2.610 Vitritis 152004 522 / Early Term. 0.752 No 153006 183 / Month 6 1.900 No 153006 183 / Month 24 2.610 Vitritis 153006 183 / Month 6 1.900 No 153006 183 / Month 24 2.070 No 153006 183 / Month 24 2.070 No 153006 183 / Month 24 1.900 No 153006 183 / Month 24 1.900 No 153006 183 / Month 24 1.900 No 158017 716 / Month 24 1.900 No 167002 717 / Month 24 1.230 No 188005 717 / Month 24 1.250 No 188005 717 / Month 24 1.250 No

 | Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No Diagnosis No 177006 358 / Month 12 2.800 Iritia No No Ranibizumab 0.5 mg 177/006 358 / Month 24 1.870 Iritis No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No No 104002 719 / Month 24 1.140 No No <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritiaocular 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 No 10001 717 / Month 24 0.922 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 722 / Month 24 1.130 No 122003 722 / Month 24 0.723 No 122003 722 / Month 24 1.630 No 122003 723 / Month 24 0.782 No</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis I Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No Io4002 719 / Month 24 1.140 No No I 106002 722 / Month 24 1.140 No No I<td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Sesay Assay Assay 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 24 0.922 No 104002 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122003 722 / Month 24 1.130 No 122003 723 / Month 24 1.630 No 122003 723 / Month 24 1.770 No</td><td>Treatment Group Positive Positive Intraocular
Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Sol / Month 12 2.770 No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 10001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122003 722 / Month 24 1.130 No 122003 722 / Month 24 1.130 No</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Sesay Assay Assay 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 24 0.922 No 104002 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122003 722 / Month 24 1.130 No 122003 723 / Month 24 1.630 No 122003 723 / Month 24 1.770 No</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Sesay Assay Assay 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 24 0.922 No 104002 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122003 722 / Month 24 1.130 No 122003 723 / Month 24 1.630 No 122003 723 / Month 24 1.770 No</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis I Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No Io4002 719 / Month 24 1.140 No No I 106002 722 / Month 24 1.140 No No I<td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis I Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No Io4002 719 / Month 24 1.140 No No I 106002 722 / Month 24 1.140 No No I<td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis I Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No Io4002 719 / Month 24 1.140 No No I 106002 722 / Month 24 1.140 No No I<td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No Diagnosis No 177006 358 / Month 12 2.800 Iritia No No Ranibizumab 0.5 mg 177/006 358 / Month 24 1.870 Iritis No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No No 104002 719 / Month 24 1.140 No No<td>Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 24 2.800 Intraocular No 177006 358/Month 24 1.850 No No 177/Month 24 1.850 No No No Ranibizumab 0.5 mg 102001 722/Month 24 1.140 No No 106002 719/Month 24 1.140 No No No No 122002 359/Month 24 1.130 No <td< td=""><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 12 2.800 Irritis Irritis Irritis Ranibizumab 0.5 mg 177/Month 24 0.922 No No Irritis 104002 719/Month 24 1.140 No No Irritis Irritis 122002 359/Month 24 1.130 No No Irritis Irritis 122002 719/Month 24 1.130 No No Irritis Irritis<</td><td>Treatment Group Positive
Subject ID Positive
Assay Intranoutiat
Intranoutiat Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intranocular 177006 358 / Month 12 1.870 Intitis 177006 358 / Month 12 1.870 Intitis 177/006 358 / Month 24 0.922 No 102001 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 722 / Month 24 1.130 No
 122003 722 / Month 24 1.630 No 122003 722 / Month 24 1.770 No</td><td>Treatment Group Ensitive
Subject ID Positive
Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initia Initia 177006 358 / Month 12 1.870 No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No 106002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.140 No No 122002 359 / Month 24 1.140 No No 122002 722 / Month 24 1.630 No No 122003 722 / Month 24 1.770 No No No 122003 722 / Month 24 1.630 No No</td></td<></td></td></td></td></td></td> | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritiaocular 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 No 10001 717 / Month 24 0.922 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 722 / Month 24 1.130 No 122003 722 / Month 24 0.723 No 122003 722 / Month 24 1.630 No 122003 723 / Month 24 0.782 No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis I Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No Io4002 719 / Month 24 1.140 No No I 106002 722 / Month 24 1.140 No No I
I I I I I <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Sesay Assay Assay 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 24 0.922 No 104002 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122003 722 / Month 24 1.130 No 122003 723 / Month 24 1.630 No 122003 723 / Month 24 1.770 No</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Sol / Month 12 2.770 No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 10001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122003 722 / Month 24 1.130 No 122003 722 / Month 24 1.130 No</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Sesay Assay Assay 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 24 0.922 No 104002 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122003 722 / Month 24 1.130 No 122003 723 / Month 24 1.630 No 122003 723 / Month 24 1.770 No</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Sesay Assay Assay 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 24 0.922 No 104002 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122003 722 / Month 24 1.130 No 122003 723 / Month 24 1.630 No 122003 723 / Month 24 1.770 No</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis I Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No Io4002 719 / Month 24 1.140 No No I 106002 722 / Month 24 1.140 No No I<td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis I Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No Io4002 719 / Month 24 1.140 No No I 106002 722 / Month 24 1.140 No No I<td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis I Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No Io4002 719 / Month 24 1.140 No No I 106002 722 / Month 24 1.140 No No I<td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No Diagnosis No 177006 358 / Month 12 2.800 Iritia No No Ranibizumab 0.5 mg 177/006 358 / Month 24 1.870 Iritis No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No No 104002 719 / Month 24 1.140 No No<td>Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 24 2.800 Intraocular No 177006 358/Month 24 1.850 No No 177/Month 24 1.850 No No No Ranibizumab 0.5 mg 102001 722/Month 24 1.140 No No 106002 719/Month 24 1.140 No No No No 122002 359/Month 24 1.130 No <td< td=""><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 12 2.800 Irritis Irritis Irritis Ranibizumab 0.5 mg 177/Month 24 0.922 No No Irritis 104002 719/Month 24
 1.140 No No Irritis Irritis 122002 359/Month 24 1.130 No No Irritis Irritis 122002 719/Month 24 1.130 No No Irritis Irritis<</td><td>Treatment Group Positive
Subject ID Positive
Assay Intranoutiat
Intranoutiat Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intranocular 177006 358 / Month 12 1.870 Intitis 177006 358 / Month 12 1.870 Intitis 177/006 358 / Month 24 0.922 No 102001 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 722 / Month 24 1.130 No 122003 722 / Month 24 1.630 No 122003 722 / Month 24 1.770 No</td><td>Treatment Group Ensitive
Subject ID Positive
Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initia Initia 177006 358 / Month 12 1.870 No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No 106002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.140 No No 122002 359 / Month 24 1.140 No No 122002 722 / Month 24 1.630 No No 122003 722 / Month 24 1.770 No No No 122003 722 / Month 24 1.630 No No</td></td<></td></td></td></td></td> | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Sesay Assay Assay 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 24 0.922 No 104002 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122003 722 / Month 24 1.130 No 122003 723 / Month 24 1.630 No 122003 723 / Month 24 1.770 No

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Sol / Month 12 2.770 No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 10001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122003 722 / Month 24 1.130 No 122003 722 / Month 24 1.130 No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Sesay Assay Assay 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 24 0.922 No 104002 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122003 722 / Month 24 1.130 No 122003 723 / Month 24 1.630 No 122003 723 / Month 24 1.770 No
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Sesay Assay Assay 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 24 0.922 No 104002 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122003 722 / Month 24 1.130 No 122003 723 / Month 24 1.630 No 122003 723 / Month 24 1.770 No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis I Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No Io4002 719 / Month 24 1.140 No No I 106002 722 / Month 24 1.140 No No I <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis I Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No Io4002 719 / Month 24 1.140 No No I 106002 722 / Month 24 1.140 No No I<td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis I Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No Io4002 719 / Month 24 1.140 No No I 106002 722 / Month 24 1.140 No No I<td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No Diagnosis No 177006 358 / Month 12 2.800 Iritia No No Ranibizumab 0.5 mg 177/006 358 / Month 24 1.870 Iritis No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No No 104002 719 / Month 24 1.140 No No<td>Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 24 2.800 Intraocular No 177006 358/Month 24 1.850 No No 177/Month 24 1.850 No No No Ranibizumab 0.5 mg 102001 722/Month 24 1.140 No No 106002 719/Month 24 1.140 No No No No 122002 359/Month 24 1.130 No <td< td=""><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 12 2.800 Irritis Irritis Irritis Ranibizumab 0.5 mg 177/Month 24 0.922 No No Irritis 104002 719/Month 24 1.140 No No Irritis Irritis 122002 359/Month 24 1.130 No No Irritis Irritis 122002 719/Month 24 1.130 No No Irritis Irritis<</td><td>Treatment Group Positive
Subject ID Positive
Assay Intranoutiat
Intranoutiat Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intranocular 177006 358 / Month 12 1.870 Intitis 177006 358 / Month 12 1.870 Intitis 177/006 358 / Month 24 0.922 No 102001 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 722 / Month 24 1.130 No 122003 722 / Month 24 1.630 No 122003 722 / Month 24 1.770 No</td><td>Treatment Group Ensitive
Subject ID Positive
Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initia Initia 177006 358 / Month 12 1.870 No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No 106002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.140 No No 122002 359 / Month 24 1.140 No No 122002 722 / Month 24 1.630 No No 122003 722 / Month 24 1.770 No No No 122003 722 / Month 24 1.630 No No</td></td<></td></td></td></td>
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis I Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No Io4002 719 / Month 24 1.140 No No I 106002 722 / Month 24 1.140 No No I <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis I Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No Io4002 719 / Month 24 1.140 No No I 106002 722 / Month 24 1.140 No No I<td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No Diagnosis No 177006 358 / Month 12 2.800 Iritia No No Ranibizumab 0.5 mg 177/006 358 / Month 24 1.870 Iritis No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No No 104002 719 / Month 24 1.140 No No<td>Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 24 2.800 Intraocular No 177006 358/Month 24 1.850 No No 177/Month 24 1.850 No No No Ranibizumab 0.5 mg 102001 722/Month 24 1.140 No No 106002 719/Month 24 1.140 No No No No 122002 359/Month 24 1.130 No <td< td=""><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 12 2.800 Irritis Irritis Irritis Ranibizumab 0.5 mg 177/Month 24 0.922 No No Irritis 104002 719/Month 24 1.140 No No Irritis Irritis 122002 359/Month 24 1.130 No No Irritis Irritis 122002 719/Month 24 1.130 No No Irritis Irritis<</td><td>Treatment Group Positive
Subject ID Positive
Assay Intranoutiat
Intranoutiat Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intranocular 177006 358 / Month 12 1.870 Intitis 177006 358 / Month 12 1.870 Intitis 177/006 358 / Month 24 0.922 No 102001 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 722 / Month 24 1.130 No 122003 722 / Month 24 1.630 No 122003 722 / Month 24 1.770 No</td><td>Treatment Group Ensitive
Subject ID Positive
Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initia Initia 177006 358 / Month 12 1.870 No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No 106002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.140 No No 122002 359 / Month 24 1.140 No No 122002 722 / Month 24 1.630 No No 122003 722 / Month 24 1.770 No No No 122003 722 / Month 24 1.630 No No</td></td<></td></td></td>
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis I Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No Io4002 719 / Month 24 1.140 No No I 106002 722 / Month 24 1.140 No No I <td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No Diagnosis No 177006 358 / Month 12 2.800 Iritia No No Ranibizumab 0.5 mg 177/006 358 / Month 24 1.870 Iritis No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No No 104002 719 / Month 24 1.140 No No<td>Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 24 2.800 Intraocular No 177006 358/Month 24 1.850 No No 177/Month 24 1.850 No No No Ranibizumab 0.5 mg 102001 722/Month 24 1.140 No No 106002 719/Month 24 1.140 No No No No 122002 359/Month 24 1.130 No <td< td=""><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 12 2.800 Irritis Irritis Irritis Ranibizumab 0.5 mg 177/Month 24 0.922 No No Irritis 104002 719/Month 24 1.140 No No Irritis Irritis 122002 359/Month 24 1.130 No No Irritis Irritis 122002 719/Month 24 1.130 No No Irritis Irritis<</td><td>Treatment Group Positive
Subject ID Positive
Assay Intranoutiat
Intranoutiat Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intranocular 177006 358 / Month 12 1.870 Intitis 177006 358 / Month 12 1.870 Intitis 177/006 358 / Month 24 0.922 No 102001 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 722 / Month 24 1.130 No 122003 722 / Month 24 1.630 No 122003 722 / Month 24 1.770 No</td><td>Treatment Group Ensitive
Subject ID Positive
Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initia Initia 177006 358 / Month 12 1.870 No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No 106002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.140 No No 122002 359 / Month 24 1.140 No No 122002 722 / Month 24 1.630 No No 122003 722 / Month 24 1.770 No No No 122003 722 / Month 24 1.630 No No</td></td<></td></td> | Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No Diagnosis No 177006 358
/ Month 12 2.800 Iritia No No Ranibizumab 0.5 mg 177/006 358 / Month 24 1.870 Iritis No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No No 104002 719 / Month 24 1.140 No No <td>Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 24 2.800 Intraocular No 177006 358/Month 24 1.850 No No 177/Month 24 1.850 No No No Ranibizumab 0.5 mg 102001 722/Month 24 1.140 No No 106002 719/Month 24 1.140 No No No No 122002 359/Month 24 1.130 No <td< td=""><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 12 2.800 Irritis Irritis Irritis Ranibizumab 0.5 mg 177/Month 24 0.922 No No Irritis 104002 719/Month 24 1.140 No No Irritis Irritis 122002 359/Month 24 1.130 No No Irritis Irritis 122002 719/Month 24 1.130 No No Irritis Irritis<</td><td>Treatment Group Positive
Subject ID Positive
Assay Intranoutiat
Intranoutiat Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intranocular 177006 358 / Month 12 1.870 Intitis 177006 358 / Month 12 1.870 Intitis 177/006 358 / Month 24 0.922 No 102001 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 722 / Month 24 1.130 No 122003 722 / Month 24 1.630 No 122003 722 / Month 24 1.770 No</td><td>Treatment Group Ensitive
Subject ID Positive
Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initia Initia 177006 358 / Month 12 1.870 No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No 106002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.140 No No 122002 359 / Month 24 1.140 No No 122002 722 / Month 24 1.630 No No 122003 722 / Month 24 1.770 No No No 122003 722 / Month 24 1.630 No No</td></td<></td> | Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No
 | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 24 2.800 Intraocular No 177006 358/Month 24 1.850 No No 177/Month 24 1.850 No No No Ranibizumab 0.5 mg 102001 722/Month 24 1.140 No No 106002 719/Month 24 1.140 No No No No 122002 359/Month 24 1.130 No No <td< td=""><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 12 2.800 Irritis Irritis Irritis Ranibizumab 0.5 mg 177/Month 24 0.922 No No Irritis 104002 719/Month 24 1.140 No No Irritis Irritis 122002 359/Month 24 1.130 No No Irritis Irritis 122002 719/Month 24 1.130 No No Irritis Irritis<</td><td>Treatment Group Positive
Subject ID Positive
Assay Intranoutiat
Intranoutiat Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intranocular 177006 358 / Month 12 1.870 Intitis 177006 358 / Month 12 1.870 Intitis 177/006 358 / Month 24 0.922 No 102001 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 722 / Month 24 1.130 No 122003 722 / Month 24 1.630 No 122003 722 / Month 24 1.770 No</td><td>Treatment Group Ensitive
Subject ID Positive
Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initia Initia 177006 358 / Month 12 1.870 No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No 106002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.140 No No 122002 359 / Month 24 1.140 No No 122002 722 / Month 24 1.630 No No 122003 722 / Month 24 1.770 No No No 122003 722 / Month 24 1.630 No No</td></td<> | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 12 2.800 Irritis Irritis Irritis Ranibizumab 0.5 mg 177/Month 24 0.922 No No Irritis 104002 719/Month 24 1.140 No No Irritis Irritis 122002 359/Month 24 1.130 No No Irritis Irritis 122002 719/Month 24 1.130 No No Irritis Irritis<
 | Treatment Group Positive
Subject ID Positive
Assay Intranoutiat
Intranoutiat Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intranocular 177006 358 / Month 12 1.870 Intitis 177006 358 / Month 12 1.870 Intitis 177/006 358 / Month 24 0.922 No 102001 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 722 / Month 24 1.130 No 122003 722 / Month 24 1.630 No 122003 722 / Month 24 1.770 No | Treatment Group Ensitive
Subject ID Positive
Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initia Initia 177006 358 / Month 12 1.870 No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No 106002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.140 No No 122002 359 / Month 24 1.140 No No 122002 722 / Month 24 1.630 No No 122003 722 / Month 24 1.770 No No No 122003 722 / Month 24 1.630 No |
| I26001 174 /Month 6 1.700 No 357 /Month 12 2.040 No 727 /Month 24 1.480 No 141008 181 /Month 6 1.570 No 726 /Month 24 1.940 No 726 /Month 24 2.340 Nintiis 141013 715 /Month 24 2.610 Nintiis 143010 722 /Month 24 2.610 Nintiis 152004 522 /Early Term. 0.752 , No 153006 183 /Month 6 1.900 No 153006 183 /Month 24 2.610 Nino 153006 183 /Month 24 2.070 No 153006 183 /Month 24 0.780 No 153007 716 /Month 24 0.780 No 167002 $717/Mont 24$ 0.780 No 167002 $717/Mont 24$ 0.780 No 167002 $717/Mont 24$ 1.250 No 167002 $717/Mont 2$

 | I26001 174 /Month 6 1.700 Nio 357 /Month 12 2.040 Nio 357 /Month 24 1.480 Nio 141008 181 /Month 6 1.570 Nio 362 /Month 24 1.940 Nio 726 /Month 24 2.340 Vitritis 141013 715 /Month 24 2.610 Vitritis 143010 722 /Month 24 2.610 Nio 152004 522 /Early Term. 0.752 ,Nio 153006 183 /Month 24 2.610 Nio 153006 183 /Month 24 2.740 Nio 153006 183 /Month 24 2.070 Nio 153006 $183/Month 24$ 0.780 Nio 153006 $183/Month 24$ 0.780 Nio 153006 $183/Month 24$ 1.900 Nio 153006 $183/Month 24$ 0.780 Nio 153006 $183/Month 24$ 0.780 Nio 159017 $716/Month 24$ 0.780 Nio 167002 $717/Mont 24$ 1.250 Nio 188005 $717/Month 24$ 1.250 Nio 188005 $717/Month 24$ 1.250 Nio 188005 $717/Month 24$ 1.250 Nio 11230 $NioNioNio11230NioNioNio11230NioNioNio1121111111111111111111111111111111111$

 | I26001 174 /Month 6 1.700 No 357 /Month 12 2.040 No 357 /Month 24 1.480 No 141008 181 /Month 6 1.570 No 726 /Month 24 2.340 No 726 /Month 24 2.340 No 143010 722 /Month 24 2.400 No 152004 522 /Early Term. 0.752 ,No 153006 183 /Month 24 2.400 No 153006 183 /Month 24 2.070 No 153006 183 /Month 24 2.070 No 153006 183 /Month 24 1.530 No 153006 183 /Month 24 1.530 No 153006 183 /Month 24 1.530 No 158017 716 /Month 24 1.200 No 167002 717 /Month 24 1.230 No 188005 717 /Month 24 1.230 No 188005 717 /Month 24 1.250 No 11230 1.250 1.1230 No 11230 1.1230 1.1230 $1.11111111111111111111111111111111111$

 | Treatment Group Fositive Fositive Immunoreactivity

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 170010 365 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177001 717 / Month 24 1.870 Intris 102001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 106002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 10001 723 / Month 24 1.170 No 1001 723 / Month 24 1.770 No

 | Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Intris No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 106002 719 / Month 24 1.360 No No No No 102001 722 / Month 24 1.140 No No No No 106002 722 / Month 24 1.130 No No </td <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Sol Month 12 2.770 No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 12 1.870 Intitis No Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No 106002 719 / Month 24 1.140 No No No No 106002 722 / Month 24 1.130 No No No No 122002 359 / Month 12 1.630 No No No No 10001 722 / Month 24 1.1700 No No No No 102001 723 / Month 24 1.7700 No No No No</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Irritis Irritis 177006 358 / Month 12 1.870 Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 106002 719 / Month 24 1.850 No No 102001 722 / Month 24 1.140 No No 102002 719 / Month 24 1.140 No No 102002 722 / Month 24 1.130 No No 102002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 10001 723 / Month 24 1.770 No No</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Sol Month 12 2.770 No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 12 1.870 Intitis No Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No 106002 719 / Month 24 1.140 No No No No 106002 722 / Month 24 1.130 No No No No 122002 359 / Month 12 1.630 No No No No 10001 722 / Month 24 1.1700 No No No No 102001 723 / Month 24 1.7700 No No No No</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Sol Month 12 2.770 No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 12 1.870 Intitis No Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No 106002 719 / Month 24 1.140 No No No No 106002 722 / Month 24 1.130 No No No No 122002 359 / Month 12 1.630 No No No No 10001 722 / Month 24 1.1700 No No No No 102001 723 / Month 24 1.7700 No No No No</td> <td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Intris No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 106002 719 / Month 24 1.360 No No No No 102001 722 / Month 24 1.140 No No No No 106002 722 / Month 24 1.130 No No<!--</td--><td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Intris No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 106002 719 / Month 24 1.360 No No No No 102001 722 / Month 24 1.140 No No No No 106002 722 / Month 24 1.130 No No<!--</td--><td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Intris No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 106002 719 / Month 24 1.360 No No No No 102001 722 / Month 24 1.140 No No No No 106002 722 / Month 24 1.130 No No<!--</td--><td>Treatment Group Fositive Fositive Immunoreactivity Immunoreactivity</td><td>Treatment Group Positive Formunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immarition Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 24 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No 106002 719 / Month 24 1.140 No No No No 106002 722 / Month 24 1.130 No No No No No 102001 722 / Month 24 1.130 No N</td><td>Treatment Group Positive
Intrancentivity Immunoreactivity Intrancoular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Intraocular No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No No 106002 722 / Month 24 1.130 No No No 122002 359 / Month 24 1.130
No No No 122002 359 / Month 12 1.630 No No No 104002 713 / Month 24 1.1770 No No No</td><td>Treatment Group Positive
Innunoreactivity Immunoreactivity Innamation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 Infammation 177006 358 / Month 12 1.870 Infia 177006 358 / Month 24 1.870 Infia 177006 358 / Month 24 1.870 Infia 102001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 359 / Month 24 1.1700 No</td><td>Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intranocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 No 177006 358 / Month 12 1.870 Intits 177006 358 / Month 12 1.870 Intits 177006 358 / Month 12 1.870 Intits 10001 717 / Month 24 1.850 No 102001 722 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 359 / Month 24 1.130 No 122002 359 / Month 24 1.1700 No 122002 359 / Month 24 1.7700 No</td><td>Treatment Group Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.770 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 104002 717 / Month 24 1.870 No No 102001 722 / Month 24 1.140 No No 122002 359 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122003 359 / Month 24 1.770 No No 122003 359 / Month 24 1.770 No No</td></td></td></td> | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Sol Month 12 2.770 No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 12 1.870 Intitis No Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No 106002 719 / Month 24 1.140 No No No No 106002 722 / Month 24 1.130 No No No No 122002 359 / Month 12 1.630 No No No No 10001 722 / Month 24 1.1700 No No No No 102001 723 / Month 24 1.7700 No No No No

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Irritis Irritis 177006 358 / Month 12 1.870 Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 106002 719 / Month 24 1.850 No No 102001 722 / Month 24 1.140 No No 102002 719 / Month 24 1.140 No No 102002 722 / Month 24 1.130 No No 102002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 10001 723 / Month 24 1.770 No No

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Sol Month 12 2.770 No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 12 1.870 Intitis No Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No 106002 719 / Month 24 1.140 No No No No 106002 722 / Month 24 1.130 No No No No 122002 359 / Month 12 1.630 No No No No 10001 722 / Month 24 1.1700 No No No No 102001 723 / Month 24 1.7700 No No No No
 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Sol Month 12 2.770 No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Intris No 177006 358 / Month 12 1.870 Intitis No Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No 106002 719 / Month 24 1.140 No No No No 106002 722 / Month 24 1.130 No No No No 122002 359 / Month 12 1.630 No No No No 10001 722 / Month 24 1.1700 No No No No 102001 723 / Month 24 1.7700 No No No No

 | Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Intris No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 106002 719 / Month 24 1.360 No No No No 102001 722 / Month 24 1.140 No No No No 106002 722 / Month 24 1.130 No No </td <td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Intris No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 106002 719 / Month 24 1.360 No No No No 102001 722 / Month 24 1.140 No No No No 106002 722 / Month 24 1.130 No No<!--</td--><td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Intris No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 106002 719 / Month 24 1.360 No No No No 102001 722 / Month 24 1.140 No No No No 106002 722 / Month 24 1.130 No No<!--</td--><td>Treatment Group Fositive Fositive Immunoreactivity Immunoreactivity</td><td>Treatment Group Positive Formunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immarition Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 24 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No 106002 719 / Month 24 1.140 No No No No 106002 722 / Month 24 1.130 No No No No No 102001 722 / Month 24 1.130 No N</td><td>Treatment Group Positive
Intrancentivity Immunoreactivity Intrancoular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Intraocular No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No No 106002 722 / Month 24 1.130 No No No 122002 359 / Month 24 1.130 No No No 122002 359 / Month 12 1.630 No No No 104002 713 / Month 24 1.1770 No No No</td><td>Treatment Group Positive
Innunoreactivity Immunoreactivity Innamation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 Infammation 177006 358 / Month 12 1.870 Infia 177006 358 / Month 24 1.870 Infia 177006 358 / Month 24 1.870 Infia 102001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 359 / Month 24 1.1700 No</td><td>Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intranocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 No 177006 358 / Month 12 1.870 Intits 177006 358 / Month 12 1.870 Intits 177006 358 / Month 12 1.870 Intits 10001 717 / Month 24 1.850 No 102001 722 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 359 / Month 24 1.130 No 122002 359 / Month 24 1.1700 No 122002 359 / Month 24 1.7700 No</td><td>Treatment Group Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.770 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 104002 717 / Month 24 1.870 No No 102001 722 / Month 24 1.140 No No 122002 359 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122003 359 / Month 24 1.770 No No 122003 359 / Month 24 1.770 No No</td></td></td>
 | Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Intris No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 106002 719 / Month 24 1.360 No No No No 102001 722 / Month 24 1.140 No No No No 106002 722 / Month 24 1.130 No No </td <td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Intris No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 106002 719 / Month 24 1.360 No No No No 102001 722 / Month 24 1.140 No No No No 106002 722 / Month 24 1.130 No No<!--</td--><td>Treatment Group Fositive Fositive Immunoreactivity Immunoreactivity</td><td>Treatment Group Positive Formunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immarition Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 24 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No 106002 719 / Month 24 1.140 No No No No 106002 722 / Month 24 1.130 No No No No No 102001 722 / Month 24 1.130 No N</td><td>Treatment Group Positive
Intrancentivity Immunoreactivity Intrancoular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Intraocular No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No No 106002 722 / Month 24 1.130 No No No 122002 359 / Month 24 1.130 No No No 122002 359 / Month 12 1.630 No No No 104002 713 / Month 24 1.1770 No No No</td><td>Treatment Group Positive
Innunoreactivity Immunoreactivity Innamation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 Infammation 177006 358 / Month 12 1.870 Infia 177006 358 / Month 24 1.870 Infia 177006 358 / Month 24 1.870 Infia 102001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 359 / Month 24 1.1700 No</td><td>Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intranocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 No 177006 358 / Month 12 1.870 Intits 177006 358 / Month 12 1.870 Intits 177006 358 / Month 12 1.870 Intits 10001 717 / Month 24 1.850 No 102001 722 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 359 / Month 24 1.130 No 122002 359 / Month 24 1.1700 No 122002 359 / Month 24 1.7700 No</td><td>Treatment Group Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.770 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 104002 717 / Month 24 1.870 No No 102001 722 / Month 24 1.140 No No 122002 359 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122003 359 / Month 24 1.770 No No 122003 359 / Month 24 1.770 No No</td></td>
 | Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Intris No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 106002 719 / Month 24 1.360 No No No No 102001 722 / Month 24 1.140 No No No No 106002 722 / Month 24 1.130 No No </td <td>Treatment Group Fositive Fositive Immunoreactivity Immunoreactivity</td> <td>Treatment Group Positive Formunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immarition Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 24 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No 106002 719 / Month 24 1.140 No No No No 106002 722 / Month 24 1.130 No No No No No 102001 722 / Month 24 1.130 No N</td> <td>Treatment Group Positive
Intrancentivity Immunoreactivity Intrancoular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Intraocular No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No No 106002 722 / Month 24 1.130 No No No 122002 359 / Month 24 1.130 No No No 122002 359 / Month 12 1.630 No No No 104002 713 / Month 24 1.1770 No No No</td> <td>Treatment Group Positive
Innunoreactivity Immunoreactivity Innamation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 Infammation 177006 358 / Month 12 1.870 Infia 177006 358 / Month 24 1.870 Infia 177006 358 / Month 24 1.870 Infia 102001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 359 / Month 24 1.1700 No</td> <td>Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intranocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 No 177006 358 / Month 12 1.870 Intits 177006 358 / Month 12 1.870 Intits 177006 358 / Month 12 1.870 Intits 10001 717 / Month 24 1.850 No 102001 722 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 359 / Month 24 1.130 No 122002 359 / Month 24 1.1700 No 122002 359 / Month 24 1.7700 No</td> <td>Treatment Group Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.770 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 104002 717 / Month 24 1.870 No No 102001 722 / Month 24 1.140 No No 122002 359 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122003 359 / Month 24 1.770 No No 122003 359 / Month 24 1.770 No No</td>
 | Treatment Group Fositive Fositive Immunoreactivity | Treatment Group Positive Formunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immarition Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 24 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No 106002 719 / Month 24 1.140 No No No No 106002 722 / Month 24 1.130 No No No No No 102001 722 / Month 24 1.130 No N
 | Treatment Group Positive
Intrancentivity Immunoreactivity Intrancoular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Intraocular No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No No 106002 722 / Month 24 1.130 No No No 122002 359 / Month 24 1.130 No No No 122002 359 / Month 12 1.630 No No No 104002 713 / Month 24 1.1770 No No No
 | Treatment Group Positive
Innunoreactivity Immunoreactivity Innamation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 Infammation 177006 358 / Month 12 1.870 Infia 177006 358 / Month 24 1.870 Infia 177006 358 / Month 24 1.870 Infia 102001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 359 / Month 24 1.1700 No | Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intranocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 No 177006 358 / Month 12 1.870 Intits 177006 358 / Month 12 1.870 Intits 177006 358 / Month 12 1.870 Intits 10001 717 / Month 24 1.850 No 102001 722 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 359 / Month 24 1.130 No 122002 359 / Month 24 1.1700 No 122002 359 / Month 24 1.7700 No | Treatment Group Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.770 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 104002 717 / Month 24 1.870 No No 102001 722 / Month 24 1.140 No No 122002 359 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122003 359 / Month 24 1.770 No No 122003 359 / Month 24 1.770 No No |
| Iz6001 174 / Month 6 1.700 No 126001 174 / Month 24 1.700 No 357 / Month 24 2.040 No 141008 181 / Month 24 1.570 No 141013 725 / Month 24 1.940 No 725 / Month 24 2.040 No 143010 722 / Month 24 2.610 Vitritis 143010 722 / Month 24 2.610 Nic 153006 153004 522 / Early Term. 0.752, No 153006 153006 183 / Month 24 2.610 Nic 153006 183 / Month 24 2.610 No No 153006 183 / Month 24 2.610 No No 153007 153006 15300 No No 153006 15300 15300 No No 153007 717 / Month 24 1.530 No No 167002 717 / Month 24 1.230 No No 15300 717 / Month 24 1.250 No No 15300 717 / Month 24 1.250 No No

 | Iz6001 174 / Month 6 1.700 No 126001 174 / Month 24 1.700 No 141008 181 / Month 24 1.800 No 141008 181 / Month 24 1.570 No 141013 715 / Month 24 1.940 No 726 / Month 24 2.610 Vitritis 143010 725 / Month 24 2.610 Nicritis 153004 522 / Early Term. 0.752 , No 153005 183 / Month 24 2.610 Nic 153006 153006 1.900 No 153006 183 / Month 24 2.610 Nic 153006 183 / Month 24 2.610 No 153007 155004 1.530 No 167002 717 / Month 24 1.530 No 167002 717 / Month 24 1.230 No 167002 717 / Month 24 1.250 No 188005 717 / Month 24 1.250 No 53401 -7/ Screening 2.520 Vitritis

 | I26001 114/Month 6 1.700 No 126001 114/Month 6 1.700 No 357/Month 12 2.040 No 141008 181/Month 6 1.570 No 141003 357/Month 24 1.480 No 725/Month 24 2.040 No 141013 715/Month 24 2.440 No 143010 722/Month 24 2.440 No 152004 522/Early Term. 0.752, No 152004 522/Early Term. 0.752, No 153006 183/Month 24 2.610 Nitritis 153006 183/Month 24 2.070 No 153006 183/Month 24 0.752, No 153006 183/Month 24 0.730 No 153007 716/Month 24 0.730 No 167002 717/Month 24 1.230 No 168005 717/Month 24 1.250 No 188005 717/Month 24 1.250 No 188005 717/Month 24 1.250 No

 | Treatment Group Fositive
Subject ID Fositive
Assay Immunoreactivity
Assay Log Titer Immation
Diagnosis 170010 365/Month 12 2.770 No 177006 358/Month 12 2.800 Iritis 177006 358/Month 12 1.870 Iritis 177006 358/Month 24 1.870 Iritis 177/006 358/Month 24 1.850 No 102001 717/Month 24 1.850 No 104002 719/Month 24 1.140 No 106002 722/Month 24 1.130 No 122002 359/Month 24 1.130 No 122002 359/Month 24 1.130 No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12
 1.870 Intraocular No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No Diagnosis 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intraocular 177 / Month 24 1.870 Intris Intris 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 122002 359 / Month 24 1.130 No 122002 359 / Month 24 1.130 No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Intraocular Diagnosis Intraocular 177006 358 / Month 12 1.870 No No No Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No Intraocular 106002 719 / Month 24 1.1400 No No Intraocular No Intraocular 106002 722 / Month 24 1.1400 No No No Intraocular No Intraocular No No No No Intraocular No No Intraocular No No No No Intraocular No No Intraocular No No No No Intraocular No No Intritis No No
 | Treatment Group Eventive Financeactivity Intraocular Treatment Group Subject ID Sasay
Assay Assay Intraocular Treatment Group Subject ID Sub Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intraocular Diagnosis 177006 358 / Month 12 1.870 No No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No No 106002 719 / Month 24 1.140 No No No No 122002 359 / Month 12 1.130 No No No No 122002 359 / Month 24 1.130 No
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Intraocular Diagnosis Intraocular 177006 358 / Month 12 1.870 No No No Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No Intraocular 106002 719 / Month 24 1.1400 No No Intraocular No Intraocular 106002 722 / Month 24 1.1400 No No No Intraocular No Intraocular No No No No Intraocular No No Intraocular No No No No Intraocular No No Intraocular No No No No Intraocular No No Intritis No No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Intraocular Diagnosis Intraocular 177006 358 / Month 12 1.870 No No No Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No Intraocular 106002 719 / Month 24 1.1400 No No Intraocular No Intraocular 106002 722 / Month 24 1.1400 No No No Intraocular No Intraocular No No No No Intraocular No No Intraocular No No No No Intraocular No No Intraocular No No No No Intraocular No No Intritis No No
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular Subject ID Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No 122002 359 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.130 No No
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular Subject ID Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No 122002 359 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.130 No No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular Subject ID Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No 122002 359 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.130 No No
 | Treatment Group Fositive
Subject ID Fositive
Assay Immunoreactivity
Assay Log Titer Immation
Diagnosis 170010 365/Month 12 2.770 No 177006 358/Month 12 2.800 Iritis 177006 358/Month 12 1.870 Iritis 177006 358/Month 24 1.870 Iritis 177/006 358/Month 24 1.850 No 102001 717/Month 24 1.850 No 104002 719/Month 24 1.140 No 106002 722/Month 24 1.130 No 122002 359/Month 24 1.130 No 122002 359/Month 24 1.130 No | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365/Month 12 2.770 No No No
 No 170010 365/Month 12 2.800 Inflammation No | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 12 1.870 Iritis Iritis 177006 358/Month 24 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 712/Month 24 1.850 No 102001 722/Month 24 1.140 No Iritis 106002 722/Month 24 1.130 No Iritis 122002 359/Month 24 1.130 No No 122002 359/Month 24 1.130 No No
 | Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intranocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No 102001 717 / Month 24 1.870 Irritis Irritis 102001 722 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.770 No No | Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intranocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Irritis 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis 102001 717 / Month 24 1.870 Irritis 102001 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 359 / Month 12 1.630 No | Treatment Group Event Positive
Subject ID Positive
Assay Intraocular
Assay Intraocular
Assay Log Titer Intraocular
Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 No No 177006 358 / Month 12 1.870 No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 106002 719 / Month 24 1.140 No No 106002 722 / Month 12 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No
 |
| I24003 722/Month 24 0.782 No 126001 174/Month 6 1.700 No 357/Month 12 2.040 No 727/Month 24 1.480 No 726/Month 24 1.570 No 141013 715/Month 24 2.340 Vitritis 143010 722/Month 24 2.440 No 152004 522/Early Term 0.752, No 152006 183/Month 24 2.440 No 153006 183/Month 24 2.440 No 153006 183/Month 24 2.070 No 153006 183/Month 24 2.070 No 167002 716/Month 24 2.070 No 167002 717/Month 24 1.530 No 167002 717/Month 24 1.250 No

 | I24003 722/Month 24 0.782 No 126001 174/Month 6 1.700 No 126001 174/Month 24 1.700 No 127/Month 24 1.480 No 141008 181/Month 24 1.570 No 141013 715/Month 24 2.340 Vitritis 143010 722/Month 24 2.610 Vitritis 143010 722/Month 24 2.610 Vitritis 152004 522/Early Term 0.752 No 153006 183/Month 24 2.610 Nin 153006 183/Month 24 2.610 Nin 153006 183/Month 24 2.070 No 153007 183/Month 24 2.070 No 153007 183/Month 24 1.530 No 167002 717/Mont 24 1.230 No 167002 717/Mont 24 1.230 No 188005 717/Mont 24 1.230 No 534001 -7/IScreening 2.520 Vitritis

 | I24003 722/ Month 24 0.782 No 126001 174 / Month 6 1.700 No 357 / Month 12 2.040 No 141008 181 / Month 6 1.570 No 141013 726 / Month 24 2.340 Nintits 143010 722 / Month 24 2.340 Nintits 143010 722 / Month 24 2.440 No 152004 522 / Early Term 0.752 / No No 153005 183 / Month 24 2.610 Nintits 153005 183 / Month 24 2.070 No 153005 183 / Month 24 2.070 No 153005 183 / Month 24 1.530 No 153005 183 / Month 24 1.230 No 153005 116 / Month 24 0.780 No 15300 717 / Mont 24 1.230 No 167002 717 / Month 24 1.250 No 188005 717 / Month 24 1.250 No

 | Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Formunoreactivity Immunoreactivity Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 I.ritis No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No No 106002 722 / Month 24 1.140 No No No 1122002 359 / Month 24 1.130 No N

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No 104002 722 / Month 24 1.140 No No 102001 722 / Month 24 1.140 No No 104002 723 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 177006 358 / Month 24 1.870 Intris 100001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 102001 723 / Month 24 1.170 No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 104002 722 / Month 24 1.140 No 106002 723 / Month 24 1.130 No 122002 359 / Month 12 1.630 No
 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group
 Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 104002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 102001 723 / Month 24 1.170 No
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 104002 722 / Month 24 1.140 No 106002 723 / Month 24 1.130 No 122002 359 / Month 12 1.630 No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 104002 722 / Month 24 1.140 No 106002 723 / Month 24 1.130 No 122002 359 / Month 12 1.630 No
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 177006 358 / Month 24 1.870 Intris 100001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 102001 723 / Month 24 1.170 No
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 177006 358 / Month 24 1.870 Intris 100001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 102001 723 / Month 24 1.170 No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 177006 358 / Month 24 1.870 Intris 100001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 102001 723 / Month 24 1.170 No
 | Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Formunoreactivity Immunoreactivity Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 I.ritis No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No No 106002 722 / Month 24 1.140 No No No 1122002 359 / Month 24 1.130 No N | Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 177006
 358 / Month 12 1.870 Iritis Iritis 177001 717 / Month 24 1.870 Iritis Iritis 104002 717 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No 104002 723 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 24 1.700 No No | Treatment Group Positive
Intraocular Positive
Intraocular Intrancoular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 170010 365/Month 12 2.800 No No 177006 358/Month 12 1.870 Irritis Irritis Ranibizumab 0.5 mg 102001 717/Month 24 1.850 No 104002 719/Month 24 1.140 No No 106002 722/Month 24 1.140 No No 102001 723/Month 24 1.130 No No 102002 723/Month 24 1.130 No No 122002 359/Month 12 1.630 No No No
 | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 170010 365/Month 12 2.800 No No 177006 358/Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717/Month 24 1.850 No 104002 719/Month 24 1.140 No No 1.130 No 102001 722/Month 24 1.140 No No 1.122002 359/Month 24 1.130 No 122002 359/Month 12 1.630 No | Treatment Group Positive
Innunoreactivity Innunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 12 2.800 Inflammation No 177006 358/Month 24 2.800 Inflammation Ranibizumab 0.5 mg 102001 717/Month 24 1.850 No 104002 719/Month 24 1.140 No No 1.130 No 106002 722/Month 24 1.130 No No 1.122002 359/Month 24 1.130 No 122002 359/Month 24 1.130 No | Treatment Group Evention From Subject ID Positive frammoreactivity frammoreactivity frammation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Initraocular 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 Initis 177006 358 / Month 12 1.870 No 104002 717 / Month 24 0.922 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 106002 723 / Month 24 1.130 No 122002 359 / Month 12 1.630 No 122002 359 / Month 24 1.130 No
 |
| I24003 722 / Month 24 0.782 No 126001 174 / Month 6 1700 No 126001 174 / Month 6 1700 No 727 / Month 24 1480 No No 727 / Month 24 1480 No No 141008 181 / Month 6 1.570 No 726 / Month 24 2.400 No No 143010 725 / Month 24 2.410 No 143010 722 / Month 24 2.610 Vitritis 143010 722 / Month 24 2.610 No 153006 183 / Month 24 2.610 No 153005 183 / Month 24 2.610 No 153005 183 / Month 24 2.070 No 153005 183 / Month 24 0.780 No 153005 183 / Month 24 0.780 No 153005 183 / Month 24 0.780 No 153005 188005 717 / Mont 24 1.000 167002

 | I24003 722/Month 24 0.782 No 126001 174/Month 6 1.700 No 357/Month 12 2.040 No No 126001 727/Month 24 1.480 No No 727/Month 12 1.940 No No No 141008 181/Month 24 1.940 No No 726/Month 12 1.940 No No No 143010 722/Month 24 2.340 Nitritis No 143010 722/Month 24 2.610 No No 153006 183/Month 24 2.610 No No 153005 183/Month 24 2.610 No No 153006 183/Month 24 2.610 No No 153005 183/Month 24 2.610 No No 153006 183/Month 24 2.610 No No 153005 18/Month 24 2.610 No No 153005 18/Month 24

 | I24003 722/Month 24 0.782 No 126001 174/Month 6 1.700 No 357/Month 12 2.040 No 357/Month 12 1.480 No 126001 174/Month 6 1.570 No 141008 181/Month 6 1.570 No 362/Month 12 1.940 No No 141003 715/Month 24 2.340 No 143010 722/Month 24 2.440 No 153006 183/Month 6 1.940 No 153006 183/Month 6 1.900 No 153006 183/Month 24 2.610 No 153006 183/Month 24 2.670 No 153006 183/Month 24 2.670 No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Fromtunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 170010 365 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177001 717 / Month 24 1.870 Intris 102001 722 / Month 24 1.850 No 102001 722 / Month 24 1.140 No 106002 722 / Month 12 1.140 No 106002 722 / Month 12 1.130 No 122002 359 / Month 12 1.630 No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 102001 722 / Month 24 1.850
 No No No No 106002 722 / Month 24 1.140 No No No No 122002 359 / Month 12 1.630 No

 | Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 102001 717 / Month 24 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No

 | Treatment Group Event Figure Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular No 177006 358 / Month 12 1.870 Intris Intris 10001 717 / Month 24 1.870 Intris Intris 102001 722 / Month 24 1.850 No No Intris 102002 722 / Month 24 1.140 No No Intris Intris <td>Treatment Group Subject ID Positive
fmmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Iritis 106002 719 / Month 24 1.140 No No 1060 102001 722 / Month 12 1.140 No No No 122002 359 / Month 12 1.130 No No No 122002 359 / Month 12 1.630 No No No</td> <td>Treatment Group Event Figure Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular No 177006 358 / Month 12 1.870 Intris Intris 10001 717 / Month 24 1.870 Intris Intris 102001 722 / Month 24 1.850 No No Intris 102002 722 / Month 24 1.140 No No Intris Intris<td>Treatment Group Event Figure Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular No 177006 358 / Month 12 1.870 Intris Intris 10001 717 / Month 24 1.870 Intris Intris 102001 722 / Month 24 1.850 No No Intris 102002 722 / Month 24 1.140 No No Intris Intris<td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 102001 717 / Month 24 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No</td><td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 102001 717 / Month 24 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No</td><td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 102001 717 / Month 24 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Fromtunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 170010 365 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177001 717 / Month 24 1.870 Intris 102001 722 / Month 24 1.850 No 102001 722 / Month 24 1.140 No 106002 722 / Month 12 1.140 No 106002 722 / Month 12 1.130 No 122002 359 / Month 12 1.630 No</td><td>Treatment Group Fositive Fositive Intraocular Incatment Group Subject ID Assay Assay Intraocular Incatt Group Subject ID Assay Assay Assay Log Titer Diagnosis Incomplexit 170010 365 / Month 12 2.770 No No Incomplexit 715 / Month 24 2.800 Intraocular No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Intitis Incomplexit 719 / Month 24 1.850 No No Incomplexit 719 / Month 24 1.140 No No Incomplexit 719 / Month 24 1.140 No No Incomplexit 722 / Month 12 1.140 No No Incomplexit 735 / Month 12 1.630 No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 Irritis
 Irritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No</td><td>Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intranocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inframmation 177006 358 / Month 12 1.870 Inframmation Ranibizumab 0.5 mg 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 1.850 No No 1122002 359 / Month 12 1.850 No No 102001 722 / Month 24 1.140 No No No 122002 359 / Month 12 1.630 No No No No 122002 359 / Month 12 1.630 No <t< td=""><td>Treatment Group Positive
Subject ID Positive
Assay Intrunoreactivity
Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intra 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 10001 717 / Month 24 1.850 No 102001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 359 / Month 12 1.630 No</td><td>Treatment Group Event Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No No No 122002 359 / Month 12 1.630 No No No No</td></t<></td></td></td> | Treatment Group Subject ID Positive
fmmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Iritis 106002 719 / Month 24 1.140 No No 1060 102001 722 / Month 12 1.140 No No No 122002 359 / Month 12 1.130 No No No 122002 359 / Month 12 1.630 No No No

 | Treatment Group Event Figure Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular No 177006 358 / Month 12 1.870 Intris Intris 10001 717 / Month 24 1.870 Intris Intris 102001 722 / Month 24 1.850 No No Intris 102002 722 / Month 24 1.140 No No Intris Intris <td>Treatment Group Event Figure Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular No 177006 358 / Month 12 1.870 Intris Intris 10001 717 / Month 24 1.870 Intris Intris 102001 722 / Month 24 1.850 No No Intris 102002 722 / Month 24 1.140 No No Intris Intris<td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 102001 717 / Month 24 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No</td><td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 102001 717 / Month 24 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No</td><td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 102001 717 / Month 24 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Fromtunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 170010 365 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177001 717 / Month 24 1.870 Intris 102001 722 / Month 24 1.850 No 102001 722 / Month 24 1.140 No 106002 722 / Month 12 1.140 No 106002 722 / Month 12 1.130 No 122002 359 / Month 12 1.630 No</td><td>Treatment Group Fositive Fositive Intraocular Incatment Group Subject ID Assay Assay Intraocular Incatt Group Subject ID Assay Assay Assay Log Titer Diagnosis Incomplexit 170010 365 / Month 12 2.770 No No Incomplexit 715 / Month 24 2.800 Intraocular No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Intitis Incomplexit 719 / Month 24 1.850
 No No Incomplexit 719 / Month 24 1.140 No No Incomplexit 719 / Month 24 1.140 No No Incomplexit 722 / Month 12 1.140 No No Incomplexit 735 / Month 12 1.630 No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 Irritis Irritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No</td><td>Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intranocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inframmation 177006 358 / Month 12 1.870 Inframmation Ranibizumab 0.5 mg 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 1.850 No No 1122002 359 / Month 12 1.850 No No 102001 722 / Month 24 1.140 No No No 122002 359 / Month 12 1.630 No No No No 122002 359 / Month 12 1.630 No <t< td=""><td>Treatment Group Positive
Subject ID Positive
Assay Intrunoreactivity
Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intra 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 10001 717 / Month 24 1.850 No 102001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 359 / Month 12 1.630 No</td><td>Treatment Group Event Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No No No 122002 359 / Month 12 1.630 No No No No</td></t<></td></td> | Treatment Group Event Figure Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular No 177006 358 / Month 12 1.870 Intris Intris 10001 717 / Month 24 1.870 Intris Intris 102001 722 / Month 24 1.850 No No Intris 102002 722 / Month 24 1.140 No No Intris Intris <td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 102001 717 / Month 24 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001
 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No</td> <td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 102001 717 / Month 24 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No</td> <td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 102001 717 / Month 24 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Fromtunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 170010 365 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177001 717 / Month 24 1.870 Intris 102001 722 / Month 24 1.850 No 102001 722 / Month 24 1.140 No 106002 722 / Month 12 1.140 No 106002 722 / Month 12 1.130 No 122002 359 / Month 12 1.630 No</td> <td>Treatment Group Fositive Fositive Intraocular Incatment Group Subject ID Assay Assay Intraocular Incatt Group Subject ID Assay Assay Assay Log Titer Diagnosis Incomplexit 170010 365 / Month 12 2.770 No No Incomplexit 715 / Month 24 2.800 Intraocular No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Intitis Incomplexit 719 / Month 24 1.850 No No Incomplexit 719 / Month 24 1.140 No No Incomplexit 719 / Month 24 1.140 No No Incomplexit 722 / Month 12 1.140 No No Incomplexit 735 / Month 12 1.630 No No</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 Irritis Irritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No</td> <td>Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intranocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inframmation 177006 358 / Month 12 1.870 Inframmation Ranibizumab 0.5 mg 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 1.850 No No 1122002 359 / Month 12 1.850 No No 102001 722 / Month 24 1.140 No No No 122002 359 / Month 12 1.630 No No No No 122002 359 / Month 12 1.630 No <t< td=""><td>Treatment Group Positive
Subject ID Positive
Assay Intrunoreactivity
Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intra 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 10001 717 / Month 24 1.850 No 102001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 359 / Month 12 1.630 No</td><td>Treatment Group Event Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No No No 122002 359 / Month 12 1.630 No No No No</td></t<></td>
 | Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 102001 717 / Month 24 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No
 | Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 102001 717 / Month 24 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No
 | Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis 102001 717 / Month 24 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Fromtunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 170010 365 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177001 717 / Month 24 1.870 Intris 102001 722 / Month 24 1.850 No 102001 722 / Month 24 1.140 No 106002 722 / Month 12 1.140 No 106002 722 / Month 12 1.130 No 122002 359 / Month 12 1.630 No
 | Treatment Group Fositive Fositive Intraocular Incatment Group Subject ID Assay Assay Intraocular Incatt Group Subject ID Assay Assay Assay Log Titer Diagnosis Incomplexit 170010 365 / Month 12 2.770 No No Incomplexit 715 / Month 24 2.800 Intraocular No Ranibizumab 0.5 mg 102001 722 / Month 24 1.870 Intitis Incomplexit 719 / Month 24 1.850 No No Incomplexit 719 / Month 24 1.140 No No Incomplexit 719 / Month 24 1.140 No No Incomplexit 722 / Month 12 1.140 No No Incomplexit 735 / Month 12 1.630 No No
 | Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 Irritis Irritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.630 No No | Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intranocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inframmation 177006 358 / Month 12 1.870 Inframmation Ranibizumab 0.5 mg 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 1.850 No No 1122002 359 / Month 12 1.850 No No 102001 722 / Month 24 1.140 No No No 122002 359 / Month 12 1.630 No No No No 122002 359 / Month 12 1.630 No No <t< td=""><td>Treatment Group Positive
Subject ID Positive
Assay Intrunoreactivity
Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intra 177006 358 / Month 12 1.870 Intris 177006 358 / Month
12 1.870 Intris 177006 358 / Month 12 1.870 Intris 10001 717 / Month 24 1.850 No 102001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 359 / Month 12 1.630 No</td><td>Treatment Group Event Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No No No 122002 359 / Month 12 1.630 No No No No</td></t<> | Treatment Group Positive
Subject ID Positive
Assay Intrunoreactivity
Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intra 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 10001 717 / Month 24 1.850 No 102001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 122002 359 / Month 12 1.630 No 122002 359 / Month 12 1.630 No | Treatment Group Event Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No No No 122002 359 / Month 12 1.630 No No No No |
| I24003 722/Month 24 0.782 Nio 126001 174/Month 24 0.782 Nio 126001 174/Month 12 2.040 Nio 12570 Nio Nio 141008 181/Month 24 1.570 Nio 141013 715/Month 24 1.940 Nio 726/Month 24 2.340 Nitritis 141013 715/Month 24 2.610 Nio 143010 722/Month 24 2.610 Nio 152004 522/Early Term. 0.752 Nio 153006 183/Month 24 2.610 Nio 153006 183/Month 24 2.070 Nio 153006 183/Month 24 2.070 Nio 155007 716/Month 24 0.780 Nio 159017 716/Month 24 0.780 Nio 1667002 717/Month 24 1.250 Nio 1667002 717/Month 24 1.250 Nio 167003 717/Month 24 1.250 Nio 167003 717/Month 24 1.250 Nio

 | I24003 722/Month 24 0.782 Nio I26001 174/Month 24 0.782 Nio I26001 174/Month 12 2.040 Nio I2570 Nio Nio 141008 181/Month 24 1.570 Nio 141013 715/Month 24 1.940 Nio 726/Month 24 2.340 Nitritis 141013 715/Month 24 2.610 Nio 143010 722/Month 24 2.610 Nio 152004 522/Early Term. 0.752, Nio 153006 183/Month 24 2.610 Nio 153006 183/Month 24 2.610 Nio 153006 183/Month 24 2.070 Nio 1550017 716/Month 24 2.070 Nio 159017 716/Month 24 2.070 Nio 1667002 717/Month 24 1.230 Nio 1667002 717/Month 24 1.250 Nio 188005 717/Month 24 1.250 Nio 167002 717/Month 24 1.250 Nio

 | I24003 722/Month 24 0.782 Nio I26001 174/Month 24 0.782 Nio I26001 174/Month 12 2.040 Nio I25001 357/Month 24 1.480 Nio I41008 181/Month 24 1.570 Nio I41013 715/Month 24 2.340 Nitritis I43010 722/Month 24 2.340 Nitritis I43010 722/Month 24 2.610 Nitritis I43010 722/Month 24 2.610 Nitritis I52004 522/Early Term. 0.752, No Nio I52004 522/Early Term. 0.752, No Nio I53006 183/Month 24 2.070 Nio I53006 188/Month 24 2.070 Nio I550017 718/Month 24 2.070 Nio I550017 718/Month 24 2.070 Nio I67002 717/Month 24 1.230 Nio I88005 717/Month 24 1.230 Nio I88005 717/Month 24 1.250 Nio I88005 717/Month 24 1.250 Nio

 | Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intraocular No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No No No Intraocular Int

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Iritiso 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 No 177001 717 / Month 24 0.922 No 104002 719 / Month 24 0.922 No No 106002 719 / Month 24 1.140 No No 106002 719 / Month 24 1.140 No No 106002 719 / Month 24 1.130 No No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Formunoreactivity Immunoreactivity Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 No No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No 1 1 106002 722 / Month 24 1.140 No No 1 1 106002 719 / Month 24 1.140 No No 1 <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No Io4002 719 / Month 24 1.140 No No Irritis Irritis</td> <td>Treatment Group Fununoreactivity Immunoreactivity Immunoreactivity<!--</td--><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No Io4002 719 / Month 24 1.140 No No Irritis Irritis</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No Io4002 719 / Month 24 1.140 No No Irritis Irritis</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Formunoreactivity Immunoreactivity Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 No No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No 1 1 106002 722 / Month 24 1.140 No No 1 1 106002 719 / Month 24 1.140 No No 1<td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Formunoreactivity Immunoreactivity Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 No No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No 1 1 106002 722 / Month 24 1.140 No No 1 1 106002 719 / Month 24 1.140 No No 1<td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Formunoreactivity Immunoreactivity Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 No No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No 1 1 106002 722 / Month 24 1.140 No No 1 1 106002 719 / Month 24 1.140 No No 1<td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intraocular No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No No No Intraocular Int</td><td>Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 Intraocular Intraocular 717 / Month 24 0.922 No 104002 719 / Month 24 0.922 No No 106002 719 / Month 24 1.140 No No 106002 719 / Month 24 1.140 No No 106002 719 / Month 24 1.130 No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immanion Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 715/Month 24 2.800 Intraocular No 177006 358/Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717/Month 24 0.922 No 106002 719/Month 24 0.922 No No 1 106002 719/Month 24 1.140 No No 1 106002 722/Month 24 1.130 No
 No No 122002 359/Month 12 1.630 No No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 170010 365/Month 12 2.800 No No No 177006 358/Month 24 2.800 Intitis No No Ranibizumab 0.5 mg 102001 717/Month 24 1.850 No <t< td=""><td>Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intranocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intrascular No No Ranibizumab 0.5 mg 107001 715 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No No No 106002 722 / Month 24 1.130 No No</td><td>Treatment Group Event From Subject ID Positive frammoreactivity frammoreactivity frammation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initraocular 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 Initis 177006 358 / Month 12 1.870 Initis 102001 717 / Month 24 0.922 No 104002 719 / Month 24 1.140 No Initis 106002 722 / Month 24 1.140 No Initis 106002 722 / Month 24 1.130 No Initis</td></t<></td></td></td></td></td> | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No Io4002 719 / Month 24 1.140 No No Irritis

 | Treatment Group Fununoreactivity Immunoreactivity Immunoreactivity </td <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No Io4002 719 / Month 24 1.140 No No Irritis Irritis</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No Io4002 719 / Month 24 1.140 No No Irritis Irritis</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Formunoreactivity Immunoreactivity Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 No No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No 1 1 106002 722 / Month 24 1.140 No No 1 1 106002 719 / Month 24 1.140 No No 1<td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Formunoreactivity Immunoreactivity Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 No No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No 1 1 106002 722 / Month 24 1.140 No No 1 1 106002 719 / Month 24 1.140 No No 1<td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Formunoreactivity Immunoreactivity Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 No No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No 1 1 106002 722 / Month 24 1.140 No No 1 1 106002 719 / Month 24 1.140 No No 1<td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intraocular No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No No No Intraocular Int</td><td>Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12
 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 Intraocular Intraocular 717 / Month 24 0.922 No 104002 719 / Month 24 0.922 No No 106002 719 / Month 24 1.140 No No 106002 719 / Month 24 1.140 No No 106002 719 / Month 24 1.130 No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immanion Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 715/Month 24 2.800 Intraocular No 177006 358/Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717/Month 24 0.922 No 106002 719/Month 24 0.922 No No 1 106002 719/Month 24 1.140 No No 1 106002 722/Month 24 1.130 No No No 122002 359/Month 12 1.630 No No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 170010 365/Month 12 2.800 No No No 177006 358/Month 24 2.800 Intitis No No Ranibizumab 0.5 mg 102001 717/Month 24 1.850 No <t< td=""><td>Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intranocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intrascular No No Ranibizumab 0.5 mg 107001 715 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No No No 106002 722 / Month 24 1.130 No No</td><td>Treatment Group Event From Subject ID Positive frammoreactivity frammoreactivity frammation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initraocular 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 Initis 177006 358 / Month 12 1.870 Initis 102001 717 / Month 24 0.922 No 104002 719 / Month 24 1.140 No Initis 106002 722 / Month 24 1.140 No Initis 106002 722 / Month 24 1.130 No Initis</td></t<></td></td></td></td> | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No Io4002 719 / Month 24 1.140 No No Irritis

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular Subject ID Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No Io4002 719 / Month 24 1.140 No No Irritis
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Formunoreactivity Immunoreactivity Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 No No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No 1 1 106002 722 / Month 24 1.140 No No 1 1 106002 719 / Month 24 1.140 No No 1 <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Formunoreactivity Immunoreactivity Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 No No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No 1 1 106002 722 / Month 24 1.140 No No 1 1 106002 719 / Month 24 1.140 No No 1<td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Formunoreactivity Immunoreactivity Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 No No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No 1 1 106002 722 / Month 24 1.140 No No 1 1 106002 719 / Month 24 1.140 No No 1<td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intraocular No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No No No Intraocular Int</td><td>Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 Intraocular Intraocular 717 / Month 24 0.922 No 104002 719 / Month 24 0.922 No No 106002 719 / Month 24 1.140 No No 106002 719 / Month 24 1.140 No No 106002 719 / Month 24 1.130 No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immanion Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 715/Month 24 2.800 Intraocular No 177006 358/Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717/Month 24 0.922 No 106002 719/Month 24 0.922 No No 1 106002 719/Month 24 1.140
 No No 1 106002 722/Month 24 1.130 No No No 122002 359/Month 12 1.630 No No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 170010 365/Month 12 2.800 No No No 177006 358/Month 24 2.800 Intitis No No Ranibizumab 0.5 mg 102001 717/Month 24 1.850 No <t< td=""><td>Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intranocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intrascular No No Ranibizumab 0.5 mg 107001 715 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No No No 106002 722 / Month 24 1.130 No No</td><td>Treatment Group Event From Subject ID Positive frammoreactivity frammoreactivity frammation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initraocular 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 Initis 177006 358 / Month 12 1.870 Initis 102001 717 / Month 24 0.922 No 104002 719 / Month 24 1.140 No Initis 106002 722 / Month 24 1.140 No Initis 106002 722 / Month 24 1.130 No Initis</td></t<></td></td></td> | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Formunoreactivity Immunoreactivity Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 No No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No 1 1 106002 722 / Month 24 1.140 No No 1 1 106002 719 / Month 24 1.140 No No 1 <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Formunoreactivity Immunoreactivity Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 No No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No 1 1 106002 722 / Month 24 1.140 No No 1 1 106002 719 / Month 24 1.140 No No 1<td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intraocular No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No No No Intraocular Int</td><td>Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 Intraocular Intraocular 717 / Month 24 0.922 No 104002 719 / Month 24 0.922 No No 106002 719 / Month 24 1.140 No No 106002 719 / Month 24 1.140 No No 106002 719 / Month 24 1.130 No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immanion Treatment Group Subject ID Assay Assay Log Titer
Diagnosis 170010 365/Month 12 2.770 No No 715/Month 24 2.800 Intraocular No 177006 358/Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717/Month 24 0.922 No 106002 719/Month 24 0.922 No No 1 106002 719/Month 24 1.140 No No 1 106002 722/Month 24 1.130 No No No 122002 359/Month 12 1.630 No No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 170010 365/Month 12 2.800 No No No 177006 358/Month 24 2.800 Intitis No No Ranibizumab 0.5 mg 102001 717/Month 24 1.850 No <t< td=""><td>Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intranocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intrascular No No Ranibizumab 0.5 mg 107001 715 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No No No 106002 722 / Month 24 1.130 No No</td><td>Treatment Group Event From Subject ID Positive frammoreactivity frammoreactivity frammation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initraocular 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 Initis 177006 358 / Month 12 1.870 Initis 102001 717 / Month 24 0.922 No 104002 719 / Month 24 1.140 No Initis 106002 722 / Month 24 1.140 No Initis 106002 722 / Month 24 1.130 No Initis</td></t<></td></td> | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Formunoreactivity Immunoreactivity Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 No No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No 1 1 106002 722 / Month 24 1.140 No No 1 1 106002 719 / Month 24 1.140 No No 1 <td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intraocular No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No No No Intraocular Int</td> <td>Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 Intraocular Intraocular 717 / Month 24 0.922 No 104002 719 / Month 24 0.922 No No 106002 719 / Month 24 1.140 No No 106002 719 / Month 24 1.140 No No 106002 719 / Month 24 1.130 No No</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immanion Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 715/Month 24 2.800 Intraocular No 177006 358/Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717/Month 24 0.922 No 106002 719/Month 24 0.922 No No 1 106002 719/Month 24 1.140 No No 1 106002 722/Month 24 1.130 No No No 122002 359/Month 12 1.630 No No No</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 170010 365/Month 12 2.800 No No No 177006
358/Month 24 2.800 Intitis No No Ranibizumab 0.5 mg 102001 717/Month 24 1.850 No <t< td=""><td>Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intranocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intrascular No No Ranibizumab 0.5 mg 107001 715 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No No No 106002 722 / Month 24 1.130 No No</td><td>Treatment Group Event From Subject ID Positive frammoreactivity frammoreactivity frammation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initraocular 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 Initis 177006 358 / Month 12 1.870 Initis 102001 717 / Month 24 0.922 No 104002 719 / Month 24 1.140 No Initis 106002 722 / Month 24 1.140 No Initis 106002 722 / Month 24 1.130 No Initis</td></t<></td> | Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intraocular No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No No No Intraocular Int
 | Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 Intraocular Intraocular 717 / Month 24 0.922 No 104002 719 / Month 24 0.922 No No 106002 719 / Month 24 1.140 No No 106002 719 / Month 24 1.140 No No 106002 719 / Month 24 1.130 No No | Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immanion Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 715/Month 24 2.800 Intraocular No 177006 358/Month 12 1.870 Intraocular
Ranibizumab 0.5 mg 102001 717/Month 24 0.922 No 106002 719/Month 24 0.922 No No 1 106002 719/Month 24 1.140 No No 1 106002 722/Month 24 1.130 No No No 122002 359/Month 12 1.630 No No No | Treatment Group Positive
Immunoreactivity Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 170010 365/Month 12 2.800 No No No 177006 358/Month 24 2.800 Intitis No No Ranibizumab 0.5 mg 102001 717/Month 24 1.850 No No <t< td=""><td>Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intranocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intrascular No No Ranibizumab 0.5 mg 107001 715 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No No No 106002 722 / Month 24 1.130 No No</td><td>Treatment Group Event From Subject ID Positive frammoreactivity frammoreactivity frammation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initraocular 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 Initis 177006 358 / Month 12 1.870 Initis 102001 717 / Month 24 0.922 No 104002 719 / Month 24 1.140 No Initis 106002 722 / Month 24 1.140 No Initis 106002 722 / Month 24 1.130 No Initis</td></t<> | Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intranocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intrascular No No Ranibizumab 0.5 mg 107001 715 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No No No 106002 722 / Month 24 1.130 No
 | Treatment Group Event From Subject ID Positive frammoreactivity frammoreactivity frammation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initraocular 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 Initis 177006 358 / Month 12 1.870 Initis 102001 717 / Month 24 0.922 No 104002 719 / Month 24 1.140 No Initis 106002 722 / Month 24 1.140 No Initis 106002 722 / Month 24 1.130 No Initis |
| I24003 723 / Month 24 1.770 No 124003 722 / Month 6 1.700 No 126001 174 / Month 6 1.700 No 126001 722 / Month 12 2.040 No 727 / Month 24 1.570 No 725 / Month 24 1.570 No 725 / Month 24 1.570 No 725 / Month 24 2.340 No 141013 715 / Month 24 2.340 715 / Month 24 2.340 Nitritis 143010 722 / Month 24 2.610 Nitritis 152004 522 / Early Term. 0.752, No No 153006 183 / Month 24 2.610 Nitritis 153006 183 / Month 24 2.070 No 155007 716 / Month 24 2.070 No 155007 716 / Month 24 1.530 No 1550017 716 / Month 24 1.230 No 1550017 716 / Month 24 1.230 No 1550017 716 / Month 24 1.250 No 1550017 717 / Month 24 1.250 No

 | Name 723 / Month 24 1.770 No 124003 722 / Month 6 1.700 No 126001 174 / Month 6 1.700 No 126001 174 / Month 6 1.700 No 725 / Month 12 2.040 No 725 / Month 24 1.480 No 725 / Month 24 1.570 No 725 / Month 24 1.570 No 725 / Month 24 2.340 Nitritis 141013 715 / Month 24 2.340 143010 722 / Month 24 2.340 153006 183 / Month 24 2.610 153006 183 / Month 24 2.610 153006 183 / Month 24 2.070 153007 718 / Month 24 2.070 153007 718 / Month 24 2.070 159017 718 / Month 24 2.070 159017 718 / Month 24 1.230 159017 716 / Month 24 1.230 1657002 717 / Mont 24 1.230 1550 No 1657001 716 / Month 24 1.250 159017 716 / Month 24 1.250 1657012 717 / Month 24 1.250 1657011 7.150 No

 | I24003 723 / Month 24 1.770 No 124003 722 / Month 6 1.700 No 126001 174 / Month 6 1.700 No 126002 357 / Month 6 1.700 No 727 / Month 6 1.570 No 141008 181 / Month 6 1.570 No 725 / Month 24 2.340 No 726 / Month 24 2.340 Nitritis 141013 715 / Month 24 2.610 Nitritis 143010 722 / Month 24 2.610 Nitritis 152004 522 / Early Term. 0.752, No No 153006 183 / Month 24 2.610 Nitritis 153006 183 / Month 24 2.070 No 153007 713 / Month 24 2.070 No 153007 717 / Mont 24 1.030 No 165002 717 / Mont 24 1.230 No 165002 717 / Mont 24 1.230 No 188005 717 / Month 24 1.250 No 188005 717 / Month 24 1.250 No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Formunoreactivity Immunoreactivity Immunoreactivity Subject ID Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No 106002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Formunoreactivity Intraocular Subject ID Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 /
Month 12 1.870 Irritis Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No Irritis Irritis Irritis 106002 722 / Month 24 1.140 No No Irritis Irritis Irritis 106002 722 / Month 24 1.130 No No Irritis

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 170010 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.360 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 106002 722 / Month 12 1.130 No 106002 722 / Month 12 1.630 No

 | Treatment Group Eventive Finaminoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Iritis No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No No 106002 719 / Month 24 1.360 No No <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 358 / Month 12 1.870 Intraocular No 177006 358 / Month 12 1.870 Intris Intris Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No Intris 106002 719 / Month 24 1.360 No No Intris Intris 106002 719 / Month 24 1.140 No No Intris No Intris Intris<td>Treatment Group Eventive Finaminoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Iritis No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No No 106002 719 / Month 24 1.360 No No<td>Treatment Group Eventive Finaminoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Iritis No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No No 106002 719 / Month 24 1.360 No No<td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 170010 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.360 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 106002 722 / Month 12 1.130 No 106002 722 / Month 12 1.630 No</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 170010 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.360 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 106002 722 / Month 12 1.130 No 106002 722 / Month 12 1.630 No</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 170010 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.360 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 106002 722 / Month 12 1.130 No 106002 722 / Month 12 1.630 No</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Formunoreactivity Immunoreactivity Immunoreactivity Subject ID Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No 106002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Intraocular No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No</td><td>Treatment Group Positive
Intrancular Positive
Intrancular Intrancular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No 1 1 106002 722 / Month 12 1.140 No No No No 106002 722 / Month 24 1.130 No No No No 122002 359 / Month 12 1.630 No No No No No</td><td>Treatment Group Positive
Immunoreactivity
Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No No No No 106002 722 / Month 24 1.140 No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 170010 358/Month 12 2.800 Inflammation 177006 358/Month 12 1.870 Inflammation Ranibizumab 0.5 mg 102001 717/Month 24 1.850 No 104002 719/Month 24 1.140 No No 106002 10220/Month 24 1.130 No 106002 722/Month 24 1.130 No No No No No 122002 359/Month 12 1.630 No No<td>Treatment Group Eventive
Subject ID Positive
Immunoreactivity Immunoreactivity Immunation Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 170010 358 / Month 12 1.870 Iritis No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No Io4002 719 / Month 24 1.140 No No No No 106002 719 / Month 24 1.140 No No No No 106002 722 / Month 12 1.140 No No</td></td></td></td></td> | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 358 / Month 12 1.870 Intraocular No 177006 358 / Month 12 1.870 Intris Intris Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No Intris 106002 719 / Month 24 1.360 No No Intris Intris 106002 719 / Month 24 1.140 No No Intris No Intris Intris <td>Treatment Group Eventive Finaminoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Iritis No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No No 106002 719 / Month 24 1.360 No No<td>Treatment Group Eventive Finaminoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Iritis No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No No 106002 719 / Month 24 1.360 No No<td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 170010 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.360 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 106002 722 / Month 12 1.130 No 106002 722 / Month 12 1.630 No</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 170010 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 177006
 358 / Month 12 1.870 Iritis 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.360 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 106002 722 / Month 12 1.130 No 106002 722 / Month 12 1.630 No</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 170010 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.360 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 106002 722 / Month 12 1.130 No 106002 722 / Month 12 1.630 No</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Formunoreactivity Immunoreactivity Immunoreactivity Subject ID Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No 106002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Intraocular No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No</td><td>Treatment Group Positive
Intrancular Positive
Intrancular Intrancular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No 1 1 106002 722 / Month 12 1.140 No No No No 106002 722 / Month 24 1.130 No No No No 122002 359 / Month 12 1.630 No No No No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No No No No 106002 722 / Month 24 1.140 No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 170010 358/Month 12 2.800 Inflammation 177006 358/Month 12 1.870 Inflammation Ranibizumab 0.5 mg 102001 717/Month 24 1.850 No 104002 719/Month 24 1.140 No No 106002 10220/Month 24 1.130 No 106002 722/Month 24 1.130 No No No No No 122002 359/Month 12 1.630 No No<td>Treatment Group Eventive
Subject ID Positive
Immunoreactivity Immunoreactivity Immunation Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 170010 358 / Month 12 1.870 Iritis No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No Io4002 719 / Month 24 1.140 No No No No 106002 719 / Month 24 1.140 No No No No 106002 722 / Month 12 1.140 No No</td></td></td></td> | Treatment Group Eventive Finaminoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Iritis No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No No 106002 719 / Month 24 1.360
 No No <td>Treatment Group Eventive Finaminoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Iritis No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No No 106002 719 / Month 24 1.360 No No<td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 170010 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.360 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 106002 722 / Month 12 1.130 No 106002 722 / Month 12 1.630 No</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 170010 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.360 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 106002 722 / Month 12 1.130 No 106002 722 / Month 12 1.630 No</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 170010 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.360 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 106002 722 / Month 12 1.130 No 106002 722 / Month 12 1.630 No</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Formunoreactivity Immunoreactivity Immunoreactivity Subject ID Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No 106002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Intraocular No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No</td><td>Treatment Group Positive
Intrancular Positive
Intrancular Intrancular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No 1 1 106002 722 / Month 12 1.140 No No No No 106002 722 / Month 24 1.130 No No No No 122002 359 / Month 12 1.630 No No No No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No No No No 106002 722 / Month 24 1.140 No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 170010 358/Month 12 2.800 Inflammation 177006 358/Month 12 1.870 Inflammation Ranibizumab 0.5 mg 102001 717/Month 24 1.850 No 104002 719/Month 24 1.140 No No 106002 10220/Month 24 1.130 No 106002 722/Month 24 1.130 No No No No No 122002 359/Month 12 1.630 No No<td>Treatment Group Eventive
Subject ID Positive
Immunoreactivity Immunoreactivity Immunation Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 170010 358 / Month 12 1.870 Iritis No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No Io4002 719 / Month 24 1.140 No No No No 106002 719 / Month 24 1.140 No No No No 106002 722 / Month 12 1.140 No No</td></td></td>
 | Treatment Group Eventive Finaminoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Iritis No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No No 106002 719 / Month 24 1.360 No No <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 170010 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.360 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 106002 722 / Month 12 1.130 No 106002 722 / Month 12 1.630 No</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 170010 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.360 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 106002 722 / Month 12 1.130 No 106002 722 / Month 12 1.630 No</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 170010 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.360 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 106002 722 / Month 12 1.130 No 106002 722 / Month 12 1.630 No</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Formunoreactivity Immunoreactivity Immunoreactivity Subject ID Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No 106002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Intraocular No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No</td> <td>Treatment Group Positive
Intrancular Positive
Intrancular Intrancular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No 1 1 106002 722 / Month 12 1.140 No No No No 106002 722 / Month 24 1.130 No No No No 122002 359 / Month 12 1.630 No No No No No</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No No No No 106002 722 / Month 24 1.140 No No</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 170010 358/Month 12 2.800 Inflammation 177006 358/Month 12 1.870 Inflammation Ranibizumab 0.5 mg 102001 717/Month 24 1.850 No 104002 719/Month 24 1.140 No No 106002 10220/Month 24 1.130 No 106002 722/Month 24 1.130 No No No No No 122002 359/Month 12 1.630 No No<td>Treatment Group Eventive
Subject ID Positive
Immunoreactivity Immunoreactivity Immunation Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 170010 358 / Month 12 1.870 Iritis No No
Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No Io4002 719 / Month 24 1.140 No No No No 106002 719 / Month 24 1.140 No No No No 106002 722 / Month 12 1.140 No No</td></td> | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 170010 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.360 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 106002 722 / Month 12 1.130 No 106002 722 / Month 12 1.630 No
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 170010 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.360 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 106002 722 / Month 12 1.130 No 106002 722 / Month 12 1.630 No
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Finnunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 170010 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.360 No 106002 722 / Month 24 1.140 No
106002 722 / Month 24 1.130 No 106002 722 / Month 12 1.130 No 106002 722 / Month 12 1.630 No | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Formunoreactivity Immunoreactivity Immunoreactivity Subject ID Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770
 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No 106002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Intraocular No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No
 | Treatment Group Positive
Intrancular Positive
Intrancular Intrancular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No 1 1 106002 722 / Month 12 1.140 No No No No 106002 722 / Month 24 1.130 No No No No 122002 359 / Month 12 1.630 No No No No No
 | Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No No No No 106002 722 / Month 24 1.140 No | Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 170010 358/Month 12 2.800 Inflammation 177006 358/Month 12 1.870 Inflammation Ranibizumab 0.5 mg 102001 717/Month 24 1.850 No 104002 719/Month 24 1.140 No No 106002 10220/Month 24 1.130 No 106002 722/Month 24 1.130 No No No No No 122002 359/Month 12 1.630 No No <td>Treatment Group Eventive
Subject ID Positive
Immunoreactivity Immunoreactivity Immunation Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 170010 358 / Month 12 1.870 Iritis No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No Io4002 719 / Month 24 1.140 No No No No 106002 719 / Month 24 1.140 No No No No 106002 722 / Month 12 1.140 No No</td> | Treatment Group Eventive
Subject ID Positive
Immunoreactivity Immunoreactivity Immunation Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 170010 358 / Month 12 1.870 Iritis No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No Io4002 719 / Month 24 1.140 No No No No 106002 719 / Month 24 1.140 No No No No 106002 722 / Month 12 1.140 No |
| No 723 / Month 24 1.770 No 126001 722 / Month 24 0.782 No 126001 174 / Month 6 1.700 No 126001 174 / Month 6 1.700 No 126001 357 / Month 12 2.040 No 141008 181 / Month 6 1.570 No 141013 715 / Month 12 1.940 No 141013 715 / Month 24 2.340 No 143010 722 / Month 24 2.340 Nithitis 143010 722 / Month 24 2.340 No 152004 522 / Early Term 0.752 No 153006 183 / Month 24 2.440 No 153006 183 / Month 24 2.970 No 153006 183 / Month 24 2.970 No 153006 183 / Month 24 1.900 No 153007 715 / Month 24 1.900 No 153017 715 / Month 24 1.230 <th>Number Number Number</th> <td>Name 723 / Month 24 1.770 No 124003 722 / Month 6 1.700 No 126001 174 / Month 6 1.700 No 126001 357 / Month 12 2.040 No 727 / Month 6 1.570 No No 141008 181 / Month 6 1.570 No 141013 715 / Month 24 2.040 No 141013 715 / Month 24 2.610 Vitritis 143010 722 / Month 24 2.610 No 143010 722 / Month 24 2.610 No 153006 183 / Month 6 1.900 No 153006 183 / Month 24 2.610 No 153006 183 / Month 24 2.070 No 153007 713 / Month 24 2.070 No 153007 183 / Month 24 2.070 No 153008 183 / Month 24 2.070 No 1530017 716 / Month 24 0.700 No 167002</td> <td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular Treatment Group Subject ID Assay Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Intris Intris Intris Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Intitis No 106002 722 / Month 24 1.140 No No No 106002 722 / Month 24 1.140 No No No 107003 350 / Month 17 1.500 No No No</td> <td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inframmation 177006 358 / Month 12 1.870 Infraocular 177006 358 / Month 12 1.870 Infrits 104002 717 / Month 24 1.870 Infits 104002 719 / Month 24 0.922 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 105001 722 / Month 24 1.130 No</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 1.850 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No</td> <td>Treatment Group Entitie Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 1.850 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular Subject ID Sob/Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 715 / Month 24 2.800 Intris No 717 / Month 24 1.870 Intris Intris 102001 715 / Month 24 1.870 Intris Intris Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No 106002 719 / Month 24 1.140 No No No No 106002 722 / Month 24 1.140 No No No No 107003 350 / Month 12 1.500 No No No No</td> <td>Treatment Group Entitive Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 104002 717 / Month 24 1.870 Intris 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.140 No</td> <td>Treatment Group Entitive Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 104002 717 / Month 24 1.870 Intris 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.140 No</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 1.850 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 1.850 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 1.850 No 106002 722 / Month 24 1.140 No
 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No</td> <td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular Treatment Group Subject ID Assay Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Intris Intris Intris Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Intitis No 106002 722 / Month 24 1.140 No No No 106002 722 / Month 24 1.140 No No No 107003 350 / Month 17 1.500 No No No</td> <td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Iritis 104002 719 / Month 24 1.140 No No 1066002 722 / Month 24 1.140 No No 105001 722 / Month 24 1.140 No No 107002 732 / Month 24 1.130 No No</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 Inflammation Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.850 No No No 106002 722 / Month 24 1.140 No No No No 105002 722 / Month 24 1.130 No No No No 105002 722 / Month 24 1.130 No No No No</td> <td>Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intranocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 Irritis Irritis 177005 358 / Month 12 1.870 Irritis Irritis 104002 717 / Month 24 1.850 No No Irritis 104002 719 / Month 24 1.350 No No Irritis 106002 722 / Month 24 1.140 No No No 105002 722 / Month 24 1.130 No No No 107003 350 / Month 13 1.530 No No No</td> <td>Treatment Group Positive
Subject ID Positive
Assay Intrunoreactivity
Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177005 358 / Month 12 1.870 Intitis 104002 717 / Month 24 1.850 No 104002 719 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 12 1.140 No 105001 722 / Month 24 1.140 No 105002 722 / Month 24 1.130 No 105002 722 / Month 12 1.500 No</td> <td>Treatment Group Event Positive
Immunoreactivity Intraocular
Immunoreactivity Intraocular
Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 Iritis No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No No No 106002 722 / Month 12 1.140 No No No No 107003 719 / Month 24 1.140 No No No No</td>
 | Number

 | Name 723 / Month 24 1.770 No 124003 722 / Month 6 1.700 No 126001 174 / Month 6 1.700 No 126001 357 / Month 12 2.040 No 727 / Month 6 1.570 No No 141008 181 / Month 6 1.570 No 141013 715 / Month 24 2.040 No 141013 715 / Month 24 2.610 Vitritis 143010 722 / Month 24 2.610 No 143010 722 / Month 24 2.610 No 153006 183 / Month 6 1.900 No 153006 183 / Month 24 2.610 No 153006 183 / Month 24 2.070 No 153007 713 / Month 24 2.070 No 153007 183 / Month 24 2.070 No 153008 183 / Month 24 2.070 No 1530017 716 / Month 24 0.700 No 167002

 | Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular Treatment Group Subject ID Assay Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Intris Intris Intris Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Intitis No 106002 722 / Month 24 1.140 No No No 106002 722 / Month 24 1.140 No No No 107003 350 / Month 17 1.500 No No No

 | Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inframmation 177006 358 / Month 12 1.870 Infraocular 177006 358 / Month 12 1.870 Infrits 104002 717 / Month 24 1.870 Infits 104002 719 / Month 24 0.922 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 105001 722 / Month 24 1.130 No

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 1.850 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No

 | Treatment Group Entitie Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 1.850 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular Subject ID Sob/Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 715 / Month 24 2.800 Intris No 717 / Month 24 1.870 Intris Intris 102001 715 / Month 24 1.870 Intris Intris Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No 106002 719 / Month 24 1.140 No No No No 106002 722 / Month 24 1.140 No No No No 107003 350 / Month 12 1.500 No No No No

 | Treatment Group Entitive Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 104002 717 / Month 24 1.870 Intris 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.140 No
 | Treatment Group Entitive Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 104002 717 / Month 24 1.870 Intris 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.140 No

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 1.850 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No
 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 1.850 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No
 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 1.850 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No
 | Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular Treatment Group Subject ID Assay Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Intris Intris Intris Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Intitis No 106002 722 / Month 24 1.140 No No No 106002 722 / Month 24 1.140 No No No 107003 350 / Month 17 1.500 No No No
 | Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Iritis 104002 719 / Month 24 1.140 No No 1066002 722 / Month 24 1.140 No No 105001 722 / Month 24 1.140 No No 107002 732 / Month 24 1.130 No No
 | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 Inflammation Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.850 No No No 106002 722 / Month 24 1.140 No No No No 105002 722 / Month 24 1.130 No No No No 105002 722 / Month 24 1.130 No No No No | Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intranocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 Irritis Irritis 177005 358 / Month 12 1.870 Irritis Irritis 104002 717 / Month 24 1.850 No No Irritis 104002 719 / Month 24 1.350 No No Irritis 106002 722 / Month 24 1.140 No No No 105002 722 / Month 24 1.130 No No No 107003 350 / Month 13 1.530 No No No
 | Treatment Group Positive
Subject ID Positive
Assay Intrunoreactivity
Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177005 358 / Month 12 1.870 Intitis 104002 717 / Month 24 1.850 No 104002 719 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 12 1.140 No 105001 722 / Month 24 1.140 No 105002 722 / Month 24 1.130 No 105002 722 / Month 12 1.500 No | Treatment Group Event Positive
Immunoreactivity Intraocular
Immunoreactivity Intraocular
Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 No No 177006 358 / Month 12 1.870 Iritis No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No No No 106002 722 / Month 12 1.140 No No No No 107003 719 / Month 24 1.140 No No No No |
| Relation 733/Month 24 1.700 No 124003 722/Month 24 1.700 No 126001 174/Month 6 1.700 No 126001 174/Month 12 2.040 No 727/Month 12 1.480 No 727/Month 12 1.480 No 727/Month 12 1.490 No 141008 181/Month 6 1.570 No 726/Month 12 1.940 No 726/Month 12 1.940 No 143010 722/Month 24 2.610 Vitritis 143010 722/Month 24 2.610 Vitritis 152004 522/Early Term 0.752 No 153006 183/Month 24 2.610 Vitritis 153006 183/Month 24 2.610 No 155007 715/Month 24 1.900 No 167002 717/Month 24 1.230 No 167002 717/Month 24 1.230 No 167002 717/Month 24 1.250 No 188005 717/Month 24 1.250 No 188005 717/Month 24 1.250 No

 | Relation 733/Month 24 1.700 No 124003 722/Month 24 1.700 No 126001 174/Month 6 1.700 No 126001 174/Month 12 2.040 No 126001 727/Month 12 2.040 No 727/Month 12 1.480 No 727/Month 24 1.480 No 141008 181/Month 6 1.570 No 726/Month 12 1.940 No 143010 722/Month 24 2.340 No 143010 722/Month 24 2.440 No 152004 522/EarlyTerrn 0.752 No 153006 183/Month 6 1.900 No 153006 183/Month 24 2.440 No 153006 183/Month 24 2.610 Vintits 153006 183/Month 24 1.900 No 159017 715/Month 24 1.230 No 167002 717/Month 24 1.230 No 188005 717/Month 24 1.250 No 188005 717/Month 24 1.250 No

 | Name Name Name 124003 723/Month 24 1.700 No 126001 174/Month 6 1.700 No 126001 174/Month 12 2.0400 No 126001 174/Month 6 1.570 No 141008 181/Month 54 1.480 No 727/Month 12 1.940 No 726/Month 12 1.940 No 141013 715/Month 24 2.340 Vitritis 143010 722/Month 24 2.440 No 152004 522/Month 12 1.900 No 153006 183/Month 6 1.900 No 153006 183/Month 6 1.900 No 153006 183/Month 24 2.070 No 153006 183/Month 24 1.900 No 153006 183/Month 24 1.530 No 153006 183/Month 24 1.530 No 153006 183/Month 24 1.350 No 167002 717/Mont 24 1.230 No 167002 717/Mont 24 1.230 No 188005 717/Mont 24 1.230 No 534001 -7/Screening 2.520 Vir <td>Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No No No 106002 722 / Month 24 1.140 No No No No</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No 104002 719 / Month 24 0.922 No No 10600 106002 722 / Month 24 1.140 No No 10600 No No No</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis I 177006 358 / Month 12 1.870 Iritis I Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No I I 106002 722 / Month 24 1.140 No No I I</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.140 No No</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Sold Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.140 No</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.140 No No</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.140 No No</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis I 177006 358 / Month 12 1.870 Iritis I Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No I I 106002 722 / Month 24 1.140 No No I I</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis I 177006 358 / Month 12 1.870 Iritis I Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No I I 106002 722 / Month 24 1.140 No No I I</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer
Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis I 177006 358 / Month 12 1.870 Iritis I Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No I I 106002 722 / Month 24 1.140 No No I I</td> <td>Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No No No 106002 722 / Month 24 1.140 No No No No</td> <td>Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No No No 106002 722 / Month 24 1.140 No No No No</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 2.800 Infammation 177006 358/Month 12 1.870 Infia Ranibizumab 0.5 mg 102001 717/Month 24 0.922 No 104002 719/Month 24 1.140 No Infia 106002 722/Month 24 1.140 No No</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 715/Month 24 2.800 Inflammation 177006 358/Month 12 1.870 No 177/005 358/Month 24 0.922 No Ranibizumab 0.5 mg 102001 717/Month 24 1.850 No 106002 719/Month 24 1.140 No No 100</td> <td>Treatment Group Positive
Innunoreactivity Innunoreactivity
Innunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 2.800 Intra No 177006 358/Month 12 1.870 Intits Intits Ranibizumab 0.5 mg 102001 717/Month 24 0.922 No 106002 719/Month 24 1.140 No No No 106002 722/Month 24 1.140 No No No No</td> <td>Treatment Group Evention From Subject ID Positive frammoreactivity frammoreactivity frammation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initraocular 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 Initis 177006 358 / Month 12 1.870 Initis 102001 717 / Month 24 0.922 No 104002 719 / Month 24 0.922 No No 106002 719 / Month 24 1.140 No No</td>
 | Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No No No 106002 722 / Month 24 1.140 No No No No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 No
 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No 104002 719 / Month 24 0.922 No No 10600 106002 722 / Month 24 1.140 No No 10600 No No No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis I 177006 358 / Month 12 1.870 Iritis I Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No I I 106002 722 / Month 24 1.140 No No I I

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.140 No No

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Sold Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No 106002 722 / Month 24 1.140 No
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.140 No No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.140 No No
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis I 177006 358 / Month 12 1.870 Iritis I Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No I I 106002 722 / Month 24 1.140 No No I I
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis I 177006 358 / Month 12 1.870 Iritis I
 Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No I I 106002 722 / Month 24 1.140 No No I I
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis I 177006 358 / Month 12 1.870 Iritis I Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No I I 106002 722 / Month 24 1.140 No No I I
 | Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No No No 106002 722 / Month 24 1.140 No No No No
 | Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No 104002 719 / Month 24 1.140 No No No No 106002 722 / Month 24 1.140 No No No No | Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 2.800 Infammation 177006 358/Month 12 1.870 Infia Ranibizumab 0.5 mg 102001 717/Month 24 0.922 No 104002 719/Month 24 1.140 No Infia 106002 722/Month 24 1.140 No No
 | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 715/Month 24 2.800 Inflammation 177006 358/Month 12 1.870 No 177/005 358/Month 24 0.922 No Ranibizumab 0.5 mg 102001 717/Month 24 1.850 No 106002 719/Month 24 1.140 No No 100 | Treatment Group Positive
Innunoreactivity Innunoreactivity
Innunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 2.800 Intra No 177006 358/Month 12 1.870 Intits Intits Ranibizumab 0.5 mg 102001 717/Month 24 0.922 No 106002 719/Month 24 1.140 No No No 106002 722/Month 24 1.140 No No No No | Treatment Group Evention From Subject ID Positive frammoreactivity frammoreactivity frammation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12
 2.800 Initraocular 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 Initis 177006 358 / Month 12 1.870 Initis 102001 717 / Month 24 0.922 No 104002 719 / Month 24 0.922 No No 106002 719 / Month 24 1.140 No No |
| Iz2002 5397 Month 12 1.0300 No 124003 7223 / Month 24 1.7700 No 124003 7221 / Month 6 1.7700 No 124003 357 / Month 12 2.0400 No 124003 357 / Month 12 2.0400 No 124003 357 / Month 12 2.0400 No 1241008 181 / Month 6 1.5700 No 1241013 715 / Month 24 2.3400 Ni 125004 522 / Month 24 2.3400 Ni 143010 722 / Month 24 2.4400 No 155004 522 / Early Terrn. 0.752 , No No 155004 15500 0.752 No 155004 522 / Month 12 1.9000 No 155004 522 / Month 24 2.6100 Virritis 155004 522 / Month 24 1.9000 No 155004 15500 0.752 No 167002 716 / Month 24 1.2300 No 167002 717 / Month 24 1.2300 No 188005 717 / Month 24 1.2500 No 188005 717 / Month 24 1.2500 No 188005

 | Iz2002 5397 Month 12 1.0300 No 124003 7223 / Month 24 1.7700 No 124003 7221 / Month 6 1.7700 No 124003 377 / Month 12 2.0400 No 124003 377 / Month 6 1.7700 No 727 / Month 12 2.0400 No 141008 181 / Month 6 1.5700 No 725 / Month 12 1.9400 No 143010 722 / Month 24 2.3400 Vitritis 143010 722 / Month 24 2.3400 No 152004 522 / Early Term. 0.752 , No No 153006 183 / Month 6 1.9000 No 153006 183 / Month 24 2.6100 Vitritis 153006 183 / Month 24 2.000 No 153006 183 / Month 6 1.9000 No 153006 183 / Month 24 2.000 No 153006 183 / Month 24 1.5300 No 153006 183 / Month 24 1.2300 No 167002 717 / Mont 24 1.2300 No 167002 717 / Month 24 1.2300 No 188005 717 / Month 24<

 | I.22002 $537/Month$ 12 1.0300 No 124003 723/Month 24 1.7700 No 124003 723/Month 24 1.7700 No 124003 723/Month 12 1.7000 No 124003 723/Month 12 1.7000 No 124003 723/Month 12 1.9400 No 141018 181/Month 6 1.5700 No 725/Month 24 2.3400 Ni 143010 722/Month 24 2.4400 No 152004 522/Early Term. 0.752 , No 153006 183/Month 6 1.9000 No 153006 183/Month 24 2.6100 Vitritis 153006 183/Month 24 2.6100 No 153006 183/Month 24 2.070 No 153006 183/Month 24 2.070 No 153006 183/Month 24 2.070 No 159017 716/Month 24 2.070 No 167002 717/Month 24 1.530 No 167002 711/Month 24 1.530 No 167002 717/Month 24 1.530 No 167002 711/Month 24 1.530 <t< td=""><td>Treatment Group Fositive Fositive Intraocular Intraocular Intraocular Intraocular Intraocular</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Sd5 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No 106002 719 / Month 24 1.140 No No</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Irritis 106002 719 / Month 24 1.360 No No No</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 Initia 177006 358 / Month 12 1.870 Initia Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 106002 719 / Month 24 1.140 No No</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Immunoreactivity Inflammation I70010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 358 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Intris Intris Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No No 106002 719 / Month 24 1.360 No No No No 106002 719 / Month 24 1.140 No No</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 Initia 177006 358 / Month 12 1.870 Initia Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 106002 719 / Month 24 1.140 No No</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 Initia 177006 358 / Month 12 1.870 Initia Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 106002 719 / Month 24 1.140 No No</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Irritis 106002 719 / Month 24 1.360 No No No</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Irritis 106002 719 / Month 24 1.360 No No No</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Irritis 106002 719 / Month 24 1.360 No No No</td><td>Treatment Group Fositive Fositive Intraocular Intraocular Intraocular Intraocular Intraocular</td><td>Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Formunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800
 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Intrancation Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intrancation 170010 365 / Month 12 2.800 No No Intrancation 177006 358 / Month 12 1.870 Intris Intra Intris Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No No 106002 719 / Month 24 1.140 No No No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 Inflammation Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 0.922 No No No 106002 722 / Month 24 1.140 No No No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunation Treatment Group Subject ID Assay Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 12 1.870 Intrascenter No No Ranibizumab 0.5 mg 102001 717/Month 24 1.850 No No</td></t<>
 | Treatment Group Fositive Fositive Intraocular Intraocular Intraocular Intraocular Intraocular

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Sd5 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No 106002 719 / Month 24 1.140 No No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Irritis 106002 719 / Month 24 1.360 No No No

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 Initia 177006 358 / Month 12 1.870 Initia Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 106002 719 / Month 24 1.140 No No

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Immunoreactivity Inflammation I70010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 358 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Intris Intris Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No No 106002 719 / Month 24 1.360 No No No No 106002 719 / Month 24 1.140 No

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 Initia 177006 358 / Month 12 1.870 Initia Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 106002 719 / Month 24 1.140 No No
 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 Initia 177006 358 / Month 12 1.870 Initia Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 106002 719 / Month 24 1.140 No No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Irritis 106002 719 / Month 24 1.360 No No No
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Irritis 106002 719 / Month 24 1.360 No No No
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Irritis 177006 358 / Month 12 1.870 Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Irritis 106002 719 / Month 24 1.360 No No No
 | Treatment Group Fositive Fositive Intraocular Intraocular Intraocular Intraocular Intraocular
 | Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Formunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No
 | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No No | Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Intrancation Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intrancation 170010 365 / Month 12 2.800 No No Intrancation 177006 358 / Month 12 1.870 Intris Intra Intris Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No No 106002 719 / Month 24 1.140 No No No No
 | Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immantion Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 Inflammation Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 0.922 No No No 106002 722 / Month 24 1.140 No No No No | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immunation Treatment Group Subject ID Assay Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 12 1.870 Intrascenter No No Ranibizumab 0.5 mg 102001 717/Month 24 1.850 No |
| 122002 339/Month 12 1.630 No 124003 723/Month 24 1.770 No 124003 722/Month 24 1.700 No 126001 174/Month 6 1.700 No 126001 174/Month 6 1.700 No 1257/Month 12 2.040 No 141008 181/Month 24 1.480 No 141013 715/Month 24 2.610 Vitritis 143010 722/Month 24 2.610 Vitritis 143010 722/Month 12 1.900 No 152004 522/Early Term. 0.752, No 153006 183/Month 6 1.900 No 153006 183/Month 24 2.610 Vitritis 153006 183/Month 24 2.070 No 153006 183/Month 24 2.070 No 153006 183/Month 24 1.530 No 153006 183/Month 24 1.530 No 155004 522/Farly Term. 0.752, No 15500 1365/Month 24 1.530 No 159017 716/Month 24 1.530 No 167002 717/Mont 24 1.250 No 188005 <th>I22002 339/Month 12 1.630 No 124003 723/Month 24 1.770 No 124003 722/Month 6 1.700 No 126001 174/Month 6 1.700 No 126001 174/Month 6 1.700 No 1257/Month 12 2.040 No No 737/Month 24 1.480 No No 735/Month 24 1.400 No No 735/Month 24 2.610 Vitritis No 141013 715/Month 24 2.610 Vitritis 143010 722/Month 24 2.610 Vitritis 152004 522/Early Term 0.752, No 153005 183/Month 6 1.900 No 15300 555/Month 12 1.530 No 15300 183/Month 6 1.900 No 159017 718/Month 24 2.070 No 159017 716/Month 24 1.530 No 159017 7150 No<td>I22002 339/Month 12 1.630 No 124003 723/Month 24 1.770 No 124003 723/Month 6 1.700 No 124003 723/Month 6 1.700 No 124003 723/Month 6 1.700 No 124003 723/Month 24 0.782 No 141013 715/Month 24 1.480 No 141013 715/Month 24 2.340 No 143010 722/Month 24 2.440 No 153006 183/Month 6 1.900 No 153006 183/Month 24 2.440 No 153006 183/Month 24 2.400 No 153006 183/Month 24 2.070 No 153006 183/Month 24 0.752 No 153006 183/Month 24 0.760 No 1550017 716/Month 24 0.760 No 1550017 716/Month 24 1.530 No 1580017 716/Month 24 <</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 715 / Month 24 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 104002 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 715 / Month 24 2.800 Intraocular No 717/006 358 / Month 12 1.870 Intris 102001 717 / Month 24 1.870 Intits 104002 719 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No Intraocular 170010 365 / Month 12 2.770 No Intraocular 715 / Month 24 2.800 Intraocular Intraocular 717 / Month 12 1.870 Intris Intrins 1.850 No Intris Intritis 1.130 No No Intritis 1.140 No No</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 715 / Month 12 1.870 No 177006 358 / Month 12 1.870 Intris 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular Subject ID Sob Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No 715 / Month 24 2.800 Intris 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intis 102001 717 / Month 24 1.870 Intis 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 715 / Month 12 1.870 No 177006 358 / Month 12 1.870 Intris 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 715 / Month 12 1.870 No 177006 358 / Month 12 1.870 Intris 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No Intraocular 170010 365 / Month 12 2.770 No Intraocular 715 / Month 24 2.800 Intraocular Intraocular 717 / Month 12 1.870 Intris Intrins 1.850 No Intris Intritis 1.130 No No Intritis 1.140 No No</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No Intraocular 170010 365 / Month 12 2.770 No Intraocular 715 / Month 24 2.800 Intraocular Intraocular 717 / Month 12 1.870 Intris Intrins 1.850 No Intris Intritis 1.130 No No Intritis 1.140 No No</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No Intraocular 170010 365 / Month 12 2.770 No Intraocular 715 / Month 24 2.800 Intraocular
Intraocular 717 / Month 12 1.870 Intris Intrins 1.850 No Intris Intritis 1.130 No No Intritis 1.140 No No</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 715 / Month 24 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 104002 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No 170010 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intitis 104002 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immantion
Immantion Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 Irritis Irritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.130 No 106002 722 / Month 24 1.130 No No</td><td>Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intranocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inframmation 177006 358 / Month 12 1.870 Inframmation Ranibizumab 0.5 mg 102001 715 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.140 No No</td><td>Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Inframmation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inframmation 177006 358 / Month 12 1.870 Inframmation Ranibizumab 0.5 mg 102001 715 / Month 24 1.850 No 104002 719 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.140 No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 No No No 8anibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 104002 719 / Month 24 1.850 No No No No 104002 719 / Month 24 1.850 No No No No 106002 722 / Month 24 1.140 No No No No</td></th>
 | I22002 339/Month 12 1.630 No 124003 723/Month 24 1.770 No 124003 722/Month 6 1.700 No 126001 174/Month 6 1.700 No 126001 174/Month 6 1.700 No 1257/Month 12 2.040 No No 737/Month 24 1.480 No No 735/Month 24 1.400 No No 735/Month 24 2.610 Vitritis No 141013 715/Month 24 2.610 Vitritis 143010 722/Month 24 2.610 Vitritis 152004 522/Early Term 0.752, No 153005 183/Month 6 1.900 No 15300 555/Month 12 1.530 No 15300 183/Month 6 1.900 No 159017 718/Month 24 2.070 No 159017 716/Month 24 1.530 No 159017 7150 No <td>I22002 339/Month 12 1.630 No 124003 723/Month 24 1.770 No 124003 723/Month 6 1.700 No 124003 723/Month 6 1.700 No 124003 723/Month 6 1.700 No 124003 723/Month 24 0.782 No 141013 715/Month 24 1.480 No 141013 715/Month 24 2.340 No 143010 722/Month 24 2.440 No 153006 183/Month 6 1.900 No 153006 183/Month 24 2.440 No 153006 183/Month 24 2.400 No 153006 183/Month 24 2.070 No 153006 183/Month 24 0.752 No 153006 183/Month 24 0.760 No 1550017 716/Month 24 0.760 No 1550017 716/Month 24 1.530 No 1580017 716/Month 24 <</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 715 / Month 24 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 104002 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 715 / Month 24 2.800 Intraocular No 717/006 358 / Month 12 1.870 Intris 102001 717 / Month 24 1.870 Intits 104002
 719 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No Intraocular 170010 365 / Month 12 2.770 No Intraocular 715 / Month 24 2.800 Intraocular Intraocular 717 / Month 12 1.870 Intris Intrins 1.850 No Intris Intritis 1.130 No No Intritis 1.140 No No</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 715 / Month 12 1.870 No 177006 358 / Month 12 1.870 Intris 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular Subject ID Sob Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No 715 / Month 24 2.800 Intris 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intis 102001 717 / Month 24 1.870 Intis 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 715 / Month 12 1.870 No 177006 358 / Month 12 1.870 Intris 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 715 / Month 12 1.870 No 177006 358 / Month 12 1.870 Intris 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No Intraocular 170010 365 / Month 12 2.770 No Intraocular 715 / Month 24 2.800 Intraocular Intraocular 717 / Month 12 1.870 Intris Intrins 1.850 No Intris Intritis 1.130 No No Intritis 1.140 No No</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No Intraocular 170010 365 / Month 12 2.770 No Intraocular 715 / Month 24 2.800 Intraocular Intraocular 717 / Month 12 1.870 Intris Intrins 1.850 No Intris Intritis 1.130 No No Intritis 1.140 No No</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No Intraocular 170010 365 / Month 12 2.770 No Intraocular 715 / Month 24 2.800 Intraocular Intraocular 717 / Month 12 1.870 Intris Intrins 1.850 No Intris Intritis 1.130 No No Intritis 1.140 No No</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 715 / Month 24 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 104002 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No 170010 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intitis 104002 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immantion
Immantion Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 Irritis Irritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.130 No 106002 722 / Month 24 1.130 No No</td> <td>Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intranocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inframmation 177006 358 / Month 12 1.870 Inframmation Ranibizumab 0.5 mg 102001 715 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.140 No No</td> <td>Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Inframmation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inframmation 177006 358 / Month 12 1.870 Inframmation Ranibizumab 0.5 mg 102001 715 / Month 24 1.850 No 104002 719 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.140 No No</td> <td>Treatment Group Subject ID Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 No No No 8anibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 104002 719 / Month 24 1.850 No No No No 104002 719 / Month 24 1.850 No No No No 106002 722 / Month 24 1.140 No No No No</td>

 | I22002 339/Month 12 1.630 No 124003 723/Month 24 1.770 No 124003 723/Month 6 1.700 No 124003 723/Month 6 1.700 No 124003 723/Month 6 1.700 No 124003 723/Month 24 0.782 No 141013 715/Month 24 1.480 No 141013 715/Month 24 2.340 No 143010 722/Month 24 2.440 No 153006 183/Month 6 1.900 No 153006 183/Month 24 2.440 No 153006 183/Month 24 2.400 No 153006 183/Month 24 2.070 No 153006 183/Month 24 0.752 No 153006 183/Month 24 0.760 No 1550017 716/Month 24 0.760 No 1550017 716/Month 24 1.530 No 1580017 716/Month 24 <

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 715 / Month 24 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 104002 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 715 / Month 24 2.800
 Intraocular No 717/006 358 / Month 12 1.870 Intris 102001 717 / Month 24 1.870 Intits 104002 719 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No Intraocular 170010 365 / Month 12 2.770 No Intraocular 715 / Month 24 2.800 Intraocular Intraocular 717 / Month 12 1.870 Intris Intrins 1.850 No Intris Intritis 1.130 No No Intritis 1.140 No No

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 715 / Month 12 1.870 No 177006 358 / Month 12 1.870 Intris 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular Subject ID Sob Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No 715 / Month 24 2.800 Intris 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intis 102001 717 / Month 24 1.870 Intis 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No
 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 715 / Month 12 1.870 No 177006 358 / Month 12 1.870 Intris 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 715 / Month 12 1.870 No 177006 358 / Month 12 1.870 Intris 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No
 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No Intraocular 170010 365 / Month 12 2.770 No Intraocular 715 / Month 24 2.800 Intraocular Intraocular 717 / Month 12 1.870 Intris Intrins 1.850 No Intris Intritis 1.130 No No Intritis 1.140 No No
 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No Intraocular 170010 365 / Month 12 2.770 No Intraocular 715 / Month 24 2.800 Intraocular Intraocular 717 / Month 12 1.870 Intris
 Intrins 1.850 No Intris Intritis 1.130 No No Intritis 1.140 No No
 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No Intraocular 170010 365 / Month 12 2.770 No Intraocular 715 / Month 24 2.800 Intraocular Intraocular 717 / Month 12 1.870 Intris Intrins 1.850 No Intris Intritis 1.130 No No Intritis 1.140 No No
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 715 / Month 24 2.800 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intris 104002 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No
 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No 170010 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris 177006 358 / Month 12 1.870 Intitis 104002 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No 106002 722 / Month 24 1.140 No | Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immantion
Immantion Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis 177006 358 / Month 12 1.870 Irritis Irritis Ranibizumab 0.5 mg 102001 722 / Month 24 1.130 No 106002 722 / Month 24 1.130 No No
 | Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intranocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inframmation 177006 358 / Month 12 1.870 Inframmation Ranibizumab 0.5 mg 102001 715 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.140 No No | Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Inframmation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inframmation 177006 358 / Month 12 1.870 Inframmation Ranibizumab 0.5 mg 102001 715 / Month 24 1.850 No 104002 719 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.140 No No | Treatment Group Subject ID Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 /
Month 12 1.870 No No No 8anibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 104002 719 / Month 24 1.850 No No No No 104002 719 / Month 24 1.850 No No No No 106002 722 / Month 24 1.140 No No No No |
| I22002 359 / Month 12 1.630 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 126001 174 / Month 6 1.700 No 725 / Month 12 2.040 No No 727 / Month 24 1.700 No No 727 / Month 24 1.570 No No 725 / Month 24 1.570 No No 725 / Month 24 1.570 No No 141013 715 / Month 24 2.340 No 143010 722 / Month 24 2.610 Vitritis 143010 722 / Month 24 2.610 No 152004 $522 / Early Term. 0.752 No 153005 183 / Month 24 2.610 No 153006 183 / Month 24 2.070 No 153006 183 / Month 24 1.900 No 153007 116 / Month 24 1.230 No $

 | I22002 359 / Month 12 1.630 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 0.782 No 126001 174 / Month 6 1.700 No 727 / Month 12 2.040 No No 727 / Month 24 1.570 No No 727 / Month 24 1.570 No No 141013 715 / Month 24 2.340 Nitritis 143010 722 / Month 24 2.610 Nitritis 143010 722 / Month 24 2.610 Nitritis 153006 183 / Month 24 2.610 No 153006 183 / Month 24 2.070 No 153006 183 / Month 24 0.780 No 153006 183 / Month 24 0.780 No 153006 183 / Month 24 0.780 No 153006 116 / Month 24 0.780 No </th <td>I22002 359/Month 12 1.630 No 124003 723/Month 24 1.770 No 124003 722/Month 24 0.782 No 126001 174/Month 6 1.700 No 126001 174/Month 12 2.040 No 727/Month 12 1.480 No No 727/Month 24 1.480 No No 727/Month 24 1.480 No No 7101 715/Month 24 1.940 No 726/Month 12 1.940 No No 141013 715/Month 24 2.610 Vitritis 143010 722/Month 24 2.640 No 152004 522/EarlyTerm 0.752 No 153006 183/Month 6 1.900 No 158007 716/Mont 24 1.900</td> <td>Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No 106002 719 / Month 24 1.140 No No No</td> <td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Subject ID Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No</td> <td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12
 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No</td> <td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No</td> <td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No</td> <td>Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No</td> <td>Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No 106002 719 / Month 24 1.140 No No No</td> <td>Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 12 2.800 Intraocular No 177006 358/Month 24 1.870 Intraocular No Ranibizumab 0.5 mg 102001 717/Month 24 1.850 No 104002 719/Month 24 1.140 No No 106002 722/Month 24 1.1400 No No</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immanion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 12 1.870 Intraocular Intraocular Ranibizumab 0.5 mg 102001 715/Month 24 1.850 No 104002 719/Month 24 1.140 No No 106002 722/Month 24 1.140 No No</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 355/Month 12 2.800 Inflammation 177006 358/Month 12 1.870 No 177006 358/Month 24 1.870 Intits 177006 358/Month 24 1.850 No 104002 717/Month 24 1.850 No 104002 719/Month 24 1.140 No 106002 722/Month 24 1.140 No</td> <td>Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intrancular 170010 365 / Month 12 2.770 No No 170010 355 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irtitis Irtitis 177006 358 / Month 12 1.870 Irtitis Irtitis Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No 106002 719 / Month 24 1.140 No No</td> <td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initia Initia 177006 358 / Month 12 1.870 Initis Initis Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No No</td>

 | I22002 359/Month 12 1.630 No 124003 723/Month 24 1.770 No 124003 722/Month 24 0.782 No 126001 174/Month 6 1.700 No 126001 174/Month 12 2.040 No 727/Month 12 1.480 No No 727/Month 24 1.480 No No 727/Month 24 1.480 No No 7101 715/Month 24 1.940 No 726/Month 12 1.940 No No 141013 715/Month 24 2.610 Vitritis 143010 722/Month 24 2.640 No 152004 522/EarlyTerm 0.752 No 153006 183/Month 6 1.900 No 158007 716/Mont 24 1.900

 | Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No 106002 719 / Month 24 1.140 No No No

 | Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Subject ID Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No

 | Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No
 | Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No
 | Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No

 | Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No
 | Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 No 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No 106002 719 / Month 24 1.140 No No No
 | Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 12 2.800 Intraocular No 177006 358/Month 24 1.870 Intraocular No Ranibizumab 0.5 mg 102001 717/Month 24 1.850 No 104002 719/Month 24 1.140 No No 106002 722/Month 24 1.1400 No No | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immanion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 12 1.870 Intraocular Intraocular Ranibizumab 0.5 mg 102001 715/Month 24 1.850 No 104002 719/Month 24 1.140 No No 106002 722/Month 24 1.140 No No
 | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 355/Month 12 2.800 Inflammation 177006 358/Month 12 1.870 No 177006 358/Month 24 1.870 Intits 177006 358/Month 24 1.850 No 104002 717/Month 24 1.850 No 104002 719/Month 24 1.140 No 106002 722/Month 24 1.140 No | Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intrancular 170010 365 / Month 12 2.770 No No 170010 355 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irtitis Irtitis 177006 358 / Month 12 1.870 Irtitis Irtitis Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No 106002 719 / Month 24 1.140 No No | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Immation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initia Initia 177006 358 / Month 12 1.870 Initis Initis Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No No
 |
| I22002 359/Month 12 1630 No 124003 722/Month 24 1.770 No 124003 722/Month 24 1.770 No 126001 174/Month 6 1.700 No 126001 357/Month 24 0.782 No 126001 722/Month 24 1.700 No 727/Month 24 1.480 No No 725/Month 24 1.570 No No 141013 715/Month 24 2.610 Vitritis 143010 722/Month 24 2.610 Vitritis 143010 722/Month 24 2.610 No 152004 522/Early Term. 0.752 No 153005 183/Month 24 2.610 No 153006 183/Month 24 1.900 No 153006 183/Month 24 1.530 No 153006 183/Month 24 1.900 No 153006 183/Month 24 1.900 No 153007 717/Mont 24

 | I22002 359/Month I2 1630 No 124003 722/Month 24 1.770 No 124003 722/Month 6 1.700 No 126001 174/Month 6 1.700 No 126001 174/Month 6 1.700 No 126001 357/Month 6 1.700 No 727/Month 6 1.570 No 727/Month 6 1.570 No 727/Month 6 1.570 No 725/Month 12 1.940 No 715/Month 24 2.340 Nitritis 141013 715/Month 24 2.440 No 725/Month 24 2.610 Vitritis 143010 722/Month 24 2.610 Nitritis 153006 183/Month 6 1.900 No 153005 183/Month 24 2.070 No 153005 183/Month 24 1.300 No 159017 716/Month 24 1.300 No 167002 717/Month 24 1.230 No 188005 717/Mont

 | I22002 339/Month I2 1.530 No I22003 723/Month 24 1.770 No I24003 722/Month 6 1.700 No I26001 174/Month 6 1.700 No I26001 174/Month 6 1.700 No I26001 727/Month 6 1.700 No I26001 727/Month 6 1.700 No I41008 181/Month 6 1.570 No I41013 715/Month 24 2.440 No I2204 522/Month 24 2.440 No I23006 183/Month 6 1.900 No I53006 183/Month 6 1.900 No I53006 183/Month 24 2.610 Nitritis I53006 183/Month 24 2.070 No I53006 183/Month 24 1.530 No I53007 18/Month 24 1.530 No I53007 18/Month 24 1.530 No I53007 18/Month 24 1.530 I53007 717/Mont 24 <td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immarion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Immunoreactivity No 177006 358 / Month 12 1.870 Infia Infia Infia Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No Intributer 719 / Month 24 1.140 No No No No</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Assay Assay 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intraocular No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No Intraocular 717 / Month 24 1.850 No No No</td> <td>Treatment Group Subject ID Positive
financeactivity Intraocular Treatment Group Subject ID Assay Assay Assay Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Intraocular No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No No No</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 358 / Month 12 1.870 Intraocular No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No Ranibizumab 0.5 mg 104002 719 / Month 24 1.140 No No</td> <td>Treatment Group Subject ID Positive
financeactivity Intraocular Treatment Group Subject ID Assay Assay Assay Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Intraocular No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No No No</td> <td>Treatment Group Subject ID Positive
financeactivity Intraocular Treatment Group Subject ID Assay Assay Assay Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Intraocular No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No No No</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Assay Assay 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intraocular No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No Intraocular 717 / Month 24 1.850 No No No</td> <td>Treatment Group Positive Intraocular Treatment Group Subject ID Formunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No</td> <td>Treatment Group Positive Intraocular Treatment Group Subject ID Formunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No</td> <td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immarion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Immunoreactivity No 177006 358 / Month 12 1.870 Infia Infia Infia Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No Intributer 719 / Month 24 1.140 No No No No</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12
 2.800 Initianmation 177006 358 / Month 12 1.870 Initis 177006 358 / Month 12 1.870 Initis 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No</td> <td>Treatment Group Positive
Intraocular Intrancular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 I.ritis No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No No No</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immantion Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No Io4002 719 / Month 24 1.140 No No No No</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 1.870 In 177006 358/Month 12 1.870 In Ranibizumab 0.5 mg 102001 722/Month 24 1.850 No 104002 719/Month 24 1.140 No No No</td> <td>Treatment Group Evolution From From From From From From From From</td>
 | Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immarion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Immunoreactivity No 177006 358 / Month 12 1.870 Infia Infia Infia Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No Intributer 719 / Month 24 1.140 No No No No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Assay Assay 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intraocular No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No Intraocular 717 / Month 24 1.850 No No No

 | Treatment Group Subject ID Positive
financeactivity Intraocular Treatment Group Subject ID Assay Assay Assay Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Intraocular No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No No No

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 358 / Month 12 1.870 Intraocular No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No Ranibizumab 0.5 mg 104002 719 / Month 24 1.140 No No
 | Treatment Group Subject ID Positive
financeactivity Intraocular Treatment Group Subject ID Assay Assay Assay Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Intraocular No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No No No

 | Treatment Group Subject ID Positive
financeactivity Intraocular Treatment Group Subject ID Assay Assay Assay Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Intraocular No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No No No
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Assay Assay 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Intraocular No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No Intraocular 717 / Month 24 1.850 No No No
 | Treatment Group Positive Intraocular Treatment Group Subject ID Formunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No

 | Treatment Group Positive Intraocular Treatment Group Subject ID Formunoreactivity Intraocular 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No
 | Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immarion Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Immunoreactivity No 177006 358 / Month 12 1.870 Infia Infia Infia Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No Intributer 719 / Month 24 1.140 No No No No
 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initianmation 177006 358 / Month 12 1.870 Initis 177006 358 / Month 12 1.870 Initis 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No | Treatment Group Positive
Intraocular Intrancular Treatment Group Subject ID Assay Assay Log Titer Intraocular 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 I.ritis No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No No No
 | Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immantion Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No Io4002 719 / Month 24 1.140 No No No No | Treatment Group Positive
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity
Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 1.870 In 177006 358/Month 12 1.870 In Ranibizumab 0.5 mg 102001 722/Month 24 1.850 No 104002 719/Month 24 1.140 No No No | Treatment Group Evolution From From From From From From From From
 |
| Norm No

 | Norm No No No 122002 359/Month 12 1.1.30 No 122002 359/Month 24 1.770 No 124003 723/Month 24 1.770 No 126001 174/Month 6 1.700 No 126001 727/Month 24 1.700 No 126001 357/Month 24 1.480 No 141013 727/Month 6 1.570 No 727/Month 6 1.570 No No 141013 715/Month 24 2.440 No 143010 722/Month 24 2.440 No 152004 522/Early Term. 0.752, No 152004 522/Month 24 2.440 No 152004 522/Month 24 1.530 No 152004 522/Month 24 2.440 No 152004 183/Month 6 1.530 No 152004 522/Month 24 1.530 No 152004 183/Month 24 1.530

 | Norm No

 | Treatment Group Fositive Fositive Immunoreactivity Immunoreactivity <thi< td=""><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No No No</td><td>Treatment Group Positive Finaminoreactivity Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 Irtitis 177006 358 / Month 12 1.870 Irtitis Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Inflammation 177006 358 / Month 12 1.870 Intris Ranibizumab 0.5 mg 102001 715 / Month 24 1.870 Intitis Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No</td><td>Treatment Group Positive Finaminoreactivity Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 Irtitis 177006 358 / Month 12 1.870 Irtitis Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No</td><td>Treatment Group Positive Finaminoreactivity Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 Irtitis 177006 358 / Month 12 1.870 Irtitis Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No</td><td>Treatment Group Positive Finaminoreactivity Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 Irtitis 177006 358 / Month 12 1.870 Irtitis Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No</td><td>Treatment Group Fositive Fositive Immunoreactivity <thi< td=""><td>Treatment Group Positive Positive Intraocular Intraocular Intraocular Intraocular Intraocular</td><td>Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770
 No No No 177006 358 / Month 12 2.800 Iritis Iritis Iritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Iritis No Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No No</td><td>Treatment Group Positive
Innunoreactivity Immunoreactivity
Innamation Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inframmation 177006 358 / Month 12 1.870 Infra 177006 358 / Month 12 1.870 Infra Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No</td><td>Treatment Group Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 No 177006 358 / Month 12 1.870 Irtis 177006 358 / Month 12 1.870 Irtis Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No 104002 719 / Month 24 0.922 No No</td></thi<></td></thi<>
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No No No

 | Treatment Group Positive Finaminoreactivity Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 Irtitis 177006 358 / Month 12 1.870 Irtitis Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Inflammation 177006 358 / Month 12 1.870 Intris Ranibizumab 0.5 mg 102001 715 / Month 24 1.870 Intitis Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No No

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No
 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No

 | Treatment Group Positive Finaminoreactivity Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 Irtitis 177006 358 / Month 12 1.870 Irtitis Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No
 | Treatment Group Positive Finaminoreactivity Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 Irtitis 177006 358 / Month 12 1.870 Irtitis Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No
 | Treatment Group Positive Finaminoreactivity Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 Irtitis 177006 358 / Month 12 1.870 Irtitis Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No
 | Treatment Group Fositive Fositive Immunoreactivity Immunoreactivity <thi< td=""><td>Treatment Group Positive Positive Intraocular Intraocular Intraocular Intraocular Intraocular</td><td>Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Iritis Iritis Iritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Iritis No Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No No</td><td>Treatment Group Positive
Innunoreactivity Immunoreactivity
Innamation Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inframmation 177006 358 / Month 12 1.870 Infra 177006 358 / Month 12 1.870 Infra Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No</td><td>Treatment Group Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 No 177006 358 / Month 12 1.870 Irtis 177006 358 / Month 12 1.870 Irtis Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No 104002 719 / Month 24 0.922 No No</td></thi<>
 | Treatment Group Positive Positive Intraocular Intraocular Intraocular Intraocular Intraocular | Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Iritis Iritis Iritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Iritis No Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No No
 | Treatment Group Positive
Innunoreactivity Immunoreactivity
Innamation Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inframmation 177006 358 / Month 12 1.870 Infra 177006 358 / Month 12 1.870 Infra Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No
 | Treatment Group Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 No 177006 358 / Month 12 1.870 Irtis 177006 358 / Month 12 1.870 Irtis Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No 104002 719 / Month 24 0.922 No No |
| I06002 722 / Month 12 1.130 No 122002 359 / Month 12 1.630 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 0.782 No 124003 722 / Month 24 0.782 No 124003 357 / Month 24 1.700 No 725 / Month 12 1.480 No No 725 / Month 12 1.900 No No 141008 181 / Month 24 2.040 No 725 / Month 12 1.900 No No 143010 725 / Month 24 2.340 Vitritis 143010 722 / Month 24 2.440 No 152004 522 / Early Term 0.752 No 153006 183 / Month 24 2.070 No 153006 183 / Month 24 2.070 No 153006 183 / Month 24 1.530 No 153007 717 / Month 24 1.230 No 167002 <

 | I06002 722 / Month 12 1.130 No 122002 335 / Month 12 1.630 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 0.782 No 124003 722 / Month 24 1.700 No 124003 725 / Month 24 1.700 No 737 / Month 12 1.480 No No 735 / Month 12 1.900 No No 735 / Month 12 1.900 No No 735 / Month 12 1.940 No No 736 / Month 12 1.940 No No 141013 715 / Month 24 2.340 Vitritis 143010 722 / Month 24 2.440 No 152004 522 / Early Term 0.752 No 153006 183 / Month 24 2.610 Vitritis 15300 713 / Month 24 0.780 No 167002 717 / Month 24 1.530 No 167002

 | I06002 722 / Month 12 I.130 No 122002 359 / Month 12 1.630 No 124003 722 / Month 24 1.770 No 126001 174 / Month 6 1.700 No 126001 357 / Month 24 0.782 No 725 / Month 12 2.040 No No 725 / Month 24 1.700 No No 725 / Month 24 1.570 No No 725 / Month 24 1.570 No No 725 / Month 24 1.570 No No 725 / Month 24 2.610 Vitritis No 141013 715 / Month 24 2.610 Ni No 143010 722 / Month 24 2.610 Ni No 153006 183 / Month 24 2.610 Ni No 153006 183 / Month 24 2.070 No No 153006 183 / Month 24 0.7780 No No 15300 153 / Month 24 <

 | Treatment Group Positive Immunoreactivity

 | Treatment Group Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular No Ranibizumab 0.5 mg 102001 715 / Month 24 1.850 No No Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No No

 | Treatment Group Positive Intraocular Treatment Group Subject ID Assay Intraocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 No 8anibizumab 0.5 mg 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 0.922 No No

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular Subject ID Sobject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intris Intris 177006 358 / Month 12 1.870 Intris Intris Ranibizumab 0.5 mg 102001 715 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No
 | Treatment Group Positive Immunoreactivity Immunoreactivity Immaniation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initia Initia 177006 358 / Month 12 1.870 Initis Initis Ranibizumab 0.5 mg 102001 715 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular Subject ID Sobject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intris Intris 177006 358 / Month 12 1.870 Intris Intris Ranibizumab 0.5 mg 102001 715 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular Subject ID Sobject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intris Intris 177006 358 / Month 12 1.870 Intris Intris Ranibizumab 0.5 mg 102001 715 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No
 | Treatment Group Positive Intraocular Treatment Group Subject ID Assay Intraocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 No 8anibizumab 0.5 mg 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 0.922 No No
 | Treatment Group Positive Intraocular Treatment Group Subject ID Assay Intraocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 No 8anibizumab 0.5 mg 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 0.922 No No
 | Treatment Group Positive Intraocular
 Treatment Group Subject ID Assay Intraocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 No 8anibizumab 0.5 mg 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 0.922 No No
 | Treatment Group Positive Immunoreactivity | Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No 177006 358 / Month 12 1.870 Intraocular 177006 358 / Month 12 1.870 Intris Ranibizumab 0.5 mg 102001 715 / Month 24 1.870 Intris 104002 719 / Month 24 1.140 No No
 | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initia Initia 177006 358 / Month 12 1.870 Initis Initis Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No | Treatment Group
Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Irritis Irritis 177006 358 / Month 12 1.870 Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No 104002 719 / Month 24 1.140 No No | Treatment Group Positive
Subject ID Positive
Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No | Treatment Group Subject ID Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 No No No 177006 358 / Month 12 1.870 No No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No 104002 719 / Month 24 1.140 No No No No |
| I06002 722/Month 24 1.130 No 122002 359/Month 12 1.630 No 122003 359/Month 24 1.770 No 124003 722/Month 24 1.770 No 124003 722/Month 24 1.700 No 124001 174/Month 6 1.700 No 124002 357/Month 12 1.700 No 725/Month 12 1.700 No No 735/Month 24 1.570 No No 735/Month 24 1.570 No No 735/Month 24 2.610 Vitritis No 143010 722/Month 24 2.440 No 153006 183/Month 6 1.900 No 153006 183/Month 24 2.610 Nitritis 153006 183/Month 6 1.900 No 153006 183/Month 24 2.070 No 153006 183/Month 24 1.900 No 1530017 715/Month 24 1.0

 | Interpretation Interpretation Interpretation No No 122002 359/Month 12 1.30 No No No 122003 359/Month 12 1.530 No No No 124003 722/Month 24 1.770 No No No 124001 174/Month 6 1.700 No No No 125001 174/Month 24 2.040 No No No 141008 181/Month 24 1.570 No No No 725/Month 12 1.570 No No No No 735/Month 24 2.040 No No No No 143010 722/Month 24 2.440 No No No 153006 183/Month 24 2.610 Nitritis No No 153006 183/Month 24 2.610 Nitritis No No 153006 183/Month 24 0.752 No No No

 | I06002 722 / Month 24 1.130 No 122002 359 / Month 12 1.530 No 124003 723 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 6 1.700 No 124003 722 / Month 12 1.700 No 126001 174 / Month 6 1.700 No 141008 181 / Month 24 2.040 No 725 / Month 12 1.940 No No 141008 181 / Month 24 2.340 Nitritis 143010 725 / Month 24 2.440 No 152064 522 / Early Term. 0.752 No 153005 183 / Month 24 2.630 No 153006 153006 183 / Month 24 2.070 153005 183 / Month 24 1.530 No 153006 153006 No No 153005 188005 717 / Month 24 1.530 No

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Iritis
 177006 358 / Month 12 1.870 Iritis Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Inframmation Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Infraocular No No 177006 358 / Month 12 1.870 Infraocular No No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No <t< td=""><td>Treatment Group Subject ID Positive
fimmunor eactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Iritis No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No No 100002 710 / Month 24 0.922 No No No No No No</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Inframmation Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Infraocular No No 177006 358 / Month 12 1.870 Infraocular No No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No <t< td=""><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Inframmation Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Infraocular No No 177006 358 / Month 12 1.870 Infraocular No No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No <t< td=""><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No</td><td>Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No</td><td>Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Infammation 170010 365/Month 12 2.770 No No No 170010 355/Month 12 2.770 No No No 177006 358/Month 12 1.870 I.ritis Iritis Iritis Ranibizumab 0.5 mg 102001 717/Month 24 0.922 No No 100002 710/Month 24 0.922 No No No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 2.800 Inframmation 177/006 358/Month 12 1.870 No 177/005 373/Month 24 1.850 No Ranibizumab 0.5 mg 102001 717/Month 24 0.922 No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 12 2.800 Intra Intra 177006 358/Month 12 1.870 No 177/Month 24 1.850 No 102001 717/Month 24 0.922 No 104002 710/Month 24 0.922 No No</td><td>Treatment Group Evolution Formunoreactivity funnumoreactivity funnumoreactivity funnumoreactivity funnumation Intraocular funnumation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12
 2.770 No No 177006 358 / Month 12 2.800 Intra No 177006 358 / Month 12 1.870 Intris Intris Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No</td></t<></td></t<></td></t<> | Treatment Group Subject ID Positive
fimmunor eactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 170010 365 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Iritis No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No No 100002 710 / Month 24 0.922 No No No No No No

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Inframmation Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Infraocular No No 177006 358 / Month 12 1.870 Infraocular No No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No <t< td=""><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Inframmation Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Infraocular No No 177006 358 / Month 12 1.870 Infraocular No No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No <t< td=""><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No</td><td>Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No</td><td>Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Infammation 170010 365/Month 12 2.770 No No No 170010 355/Month 12 2.770 No No No 177006 358/Month 12 1.870 I.ritis Iritis Iritis Ranibizumab 0.5 mg 102001 717/Month 24 0.922 No No 100002 710/Month 24 0.922 No No No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12
 2.770 No No 177006 358/Month 12 2.800 Inframmation 177/006 358/Month 12 1.870 No 177/005 373/Month 24 1.850 No Ranibizumab 0.5 mg 102001 717/Month 24 0.922 No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 12 2.800 Intra Intra 177006 358/Month 12 1.870 No 177/Month 24 1.850 No 102001 717/Month 24 0.922 No 104002 710/Month 24 0.922 No No</td><td>Treatment Group Evolution Formunoreactivity funnumoreactivity funnumoreactivity funnumoreactivity funnumation Intraocular funnumation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intra No 177006 358 / Month 12 1.870 Intris Intris Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No</td></t<></td></t<> | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Inframmation Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Infraocular No No 177006 358 / Month 12 1.870 Infraocular No No No Ranibizumab 0.5 mg 102001 717 / Month 24 0.922
 No No <t< td=""><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No</td><td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No</td><td>Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No</td><td>Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Infammation 170010 365/Month 12 2.770 No No No 170010 355/Month 12 2.770 No No No 177006 358/Month 12 1.870 I.ritis Iritis Iritis Ranibizumab 0.5 mg 102001 717/Month 24 0.922 No No 100002 710/Month 24 0.922 No No No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 2.800 Inframmation 177/006 358/Month 12 1.870 No 177/005 373/Month 24 1.850 No Ranibizumab 0.5 mg 102001 717/Month 24 0.922 No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 12 2.800 Intra Intra 177006 358/Month 12 1.870 No 177/Month 24 1.850 No 102001 717/Month 24 0.922 No 104002 710/Month 24 0.922 No No</td><td>Treatment Group Evolution Formunoreactivity funnumoreactivity funnumoreactivity funnumoreactivity funnumation Intraocular funnumation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intra No 177006 358 / Month 12 1.870 Intris Intris Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No</td></t<>
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No No
 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No 177006 358 / Month 12 1.870 Iritis 177006 358 / Month 12 1.870 Iritis Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No
 | Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No
 | Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Infammation 170010 365/Month 12 2.770 No No No 170010 355/Month 12 2.770 No No No 177006 358/Month 12 1.870 I.ritis Iritis Iritis Ranibizumab 0.5 mg 102001 717/Month 24 0.922 No No 100002 710/Month 24 0.922 No No No No | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer
 Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 2.800 Inframmation 177/006 358/Month 12 1.870 No 177/005 373/Month 24 1.850 No Ranibizumab 0.5 mg 102001 717/Month 24 0.922 No | Treatment Group Positive
Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 12 2.800 Intra Intra 177006 358/Month 12 1.870 No 177/Month 24 1.850 No 102001 717/Month 24 0.922 No 104002 710/Month 24 0.922 No No | Treatment Group Evolution Formunoreactivity funnumoreactivity funnumoreactivity funnumoreactivity funnumation Intraocular funnumation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intra No 177006 358 / Month 12 1.870 Intris Intris Ranibizumab 0.5 mg 102001 717 / Month 24 0.922 No |
| I06002 722/Month 24 1130 No 122002 359/Month 12 1.630 No 124003 722/Month 24 1.770 No 124001 174/Month 6 1.700 No 126001 172/Month 12 2.040 No 141018 181/Month 6 1.570 No 141013 715/Month 12 1.940 No 755/Month 12 1.940 No 143010 722/Month 24 2.440 No 153006 183/Month 24 2.440 No 153005 183/Month 24 2.640 No 153005 183/Month 24 2.640 No 153005 183/Month 24 2.640 No 153005 173/Month 24 2.640 No 153005 183/Month 24 2.640 No 167002 718/Month 24 0.752 No 153005 183/Month 24 1.900 No 153005 183/Month 24 1.900 No 167002 711/Month 24

 | Interpretation Interpreation Interpretation Interpr

 | I06002 722/Month 24 1.130 No 122002 359/Month 24 1.170 No 124003 722/Month 24 1.770 No 126001 174/Month 6 1.700 No 126001 174/Month 24 0.782 No 126001 174/Month 6 1.700 No 126001 174/Month 24 1.630 No 141008 181/Month 24 1.640 No 141013 715/Month 12 1.940 No 143010 725/Month 24 2.340 Nitritis 143010 725/Month 24 2.340 No 143010 725/Month 24 2.340 No 153006 183/Month 24 2.610 No 153006 183/Month 24 2.070 No 153005 183/Month 24 1.900 No 153005 183/Month 24 1.900 No 153005 183/Month 24 1.900 No 153005 183/Month 24

 | Treatment Group Fositive Fositive Immunoreactivity

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 358 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 712 / Month 24 0.922 No No

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular No Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No No

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Intraocular Intraocular 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Irritis Irritis Irritis Ranibizumab 0.5 mg 102001 712 / Month 24 0.922 No No

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No
 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular No Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No No
 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular No Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No No
 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular No Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No No
 | Treatment Group Fositive Fositive Immunoreactivity
 | Treatment Group Positive Positive Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Iritis Iritis Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No
 | Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 2.800 Iritis Intraocular Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Iritis No | Treatment Group Positive
Intraocular Intunoreactivity
Assay Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 2.800 Intraocular Intraocular Ranibizumab 0.5 mg 102001 717 / Month 24 1.870 Intris
 | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Infiammation 177006 358 / Month 12 1.870 Infia Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunation Treatment Group Subject ID Assay Assay Assay Inframmation 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 No No No 177006 358 / Month 12 1.870 Intris No No Ranibizumab 0.5 mg 102001 717 / Month 24 1.850 No No |
| Identity 1.140 No 12002 722 Month 24 1.140 No 122002 357 Month 24 1.130 No 122002 357 Month 24 1.770 No 126001 174 Month 6 1.700 No 126001 174 Month 6 1.700 No 126001 174 Month 12 2.040 No 126001 174 Month 24 0.782 No 141018 181 Month 24 0.782 No 141013 715 Month 12 1.940 No 143010 725 Month 24 2.340 Vitritis 143010 725 Month 24 2.340 No 15004 522 Larty Term. 0.752 . No 153006 183 Month 24 2.340 No 153006 183 Month 24 2.340 No 153006 183 Month 24 0.752 . No 153006 183 Month 24 1.900 No

 | Identity 1.140 No 12002 722 Month 24 1.140 No 122002 357 Month 24 1.130 No 122002 357 Month 24 1.770 No 126001 174 Month 6 1.700 No 126001 174 Month 6 1.700 No 126001 174 Month 12 2.040 No 126001 174 Month 24 0.782 No 141008 181 Month 24 0.782 No 141013 715 Month 12 1.940 No 143010 722 Month 24 2.340 Vitritis 143010 725 Month 24 2.340 No 133006 183 Month 6 1.900 No 152004 522 Larty Term 0.752 No 153006 183 Month 6 1.900 No 150017 716 Month 24 2.340 No 138005 183 Month 6 1.900 No

 | Identity (140) No 112002 722 / Month 24 1.140 No 112002 357 / Month 12 1.130 No 112002 722 / Month 12 1.000 No 126001 174 / Month 6 1.700 No 126001 174 / Month 12 1.000 No 126001 174 / Month 12 2.040 No 126001 174 / Month 12 1.700 No 141008 181 / Month 24 0.782 No 141013 715 / Month 12 1.940 No 143010 722 / Month 12 1.940 No 143010 725 / Month 24 2.610 Nic 143010 715 / Month 24 2.610 Nic 153006 183 / Month 12 1.930 No 153006 183 / Month 24 0.780 No 15300 1530 No No 15300 1350 No No 153005 183 / Month 24 1.530

 | Treatment Group Positive Immunoreactivity

 | Treatment Group Positive Immunoreactivity

 | Treatment Group Evolution Positive Intraocular Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No

 | Treatment Group Subject ID Positive Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immation Treatment Group Subject ID 365 / Month 12 2.770 No No <td< td=""><td>Treatment Group Subject ID Positive Immunoreactivity Immunoreactivity Immania Treatment Group Subject ID 365 / Month 12 2.770 No No</td><td>Treatment Group Subject
ID Positive Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immation Treatment Group Subject ID 365 / Month 12 2.770 No <td< td=""><td>Treatment Group Subject ID Positive Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immation Treatment Group Subject ID 365 / Month 12 2.770 No <td< td=""><td>Treatment Group Evolution Positive Intraocular Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No</td><td>Treatment Group Evolution Positive Intraocular Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No</td><td>Treatment Group Evolution Positive Intraocular Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No</td><td>Treatment Group Positive Immunoreactivity Immunoreactivity</td><td>Treatment Group Positive Fositive Immunoreactivity <thi< td=""><td>Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No <td< td=""><td>Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intrancular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intra 177006 358 / Month 12 1.870 Intris Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No</td><td>Treatment Group Positive
Subject ID Positive
Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intris Intris Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 No No No Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No No</td></td<></td></thi<></td></td<></td></td<></td></td<>
 | Treatment Group Subject ID Positive Immunoreactivity Immunoreactivity Immania Treatment Group Subject ID 365 / Month 12 2.770 No
 | Treatment Group Subject ID Positive Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immation Treatment Group Subject ID 365 / Month 12 2.770 No No <td< td=""><td>Treatment Group Subject ID Positive Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immation Treatment Group Subject ID 365 / Month 12 2.770 No <td< td=""><td>Treatment Group Evolution Positive Intraocular Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No</td><td>Treatment Group Evolution Positive Intraocular Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No</td><td>Treatment Group Evolution Positive Intraocular Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No</td><td>Treatment Group Positive Immunoreactivity Immunoreactivity</td><td>Treatment Group Positive Fositive Immunoreactivity <thi< td=""><td>Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No <td< td=""><td>Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intrancular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intra 177006 358 / Month 12 1.870 Intris Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No</td><td>Treatment Group Positive
Subject ID Positive
Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intris Intris Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 No No No Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No No</td></td<></td></thi<></td></td<></td></td<>
 | Treatment Group Subject ID Positive Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immation Treatment Group Subject ID 365 / Month 12 2.770 No No <td< td=""><td>Treatment Group Evolution Positive Intraocular Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No</td><td>Treatment Group Evolution Positive Intraocular Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No</td><td>Treatment Group Evolution Positive Intraocular Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No</td><td>Treatment Group Positive Immunoreactivity Immunoreactivity</td><td>Treatment Group Positive Fositive Immunoreactivity <thi< td=""><td>Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No <td< td=""><td>Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intrancular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intra 177006 358 / Month 12 1.870 Intris Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No</td><td>Treatment Group Positive
Subject ID Positive
Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intris Intris Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 No No No Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No No</td></td<></td></thi<></td></td<>
 | Treatment Group Evolution Positive Intraocular Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No
 | Treatment Group Evolution Positive Intraocular Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No

 | Treatment Group Evolution Positive Intraocular Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Inflammation 177006 358 / Month 12 1.870 No Ranibizumab 0.5 mg 102001 712 / Month 24 1.850 No
 | Treatment Group Positive Immunoreactivity | Treatment Group Positive Fositive Immunoreactivity Immunoreactivity <thi< td=""><td>Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No <td< td=""><td>Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intrancular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intra 177006 358 / Month 12 1.870 Intris Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No</td><td>Treatment Group Positive
Subject ID Positive
Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intris Intris Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 No No No Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No No</td></td<></td></thi<>
 | Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No <td< td=""><td>Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intrancular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intra 177006 358 / Month 12 1.870 Intris Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No</td><td>Treatment Group Positive
Subject ID Positive
Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intris Intris Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 No No No Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No No</td></td<> | Treatment Group Positive
Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intrancular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intra 177006 358 / Month 12 1.870 Intris Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No
 | Treatment Group Positive
Subject ID Positive
Assay Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intris Intris Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No | Treatment Group Subject ID Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 No No No Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No No |
| I04002 719/Month 24 1140 No 106002 722/Month 24 1130 No 122002 359/Month 12 1.630 No 124003 723/Month 24 1.770 No 124001 174/Month 6 1.700 No 126001 174/Month 5 0.782 No 126001 174/Month 5 1.700 No 126001 174/Month 5 1.700 No 141008 181/Month 6 1.570 No 141013 727/Month 24 1.480 No 141013 715/Month 24 1.940 No 143010 722/Month 24 1.940 No 143010 725/Month 24 2.610 No 143010 725/Month 24 2.610 No 143010 725/Month 24 1.940 No 133006 183/Month 6 1.970 No 133006 183/Month 24 2.610 No 153005 183/Month 24 1.97

 | I04002 719/Month 24 1140 No 106002 722/Month 24 1130 No 122002 359/Month 12 1.630 No 124003 723/Month 24 1.770 No 124001 174/Month 6 1.700 No 126001 174/Month 24 1.700 No 126001 174/Month 24 1.700 No 126001 174/Month 24 1.480 No 141008 181/Month 6 1.570 No 141013 715/Month 24 1.940 No 143010 722/Month 24 1.940 No 143010 725/Month 24 1.940 No 143010 725/Month 24 2.610 Nin 143010 725/Month 24 2.610 No 133006 183/Month 6 1.900 No 133006 183/Month 24 2.610 No 153006 183/Month 24 1.530 No 153005 183/Month 24

 | I04002 719/Month 24 1140 No 106002 722/Month 24 1130 No 122002 359/Month 12 1.530 No 124003 723/Month 24 1.770 No 124001 174/Month 24 1.770 No 126001 174/Month 24 1.770 No 126001 174/Month 24 1.480 No 126001 174/Month 24 1.480 No 141008 181/Month 6 1.570 No 141013 715/Month 24 1.480 No 143010 722/Month 24 1.940 No 143010 722/Month 24 1.570 No 143010 722/Month 24 1.570 No 153004 527/Month 24 2.440 No 153004 527/Month 24 1.530 No 153004 527/Month 24 1.530 No 153004 527/Month 24 1.530 No 153005 1.1530 No <td>Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 2.800 Iritis Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No</td> <td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immation Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Immunoreactivity Immunoreactivity 177006 358 / Month 12 2.800 Iritis Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis Iritis Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No No</td> <td>Treatment Group Positive Intraocular Treatment Group Subject ID Assay Intraocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 No 177/006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No</td> <td>Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 1.870 Intraocular Intraocular Intraocular Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No No</td> <td>Treatment Group Positive
Innunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 1.870 Intraocular Intraocular No Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No No</td> <td>Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 1.870 Intraocular Intraocular Intraocular Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No No</td> <td>Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 1.870 Intraocular Intraocular Intraocular Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No No</td> <td>Treatment Group Positive Intraocular Treatment Group Subject ID Assay Intraocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 No 177/006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No</td> <td>Treatment Group Positive Intraocular Treatment Group Subject ID Assay Intraocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 No 177/006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No</td> <td>Treatment Group Positive Intraocular Treatment Group Subject ID Assay Intraocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 No 177/006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No</td> <td>Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 2.800 Iritis Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No</td> <td>Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365/Month 12 2.770 No No No 177006 358/Month 12 2.800 Intraocular No No 177006 358/Month 12 1.870 No No No 177006 358/Month 12 1.870 Intris No No Ranibizumab 0.5 mg 102001 722/Month 24 0.922 No No</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 12 1.870
 Intraocular Intraocular 177006 358/Month 12 1.870 Intris No Ranibizumab 0.5 mg 102001 722/Month 24 0.922 No</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 12 1.870 Intra Intris No 177006 358/Month 12 1.870 Intis No No Ranibizumab 0.5 mg 102001 722/Month 24 0.922 No No</td> <td>Treatment Group Positive
Subject ID Positive
Assay Intranocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Irritis Irritis 177006 358 / Month 12 1.870 No No Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No</td> <td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td>
 | Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 2.800 Iritis Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No

 | Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immation Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Immunoreactivity Immunoreactivity 177006 358 / Month 12 2.800 Iritis Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis Iritis Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No No

 | Treatment Group Positive Intraocular Treatment Group Subject ID Assay Intraocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 No 177/006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No

 | Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 1.870 Intraocular Intraocular Intraocular Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No No
 | Treatment Group Positive
Innunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 1.870 Intraocular Intraocular No Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No No

 | Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 1.870 Intraocular Intraocular Intraocular Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No No

 | Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 1.870 Intraocular Intraocular Intraocular Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No No
 | Treatment Group Positive Intraocular Treatment Group Subject ID Assay Intraocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 No 177/006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No
 | Treatment Group Positive Intraocular Treatment Group Subject ID Assay Intraocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 No 177/006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No
 |
Treatment Group Positive Intraocular Treatment Group Subject ID Assay Intraocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 No 177/006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No
 | Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 2.800 Iritis Intraocular 177006 358 / Month 12 1.870 Intraocular Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No | Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365/Month 12 2.770 No No No 177006 358/Month 12 2.800 Intraocular No No 177006 358/Month 12 1.870 No No No 177006 358/Month 12 1.870 Intris No No Ranibizumab 0.5 mg 102001 722/Month 24 0.922 No No
 | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 12 1.870 Intraocular Intraocular 177006 358/Month 12 1.870 Intris No Ranibizumab 0.5 mg 102001 722/Month 24 0.922 No
 | Treatment Group Positive
Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No No 177006 358/Month 12 1.870 Intra Intris No 177006 358/Month 12 1.870 Intis No No Ranibizumab 0.5 mg 102001 722/Month 24 0.922 No No | Treatment Group Positive
Subject ID Positive
Assay Intranocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Irritis Irritis 177006 358 / Month 12 1.870 No No Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit |
| Io4002 719/Month 24 1140 No No 12002 359/Month 12 1.130 No No 122002 359/Month 24 1.130 No No 124003 722/Month 24 1.770 No No 124003 357/Month 24 1.770 No No 124003 357/Month 24 1.770 No No 12401 357/Month 24 1.770 No No 12401 357/Month 24 1.770 No No 12401 727/Month 24 1.480 No No 141008 181/Month 24 1.570 No No 141013 715/Month 24 1.570 No No 143010 722/Month 24 2.440 No No 152004 522/Month 24 1.570 No No 153004 522/Month 24 1.530 No No 153004 522/Month 24 1.530 No No

 | Io4002 719/Month 24 1140 No 12002 359/Month 12 1.130 No 122002 359/Month 12 1.630 No 124003 722/Month 24 1.770 No 124003 722/Month 24 1.770 No 124003 357/Month 24 1.770 No 126001 174/Month 6 1.770 No 126001 727/Month 24 1.700 No 141008 181/Month 6 1.570 No 141003 181/Month 24 1.480 No 141013 715/Month 24 1.570 No 141013 715/Month 24 1.570 No 143010 722/Month 24 2.610 Vitritis 143010 722/Month 24 2.610 No 153004 535/Month 12 1.940 No 153004 535/Month 24 2.610 Ni 153004 522/Month 24 1.530 No 153004 1.530 N

 | I04002 719/Month 24 1140 No 122002 359/Month 12 1.130 No 122002 359/Month 24 1.130 No 124003 722/Month 24 1.700 No 124003 722/Month 24 1.770 No 124003 722/Month 24 1.700 No 124003 722/Month 12 1.700 No 12400 727/Month 24 1.700 No 12400 727/Month 24 1.570 No 141008 181/Month 6 1.570 No 141013 715/Month 24 1.940 No 143010 722/Month 24 1.570 No 143010 722/Month 24 1.940 No 153004 522/Early Term 0.752 No 153006 15300 No No 153006 15300 No No 153007 523/Month 24 1.070 No 153007 15300 No No <td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immation Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Iritis No 177006 358 / Month 12 1.870 Iritis No Ranihirumah 0.5 mm 102001 272 / Month 24 1.850 No No</td> <td>Treatment Group Fositive Immunoreactivity Immunoreactivity</td> <td>Treatment Group Positive Intraocular Treatment Group Subject ID Finnunoreactivity Inframmation 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 715 / Month 24 2.800 Iritis 177006 358 / Month 12 1.870 Iritis Parititization A form 717 / Month 24 1.870 Iritis</td> <td>Treatment Group Subject ID Positive
finamination Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initia 177006 358 / Month 12 1.870 Initis Ranihirumoh 0.5 mg 717 / Month 24 1.850 No</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Immunoreactivity Inflammation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initia Initia 177006 358 / Month 12 1.870 Initis Initis Ranihirumoh 0.5 mm 102001 202 / Month 24 1.850 Initis</td> <td>Treatment Group Subject ID Positive
finamination Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initia 177006 358 / Month 12 1.870 Initis Ranihirumoh 0.5 mg 717 / Month 24 1.850 No</td> <td>Treatment Group Subject ID Positive
finamination Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initia 177006 358 / Month 12 1.870 Initis Ranihirumoh 0.5 mg 717 / Month 24 1.850 No</td> <td>Treatment Group Positive Intraocular Treatment Group Subject ID Finnunoreactivity Inframmation 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 715 / Month 24 2.800 Iritis 177006 358 / Month 12 1.870 Iritis Parititization A form 717 / Month 24 1.870 Iritis</td> <td>Treatment Group Positive Intraocular Treatment Group Subject ID Finnunoreactivity Inframmation 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 715 / Month 24 2.800 Iritis 177006 358 / Month 12 1.870 Iritis Parititization A form 717 / Month 24 1.870 Iritis</td> <td>Treatment Group Positive Intraocular Treatment Group Subject ID Finnunoreactivity Inframmation 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 715 / Month 24 2.800 Iritis 177006 358 / Month 12 1.870 Iritis Parititization A form 717 / Month 24 1.870 Iritis</td> <td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immation Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Iritis No 177006 358 / Month 12 1.870 Iritis No Ranihirumah 0.5 mm 102001 272 / Month 24 1.850 No No</td> <td>Treatment Group Positive Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Iritis Iritis No 177006 358 / Month 12 1.870 Iritis No No Ranihirumah 0.5 mm 102001 2717 / Month 24 1.850 No No</td> <td>Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 2.800 Intra Intra 177006 358 / Month 12 1.870 Intris Intris Ranihirumah 0.5 mm 102001 270.000 270.000 270.000 No</td> <td>Treatment Group Positive
Intraocular Intrancular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Intraocular Intraocular 177006 358 / Month 12 1.870 Intris No Ranihirumah 0.5 mm 102001 270.000 270.000 No
No</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initis Initis 177006 358 / Month 12 1.870 Initis Initis Ranihirumah 0.5 mm 102001 272 / Month 24 1.850 No</td> <td>Treatment Group Routing Finnunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Inframmation 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Initia No No 177006 358 / Month 12 1.870 Initis No No Ranihizumah 0.5 mm 102001 270 / Month 24 1.850 No No</td>
 | Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immation Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Iritis No 177006 358 / Month 12 1.870 Iritis No Ranihirumah 0.5 mm 102001 272 / Month 24 1.850 No No

 | Treatment Group Fositive Immunoreactivity

 | Treatment Group Positive Intraocular Treatment Group Subject ID Finnunoreactivity Inframmation 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 715 / Month 24 2.800 Iritis 177006 358 / Month 12 1.870 Iritis Parititization A form 717 / Month 24 1.870 Iritis

 | Treatment Group Subject ID Positive
finamination Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initia 177006 358 / Month 12 1.870 Initis Ranihirumoh 0.5 mg 717 / Month 24 1.850 No

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Immunoreactivity Inflammation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initia Initia 177006 358 / Month 12 1.870 Initis Initis Ranihirumoh 0.5 mm 102001 202 / Month 24 1.850 Initis

 | Treatment Group Subject ID Positive
finamination Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initia 177006 358 / Month 12 1.870 Initis Ranihirumoh 0.5 mg 717 / Month 24 1.850 No
 | Treatment Group Subject ID Positive
finamination Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initia 177006 358 / Month 12 1.870 Initis Ranihirumoh 0.5 mg 717 / Month 24 1.850 No

 | Treatment Group Positive Intraocular Treatment Group Subject ID Finnunoreactivity Inframmation 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 715 / Month 24 2.800 Iritis 177006 358 / Month 12 1.870 Iritis Parititization A form 717 / Month 24 1.870 Iritis
 | Treatment Group Positive Intraocular Treatment Group Subject ID Finnunoreactivity Inframmation 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 715 / Month 24 2.800 Iritis 177006 358 / Month 12 1.870 Iritis Parititization A form 717 / Month 24 1.870 Iritis
 | Treatment Group Positive Intraocular Treatment Group Subject ID Finnunoreactivity Inframmation 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 715 / Month 24 2.800 Iritis 177006 358 / Month 12 1.870 Iritis Parititization A form 717 / Month 24 1.870 Iritis
 | Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immation Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Iritis No 177006 358 / Month 12 1.870 Iritis No Ranihirumah 0.5 mm 102001 272 / Month 24 1.850 No No
 | Treatment Group Positive Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Iritis Iritis No 177006 358 / Month 12 1.870 Iritis No No Ranihirumah 0.5 mm 102001 2717 / Month 24 1.850 No No
 | Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 2.800 Intra Intra 177006 358 / Month 12 1.870 Intris Intris Ranihirumah 0.5 mm 102001 270.000 270.000 270.000 No |
Treatment Group Positive
Intraocular Intrancular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Intraocular Intraocular 177006 358 / Month 12 1.870 Intris No Ranihirumah 0.5 mm 102001 270.000 270.000 No No | Treatment Group Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initis Initis 177006 358 / Month 12 1.870 Initis Initis Ranihirumah 0.5 mm 102001 272 / Month 24 1.850 No | Treatment Group Routing Finnunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Inframmation 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Initia No No 177006 358 / Month 12 1.870 Initis No No Ranihizumah 0.5 mm 102001 270 / Month 24 1.850 No No |
| I04002 719/ Month 24 1140 No 106002 722 / Month 24 1130 No 122002 359 / Month 12 1.630 No 122002 359 / Month 24 1.170 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124001 174 / Month 6 1.700 No 124003 722 / Month 12 1.700 No 124001 174 / Month 24 0.782 No 141008 181 / Month 24 1.570 No 141013 715 / Month 24 1.460 No 143010 722 / Month 24 1.570 No 152004 522 / Early Term 0.752 No 153006 183 / Month 24 2.440 No 153006 183 / Month 24 2.400 No 153006 183 / Month 24 1.530 No 153006 183 / Month 24 1.530 No 155004 522 / Early Term 0.752 No 155007 18000 No No 155017 716 / Month 24 1.250 No 155017 7110 / Month 24 1.250 No <th>I04002 719/ Month 24 1140 No 106002 722 / Month 24 1130 No 122002 359 / Month 12 1.650 No 122001 723 / Month 24 1.170 No 124003 722 / Month 24 1.700 No 124001 174 / Month 24 1.700 No 124003 722 / Month 12 1.700 No 124001 174 / Month 24 0.782 No 141008 181 / Month 24 1.480 No 141013 715 / Month 24 1.470 No 141013 715 / Month 24 1.470 No 15004 522 / Early Term. 0.752 No 153006 183 / Month 24 2.440 No 153006 183 / Month 24 2.400 No 153006 183 / Month 24 2.070 No 153006 183 / Month 24 1.530 No 153006 183 / Month 24 1.530 No 155007 713 / Month 24 1.250 No 159017 716 / Month 24 1.250 No 158005 717 / Month 24 1.250 No 188005 717 / Month 24 1.250 <</th> <td>Ioboliz 719/Month 24 1.140 No 122002 359/Month 12 1.630 No 122002 359/Month 12 1.630 No 124003 722/Month 24 1.170 No 124003 722/Month 24 1.770 No 124003 722/Month 24 1.770 No 124003 722/Month 24 0.782 No 126001 174/Month 6 1.700 No 126001 174/Month 24 2.040 No 727/Month 12 1.940 No No 715/Month 24 2.340 Ni No 141013 715/Month 24 2.610 Ni 152004 522/Early Term. 0.752. No 153006 183/Month 24 2.070 No 153005 183/Month 24 1.900 No 153005 183/Month 24 1.900 No 153005 183/Month 24 1.900 No 153005 1.33/Month 24 <td< td=""><td>Treatment Group Positive Immunoreactivity Immunoreactivity</td><td>Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 388 / Month 12 2.800 Intraocular 177006 378 / Month 12 1.870 Intris</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No No No 177006 388 / Month 12 1.870 1.870 Irritis No</td><td>Treatment Group Subject ID Positive
fimmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No No 177006 378 / Month 12 1.870 Irritis Irritis</td><td>Treatment Group Subject ID Positive
Innunoreactivity Innunoreactivity Intraocular Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No No 177006 378 / Month 12 1.870 Intris Intris</td><td>Treatment Group Subject ID Positive
fimmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No No 177006 378 / Month 12 1.870 Irritis Irritis</td><td>Treatment Group Subject ID Positive
fimmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No No 177006 378 / Month 12 2.800 Irritis Irritis</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No No No 177006 388 / Month 12 1.870 1.870 Irritis No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No No No 177006 388 / Month 12 1.870 1.870 Irritis No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No No No 177006 388 / Month 12 1.870 1.870 Irritis No</td><td>Treatment Group Positive Immunoreactivity Immunoreactivity</td><td>Treatment Group Positive Immunoreactivity Immunoreactivity</td><td>Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Assay Assay Inframmation 170010 365 / Month 12 2.770 No No No No No 177006 358 / Month 12 1.870 Intraocular Intraocular No No</td></td<><td>Treatment Group Positive Innunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 2.800 Intraocular No Intraocular 177006 358 / Month 12 1.870 Intris Intris Intris</td><td>Treatment Group Positive
Intraocular Intrancular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Iritis Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis Iritis</td><td>Treatment Group Subject ID Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Inflammation 170010 365 / Month 12 2.770 No No Inflammation 177006 358 / Month 12 2.800 Initia Initia 177006 358 / Month 12 1.870 Initia Initia</td></td>

 | I04002 719/ Month 24 1140 No 106002 722 / Month 24 1130 No 122002 359 / Month 12 1.650 No 122001 723 / Month 24 1.170 No 124003 722 / Month 24 1.700 No 124001 174 / Month 24 1.700 No 124003 722 / Month 12 1.700 No 124001 174 / Month 24 0.782 No 141008 181 / Month 24 1.480 No 141013 715 / Month 24 1.470 No 141013 715 / Month 24 1.470 No 15004 522 / Early Term. 0.752 No 153006 183 / Month 24 2.440 No 153006 183 / Month 24 2.400 No 153006 183 / Month 24 2.070 No 153006 183 / Month 24 1.530 No 153006 183 / Month 24 1.530 No 155007 713 / Month 24 1.250 No 159017 716 / Month 24 1.250 No 158005 717 / Month 24 1.250 No 188005 717 / Month 24 1.250 <

 | Ioboliz 719/Month 24 1.140 No 122002 359/Month 12 1.630 No 122002 359/Month 12 1.630 No 124003 722/Month 24 1.170 No 124003 722/Month 24 1.770 No 124003 722/Month 24 1.770 No 124003 722/Month 24 0.782 No 126001 174/Month 6 1.700 No 126001 174/Month 24 2.040 No 727/Month 12 1.940 No No 715/Month 24 2.340 Ni No 141013 715/Month 24 2.610 Ni 152004 522/Early Term. 0.752. No 153006 183/Month 24 2.070 No 153005 183/Month 24 1.900 No 153005 183/Month 24 1.900 No 153005 183/Month 24 1.900 No 153005 1.33/Month 24 <td< td=""><td>Treatment Group Positive Immunoreactivity Immunoreactivity</td><td>Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 388 / Month 12 2.800 Intraocular 177006 378 / Month 12 1.870 Intris</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No No No 177006 388 / Month 12 1.870 1.870 Irritis No</td><td>Treatment Group Subject ID Positive
fimmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No No 177006 378 / Month 12 1.870 Irritis Irritis</td><td>Treatment Group Subject ID Positive
Innunoreactivity Innunoreactivity Intraocular Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No No 177006 378 / Month 12 1.870 Intris Intris</td><td>Treatment Group Subject ID Positive
fimmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No No 177006 378 / Month 12 1.870
Irritis Irritis</td><td>Treatment Group Subject ID Positive
fimmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No No 177006 378 / Month 12 2.800 Irritis Irritis</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No No No 177006 388 / Month 12 1.870 1.870 Irritis No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No No No 177006 388 / Month 12 1.870 1.870 Irritis No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No No No 177006 388 / Month 12 1.870 1.870 Irritis No</td><td>Treatment Group Positive Immunoreactivity Immunoreactivity</td><td>Treatment Group Positive Immunoreactivity Immunoreactivity</td><td>Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Assay Assay Inframmation 170010 365 / Month 12 2.770 No No No No No 177006 358 / Month 12 1.870 Intraocular Intraocular No No</td></td<> <td>Treatment Group Positive Innunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 2.800 Intraocular No Intraocular 177006 358 / Month 12 1.870 Intris Intris Intris</td> <td>Treatment Group Positive
Intraocular Intrancular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Iritis Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis Iritis</td> <td>Treatment Group Subject ID Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Inflammation 170010 365 / Month 12 2.770 No No Inflammation 177006 358 / Month 12 2.800 Initia Initia 177006 358 / Month 12 1.870 Initia Initia</td>
 | Treatment Group Positive Immunoreactivity

 | Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 388 / Month 12 2.800 Intraocular 177006 378 / Month 12 1.870 Intris

 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No No No 177006 388 / Month 12 1.870 1.870 Irritis No

 | Treatment Group Subject ID Positive
fimmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No No 177006 378 / Month 12 1.870 Irritis Irritis
 | Treatment Group Subject ID Positive
Innunoreactivity Innunoreactivity Intraocular Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No No 177006 378 / Month 12 1.870 Intris Intris

 | Treatment Group Subject ID Positive
fimmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No No 177006 378 / Month 12 1.870 Irritis Irritis

 | Treatment Group Subject ID Positive
fimmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No No 177006 378 / Month 12 2.800 Irritis Irritis
 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No No No 177006 388 / Month 12 1.870 1.870 Irritis No
 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No No No 177006 388 / Month 12 1.870 1.870 Irritis No

 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No No No 177006 388 / Month 12 1.870 1.870 Irritis No
 | Treatment Group Positive Immunoreactivity | Treatment Group Positive Immunoreactivity
 | Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Assay Assay Inframmation 170010 365 / Month 12 2.770 No No No No No 177006 358 / Month 12 1.870 Intraocular Intraocular No | Treatment Group Positive Innunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 2.800 Intraocular No Intraocular 177006 358 / Month 12 1.870 Intris Intris Intris
 | Treatment Group Positive
Intraocular Intrancular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 2.800 Iritis Iritis Iritis 177006 358 / Month 12 1.870 Iritis Iritis Iritis | Treatment Group Subject ID Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Inflammation 170010 365 / Month 12 2.770 No No Inflammation 177006 358 / Month 12 2.800 Initia Initia 177006 358 / Month 12 1.870 Initia Initia |
| Maintourner 102/01 7/27 Month 24 0.922 No 104002 719/Month 24 1.140 No No 102002 357/Month 24 1.130 No No 122002 359/Month 24 1.700 No No 122002 357/Month 24 1.700 No No 122001 174/Month 6 1.700 No No 126001 174/Month 24 1.480 No No 141013 715/Month 24 1.940 No No 143010 725/Month 24 2.340 Vitritis No 143010 725/Month 24 1.940 No No 152014 525/Month 24 2.440 No No 153006 183/Month 24 1.940 No No

 | Maintourner 102/01 712 / Month 24 0.922 No 104002 719 / Month 24 1.140 No No 102002 357 / Month 24 1.130 No No 122002 359 / Month 24 1.700 No No 122002 357 / Month 24 1.700 No No 122001 174 / Month 6 1.700 No No 126001 174 / Month 24 1.700 No No 126001 174 / Month 6 1.700 No No 126001 174 / Month 24 1.400 No No 128004 181 / Month 24 1.400 No No 141013 715 / Month 24 2.340 No No 143010 725 / Month 24 2.340 No No 152014 522 / Early Term 0.752 No No 153006 183 / Month 24 1.900 No No 155017 716 / Month 24 1.230 No<

 | Maintourner 102/01 /22 / Month 24 0.922 No 104002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 357 / Month 24 1.700 No No 122001 174 / Month 6 1.700 No No 122001 174 / Month 6 1.700 No No 126001 174 / Month 6 1.700 No No 141003 181 / Month 6 1.570 No No 143010 725 / Month 24 2.340 No No 143010 725 / Month 24 1.940 No No 152014 525 / Month 24 2.340 No No 153006 183 / Month 24 1.530 No

 | Treatment Group Positive Immunoreactivity

 | Treatment Group Positive Fositive Intraocular Treatment Group Subject ID Assay Assay Inframmation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 No

 | Treatment Group Subject ID Positive Immunoreactivity Immunoreactivity Inframmation Treatment Group Subject
ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Inframmation 177006 358 / Month 12 1.870 Inframation Intris Intris 177006 378 / Month 12 1.870 Intris Intris Intris

 | Treatment Group Subject ID Positive Immunoreactivity Immunoreactivity Immunoreactivity Immation 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 2.800 Intriso No 1 177006 358 / Month 12 1.870 No 1 1
 | Treatment Group Positive
Innunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 1.870 Intraocular Intraocular 177006 358 / Month 12 1.870 Intraocular Intraocular

 | Treatment Group Subject ID Positive Immunoreactivity Immunoreactivity Immunoreactivity Immation 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 2.800 Intriso No 1 177006 358 / Month 12 1.870 No 1 1
 |
Treatment Group Subject ID Positive Immunoreactivity Immunoreactivity Immunoreactivity Immation 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 2.800 Intriso No 1 177006 358 / Month 12 1.870 No 1 1
 | Treatment Group Subject ID Positive Immunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Inframmation 177006 358 / Month 12 1.870 Inframation Intris Intris 177006 378 / Month 12 1.870 Intris Intris Intris
 | Treatment Group Subject ID Positive Immunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Inframmation 177006 358 / Month 12 1.870 Inframation Intris Intris 177006 378 / Month 12 1.870 Intris Intris Intris
 | Treatment Group Subject ID Positive Immunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Inframmation 177006 358 / Month 12 1.870 Inframation Intris Intris 177006 378 / Month 12 1.870
Intris Intris Intris | Treatment Group Positive Immunoreactivity
 | Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 1.870 Irtitis Irtitis 177006 378/Month 12 1.870 Irtitis Irtitis
 | Treatment Group Positive
Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 1.870 Intraocular 177006 378/Month 12 1.870 Intitis | Treatment Group Positive
Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intris Intris 177006 3717 / Month 24 1.870 Intis Intis
 | Treatment Group Positive
Subject ID Positive
Assay Intraocular 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Initis 177006 358 / Month 12 1.870 Initis | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 No Initia 177006 358 / Month 12 1.870 Initia Initia |
| Ratilizumab 0.5 mg 102001 722 / Month 24 0.922 No 104002 719 / Month 24 1.140 No No 122002 359 / Month 124 1.130 No No 122002 359 / Month 124 1.170 No No 124003 722 / Month 24 1.770 No No 124013 725 / Month 24 1.570 No No 141013 715 / Month 24 1.570 No No 143010 715 / Month 24 2.340 Nitritis No 143010 715 / Month 24 1.900 No No 152064 522 / Early Terru 0.722 No No 153006 183 / Month 24 1.900 No No 167002 717 / Month 24 1.230 <th>Ratilizumab 0.5 mg 102001 722 / Month 24 0.922 No 104002 719 / Month 24 1.140 No No 122002 359 / Month 124 1.130 No No 122002 359 / Month 124 1.170 No No 124003 722 / Month 124 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 12 1.770 No No 124003 722 / Month 12 1.770 No No 725 / Month 12 1.770 No No No 725 / Month 12 1.940 No No No 141013 715 / Month 24 1.570 No No 143010 715 / Month 24 2.440 No No 152016 183 / Month 24 1.570 No No 152016 183 / Month 24 1.530 No No 155006 183 / Month 24 1.530 N</th> <td>Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No 104002 719 / Month 24 1.140 No No 12002 739 / Month 12 1.630 No No 12001 722 / Month 24 1.130 No No 12002 739 / Month 24 1.770 No No 124003 722 / Month 12 1.770 No No 124003 722 / Month 12 1.770 No No 124003 722 / Month 12 1.700 No No 725 / Month 12 1.940 No No No 141013 715 / Month 24 1.570 No No 143010 715 / Month 24 1.570 No No 153006 183 / Month 24 1.570 No<</td> <td>Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 1.870 Iritis Intraocular 177006 358 / Month 12 1.870 Iritis Intraocular</td> <td>Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immarion Treatment Group Subject ID Assay Assay Log Titer Diagnosis Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 1.870 Intris Intris Intris 717 / Month 24 1.850 Intris Intris Intris Intris</td> <td>Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Finnunoreactivity Inframmation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Irritis 177006 358 / Month 12 1.870 Irritis</td> <td>Treatment Group Subject ID Positive
fimmunor eactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 1.870 Intraocular Intraocular 177006 358 / Month 12 1.870 Intris Intris</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Finnunoreactivity Inframmation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Irritis 177006 358 / Month 12 1.870 Irritis</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Finnunoreactivity Inframmation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Irritis 177006 358 / Month 12 1.870 Irritis</td> <td>Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris</td> <td>Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris</td> <td>Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris</td> <td>Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 1.870 Iritis Intraocular 177006 358 / Month 12 1.870 Iritis Intraocular</td> <td>Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 1.870 Iritis Iritis Iritis</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irtis Irtis 717 / Month 24 1.850 Irtis Irtis Irtis</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity Intrancular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irtis Irtis 717 / Month 24 1.850 Irtis Irtis Irtis</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 1.870 Intra Intris 177006 358/Month 12 1.870 Intris Intris</td> <td>Treatment Group Event Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Iritis Iritis Iritis</td>

 | Ratilizumab 0.5 mg 102001 722 / Month 24 0.922 No 104002 719 / Month 24 1.140 No No 122002 359 / Month 124 1.130 No No 122002 359 / Month 124 1.170 No No 124003 722 / Month 124 1.770 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 12 1.770 No No 124003 722 / Month 12 1.770 No No 725 / Month 12 1.770 No No No 725 / Month 12 1.940 No No No 141013 715 / Month 24 1.570 No No 143010 715 / Month 24 2.440 No No 152016 183 / Month 24 1.570 No No 152016 183 / Month 24 1.530 No No 155006 183 / Month 24 1.530 N

 | Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No 104002 719 / Month 24 1.140 No No 12002 739 / Month 12 1.630 No No 12001 722 / Month 24 1.130 No No 12002 739 / Month 24 1.770 No No 124003 722 / Month 12 1.770 No No 124003 722 / Month 12 1.770 No No 124003 722 / Month 12 1.700 No No 725 / Month 12 1.940 No No No 141013 715 / Month 24 1.570 No No 143010 715 / Month 24 1.570 No No 153006 183 / Month 24 1.570 No<

 | Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 1.870 Iritis Intraocular 177006 358 / Month 12 1.870 Iritis Intraocular

 | Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immarion Treatment Group Subject ID Assay Assay Log Titer Diagnosis Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 1.870 Intris Intris Intris 717 / Month 24 1.850 Intris Intris Intris Intris

 | Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Finnunoreactivity Inframmation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Irritis 177006 358 / Month 12 1.870 Irritis
 | Treatment Group Subject ID Positive
fimmunor eactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis
 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 1.870 Intraocular Intraocular 177006 358 / Month 12 1.870 Intris Intris
 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Finnunoreactivity Inframmation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Irritis 177006 358 / Month 12 1.870 Irritis

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Finnunoreactivity Inframmation 170010 365 / Month 12 2.770 No 177006 358 / Month 12 2.800 Irritis 177006 358 / Month 12 1.870 Irritis
 | Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris
 | Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris

 | Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular 177006 358 / Month 12 1.870 Intris
 | Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 1.870 Iritis Intraocular 177006 358 / Month 12 1.870 Iritis Intraocular | Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID
 Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 1.870 Iritis Iritis Iritis | Treatment Group Positive
Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irtis Irtis 717 / Month 24 1.850 Irtis Irtis Irtis
 | Treatment Group Positive
Immunoreactivity Immunoreactivity Intrancular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irtis Irtis 717 / Month 24 1.850 Irtis Irtis Irtis | Treatment Group Positive
Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 1.870 Intra Intris 177006 358/Month 12 1.870 Intris Intris | Treatment Group Event Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 177006 358 / Month 12 1.870 Iritis Iritis Iritis
 |
| Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No 104002 719 / Month 24 1.140 No No 106002 723 / Month 24 1.130 No No 122002 339 / Month 24 1.170 No No 124003 723 / Month 24 1.770 No No 124003 723 / Month 24 1.770 No No 124003 723 / Month 24 1.770 No No 124003 723 / Month 12 2.040 No No 726/01 174 / Month 6 1.570 No No 725 / Month 12 1.940 No No No 726 / Month 24 1.570 No No No 141013 715 / Month 24 2.340 Nithits No 143010 725 / Month 24 1.570 No No 143010 715 / Month 24 1.940 No No 135006 183 / Month 24 2.340 <td< th=""><th>Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No 104002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 339 / Month 24 1.170 No No 124003 723 / Month 24 1.770 No No 124003 723 / Month 24 1.770 No No 124003 723 / Month 24 1.770 No No 124003 723 / Month 12 2.040 No No 726 / Month 12 1.940 No No No 141013 715 / Month 24 1.570 No No 143010 725 / Month 24 1.940 No No 143010 715 / Month 24 1.940 No No 143010 715 / Month 24 1.940 No No 143010 715 / Month 24 1.940 No No 135006 183 / Month 24 1.940 <td< th=""><td>Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No 104002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 335 / Month 24 1.170 No No 124003 723 / Month 24 1.770 No No 124003 723 / Month 12 0.782 No No 124003 723 / Month 12 0.782 No No 124003 723 / Month 12 0.782 No No 124003 723 / Month 12 1.940 No No 124003 723 / Month 24 1.460 No No 141013 715 / Month 24 1.940 No No 143010 722 / Month 24 1.940 No No 153004 522 / Month 24 1.940 No No 153006 522 / Month 24 1.940 No No 153006 523 / Month 24 1.940</td><td>Treatment Group Positive Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Assay No 170010 365 / Month 12 2.770 No No No No 177006 358 / Month 12 1.870 I.ritis Iritis Iritis</td><td>Treatment Group Positive Immunoreactivity Immunoreactivity</td><td>Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis Iritis</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis Iritis</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis</td><td>Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis Iritis</td><td>Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis Iritis</td><td>Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis Iritis</td><td>Treatment Group Positive Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Assay No 170010 365 / Month 12 2.770 No No No No 177006 358 / Month 12 1.870 I.ritis Iritis Iritis</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 1.870 Irtis 1 717 / Month 24 1.860 Irtis 1</td><td>Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 1.870 Irritis Intraocular Intraocular 177006 358 / Month 12 1.870 Irritis Intris Intris</td><td>Treatment Group Positive
Intraocular Intrancoular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 1.870 Intris Intris Intris</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 1.870 Iritis 1 1 717 / Month 24 1.870 Iritis 1 1 1 1</td><td>Treatment Group Robic Inframoreactivity Intraocollar Intraocollar Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocollar 177006 358 / Month 12 1.870 Lritis Intris Intris</td></td<></th></td<>

 | Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No 104002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 339 / Month 24 1.170 No No 124003 723 / Month 24 1.770 No No 124003 723 / Month 24 1.770 No No 124003 723 / Month 24 1.770 No No 124003 723 / Month 12 2.040 No No 726 / Month 12 1.940 No No No 141013 715 / Month 24 1.570 No No 143010 725 / Month 24 1.940 No No 143010 715 / Month 24 1.940 No No 143010 715 / Month 24 1.940 No No 143010 715 / Month 24 1.940 No No 135006 183 / Month 24 1.940 <td< th=""><td>Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No 104002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 335 / Month 24 1.170 No No 124003 723 / Month 24 1.770 No No 124003 723 / Month 12 0.782 No No 124003 723 / Month 12 0.782 No No 124003 723 / Month 12 0.782 No No 124003 723 / Month 12 1.940 No No 124003 723 / Month 24 1.460 No No 141013 715 / Month 24 1.940 No No 143010 722 / Month 24 1.940 No No 153004 522 / Month 24 1.940 No No 153006 522 / Month 24 1.940 No No 153006 523 / Month 24 1.940</td><td>Treatment Group Positive Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Assay No 170010 365 / Month 12 2.770 No No No No 177006 358 / Month 12 1.870 I.ritis Iritis Iritis</td><td>Treatment Group Positive Immunoreactivity Immunoreactivity</td><td>Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis Iritis</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis Iritis</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis</td><td>Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis Iritis</td><td>Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer
 Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis Iritis</td><td>Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis Iritis</td><td>Treatment Group Positive Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Assay No 170010 365 / Month 12 2.770 No No No No 177006 358 / Month 12 1.870 I.ritis Iritis Iritis</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 1.870 Irtis 1 717 / Month 24 1.860 Irtis 1</td><td>Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 1.870 Irritis Intraocular Intraocular 177006 358 / Month 12 1.870 Irritis Intris Intris</td><td>Treatment Group Positive
Intraocular Intrancoular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 1.870 Intris Intris Intris</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 1.870 Iritis 1 1 717 / Month 24 1.870 Iritis 1 1 1 1</td><td>Treatment Group Robic Inframoreactivity Intraocollar Intraocollar Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocollar 177006 358 / Month 12 1.870 Lritis Intris Intris</td></td<>
 | Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No 104002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 335 / Month 24 1.170 No No 124003 723 / Month 24 1.770 No No 124003 723 / Month 12 0.782 No No 124003 723 / Month 12 0.782 No No 124003 723 / Month 12 0.782 No No 124003 723 / Month 12 1.940 No No 124003 723 / Month 24 1.460 No No 141013 715 / Month 24 1.940 No No 143010 722 / Month 24 1.940 No No 153004 522 / Month 24 1.940 No No
 153006 522 / Month 24 1.940 No No 153006 523 / Month 24 1.940

 | Treatment Group Positive Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Assay No 170010 365 / Month 12 2.770 No No No No 177006 358 / Month 12 1.870 I.ritis Iritis Iritis

 | Treatment Group Positive Immunoreactivity

 | Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis Iritis

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis Iritis

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis
 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irritis Irritis

 | Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis Iritis
 | Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis Iritis
 | Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritis Iritis
 | Treatment Group Positive Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Assay No 170010 365 / Month 12 2.770 No No No No 177006 358 / Month 12 1.870 I.ritis Iritis Iritis
 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 1.870 Irtis 1 717 / Month 24 1.860 Irtis 1
 | Treatment Group Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 1.870 Irritis Intraocular Intraocular 177006 358 / Month 12 1.870 Irritis Intris Intris | Treatment Group Positive
Intraocular Intrancoular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocular 177006 358 / Month 12 1.870 Intris Intris Intris
 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 1.870 Iritis 1 1 717 / Month 24 1.870 Iritis 1 1 1 1 | Treatment Group Robic Inframoreactivity Intraocollar Intraocollar Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No Intraocollar 177006 358 / Month 12 1.870 Lritis Intris Intris |
| Ranthizumab 0.5 mg 102001 722 / Month 24 1.140 No 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.130 No No 122002 359 / Month 24 1.130 No No 124003 722 / Month 24 1.700 No No 124003 727 / Month 24 1.700 No No 727 / Month 24 1.570 No No No 727 / Month 24 1.570 No No No 728 / Month 24 1.570 No No

 | Ranthizumab 0.5 mg 102001 722 / Month 24 1.140 No 104002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 124003 722 / Month 24 1.700 No No 124003 727 / Month 24 1.570 No No 124003 715 / Month 24 1.570 No No 141013 715 / Month 24 1.570 No No 150010 722 / Month 24 1.570 No No 150010 715 / Month 24 1.570 No No 150010 722 / Month 24 1.570 No No 150010 715 / Month 24 2.440

 | Ranthizumab 0.5 mg 102001 722 / Month 24 1.140 No 104002 719 / Month 24 1.140 No No 122002 359 / Month 12 1.130 No No 122002 359 / Month 24 1.140 No No 124003 722 / Month 24 1.700 No No 124003 722 / Month 24 1.700 No No 124003 722 / Month 24 1.700 No No 124003 722 / Month 24 1.570 No No 124003 722 / Month 24 1.570 No No 725 / Month 24 1.570 No No No 735 / Month 24 1.570 No No No 735 / Month 24 1.570 No No No 735 / Month 24 1.570 No No No 141013 715 / Month 24 1.570 No No 153006 153 / Month 24 1.330 No

 | Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay Assay 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis Iritis

 | Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initis Initis

 | Treatment Group Subject ID Positive
fimmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis Iritis

 | Treatment Group Subject ID Positive
fmmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis Iritis
 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immaniation Treatment Group Subject ID Assay Assay Log Titer
 Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Initia Initia
 | Treatment Group Subject ID Positive
fmmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis Iritis

 | Treatment Group Subject ID Positive
fmmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis Iritis
 | Treatment Group Subject ID Positive
fimmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis Iritis
 | Treatment Group Subject ID Positive
fimmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis Iritis

 | Treatment Group Subject ID Positive
fimmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis Iritis
 | Treatment Group Positive Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay Assay 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis Iritis | Treatment Group Positive Fositive Intraocular Treatment Group
 Subject ID Assay Assay Assay Assay 170010 365 / Month 12 2.770 No No 177006 158 / Month 12 1.870 Iritis | Treatment Group Positive
Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intriso Intriso
 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initia | Treatment Group Subject ID Positive
fimmunor eactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intris Intris | Treatment Group Subject ID Positive
Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Initia Initia
 |
| Ranithizumab 0.5 mg 102001 722 / Month 24 0.922 No 104002 719 / Month 24 1.130 No No 104002 721 / Month 24 1.130 No No 122002 339 / Month 12 1.630 No No 122001 174 / Month 6 1.700 No No 124003 722 / Month 24 1.700 No No 124003 722 / Month 24 1.700 No No 124003 722 / Month 24 1.700 No No 124003 727 / Month 24 1.570 No No 124003 727 / Month 24 1.570 No No 141013 715 / Month 24 1.570 No No 15004 522 / Barly Term 0.752 No No 153006 135 / Month 24 1.570 No No 153006 1530/Month 24 1.570 No No 153006 1530/Month 24 1.530 <

 | Ranihizumab 0.5 mg 102001 722 / Month 24 0.922 No 104002 719 / Month 24 1.130 No No 104002 721 / Month 24 1.130 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.170 No No 122001 174 / Month 6 1.700 No No 124003 722 / Month 12 1.600 No No 124003 722 / Month 6 1.700 No No 124013 715 / Month 6 1.570 No No 141013 715 / Month 6 1.570 No No 143010 722 / Month 24 1.570 No No 152014 522 / Early Term. 0.752 No No 153004 522 / Early Term. 0.752 No No 153004 522 / Early Term. 0.752 No No 153005 153 / Month 24 1.330

 | Ranthizumab 0.5 mg 102001 722 / Month 24 0.922 No 104002 719 / Month 24 1.130 No No 104002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.630 No No 122002 359 / Month 12 1.700 No No 122001 174 / Month 6 1.700 No No 124003 722 / Month 12 1.700 No No 124003 722 / Month 24 1.700 No No 124003 722 / Month 24 1.400 No No 737 / Month 24 1.570 No No No 141013 715 / Month 24 1.940 No No 153004 522 / Early Term. 0.752 No No 153004 522 / Early Term. 0.752 No No 153004 522 / Early Term. 0.750 No No 153004 153000 No No<

 | Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 1.870 Intraocular

 | Treatment Group Subject ID Positive Immunoreactivity Immunoreactivity <t< td=""><td>Treatment Group Subject ID Positive Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No
 No 177006 358 / Month 12 1.870 Irtis Irtis</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immanian Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irtis Irtis</td><td>Treatment Group Subject ID Positive Intraocular Treatment Group Subject ID Assay Assay Assay Namunoreactivity 170010 365 / Month 12 2.770 No No 177006 177006 358 / Month 12 1.870 Irtitis</td><td>Treatment Group Subject ID Positive Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irtis Irtis</td><td>Treatment Group Subject ID Positive Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irtis Irtis</td><td>Treatment Group Subject ID Positive Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irtis Irtis</td><td>Treatment Group Subject ID Positive Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irtis Irtis</td><td>Treatment Group Subject ID Positive Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irtis Irtis</td><td>Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 1.870 Intraocular</td><td>Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 1.870 Intraocular</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 1.870 Intra Intra</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 1.870 Intris Intris</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intris Intris</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initia Initia</td></t<>

 | Treatment Group Subject ID Positive Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irtis Irtis

 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immanian Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irtis Irtis
 | Treatment Group Subject ID Positive Intraocular Treatment Group Subject ID Assay Assay Assay Namunoreactivity 170010 365 / Month 12 2.770 No No 177006 177006 358 / Month 12 1.870 Irtitis

 | Treatment Group Subject ID Positive Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irtis Irtis

 | Treatment Group Subject ID Positive Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irtis Irtis
 | Treatment Group Subject ID Positive Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irtis Irtis
 | Treatment Group Subject ID Positive Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irtis Irtis
 |
Treatment Group Subject ID Positive Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Irtis Irtis
 | Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 1.870 Intraocular | Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 1.870 Intraocular
 | Treatment Group Positive
Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 1.870 Intra Intra
 | Treatment Group Positive
Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 177006 358/Month 12 1.870 Intris Intris | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intris Intris | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initia Initia
 |
| Ranibizumab 0.5 mg 102001 717/ Month 24 1.850 No 104002 719/ Month 24 1.130 No No 104002 722/ Month 12 1.130 No No 105002 722/ Month 12 1.130 No No 122002 359/ Month 12 1.630 No No 122002 357/ Month 24 1.170 No No 124003 722/ Month 24 1.700 No No 124003 722/ Month 24 1.700 No No 124003 722/ Month 24 1.700 No No 725/ Month 12 1.700 No No No 725/ Month 24 1.300 No No No 726/ Month 24 1.940 No No No <th>Ranibizumab 0.5 mg 102001 717/ Month 24 1.850 No 104002 719/ Month 24 1.130 No No 104002 722/ Month 24 1.130 No No 105002 722/ Month 24 1.130 No No 122002 359/ Month 12 1.630 No No 122002 359/ Month 24 1.170 No No 124003 722/ Month 24 1.770 No No 124003 722/ Month 24 1.770 No No 124003 722/ Month 24 1.700 No No 737/ Month 24 1.700 No No No 737/ Month 24 1.570 No No No 141013 715/ Month 24 1.570 No No 152004 522/ Early Term 0.732, NO No No 152004 536/ Month 24 2.610 Ni No 152004 522/ Early Term 0.732 No</th> <td>Ranibizumab 0.5 mg 102001 71//Month 24 1.850 No 104002 722/Month 24 1.140 No 106002 722/Month 24 1.140 No 106002 722/Month 24 1.130 No 106002 722/Month 24 1.170 No 122002 359/Month 24 1.700 No 124003 722/Month 6 1.700 No 124001 174/Month 6 1.700 No 124001 174/Month 6 1.700 No 124003 722/Month 24 1.900 No 735/Month 24 1.900 No No 141008 181/Month 24 1.900 No 143010 722/Month 24 2.400 No 153006 183/Month 24 2.400 No 153006 183/Month 24 1.900 No 153006 153/Month 24 1.900 No 153006 153/Month 24 1.900 No 159017 <</td> <td>Treatment Group Positive
finnunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 1.870 Intraocular Intraocular Intraocular</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 1.870 Intraocular Intraocular</td> <td>Treatment Group Subject ID Positive
fimmunor eactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 1.870 Intraocular Intraocular</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 1.870 Intraocular Intraocular</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 1.870 Intraocular Intraocular</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 1.870 Intraocular Intraocular Intraocular</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 1.870 Intraocular Intraocular Intraocular</td> <td>Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 1.870 Intraocular Intraocular Intraocular</td> <td>Treatment Group Positive
finnunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular</td> <td>Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intra Intra</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity Intrancular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intris Intris</td> <td>Treatment Group Positive
Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intris Intris</td> <td>Treatment Group Event From Free Free Free Free Free Free Free Fre</td>

 | Ranibizumab 0.5 mg 102001 717/ Month 24 1.850 No 104002 719/ Month 24 1.130 No No 104002 722/ Month 24 1.130 No No 105002 722/ Month 24 1.130 No No 122002 359/ Month 12 1.630 No No 122002 359/ Month 24 1.170 No No 124003 722/ Month 24 1.770 No No 124003 722/ Month 24 1.770 No No 124003 722/ Month 24 1.700 No No 737/ Month 24 1.700 No No No 737/ Month 24 1.570 No No No 141013 715/ Month 24 1.570 No No 152004 522/ Early Term 0.732, NO No No 152004 536/ Month 24 2.610 Ni No 152004 522/ Early Term 0.732 No

 | Ranibizumab 0.5 mg 102001 71//Month 24 1.850 No 104002 722/Month 24 1.140 No 106002 722/Month 24 1.140 No 106002 722/Month 24 1.130 No 106002 722/Month 24 1.170 No 122002 359/Month 24 1.700 No 124003 722/Month 6 1.700 No 124001 174/Month 6 1.700 No 124001 174/Month 6 1.700 No 124003 722/Month 24 1.900 No 735/Month 24 1.900 No No 141008 181/Month 24 1.900 No 143010 722/Month 24 2.400 No 153006 183/Month 24 2.400 No 153006 183/Month 24 1.900 No 153006 153/Month 24 1.900 No 153006 153/Month 24 1.900 No 159017 <

 | Treatment Group Positive
finnunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 1.870 Intraocular Intraocular Intraocular

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 1.870 Intraocular Intraocular

 | Treatment Group Subject ID Positive
fimmunor eactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 1.870 Intraocular Intraocular
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 1.870 Intraocular Intraocular

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 1.870 Intraocular Intraocular
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 1.870 Intraocular Intraocular Intraocular
 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 1.870 Intraocular Intraocular Intraocular

 | Treatment Group Fositive Fositive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 1.870 Intraocular Intraocular Intraocular
 | Treatment Group Positive
finnunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular
 | Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intraocular | Treatment Group Positive
Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intra Intra
 | Treatment Group Positive
Immunoreactivity Immunoreactivity Intrancular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intris Intris | Treatment Group Positive
Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intris Intris | Treatment Group Event From Free Free Free Free Free Free Free Fre
 |
| Rantibizumab 0.5 mg 711/ Month 24 1850 No Rantibizumab 0.5 mg 102001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No 102001 722 / Month 24 1.130 No No 122002 359 / Month 24 1.130 No No 122002 357 / Month 24 1.770 No No 122001 174 / Month 6 1.770 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 6 1.770 No No 126001 174 / Month 24 0.782 No No 126001 174 / Month 24 0.782 No No 141008 181 / Month 24 0.772 No No 152004 536 / Month 24 1.570 No No 152004 536 / Month 24 1.570 No No 152004 536 / Month 24 1.940 No

 | Rantibizumab 0.5 mg 711/ Month 24 1850 No Rantibizumab 0.5 mg 102001 722 / Month 24 1.850 No 104002 719 / Month 24 1.140 No No 106002 723 / Month 24 1.130 No No 122002 359 / Month 24 1.140 No No 122002 357 / Month 24 1.770 No No 122001 174 / Month 6 1.770 No No 126001 174 / Month 24 0.782 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No 126001 181 / Month 24 1.770 No No 126001 181 / Month 24 1.780 No No 152004 535 / Month 24 1.940 No No 152004 183 / Month 24 2.610 No <td>Rantibizumab 0.5 mg 711/ Month 24 1850 No Rantibizumab 0.5 mg 102001 722 / Month 24 0.922 No 104002 719 / Month 24 1.140 No No 105001 723 / Month 24 1.130 No No 122002 359 / Month 24 1.770 No No 122001 174 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.480 No No 126001 174 / Month 24 1.480 No No 126001 174 / Month 24 1.480 No No 141013 715 / Month 24 1.570 No No 152064 527 / Early Term. 0.752 No No 152061 715 / Month 24 2.610 Vitritis No 152061 715 / Month 24 0.780</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 1.870 Initia Initia</td> <td>Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Inflammation</td> <td>Treatment Group Subject ID Positive
fmmunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Initia</td> <td>Treatment Group Subject ID Positive
fimumoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No
170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis</td> <td>Treatment Group Subject ID Positive
fmmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis</td> <td>Treatment Group Subject ID Positive
fimumoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis</td> <td>Treatment Group Subject ID Positive
fimumoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis</td> <td>Treatment Group Subject ID Positive
fmmunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Initia</td> <td>Treatment Group Subject ID Positive
fmmunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Initia</td> <td>Treatment Group Subject ID Positive
fmmunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Initia</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 1.870 Initia Initia</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Assay No 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 1.870 Initia Initia</td> <td>Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intra</td> <td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis</td> <td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 1.870 Iritis Iritis</td> <td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td>

 | Rantibizumab 0.5 mg 711/ Month 24 1850 No Rantibizumab 0.5 mg 102001 722 / Month 24 0.922 No 104002 719 / Month 24 1.140 No No 105001 723 / Month 24 1.130 No No 122002 359 / Month 24 1.770 No No 122001 174 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 126001 174 / Month 24 1.770 No No 126001 174 / Month 24 1.480 No No 126001 174 / Month 24 1.480 No No 126001 174 / Month 24 1.480 No No 141013 715 / Month 24 1.570 No No 152064 527 / Early Term. 0.752 No No 152061 715 / Month 24 2.610 Vitritis No 152061 715 / Month 24 0.780

 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 1.870 Initia Initia

 | Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Inflammation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Inflammation

 | Treatment Group Subject ID Positive
fmmunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Initia

 | Treatment Group Subject ID Positive
fimumoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis
 | Treatment Group Subject ID Positive
fmmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis

 | Treatment Group Subject ID Positive
fimumoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis

 | Treatment Group Subject ID Positive
fimumoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.800 No No 177006 358 / Month 12 1.870 Iritis
 | Treatment Group Subject ID Positive
fmmunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Initia
 | Treatment Group Subject ID Positive
fmmunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Initia
 |
Treatment Group Subject ID Positive
fmmunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Initia
 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 1.870 Initia Initia | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Assay No 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 1.870 Initia Initia
 | Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Intra
 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 1.870 Iritis | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1 177006 358 / Month 12 1.870 Iritis Iritis | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit |
| Ranibizumab 0.5 mg 717/Month 24 1.850 No Ranibizumab 0.5 mg 102001 722/Month 24 0.922 No 104002 719/Month 24 1.140 No No 106002 722/Month 12 1.130 No No 122002 355/Month 12 1.130 No No 122001 174/Month 6 1.770 No No 122002 357/Month 12 1.700 No No 122001 174/Month 6 1.770 No No 124003 722/Month 24 0.782 No No 124001 174/Month 6 1.770 No No 124002 725/Month 24 0.782 No No 141013 715/Month 24 2.340 No No 152064 522/Early Term 0.752 No No 152004 723/Month 24 2.440 No No 152005 183/Month 6 1.970 No No <th>Ranibizumab 0.5 mg 717/Month 24 1.850 No Ranibizumab 0.5 mg 102001 722/Month 24 0.922 No 104002 719/Month 24 1.140 No No 106002 722/Month 12 1.130 No No 122002 355/Month 12 1.700 No No 122001 174/Month 6 1.770 No No 122002 357/Month 12 1.700 No No 122001 174/Month 6 1.770 No No 124003 722/Month 24 0.782 No No 124001 174/Month 6 1.770 No No 141018 181/Month 24 2.340 No No 152064 522/Early Term. 0.752 No No 152004 725/Month 24 2.440 No No 152004 725/Month 24 2.440 No No 152004 521/Early Term. 0.752 No No</th> <td>Ranibizumab 0.5 mg 717/Month 24 1.850 No Ranibizumab 0.5 mg 102001 722/Month 24 0.922 No 106002 719/Month 24 1.140 No No 106002 722/Month 12 1.130 No No 122002 357/Month 12 1.770 No No 122001 174/Month 6 1.770 No No 122002 357/Month 12 1.770 No No 122001 174/Month 6 1.770 No No 126001 174/Month 24 0.782 No No 126001 181/Month 24 1.480 No No 141008 181/Month 24 2.610 Vitritis No 143010 725/Month 12 1.570 No No 152004 527/Early Term. 0.752 No No 152004 725/Month 24 2.610 Vitritis No 152004 527/Early Term. 0.752 No <</td> <td>Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 No 1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.</td> <td>Treatment Group Subject ID Positive
fimmunoreactivity Innunoreactivity Inflammation Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1.77006 1.77006 3.58 / Month 12 2.800 Trait Trait</td> <td>Treatment Group Subject ID Positive
fmmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initia</td> <td>Treatment Group Subject ID Positive Immunoreactivity Immanition Immunoreactivity Immunoreactivity Immanition Immanition</td> <td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immaniation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular</td> <td>Treatment Group Subject ID Positive Immunoreactivity Immanition Immunoreactivity Immunoreactivity Immanition Immanition</td> <td>Treatment Group Subject ID Positive Immunoreactivity Immanition Immunoreactivity Immunoreactivity Immanition Immanition</td> <td>Treatment Group Subject ID Positive
fmmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initia</td> <td>Treatment Group Subject ID Positive
fmmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initia</td> <td>Treatment Group Subject ID Positive
fmmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initia</td> <td>Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 No 1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1.77006 1.670 1.670 1.670 1.640</td> <td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 1670 16700 1.45</td> <td>Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 177006 177006 358 / Month 12 1.800 1.670 No 1.670</td> <td>Treatment Group Subject ID Positive
fmmunor eactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 28 / Month 12 2.800 No Intraocular</td> <td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 100 177006 368 / Month 12 2.800 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
1.000 1.000</td>
 | Ranibizumab 0.5 mg 717/Month 24 1.850 No Ranibizumab 0.5 mg 102001 722/Month 24 0.922 No 104002 719/Month 24 1.140 No No 106002 722/Month 12 1.130 No No 122002 355/Month 12 1.700 No No 122001 174/Month 6 1.770 No No 122002 357/Month 12 1.700 No No 122001 174/Month 6 1.770 No No 124003 722/Month 24 0.782 No No 124001 174/Month 6 1.770 No No 141018 181/Month 24 2.340 No No 152064 522/Early Term. 0.752 No No 152004 725/Month 24 2.440 No No 152004 725/Month 24 2.440 No No 152004 521/Early Term. 0.752 No No

 | Ranibizumab 0.5 mg 717/Month 24 1.850 No Ranibizumab 0.5 mg 102001 722/Month 24 0.922 No 106002 719/Month 24 1.140 No No 106002 722/Month 12 1.130 No No 122002 357/Month 12 1.770 No No 122001 174/Month 6 1.770 No No 122002 357/Month 12 1.770 No No 122001 174/Month 6 1.770 No No 126001 174/Month 24 0.782 No No 126001 181/Month 24 1.480 No No 141008 181/Month 24 2.610 Vitritis No 143010 725/Month 12 1.570 No No 152004 527/Early Term. 0.752 No No 152004 725/Month 24 2.610 Vitritis No 152004 527/Early Term. 0.752 No <

 | Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 No 1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.

 | Treatment Group Subject ID Positive
fimmunoreactivity Innunoreactivity Inflammation Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1.77006 1.77006 3.58 / Month 12 2.800 Trait Trait

 | Treatment Group Subject ID Positive
fmmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initia

 | Treatment Group Subject ID Positive Immunoreactivity Immanition Immunoreactivity Immunoreactivity Immanition

 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immaniation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Intraocular

 | Treatment Group Subject ID Positive Immunoreactivity Immanition Immunoreactivity Immunoreactivity Immanition
 | Treatment Group Subject ID Positive Immunoreactivity Immanition Immunoreactivity Immunoreactivity Immanition
 | Treatment Group Subject ID Positive
fmmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initia

 | Treatment Group Subject ID Positive
fmmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initia
 | Treatment Group Subject ID Positive
fmmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Initia
 | Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 No 1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.
 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 1.77006 1.670 1.670 1.670 1.640 | Treatment Group Positive Positive Intraocular
 Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 1670 16700 1.45 | Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Assay Intraocular 170010 365 / Month 12 2.770 No No 177006 177006 358 / Month 12 1.800 1.670 No 1.670 | Treatment Group Subject ID Positive
fmmunor eactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 177006 28 / Month 12 2.800 No Intraocular
 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 100 177006 368 / Month 12 2.800 1.000 |
| Ranibizumab 0.5 mg 717/ Month 24 1.850 No Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No 106002 722 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.130 No No 122002 722 / Month 12 1.650 No No 124003 722 / Month 12 1.630 No No 124003 722 / Month 12 1.700 No No 124003 722 / Month 24 0.782 No No 124003 723 / Month 24 1.700 No No 124010 725 / Month 24 1.630 No No 15004 181 / Month 24 1.900 No <th>Ranibizumab 0.5 mg 717/ Month 24 1850 No Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No 104002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.130 No No 122002 722 / Month 12 1.130 No No 122001 174 / Month 6 1.700 No No 124003 722 / Month 12 1.630 No No 124003 723 / Month 24 0.782 No No 124001 174 / Month 24 0.780 No No 124003 725 / Month 12 1.700 No No 124001 715 / Month 24 0.780 No No 125004 535 / Month 24 1.940 No No 152004 522 / Early Term. 0.752 No No 152004 523 / Month 24 0.780 No<!--</th--><td>Ranibizumab 0.5 mg 717/ Month 24 1.850 No Ranibizumab 0.5 mg 102001 722/ Month 24 0.922 No 106002 722/ Month 24 1.140 No No 106002 722/ Month 24 1.130 No No 122002 359/ Month 12 1.130 No No 122001 722/ Month 12 1.650 No No 124003 722/ Month 12 1.670 No No 124001 723/ Month 12 1.700 No No 124003 722/ Month 24 0.782 No No 124001 717/ Month 24 1.480 No No 125004 181 / Month 24 1.570 No No 141013 715 / Month 24 2.610 Vittitis No 152004 522 / Early Term. 0.752 No No 153005 183 / Month 24 2.610 Vittitis No 153006 183 / Month 24 0.750 <td< td=""><td>Treatment Group Subject ID Positive
finnunoreactivity Innunoreactivity
finnunoreactivity Intraocular
finiammation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 715/Month 24 2.800 No No</td><td>Treatment Group Subject ID Positive
fmmunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immanion Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immaniation Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immation Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immaniation Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immaniation Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immanion Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immanion Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immanion Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No</td><td>Treatment Group Subject ID Positive
finnunoreactivity Innunoreactivity
finnunoreactivity Intraocular
finiammation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 715/Month 24 2.800 No No</td><td>Treatment Group Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intraocular
Inflammation 170010 365 / Month 12 2.770 No 715 / Month 24 2.800 No</td><td>Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 715 / Month 24 2.800 No No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 715/Month 24 2.800 No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Inflammation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 715 / Month 24 2.800 No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 715 / Month 24 2.800 No No</td></td<></td></th>

 | Ranibizumab 0.5 mg 717/ Month 24 1850 No Ranibizumab 0.5 mg 102001 722 / Month 24 0.922 No 104002 719 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.130 No No 122002 722 / Month 12 1.130 No No 122001 174 / Month 6 1.700 No No 124003 722 / Month 12 1.630 No No 124003 723 / Month 24 0.782 No No 124001 174 / Month 24 0.780 No No 124003 725 / Month 12 1.700 No No 124001 715 / Month 24 0.780 No No 125004 535 / Month 24 1.940 No No 152004 522 / Early Term. 0.752 No No 152004 523 / Month 24 0.780 No </th <td>Ranibizumab 0.5 mg 717/ Month 24 1.850 No Ranibizumab 0.5 mg 102001 722/ Month 24 0.922 No 106002 722/ Month 24 1.140 No No 106002 722/ Month 24 1.130 No No 122002 359/ Month 12 1.130 No No 122001 722/ Month 12 1.650 No No 124003 722/ Month 12 1.670 No No 124001 723/ Month 12 1.700 No No 124003 722/ Month 24 0.782 No No 124001 717/ Month 24 1.480 No No 125004 181 / Month 24 1.570 No No 141013 715 / Month 24 2.610 Vittitis No 152004 522 / Early Term. 0.752 No No 153005 183 / Month 24 2.610 Vittitis No 153006 183 / Month 24 0.750 <td< td=""><td>Treatment Group Subject ID Positive
finnunoreactivity Innunoreactivity
finnunoreactivity Intraocular
finiammation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 715/Month 24 2.800 No No</td><td>Treatment Group Subject ID Positive
fmmunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immanion Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immaniation Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12
2.770 No No No 715 / Month 24 2.800 No No No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immation Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immaniation Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immaniation Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immanion Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immanion Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immanion Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No</td><td>Treatment Group Subject ID Positive
finnunoreactivity Innunoreactivity
finnunoreactivity Intraocular
finiammation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 715/Month 24 2.800 No No</td><td>Treatment Group Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intraocular
Inflammation 170010 365 / Month 12 2.770 No 715 / Month 24 2.800 No</td><td>Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 715 / Month 24 2.800 No No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 715/Month 24 2.800 No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Inflammation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 715 / Month 24 2.800 No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 715 / Month 24 2.800 No No</td></td<></td>

 | Ranibizumab 0.5 mg 717/ Month 24 1.850 No Ranibizumab 0.5 mg 102001 722/ Month 24 0.922 No 106002 722/ Month 24 1.140 No No 106002 722/ Month 24 1.130 No No 122002 359/ Month 12 1.130 No No 122001 722/ Month 12 1.650 No No 124003 722/ Month 12 1.670 No No 124001 723/ Month 12 1.700 No No 124003 722/ Month 24 0.782 No No 124001 717/ Month 24 1.480 No No 125004 181 / Month 24 1.570 No No 141013 715 / Month 24 2.610 Vittitis No 152004 522 / Early Term. 0.752 No No 153005 183 / Month 24 2.610 Vittitis No 153006 183 / Month 24 0.750 <td< td=""><td>Treatment Group Subject ID Positive
finnunoreactivity Innunoreactivity
finnunoreactivity Intraocular
finiammation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 715/Month 24 2.800 No No</td><td>Treatment Group Subject ID Positive
fmmunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immanion Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immaniation Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immation Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immaniation Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immaniation Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immanion Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immanion Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immanion Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No</td><td>Treatment Group Subject ID Positive
finnunoreactivity Innunoreactivity
finnunoreactivity Intraocular
finiammation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 715/Month 24 2.800 No No</td><td>Treatment Group Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intraocular
Inflammation 170010 365 / Month 12 2.770 No 715 / Month 24 2.800 No</td><td>Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 715 / Month 24 2.800 No No No</td><td>Treatment Group Positive
Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 715/Month 24 2.800 No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Inflammation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 715 / Month 24 2.800 No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 715 / Month 24 2.800 No No</td></td<>

 | Treatment Group Subject ID Positive
finnunoreactivity Innunoreactivity
finnunoreactivity Intraocular
finiammation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 715/Month 24 2.800 No No

 | Treatment Group Subject ID Positive
fmmunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No

 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immanion Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No

 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immaniation Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No

 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immation Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No
 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immaniation Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No

 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immaniation Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No
 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immanion Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No
 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immanion Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No

 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immanion Treatment Group Subject ID Assay Assay Assay No 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No
 | Treatment Group Subject ID Positive
finnunoreactivity Innunoreactivity
finnunoreactivity Intraocular
finiammation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 715/Month 24 2.800 No No
 | Treatment Group Subject ID Positive
Assay Immunoreactivity
Assay Log Titer Intraocular
Inflammation 170010 365 / Month 12 2.770 No 715 / Month 24 2.800 No | Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 715 / Month 24 2.800 No No No
 | Treatment Group Positive
Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No 715/Month 24 2.800 No No | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Inflammation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 715 / Month 24 2.800 No No | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 715 / Month 24 2.800 No No
 |
| Rantibizumab 0.5 mg 1/7000 2/35/ Month 24 1.0.70 4.103 No Rantibizumab 0.5 mg 102001 721/ Month 24 1.130 No No 104002 719 / Month 24 1.130 No No No 122002 359 / Month 12 1.630 No No No 122002 359 / Month 12 1.630 No No No 122002 359 / Month 12 1.770 No No No 122003 722 / Month 24 1.770 No No No 126001 174 / Month 6 1.770 No No No 126001 174 / Month 6 1.770 No No No 126001 181 / Month 6 1.570 No No No 126001 171 / Month 24 1.940 No No No 141013 715 / Month 24 1.940 No No No 152004 536 / Month 12 1.940 No

 | Rantibizumab 0.5 mg 1/7000 2/30/1001112 1/300 4.100 Rantibizumab 0.5 mg 102001 721/Month 24 1.130 N/0 104002 719/Month 24 1.130 N/0 N/0 122002 359/Month 12 1.630 N/0 N/0 122002 359/Month 12 1.630 N/0 N/0 122002 359/Month 12 1.770 N/0 N/0 122002 359/Month 12 1.770 N/0 N/0 122003 722/Month 24 1.770 N/0 N/0 126001 174/Month 6 1.770 N/0 N/0 126001 174/Month 6 1.770 N/0 N/0 126001 171/Month 24 1.940 N/0 N/0 126001 181/Month 6 1.570 N/0 N/0 125004 535/Month 12 1.940 N/0 N/0 152004 181/Month 6 1.570 N/0 N/0 152004 183/Month 12 1.940 </th <td>Ranibizumab 0.5 mg 177000 2357 Month 24 1.870 4.1130 No Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No No 104002 719 / Month 24 1.130 No No No 122002 359 / Month 12 1.130 No No No 122002 359 / Month 12 1.770 No No No 124003 722 / Month 12 1.770 No No No 124003 723 / Month 12 1.700 No No No 124003 717 / Month 24 0.732 No No No 712 / Month 12 1.570 No No No No 715 / Month 12 1.900 No 1.570 No No 141013 715 / Month 24 2.610 Nin No No 152004 522 / Early Term 0.752 No No No 153005 183 / Month 12 1.900 No</td> <td>Treatment Group Positive Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No</td> <td>Treatment Group Positive Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No</td> <td>Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No</td> <td>Treatment Group Subject ID Positive
fimmunor eactivity Intraocular Treatment Group Subject ID Assay Assay Assay 170010 365 / Month 12 2.770 No 715 / Month 24 2.800 No</td> <td>Treatment Group Subject ID Positive
fimmunor
eactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No</td> <td>Treatment Group Subject ID Positive
fimmunor eactivity Intraocular Treatment Group Subject ID Assay Assay Assay 170010 365 / Month 12 2.770 No 715 / Month 24 2.800 No</td> <td>Treatment Group Subject ID Positive
fimmunor eactivity Intraocular Treatment Group Subject ID Assay Assay Assay 170010 365 / Month 12 2.770 No 715 / Month 24 2.800 No</td> <td>Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No</td> <td>Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No</td> <td>Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No</td> <td>Treatment Group Positive Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No</td> <td>Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No</td> <td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No</td> <td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Intrancular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No</td> <td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Intrancation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No</td> <td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No</td>

 | Ranibizumab 0.5 mg 177000 2357 Month 24 1.870 4.1130 No Ranibizumab 0.5 mg 102001 722 / Month 24 1.140 No No 104002 719 / Month 24 1.130 No No No 122002 359 / Month 12 1.130 No No No 122002 359 / Month 12 1.770 No No No 124003 722 / Month 12 1.770 No No No 124003 723 / Month 12 1.700 No No No 124003 717 / Month 24 0.732 No No No 712 / Month 12 1.570 No No No No 715 / Month 12 1.900 No 1.570 No No 141013 715 / Month 24 2.610 Nin No No 152004 522 / Early Term 0.752 No No No 153005 183 / Month 12 1.900 No

 | Treatment Group Positive Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No

 | Treatment Group Positive Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No

 | Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No

 | Treatment Group Subject ID Positive
fimmunor eactivity Intraocular Treatment Group Subject ID Assay Assay Assay 170010 365 / Month 12 2.770 No 715 / Month 24 2.800 No

 | Treatment Group Subject ID Positive
fimmunor eactivity Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No
 | Treatment Group Subject ID Positive
fimmunor eactivity Intraocular Treatment Group Subject ID Assay Assay Assay 170010 365 / Month 12 2.770 No 715 / Month 24 2.800 No

 | Treatment Group Subject ID Positive
fimmunor eactivity Intraocular Treatment Group Subject ID Assay Assay Assay 170010 365 / Month 12 2.770 No 715 / Month 24 2.800 No
 | Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No
 | Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No

 | Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No
 | Treatment Group Positive Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No
 | Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No
 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Intrancular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Intrancation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No
 |
| Ranibizumab 0.5 mg 17/006 538/Month 12 1.870 Intus Ranibizumab 0.5 mg 102001 727/Month 24 1.850 No 104002 717/Month 24 1.130 No No 104002 722/Month 12 1.630 No No 122002 359/Month 12 1.630 No No 122002 359/Month 12 1.770 No No 124003 722/Month 24 1.170 No No 124003 722/Month 24 1.770 No No 124003 722/Month 24 1.770 No No 124003 722/Month 24 1.770 No No 725/Month 24 1.770 No No No 725/Month 24 1.770 No No No 722/Month 24 1.770 No No No 12400 722/Month 24 1.570 No No 141013 715/Month 24 1.940 No

 | Ranibizumab 0.5 mg 17/006 538/Month 12 1.870 Intus Ranibizumab 0.5 mg 102001 727/Month 24 1.850 No 104002 717/Month 24 1.130 No No 104002 722/Month 12 1.630 No No 122002 359/Month 12 1.630 No No 122002 359/Month 12 1.770 No No 124003 722/Month 24 1.170 No No 124003 722/Month 24 1.770 No No 124003 722/Month 24 1.770 No No 725/Month 24 1.770 No No No 725/Month 24 1.770 No No No 725/Month 24 1.770 No No No 141013 715/Month 24 1.570 No No 152004 535/Month 24 1.940 No No 152004 535/Month 24 1.940 No <td< th=""><td>Ranibizumab 0.5 mg 17/000 538/Month 12 1.870 Intus Ranibizumab 0.5 mg 102001 727/Month 24 1.850 No Ranibizumab 0.5 mg 102001 722/Month 24 1.130 No 104002 722/Month 12 1.630 No No 122002 359/Month 12 1.630 No No 122002 359/Month 12 1.770 No No 124003 722/Month 24 1.770 No No 124003 722/Month 24 1.770 No No 124003 722/Month 24 1.700 No No 124003 722/Month 24 1.700 No No 737/Month 24 1.700 No No No 737/Month 24 1.700 No No No 737/Month 24 1.700 No No No 737/Month 24 1.670 No No No 735/Month 24 1.940 No No</td><td>Treatment Group Positive Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Assay Assay 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No</td><td>Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 715 / Month 24 2.800 No No No</td><td>Treatment Group Subject ID Positive
fmmunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 715 / Month 24 2.800 No No No</td><td>Treatment Group Subject ID Positive
fmmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No
 715 / Month 24 2.800 No No No</td><td>Treatment Group Subject ID Positive
fmmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No No</td><td>Treatment Group Subject ID Positive
fmmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No 715 / Month 24 2.800 No No No</td><td>Treatment Group Subject ID Positive
fmmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No 715 / Month 24 2.800 No No No</td><td>Treatment Group Subject ID Positive
fmmunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 715 / Month 24 2.800 No No No</td><td>Treatment Group Subject ID Positive
fmmunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 715 / Month 24 2.800 No No No</td><td>Treatment Group Subject ID Positive
fmmunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 715 / Month 24 2.800 No No No</td><td>Treatment Group Positive Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Assay Assay 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No</td><td>Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Assay Assay No 170010 365 / Month 12 2.770 No No No No 715 / Month 24 2.800 2.800 No No No No</td><td>Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No</td><td>Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 715 / Month 24 2.800 No No</td><td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit</td></td<>

 | Ranibizumab 0.5 mg 17/000 538/Month 12 1.870 Intus Ranibizumab 0.5 mg 102001 727/Month 24 1.850 No Ranibizumab 0.5 mg 102001 722/Month 24 1.130 No 104002 722/Month 12 1.630 No No 122002 359/Month 12 1.630 No No 122002 359/Month 12 1.770 No No 124003 722/Month 24 1.770 No No 124003 722/Month 24 1.770 No No 124003 722/Month 24 1.700 No No 124003 722/Month 24 1.700 No No 737/Month 24 1.700 No No No 737/Month 24 1.700 No No No 737/Month 24 1.700 No No No 737/Month 24 1.670 No No No 735/Month 24 1.940 No No

 | Treatment Group Positive Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Assay Assay 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No

 | Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 715 / Month 24 2.800 No No No

 | Treatment Group Subject ID Positive
fmmunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 715 / Month 24 2.800 No No No

 | Treatment Group Subject ID Positive
fmmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No 715 / Month 24 2.800 No No No
 | Treatment Group Subject ID Positive
fmmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No No

 | Treatment Group Subject ID Positive
fmmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No 715 / Month 24 2.800 No No No

 | Treatment Group Subject ID Positive
fmmunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID 365 / Month 12 2.770 No 715 / Month 24 2.800 No No No
 | Treatment Group Subject ID Positive
fmmunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 715 / Month 24 2.800 No No No
 | Treatment Group Subject ID Positive
fmmunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 715 / Month 24 2.800 No No No
 |
Treatment Group Subject ID Positive
fmmunoreactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 715 / Month 24 2.800 No No No
 | Treatment Group Positive Immunoreactivity Immunoreactivity Intraocular Treatment Group Subject ID Assay Assay Assay Assay Assay 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Assay Assay No 170010 365 / Month 12 2.770 No No No No 715 / Month 24 2.800 2.800 No No No No
 | Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No
 | Treatment Group Positive
Intraocular Positive
Intraocular Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No 715 / Month 24 2.800 No No | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivit |
| Rantbizumab 0.5 mg 177006 338 / Month 12 1870 Iritis Rantbizumab 0.5 mg 102001 722 / Month 24 1.850 Iritis 104002 717 / Month 24 1.870 No No 104002 722 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.170 No No 122003 722 / Month 24 1.770 No No 122003 722 / Month 24 1.770 No No 715 / Month 24 1.770 No No No 715 / Month 24 1.770 No No No 715 / Month 24 1.370 No No No 715 / Month 24 1.940 No

 | Ranthizumab 0.5 mg 177006 338/Month 12 1.870 Iritis Ranthizumab 0.5 mg 102001 722/Month 24 1.850 Nio 10002 721/Month 24 1.140 Nio Nio 122002 359/Month 24 1.130 Nio Nio 122002 359/Month 24 1.770 Nio Nio 122002 357/Month 24 1.770 Nio Nio 122003 722/Month 24 1.770 Nio Nio 124003 722/Month 24 1.770 Nio Nio 126001 174/Month 24 1.770 Nio Nio 126001 174/Month 24 1.700 Nio Nio 126001 174/Month 24 1.700 Nio Nio 126001 181/Month 24 1.700 Nio Nio 141013 715/Month 24 1.670 Nio Nio 152004 522/Month 24 2.610 Nin Nio 152004 183/Month 24 1.94

 | Ranthizumab 0.5 mg 177006 338/Month 12 1.870 Iritis Ranthizumab 0.5 mg 102001 722/Month 24 1.850 No 106002 722/Month 24 1.140 No No 122002 359/Month 24 1.130 No No 122002 723/Month 24 1.770 No No 122003 723/Month 24 1.770 No No 126001 174/Month 24 1.770 No No 126001 181/Month 24 1.670 No No 141013 715/Month 24 1.570 No No 152064 522/Early Term. 0.752 No No 152004 183/Month 24 2.610 No

 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No

 | Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No

 | Treatment Group Subject ID Assay Immunoreactivity I

 | Treatment Group Subject ID Assay Immunoreactivity I
 | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No

 | Treatment Group Subject ID Assay Immunoreactivity I
 | Treatment Group Subject ID Assay Immunoreactivity I

 | Treatment Group Subject ID Assay Immunoreactivity I
 | Treatment Group Subject ID Assay Immunoreactivity I
 | Treatment Group Subject ID Assay Immunoreactivity I
 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No
 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No | Treatment Group Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No
 | Treatment Group Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Inframmation Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No No 715 / Month 24 2.800 No No No No
 |
| I77006 358 / Month 12 1.870 Iritis Raulbizumab 0.5 mg 102001 722 / Month 24 1.850 No 106002 722 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 12001 722 / Month 24 1.130 No No 12002 357 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124003 715 / Month 24 1.770 No No 124003 715 / Month 24 1.770 No No 124001 715 / Month 24 1.940 No No 135004 522 / Month 24 2.440 No

 | I77006 358 / Month 12 1.870 Iritis Rautbizumab 0.5 mg 102001 722 / Month 24 1.850 No 106002 722 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 106002 722 / Month 24 1.130 No No 122002 357 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124001 174 / Month 6 1.770 No No 124003 722 / Month 24 1.770 No No 124001 174 / Month 6 1.770 No No 124013 715 / Month 24 1.770 No No 141013 715 / Month 24 1.570 No No 143010 722 / Month 24 1.900 No No 152004 522 / Month 24 2.400 No No 153006 153 / Month 24 2.400 No

 | Introduct Introduct <thintroduct< th=""> <thintroduct< th=""> <th< td=""><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No</td><td>Treatment Group Subject ID Assay Assay Innunoreactivity Innunoreactivity 170010 365 / Month 12 2.770 No No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Assay 170010 365 / Month 12 2.770 No No</td><td>Positive Positive Intraocular Intraocular Intraocular Intraocular Intraocular Assay Assay Assay Intraocular Intraocular Intraocular Intraocular Assay Assay Intraocular Intraocular Assay Assay Assay</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Assay 170010 365 / Month 12 2.770 No No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Assay 170010 365 / Month 12 2.770 No No</td><td>Treatment Group Subject ID Assay Assay Innunoreactivity Innunoreactivity 170010 365 / Month 12 2.770 No No</td><td>Treatment Group Subject ID Assay Assay Innunoreactivity Innunoreactivity 170010 365 / Month 12 2.770 No No</td><td>Treatment Group Subject ID Assay Assay Innunoreactivity Innunoreactivity 170010 365 / Month 12 2.770 No No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No</td><td>Treatment Group Subject ID Round and an and a stage Intraocular Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No</td></th<></thintroduct<></thintroduct<>

 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No

 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No

 | Treatment Group Subject ID Assay Assay Innunoreactivity Innunoreactivity 170010 365 / Month 12 2.770 No No

 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Assay 170010 365 / Month 12 2.770 No No
 | Positive Positive Intraocular Intraocular Intraocular Intraocular Intraocular Assay Assay Assay Intraocular Intraocular Intraocular Intraocular Assay Assay Intraocular Intraocular Assay Assay Assay

 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Assay 170010 365 / Month 12 2.770 No No

 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Assay 170010 365 / Month 12 2.770 No No
 | Treatment Group Subject ID Assay Assay Innunoreactivity Innunoreactivity 170010 365 / Month 12 2.770 No No
 | Treatment Group Subject ID Assay Assay Innunoreactivity Innunoreactivity 170010 365 / Month 12 2.770 No No
 | Treatment Group Subject ID Assay Assay Innunoreactivity Innunoreactivity 170010 365 / Month 12 2.770 No No

 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No
 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No
 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365/Month 12 2.770 No No | Treatment Group Subject ID Round and an and a stage Intraocular Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No
 |
| Ranthizumab 0.5 mg 177006 337 / Month 24 2.000 Iritis Ranthizumab 0.5 mg 102001 717 / Month 24 1870 Iritis 104002 719 / Month 24 130 No 106002 722 / Month 24 1140 No 122002 359 / Month 12 1630 No 122002 359 / Month 12 1630 No 122002 357 / Month 24 1770 No 124003 722 / Month 24 1770 No 124003 722 / Month 24 1770 No 124013 712 / Month 6 1.770 No 141018 181 / Month 24 1.940 No 15004 522 / Month 12 1.940 No 153006 183 / Month 24 2.610 Vitritis 153006 183 / Month 24 1.970 No 153006 183 / Month 24 1.900 No 153006 183 / Month 24 1.900 No 1530017 716 / Month 24 2.0

 | Ranthizumab 0.5 mg 177006 337 / Month 24 2.000 Iritis Ranthizumab 0.5 mg 102001 717 / Month 24 1870 Iritis 104002 717 / Month 24 1300 No 106002 722 / Month 24 1140 No 124003 722 / Month 24 1130 No 124003 722 / Month 24 1770 No 124003 722 / Month 24 1370 No 141018 715 / Month 24 1370 No 143010 726 / Month 24 1340 No 153006 183 / Month 24 2610 Virthis 153006 183 / Month 24 1360 No 153006 183 / Month 24 10780 No 153006 183 / Month 24 10780 No 153006 183 / Month 24 2700 <td>Ranibizumab 0.5 mg 177006 337 / Month 24 2.000 Iritis Ranibizumab 0.5 mg 102001 717 / Month 24 1870 Iritis 104002 722 / Month 24 1.300 No No 106002 722 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 124003 722 / Month 24 1.130 No No 124003 722 / Month 24 1.1700 No No 124003 722 / Month 24 1.700 No No 124003 722 / Month 12 1.630 No No 124013 715 / Month 24 1.770 No No 725 / Month 12 2.610 Vitritis No No 13010 722 / Month 24 1.570 No No 143010 722 / Month 24 1.570 No No 153006 183 / Month 24 2.610 Vitritis No 153006 183 / Month 24</td> <td>Positive Positive Intraocular Incatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No</td> <td>Treatment Group Subject ID Positive
financeactivity Immunoreactivity Inframmation Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No</td> <td>Treatment Group Subject ID Positive
fmmunor eactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No</td> <td>Treatment Group Subject ID Positive
fimmunor eactivity Innunor eactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td> <td>Treatment Group Subject ID Positive
fimmunor eactivity Immunor eactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No
 No</td> <td>Treatment Group Subject ID Positive
fimmunor eactivity Innunor eactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td> <td>Treatment Group Subject ID Positive
fimmunor eactivity Innunor eactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td> <td>Treatment Group Subject ID Positive
fmmunor eactivity Intraocular
fmmunor eactivity Intraocular
fmmunor eactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No</td> <td>Treatment Group Subject ID Positive
fmmunor eactivity Intraocular
fmmunor eactivity Intraocular
fmmunor eactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No</td> <td>Treatment Group Subject ID Positive
fmmunor eactivity Intraocular
fmmunor eactivity Intraocular
fmmunor eactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No</td> <td>Positive Positive Intraocular Incatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No</td> <td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No</td> <td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No</td> <td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No</td> <td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No</td> <td>Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td>

 | Ranibizumab 0.5 mg 177006 337 / Month 24 2.000 Iritis Ranibizumab 0.5 mg 102001 717 / Month 24 1870 Iritis 104002 722 / Month 24 1.300 No No 106002 722 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 124003 722 / Month 24 1.130 No No 124003 722 / Month 24 1.1700 No No 124003 722 / Month 24 1.700 No No 124003 722 / Month 12 1.630 No No 124013 715 / Month 24 1.770 No No 725 / Month 12 2.610 Vitritis No No 13010 722 / Month 24 1.570 No No 143010 722 / Month 24 1.570 No No 153006 183 / Month 24 2.610 Vitritis No 153006 183 / Month 24

 | Positive Positive Intraocular Incatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No

 | Treatment Group Subject ID Positive
financeactivity Immunoreactivity Inframmation Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No

 | Treatment Group Subject ID Positive
fmmunor eactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No

 | Treatment Group Subject ID Positive
fimmunor eactivity Innunor eactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No

 | Treatment Group Subject ID Positive
fimmunor eactivity Immunor eactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No
 | Treatment Group Subject ID Positive
fimmunor eactivity Innunor eactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No

 | Treatment Group Subject ID Positive
fimmunor eactivity Innunor eactivity Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No
 | Treatment Group Subject ID Positive
fmmunor eactivity Intraocular
fmmunor eactivity Intraocular
fmmunor eactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No
 | Treatment Group Subject ID Positive
fmmunor eactivity Intraocular
fmmunor eactivity Intraocular
fmmunor eactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No

 | Treatment Group Subject ID Positive
fmmunor eactivity Intraocular
fmmunor eactivity Intraocular
fmmunor eactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No
 | Positive Positive Intraocular Incatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No
 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No
 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No No | Treatment Group Subject ID Positive
Immunoreactivity Immunoreactivity Immunoreactivity Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No
 |
| Rantbizumab 0.5 mg 715 / Month. 12 2.800 Irritis 717/006 358 / Month. 124 1.870 Irritis 711 / 1002 719 / Month. 24 1.870 Irritis 8 102001 722 / Month. 24 1.140 No 106002 722 / Month. 24 1.130 No No 12001 722 / Month. 24 1.130 No No 12002 359 / Month. 24 1.130 No No 12001 174 / Month. 24 1.770 No No 722 / Month. 24 1.770 No No No 723 / Month. 24 1.770 No No No 725 / Month. 12 720 No No No 722 / Month. 24 1.370 No No No 722 / Month. 24 1.570 No No No 722 / Month. 24 1.340 No No No 722 / Month. 24 1.8600 No No No <t< th=""><th>Rantbizumab 0.5 mg 715 / Month. 12 2.800 Irritis 717/006 358 / Month. 124 1.870 Irritis 717/005 358 / Month. 24 1.870 Irritis 717/005 358 / Month. 24 1.870 No 102002 722 / Month. 24 1.140 No 12002 359 / Month. 24 1.130 No 12003 359 / Month. 24 1.700 No 12001 174 / Month. 64 1.770 No 12001 174 / Month. 64 1.770 No 722 / Month. 12 2.640 No No 723 / Month. 24 0.782 No No 723 / Month. 24 1.770 No No 723 / Month. 24 1.770 No No 723 / Month. 24 1.770 No No 722 / Month. 24 1.770 No No 723 / Month. 24 1.770 No No 723 / Month. 24 1.770 No No 730 /</th><td>Rantbizumab 0.5 mg 715 / Month. 12 2.800 Irritis 717/006 358 / Month. 124 1.870 Irritis 717/006 358 / Month. 24 1.870 Irritis 717/006 358 / Month. 24 1.140 No 102001 722 / Month. 24 1.130 No 12002 723 / Month. 24 1.130 No 124003 723 / Month. 24 1.770 No 124001 724 / Month. 24 1.770 No 124001 724 / Month. 24 1.770 No 124001 724 / Month. 24 1.770 No 725 / Month. 24 1.770 No No 727 / Month. 24 1.770 No No 722 / Month. 24 1.770 No No 723 / Month. 24 1.800 No No <t< td=""><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td><td>Treatment Group Subject ID Rositive
fimmunoreactivity Innunoreactivity Inframmation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td><td>Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td><td>Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td><td>Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td><td>Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td><td>Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td><td>Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td><td>Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td><td>Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td></t<></td></t<>

 | Rantbizumab 0.5 mg 715 / Month. 12 2.800 Irritis 717/006 358 / Month. 124 1.870 Irritis 717/005 358 / Month. 24 1.870 Irritis 717/005 358 / Month. 24 1.870 No 102002 722 / Month. 24 1.140 No 12002 359 / Month. 24 1.130 No 12003 359 / Month. 24 1.700 No 12001 174 / Month. 64 1.770 No 12001 174 / Month. 64 1.770 No 722 / Month. 12 2.640 No No 723 / Month. 24 0.782 No No 723 / Month. 24 1.770 No No 723 / Month. 24 1.770 No No 723 / Month. 24 1.770 No No 722 / Month. 24 1.770 No No 723 / Month. 24 1.770 No No 723 / Month. 24 1.770 No No 730 /

 | Rantbizumab 0.5 mg 715 / Month. 12 2.800 Irritis 717/006 358 / Month. 124 1.870 Irritis 717/006 358 / Month. 24 1.870 Irritis 717/006 358 / Month. 24 1.140 No 102001 722 / Month. 24 1.130 No 12002 723 / Month. 24 1.130 No 124003 723 / Month. 24 1.770 No 124001 724 / Month. 24 1.770 No 124001 724 / Month. 24 1.770 No 124001 724 / Month. 24 1.770 No 725 / Month. 24 1.770 No No 727 / Month. 24 1.770 No No 722 / Month. 24 1.770 No No 723 / Month. 24 1.800 No No <t< td=""><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td><td>Treatment Group Subject ID Rositive
fimmunoreactivity Innunoreactivity Inframmation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td><td>Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td><td>Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td><td>Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td><td>Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td><td>Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td><td>Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td><td>Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td><td>Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No</td></t<>

 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No

 | Treatment Group Subject ID Rositive
fimmunoreactivity Innunoreactivity Inframmation Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No

 | Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No

 | Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No

 | Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No
 | Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No

 | Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No
 | Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No
 | Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No

 | Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No
 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No
 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No
 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2.770 No
 |
| Ranibizumab 0.5 mg 715 / Month 24 2800 Intis Ranibizumab 0.5 mg 177006 538 / Month 24 1.870 Intis Ranibizumab 0.5 mg 102001 721 / Month 24 1.850 No 106002 722 / Month 24 1.140 No No 124003 723 / Month 24 1.130 No No 124003 723 / Month 24 1.770 No No 721/Month 6 1.770 No No No 721/Month 24 1.770 No No No 723 / Month 24 1.770 No No No 723 / Month 24 1.700 No No No 723 / Month 24 1.770 No No No 723 / Month 24 1.800 No No

 | Ranibizumab 0.5 mg 715 / Month 24 2800 Intis Ranibizumab 0.5 mg 177006 538 / Month 24 1.870 Intis Ranibizumab 0.5 mg 102001 721 / Month 24 1.850 No Ranibizumab 0.5 mg 102002 717 / Month 24 1.140 No 106002 722 / Month 24 1.130 No No 1124003 723 / Month 24 1.770 No No 124003 723 / Month 24 1.770 No No 124003 723 / Month 12 1.630 No No 124003 723 / Month 24 1.770 No No 124013 715 / Month 24 1.770 No No 723 / Month 24 1.770 No No No 723 / Month 24 1.800 No <td>Ranibizumab 0.5 mg 715 / Month 24 2800 Intis <thi< td=""><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Diagnosis 170010 365 / Month 12 770 No</td><td>Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Diagnosis 170010 365 / Month 12 770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Assay 170010 365 / Month 12 770 No</td><td>Positive Positive Intraocular Intraocular Intraocular Intraocular Intraocular Intraocular Intraocular Inteatment Group Subject ID Assay Assay Assay Inteatment Group 170010 365 / Month 12 770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Assay 170010 365 / Month 12 770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Assay 170010 365 / Month 12 770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Diagnosis 170010 365 / Month 12 770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Diagnosis 170010 365 / Month 12 770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Diagnosis 170010 365 / Month 12 770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Diagnosis 170010 365 / Month 12 770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 770 No</td><td>Positive
 Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 7 770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 7 770 No</td><td>Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 7.70 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2 770 No</td></thi<></td>

 | Ranibizumab 0.5 mg 715 / Month 24 2800 Intis Intis <thi< td=""><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Diagnosis 170010 365 / Month 12 770 No</td><td>Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Diagnosis 170010 365 / Month 12 770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Assay 170010 365 / Month 12 770 No</td><td>Positive Positive Intraocular Intraocular Intraocular Intraocular Intraocular Intraocular Intraocular Inteatment Group Subject ID Assay Assay Assay Inteatment Group 170010 365 / Month 12 770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Assay 170010 365 / Month 12 770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Assay 170010 365 / Month 12 770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Diagnosis 170010 365 / Month 12 770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Diagnosis 170010 365 / Month 12 770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Diagnosis 170010 365 / Month 12 770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Diagnosis 170010 365 / Month 12 770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 7 770 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 7 770 No</td><td>Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 7.70 No</td><td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2 770 No</td></thi<>

 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Diagnosis 170010 365 / Month 12 770 No

 | Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 770 No

 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Diagnosis 170010 365 / Month 12 770 No

 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Assay 170010 365 / Month 12 770 No

 | Positive Positive Intraocular Intraocular Intraocular Intraocular Intraocular Intraocular Intraocular Inteatment Group Subject ID Assay Assay Assay Inteatment Group 170010 365 / Month 12 770 No

 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Assay 170010 365 / Month 12 770 No
 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Assay 170010 365 / Month 12 770 No

 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Diagnosis 170010 365 / Month 12 770 No
 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Diagnosis 170010 365 / Month 12 770 No
 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Diagnosis 170010 365 / Month 12 770 No
 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Assay Diagnosis 170010 365 / Month 12 770 No
 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 770 No
 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 7 770 No
 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 7 770 No | Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 7.70 No | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis 170010 365 / Month 12 2 770 No |
| Rantbizurrab 0.5 mg 715 / Month 24 2.800 Tritis Rantbizurrab 0.5 mg 177006 338 / Month 24 1.870 Litits 177006 338 / Month 24 1.870 Litits No 102001 722 / Month 24 1.130 No No 104002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.650 No No 122002 357 / Month 24 1.170 No No 124003 722 / Month 24 1.770 No No 141013 715 / Month 24 1.900

 | Rantbizurrab 0.5 mg 715 / Month 24 2.800 Tritis Rantbizurrab 0.5 mg 177006 338 / Month 24 1.870 Litits 177006 338 / Month 24 1.870 Litits No 102001 722 / Month 24 1.130 No No 104002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.650 No No 122002 357 / Month 24 1.170 No No 124003 722 / Month 24 1.770 No No 124003 722 / Month 24 1.700 No No 1410103 716 / Month 24 1.700

 | Ranthizumab 0.5 mg 715 / Month 24 2 800 Tritis Ranthizumab 0.5 mg 177006 358 / Month 24 1 870 Littis Ranthizumab 0.5 mg 102001 722 / Month 24 1 130 No 106402 722 / Month 24 1 130 No 106402 722 / Month 24 1 130 No 122002 359 / Month 12 1630 No 122002 359 / Month 24 1 170 No 122002 357 / Month 6 1 770 No 124003 722 / Month 24 1 1700 No 124001 724 / Month 6 1 770 No 126001 174 / Month 6 1 770 No 126001 727 / Month 24 1 300 No 141013 726 / Month 24 1 300 No 141010 725 / Month 24 1 370 No 15004 527 / Month 24 1 370 No 15100 726 / Month 24 1 370 No 151010 722 / Month 24

 | Positive Positive Intraocular Increation Immunoreactivity Immunoreactivity Inflammation Increation Subject ID Assay Assay Log Titer Diagnosis

 | Treatment Group Subject ID Assay Assay Log Titer Diagnosis

 | Treatment Group Subject ID Assay Assay Log Titer Diagnosis

 | Treatment Group Subject ID Assay Assay Log Titer Diagnosis
 | Treatment Group Subject ID Assay Assay Log Titer Diagnosis

 | Treatment Group Subject ID Assay Assay Log Titer Diagnosis

 | Treatment Group Subject ID Assay Assay Log Titer Diagnosis
 | Treatment Group Subject ID Assay Assay Log Titer Diagnosis
 | Treatment Group Subject ID Assay Assay Log Titer Diagnosis

 | Treatment Group Subject ID Assay Assay Log Titer Diagnosis
 | Positive Positive Intraocular Increation Immunoreactivity Immunoreactivity Inflammation Increation Subject ID Assay Assay Log Titer Diagnosis | Positive Positive Intraocular Incraocular Immunoreactivity Inflammation Incraocular Assay Assay Incraocular
 | Positive Positive Intraocular Intraocular Intraocular Intraocular Intertion Subject ID Assay Assay Log Titer Diagnosis
 | Positive Positive Intraocular Intraocular Immunoreactivity Inflammation Inteatment Group Subject ID Assay Assay Log Titer Diagnosis | Positive Positive Intraocular Intraocular Immunoreactivity Immunoreactivity Immanion Treatment Group Subject ID Assay Assay Log Titer Diagnosis | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis
 |
| Ranthizumab 0.5 mg 170016 338 / Month 12 2.7/0 No 177006 338 / Month 24 1.870 Irtits 177006 338 / Month 24 1.870 Irtits 177006 338 / Month 24 1.870 No 17700 722 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 353 / Month 24 1.700 No 122002 357 / Month 24 1.700 No 124003 722 / Month 24 1.570 No 12400 722 / Month 24 1.570 No <

 | Ranthizumab 0.5 mg 1700/0 353 / Month 12 2.7/0 No 177006 338 / Month 24 1.870 Irtits 177006 338 / Month 24 1.870 Irtits 177006 338 / Month 24 1.870 Irtits 100002 722 / Month 24 1.140 No 102002 322 / Month 24 1.130 No 122002 353 / Month 24 1.700 No 122002 722 / Month 24 1.700 No 124003 722 / Month 24 1.570 No 124003 722 / Month 24 1.570 No 124003 722 / Month 24 1.570 No 141013 722 / Month 24 1.570 No 141013 726 / Month 24 1.570 No

 | Rantibizumab 0.5 mg 17000 539 / Month 24 2.070 No 177006 358 / Month 24 1870 Lintis No 177006 358 / Month 24 1870 Lintis No 177006 358 / Month 24 1870 Intits No 106002 722 / Month 24 1130 No No 106002 723 / Month 24 1130 No No 122003 723 / Month 24 1770 No No 122003 723 / Month 24 1770 No No 124003 723 / Month 24 1770 No No 124001 174 / Month 6 1770 No No 124013 725 / Month 24 1480 No No 141018 181 / Month 6 1.700 No No 143010 725 / Month 24 2.440 No No 143010 725 / Month 24 1.340 No No 143010 725 / Month 24 0.750

 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis

 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis

 | Treatment Group Subject ID Assay Assay Log Titer Diagnosis

 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis
 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis

 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis

 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis
 | Treatment Group Subject ID Assay Assay Log Titer Diagnosis
 | Treatment Group Subject ID Assay Assay Log Titer Diagnosis

 | Treatment Group Subject ID Assay Assay Log Titer Diagnosis
 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer
Diagnosis | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis
 | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis
 |
| Introl 365 / Month 12 2.770 No Ranibizumab 0.5 mg 177006 356 / Month 24 1.850 Iritis Ranibizumab 0.5 mg 107001 722 / Month 24 1.850 No 177005 359 / Month 24 1.140 No No 100002 721 / Month 24 1.140 No No 100002 723 / Month 24 1.130 No No 112002 359 / Month 24 1.1700 No No 122003 359 / Month 24 1.1700 No No 122003 721 / Month 24 1.1700 No No 122003 722 / Month 24 1.700 No No 124003 722 / Month 24 1.700 No No 1241013 722 / Month 24 1.700 No No 141008 181 / Month 6 1.570 No No 141013 715 / Month 24 1.940 No No 1141013 716 / Month 24 1.940

 | Introl 365 / Month 12 2.770 No Ranibizumab 0.5 mg 177006 356 / Month 24 1.850 Iritis I 77006 355 / Month 24 1.850 Iritis Iritis I 77005 355 / Month 24 1.850 No Iritis I 00002 719 / Month 24 1.850 No No I 00002 723 / Month 24 1.140 No No I 12002 359 / Month 24 1.170 No No I 12003 359 / Month 24 1.170 No No I 12003 721 / Month 24 1.700 No No I 12003 722 / Month 24 1.700 No No I 12003 722 / Month 24 1.700 No No I 141018 181 / Month 6 1.700 No No I 141018 181 / Month 6 1.570 No No I 141013 716 / Month 24 1.570 No No I 141013 716 / Month 24 1.940 <td>I70010 365 / Month 12 2.770 No Ranibizumab 0.5 mg 177006 355 / Month 24 1.870 Irrius 177005 355 / Month 24 1.870 Irrius Irrius 177005 355 / Month 24 1.870 No No 177005 717 / Month 24 1.870 No No 104002 719 / Month 24 1.140 No No 1122002 359 / Month 12 1.130 No No 1122002 723 / Month 24 1.1700 No No 1122002 723 / Month 24 1.1700 No No 1122003 723 / Month 24 1.1700 No No 1122003 722 / Month 24 1.1700 No No 1122003 722 / Month 24 1.700 No No 1124010 1141008 181 / Month 6 1.570 No 1141013 722 / Month 12 1.680 No No 1141013 715 / Month 24 1.700</td> <td>Positive Positive Intraocular Intraocular Intraocular Intraocular Interment Group Subject ID Assay Assay Log Titer Diagnosis</td> <td>Positive Positive Intraocular Intraocular Intraocular Intraocular Interment Group Subject ID Assay Assay Log Titer Diagnosis</td> <td>Positive Positive Intraocular Intraocular Intraocular Intraocular</td> <td>Positive Positive Intraocular Intraocular Intraocular Intraocular</td> <td>Positive Positive Intraocular Intraocular Intraocular Intraocular Interment Group Subject ID Assay Assay Log Titer Diagnosis</td> <td>Positive Positive Intraocular Intraocular Intraocular Intraocular</td> <td>Positive Positive Intraocular Intraocular Intraocular Intraocular</td> <td>Positive Positive Intraocular Intraocular Intraocular
Intraocular</td> <td>Positive Positive Intraocular Intraocular Intraocular Intraocular</td> <td>Positive Positive Intraocular Intraocular Intraocular Intraocular</td> <td>Positive Positive Intraocular Intraocular Intraocular Intraocular Interment Group Subject ID Assay Assay Log Titer Diagnosis</td> <td>Positive Positive Intraocular Intraocular Immunoreactivity Immunoreactivity Interment Group Subject ID Assay Assay Log Titer Diagnosis</td> <td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis</td> <td>Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis</td> <td>Treatment Group Subject ID Assay Assay Log Titer Diagnosis</td> <td>Positive Positive Intraocular Intraocular Intraocular Intraocular Intraocular Intraocular Interment Group Subject ID Assay Assay Log Titer</td>
 | I70010 365 / Month 12 2.770 No Ranibizumab 0.5 mg 177006 355 / Month 24 1.870 Irrius 177005 355 / Month 24 1.870 Irrius Irrius 177005 355 / Month 24 1.870 No No 177005 717 / Month 24 1.870 No No 104002 719 / Month 24 1.140 No No 1122002 359 / Month 12 1.130 No No 1122002 723 / Month 24 1.1700 No No 1122002 723 / Month 24 1.1700 No No 1122003 723 / Month 24 1.1700 No No 1122003 722 / Month 24 1.1700 No No 1122003 722 / Month 24 1.700 No No 1124010 1141008 181 / Month 6 1.570 No 1141013 722 / Month 12 1.680 No No 1141013 715 / Month 24 1.700

 | Positive Positive Intraocular Intraocular Intraocular Intraocular Interment Group Subject ID Assay Assay Log Titer Diagnosis

 | Positive Positive Intraocular Intraocular Intraocular Intraocular Interment Group Subject ID Assay Assay Log Titer Diagnosis

 | Positive Positive Intraocular Intraocular Intraocular Intraocular

 | Positive Positive Intraocular Intraocular Intraocular Intraocular

 | Positive Positive Intraocular Intraocular Intraocular Intraocular Interment Group Subject ID Assay Assay Log Titer Diagnosis

 | Positive Positive Intraocular Intraocular Intraocular Intraocular
 | Positive Positive Intraocular Intraocular Intraocular Intraocular
 | Positive Positive Intraocular Intraocular Intraocular Intraocular

 | Positive Positive Intraocular Intraocular Intraocular Intraocular
 | Positive Positive Intraocular Intraocular Intraocular Intraocular
 | Positive Positive Intraocular Intraocular Intraocular Intraocular Interment Group Subject ID Assay Assay Log Titer Diagnosis
 | Positive Positive Intraocular Intraocular Immunoreactivity Immunoreactivity Interment Group Subject ID Assay Assay Log Titer Diagnosis | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer
 Diagnosis | Positive Positive Intraocular Treatment Group Subject ID Assay Assay Log Titer Diagnosis | Treatment Group Subject ID Assay Assay Log Titer Diagnosis
 | Positive Positive Intraocular Intraocular Intraocular Intraocular Intraocular Intraocular Interment Group Subject ID Assay Assay Log Titer |
| Interpret in the interpret inter

 | Interpret in the interpret inter

 | Interpret Name Interpret Name Interpret Name Interpret Name Nu

 | Positive Positive Intraocular Intraocular Immunoreactivity Inflammation Inteatment Group Subject ID Assav Assav

 | Positive Positive Intraocular Intraocular Immunoreactivity Inflammation Treatment Group Subject ID Assay Assay 1.00 Ther Disconcils

 | Positive Positive Intraocular Intraocular Immunoreactivity Inflammation Treatment Group Subject ID Assay Assay 1.00 Ther Disconcils

 | Positive Positive Intraocular Intraocular Immunoreactivity Inflammation Interment Group Subject ID Assay 1.00 Ther Disconcils

 | Positive Positive Intraocular Intraocular Assav Assav Assav Assav Assav

 | Positive Positive Intraocular Intraocular Immunoreactivity Inflammation Interment Group Subject ID Assay 1.00 Ther Disconcils
 | Positive Positive Intraocular Intraocular Immunoreactivity Inflammation Interment Group Subject ID Assay 1.00 Ther Disconcils

 | Positive Positive Intraocular Intraocular Immunoreactivity Inflammation Treatment Group Subject ID Assay Assay 1.00 Ther Disconcils
 | Positive Positive Intraocular Intraocular Immunoreactivity Inflammation Treatment Group Subject ID Assay Assay 1.00 Ther Disconcils
 | Positive Positive Intraocular Intraocular Immunoreactivity Inflammation Treatment Group Subject ID Assay Assay 1.00 Ther Disconcils
 | Positive Positive Intraocular Intraocular Immunoreactivity Inflammation IntertmentGroup Subject ID Assay Assay 1.00 Ther Disconcils
 | Positive Positive Intraocular Intraocular Immunoreactivity Inflammation Inteatment Group Subject ID Assay Assay 1.00 Ther Disconcils
 | Positive Intraocular Intraocular Immunoreactivity Intraocular Assav Assav Assav | Positive Intraocular Intraocular Immunoreactivity Intrammation Assav
 | Positive Intraocular Intraocular Immunoreactivity Interment Group Subject ID Assay Assay | Positive Positive Intraocular Intraocular Immunoreactivity Immunoreactivity Immunoreactivity Interment Group Subject ID Assay Assay 1.or Titer Dispervets |
| Interpretation Interpreation Interpretation Interpr

 | Interpret in the interpret interinterpret interpret interpret interpret interpret

 | Internation

 | Positive Intraocular
Intraocular

 | Positive
Intraocular
Intraocular

 | Positive
Intraocular
Intraocular

 | Positive
Immunoreactivity Immunoreactivity Immunoreactivity

 | Positive
Immunoreactivity Immunoreactivity Inframmation

 | Positive
Immunoreactivity Immunoreactivity Immunoreactivity
 | Positive
Immunoreactivity Immunoreactivity Immunoreactivity

 | Positive
Intraocular
Intraocular
 | Positive
Intraocular
Intraocular
 | Positive
Intraocular
Intraocular
 | Positive Intraocular
Intraocular
 | Positive Intraocular Intraocular
 | Positive Positive Intraocular Intraocular Intraocular | Positive Intraocular Intraocular Information
 | Positive Intraocular Intraocular Intraocular Intraocular | Positive
Intraocular
Immunoreactivity Immunoreactivity Inflammation |
| Amount Amount<

 | Amount Standy Amount Amount<

 | Amount Construction Construction <thconstruction< th=""> Construction</thconstruction<>

 | Positive Positive Intraocular Intraocular Intraocular Intraocular Intraocular

 | Positive Intraocular
Immunoreactivity Immunoreactivity Inflammation

 | Positive Intraocular
Immunoreactivity Immunoreactivity Inflammation

 | Positive Intraocular
Immunoreactivity Immunoreactivity Inflammation

 | Positive
Immunoreactivity Immunoreactivity Inflammation

 | Positive Intraocular
Immunoreactivity Immunoreactivity Inflammation
 | Positive Intraocular
Immunoreactivity Immunoreactivity Inflammation

 | Positive Intraocular
Immunoreactivity Immunoreactivity Inflammation
 | Positive Intraocular
Immunoreactivity Immunoreactivity Inflammation
 | Positive Intraocular
Immunoreactivity Immunoreactivity Inflammation
 | Positive Positive Intraocular Intraocular Intraocular Intraocular Intraocular
 | Positive Intraocular
Immunoreactivity Immunoreactivity Inflammation
 | Positive
Intraocular
Immunoreactivity Immunoreactivity Inflammation | Positive
Intraocular
Immunoreactivity Immunoreactivity Inflammation
 | Positive Positive Intraocular Intraocular Intraocular Intraocular Intraocular | Positive Intraocular |
| Treatment Group Subject ID Assay Assay Log Titler Diagnois 170010 365 / Month 12 2.770 No No 177005 358 / Month 24 1.850 Irtits Ranibizumab 0.5 mg 107001 717 / Month 24 1.850 Irtits Ranibizumab 0.5 mg 102001 722 / Month 24 1.830 No 122002 359 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 122002 723 / Month 24 1.700 No No 122003 359 / Month 24 1.700 No No 122003 723 / Month 24 1.700 No No 122003 725 / Month 24 1.700 No No 122003 721 / Month 24 1.700 No No 124003 722 / Month 24 1.700 No No 124003 722 / Month 24 1.700 No No 125004 141008 <t< th=""><th>Treatment Group Subject ID Assay Log Titer Diagnois 170010 365 / Month 12 2.770 No No 177006 358 / Month 24 1.830 Irttis Ranibizumab 0.5 mg 177/006 358 / Month 24 1.830 No 177001 717 / Month 24 1.830 No No 177002 359 / Month 24 1.140 No No 122002 723 / Month 24 1.130 No No 122003 359 / Month 24 1.130 No No 122003 723 / Month 24 1.130 No No 122003 723 / Month 24 1.1700 No No 122003 723 / Month 24 1.700 No No 122003 722 / Month 24 1.700 No No 124003 722 / Month 24 1.700 No No 124003 722 / Month 24 1.700 No No 12400 726 / Month 24 1.700</th><td>Main Subject ID Assay Log Titer Diagnois I Toolio 365 / Month 12 2.770 No No I 77006 355 / Month 24 1.850 Irrtis I 77005 371 / Month 24 1.850 Irrtis I 77005 375 / Month 24 1.830 No I 122002 717 / Month 24 1.830 No I 122002 723 / Month 24 1.130 No I 122003 357 / Month 24 1.700 No I 12003 722 / Month 24 1.700 No I 12003 722 / Month 12 1.800 No I 12003 722 / Month 12 1.700 No I 141013 722 / Month 12 1.700 No I 141013 721 / Month 24 1.700 No I 141013 725 / Month 12 <t< td=""><td>Positive Intraocular
Immunoreactivity Immunoreactivity Inflammeria</td><td>Positive Intraocular Intraocular</td><td>Positive Intraocular</td><td>Positive
Immunoreactivity Immunoreactivity Inflammation</td><td>Positive
Immunoreactivity Immunoreactivity Inflammation</td><td>Positive
Immunoreactivity Immunoreactivity Inflammation</td><td>Positive
Immunoreactivity Immunoreactivity Inflammation</td><td>Positive Intraocular</td><td>Positive Intraocular</td><td>Positive Intraocular</td><td>Positive Intraocular
Immunoreactivity Immunoreactivity Inflammeria</td><td>Positive Intraocular
Immunoreactivity Immunoreactivity Inflammonian</td><td>Positive Intraocular
Timminoreactivity Timminoreactivity Tinfammasian</td><td>Positive Intraocular
Immunoreactivity Immunoreactivity Inframmation</td><td>Positive
Immunoreactivity Immunoreactivity Inframmasian</td><td>Positive
Intraocular
Imminoreactivity Imminoreactivity Indomination</td></t<></td></t<>

 | Treatment Group Subject ID Assay Log Titer Diagnois 170010 365 / Month 12 2.770 No No 177006 358 / Month 24 1.830 Irttis Ranibizumab 0.5 mg 177/006 358 / Month 24 1.830 No 177001 717 / Month 24 1.830 No No 177002 359 / Month 24 1.140 No No 122002 723 / Month 24 1.130 No No 122003 359 / Month 24 1.130 No No 122003 723 / Month 24 1.130 No No 122003 723 / Month 24 1.1700 No No 122003 723 / Month 24 1.700 No No 122003 722 / Month 24 1.700 No No 124003 722 / Month 24 1.700 No No 124003 722 / Month 24 1.700 No No 12400 726 / Month 24 1.700

 | Main Subject ID Assay Log Titer Diagnois I Toolio 365 / Month 12 2.770 No No I 77006 355 / Month 24 1.850 Irrtis I 77005 371 / Month 24 1.850 Irrtis I 77005 375 / Month 24 1.830 No I 122002 717 / Month 24 1.830 No I 122002 723 / Month 24 1.130 No I 122003 357 / Month 24 1.700 No I 12003 722 / Month 24 1.700 No I 12003 722 / Month 12 1.800 No I 12003 722 / Month 12 1.700 No I 141013 722 / Month 12 1.700 No I 141013 721 / Month 24 1.700 No I 141013 725 / Month 12 <t< td=""><td>Positive Intraocular
Immunoreactivity Immunoreactivity Inflammeria</td><td>Positive Intraocular Intraocular</td><td>Positive Intraocular</td><td>Positive
Immunoreactivity Immunoreactivity Inflammation</td><td>Positive
Immunoreactivity Immunoreactivity Inflammation</td><td>Positive
Immunoreactivity Immunoreactivity Inflammation</td><td>Positive
Immunoreactivity Immunoreactivity Inflammation</td><td>Positive Intraocular</td><td>Positive Intraocular</td><td>Positive Intraocular</td><td>Positive Intraocular
Immunoreactivity Immunoreactivity Inflammeria</td><td>Positive Intraocular
Immunoreactivity Immunoreactivity Inflammonian</td><td>Positive Intraocular
Timminoreactivity Timminoreactivity Tinfammasian</td><td>Positive Intraocular
Immunoreactivity Immunoreactivity Inframmation</td><td>Positive
Immunoreactivity Immunoreactivity Inframmasian</td><td>Positive
Intraocular
Imminoreactivity Imminoreactivity Indomination</td></t<>

 | Positive Intraocular
Immunoreactivity Immunoreactivity Inflammeria

 | Positive Intraocular Intraocular

 | Positive Intraocular

 | Positive
Immunoreactivity Immunoreactivity Inflammation

 | Positive
Immunoreactivity Immunoreactivity Inflammation
 | Positive
Immunoreactivity Immunoreactivity Inflammation

 | Positive
Immunoreactivity Immunoreactivity Inflammation
 | Positive Intraocular
 | Positive Intraocular

 | Positive Intraocular
 | Positive Intraocular
Immunoreactivity Immunoreactivity Inflammeria
 | Positive Intraocular
Immunoreactivity Immunoreactivity Inflammonian | Positive Intraocular
Timminoreactivity Timminoreactivity Tinfammasian
 | Positive Intraocular
Immunoreactivity Immunoreactivity Inframmation | Positive
Immunoreactivity Immunoreactivity Inframmasian | Positive
Intraocular
Imminoreactivity Imminoreactivity Indomination
 |
| Treatment Group Subject ID Asary Log Titer Diagnois 170010 365 /Month 12 2.770 No 177006 375 /Month 24 1.870 Iritis Ranibizumab 0.5 mg 177/006 375 /Month 24 0.922 No Ranibizumab 0.5 mg 10002 717 /Month 24 0.922 No 122010 722 /Month 24 1.140 No No 122002 723 /Month 24 1.130 No No 122002 723 /Month 24 1.130 No No 122002 723 /Month 24 1.130 No No 122003 723 /Month 24 1.700 No No 122003 723 /Month 24 1.700 No No 122004 121003 722 / Month 24 1.700 No 123003 362 / Month 12 1.630 No No 124003 722 / Month 24 1.700 No No 124003 722 / Month 24 1.700 No N

 | Treatment Group Subject ID Asary Log Titer Diagnois 170010 365/Month 12 2.770 No 177006 375/Month 24 1.870 Irtis Ranibizumab 0.5 mg 177/Month 24 1.870 Irtis Ranibizumab 0.5 mg 10002 717/Month 24 0.922 No 122012 722/Month 24 0.922 No No 122002 723/Month 24 1.140 No No 122002 723/Month 24 1.130 No No 122002 723/Month 24 1.130 No No 122003 723/Month 24 1.700 No No 122004 723/Month 24 1.700 No No 122005 723/Month 24 1.700 No No 122004 735/Month 24 1.700 No No 122003 722/Month 24 1.700 No No 123004 181/Month 6 1.700 No No 141013 </th <td>Liteatment Group Subject ID Asary Log Titer Diagnois 170010 365/Month 12 2.770 No 177006 371/Month 24 2.800 Irtis 177005 717/Month 24 1.870 Irtis 177005 717/Month 24 0.922 No 12002 722/Month 24 0.922 No 122002 723/Month 24 0.922 No 122002 723/Month 24 1.140 No 122002 723/Month 24 1.700 No 122003 723/Month 24 1.700 No 122004 122002 723/Month 24 1.700 No 122016 1131/Month 6 1.700 No No 122013 723/Month 12 1.630 No No 122014 131/Month 6 1.700 No No 122015 723/Month 12 1.700 No No 1220101 174/Month 6 1.700 No No 12400</td> <td>Positive</td>

 | Liteatment Group Subject ID Asary Log Titer Diagnois 170010 365/Month 12 2.770 No 177006 371/Month 24 2.800 Irtis 177005 717/Month 24 1.870 Irtis 177005 717/Month 24 0.922 No 12002 722/Month 24 0.922 No 122002 723/Month 24 0.922 No 122002 723/Month 24 1.140 No 122002 723/Month 24 1.700 No 122003 723/Month 24 1.700 No 122004 122002 723/Month 24 1.700 No 122016 1131/Month 6 1.700 No No 122013 723/Month 12 1.630 No No 122014 131/Month 6 1.700 No No 122015 723/Month 12 1.700 No No 1220101 174/Month 6 1.700 No No 12400

 | Positive

 | Positive

 | Positive

 | Positive

 | Positive
 | Positive

 | Positive
 | Positive
 | Positive

 | Positive
 | Positive
 | Positive | Positive
 | Positive | Positive | Positive
 |
| Treatment Group Subject ID Assy Assay Log Titer Diagnois 170010 365 / Month 12 2.770 No No 177006 715 / Month 24 2.800 Iritis No 177006 715 / Month 24 1.870 Iritis No 177006 715 / Month 24 1.140 No No 122002 722 / Month 24 1.140 No No 122002 723 / Month 24 1.140 No No 122002 723 / Month 24 1.140 No No 122002 735 / Month 24 1.700 No No 122002 723 / Month 24 1.700 No No 122003 723 / Month 24 1.700 No No 122004 181 / Month 6 1.700 No No 122003 722 / Month 12 1.700 No No 122004 181 / Month 6 1.700 No No 125001 725 / Month 12 1.700<

 | Treatment Group Subject ID Assy Assay Log Titer Diagnois 170010 365 / Month 12 2.770 No No 177006 715 / Month 24 2.800 Intitis No 177006 715 / Month 24 1.870 Intitis No 177006 715 / Month 24 1.140 No No 122002 722 / Month 24 1.140 No No 122002 725 / Month 24 1.140 No No 122002 725 / Month 24 1.770 No No 122002 725 / Month 24 1.770 No No 122001 174 / Month 6 1.770 No No 122002 725 / Month 12 1.770 No No 122003 725 / Month 24 1.770 No No 122004 181 / Month 24 1.700 No No 122002 725 / Month 12 1.700 No No 122001 181 / Month 24 1.7

 | Treatment Group Subject ID Assy Assay Log Titer Diagnois 170010 365 / Month 12 2.770 No No 177006 715 / Month 24 2.820 No No 177006 715 / Month 24 1.850 Iritis Iritis Rantbizumab 0.5 mg 102001 722 / Month 24 1.140 No 122002 722 / Month 24 1.140 No No 122002 722 / Month 24 1.140 No No 122002 722 / Month 24 1.1700 No No 122002 722 / Month 24 1.7700 No No 122003 722 / Month 24 1.7700 No No 122001 174 / Month 24 1.7700 No No 122002 722 / Month 12 1.7700 No No 122003 181 / Month 24 1.7700 No No 122004 181 / Month 24 1.7700 No No 122001 722 / Month 2

 | Positive

 | Positive

 | Positive

 | Positive

 | Positive
 | Positive

 | Positive
 | Positive
 | Positive

 | Positive
 | Positive
 | Positive | Positive
 | Positive | Positive in the second se | Positive
 |
| Treatment Group Subject ID Assay Assay </th <th>Treatment Group Subject ID Assay Assay<!--</th--><td>Treatment Group Subject ID Assay Asay<td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive Associate</td><td>Positive</td><td>Positive</td><td>Positive</td></td></th>

 | Treatment Group Subject ID Assay Assay </th <td>Treatment Group Subject ID Assay Asay<td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive Associate</td><td>Positive</td><td>Positive</td><td>Positive</td></td>

 | Treatment Group Subject ID Assay Asay <td>Positive</td> <td>Positive Associate</td> <td>Positive</td> <td>Positive</td> <td>Positive</td>

 | Positive

 | Positive

 | Positive

 | Positive

 | Positive
 | Positive

 | Positive
 | Positive

 | Positive
 | Positive
 | Positive
 | Positive
 | Positive Associate | Positive | Positive
 | Positive |
| Treatment/Group Subject ID Assay Assay Annunoreactivity Infamination 170010 365 /Month 12 2.8700 No No No 170010 365 /Month 12 1.870 Irrits Diagnois Ranibizumab 0.5 mg 170010 355 /Month 12 1.870 Irrits Ranibizumab 0.5 mg 102002 722 /Month 24 1.870 No 1170002 722 /Month 24 1.140 No No 106002 722 /Month 24 1.130 No No 122002 357 /Month 24 1.1700 No No 122002 357 /Month 24 1.700 No No 122003 357 /Month 24 1.700 No No 122004 717 /Month 24 1.570 No No 123004 357 /Month 24 1.940 No No 124013 715 /Month 24 1.940 No No 125004 357 / Month 24 1.940 No No

 | Treatment/Group Subject ID Assivy Annunoreactivity Infamination 170010 365 / Month 12 2 8700 No No 170010 365 / Month 12 2 8800 Iritis Diagnois Ranibizumab 0.5 mg 170010 355 / Month 12 1 8870 Iritis Ranibizumab 0.5 mg 102002 722 / Month 24 1 8870 No 104002 722 / Month 24 1 1400 No No 102001 722 / Month 24 1 1300 No No 126001 722 / Month 24 1 1300 No No 122002 357 / Month 24 1 1770 No No 126001 722 / Month 24 1 570 No No 122002 357 / Month 24 1 570 No No 122001 722 / Month 24 1 570 No No 122001 722 / Month 24 1 570 No No 126001 721 / Month 24 1 570 No No 125006<

 | Treatment Group Bubject ID Immunoreactivity Immunoreactivity Infammation 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.870 No No 170010 355 / Month 12 1.870 Intitis No 170010 355 / Month 24 1.850 No No 170010 717 / Month 24 1.300 No No 122002 359 / Month 24 1.130 No No 122002 357 / Month 24 1.130 No No 124003 722 / Month 24 1.770 No No 122001 174 / Month 64 1.770 No No 124003 722 / Month 12 1.630 No No 122004 727 / Month 24 1.770 No No 12001 174 / Month 24 1.770 No No 12001 177 / Month 24 1.770 No No 121008 11// Month 24

 | Positive

 | Positive

 | Posifiye

 | Positive

 | Positive
 | Positive

 | Positive
 | Posifiye
 | Posifiye

 | Posifiye
 | Positive
 | Lintracentar was | Post os a series of the series
 | Dosidye State Posidye | Positive | Positive P |
| Treatment Group Subject ID Immunoreactivity

 | Treatment Group Subject ID Immunoreactivity

 | Treatment Group Subject ID Immunoreactivity

 | Positive

 | Positive

 | Positive

 | Dositive

 | Positive and a second se

 | Dositive
 | Dositive

 | Positive
 | Positive
 | Positive
 | Positive
 | Positive
 | |
 | | |
| Treatment Group Subject ID Assay Lass Log Infinituoreactivity Infinituoreactivity Infinituoreactivity Infinituois 170010 35 / Month 12 2770 No No No 177006 358 / Month 12 1870 Irritis No Rantbizumab 0.5 mg 102001 715 / Month 24 1.870 Irritis Rantbizumab 0.5 mg 102001 722 / Month 24 1.140 No 106002 717 / Month 24 1.130 No No 106002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.700 No No 122002 722 / Month 24 1.130 No No 122003 357 / Month 24 1.700 No No 122001 722 / Month 24 1.570 No No 124003 712 / Month 24 1.570 No No 122004 722 / Month 24 1.570 No No 123004 181 / Month 6 </th <th>Treatment Group Subject ID Assay Lannuioreactivity Inmunoreactivity Inmunoreactivity Infinimmation 170010 355 / Month 12 2770 No No No 170010 355 / Month 12 1870 Irrinis No 177006 358 / Month 12 1870 Irrinis No 177006 358 / Month 12 1870 Irrinis No Ranthizumab 0.5 mg 102001 722 / Month 24 1130 No 106002 717 / Month 24 1130 No No 102001 722 / Month 12 1650 No No 122002 359 / Month 12 1700 No No 122002 722 / Month 24 1700 No No 122003 357 / Month 24 1700 No No 124001 722 / Month 24 1570 No No 12001 722 / Month 24 1570 No No 12001 722 / Month 24 1570 No</th> <td>Treatment Group Subject ID Assay Lammunoreactivity Infimumation 170010 35 / Month 12 2770 No 177006 358 / Month 12 2770 No 177006 358 / Month 12 1870 Irritis 177006 358 / Month 12 1870 Irritis 177006 358 / Month 12 1870 Irritis 177005 359 / Month 12 1870 Irritis 104002 717 / Month 24 1130 No 102001 722 / Month 24 1130 No 122002 359 / Month 12 16400 No 122002 727 / Month 24 1130 No 124001 722 / Month 24 1.700 No 124003 722 / Month 24 1.900 No 124003 722 / Month 24 1.900 No 124003 722 / Month 24 1.900 No 124001 722 / Month 24 1.900 No 124001 722 / Month 24 1.900</td> <td>Positive</td> <td>Positive Target and the second s</td> <td></td> <td></td> <td></td> <td></td>

 | Treatment Group Subject ID Assay Lannuioreactivity Inmunoreactivity Inmunoreactivity Infinimmation 170010 355 / Month 12 2770 No No No 170010 355 / Month 12 1870 Irrinis No 177006 358 / Month 12 1870 Irrinis No 177006 358 / Month 12 1870 Irrinis No Ranthizumab 0.5 mg 102001 722 / Month 24 1130 No 106002 717 / Month 24 1130 No No 102001 722 / Month 12 1650 No No 122002 359 / Month 12 1700 No No 122002 722 / Month 24 1700 No No 122003 357 / Month 24 1700 No No 124001 722 / Month 24 1570 No No 12001 722 / Month 24 1570 No No 12001 722 / Month 24 1570 No

 | Treatment Group Subject ID Assay Lammunoreactivity Infimumation 170010 35 / Month 12 2770 No 177006 358 / Month 12 2770 No 177006 358 / Month 12 1870 Irritis 177006 358 / Month 12 1870 Irritis 177006 358 / Month 12 1870 Irritis 177005 359 / Month 12 1870 Irritis 104002 717 / Month 24 1130 No 102001 722 / Month 24 1130 No 122002 359 / Month 12 16400 No 122002 727 / Month 24 1130 No 124001 722 / Month 24 1.700 No 124003 722 / Month 24 1.900 No 124003 722 / Month 24 1.900 No 124003 722 / Month 24 1.900 No 124001 722 / Month 24 1.900 No 124001 722 / Month 24 1.900

 | Positive

 | Positive

 | Positive

 | Positive
 | Positive

 | Positive

 | Positive
 | Positive
 | Positive

 | Positive
 | Positive | Positive Target and the second s
 |
 | | |
 |
| Treatment Group Subject ID fiminioreactivity Immunoreactivity

 | Treatment Group Subject ID fimininoreactivity Immunoreactivity

 | Treatment Group Subject ID finiminoreactivity Timimiroreactivity Timimiroreactivity Infinimiration 170010 365 (Month 12 2770 No No 177006 358 (Month 12 2770 No 177006 358 (Month 12 1570 No 1870 Iritis No 177006 358 (Month 12 1870 Iritis No No No 177005 359 (Month 12 1870 Iritis No No No 106002 717 (Month 24 1130 No No No No 122002 357 (Month 24 1130 No No No No 126001 727 (Month 24 1.700 No No No No 126001 727 (Month 24 1.700 No No No No 128001 727 (Month
24 1.700 No No No No 128001 727 (Month 24 1.700 No No No

 | Designed and the second se

 |

 | DARAGE

 |

 |

 |
 |

 | DARAGE
 | DARAGE
 | DARAGE
 | Designed and the second se
 |
 | ※第二次のためではないではないです。 |
 | | |
| Treatment Group Subject ID Assay Lunumoreactivity Innumoreactivity No Ranthizumab 0.5 mg 177006 338 / Month 12 15870 Intitis 17700 No 177005 338 / Month 24 11340 No No No No 126001 722 / Month 24 11300 No No No No 126001 722 / Month 24 11300 No No No No 126001 722 / Month 24 1300 722 / Month 24 1300 No No No 128001 722 / Month 24 1300 722 / Month 24 1300 No No 128001 720 / Month 24 1300 722 / Month 24 1300 No No

 | Treatment Group Subject ID Assay Immunoreactivity No No <th< th=""><td>Treatment Group Subject ID Assay Immunoreactivity No <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>2019年間1月1日の1日には1月1日には1日には1日には1日には1日には1日には1日には1日には1日には1日には</td><td> </td><td>☆☆は開始ないたり間違いではないながではない。 またし 1000 minutes いったい アンドロ・アンドログ Alia Alia Alia Alia Alia Alia Alia Alia</td><td>多少なながらはない。「小田ははないはおかけない」「「」」「「」」」「「」」」「「」」」「「」」」」「「」」」」」」」」「」」」」</td></th<></td></th<>

 | Treatment Group Subject ID Assay Immunoreactivity No No <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>2019年間1月1日の1日には1月1日には1日には1日には1日には1日には1日には1日には1日には1日には1日には</td><td> </td><td>☆☆は開始ないたり間違いではないながではない。 またし 1000 minutes いったい アンドロ・アンドログ Alia Alia Alia Alia Alia Alia Alia Alia</td><td>多少なながらはない。「小田ははないはおかけない」「「」」「「」」」「「」」」「「」」」「「」」」」「「」」」」」」」」「」」」」</td></th<>

 |

 |

 |

 |

 |

 |
 |

 |
 |
 |
 |
 |
 | 2019年間1月1日の1日には1月1日には1日には1日には1日には1日には1日には1日には1日には1日には1日には |
 | ☆☆は開始ないたり間違いではないながではない。 またし 1000 minutes いったい アンドロ・アンドログ Alia Alia Alia Alia Alia Alia Alia Alia | 多少なながらはない。「小田ははないはおかけない」「「」」「「」」」「「」」」「「」」」「「」」」」「「」」」」」」」」「」」」」 |
| Treatment Group Subject ID Assay Lunturoreactivity Intranuoreactivity Intranuoreactity Intranuoreactivity <t< th=""><th>Treatment Group Subject ID Assay Lunturoreactivity Intranuoreactivity Intranuoreactity Intranuoreactity</th><td>Treatment Group Subject ID Assay Turnutoreactivity Inflammation I rotio 365 / Month 12 2.770 No I 77016 358 / Month 12 2.800 Intitis Ranibizumab 0.5 mg 177/066 358 / Month 24 1.870 No Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No 177005 358 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.1700 No No 122002 359 / Month 24 1.1700 No No 122002 359 / Month 24 1.1700 No No 122003 357 / Month 24 1.1700 No No 122003 357 / Month 24 1.1700 No No 122003 357 / Month 24 1.1700 No No 124003 721 / Month 24 1.700 No No 124001 725 / Month 24 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>2019年1月1日、1月1日は1日には1日には1日には1日に、1日に、1日に、1日に、1日には1日には1日には1日には1日には1日に、1日に、1日に、1日に、1日に、1日に、1日に、1日に、1日に、1日に、</td><td>2019年1月1日、1月1日日には1日には1日には1日には1日に、1日に、1日に、1日には1日には1日には1日には1日に、1日に、1日に、1日に、1日に、1日に、1日に、1日に、1日に、1日に、</td><td>- 1997年1997年1997年1997日の1997年1997日の1997年1997日の1997年1997日の1997年1997日の1997年1997日の1997日の1997日の1997日の1997日の1997日の1997</td><td></td></td<></td></t<>

 | Treatment Group Subject ID Assay Lunturoreactivity Intranuoreactivity Intranuoreactity Intranuoreactity

 | Treatment Group Subject ID Assay Turnutoreactivity Inflammation I rotio 365 / Month 12 2.770 No I 77016 358 / Month 12 2.800 Intitis Ranibizumab 0.5 mg 177/066 358 / Month 24 1.870 No Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No 177005 358 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.1700 No No 122002 359 / Month 24 1.1700 No No 122002 359 / Month 24 1.1700 No No 122003 357 / Month 24 1.1700 No No 122003 357 / Month 24 1.1700 No No 122003 357 / Month 24 1.1700 No No 124003 721 / Month 24 1.700 No No 124001 725 / Month 24 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>2019年1月1日、1月1日は1日には1日には1日には1日に、1日に、1日に、1日に、1日には1日には1日には1日には1日には1日に、1日に、1日に、1日に、1日に、1日に、1日に、1日に、1日に、1日に、</td><td>2019年1月1日、1月1日日には1日には1日には1日には1日に、1日に、1日に、1日には1日には1日には1日には1日に、1日に、1日に、1日に、1日に、1日に、1日に、1日に、1日に、1日に、</td><td>- 1997年1997年1997年1997日の1997年1997日の1997年1997日の1997年1997日の1997年1997日の1997年1997日の1997日の1997日の1997日の1997日の1997日の1997</td><td></td></td<>

 |

 |

 |

 |

 |

 |
 |

 |
 |
 |
 |
 |
 | 2019年1月1日、1月1日は1日には1日には1日には1日に、1日に、1日に、1日に、1日には1日には1日には1日には1日には1日に、1日に、1日に、1日に、1日に、1日に、1日に、1日に、1日に、1日に、 | 2019年1月1日、1月1日日には1日には1日には1日には1日に、1日に、1日に、1日には1日には1日には1日には1日に、1日に、1日に、1日に、1日に、1日に、1日に、1日に、1日に、1日に、
 | - 1997年1997年1997年1997日の1997年1997日の1997年1997日の1997年1997日の1997年1997日の1997年1997日の1997日の1997日の1997日の1997日の1997日の1997 | |
| Treatment Group Subject ID Assay Immunoreactivity Inflammation 170010 365 / Month 12 2.770 No No 177006 358 / Month 12 2.800 Iritian 177006 358 / Month 24 1.850 Iritian 177006 358 / Month 24 1.850 Iritian 177005 358 / Month 24 1.850 No 105001 722 / Month 24 1.140 No 106002 719 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 126001 174 / Month 6 1.700 No 126001 174 / Month 6 1.

 | Treatment Group Subject ID Assay Immunoreactivity Immunoreactity Immunoreactivity Imm

 | Treatment Group Subject ID Assay Immunoreactivity Immunoreactitity Immunoreactitity I

 |

 |

 | この時間であた。この一般で強いには、「は、する」をして、 し、、、、、、、、、、、、、、、、、、、、、、、、、、、、、、、、、、

 |

 |

 |
 |

 | この時間であた。この一般で強いには、「は、する」をして、 し、、、、、、、、、、、、、、、、、、、、、、、、、、、、、、、、、、
 | この時間であた。この一般で強いには、「は、する」をして、 し、、、、、、、、、、、、、、、、、、、、、、、、、、、、、、、、、、
 | この時間であた。この時では「「「「」」」です。また、「」」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」
 |
 |
 | |
 | | |
| Treatment Group Subject ID Assay Immunoreactivity Inflammation 170010 365 Mouth 12 2770 No No 177006 715 Mouth 24 2800 Litits No 177006 715 Mouth 24 1870 Litits No 177006 717 Mouth 24 1970 No No 100001 722 Mouth 24 1140 No No 106002 723 Mouth 24 1140 No No 106002 723 Mouth 24 1130 No No 122002 357 Mouth 24 1130 No No 122002 723 Mouth 24 1700 No No 122002 723 Mouth 24 1700 No No 122002 723 Mouth 24 1700 No No 122003 723 Mouth 24 1700 No No 12400 174 Mouth 6 1700 No No 12400 721 Mouth 6 1700 No N

 | Treatment Group Subject ID Assay Immunoreactivity Inflammation 170010 365 Month 12 2770 No No 177006 715 Month 24 2800 Iritis No 177006 715 Month 12 1870 Iritis No 177006 717 Month 124 1870 Iritis No 177005 719 Month 24 0.922 No No 106002 722 Month 24 1.140 No No 106002 723 Month 24 1.130 No No 122002 357 Month 24 1.130 No No 122002 723 Month 24 1.700 No No 122002 357 Month 24 0.782 No No 12400 722 Month 24 1.700 No No 12400 721 Month 24 1.700 No No 12400 721 Month 24 1.700 No No 12400 714 Month 24 1.700 No <td>Treatment Group Assay Tummoreactivity Infinamiation 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 715 / Month 12 2.800 Littis 177006 715 / Month 12 1.870 Littis 177006 719 / Month 12 1.870 Littis 177005 375 / Month 12 1.870 No 122002 719 / Month 24 0.922 No 106002 722 / Month 12 1.650 No 122002 357 / Month 12 1.630 No 122002 357 / Month 24 0.782 No 126001 174 / Month 24 0.780 No 126001 174 / Month 24 0.780 No 126001 174 / Month 24 0.790 No <</td> <td></td> <td>いた。「「「「「「」」」「「」」」」「「」」」」「「」」」」「「」」」」「「」」」」「「」」」」</td>

 | Treatment Group Assay Tummoreactivity Infinamiation 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 715 / Month 12 2.800 Littis 177006 715 / Month 12 1.870 Littis 177006 719 / Month 12 1.870 Littis 177005 375 / Month 12 1.870 No 122002 719 / Month 24 0.922 No 106002 722 / Month 12 1.650 No 122002 357 / Month 12 1.630 No 122002 357 / Month 24 0.782 No 126001 174 / Month 24 0.780 No 126001 174 / Month 24 0.780 No 126001 174 / Month 24 0.790 No <

 |

 |

 |

 |
 |

 |

 |
 |
 |

 |
 |
 | |
 | | | いた。「「「「「「」」」「「」」」」「「」」」」「「」」」」「「」」」」「「」」」」「「」」」」
 |
| Treatment Group Subject ID Assry Turninoreactivity Infinametun 170010 365 / Month 12 2770 No 177006 715 / Month 12 2770 No 177010 365 / Month 12 2770 No 177015 385 / Month 12 1870 Littis 177016 715 / Month 12 1870 Littis 177016 717 / Month 12 1870 Littis 1177015 717 / Month 24 0.922 No 106002 722 / Month 24 1.130 No 1122002 357 / Month 24 1.130 No 122002 357 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003 721 / Month 24 1.700 No 124003 721 / Month 24 1.700 No 124003 711 / Month 24 1.700 No 143010 725 / Month 24 1.940 <td< th=""><th>Treatment Group Subject ID Assry Turninoreactivity Infinamentania 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 715 / Month 12 1.870 Littis 177010 365 / Month 12 1.870 Littis 177010 355 / Month 12 1.870 Littis 177010 355 / Month 12 1.870 Littis 177010 371 / Month 24 0.922 No 106002 722 / Month 24 1.140 No 1122002 357 / Month 24 1.130 No 122002 357 / Month 24 0.782 No 126001 1/14 / Month 6 1.700 No 126001 1/14 / Month 6 1.700 No 126001 1/14 / Month 6 1.700 No 124003 725 / Month 24 0.782 No 126001 1/14 / Month 6 1.700 No 141013 715 / Month 24 0.790</th><td>Treatment Group Dispect ID Assay Tumminoreactivity Infinamentania 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 715 / Month 24 2.800 Irtitis 177006 715 / Month 24 0.922 No 177006 717 / Month 24 0.922 No 104002 719 / Month 24 0.922 No 105001 722 / Month 24 1.140 No 106002 723 / Month 24 1.130 No 122002 357 / Month 24 1.700 No 122002 357 / Month 24 0.782 No 126001 174 / Month 24 0.780 No 126001 174 / Month 24 0.780 No 126001 174 / Month 24 0.780 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>2019年1月19日には、1919年1月19日には、1919年1日、1919</td><td>2011年1月1日には、1911年1日に</td></td<></td></td<>

 | Treatment Group Subject ID Assry Turninoreactivity Infinamentania 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 715 / Month 12 1.870 Littis 177010 365 / Month 12 1.870 Littis 177010 355 / Month 12 1.870 Littis 177010 355 / Month 12 1.870 Littis 177010 371 / Month 24 0.922 No 106002 722 / Month 24 1.140 No 1122002 357 / Month 24 1.130 No 122002 357 / Month 24 0.782 No 126001 1/14 / Month 6 1.700 No 126001 1/14 / Month 6 1.700 No 126001 1/14 / Month 6 1.700 No 124003 725 / Month 24 0.782 No 126001 1/14 / Month 6 1.700 No 141013 715 / Month 24 0.790

 | Treatment Group Dispect ID Assay Tumminoreactivity Infinamentania 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177006 715 / Month 24 2.800 Irtitis 177006 715 / Month 24 0.922 No 177006 717 / Month 24 0.922 No 104002 719 / Month 24 0.922 No 105001 722 / Month 24 1.140 No 106002 723 / Month 24 1.130 No 122002 357 / Month 24 1.700 No 122002 357 / Month 24 0.782 No 126001 174 / Month 24 0.780 No 126001 174 / Month 24 0.780 No 126001 174 / Month 24 0.780 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>2019年1月19日には、1919年1月19日には、1919年1日、1919</td><td>2011年1月1日には、1911年1日に</td></td<>

 |

 |

 |

 |

 |
 |

 |
 |
 |

 |
 |
 | |
 | | 2019年1月19日には、1919年1月19日には、1919年1日、1919 |
2011年1月1日には、1911年1日に |
| Treatment Group Display function and first in the control of the intermediation and says Display function and first intermediation and and and and and and and and and an

 | Treatment Group Display function and first in the control of the intermediativity Intransition and first intermediativity Ranibizumab 0.5 mg 102001 712 Month 24 0.922 No No 122002 723 Month 24 1.130 No No No 122002 723 Month 24 1.130 No No 124003 1.14 Month 6 1.700 No 124003 725 Month 24 1.480 No 141013 715 Month 6 <td< th=""><td>Treatment Group Display function starty Intransion Treatment Group Subject ID Jestity Intransient Intransient 170010 365 / Month 12 2.770 No No 177006 355 / Month 12 2.770 No No 177006 355 / Month 12 2.800 Intransient 177006 355 / Month 24 0.922 No 177006 713 / Month 24 1.130 No 104002 714 / Month 24 1.130 No 104002 722 / Month 24 1.130 No 122002 359 / Month 24 1.1700 No 122002 357 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 717 / Month 24 1.700 No 124003 715 / Month 24 1.700 No 124003 717 / Month 24 1.700 No 141013 131 / Month 2</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>

 | Treatment Group Display function starty Intransion Treatment Group Subject ID Jestity Intransient Intransient 170010 365 / Month 12 2.770 No No 177006 355 / Month 12 2.770 No No 177006 355 / Month 12 2.800 Intransient 177006 355 / Month 24 0.922 No 177006 713 / Month 24 1.130 No 104002 714 / Month 24 1.130 No 104002 722 / Month 24 1.130 No 122002 359 / Month 24 1.1700 No 122002 357 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 717 / Month 24 1.700 No 124003 715 / Month 24 1.700 No 124003 717 / Month 24 1.700 No 141013 131 / Month 2

 |

 |

 |

 |
 |

 |

 |
 |
 |

 |
 | |
 |
 | | |
 |
| Treatment Group Distince
Intransectivity Intransectivity
Assay Log Titer Intransectivity
Intransation 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 170010 365 / Month 24 2.800 Iritis 170010 358 / Month 12 1.870 Iritis 177006 358 / Month 24 1.870 Iritis 105001 717 / Month 24 1.130 No 102001 722 / Month 24 1.130 No 106002 723 / Month 24 1.770 No 122002 357 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 722 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 124003 725 / Month 24 1.770 No 141013 114 / Month 6 <

 | Treatment Group Distince
Intransectivity Intransectivity
Assay Log Titer Intransectivity
Intransation 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177015 715 / Month 24 1.870 Intris 177015 717 / Month 24 1.130 No 102001 722 / Month 24 1.130 No 102001 722 / Month 24 1.130 No 104002 714 / Month 6 1.7700 No 122002 359 / Month 24 1.130 No 122002 722 / Month 24 1.7700 No 124003 722 / Month 24 1.7700 No 124003 722 / Month 24 1.7700 No 124003 725 / Month 24 1.7700 No 124003 725 / Month 24 1.7700 No 124003 725 / Month 24 1.780 No 124001 725 / Month 24 <td< th=""><td>Treatment Group Distince
Intranscientivy Diamonation
Assoy Log Titery Intranscientivity
Assoy Log Titery Intranscientivity
Intranscientivity Intranscientivity
Assoy Log Titery Intranscientivity
Non 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 358 / Month 12 1.870 Intris Intrascientivity Rantbizumab 0.5 mg 102001 712 / Month 24 1.140 No 117005 339 / Month 12 1.130 No No 122002 339 / Month 24 1.140 No No 124003 722 / Month 24 1.770 No No 124001 174 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124001 725 / Month 24 1.770 No No 124003 727 / Month 24 1.770 No No 124001 726 / Month 24 1.770 No No <</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>

 | Treatment Group Distince
Intranscientivy Diamonation
Assoy Log Titery Intranscientivity
Assoy Log Titery Intranscientivity
Intranscientivity Intranscientivity
Assoy Log Titery Intranscientivity
Non 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.770 No No 170010 358 / Month 12 1.870 Intris Intrascientivity Rantbizumab 0.5 mg 102001 712 / Month 24 1.140 No 117005 339 / Month 12 1.130 No No 122002 339 / Month 24 1.140 No No 124003 722 / Month 24 1.770 No No 124001 174 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124001 725 / Month 24 1.770 No No 124003 727 / Month 24 1.770 No No 124001 726 / Month 24 1.770 No No <

 |

 |

 |

 |

 |
 |

 |
 |
 |

 |
 |
 | |
 | | |
 |
| Treatment Group Dotitive Intransferenting Intransferenting Arrentinent Group Subject ID Assay Log Ther Infamilion 170010 365 / Month 12 2.770 No 170010 365 / Month 24 2.800 Infus 170010 365 / Month 12 1.850 No 177006 358 / Month 24 1.130 No 117001 717 / Month 24 1.130 No 105002 722 / Month 24 1.130 No 106002 722 / Month 24 1.130 No 106002 722 / Month 24 1.1700 No 122002 359 / Month 24 1.770 No 124003 722 / Month 24 0.790

 | Treatment Group Districts Intransferent view Intransferent view<

 | Treatment Group Robitive Intransicult Intransicult Intransicult Arrent Treatment Group Subject ID Assay Log Ther Intransicult Intransicult 170010 365 / Month 24 2.800 No No 177006 358 / Month 24 1.850 No No 177006 358 / Month 24 1.130 No No 105002 722 / Month 24 1.130 No No 105002 722 / Month 24 1.130 No No 112002 739 / Month 24 1.1700 No No 122002 359 / Month 24 1.1700 No No 122002 722 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124001 174 / Month 24 1.770 No No 124003 722 / Month 24 1.770 No No 124001 174 / Month 24 1.770 No No 141013

 |

 |

 |

 |
 |

 |

 |
 |
 |
 |
 |
 |
 |
 | | | |
| Treatment Group Subject ID Assay Lumoreactivity Immonsativity IToolio 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177015 355 / Month 12 2.800 Iritis 177016 355 / Month 12 1.870 Iritis 177015 715 / Month 24 0.922 No 177016 722 / Month 24 1.130 No 104002 719 / Month 24 1.130 No 122002 357 / Month 24 1.130 No 122002 357 / Month 24 1.700 No 122002 357 / Month 24 0.782 No 124003 722 / Month 24 0.782 No 124003 725 / Month 24 0.782 No 124003 725 / Month 24 0.782 No 124003 715 / Month 6 1.700 No 124003 715 / Month 24 0.782 No 124003 715 / Month 24 0.780

 | Treatment Group Turnacentivity Immunorescrivity Immonorescrivity Immonorescrivity <td>Treatment Group Turnocentivity Immunorestrivity
Immunorestrivity<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>2019年1月19日には、1919年1月19日には、1919年1日、1919</td><td>2011年1月1日には、1911年1日に</td></td>

 | Treatment Group Turnocentivity Immunorestrivity Immunorestrivity <td></td> <td>2019年1月19日には、1919年1月19日には、1919年1日、1919</td> <td>2011年1月1日には、1911年1日に</td>

 |

 |

 |

 |
 |

 |

 |
 |
 |

 |
 | |
 |
 | | 2019年1月19日には、1919年1月19日には、1919年1日、1919 |
2011年1月1日には、1911年1日に |
| Treatment Group Subject ID Assay Tummoreactivity Inflammorian 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 177016 715 / Month 24 2.800 Lritis 177016 715 / Month 12 1.870 Lritis 177016 717 / Month 12 1.870 Lritis 177016 717 / Month 24 0.922 No 104002 719 / Month 24 1.140 No 1122002 357 / Month 12 1.650 No 122002 723 / Month 24 1.1700 No 122002 723 / Month 24 0.782 No 124003 722 / Month 24 0.782 No 126001 174 / Month 6 1.700 No 126001 724 / Month 24 0.782 No 124003 725 / Month 24 1.940 No 126001 714 / Month 6 1.700 No 124003 726 / Month 24 0.780

 | Treatment Group Subject ID Assay Tummoreactivity Timmoreactivity No 170010 365 / Month 12 2.770 No 10000 715 / Month 24 2800 Livitis 177006 373 / Month 24 1.140 No No No 10000 122002 723 / Month 24 1.130 No No 10000 No 10000 No No No No No No 10000 No

 | Treatment Group Subject ID Assay Tummoreactivity No 170010 365 / Month 12 2.770 No 1 1 No 1 1 No 1 1 1 No 1 1 No 1

 |

 |

 |

 |
 |

 |

 |
 |
 |

 |
 | |
 |
 | | | いた。「「「「「「「」」「「」」「「」」」「「」」」「「」」」「「」」」」「「」」」」
 |
| Treatment Group Subject ID Assry Turninoreactivity Infinamentanian 170010 365 / Month 12 2.770 No 177006 715 / Month 12 2.800 Irtitis 17701 715 / Month 12 1.870 Irtitis 17701 717 / Month 12 1.870 Irtitis 17701 717 / Month 12 1.870 Irtitis 17701 717 / Month 24 0.922 No 106002 722 / Month 24 1.140 No 1122002 357 / Month 24 1.130 No 122002 723 / Month 24 1.130 No 122002 723 / Month 24 1.700 No 122002 723 / Month 24 0.782 No 124003 722 / Month 24 1.700 No 124003 723 / Month 24 1.700 No 124003 721 / Month 24 1.700 No 124003 721 / Month 24 1.700 No 141013 726 / Month 24 1.700 <th>Treatment Group Subject ID Assry Tumminoractivity Infinametion 170010 365 / Month 12 2.770 No 177006 715 / Month 24 2.800 Irtis 177010 365 / Month 12 1.870 Irtis 177015 385 / Month 12 1.870 Irtis 177016 715 / Month 24 0.922 No 177015 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 357 / Month 24 1.130 No 122002 357 / Month 24 1.700 No 122002 723 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003 725 / Month 24 1.700 No 124003 725 / Month 24 1.700 No 124003 715 / Month 24 1.700 No 141013 715 / Month 24 1.940 <t< th=""><td>Treatment Group Subject ID Assry Turninoreactivity Infinamentanian 170010 365 / Month 12 2.770 No 177006 715 / Month 12 2.800 Irtitis 177010 365 / Month 12 2.800 Irtitis 177006 715 / Month 12 1.870 Irtitis 177005 355 / Month 12 1.870 Irtitis 177006 717 / Month 24 0.922 No 106002 722 / Month 24 1.140 No 106002 723 / Month 24 1.130 No 122002 357 / Month 24 1.700 No 122002 357 / Month 24 1.700 No 124003 722 / Month 24 0.782 No 126001 174 / Month 24 1.700 No 126001 174 / Month 24 0.782 No 126001 174 / Month 24 1.700 No 126001 174 / Month 24 0.780 No 126001 174 / Month 24 0.790<</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<></th>

 | Treatment Group Subject ID Assry Tumminoractivity Infinametion 170010 365 / Month 12 2.770 No 177006 715 / Month 24 2.800 Irtis 177010 365 / Month 12 1.870 Irtis 177015 385 / Month 12 1.870 Irtis 177016 715 / Month 24 0.922 No 177015 719 / Month 24 1.140 No 106002 722 / Month 24 1.130 No 122002 357 / Month 24 1.130 No 122002 357 / Month 24 1.700 No 122002 723 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003 722 / Month 24 1.700 No 124003 725 / Month 24 1.700 No 124003 725 / Month 24 1.700 No 124003 715 / Month 24 1.700 No 141013 715 / Month 24 1.940 <t< th=""><td>Treatment Group Subject ID Assry Turninoreactivity Infinamentanian 170010 365 / Month 12 2.770 No 177006 715 / Month 12 2.800 Irtitis 177010 365 / Month 12 2.800 Irtitis 177006 715 / Month 12 1.870 Irtitis 177005 355 / Month 12 1.870 Irtitis 177006 717 / Month 24 0.922 No 106002 722 / Month 24 1.140 No 106002 723 / Month 24 1.130 No 122002 357 / Month 24 1.700 No 122002 357 / Month 24 1.700 No 124003 722 / Month 24 0.782 No 126001 174 / Month 24 1.700 No 126001 174 / Month 24 0.782 No 126001 174 / Month 24 1.700 No 126001 174 / Month 24 0.780 No 126001 174 / Month 24 0.790<</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>

 | Treatment Group Subject ID Assry Turninoreactivity Infinamentanian 170010 365 / Month 12 2.770 No 177006 715 / Month 12 2.800 Irtitis 177010 365 / Month 12 2.800 Irtitis 177006 715 / Month 12 1.870 Irtitis 177005 355 / Month 12 1.870 Irtitis 177006 717 / Month 24 0.922 No 106002 722 / Month 24 1.140 No 106002 723 / Month 24 1.130 No 122002 357 / Month 24 1.700 No 122002 357 / Month 24 1.700 No 124003 722 / Month 24 0.782 No 126001 174 / Month 24 1.700 No 126001 174 / Month 24 0.782 No 126001 174 / Month 24 1.700 No 126001 174 / Month 24 0.780 No 126001 174 / Month 24 0.790<

 |

 |

 |

 |

 |
 |

 |
 |
 |

 |
 |
 | |
 | | |
 |
| Treatment Group Bubject ID Assay Immunoreactivity I

 | Treatment Group Bubjett ID Assay Immunoreactivity I

 | Treatment Group Bubject ID Assay Immunoreactivity I

 |

 |

 | この時間であた。この時では「「「「」」」です。また、「」」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」

 |

 |

 |
 |

 | この時間であた。この時では「「「「」」」です。また、「」」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」
 | この時間であた。この時では「「「「」」」です。また、「」」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」
 | この時間であた。この時では「「「「」」」です。また、「」」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」
 |
 |
 | |
 | | |
| Treatment Group Subject ID Assay Immunoreactivity Inflammation 170010 365 / Month 12 2.770 No No 177006 355 / Month 12 2.800 Inflammation Ranibizumab 0.5 mg 177006 355 / Month 24 1.850 Inflammation 177006 358 / Month 24 1.850 Inflammation 177001 717 / Month 24 1.850 No 106002 719 / Month 24 1.140 No 122002 359 / Month 24 1.130 No 122002 323 / Month 24 1.130 No 122002 323 / Month 24 1.700 No 126001 174 / Month 6 1.570 No 126001 174 / Month 24 1.700 No 126001 174 / Month 6 1.570 No 14101

 | Treatment Group Subject ID Assay Immunoreactivity Inflammation 170010 365 / Month 12 2.770 No No 177006 355 / Month 12 2.800 Inflammation Ranibizumab 0.5 mg 177006 355 / Month 24 1.850 Intition 177006 358 / Month 24 1.850 Intition 177005 719 / Month 24 1.850 No 106002 719 / Month 24 1.140 No 122002 359 / Month 24 1.130 No 122002 359 / Month 24 1.130 No 122002 723 / Month 24 1.700 No 126001 174 / Month 6 1.700 No 126001 724 / Month 24 0.782 No 126001 174 / Month 6 1.700 No 126001 724 / Month 24 0.782 No 126001 724 / Month 6 1.700 No 126001 724 / Month 6 1.700 No 141013

 | Treatment Group Subject ID Assay Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Immunoreactivity Diagnosis 17010 365 / Month 12 2700 No 1 No No 177006 358 / Month 24 1880 Irrits No No 177005 358 / Month 24 1380 No No No 177005 358 / Month 24 1390 No No No 122002 722 / Month 24 1330 No No No 122003 359 / Month 24 1330 No No No 122003 722 / Month 24 1300 No No No 122003 357 / Month 24 1300 No No No 123003 722 / Month 24 1300 No No No 124003 722 / Month 24 1300 No No No 141013 1520 726 / Month 24 <td></td> <td>2019年1月1日には、1919年1月1日には、1919年1日には、19199年1日には、1919年1日には、1919年1日には、1919年1日には、1919年1日には、1919年1日には、1919年1日には</td> <td>2.1111日間には、1111日間には1111日には、1111日日、1111日、1111日、1111日には111日間には1111日、111日、11日、11日</td> <td>は彼然は「我は、「我は、我はないからない」が、「」「「」」「「」」「「」」」「「」」」「「」」」」が、「」」」」」「」」」」」」」「」」」」」」「」」」」」」」」</td> <td>一部には自然は、「小小市ははないたいたいたいたい」が、「小市」「「「「「「「「「」」」「「」」」「「」」」「「」」」」「「」」」」「「」」」」</td> <td></td>

 |

 |

 |

 |

 |
 |

 |
 |
 |

 |
 |
 | 2019年1月1日には、1919年1月1日には、1919年1日には、19199年1日には、1919年1日には、1919年1日には、1919年1日には、1919年1日には、1919年1日には、1919年1日には | 2.1111日間には、1111日間には1111日には、1111日日、1111日、1111日、1111日には111日間には1111日、111日、11日、11日
 | は彼然は「我は、「我は、我はないからない」が、「」「「」」「「」」「「」」」「「」」」「「」」」」が、「」」」」」「」」」」」」」「」」」」」」「」」」」」」」」 | 一部には自然は、「小小市ははないたいたいたいたい」が、「小市」「「「「「「「「「」」」「「」」」「「」」」「「」」」」「「」」」」「「」」」」 |
 |
| Treatment Group Subject ID Assay Immunoreactivity I

 | Treatment Group Subject ID Assay Immunoreactivity I

 | Treatment Group Subject ID Assay Immunoreactivity I

 |

 |

 |

 |

 |

 |
 |

 |
 |
 |
 |
 |
 | 2019年1月1日、1月1日は1日には1日には1日には1日に、1日に、1日に、1日に、1日には1日には1日には1日には1日には1日に、1日に、1日に、1日に、1日に、1日に、1日に、1日に、1日に、1日に、 | 2019年1月1日、1日には1月1日には1日には1日には1日に、1日に、1日に、1日には1日には1日には1日には1日に、1日に、1日に、1日に、1日に、1日に、1日に、1日に、1日に、1日に、
 | - 1997年1997年1997年1997日の1997年1997日の1997年1997日の1997年1997日の1997年1997日の1997年1997日の1997日の1997日の1997日の1997日の1997日の1997 | |
| Treatment Group Subject ID Assay Lunturoreactivity Intranuoreactivity Intranuoreactity Intranuoreactivity <t< th=""><th>Treatment Group Subject ID Assay Lunturoreactivity Intranuoreactivity Intranuoreactity Intranuoreactity</th><td>Treatment Group Subject ID Assay Turnutoreactivity Inflammation I rotio 365 / Month 12 2.770 No I 77016 358 / Month 12 2.800 Intitis Ranibizumab 0.5 mg 177/066 358 / Month 24 1.870 No Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No 177005 358 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.1700 No No 122002 359 / Month 24 1.1700 No No 122002 359 / Month 24 1.1700 No No 122003 357 / Month 24 1.1700 No No 122003 357 / Month 24 1.1700 No No 122003 357 / Month 24 1.1700 No No 124003 721 / Month 24 1.700 No No 124001 725 / Month 24 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>1999年1月1日、1999年1月1日は1日、1997年1日、1997年1日、1997年1日、1997年1月1日は1997年1月1日は1997年1月1日、1997年1</td><td>1998年11月1日日の11日日の11日日の11日日、11日日、11日日、11日、11日、11日</td><td>●「「「「」」では、「「」」では、「」」「「」」」「」」「」」」「」」」「」」」」「」</td><td>るな感染が可能なな、小人はな情報が見なするないでは良い。 - Aline - Alin
Aline - Aline -</td></td<></td></t<>

 | Treatment Group Subject ID Assay Lunturoreactivity Intranuoreactivity Intranuoreactity Intranuoreactity

 | Treatment Group Subject ID Assay Turnutoreactivity Inflammation I rotio 365 / Month 12 2.770 No I 77016 358 / Month 12 2.800 Intitis Ranibizumab 0.5 mg 177/066 358 / Month 24 1.870 No Ranibizumab 0.5 mg 102001 722 / Month 24 1.850 No 177005 358 / Month 24 1.140 No No 122002 359 / Month 24 1.130 No No 122002 359 / Month 24 1.1700 No No 122002 359 / Month 24 1.1700 No No 122002 359 / Month 24 1.1700 No No 122003 357 / Month 24 1.1700 No No 122003 357 / Month 24 1.1700 No No 122003 357 / Month 24 1.1700 No No 124003 721 / Month 24 1.700 No No 124001 725 / Month 24 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>1999年1月1日、1999年1月1日は1日、1997年1日、1997年1日、1997年1日、1997年1月1日は1997年1月1日は1997年1月1日、1997年1</td><td>1998年11月1日日の11日日の11日日の11日日、11日日、11日日、11日、11日、11日</td><td>●「「「「」」では、「「」」では、「」」「「」」」「」」「」」」「」」」「」」」」「」</td><td>るな感染が可能なな、小人はな情報が見なするないでは良い。 - Aline - Alin
Aline - Aline -</td></td<>

 |

 |

 |

 |

 |
 |

 |
 |

 |
 |
 |
 | |
1999年1月1日、1999年1月1日は1日、1997年1日、1997年1日、1997年1日、1997年1月1日は1997年1月1日は1997年1月1日、1997年1 | 1998年11月1日日の11日日の11日日の11日日、11日日、11日日、11日、11日、11日 | ●「「「「」」では、「「」」では、「」」「「」」」「」」「」」」「」」」「」」」」「」
 | るな感染が可能なな、小人はな情報が見なするないでは良い。 - Aline - Alin
Aline - Aline - |
| Treatment Group Subject ID Assay Lunumoreactivity Innumoreactivity No Ranthizumab 0.5 mg 177006 338 / Month 12 15870 Intitis 17700 No 177005 338 / Month 24 11340 No No No No 126001 722 / Month 24 11300 No No No No 126001 722 / Month 24 11300 No No No No 126001 722 / Month 24 1300 722 / Month 24 1300 No No No 128001 722 / Month 24 1300 722 / Month 24 1300 No No 128001 720 / Month 24 1300 722 / Month 24 1300 No No

 | Treatment Group Subject ID Assay Immunoreactivity No No <th< th=""><td>Treatment Group Subject ID Assay Immunoreactivity No <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>※第二次の時間では、「日本の時間では、「「「」」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」、</td><td>※第二、「「「「」」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」</td><td>※認識部長、小別設備設備設備設備には、「「」」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「</td><td></td></th<></td></th<>

 | Treatment Group Subject ID Assay Immunoreactivity No No <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>※第二次の時間では、「日本の時間では、「「「」」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」、</td><td>※第二、「「「「」」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」</td><td>※認識部長、小別設備設備設備設備には、「「」」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「</td><td></td></th<>

 |

 |

 |

 |

 |

 |
 |

 |
 |
 |
 |
 |
 | ※第二次の時間では、「日本の時間では、「「「」」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」、 | ※第二、「「「「」」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」
 | ※認識部長、小別設備設備設備設備には、「「」」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「」、「 | |
| Treatment Group Subject ID fiminioreactivity Immunoreactivity

 | Treatment Group Subject ID fimininoreactivity Immunoreactivity

 | Treatment Group Subject ID finiminoreactivity Timimiroreactivity Timimiroreactivity Infinimiration 170010 365 (Month 12 2770 No No 177006 358 (Month 12 2770 No 177006 358 (Month 12 1570 No 1870 Iritis No 177006 358 (Month 12 1870 Iritis No No No 177005 359 (Month 12 1870 Iritis No No No 106002 717 (Month 24 1130 No No No No 122002 357 (Month 24 1130 No No No No 126001 727 (Month 24 1.700 No No No No 126001 727 (Month 24 1.700 No No No No 128001 727 (Month
24 1.700 No No No No 128001 727 (Month 24 1.700 No No No

 | Desitive states and the second s

 |

 | Definition of the second s

 | Postitives and a second s

 | Posting and a second

 | Postitives and a second s
 | Postitives and a second s

 | Definition of the second s
 | Definition of the second s
 | Definition of the second s
 | Desitive states and the second s
 |
 | |
 | | |
| Treatment Group Subject ID Assay Lass Log Infinituoreactivity Infinituoreactivity Infinituoreactivity Infinituois 170010 35 / Month 12 2770 No No No 177006 358 / Month 12 1870 Irritis No Rantbizumab 0.5 mg 102001 715 / Month 24 1.870 Irritis Rantbizumab 0.5 mg 102001 722 / Month 24 1.140 No 106002 717 / Month 24 1.130 No No 106002 722 / Month 24 1.130 No No 122002 359 / Month 12 1.700 No No 122002 722 / Month 24 1.130 No No 122003 357 / Month 24 1.700 No No 122001 722 / Month 24 1.570 No No 124003 712 / Month 24 1.570 No No 122004 722 / Month 24 1.570 No No 123004 181 / Month 6 </th <th>Treatment Group Subject ID Assay Lannuioreactivity Inmunoreactivity Inmunoreactivity Infinimmation 170010 355 / Month 12 2770 No No No 170010 355 / Month 12 1870 Irrinis No 177006 358 / Month 12 1870 Irrinis No 177006 358 / Month 12 1870 Irrinis No Ranthizumab 0.5 mg 102001 722 / Month 24 1130 No 106002 717 / Month 24 1130 No No 102001 722 / Month 12 1650 No No 122002 359 / Month 12 1700 No No 122002 722 / Month 24 1700 No No 122003 357 / Month 24 1700 No No 124001 722 / Month 24 1570 No No 12001 722 / Month 24 1570 No No 12001 722 / Month 24 1570 No</th> <td>Treatment Group Subject ID Assay Lammunoreactivity Infimumation 170010 35 / Month 12 2770 No 177006 358 / Month 12 2770 No 177006 358 / Month 12 1870 Irritis 177006 358 / Month 12 1870 Irritis 177006 358 / Month 12 1870 Irritis 177005 359 / Month 12 1870 Irritis 104002 717 / Month 24 1130 No 102001 722 / Month 24 1130 No 122002 359 / Month 12 16400 No 122002 727 / Month 24 1130 No 124001 722 / Month 24 1.700 No 124003 722 / Month 24 1.900 No 124003 722 / Month 24 1.900 No 124003 722 / Month 24 1.900 No 124001 722 / Month 24 1.900 No 124001 722 / Month 24 1.900</td> <td>Positive</td> <td>Positive</td> <td>Positive</td> <td>Dositive</td> <td>Positive and a second se</td> <td>Dositive</td> <td>Dositive</td> <td>Positive</td> <td>Positive</td> <td>Positive</td> <td>Positive</td> <td>Positive</td> <td></td> <td></td> <td></td> <td></td>

 | Treatment Group Subject ID Assay Lannuioreactivity Inmunoreactivity Inmunoreactivity Infinimmation 170010 355 / Month 12 2770 No No No 170010 355 / Month 12 1870 Irrinis No 177006 358 / Month 12 1870 Irrinis No 177006 358 / Month 12 1870 Irrinis No Ranthizumab 0.5 mg 102001 722 / Month 24 1130 No 106002 717 / Month 24 1130 No No 102001 722 / Month 12 1650 No No 122002 359 / Month 12 1700 No No 122002 722 / Month 24 1700 No No 122003 357 / Month 24 1700 No No 124001 722 / Month 24 1570 No No 12001 722 / Month 24 1570 No No 12001 722 / Month 24 1570 No

 | Treatment Group Subject ID Assay Lammunoreactivity Infimumation 170010 35 / Month 12 2770 No 177006 358 / Month 12 2770 No 177006 358 / Month 12 1870 Irritis 177006 358 / Month 12 1870 Irritis 177006 358 / Month 12 1870 Irritis 177005 359 / Month 12 1870 Irritis 104002 717 / Month 24 1130 No 102001 722 / Month 24 1130 No 122002 359 / Month 12 16400 No 122002 727 / Month 24 1130 No 124001 722 / Month 24 1.700 No 124003 722 / Month 24 1.900 No 124003 722 / Month 24 1.900 No 124003 722 / Month 24 1.900 No 124001 722 / Month 24 1.900 No 124001 722 / Month 24 1.900

 | Positive

 | Positive

 | Positive

 | Dositive
 | Positive and a second se

 | Dositive

 | Dositive
 | Positive
 | Positive

 | Positive
 | Positive | Positive
 |
 | | |
 |
| Treatment Group Subject ID Assay Lammunoreactivity Infimumation 170010 365 / Month 12 2770 No No 170010 355 / Month 12 2870 No No 170010 355 / Month 12 1870 Irtits Diagnois 170010 355 / Month 12 1870 Irtits Diagnois 717 / Month 24 1140 No No No 106002 722 / Month 24 1140 No No 126001 722 / Month 24 1140 No No 122002 357 / Month 24 11700 No No 122001 722 / Month 24 11700 No No 122002 357 / Month 24 1700 No No 122001 722 / Month 24 1570 No No 123001 715 / Month 24 1570 No No 124001 722 / Month 24 1570 No No 124001 722 / Month 24

 | Treatment Group Subject ID Assay Lumunoreactivity Infimumation 170010 365 / Month 12 2770 No No 170010 355 / Month 12 2870 No No 170010 355 / Month 12 1870 Irtitis No 170010 355 / Month 12 1870 Irtitis No 717 / Month 24 1140 No No No 106002 722 / Month 12 1140 No No 126001 722 / Month 24 1140 No No 122002 357 / Month 24 11700 No No 122001 722 / Month 24 17700 No No 122002 357 / Month 24 17700 No No 122003 357 / Month 24 17700 No No 122004 712 / Month 24 15700 No No 126001 722 / Month 24 15700 No No 12000 715 / Month 24 15700 <td>Treatment/Group Bubjert ID Immunoreactivity Immunoreactivity</td> <td>Positive</td> <td>Positive</td> <td>Posifiye</td> <td>Positive</td> <td>Positive</td> <td>Positive</td> <td>Positive</td> <td>Posifiye</td> <td>Posifiye</td> <td>Posifiye</td> <td>Positive</td> <td>Lintracentar was</td> <td>Post os a series of the series</td> <td>Dosidye State Posidye</td> <td>Positive</td> <td>Positive Positive P</td>

 | Treatment/Group Bubjert ID Immunoreactivity

 | Positive

 | Positive

 | Posifiye

 | Positive

 | Positive
 | Positive

 | Positive
 | Posifiye

 | Posifiye
 | Posifiye
 | Positive
 | Lintracentar was
 | Post os a series of the series | Dosidye State Posidye | Positive
 | Positive P |
| Treatment Group Subject ID annunosescrivity Innnunosescrivity Inn

 | Treatment Group Subject ID numunoreactivity Intimunoreactivity Intimunation 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.800 Intimutoreactivity Intimutoreactivity Ranibizumab 0.5 mg 177006 358 / Month 12 1.870 Irrits 170010 355 / Month 24 1.830 No No 102002 722 / Month 24 1.140 No No 106002 722 / Month 24 1.130 No No 122002 357 / Month 24 1.1700 No No 122002 357 / Month 24 1.700 No No 124003 722 / Month 24 1.700 No No 122002 357 / Month 24 1.700 No No 124003 722 / Month 24 1.700 No No 122004 357 / Month 24 1.700 No No 124013 715 / Month 24 1.940 No No

 | Treatment Group Subject ID Intumunos exervity
(17010) Intumunos exervity
(17010) Intumunos exervity
(17010) Intumunos exervity
(17000)

 | Positive

 | Positive

 | Positive

 | Positive

 | Positive

 | Positive
 | Positive

 | Positive
 | Positive
 | Positive
 | Positive
 | Positive
 | Positive | Dord of the second of the seco
 | Positive P | Positive |
| Treatment Group Subject ID Assay Assay </th <th>Treatment Group Subject ID Assay Assay<!--</th--><td>Treatment Group Subject ID Assay Asay<td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive Associate</td><td>Positive</td><td>Positive</td><td>Positive</td></td></th>

 | Treatment Group Subject ID Assay Assay </th <td>Treatment Group Subject ID Assay Asay<td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive Associate</td><td>Positive</td><td>Positive</td><td>Positive</td></td>

 | Treatment Group Subject ID Assay Asay <td>Positive</td> <td>Positive Associate</td> <td>Positive</td> <td>Positive</td> <td>Positive</td>

 | Positive

 | Positive

 | Positive

 | Positive

 | Positive
 | Positive

 | Positive
 | Positive

 | Positive
 | Positive
 | Positive
 | Positive
 | Positive Associate | Positive | Positive
 | Positive |
| Treatment Group Subject ID Assy Assay Log Titery Diagnosis 170010 365 / Month 12 2.770 No No 170010 365 / Month 12 2.870 No No 170010 365 / Month 12 1.870 Iritis No 170010 357 / Month 24 1.870 Iritis No 170010 715 / Month 24 1.140 No No 122002 725 / Month 24 1.140 No No 122002 725 / Month 24 1.770 No No 122002 725 / Month 24 1.770 No No 122001 124003 721 / Month 24 1.770 No 122002 725 / Month 12 1.770 No No 122003 725 / Month 24 1.770 No No 122004 181 / Month 6 1.770 No No 122001 725 / Month 12 0.782 No No 122001 725 / Month 12 <td< th=""><th>Treatment Group Subject ID Assy Assay Log Titery Diagnosis 170010 365 / Mouth 12 2.770 No No 177006 355 / Mouth 12 2.870 No No 177006 355 / Mouth 24 1.870 Iritis No 170010 357 / Mouth 24 1.140 No No 122002 722 / Mouth 24 1.140 No No 122002 725 / Mouth 24 1.140 No No 122002 725 / Mouth 24 1.140 No No 122002 725 / Mouth 24 1.770 No No 122002 725 / Mouth 24 1.770 No No 122003 725 / Mouth 24 1.770 No No 122004 181 / Mouth 24 1.770 No No 122001 725 / Mouth 12 1.770 No No 122001 725 / Mouth 24 1.770 No No 122001 725 / Mouth 24 1.770<</th><td>Treatment Group Subject ID Assy Assay Log Titery Inagnois 170010 365 / Mouth 12 2.770 No No 177006 355 / Mouth 12 2.870 No No 177006 715 / Mouth 24 1.870 Iritis 177006 719 / Mouth 24 1.140 No 104002 719 / Mouth 24 1.140 No 122002 722 / Mouth 12 1.650 No 122002 722 / Mouth 24 1.140 No 122002 722 / Mouth 24 1.140 No 124003 722 / Mouth 12 1.650 No 122001 174 / Mouth 24 1.770 No 122002 722 / Mouth 12 1.670 No 122003 722 / Mouth 12 1.770 No 122004 181 / Mouth 24 1.770 No 122003 722 / Mouth 12 1.770 No 122004 181 / Mouth 24 1.770 No 122001 181 / Mouth 24</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive</td><td>Positive for the second se</td><td>Positive</td></td<>

 | Treatment Group Subject ID Assy Assay Log Titery Diagnosis 170010 365 / Mouth 12 2.770 No No 177006 355 / Mouth 12 2.870 No No 177006 355 / Mouth 24 1.870 Iritis No 170010 357 / Mouth 24 1.140 No No 122002 722 / Mouth 24 1.140 No No 122002 725 / Mouth 24 1.140 No No 122002 725 / Mouth 24 1.140 No No 122002 725 / Mouth 24 1.770 No No 122002 725 / Mouth 24 1.770 No No 122003 725 / Mouth 24 1.770 No No 122004 181 / Mouth 24 1.770 No No 122001 725 / Mouth 12 1.770 No No 122001 725 / Mouth 24 1.770 No No 122001 725 / Mouth 24 1.770<

 | Treatment Group Subject ID Assy Assay Log Titery Inagnois 170010 365 / Mouth 12 2.770 No No 177006 355 / Mouth 12 2.870 No No 177006 715 / Mouth 24 1.870 Iritis 177006 719 / Mouth 24 1.140 No 104002 719 / Mouth 24 1.140 No 122002 722 / Mouth 12 1.650 No 122002 722 / Mouth 24 1.140 No 122002 722 / Mouth 24 1.140 No 124003 722 / Mouth 12 1.650 No 122001 174 / Mouth 24 1.770 No 122002 722 / Mouth 12 1.670 No 122003 722 / Mouth 12 1.770 No 122004 181 / Mouth 24 1.770 No 122003 722 / Mouth 12 1.770 No 122004 181 / Mouth 24 1.770 No 122001 181 / Mouth 24

 | Positive

 | Positive

 | Positive

 | Positive

 | Positive
 | Positive

 | Positive
 | Positive
 | Positive

 | Positive
 | Positive
 | Positive | Positive
 | Positive | Positive for the second se | Positive
 |
| Treatment Group Subject ID Asay Assay Log Titer Diagnois 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 170010 365 / Month 12 1.870 Irris 170010 715 / Month 24 1.870 Irris 170002 719 / Month 24 1.140 No 122002 722 / Month 24 1.140 No 122002 723 / Month 24 1.130 No 122002 723 / Month 24 1.700 No 122002 723 / Month 24 1.700 No 122003 721 / Month 24 1.700 No 122004 131 / Month 6 1.700 No 122003 725 / Month 12 1.700 No 122014 722 / Month 24 1.700 No 122004 181 / Month 6 1.700 No 122004 725 / Month 12 1.700 No 122010 725 / Month 12 1.700 No

 | Treatment Group Subject ID Asay Assay Log Titer Diagnois 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 170010 365 / Month 12 1.870 Irris 170010 357 / Month 24 1.870 Irris 170002 715 / Month 24 1.140 No 122002 722 / Month 24 1.140 No 122002 723 / Month 24 1.140 No 122002 735 / Month 24 1.170 No 122002 723 / Month 24 1.700 No 122003 725 / Month 24 1.700 No 122004 1212002 725 / Month 24 1.700 No 122010 725 / Month 24 1.700 No No 122010 725 / Month 24 1.700 No No 122010 725 / Month 24 1.700 No No 122010 725 / Month 12 0.752 No No

 | Treatment Group Subject ID Asay Assay Log Titer Diagnois 170010 365 / Month 12 2.770 No 170010 365 / Month 12 2.770 No 170010 355 / Month 12 1.870 Irris 170010 715 / Month 24 1.870 Irris 170010 722 / Month 24 1.140 No 122002 723 / Month 24 1.140 No 122002 723 / Month 24 1.140 No 122002 723 / Month 24 1.770 No 122002 723 / Month 24 1.770 No 122003 723 / Month 24 1.770 No 122003 723 / Month 24 1.770 No 122001 174 / Month 24 1.770 No 122001 723 / Month 12 1.770 No 122001 181 / Month 24 1.770 No 122001 724 / Month 24 1.700 No 141008 181 / Month 24 1.790 No

 | Positive

 | Positive

 | Positive

 | Positive

 | Positive
 | Positive

 | Positive
 | Positive
 | Positive

 | Positive
 | Positive
 | Positive | Positive
 | Positive | Positive | Positive
 |
| Treatment Group Subject ID Asay Log Titer Diagnois 170010 365/Month 12 2.770 No 170010 365/Month 12 1.870 Irtis 177006 715/Month 24 1.870 Irtis 177001 717/Month 24 0.922 No 177005 719/Month 24 0.922 No 104002 722/Month 24 0.922 No 122002 723/Month 24 0.782 No 122002 723/Month 24 1.130 No 122002 723/Month 24 0.782 No 122003 723/Month 24 1.700 No 122004 124003 721/Month 24 1.700 No 122002 723/Month 24 1.700 No No 122003 723/Month 24 1.700 No No 122003 723/Month 24 1.700 No No 124003 722/Month 24 1.700 No No 124001 723/Month 2

 | Treatment Group Subject ID Asay Log Titer Diagnois 170010 365/Month 12 2.770 No 170010 365/Month 12 1.870 Irtis 177006 715/Month 24 1.870 Irtis 177001 722/Month 24 0.922 No 177005 719/Month 24 0.922 No 104002 723/Month 24 0.922 No 122002 723/Month 24 1.140 No 122002 723/Month 24 1.700 No 122002 723/Month 24 1.700 No 122003 723/Month 24 1.700 No 122004 124003 721/Month 24 1.700 No 122005 723/Month 12 1.800 No No 122004 721/Month 24 1.700 No No 122003 723/Month 12 1.700 No No 123004 181/Month 6 1.700 No No 141010 725/Month 12

 | Treatment Group Subject ID Asay Log Titer Diagnois 170010 365/Month 12 2.770 No 170010 365/Month 12 1.870 Irtis 177006 715/Month 24 1.870 Irtis 177001 717/Month 24 1.870 Irtis 177005 717/Month 24 1.140 No 170010 722/Month 24 1.140 No 122002 723/Month 24 1.140 No 122002 723/Month 24 1.130 No 122002 723/Month 24 1.170 No 122003 723/Month 24 1.700 No 122011 174/Month 6 1.700 No 122012 723/Month 24 1.700 No 122013 721/Month 24 1.700 No 122014 181/Month 24 1.700 No 122013 721/Month 24 1.700 No 122014 181/Month 24 1.700 No 122013 <

 | Positive Intraocular

 | Positive Intraocular

 | Positive Intraocular

 | Positive

 | Positive
 | Positive

 | Positive
 | Positive Intraocular
 | Positive Intraocular

 | Positive Intraocular
 | Positive Intraocular
 | Positive Intraocular | Positive
 | Positive | Positive | Positive
 |
| Literthreint Group Subject ID Assay Log Titer Diagnois 170010 365 /Month 12 2.770 No 177006 375 /Month 24 2.800 Iritis 177005 717 /Month 24 1.870 Iritis Ranibizumab 0.5 mg 10002 719 /Month 24 0.922 No 122002 723 /Month 24 0.922 No No 122002 723 /Month 24 1.130 No No 122002 723 /Month 24 1.130 No No 122003 723 /Month 24 1.130 No No 122003 723 /Month 24 1.130 No No 122003 723 /Month 24 1.700 No No 122003 723 /Month 24 1.700 No No 123003 723 /Month 24 1.700 No No 12400 722 /Month 24 1.700 No No 12400 722 /Month 24 1.700 No No 14

 | Liteatment Group Subject ID Assay Log Titer Diagnois 170010 365 /Month 12 2.770 No 177006 375 /Month 24 1870 Iritis Ranibizumab 0.5 mg 177/Month 24 1870 Iritis 177006 717 /Month 24 0.922 No 122002 723 /Month 24 0.922 No 122002 723 /Month 24 1.140 No 122002 723 /Month 24 1.130 No 122002 723 /Month 24 1.130 No 122003 723 /Month 24 1.130 No 122004 723 /Month 24 1.130 No 122003 723 /Month 24 1.130 No 122004 721 /Month 24 1.300 No 122003 722 /Month 24 1.300 No 123003 722 /Month 24 1.300 No 124001 722 /Month 24 1.300 No 124003 722 / Month 24 1.300 No

 | Month Intertification Subject ID Assay Log Titer Diagnois ITron10 365 /Month 12 2.770 No IT7006 355 /Month 12 2.770 No IT7005 717 /Month 24 1.870 Irtis Ranibizumab 0.5 mg 109002 717 /Month 24 0.922 No Iz2002 722 /Month 24 0.922 No No I22002 723 /Month 24 0.922 No No I22002 723 /Month 24 0.782 No No I22002 723 /Month 24 1.130 No No I22002 723 /Month 24 1.1700 No No I22003 723 /Month 12 1.1700 No No I22003 723 /Month 12 1.1700 No No I22003 723 /Month 12 1.700 No No I22004 181 /Month 6 1.700 No No I2400 725 /Month 12 1.700 No No <td< td=""><td>Positive Intraocular</td><td>Positive Intraocular</td><td>Positive Intraocular</td><td>Positive Intraction</td><td>Positive Intraocular</td><td>Positive Intraction</td><td>Positive Intraction</td><td>Positive Intraocular</td><td>Positive Intraocular</td><td>Positive Intraocular</td><td>Positive Intraocular</td><td>Positive Intraocular</td><td>Positive 1</td><td>Positive 1</td><td>Positive Annual Threader T</td><td>Positive
Imminacianticity</td></td<>

 | Positive Intraocular

 | Positive Intraocular

 | Positive Intraocular

 | Positive Intraction

 | Positive Intraocular
 | Positive Intraction

 | Positive Intraction
 | Positive Intraocular
 | Positive Intraocular

 | Positive Intraocular
 | Positive Intraocular
 | Positive Intraocular | Positive 1
 | Positive 1 | Positive Annual Threader T | Positive
Imminacianticity
 |
| Main State Assay Log Titer Diagnois ITronic 365/Month 12 2770 No IT7006 365/Month 24 1870 Iritis IT7005 371/Month 24 1870 Iritis Ranibizumab 0.5 mg 10002 717/Month 24 0.922 No Iz001 722/Month 24 1.130 No No I22002 723/Month 24 1.130 No No I22003 723/Month 24 1.170 No No I22003 723/Month 24 1.700 No No I22003 722/Month 24 1.700 No No I23003 723/Month 6 1.700 No No I2400 722/Month 24 1.700 No No I241010 722/Month 6 </th <th>Main State Assay Log Titer Diagnois ITronio 365/Month 12 2770 No 177006 365/Month 24 1870 Iritis IT7005 371/Month 24 1870 Iritis Ranibizumab 0.5 mg 10002 717/Month 24 0.922 No 12002 719/Month 24 1.130 No No 122002 723/Month 24 1.130 No No 122003 723/Month 24 1.130 No No 122003 723/Month 24 1.700 No No 122003 722/Month 24 1.300 No No 123003 723/Month 24 1.700 No No 12400 722/Month 24 1.700 No No 141013 181/Month 24<</th> <td>Matrix Assay Log Titer Diagnois ITronio 365 /Month 12 2770 No 177006 365 /Month 24 2800 Iritis 177006 371 / Month 24 1870 Iritis Ranibizumab 0.5 mg 10002 719 / Month 24 0.922 No 122002 723 / Month 24 1.130 No No 122003 723 / Month 24 1.1700 No No 122003 723 / Month 24 1.700 No No 122014 722 / Month 24 1.700 No No 122003 723 / Month 24 1.700 No No 122004 181 / Month 6 1.700 No No 12400 726 / M</td> <td>Positive Intraocular</td> <td>Positive Intraocular</td> <td>Positive
Immersorities Transaction</td> <td>Positive Intraction</td> <td>Positive
Immersorities Immersorities</td> <td>Positive Intraction</td> <td>Positive Intraction</td> <td>Positive
Immersorities Transaction</td> <td>Positive
Immersorities Transaction</td> <td>Positive
Immersorities Transaction</td> <td>Positive Intraocular</td> <td>Positive Interesting Interesting</td> <td>Tosidye
Tmmussaartvis</td> <td>Torraceular
Terminarea Arvice Terminaria Terminaria</td> <td>Positive Trumped Trumped Trumped Trumped</td> <td>Tositiye</td>

 | Main State Assay Log Titer Diagnois ITronio 365/Month 12 2770 No 177006 365/Month 24 1870 Iritis IT7005 371/Month 24 1870 Iritis Ranibizumab 0.5 mg 10002 717/Month 24 0.922 No 12002 719/Month 24 1.130 No No 122002 723/Month 24 1.130 No No 122003 723/Month 24 1.130 No No 122003 723/Month 24 1.700 No No 122003 722/Month 24 1.300 No No 123003 723/Month 24 1.700 No No 12400 722/Month 24 1.700 No No 141013 181/Month 24<

 | Matrix Assay Log Titer Diagnois ITronio 365 /Month 12 2770 No 177006 365 /Month 24 2800 Iritis 177006 371 / Month 24 1870 Iritis Ranibizumab 0.5 mg 10002 719 / Month 24 0.922 No 122002 723 / Month 24 1.130 No No 122003 723 / Month 24 1.1700 No No 122003 723 / Month 24 1.700 No No 122014 722 / Month 24 1.700 No No 122003 723 / Month 24 1.700 No No 122004 181 / Month 6 1.700 No No 12400 726 / M

 | Positive Intraocular

 | Positive Intraocular

 | Positive
Immersorities Transaction

 | Positive Intraction
 | Positive
Immersorities Immersorities

 | Positive Intraction

 | Positive Intraction
 | Positive
Immersorities Transaction
 | Positive
Immersorities Transaction

 | Positive
Immersorities Transaction
 | Positive Intraocular | Positive Interesting Interesting
 | Tosidye
Tmmussaartvis
 | Torraceular
Terminarea Arvice Terminaria Terminaria | Positive Trumped Trumped Trumped Trumped | Tositiye
 |
| Main State Assay Log Titer Diagnois 170010 365 / Month 12 2.770 No 177006 355 / Month 24 1850 Iritis 177006 355 / Month 24 1850 Iritis 177006 358 / Month 24 1870 Iritis 177005 717 / Month 24 0.922 No 122002 723 / Month 24 1.140 No 122003 359 / Month 24 1.130 No 122003 357 / Month 24 1.130 No 122003 357 / Month 24 1.130 No 122003 357 / Month 24 1.1700 No 122004 722 / Month 24 1.1700 No 122003 722 / Month 24 1.700 No 122004 722 / Month 24 1.200 No 123005 181 / Month 6 1.700 No 141013 722 / Month 24 1.360 No 141013 726 / Month 24 1.940 No 14

 | Main State Assay Log Titer Diagnois ITrottheirtGroup 365/Month 12 2.770 No IT7006 365/Month 24 2.800 Iritis IT7005 371/Month 24 1870 Iritis Ranibizumab 0.5 mg 107002 717/Month 24 0.922 No Ranibizumab 0.5 mg 10002 719/Month 24 1.140 No 122002 723/Month 24 1.130 No No 122003 359/Month 24 1.130 No No 122003 723/Month 24 1.130 No No 122003 723/Month 24 1.1700 No No 122003 723/Month 24 1.700 No No 122003 723/Month 24 1.700 No No 123003 722/Month 24 1.700 No No 12400 722/Month 24 1.700 No No 12400 722/Month 24 1.700 No No 12400 <td>Main Sasy Log Titer Diagnois ITrottheir Group 365 / Month 12 2.770 No I77006 365 / Month 24 1.870 Iritis I77005 371 / Month 24 1.870 Iritis Ranibizumab 0.5 mg 10002 719 / Month 24 0.922 No 122002 723 / Month 24 0.922 No No 122002 723 / Month 24 1.130 No No 122002 723 / Month 24 1.130 No No 122002 723 / Month 24 1.1700 No No 122002 723 / Month 24 1.1700 No No 122003 723 / Month 24 1.1700 No No 122003 723 / Month 24 1.700 No No 122003 723 / Month 54 1.700 No No 122003 723 / Month 54 1.700 No No 123003 131 / Month 6 1.700 No No 141010</td> <td>Positive Intraocular</td> <td>Positive Intraocular</td> <td>Positive
Immersorities Transaction</td> <td>Positive Intraction</td> <td>Positive
Immersorities Immersorities</td> <td>Positive Intraction</td> <td>Positive Intraction</td> <td>Positive
Immersorities Transaction</td> <td>Positive
Immersorities Transaction</td> <td>Positive
Immersorities Transaction</td> <td>Positive Intraocular</td> <td>Positive Interesting Interesting</td> <td>Tosidye
Tmmussaartvis</td> <td>Torraceular
Terminarea Arvice Terminaria Terminaria</td> <td>Positive Trumped Trumped Trumped Trumped</td> <td>Tositiye</td>

 | Main Sasy Log Titer Diagnois ITrottheir Group 365 / Month 12 2.770 No I77006 365 / Month 24 1.870 Iritis I77005 371 / Month 24 1.870 Iritis Ranibizumab 0.5 mg 10002 719 / Month 24 0.922 No 122002 723 / Month 24 0.922 No No 122002 723 / Month 24 1.130 No No 122002 723 / Month 24 1.130 No No 122002 723 / Month 24 1.1700 No No 122002 723 / Month 24 1.1700 No No 122003 723 / Month 24 1.1700 No No 122003 723 / Month 24 1.700 No No 122003 723 / Month 54 1.700 No No 122003 723 / Month 54 1.700 No No 123003 131 / Month 6 1.700 No No 141010

 | Positive Intraocular

 | Positive Intraocular

 | Positive
Immersorities Transaction

 | Positive Intraction

 | Positive
Immersorities Immersorities
 | Positive Intraction

 | Positive Intraction
 | Positive
Immersorities Transaction
 | Positive
Immersorities Transaction

 | Positive
Immersorities Transaction
 | Positive Intraocular
 | Positive Interesting Interesting | Tosidye
Tmmussaartvis
 | Torraceular
Terminarea Arvice Terminaria Terminaria | Positive Trumped Trumped Trumped Trumped | Tositiye
 |

1 In Study FVF2428g, intravitreal injections (sham or ranibizumab 0.5 mg) were given every month and verteporfin PDT every 3 months. 2 Iritis diagnosed 1 day after Month 4 injection.

123

C J BLA Rhea A. Lloyd, MD 125156

I ncentie (r

Rhea A. Lloyd, MD **J BLA** 25156 ں

Lucentis (ranibizumab injection)

3 Iritis diagnosed day of injection. Injection was not held. 4 No resolution of uveitis noted in CRFs submitted.

5 Uveitis diagnosed 3 days post Month 7 injection. Serious AE led to treatment discontinuation in Month 9. 6 Treatment discontinued.

Reviewer's Comment:

Fifty subjects in Stadies FVF2428g, FVF2587g and FVF2598g had measurable immunoreactivity based upon initial and confirmatory assays. Thirteen of these subjects experienced episodes of intraocular inflammation.

In subjects with an immunoreactivity assay log liter of > 2.00, 31% experienced at least one episode of intraocular inflammation.

In subjects with an immunoreactivity assay log titer of >3.00, 100% experienced an episode of intraocular inflammation.

Appears This Way On Original

7.1.11 Human Carcinogenicity

Not applicable.

7.1.12 Special Safety Studies

Safety analysis was based on an evaluation of other safety parameters, as well, which included visual acuity (best corrected), intraocular pressure, ocular signs by slit lamp examination and indirect ophthalmoscopy the results of which are included throughout the safety review.

7.1.13 Withdrawal Phenomena and/or Abuse Potential Not applicable. This is not a therapeutic class with known abuse potential or apparent withdrawal potential.

7.1.14 Human Reproduction and Pregnancy Data There are no adequate and well-controlled studies in pregnant women. There was no inadvertent exposure to the product in pregnant women during the development program.

7.1.15 Assessment of Effect on Growth

The intended population for this product is adults with age-related macular degeneration, a disease that does not exist in the pediatric age group. This application contains no pediatric data.

7.1.16 Overdose Experience

This product has no overdose potential and no studies were performed.

7.1.17 Postmarketing Experience

This product has not yet been marketed.

7.2 Adequacy of Patient Exposure and Safety Assessments

The safety and exposure database for Ranibizumab included in this application is derived from 976 ranibizumab-treated subjects with neovascular age-related macular degeneration, in six clinical trials.

7.2.1 Description of Primary Clinical Data Sources (Populations Exposed and Extent of Exposure) Used to Evaluate Safety

The submitted clinical study reports and clinical protocols related to the development program of ranibizumab were analyzed in this review. Proposed draft labeling and Case Report Forms for discontinued subjects in studies FVF2587g and FVF2598g were provided and reviewed. Refer to Section 4.1.

7.2.1.1 Study type and design/patient enumeration

Refer to Section 4.2 for the table of clinical studies.

7.2.1.2 Demographics

Refer to Table 6.1.3.1-9 and Table 6.1.3.2-9 Demographic Statistics by Treatment Group for Studies FVF2598g and FVF2587g.

Reviewer's Comments:

There are no remarkable differences between treatment groups in baseline demographic characteristics.

Subgroup analyses did not reveal any differences in the studies' success on the primary efficacy endpoint.

7.2.1.3 Extent of exposure (dose/duration)

Table 7.2.1.3-1 Extent of Exposure to Study Drug or Sham Injection Safety Evaluable Subjects

	5	049	4			
	5 Shi miyaa. 1. 2002 (62.)	C)		archonnie gour status	0.3 mg	20mab 0.5 mg N=140
Number of injections ^a						
Mean (SD)	11.7 (2.7)	12.4 (1.9)	12.3 (2.2)	12.0 (2.5)	12.2 (2.1)	12.1 (2.2)
Frequency						
< 10	27 (11.4%)	10 (4.2%)	15 (6.3%)	17 (11.9%)	9 (6.6%)	13 (9.3%)
10-12	55 (23.3%)	36 (15.1%)	40 (16.7%)	21 (14.7%)	29 (21.2%)	29 (20.7%)
13	154 (65.3%)	192 (80.7%)	184 (77.0%)	105 (73.4%)	99 (72.3%)	98 (70.0%)
Treatment duration (days) ^b						
Mean (SD)	332.7 (80.0)	350.6 (54.7)	346.2 (61.5)	337.1 (75.0)	346.2 (61.8)	345.6 (59.7)

a Of 13 scheduled injections from Day 0 to Month 12 visits. The verteporfin PDT group received sham injections.

b The number of days between the first and the last injection on or prior to Month 12 visit.

Reviewer's Comment:

The extent of exposure was similar between all treatment groups in each study. The vast majority of subjects received 10 or more treatment injections. The mean treatment duration ranged from 332.7 days to 350.6 days among the treatment groups.

Table 7.2.1.3-2

Extent of Exposure to Study Treatment with Verteporfin or Sham PDT Safety Evaluable Subjects in the First Treatment Year

		11 dy 11 V 102/587/	
	. Automit		zdmab
	2月1日) 1月1日日 1月1日日		0.5 mg
Number of Treatments			
Mean (SD)	3.1 (1.3)	1.9 (1.3)	1.8 (1.1)
1	18 (12.6%)	76 (55.5%)	79 (56.4%)
2	33 (23.1%)	32 (23.4%)	29 (20.7%)
3 .	36 (25.2%)	12 (8.8%)	19 (13.6%)
4	26 (18.2%)	5 (3.6%)	9 (6.4%)
5.	30 (21.0%)	12 (8.8%)	4 (2.9%)
Treatment duration (days) b			
Mean (SD)	228.1 (129.0)	95.8 (129.2)	84.2 (116.3)

a Of 5 possible treatments form Day 0 to Month 12 visits. The ranibizumab groups received sham PDT. b The number of days between the first and the last treatment on or prior to Month 12 visit.

Table 7.2.1.3-3

Number of Study Drug or Sham Injection Treatments Held Per Protocol-Specified Criteria During the First Treatment Year Safety Evaluable Subjects

				let a secondaria A recordaria	tudy FYF2587 Ranib	the second se
Injections Held	N=236	N 268 H.	and	PDT NE(43	0.3 mg N=137	0.5 mg N=140
Mean	0.1 (0.4)	0.1 (0.4)	0.1 (0.4)	0.0 (0.2)	0.0 (0.2)	0.2 (0.7)
0	224 (94.9%)	227 (95.4%)	229 (95.8%)	140 (97.9%)	131 (95.6%)	129 (92.1%)
1	7 (3.0%)	9 (3.8%)	7 (2.9%)	2 (1.4%)	6 (4.4%)	6 (4.3%)
2	3 (1.3%)	0	2 (0.8%)	1 (0.7%)	0	3 (2.1%)
3	1 (0.4%)	1 (0.4%)	0	0	0	0
4	1 (0.4%)	1 (0.4%)	1 (0.4%)	0	0	0
5	0	0	0	0	0	2 (1.4%)

Reviewer's Comment:

The vast majority, more than 92% of patients in each treatment group, did not require that treatments be held due to the protocol-specified dose-holding criteria.

Table 7.2.1.3-4

Study Drug or Sham Injection Held per Protocol-Specified Criteria by Criterion Met First Treatment Year: Safety Evaluable Subjects

	8	10.00002598		s s	tudy FYF2587	
Criterion	Sham	Contraction in the second	zumili tri sei	Verteporfin	Ranibi	Comparison of the second second second second
	N=236	1012 iiig. 1013 iig. 1	0.5 mg	PDT N=143	0.3 mg N=137	0.5 mg N=140
Any Treatment Held	12 (5.1%)	11 (4.6%)	10 (4.2%)	3 (2.1%)	6 (4.4%)	11 (7.9%)
Intraocular inflammation	0	2 (0.8%)	4 (1.7%)	0	1 (0.7%)	3 (2.1%)
Visual acuity loss	6 (2.5%)	1 (0.4%)	1 (0.4%)	1 (0.7%)	· 0	0
IOP elevation	0	0	1 (0.4%)	0 -	1 (0.7%)	2 (1.4%)
Vitreous hemorrhage	0	2 (0.8%)	· 0	0	0	0
Sensory rhegmatogenous	1 (0.4%)	1 (0.4%)	1 (0.4%)	0	1 (0.7%)	0
retinal detachment / break	1 (0.470)	1 (0.478)	1 (0.475)	v	1 (0.770)	
Subfoveal hemorrhage	5 (2.1%)	1 (0.4%)	0	2 (1.4%)	0	2 (1.4%)
Local or systemic infxn	0	4 (1.7%)	2 (0.8%)	0	2 (1.5%)	4 (2.9%)
Intraocular surgery	0	0	2 (0.8%)	0	1 (0.7%)	1 (0.7%)

Note: Tabulation was based on the 13 scheduled injections from Day 0 to Mont 12. Multiple injections that were held because of the same criterion for a given subject were counted once in the overall incidence for the criterion. Multiple occurrences of injections held in a subject were counted once in the overall incidence.

Reviewer's Comment:

Approximately 5% of subjects in each treatment group in Study FVF2598g required that at least one treatment be held due to the protocol-specified dose-holding criteria. In the sham treatment group, the reason for dose holding was most frequently visual acuity loss or subformal hemorrhage. In the ranibizumab treatment groups, no single criterion was met in the majority of cases. In Study FVF2587g, treatments were held for protocol-specified holding criteria least often in the verteporfin PDT group and most frequently in the 0.5 mg ranibizumab group. Intraocular inflammation and local or systemic infection were the most frequent criteria met in the 0.5 mg ranibizumab group.

7.2.2 Description of Secondary Clinical Data Sources Used to Evaluate Safety The medical reviewer conducted a PubMed electronic literature search to supplement the submitted review of the relevant literature. There was no significant new information found in the published literature.

7.2.2.1 Other studies

No other studies were used to evaluate safety.

7.2.2.2 Postmarketing experience

The product has not yet been marketed. No postmarketing data were used to evaluate safety. 7.2.2.3 Literature

The applicant's literature search was complete, including important is sues of safety and efficacy. 7.2.3 Adequacy of Overall Clinical Experience

The overall clinical experience was adequate.

The pivotal studies, FVF2587g and FVF2598g, were adequate and well-controlled studies which demonstrated the efficacy of ranibizumab. An adequate number of subjects from relevant demographic groups were exposed to this formulation of ranibizumab to assess potential during the development program. The study designs were appropriate.

7.2.4 Adequacy of Special Animal and/or In Vitro Testing Refer to the Pharmacology/Toxicology review for details.

7.2.5 Adequacy of Routine Clinical Testing

Routine clinical testing and monitoring of study subject was adequate to elicit adverse events.

7.2.6 Adequacy of Metabolic, Clearance, and Interaction Workup Studies to evaluate metabolism, clearance and interaction were not performed due to the negligible systemic absorption of ranibizumab given by the intravitreal route of administration.

Appears This Way On Original

			injection)	
BLA	Shea A. Lioyd, MD		ucentis (ranibizumab injection)	
с	Rhea A.]	125156	ucentis	

7.2.7 Adequacy of Evaluation for Potential Adverse Events for Any New Drug and Particularly for Drugs in the Class Represented by the New Drug; Recommendations for Further Study

The applicant has made adequate efforts to detect specific adverse events for ranibizumab as a biologic and a VEGF inhibitor.

treatment groups prior to initial administration of study drug, possibly due to preexisting anti-Fab antibodies. There was no imbalance Serum samples for the evaluation of immunoreactivity to ranibizumab were obtained from subjects at screening and prior to study drug administration at Months 6 and 12. The assay demonstrated immunoreactivity in a small percentage of subjects in all three between ranibizumab-treated and sham-treated subjects regarding immunoreactivity to ranibizumab. Refer to Section 7.1.10 for details. Analyses of potential side effects related to systemic VEGF inhibition focused on the incidence of hypertension, arterial thromboembolic events and non-ocular hemorrhage.

Table 7.2.7-1 Serious Adverse Events Potentially Related to Systemic VEGF Inhibition during the First Treatment Year: Studies FVF2598g and FVF2587g

									_
A three and the second of the second second	zometh		STATES AND	8 (5.7%)	0	4 (2.9%)	3 (2.1%)	1 (0.7%)	
Study level 289 g	Minister Rumin			4 (2.9%)	0	2 (1.4%)	2 (1.5%)	1 (0.7%)	all incidence.
	Verteporfin	- PDT	N-145	3 (2.1%)	0	.2 (1.4%)	0	1 (0.7%)	nce in the over
and the second	umab	A DESCRIPTION OF	N-239	9(3.8%)	0	8 (3.3%)	0	1 (0.4%)	vere counted of
udy.FVE2598g	Apple 101			8 (3.4%)	1 (0.4%)	5 (2.1%)	1 (0.4%)	1 (0.4%)	t for a subject v
	Change and			2 (0.8%)	0	2 (0.8%)	0	0	f the same type of event for a subject were counted once in the overall incidence
	A DESCRIPTION OF A DESC			TOTAL ¹	Hypertension events	Arterial thromboembolic events	Non-ocular hemorrhages	Other potentially associated events	Note: Multiple occurrences of the san

Reviewer's Comment:

a lesser extent, in serious non-ocular hemorrhages (but not in serious hypertension or proteinuria). No imbalance in overall adverse was noted, particularly in the ranibizumab 0.5-mg dose group. This reflects trends in serious arterial thromboembolic events and, to In the two phase 3 studies, a small trend in the occurrence of serious adverse events potentially related to systemie VEGF inhibition events potentially related to systemic VEGF inhibition was observed among treatment groups.

7.2.8 Assessment of Quality and Completeness of Data The data presented were complete and of good quality.

7.2.9 Additional Submissions, Including Safety Update The sponsor has submitted the following additional submissions of clinical safety and efficacy data during the review cycle. Amendments 003 and 006 were submitted in response to reviewer requests for additional analyses of the safety database. These amendments have been reviewed individually and the results incorporated into the rest of the review.

- Amendment 003 Analysis of all of the thromboembolic adverse events in the ranibizumab trials including a comparison of risk factors and concomitant medications between patients who experienced thromboembolic events and all enrolled patients. (Submitted February 17, 2006)
- Amendment 006 Request for information on all discontinued subjects regardless of attribution to study treatment, all serious adverse events and all adverse events occurring ≥ 1% of subjects in any treatment group for both Phase 3 studies. (Submitted March 17, 2006)
- Amendment 008 Study FVF2598g Year 2 Data and Updated Draft Labeling (Submitted March 31 2006)

On April 28, 2006, the sponsor submitted the 120-Day Safety Update which is considered in this section. This update to the Summary of Clinical Safety includes additional safety information available from Study FVF2598g. Since the submission of the BLA, the collection and cleaning of second-treatment-year data from Study FVF2598g has been completed, and this update includes summaries based on final 2-year data from the study. No additional safety analyses are provided in the SCS update for Study FVF2587g because the trial is still ongoing, or for Study FVF2428g per prior agreement with the FDA. There are no updates to the safety analyses provided for Studies FVF2128g, FVF2425g, and FVF1770g because these trials were complete at the time of the original SCS.

All summaries presented within this report for Study FVF2598g are based on the safetyevaluable population (all subjects who received at least one ranibizumab or sham injection). In addition, subjects are grouped according to the actual treatment received, as defined from the safety analyses presented in the FVF2598g CSR Addendum. Subjects in the sham-injection group who crossed over to receive 0.5 mg ranibizumab per the sixth protocol amendment are included in the safety analyses. These subjects are included in the sham-injection group.

The original SCS included safety data from 1413 subjects, 976 of whom received treatment with ranibizumab. Of the six studies included in the SCS, Study FVF2598g was the largest with a total of 713 safety-evaluable subjects, 477 of whom received treatment with ranibizumab. As summarized in the original SCS, more than 5,800 ranibizumab injections and 2,700 sham injections were administered during the first treatment year of Study FVF2598g.

		Ranib	izumab
		pad Song	0.5 mg
	Öriginal SCS	298 States	1259 N 239
Number of injections ²			
Total	2765	2952	2929
Mean (SD) ^b	11.7 (2.7)	12.4 (1.9)	12.3 (2.2)
Treatment duration (days) ^c			
Mean (SD)	332.7 (80.0)	350.6 (54.7)	346.2 (61.5)
	Update to SCS		
Number of injections ⁴			
Total	4709	5248	5195
Mean (SD) ^b	20.0 (6.3)	22.1 (4.4)	21.7 (5.0)
Treatment duration (days) ^c			>
Mean (SD)	` 590.1 (191.2)	651.4 (130.2)	639.9 (148.2)

Table 7.2.9-1 Extent of Study Drug Exposure: Study FVF2598g

a Intravitreal ranibizumab injection or sham injection b Number of injections per subject, or 24 scheduled injections during the 2-year treatment period. The summary includes ranibizumab injections received by subjects in the sham-injection group after crossover and a Month 24 injection received by Subject 144001 in the 0.5-mg group. c Number of days between the first and the last injection during the study period.

Reviewer's Comments:

The extent of study drug exposure was well balanced between the treatment groups in the first and second years of the study.

Table 7.2.9-3 Treatment and Study Discontinuations during the 2-Year Treatment Period: Safety Evaluable Subjects - Study FVF2598g

	Ranibizumab.		
	N=250	0.3 mg N=238	0.5 mg N=239
Crossed over to receive 0.5 mg ranibizumab	12 (5.1%)		
At Month 22	5 (2.1%)	~=	
At Month 23	7 (3.0%)	·	
Discontinued treatment ^a	66 (28.0%)	30 (12.6%)	32 (13.4%)
Death	5 (2.1%)	5 (2.1%)	3 (1.3%) ^b
Adverse event	13 (5.5%)	8 (3.4%)	14 (5.9%) ^b
Lost to follow-up	2 (0.8%)	2 (0.8%)	3 (1.3%)
Subject's decision	24 (10.2%)	17 (7.1%)	13 (5.4%)
Physician's decision	1 (0.4%)	1 (0.4%)*	2 (0.8%)
Subject non-compliance	1 (0.4%)	0	0
Subject's condition mandated other therapeutic intervention	23 (9.7%)	1 (0.4%)	0

a Some subjects remained in the study after treatment discontinuation.

b Three subjects discontinued from treatment because of an adverse event that resulted in death (the primary reason for study discontinuation).

Salety Evaluation	A A A A A A A A A A A A A A A A A A A	1	Contract of the second s
		Ranibiz	umab,
Theperod			0.5 mg
		28.8	N=239
Overall	6 (2.5%)	5 (2.1%)	6 (2.5%)
Year 1	0	1 (0.4%)	2 (0.8%)
Year 2	6 (2.5%)	4 (1.7%)	4 (1.7%)

Table 7.2.9-4 Deaths during the 2-Year Treatment Period: Safety Evaluable Subjects - Study FVF2598g

Table 7.2.9-5 Primary Cause of Deaths that Occurred during the 2-Year Treatment Period: Study FVF2598g

Time period	Treatment Group	Age/ Sex	n an	Study Day	Days Since Last Study Treatment
Year 1 ^ª	0.3 mg	78/F	Heart attack -		11
	0.5 mg	78/F	Small bowel infarct	178	24
		90/F	Chronic asthma / COPD	155	2
Year 2	Sham	74/F	Unknown cause	481	3
		88/M	Congestive heart failure	724	91
		76/F	Cerebrovascular accident	673	35
		77/M	Acute or chronic renal failure	656	45
		80/M	Cerebral vascular accident; bilateral parietal lobe and cerebellum	576	31
		71/M	Acute respiratory failure	400	67
	0.3 mg	91/F	Unknown	669	99
· · · · · · · · · · · · · · · · · · ·		77/F	Complications of Non- Hodgkin's Lymphoma	752	425
		91/F	Myocardial infarction	- 570	23
		81/M	Pneumonia	_617	47
	0.5 mg	72/M	Closed head injury resulting from automobile accident	627	57
		87/F	Stroke	667	461
	1	76/M	Sepsis	496	16
		85/F	Hemorrhagic cerebrovascular accident	428	14

Reviewer's Comment:

An additional 14 deaths occurred in the second treatment year. Overall, no imbalance was noted between the treatment groups in the numbers or causes of death during the 2 year treatment period. The primary causes of death were common events in this elderly population of patients. Table 7.2.9-6 Ocular Serious Adverse Events in the Study Eye during the 2-YearTreatment Period (Occurring in > 1 Subject Overall): Study FVF2598g

		Ramb	Ranibizumab	
MedDRA Brepried Terms and		011 mg 177 N=238	0.5 mg N=239	
Total Ocular Events in the Study Eye [*]	17 (7.2%)	20 (8.4%)	- 21 (8.8%)	
Choroidal neovascularization	2 (0.8%)	· 0 -	0	
Detachment of RPE	0	1 (0.4%)	1 (0.4%)	
Endophthalmitis	0	2 (0.8%)	2 (0.8%)	
IOP increased	0	1 (0.4%)	2 (0.8%)	
Iridocyclitis	0	1 (0.4%)	2 (0.8%)	
Macular degeneration	6 (2.5%)	1 (0.4%)	2 (0.8%)	
Medication error	0	1 (0.4%)	1 (0.4%)	
Retinal detachment	1 (0.4%) ^b	1 (0.4%) ^c	0	
Retinal hemorrhage	4 (1.7%)	2 (0.8%)	1 (0.4%)	
Retinal tear	0 -	1 (0.4%)	1 (0.4%)	
Uveitis	0	1(0.4%)	1 (0.4%)	
Visual acuity reduced	3 (1.3%)	3 (1.3%)	1 (0.4%)	
Vitreous hemorrhage	2 (0.8%)	1 (0.4%)	1 (0.4%)	

Note: Multiple occurrences of the same event in a subject were counted once in the overall incidence. a Represents the number of subjects with at least one ocular adverse event in the study eye.

b Rhegmatogenous retinal detachment

c Exudative retinal detachment

Reviewer's Comment:

Generally, serious ocular adverse events occurred in a very low percentage of subjects regardless of treatment group. The results are similar to those seen in the first treatment year.

Given the numbers of intravitreal injections in each treatment group (See Table 7.2.9-1), the perinjection rates of endophthalmitis, traumatic cataract, intraocular inflammation and retinal detachment were all very low approximately $\leq 0.10\%$ per injection in each dose group.

Conjunctival hemorrhage, increased intraocular pressure, vitreous floaters, and vitritis occurred more frequently in the ranibizumab groups than in the sham injection group.

Choroidal neovascularization, macular degeneration, retinal hemorrhage, and subretinal fibrosis, manifestations of active neovascular AMD lesions were more common in the shaminjection group than in the ranibizumab groups.

Table 7.2.9-7 Non-Ocular Serious Adverse Events during the 2-Year Treatment Peri	od
(Occurring in > 1 Subject Overall): Study FVF2598g	

(Occurring in > 1 Subject Overall): Study FVF2598g				
MedDICA entrance a contra		Rambi L m	20mab 0.5 mg N=239	
Total Non-Ocular Events	73 (30.9%)	82 (34.5%)	76 (31.8%)	
Abdominal pain upper	3 (1.3%)	0	0	
Acute myocardial infarction	0	3 (1.3%) ^b	0	
Angina unstable	0	2 (0.8%)	0	
Arthritis	0	2 (0.8%)	0	
Asthma	1 (0.4%)	1 (0.4%)	2 (0.8%)	
Atrial fibrillation	4 (1.7%)	3 (1.3%)	5 (2.1%)	
B-cell lymphoma	2 (0.8%)	0	0	
Back pain	0	2 (0.8%)	0	
Breast cancer	2 (0.8%)	0	0	
Cardiac failure congestive	6 (2.5%)	4 (<u>1.7%</u>)	1 (0.4%)	
Carotid artery stenosis	0	0	2 (0.8%)	
Cellulitis	5 (2.1%)	1 (0.4%)	0	
Cerebrovascular accident	3 (1.3%)	3 (1.3%)	6 (2.5%)	
Chest pain	3 (1.3%)	4 (1.7%)	3 (1.3%)	
Chronic obstructive pulmonary disease	2 (0.8%)	4 (1.7%)	4 (1.7%)	
Coronary artery disease	5 (2.1%)	2 (0.8%0	4 (1.7%)	
Coronary artery occlusion	1 (0.4%)	0	2 (0.8%)	
Deep vein thrombosis	0	3 (1.3%)	0	
Dehydration	0	1 (0.4%)	2 (0.8%)	
Diverticulitis	1 (0.4%)	2 (0.8%)	4 (1.7%)	
Gout	2 (0.8%)	0	0	
Hip fracture	1 (0.4%)	5 (2.1%)	1 (0.4%)	
Lobar pneumonia	1 (0.4%)	2 (0.8%)	0	
Lumbar spinal stenosis	2 (0.8%)	0	0	
Lung neoplasm malignant	3 (1.3%)	2 (0.8%)	2 (0.8%)	
Myocardial infarction	4 (1.7%)	4 (1.7%)	2 (0.8%)	
Non-cardiac chest pain	0	0	2 (0.8%)	
Osteoarthritis	3 (1.3%)	1 (0.4%)	0	
Pneumonia	4 (1.7%)	9 (3.8%)	7 (2.9%)	
Renal cell carcinoma stage unspecified	2 (0.8%)	0	0	
Sepsis	0	0	3 (1.3%)	
Syncope	6 (2.5%)	3 (1.3%)	2 (0.8%)	
Transient ischemic attack	1 (0.4%)	2 (0.850	3 (1.3%)	

Note: Multiple occurrences of the same event for a subject were counted once in the overall incidence.

a Represents the number of subjects with at least one non-ocular serious adverse event.

b Includes Subject 101020 with a serious adverse event of acute myocardial infarction even though the event was removed from final study database based on a investigator correction form submitted after the completion of the FVF2598g CS.

c The sham-treated subject (118004) who experiences a subacute parietooccipital CVA (reported as an ocular serious adverse event) had received a single injection of 0.5 mg ranibizumab in error approximately 8 months prior to the event. d Includes one case reported as a cerebral ischemia.

Reviewer's Comment:

The adverse events which were seen more frequently in the ranibizumab 0.5 mg group versus control are highlighted. The percentages of subjects with non-ocular serious adverse events were well balanced among the treatment groups and similar to those seen in the first treatment year.

Table 7.2.9-8 Ocular Adverse Events in the Study Eye that Led to Discontinuation from Study or from Treatment during the 2-Year Treatment Period: Study FVF2598g

	Sham	S. C. Schildlamab.	
MedDRA Preferred Termines.	IN 236	0.6 mg 2.1 N=238 T	
Total ^a	15 (6.4%)	6 (2.5%)	7 (2.9%)
Choroidal neovascularization	7 (3.0%)	0	0
Conjunctivitis allergic	0	0	1 (0.4%)
Eye pain	0	0	2 (0.8%)
Glaucoma	0		1 (0.4%)
Нуроруоп	0	0	1 (0.4%)
Iridocyclitis	0	0	2 (0.8%)
Iris adhesions	0	0	1 (0.4%)
Iritis	0	3 (1.3%)	0
Macular degeneration	6 (2.5%)	0	0
Macular hole	0	1 (0.4%)	0
Maculopathy	0	1 (0.4%)	0
Retinal detachment	1 (0.4%)	0	0
Retinal hemorrhage	4 (1.7%)	1 (0.4%)	0
Retinal tear	1 (0.4%)	0	0
Uveitis	0	0	2 (0.8%)
Visual acuity reduced	2 (0.8%)	0	0
Vitreous detachment	1 (0.4%)	0	0
Vitreous floaters	0	0-	1 (0.4%)
Vitritis	0	0	1 (0.4%)

Note: Multiple occurrences of the same event in a subject were counted once in the overall incidence. a Represents the number of subjects with at least one ocular adverse event in the study eye that led to discontinuation of study or treatment.

Reviewer's Comment:

There was a larger discontinuation rate in the sham-injection group than in either ranibizumab group usually due to signs and symptoms of worsening macular degeneration.

Ranibizumab group discontinuations were caused by signs and symptoms that may be associated with intraocular inflammation. These findings are similar to those in the first treatment year.

Table 7.2.9-9 Ocular Adverse Events in the Study Eye during the 2-Year Treatment Period (Occurring in ≥ 10% of Subjects in Any Group): Study FVF2598g

MedDkAPFacestern		Reamburger	0.5 mg
《上云》。神教初期,中国 的		i i i i i i i i i i i i i i i i i i i	4 N 239
Total ^a	234 (99.2%)	236 (99.2%)	235 (98.3%)
Blepharitis	21 (8.9%)	26 (10.9%)	32 (13.4%)
Cataract NOS ^b	37 (15.7%)	37 (15.5%)	37 (15.5%)
Choroidal neovascularization	40 (16.9%)	1 (0.4%)	4 (1.7%)
Conjunctival hemorrhage	156 (66.1%)	184 (77.3%)	181 (75.7%)
Detachment of RPE	36 (15.3%)	27 (11.3%)	22 (9.2%)
Dry eye	15 (6.4%)	16 (6.7%)	24 (10.0%)
Eye irritation	47 (19.9%)	38 (16.0%)	46 (19.2%)
Eye pain	79 (33.5%)	86 (<u>36.1</u> %)	89 (37.2%)
Eye pruritus	29 (12.3%)	23 (9.7%)	32 (13.4%)
Foreign body sensation in eyes	34 (14.4%)	43 (18.1%)	45 (18.8%)
Intraocular inflammation ^c	25 (10.6%)	33 (13.9%)	43 (18.0%)
IOP increased	14 (5.9%)	57 (23.9%)	57 (23.8%)
Lacrimation increased	38 (16.1%)	41 (17.2%)	39 (16.3%)
Macular degeneration	159 (67.4%)	111 (46.6%)	109 (45.6%)
Macular edema	27 (11.4%)	6 (2.5%)	12 (5.0%)
Maculopathy	27 (11.4%)	20 (8.4%)	23 (9.6%)
Ocular hyperemia	24 (10.2%)	24 (10.1%)	24 (10.0%)
Retinal degeneration	16 (6.8%)	25 (10.5%)	24 (10.0%)
Retinal disorder	22 (9.3%)	27 (11.3%)	30 (12.6%)
Retinal exudates	25 (10.6%)	21 (8.8%)	16 (6.7%)
Retinal hemorrhage	132 (55.9%)	61 (25.6%)	58 (24.3%)
Subretinal fibrosis	37 (15.7%)	22 (9.2%)	15 (6.3%)
Vision blurred	20 (8.5%)	34 (14.3%)	22 (9.2%)
Visual acuity reduced	39 (16.5%)	26 (10:9%)	24 (10.0%)
Visual disturbance	21 (8.9%)	27 (11.3%)	33 (13.8%)
Vitreous detachment	42(17.8%)	52 (21.8%)	53 (22.2%)
Vitreous floaters	24 (10.2%)	76 (31.9%)	71 (29.7%)
Vitritis	8 (3.4%)	17 (7.1%)	30 (12.6%)

Note: Multiple occurrences of the same event in a subject were counted once in the overall incidence. a Represents the number of subjects with at least one ocular adverse event in the study eye. b Includes the preferred terms: cataract, cataract cortical, cataract nuclear, cataract subcapsular, cataract traumatic, and lenticular opacities. c Includes the preferred terms anterior chamber inflammation, hypopyon, iridocyclitis, iritis, uveitis and vitritis.

Reviewer's Comment:

The adverse events which were seen more frequently in the ranibizumab 0.5 mg group versus control are highlighted. Conjunctival hemorrhage, increased intraocular pressure, vitreous floaters, and vitritis occurred more frequently in the ranibizumab groups than in the sham injection group. These findings are similar to those in the first treatment year.

Choroidal neovascularization, macular degeneration, retinal hemorrhage, and subretinal fibrosis, manifestations of active neovascular AMD lesions were more common in the shaminjection group than in the ranibizumab groups.

The apparent dose dependent trend in the incidence of intraocular inflammation adverse events in the study eye was slightly increased in the 2-year treatment period data Seven of the ranibizumab-treated subjects (1.5%) experienced at least one serious intraocular inflammation adverse event in the study eye. All of the serious intraocular inflammation adverse events were considered by the investigator to be related to study drug. Six of the seven subjects had study treatment held or discontinued from study treatment because of serious intraocular inflammation. One subject in the ranibizumab 0.5-mg group was reported to have serious uveitis and was treated with intravitreal antibiotics. The sponsor considered this adverse event a presumed case of endophthalmitis.

Elevated intraocular pressure adverse events were noted more frequently in the ranibizumab treated groups. Most events were reported as mild or moderate in severity though three ranibizumab-treated subjects had severe events. For those events that required treatment, medication was used most frequently though paracenteses and anterior chamber taps were required in eight of the 305 reported events.

Appears This Way On Original

Original BLA Rhea A. Lloyd, MD 125156 Lucentis (ranibizumab injection)

Table 7.2.9-10 Non-Ocular Adverse Events in the Study Eye during the 2-Year Treatment Period (Occurring in ≥ 5% of Subjects in Any Group): Study FVF2598g

		Ranibi	zumab
MedDikA Preferren Fern			
Total ^a	214 (90.7%)	228 (95 .8%)	228 (95.8%)
Anemia	19 (8.1%)	17 (7.1%) 著	18 (7.5%)
Anxiety	7 (3.0%)	10 (4.2%)	12 (5.0%)
Arthralgia	21 (8.9%)	26 (10.9%)	27 (11.3%)
Arthritis	20 (8.5%)	17 (7.1%)	19 (7.9%)
Back pain	22 (9.3%)	24 (10.1%)	22 (9.2%)
Blood pressure increased	18 (7.6%)	16 (6.7%)	20 (8.4%)
Bronchitis	20 (8.5%)	23 (9.7%)	25 (10.5%)
Chest pain	13 (5.5%)	10 (4.2%)	9 (3.8%)
Constipation	18 (7.6%)	15 (6.3%)	13 (5.4%)
Contusion	20 (8.5%)	10 (4.2%)	9 (3.8%)
Cough	17 (7.2%)	23 (9.7%)	25 (10.5%)
Depression	16 (6.8%)	12 (5.0%)	14 (5.9%)
Diarrhea	20 (8.5%)	18 (7.6%)	10(4.2%)
Dizziness	23 (9.7%)	18 (7.6%)	11 (4.6%)
Dyspnea	6 (2.5%)	12 (5.0%)	8 (3.3%)
Edema peripheral	14 (5.9%)	17 (7.1%)	10 (4.2%)
Gastroesophageal reflux disease	12 (5.1%)	15 (6.3%)	9 (3.8%)
Headache	24 (10.2%)	36 (15.1%)	24 (10.0%)
Herpes zoster	5 (2.1%)	13 (5.5%)	10 (4.2%)
Hypercholesterolemia	11 (4.7%)	10 (4.2%)	13 (5.4%)
Hypertension	38 (16.1%)	41 (17.2%)	39 (16.3%)
Influenza	12 (5.1%)	23 (9.7%)	19 (7.9%)
Insomnia	13 (5.5%)	10 (4.2%)	14 (5.9%)
Nasopharyngitis	31 (13.1%)	32 (13.4%)	38 (15.9%)
Nausea	13 (5.5%)	21 (8.8%)	21 (8.8%)
Pain in extremity	14 (5.9%)	15 (6.3%)	13 (5.4%)
Pneumonia	13 (5.5%)	18 (7.6%)	11 (4.6%)
Sinusitis	13 (5.5%)	18 (7.6%)	20 (8.4%)
Upper respiratory tract infection	23 (9.7%)	36 (5.1%)	18 (7.5%)
Urinary tract infection	18 (7.6%)	21 (8.8%)	17 (7.1%)

Note: Multiple occurrences of the same event in a subject were counted once in the overall incidence. a Represents the number of subjects with at least one ocular adverse event in the study eye.

Reviewer's Comment:

The adverse events which were seen more frequently in the ranibizumab 0.5 mg group versus control are highlighted. The reported adverse events during the 2-year treatment period were consistent with those seen in an elderly population and the first treatment year results.

Reviewer's Comment:

The overall 2-year safety profile in Study FVF2598g was similar to that observed based on firsttreatment-year data. The most common adverse events in the study eye observed more frequently in the ranibizumab groups than in the sham-injection group were conjunctival hemorrhage, increased intraocular pressure and vitreous floaters.

The dose dependent association of ranibizumab and intraocular inflammation noted during the first treatment year persisted in the second treatment year. Cumulative 2-year rates of reported intraocular inflammation adverse events in the study eye of 13.9% and 18.0% in the 0.3-mg and 0.5-mg ranibizumab groups compared with the sham-injection group, 10.6%. The observed intraocular inflammation adverse events were usually mild in severity and occurrence was well-balanced among the subgroups studied. Serious intraocular inflammation adverse events only occurred in the ranibizumab groups with a cumulative rate of $\leq 1.7\%$ during the 2-year treatment period.

Table 7.2.9-11 APTC Arterial Thromboembolic Events during the 2-Year Treatment Period: Safety-Evaluable Subjects - Study FVF2598g

Event Type						
	UN 236	N=238	N=239			
Total	9 (3.8%)	11 (4.6%)	11 (4.6%)			
Vascular deaths	4 (1.7%) ^a	3 (1.3%) ^b	3 (1.3%)			
Nonfatal myocardial infarction	4 (1.7%)	6 (2.5%) ^c	3 (1.3%)			
Nonfatal ischemic stroke	2 (0.8%) ^{a, e}	3 (1.3%) ^b	5 (2.1%) ^f			
Nonfatal hemorrhagic stroke	0	0	I (0.4%) ^d			

Note: Antiplatelet Trialists' Collaboration. BMJ. 1994 Jan 8; 308(6921):81-106.

a Subject 136007 had a prior non-fatal ischemic stroke.

b Subject 101019 had a non-fatal ischemic stroke and died of an unknown cause.

c Subject 109001 had two events of MI.

d Subject 158001 had an MI and a hemorrhagic stoke, both non-fatal.

e The sham-treated subject (118004) who suffered a subacute parietooccipital lobe CVA (reported as an ocular serious adverse event) had received a single injection of ranibizumab 0.5 mg in error approximately 8 months prior to the stroke.

f Include 1 subject (200001) with cerebral ischemia who had MRI evidence of infarction I the pons and thalamus.

Reviewer's Comment:

In the second treatment year, the trend toward higher rates of APTC arterial thromboembolic events was somewhat decreased because the number of subjects who experienced events in the second treatment year was similar among the treatment groups (1 subjects [3.2%] in the shaminjection group, 8 subjects [3.4%] in the 0.3 mg ranibizumab group, and 6 subjects [2.6%] in the 0.5 mg ranibizumab group).

7.3 Summary of Selected Drug-Related Adverse Events, Important Limitations of Data, and Conclusions

The trend in intraocular inflammation adverse events observed during the first treatment year was also observed through the second treatment year of Study FVF2598g, with cumulative 2year rates of reported intraocular inflammation adverse events in the study eye of 13.9% and 18.0% in the 0.3-mg and 0.5-mg ranibizumab groups, respectively, compared with 10.6% in the sham-injection group. However, the reported intraocular inflammation adverse events were generally mild in severity. The incidence of intraocular inflammation adverse events did not differ substantially between the subgroups examined, and rates were lower in the second treatment year compared with the first treatment year. The incidence of intraocular inflammation adverse events adverse events were adverse events was consistent with results based on slit lamp examination.

In Study FVF2598g, serious intraocular inflammation adverse events were observed only in the ranibizumab groups but were uncommon for both dose groups ($\leq 1.7\%$ cumulative rate over the 2-year treatment period).

The frequency of intraocular inflammation adverse events in the study eye was higher in the ranibizumab groups (10.2% in the 0.3-mg group and 15.0% in the 0.5-mg group) compared with the verteporfin PDT group (2.8%).

7.4 General Methodology

7.4.1 Pooling Data Across Studies to Estimate and Compare Incidence 7.4.1.1 Pooled data vs. individual study data

	The Control and	Ranibizumab		
MedDRA Preferred Term		1) & mg. New 7075	0.5 mg N=379	
Total ^a	11 (2.9%)	11 (2.9%)	15 (4.0%)	
Acute Coronary Syndrome	0	1 (0.3%)	0	
Acute myocardial infarction	0	1 (0.3%)	0	
Angina pectoris	2 (0.5%)	3 (0.8%)	2 (0.5%)	
Angina unstable	0	1 (0.3%)	0	
Cerebral infarction	0	1 (0.3%)	0	
Cerebral ischemia	0	0	1 (0.3%)	
Cerebrovascular accident	2 (0.5%) ^b	1 (0.3%)	3 (0.8%)	
Embolism	0	0	1 (0.3%)	
Femoral artery occlusion	1 (0.3%)	0	0	
Intestinal infarction	0	0	1 (0.3%)	
Myocardial infarction	2 (0.5%)	2 (0.5%)	4 (1.1%)	
Retinal artery occlusion	0	1 (0.3%)	0	

Table 7.4.1.1-1 Arterial Thromboembolic Events during the First Treatment Year: Studies FVF2598g and FVF2587g Pooled (Safety Evaluable Subjects)

MedDRA Brenefred i e m	9 (1117)) N (297)	Band Daving Sec.7	20mab 0.5 mg. N=379
Transient ischemic attack	4 (1.1%)	0	4 (1.1%)
Vascular graft occlusion	0	1 (0.3%)	0
Vascular occlusion	0	1 (0.3%)	0

a Represents the number of subjects with at least one arterial thromboembolic event

b A sham-treated subject in Study FVF2598g who experienced a subacute parietooccipital CVA (reported as an ocular serious adverse event) had received a single injection of 0.5 mg ranibizumab in error approximately 8 months prior to the event.

Reviewer's Comment:

The adverse events which were seen more frequently in the ranibizumab 0.5 mg group versus control are highlighted. The number of subjects with an arterial thromboembolic event was small in the pooled analysis of studies FVF2598g and FVF2587g. A direct relationship between ranibizumab dose and arterial thromboembolic events can not be ruled out.

A sham-treated subject in Study FVF2598g who experienced a subacute parietooccipital CVA (reported as an ocular serious adverse event) had received a single injection of 0.5 mg ranibizumab in error approximately 8 months prior to the event.

Appears This Way

Original BLA Rhea A. Lloyd, MD 125156 Lucentis (ranibizumab injection) Table 7.4.1.1-2 Potential Risk Factors and Baseline Concomitant Medication Use for Subjects with Arterial Thromboembolic versus All Subjects: Studies FVF2598g and FVF2587g Pooled (Safetv-Evaluable Subjects)

	1 OUTTO	201		C BEITH TINTEN		and a stand of the stand of the stand
-			0.3 mg	C	3mg.0.5.0	1g
	Subjects w/ ATF	All Subjects	Subjects w/ ATE	All Subjects	Subjects w/ ATE	All Subjects
1000-1000-1000-1000-1000-1000-1000-100		: مۇنىي		n=375	11-15 1	n=379
Potential Risk Factor						
Ace > 75 vears	8 (72.7%)	259 (68.3%)	8 (72.7%)	262 (69.9%)	12 (80.0%)	244 (64.4%)
Male	7 (63.6%)	143 (37.7%)	2 (18.2%)	156 (41.6%)	5 (33.3%)	163 (43.0%)
History of hypertension or			-			(10) (10) (10)
hvmertension at baseline ^b	7 (63.6%)	249 (65.7%)	9 (1.8%)	265 (70.7%)	10 (66.7%)	265 (09.4%)
History of ATF	6 (54.5%)	112 (29.6%)	8 (72.7%)	117 (31.2%)	7 (46.7%)	107 (28.2%)
History of atherosclerosis	(%) 2 (9%)	125 (33.0%)	9 (81.8%)	127 (33.9%)	7 (46.7%)	124 (32.7%)
Tristen of diskate maline	3 (77 3%)	46 (12.1%)	4 (36.4%)	47 (12.5%)	3 (20.0%)	59 (15.6%)
Littleton of municipal information	1 (0 1%)	29 (7.7%)	2 (18.2%)	22 (5.9%)	3-620-000	27 (7.1%)
	2 (18 2%)	31 (8.2%)	3 (27.3%)	26 (6.9%)	3 (20:0%)	28 (7.4%)
History of venue thromhosis	0	9 (2.4%)	1 (9.1%)	13 (3.5%)	1 (6.7%)	13 (3.4%)
Decelies concomitent medication use						
	6 151 502)	161 (42 50%)	4 (36 4%)	146 (38.9%)	7 (46.7%)	142 (37.5%)
Aspurn	(0/ C+C) 0	(0/ C-74) TOT	Invition L	0	0	0
Persantine	0	0	2	N	100000	176 142 401
Anti-platelet agents	4 (36.4%)	167 (44.1%)	9 (81.8%)	168 (44.8%)	(0% 5.25) C	1 /0 40.4 /0)
Anti-coagulant agents	2 (18.2%)	27 (7.1%)	1 (9.1%)	26 (6.9%)	1 (6.7%)	18 (4.7%)
Lipid-lowering agents	4 (36.4%)	153 (40.4%)	4 (36.4%) 153 (40.4%) 5 (45.5%) 150 (40.0%) 3 (20.0%) 151 (39.	150 (40.0%)	3 (20.0%)	151 (39.8%)

single injection of 0.5 mg ranibizurnab in error approximately 8 months prior to the event. b Hypertension at baseline was defined as systolic blood pressure >150 mmHg, diastolic blood pressure > 100 mmHg, or a use of a concomitant medication indicated for hypertension.

Reviewer's Comment:

For all subjects, potential risk factors for ATEs and baseline concomitant medication use were well balanced across the the anguer groups in terms of percentages.

The number of subjects with ATE was small making comparisons somewhat difficult. Though subjects in the ranibizumab 0.5 mg group with an ATE did not have the highest aspirin use, their aspirin use was higher than all subjects in the ranibizumab 0.5 mg group.

Subjects with an ATE in the ranibizumab 0.5 mg group generally had potential risk factors at a higher percentage than the group as a whole.

7.4.1.2 Combining data

Studies FVF2598g and FVF2587g were sufficiently similar to allow data to be combined by adding the numerator events and denominators of the treatment groups across the studies.

7.4.2 Explorations for Predictive Factors

A detailed discussion of the adverse events is presented in Sections 7.1.1 through 7.1.6. No clear predictive factors for a drug-related adverse event were identified.

7.4.3 Causality Determination

Due to the small number of patients, no determination of causality could be made regarding the adverse events in the Phase 3 studies.

8 ADDITIONAL CLINICAL ISSUES

8.1 Dosing Regimen and Administration

The sponsor has performed adequate dose ranging studies during the drug development program. Lucentis (ranibizumab) 0.5 mg dose has been demonstrated to be safe and effective in two Phase 3 clinical trials. The dosing interval in the two pivotal Phase 3 trials was once monthly resulting in the improvement and maintenance of visual acuity and function, and for the reduction of vascular leakage and retinal edema, in patients with neovascular (wet) age-related macular degeneration.

8.2 Drug-Drug Interactions

No important drug-drug interactions have been identified.

8.3 Special Populations

The sponsor has adequately evaluated gender effects on both the safety and efficacy outcomes. Subgroup analyses did not reveal any differences in the primary efficacy endpoint between males and females. The safety profiles seen in males and females, including the types and rates of adverse events, are similar.

Trials for this indication were conducted in a population that was overwhelmingly elderly and Caucasian. This is reflective of the population in which age-related macular degeneration occurs and does not reflect a problem with study enrollment.

8.4 Pediatrics

The applicant requested a waiver of the pediatric study requirements for the original Biologics License Application. The waiver was requested because the disease under study age-related macular degeneration does not occur in the pediatric age group.

8.5 Advisory Committee Meeting

Not applicable. No Advisory Committee Meeting will be held regarding this application.

8.6 Literature Review

The medical reviewer conducted a PubMed electronic literature search to supplement the submitted review of the relevant literature. There was no significant new information found in the published literature.

8.7 Postmarketing Risk Management Plan

No postmarketing risk management plan has been submitted.

8.8 Other Relevant Materials

Comments received from DDMAC and the Office of Drug Safety have been incorporated in the labeling review as appropriate.

9 OVERALL ASSESSMENT

9.1 Conclusions

The submitted studies in BLA 125156 are sufficient to establish efficacy for the use of ranibizumab 0.5 mg injection in the treatment of the neovascular age-related macular degeneration. The two Phase 3 studies provide replicative demonstration that monthly ranibizumab injections are able to stabilize and prevent vision loss in patients with neovascular macular degeneration compared to monthly sham and verteporfin PDT treatment.

9.2 Recommendation on Regulatory Action

BLA 125156 is recommended for approval from a clinical perspective for the treatment of patients with neovascular (wet) age-related macular degeneration with the labeling revisions within this review.

9.3 Recommendation on Postmarketing Actions

9.3.1 Risk Management Activity

Not applicable. No postmarketing risk management activity is recommended at this time.

9.3.2 Required Phase 4 Commitments

1. Develop and validate assays to detect and characterize immune responses to ranibizumab:

A. Develop and validate a confirmatory assay capable of detecting both IgG and IgM isotype responses.

B. Develop and validate an assay to detect neutralizing anti-ranibizumab antibodies.

The assay methodology and validation reports will be provided by September 28, 2007.

 To characterize further the immune response to ranibizumab, serum samples collected in studies FVF2587g, FVF2598g, FVF3192g will be assayed using the validated methods described above in Postmarketing Commitment The data obtained will be analyzed to discover and evaluate any association between immunoreactivity and dosing frequency as well as any potential impact of immunoreactivity on efficacy or safety outcomes.

Date of submission of protocol and statistical analysis plan: February 28, 2007

Date of submission of final study report: September 2008,

3. The need for an additional clinical study will be determined based on the results from the analysis described above.

9.3.3 Other Phase 4 Requests

Not applicable. There are no additional Phase 4 requests.

9.4 Labeling Review

Refer to the Appendix, Section 10.2 for the medical officer's labeling review.

9.5 Comments to Applicant

There are no comments pertaining to specific deficiencies.

§ 552(b)(4) Trade Secret / Confidential
§ 552(b)(4) Draft Labeling
§ 552(b)(5) Deliberative Process

Withheld Track Number: Medical-_____

APOTEX V. REGENERON IPR2022-01524 REGENERON EXHIBIT 2024 PAGE 171